<SEC-DOCUMENT>0001564590-21-013329.txt : 20210316
<SEC-HEADER>0001564590-21-013329.hdr.sgml : 20210316
<ACCEPTANCE-DATETIME>20210316081540
ACCESSION NUMBER:		0001564590-21-013329
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210316
DATE AS OF CHANGE:		20210316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cabaletta Bio, Inc.
		CENTRAL INDEX KEY:			0001759138
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39103
		FILM NUMBER:		21743703

	BUSINESS ADDRESS:	
		STREET 1:		2929 ARCH STREET
		STREET 2:		SUITE 600
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		(267) 759-3100

	MAIL ADDRESS:	
		STREET 1:		2929 ARCH STREET
		STREET 2:		SUITE 600
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>caba-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
caba-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-K<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark&#160;One) </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Segoe UI Symbol;font-size:10pt;"><font style="font-family:Times New Roman;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended December 31, 2020</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Segoe UI Symbol;font-size:10pt;"><font style="font-family:Times New Roman;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number&#160;001-39103 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">CABALETTA BIO, INC.</font><font style="font-size:10pt;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Delaware</font></p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">82-1685768</font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">2929 Arch Street, Suite 600</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Philadelphia, PA</font></p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">19104</font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: <font style="Background-color:#FFFFFF;">(267)&#160;759-3100</font> </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Common Stock, par value $0.00001 per share</font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CABA</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Nasdaq Global Select Market</font></p></td>
</tr>
</table></div>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: None </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;Yes&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> No&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section 15(d) of the Act. &#160;Yes&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> No&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;Yes&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> No&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;Yes&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> No&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</p></td>
<td colspan="2" valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). &#160;Yes&#160;<font style="font-family:Segoe UI Symbol;">&#9744; </font>No&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2020 (the last business day of the registrant's most recently completed second fiscal quarter), the aggregate market value of the registrant's common stock held by non-affiliates was approximately $214 million based on the last reported sale price of the registrant's common stock on the Nasdaq Global Select Market on June 30, 2020.  </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of registrant&#8217;s Common Stock outstanding as of March 10, 2021 was 24,062,775. </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Part III of this Annual Report on Form 10-K incorporates by reference certain information from the registrant&#8217;s definitive Proxy Statement for its 2021 annual meeting of shareholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year end of December&#160;31, 2020. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part of this Form&#160;10-K.</font></p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><font style="text-decoration:underline;">PART I</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><font style="text-decoration:underline;">Business</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><font style="text-decoration:underline;">Unresolved Staff Comments</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><font style="text-decoration:underline;">Properties</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><font style="text-decoration:underline;">Legal Proceedings</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><font style="text-decoration:underline;">Mine Safety Disclosures</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><font style="text-decoration:underline;">PART&#160;II</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><font style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><font style="text-decoration:underline;">Selected Financial Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><font style="text-decoration:underline;">Financial Statements and Supplementary Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><font style="text-decoration:underline;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">Controls and Procedures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><font style="text-decoration:underline;">Other Information</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><font style="text-decoration:underline;">PART&#160;III</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><font style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><font style="text-decoration:underline;">Executive Compensation</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><font style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><font style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><font style="text-decoration:underline;">Principal Accounting Fees and Services</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><font style="text-decoration:underline;">PART&#160;IV</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><font style="text-decoration:underline;">Exhibits, Financial Statement Schedules</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td>
</tr>
<tr style="height:2.25pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10_K_SUMMARY"><font style="text-decoration:underline;">Form 10-K Summary</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td>
</tr>
<tr style="height:2.25pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><font style="text-decoration:underline;">Signatures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Summary of the Material and Other Risks Associated with Our Business</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">We are a clinical-stage company with a limited operating history, have incurred significant losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">We are highly dependent on our relationship with University of Pennsylvania, or Penn, for our preclinical research and development activities, key technology and our current manufacturing needs for our clinical trial of DSG3-CAART, or the DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial, and if Penn&#8217;s manufacturing capacity is reduced or otherwise delayed or limited, this could adversely impact enrollment in our DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">We are reliant on intellectual property licensed to us by Penn and termination of our license agreement with Penn would result in the loss of significant rights, which would have a material adverse effect on our business.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">If we are unable to obtain and maintain sufficient intellectual property protection for DSG3-CAART, our other product candidates and technologies or any future product candidates, we may not be able to compete effectively in our markets.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">We will need to raise substantial additional funding before we can expect to complete development of any of our product candidates or generate any revenues from product sales.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">If we are unable to successfully develop our current programs into a portfolio of product candidates, or experience significant delays in doing so, we may not realize the full commercial potential of our current and future product candidates.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">If we encounter difficulties enrolling patients in our DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial or future clinical trials, these clinical development activities could be delayed or otherwise adversely affected.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Results of earlier studies may not be predictive of future study or trial results, and we may fail to establish an adequate safety and efficacy profile to conduct clinical trials or obtain regulatory approval for our product candidates.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">If serious adverse events, undesirable side effects or unexpected characteristics are identified during the development of any of our product candidates, we may need to delay, abandon or limit our further clinical development of those product candidates.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The COVID-19 pandemic and the future outbreak of other highly infectious or contagious diseases could seriously harm our research, development and potential future commercialization efforts, increase our costs and expenses and have a material adverse effect on our business, financial condition and results of operations.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Manufacturing and administering our product candidates is complex and we may encounter difficulties in technology transfer from Penn to a contract manufacturing organization.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">We may establish our own manufacturing facility and infrastructure in addition to or in lieu of relying on third parties for the manufacture of our product candidates, which will be costly and time-consuming, and which may not be successful.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Our future success depends in part upon our ability to retain our key employees, consultants and advisors and to attract, retain and motivate other qualified personnel.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K, including the sections entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; contains express or implied forward-looking statements that are based on our management&#8217;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Annual Report on Form 10-K include, but are not limited to, statements about:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the success, cost and timing and conduct of our clinical trial program, including our clinical trial of DSG3-CAART, or the DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial, and our other product candidates, including statements regarding the timing of initiation and completion of the clinical trials and the period during which the results of the clinical trials will become available;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the timing of and our ability to obtain and maintain regulatory approval of our product candidates, including DSG3-CAART, MuSK-CAART, FVIII-CAART and DSG3/1-CAART, in any of the indications for which we plan to develop them, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the impact of any business interruptions to our operations, including the timing and enrollment of patients in our ongoing and planned clinical trials and our planned Investigational New Drug application submissions, or to those of our clinical sites, manufacturers, suppliers, or other vendors resulting from the coronavirus disease (COVID-19) pandemic or similar public health crisis;</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our expected use of proceeds from the initial public offering and the period over which such proceeds, together with cash, will be sufficient to meet our operating needs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our plans to pursue research and development of other product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our plan to infuse our DSG3-CAART product candidate without lymphodepletion or other preconditioning agents initially in our DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the potential advantages of our proprietary Cabaletta Approach for selective B cell Ablation platform, called our CABA platform, and our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the extent to which our scientific approach and CABA platform may potentially address a broad range of diseases;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the potential benefits and success of our arrangements and our expanded sponsored research agreement with the Trustees of the University of Pennsylvania, or Penn, and the Children&#8217;s Hospital of Philadelphia, or CHOP, and our scientific co-founders, Drs. Milone and Payne;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to successfully commercialize our product candidates, including DSG3-CAART and our other product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the potential receipt of revenue from future sales of DSG3-CAART and our other product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the rate and degree of market acceptance and clinical utility of DSG3-CAART and our other product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our estimates regarding the potential market opportunity for DSG3-CAART and our other product candidates, and our ability to serve those markets;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our sales, marketing and distribution capabilities and strategy, whether alone or with potential future collaborators;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to establish and maintain arrangements or a facility for manufacture of DSG3-CAART and our other product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to obtain funding for our operations, including funding necessary to initiate and complete our&nbsp;&nbsp;DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial and our ongoing preclinical studies of MuSK-CAART, DSG3/1-CAART and FVIII-CAART;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the potential achievement of milestones and receipt of payments under our collaborations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to enter into additional collaborations with existing collaborators or other third parties;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates and our ability to operate our business without infringing on the intellectual property rights of others;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the success of competing therapies that are or become available, and our competitive position;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the impact of government laws and regulations in the United States and foreign countries; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to attract and retain key scientific or management personnel.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this Annual Report on Form 10-K. The forward-looking statements contained in this Annual Report on Form 10-K are made as of the date of this Annual Report on Form 10-K, and we undertake no obligations to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I"></a>PAR</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">T I</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_BUSINESS"></a><a name="ITEM_1_BUSINESS"></a>Item 1. Business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biotechnology company focused on the discovery and development of engineered T&#160;cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B&#160;cell-mediated autoimmune diseases. Our proprietary technology utilizes&#160;<font style="text-decoration:underline;">C</font>himeric&#160;<font style="text-decoration:underline;">A</font>uto<font style="text-decoration:underline;">A</font>ntibody&#160;<font style="text-decoration:underline;">R</font>eceptor, or CAAR, T&#160;cells that are designed to selectively bind and eliminate only specific B&#160;cells that produce disease-causing autoantibodies, or pathogenic B&#160;cells, while sparing normal B&#160;cells. Our lead CAAR&#160;T cell product candidate was designed based on the clinically validated and commercially approved Chimeric Antigen Receptor, or CAR, T&#160;cell technology that is marketed for the treatment of B&#160;cell cancers. By harnessing the power of targeted cell therapy, we believe our CAAR T product candidates have the potential to provide responses that may be a safer and more effective option than current treatments. We believe our technology, in combination with our proprietary&#160;<font style="text-decoration:underline;">C</font>abaletta&#160;<font style="text-decoration:underline;">A</font>pproach for selective&#160;<font style="text-decoration:underline;">B</font>&#160;cell&#160;<font style="text-decoration:underline;">A</font>blation platform, called our CABA platform, has applicability across over two dozen B&#160;cell-mediated autoimmune diseases that we have identified, evaluated and prioritized. Our initial focus is mucosal pemphigus vulgaris, or mPV, which is an autoimmune blistering disease. Our lead product candidate, DSG3-CAART, designed to treat patients with mPV, is currently enrolling patients for a Phase 1 trial, or the DesCAARTes<font style="Background-color:#FFFFFF;font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font><font style="Background-color:#FFFFFF;">&#160;</font>&#160;trial. We expect to report the acute safety data from the first cohort of patients in the DesCAARTes<font style="Background-color:#FFFFFF;font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font><font style="Background-color:#FFFFFF;">&#160;</font>&#160;trial in the first half of 2021, with additional topline data on any completed dose cohorts throughout the second half of 2021. Our lead preclinical product candidate, designed for the treatment of muscle-specific kinase myasthenia gravis, or MuSK MG, is currently in Investigational New Drug, or IND, enabling studies with an IND submission expected in the second half of 2021. We are also advancing additional product candidates currently in discovery-stage or preclinical development for the treatment of mucocutaneous PV, or mcPV, and Hemophilia A with Factor VIII, or FVIII, alloantibodies in addition to three undisclosed targets.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B&#160;cell-mediated autoimmune diseases occur when certain populations of B cells mistakenly produce autoantibodies, which are directed against specific healthy tissue or cells in the body. The presence of autoantibodies can manifest in a variety of autoimmune diseases and result in the destruction of healthy tissue in the body. Current treatment options for B cell-mediated autoimmune diseases are generally limited to corticosteroids and other generalized immunosuppressants that offer only temporary disease suppression, may require chronic,&#160;in-hospital&#160;administration and are associated with potentially life-threatening side effects. We believe the ideal therapy for B&#160;cell-mediated autoimmune diseases would selectively and completely eliminate the pathogenic B&#160;cells while sparing the body&#8217;s normal B&#160;cells.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are pioneering the development of a new class of engineered T&#160;cell therapies that express CAARs to selectively engage and eliminate pathogenic B&#160;cells. Our CAARs build upon the scientific foundation of CARs, differing primarily in the use of the antigen rather than an antibody fragment, which enables the CAAR T cells to serve as a &#8220;decoy&#8221; for specific autoantibodies expressed on the surface of B cells. This allows these pathogenic B cells to engage with the CAAR T cells instead of benign antigens, resulting in their elimination. We have developed our CABA platform to inform product candidate development from scientific, clinical and commercial assessment through CAAR design. Using our CABA platform, we have identified and thoroughly evaluated over two dozen B&#160;cell-mediated autoimmune diseases that we believe will be amenable to treatment with the Cabaletta approach and have advanced several of our highest priority targets into discovery and preclinical testing.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current product candidate pipeline is illustrated below. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gaz3apgusshz000001.jpg" title="" alt="" style="width:624px;height:239px;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">*</font><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In our discovery stage, we perform epitope mapping and optimize CAAR construct and design.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">**</font><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">May not be required if Phase 2 is a registrational clinical trial, subject to discussion with the FDA.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66448229"></a><font style="Background-color:#FFFFFF;">Our initial therapeutic focus is on pemphigus vulgaris, or PV, a chronic, autoimmune blistering skin disease. Despite a current standard of care that includes corticosteroids and adjunctive immunosuppressive agents, PV </font>remains associated with frequent recurrences as well as substantial morbidity and mortality. Our lead product candidate, DSG3-CAART, is being evaluated for the treatment of mPV, a subtype of PV that affects mucosal surfaces. mPV is caused by autoantibodies against the cell adhesion protein desmoglein 3, or DSG3. DSG3-CAART is designed to selectively target B cells expressing autoantibodies specific for DSG3, which may prevent these B&#160;cells from producing DSG3 antibodies that are the cause of mPV while preserving general B cell immune function. In January 2020, the U.S. Food and Drug Administration, or the FDA, granted orphan drug designation to DSG3-CAART for the treatment of PV. In May 2020, DSG3-CAART received fast track designation from the FDA for improving healing of mucosal blisters in patients with mPV. In December 2020, we announced that the first patient had been dosed in the DesCAARTes&#8482; trial. Our next&#160;PV-directed&#160;product candidate,&#160;DSG3/1-CAART,&#160;is being designed to target B cells expressing autoantibodies against DSG3 and desmoglein 1, or DSG1. It is being developed for the treatment of mucocutaneous PV, or mcPV, another subtype of PV that affects both mucosal and skin surfaces and is caused by autoantibodies against DSG3 and DSG1, respectively.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead preclinical product candidate, MuSK-CAART, is designed to treat a subset of patients with myasthenia gravis, or MG. MG is an autoimmune disease induced by autoantibodies targeting the neuromuscular junction, or NMJ, which can lead to life-threatening muscle weakness. Our product candidate targets B cells expressing autoantibodies against a transmembrane protein, muscle-specific kinase, or MuSK, and is being developed for the treatment of MuSK MG. Data from our initial in vitro and&#160;<font style="font-style:italic;">in vivo</font>&#160;studies of MuSK-CAART was presented at the American Academy of Neurology&#8217;s Science Highlights Virtual Platform in May 2020. The efficacy and safety of MuSK CAAR T cells were investigated using in vitro cytotoxicity assays, in vitro screens for&#160;off-target&#160;toxicity and a mouse model to evaluate the efficacy of human MuSK CAAR T cells against MuSK antibody expressing B cells&#160;<font style="font-style:italic;">in vivo</font>. In preclinical studies, MuSK CAAR T cells demonstrated in vitro cytotoxicity towards a B cell line expressing anti-MuSK antibodies, but we did not observe any cytotoxicity when the anti-MuSK antibody was not expressed. In addition, MuSK CAAR T cells also targeted and eliminated a panel of B cells targeting different MuSK epitopes. In an&#160;<font style="font-style:italic;">in vivo</font>&#160;mouse model, MuSK CAAR T cells, but not control CAAR T cells, showed biological activity by blocking the growth of B cell lines expressing an anti-MuSK antibody. Based in part on these results,&#160;IND-enabling&#160;studies have been initiated and an IND submission is anticipated in the second half of 2021.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also pursuing development of an additional product candidate, FVIII-CAART, which is being designed to treat a subset of patients with Hemophilia A, an&#160;X-linked&#160;bleeding disorder caused by mutations in the FVIII gene. While our CABA platform is primarily focused on the treatment of B cell-mediated autoimmune diseases, we believe our approach may be applicable in other instances where B cell antibody production is </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">implicated in response to exogenous FVIII, which is administered for the treatment of Hemophilia A. Specifically, we have identified an unmet need in cases where the immune system produces antibodies against exogenous antigens, which is known as an alloimmune response. Some patients receiving repeated administrations of exogenous FVIII will develop alloantibodies against the treatment, also known as inhibitors, neutralizing its therapeutic potential. Patients with FVIII alloantibodies may often require high-dose FVIII, immune tolerance induction with FVIII, agents that mimic FVIII or plasmapheresis to remove the FVIII alloantibodies. FVIII-CAART leverages a CAAR designed to target B&#160;cells expressing alloantibodies against FVIII, and it is initially being developed as an adjunctive therapy for Hemophilia A patients who develop FVIII alloantibodies.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our manufacturing strategy is a three-stage process designed to initially leverage the extensive early-stage manufacturing expertise of our academic partners while migrating to contract manufacturing organization, or CMO, partnerships and ultimately aiming to achieve full manufacturing independence. We believe partnering with proven and reputable manufacturing partners has allowed us to efficiently deploy financial and personnel resources. Stage 1 leverages the expertise in cell and vector manufacturing of our partners at the Children&#8217;s Hospital of Philadelphia, or CHOP, and the University of Pennsylvania, or Penn. This stage included early development work, support of the DSG3-CAART IND, and cell and vector product manufacturing for our DesCAARTes<font style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font>&#160;trial. We believe these partnerships and use of these established facilities have allowed us to move efficiently into clinical trials, but are not sufficient to support a commercial license. Stage 2, which is<font style="font-size:12pt;"> </font>ongoing, is designed to engage partners who are qualified for manufacturing of vectors at commercial grade and scale and who have experience with cell processing. In January 2021, we initiated a collaboration with WuXi Advanced Therapies, Inc. or WuXi, to serve as our cell processing manufacturing partner for the anticipated MuSK-CAART Phase 1 clinical trial.  Contingent on sufficient clinical evidence from the DesCAARTes<font style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font>&#160;trial, we plan to advance the third stage of our manufacturing strategy which will include building, qualifying and operating our own manufacturing facility. We believe this additional stage will enable full control of product development and commercial supply for products arising from our CABA platform, enabling us to achieve continuous improvement of our product candidates. Our Chief Executive Officer and Executive Vice President, Science and Technology, have both, in prior roles, built and led organizations that have constructed and commissioned cell therapy facilities which we hope will enable us to smoothly transition to stage 3 when feasible.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to build upon our first mover advantage in the field of targeted cell therapy for B cell-mediated autoimmune diseases and further advance the discovery, development and commercialization of our CAAR T portfolio. Our extensive correlative study program has been designed to inform clinical observations from the DesCAARTes<font style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font>&#160;trial in order to preserve and expand our industry leading insights into the impact of CAAR T therapies in patients. Our scientific founders are leading experts in B cell-mediated autoimmune diseases and CAR T technology, and we are led by an experienced team with demonstrated success in discovering, developing, manufacturing, and evaluating novel cell therapy products in clinical trials. In addition, we have partnered our discovery and initial development efforts with Penn, a pioneer in cell and gene therapy with a proven track record of expertise in the translational research, clinical development and manufacturing of cell therapy products, in order to advance our lead product candidate in clinical trials along with our preclinical product candidates.<font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our History and Team </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our scientific co-founders, Aimee Payne, M.D., Ph.D., and Michael Milone, M.D., Ph.D., began partnering at Penn in 2013 to combine Dr.&#160;Payne&#8217;s expertise in B cell-mediated autoimmune diseases with Dr.&#160;Milone&#8217;s deep and experienced insights into the design and implementation of CAR T products. Dr.&#160;Payne is a worldwide leader in characterizing B cell-mediated autoantibody repertoires in PV and other autoimmune diseases. Dr.&#160;Milone is a renowned scientist in CAR T therapy and was a co-inventor of and a key driver in the preclinical discovery and development efforts that yielded Kymriah, the first FDA-approved CAR T therapy for the treatment of B cell cancers. Dr.&#160;Payne&#8217;s laboratory surmised that by incorporating an antigen instead of an antibody fragment as the extracellular domain of the CAAR, specific pathogenic B&#160;cells could be targeted. This resulted in a collaboration between the two investigators to apply the scientific foundation of CAR T technology as it has been advanced by Drs. Payne and Milone in order to address B cell-mediated autoimmune diseases. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Their first scientific publication, &#8220;Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease&#8221; (<font style="font-style:italic;">Science</font>, July 2016), attracted the attention of a colleague, Steven Nichtberger, M.D., who is an adjunct professor at the Wharton School at the University of Pennsylvania, teaching a class on biotech company </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">formation, financing and leadership in the Vagelos Life Sciences&#160;&amp;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management Program. Additionally, Dr.&#160;Nichtberger has experience creating and building companies, including a novel cellular therapy company, which required transferring the technology from an academic institution, establishing a research and development organization, hiring of manufacturing and quality teams, creating novel manufacturing processes, reaching agreement with the FDA on novel clinical development pathways and constructing a commercial-scale Good Manufacturing Practices, or GMP, facility that manufactured autologous cell therapy products for clinical trials. In 2017, based on over a year of interaction and discussions regarding the optimal strategy to advance the scientific opportunity into a commercially developed product portfolio that could offer potentially curative treatment options to patients, Drs. Payne, Milone and Nichtberger decided to launch Cabaletta Bio. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The longstanding and highly productive partnership between our co-founders has been complemented by additional management experience that brings a successful history of translating academic cellular therapy research from Penn and elsewhere into commercially sponsored clinical trials and the establishment of a GMP manufacturing facility and organization. Gwendolyn Binder, Ph.D., our Executive Vice President, Science and Technology, was an early member of the Translational Research Program Operations team at Penn for over five years and participated in the submission and acceptance of multiple INDs for novel engineered T cell therapy products. As part of the cell therapy organization at Penn, Dr.&#160;Binder partnered with Dr.&#160;Milone and others to drive the IND-enabling translational studies that facilitated the initial CAR T clinical trial in B cell cancers at Penn. Dr.&#160;Binder also built and led a clinical stage biotechnology company&#8217;s manufacturing operations and quality teams, including creation of a fully functioning commercial grade GMP facility. Dr.&#160;Binder also built the translational research program and ultimately led the company&#8217;s research organization.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Research and Manufacturing Collaboration with Penn </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our CABA platform has already produced multiple product candidates through our sponsored research agreements, or SRAs, with Penn for the laboratories of our scientific co-founders, Drs. Payne and Milone. Our continuing relationship with our scientific co-founders provides important guidance and insights to us. Our contractual relationship with Penn through ongoing licensing and research arrangements also provides important services around manufacturing supply. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, we amended and restated our worldwide license agreement with Penn to develop our CAAR T technology to treat B cell-mediated autoimmune and alloimmune diseases. This license agreement provides us with access to multiple patent families covering CAAR T therapy as applied to the field of B cell-mediated autoimmune and alloimmune diseases and to the robust intellectual property portfolio created by Penn under these SRAs in this field. See &#8220;&#8212;Our Material Agreements&#8212;Amended and Restated License Agreement with Penn.&#8221; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ongoing collaboration with Penn is also based on a Master Translational Research Services Agreement, or the Services Agreement, that we entered into in October 2018, along with multiple additional agreements under the Services Agreement to engage and partner in individual Penn entities, including cell product manufacturing, correlative research, vector manufacturing, clinical trial operations and protocol development. In addition to the Services Agreement, we have agreements in place with various functional areas and centers that provide additional resources to Penn as well as contractual commitments from Penn with the goal of providing the capacity to manufacture our lead product candidate, DSG3-CAART. Penn has also agreed to manufacture vector product for use in our clinical trials. Penn&#8217;s obligations are subject to certain limitations and termination rights. See &#8220;&#8212;Our Material Agreements&#8212;Master Translational Research Services Agreement with Penn&#8221;. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe Penn is uniquely suited to be our partner in our efforts to develop product candidates leveraging our CAAR T technology based on a decade of experience, including manufacturing and clinical support for approximately a dozen active cell therapy clinical trials. The original manufacturing process for the first FDA-approved CAR T therapy was developed at Penn before being transferred to Novartis Pharmaceuticals Corporation during late-stage clinical trials. We are leveraging Penn&#8217;s experience, validated standard operating procedures, manufacturing facilities and staffing to accelerate development efforts for our lead product candidate. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal is to build upon our first mover advantage and expertise in cell therapies for B cell-mediated autoimmune diseases to accelerate the discovery, development and commercialization of our CAAR&#160;T cell therapies, with a focus on reliable manufacturing. We believe achieving this goal could result in potentially curative therapies for patients with unmet medical needs who suffer from certain B cell-mediated autoimmune diseases. To achieve this goal, key elements of our strategy include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Achieving clinical proof-of-concept for our lead product candidate, DSG3-CAART in mPV, the first in a series of well-understood and validated B cell-mediated autoimmune diseases for which we are developing CAAR&#160;T cell product candidates. </font><font style="font-size:10pt;color:#000000;">It is well-established that the presence of DSG3 autoantibodies and DSG3 autoantibody producing B cells in patients are both necessary and sufficient to cause mPV in the vast majority of cases. We believe our biologic understanding coupled with the well-understood clinical signs, symptoms and natural course of the disease, identify mPV as a model disease to evaluate our CAAR T approach. In addition, we have made significant investment in the design and development of DSG3-CAART, generating a lead candidate that has demonstrated robust target engagement and no off-target toxicities in preclinical studies. Taken together, our Phase 1 clinical trial evaluating DSG3-CAART for the treatment of mPV represents an optimal first opportunity to establish initial clinical proof-of-concept of our CABA platform. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Leveraging our CABA platform to identify optimal targets for the CAAR T approach and apply learnings from DSG3-CAART to advance additional product candidates.</font><font style="font-size:10pt;color:#000000;"> Shortly after inception, we undertook a comprehensive review of all known B cell-mediated autoimmune diseases in order to evaluate and prioritize the opportunity for selective destruction of B cells in an effort to cure B cell-mediated autoimmune diseases. Central to this analysis were (i)&#160;scientific, clinical and commercial assessment, (ii)&#160;epitope mapping to determine regions targeted by autoantibodies, (iii)&#160;evaluation of the ability to optimize the CAAR construct and design with the goal of selectively ablating reactive B cells, and (iv)&#160;evaluation of existing or required development of new preclinical models and </font><font style="font-style:italic;font-size:10pt;color:#000000;">in vitro</font><font style="font-size:10pt;color:#000000;"> and </font><font style="font-style:italic;font-size:10pt;color:#000000;">in vivo</font><font style="font-size:10pt;color:#000000;"> clinical testing. As we performed this analysis of potential product candidates, we considered possible paths for clinical trial design and regulatory approval. This analysis incorporated the extensive learnings gleaned from years of effort devoted to development of DSG3-CAART. We prioritized the targets and since then have been focused on being first to discover and develop a series of products with each providing the potential for cure of an important B cell-mediated autoimmune disease in patients. We intend to continue to apply our proprietary learnings from DSG3-CAART, including scientific and regulatory learnings, to most effectively advance these additional opportunities. Preclinical studies that are generally similar to, and informed by, DSG3-CAART preclinical studies are actively ongoing with other CAAR T cell product candidates. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Expanding upon our established IP position and first mover advantage in CAAR T therapy targeted towards B cell-mediated autoimmune diseases</font><font style="font-size:10pt;color:#000000;">. We are focused on protecting our intellectual property as we continue to pursue the development of future product candidates. We believe the issued U.S. patent on our initial CAAR constructs is the first patent covering cells engineered to express the known pathogenic epitopes recognized by DSG3 and DSG1 autoantibodies, which we are working to supplement with additional patent filings. The design of a broadly effective CAAR requires a deep understanding of the location of immunogenic epitopes targeted by autoantibodies, a competency that we believe we are uniquely positioned to utilize in product candidate development. We believe there is a particularly high value to the first mover advantage including, but not limited to, experience in discovery, preclinical development, regulatory efforts, intellectual property and insights from clinical trials that can be translated across programs. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Leveraging our cellular therapy experience and knowledge in addition to knowledge gained through our Penn collaboration to rapidly build our own fully-integrated internal infrastructure.</font><font style="font-size:10pt;color:#000000;"> We have differentiated expertise that we believe is uniquely suited for the continued buildout of our CABA platform specializing in B cell-mediated autoimmune diseases. Our scientific co-founders who initially developed our technology continue to collaborate closely with us through SRAs. In addition, our management team has a successful history of building the capabilities of cell therapy-based companies from the discovery and preclinical stage through Phase 3 readiness. In combination with our team, which possesses significant experience in executing on manufacturing strategies for cell therapy products, our partnership with Penn allows us to utilize their existing infrastructure, which accelerated our ability to submit our first IND. In parallel, we continue to build out an experienced team to manage the relationship with Penn while also developing and continuing to implement a path to our manufacturing independence. Ultimately, we intend to prepare and build our own manufacturing facility depending on the achievement of sufficient initial clinical trial data for DSG3-CAART. </font></p></td></tr></table></div><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">B Cell-Mediated Autoimmune Diseases: Overview and Current Treatment Paradigm </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The body&#8217;s immune system, which is designed to protect the body from infection and cancer, includes B cells and T cells. B cells are responsible for producing antibodies against antigens that the body perceives as foreign whereas T cells are responsible for cell-mediated immunity. In the case of B cell-mediated autoimmune diseases, certain populations of the patient&#8217;s B cells mistakenly produce antibodies directed against normal tissues and cells, leading to disease. While these autoantibodies are the major effectors of B cell-mediated autoimmune diseases, the underlying root cause of each B cell-mediated autoimmune disease is the defective B cells that mistakenly make these pathogenic antibodies. These pathogenic B cells express autoantibodies on their surface with the same antigen specificity as the circulating pathogenic autoantibodies, which can be used to distinguish them from the healthy B cell population, as shown in the figure below. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gaz3apgusshz000002.jpg" title="" alt="" style="width:578px;height:236px;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Antibodies are B cell receptors that drive B cell maturation.<font style="font-weight:normal;"> CD19 serves as a B cell marker throughout the na&#239;ve B cell phase, while CD20 is a surface marker expressed later in B cell maturation. CAAR T is designed to eliminate antigen specific B cells and prevent their further development to antibody producing plasma cells. IgM: immunoglobulin M; IgD: immunoglobulin D; IgA: immunoglobulin A; sIg: surface immunoglobulin, representing the autoantibody on the B cell surface.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current treatment options for autoimmune mediated diseases involve generalized immune suppression, achieved through corticosteroids, immunosuppressive medications and biologics. Most commonly, corticosteroids are used on both a chronic and acute basis to control disease, and act via a variety of mechanisms to control or downregulate multiple inflammatory pathways. In many cases, systemic immunosuppressive medications often used in chemotherapy such as mycophenolate, azathioprine and methotrexate, are added in an effort to minimize symptoms and manage the expected recurrences in patients. Biologic therapies have emerged as a new class of therapies and have a variety of targets including cytokines, B cells, and co-stimulation molecules. One particular biologic, rituximab, is an anti-CD20 antibody and is employed in multiple autoimmune diseases. Rituximab was approved by the FDA in 2018 for treatment of moderate to severe PV. Currently existing treatment options target parts of the immune system in addition to disease-causing B cells, and in general require chronic administration to reduce recurrence rates. We believe the ideal therapy in autoimmune diseases would completely and specifically eliminate the pathogenic B cells while sparing the immune cells that protect against infection, without requiring chronic administration. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Approach </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Using our CABA platform, we are developing engineered T cell therapy candidates that express CAARs, which serve as &#8220;decoys&#8221; for antibodies expressed on the surface of B cells. We believe these CAARs enable the T cells to specifically engage and eliminate pathogenic B cells while sparing normal B cells. By harnessing the power of cell therapy, our technology has the potential to overcome the ability of these B cells to evade elimination and thus lead to durable responses. Our CAAR T platform is based on the foundation of established CAR T therapeutics, differing primarily in their use of the antigen rather than an antibody fragment to target pathogenic B cells. We </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">believe our technology has broad applicability and we are building a portfolio of product candidates for B cell-mediated autoimmune diseases. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Background: CAR T Cells </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Engineered T cell therapy is a type of immunotherapy in which human T cells are genetically modified to express specific receptors, enabling the T cells to recognize and eliminate pathogenic cells. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A key application of engineered cell therapy involves the use of CARs, which are engineered molecules that enable T cells to identify specific antigens present on the surface of diseased cells. When expressed on the patient&#8217;s T cells, the CAR directs the T cells to kill cells that express a particular antigen. These CAR-expressing T cells, or CAR T cells, can proliferate, generating memory CAR T cells. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies are using CAR T technology to develop therapies for the treatment of B cell cancers. Several drug candidates have demonstrated clinical success, leading to the first FDA regulatory approvals of CAR T therapies for certain B&#160;cell cancers. In these B cell cancers, CAR T therapy has resulted in complete remission of disease in many patients, even in cancer patients with severe, refractory disease. Despite success in treating certain B&#160;cell cancers, we believe that CARs have not yet been developed or evaluated as a treatment option for other types of B cell-mediated autoimmune diseases in patients. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Technology: CAARs </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our CAAR T platform builds upon the scientific foundation of CARs to enable targeted B cell elimination in an autoimmune setting, which may lead to complete and durable remission of disease while sparing all other B&#160;cell populations that can provide beneficial immunity from infection. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The co-stimulatory domain and the signaling domain of both a CAR T cell and CAAR T cell carry out the same activation and cytotoxic functions once the engineered cell therapy engages a B cell. Our CAAR T cells differ from CAR T cells primarily in the extracellular targeting domain. Our CAAR T cells incorporate the relevant parts of the autoantigen that is subject to attack in autoimmune disease, as shown in the figure below. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gaz3apgusshz000003.jpg" title="" alt="" style="width:624px;height:274px;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Key differences between CAR T (left) vs. CAAR T therapy (right)<font style="font-weight:normal;">. A CAR T cell typically contains a signaling domain and a co-stimulatory domain and incorporates antibody fragments that recognize a specific antigen, such as CD19, which is present in both B cell leukemia cells and healthy B cells. In contrast, a CAAR T cell typically contains an antigen as its targeting domain rather than an antibody fragment. The antigen is recognized by the specific, pathogenic antibody along with the limited population of B cells that produce the antibody. The model </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">CAAR T cell depicted here contains an identical signaling domain and a co-stimulatory domain. The primary difference between a CAR T cell and a CAAR T cell is the target domain expressed on the cell surface. The example shown demonstrates the pan-B cell ablation that happens when targeting the B cell lineage marker, CD19, and the highly selective </font><font style="font-weight:normal;">pathogenic </font><font style="font-weight:normal;">B cell targeting approach of CAAR T. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Potential Advantages of CAAR T Cell Therapy in B Cell-Mediated Autoimmune Diseases </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In contrast to currently available therapies for B cell-mediated autoimmune diseases, based on observations of CAR T activity in refractory B cell cancers, we believe a single CAAR T treatment could potentially offer complete and durable remission of certain specific B cell-mediated autoimmune diseases while leaving the humoral, or bodily fluid, antibody-producing immune system intact. We believe our CAAR T cells can recognize the specific autoantibodies that are responsible for causing an underlying disease and kill the cells that express the autoantibodies on their surface. As a result, we believe CAAR T cell therapy used in B cell-mediated autoimmune disease has the potential for durable elimination of pathogenic B cells and an associated elimination of clinical recurrences with an improved adverse event, or tolerability, profile relative to the current standard of care. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Enhanced target specificity and preservation of humoral immune system </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preservation of the humoral immune system with CAAR T cell therapy represents a potentially meaningful benefit over existing CD19- or CD20-targeting methods for B cell ablation, as patients would be less susceptible to infection they may encounter after non-specific B cell elimination and would not require chronic in-hospital treatment with intravenous immunoglobulin, or IVIG, or other prophylactic therapies. Additionally, because self-reactive B cells make up only 0.01% to 1% of the normal B cell population, we believe the risk of on-target toxicity may be reduced compared to systemically immunosuppressive medications that non-specifically weaken the immune system. Continued use of these drugs poses significant risks, such as the potential for fatal infections due to the non-specific tempering of the immune system related to the complete depletion of CD20+ or CD19+ B cells. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Potential for complete, long-lasting elimination of pathogenic B cells </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current standard of care for B cell-mediated autoimmune disease displays limited and transient therapeutic benefit while also weakening the humoral immune system. We believe our CAAR T cells have the potential to eliminate the reactive, antibody-producing B cells that are ultimately responsible for disease, while sparing normal B cells. The curative potential of CAAR T cells would be consistent with clinical findings from use of CAR T products in B cell cancers and would be a significant improvement relative to the current standard of care for certain B cell-mediated autoimmune diseases. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While CAR T has demonstrated significant clinical success in B cell cancers, cancer cells employ a variety of mechanisms to evade detection by targeting immune cells, and antigen escape poses a significant risk of failure for CAR T cell treatment in oncology. Antigen escape in CAR T treatment occurs when the antigen that the CAR T cell targets is lost from the malignant cell. Clinically, this results in response rates that decline from an initial complete response level of about 80% to approximately 50% over a period of years. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe this risk of antigen escape is reduced in our setting as mechanisms to evade CAAR T therapy would involve B cell receptor down-regulation or mutation such that antigen specificity is lost. We believe that the implication of this is that the mutated B cell would no longer produce autoantibodies that recognize the antigen and therefore should no longer be pathogenic. We also believe that a single infusion of CAAR T cells has the potential for curative effects due to either complete ablation of pathogenic cells or production of memory CAAR T cells. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our CABA Platform </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our team has developed our CABA platform to inform product candidate development from indication selection through preclinical studies. Using our CABA platform, our team has identified our highest priority target indications following a rigorous analysis of B cell-mediated autoimmune diseases. A deep understanding of the antigenic epitopes targeted in these diseases is required to design and construct a successful CAAR. Our scientific founders have studied B cell repertoires for many years in the context of PV. Their expertise is essential to provide insights and guidance regarding our portfolio of products. We leverage the experience and insight gained from the development of each product candidate to improve the efficiency of our CABA platform in evaluating additional potential product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gaz3apgusshz000004.jpg" title="" alt="" style="width:624px;height:147px;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Scientific, Clinical and Commercial Assessment </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through broad literature review and consultation with internal and external experts, we have identified and continue to monitor the universe of diseases where pathogenic B cells are implicated in disease pathophysiology. From this set of possible indications, our team then evaluates each disease based on numerous criteria, which include, but are not limited to: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Biologic Opportunity for Cure </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the presence of the antibody is well established in patients with the clinical manifestations of the disease; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the identified antibody has been shown to be necessary and sufficient in causing clinical disease; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">there is a correlation between antibody titer and disease activity; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">B cell-depleting therapies are shown or believed to be effective in treating the disease; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the antibody repertoire has been or can be characterized for the disease; </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Identifiable and Underserved Patient Populations </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a routine and established antibody test exists or can be developed for diagnosis and biomarker assessment; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the clinical course and severity of the disease warrant a cellular therapy despite current standard of care; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">products in development do not have the potential to materially improve outcomes versus the current standard of care; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Evaluation of Preclinical and Clinical Development Pathway </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">preclinical </font><font style="font-style:italic;font-size:10pt;color:#000000;">in vitro</font><font style="font-size:10pt;color:#000000;"> and </font><font style="font-style:italic;font-size:10pt;color:#000000;">in vivo</font><font style="font-size:10pt;color:#000000;"> models exist or can be developed; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">potential clinical trial designs and endpoints appear reasonable and achievable. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to assessing the underlying biologic and clinical rationale for each potential target, we also assess commercial feasibility of CAAR T therapy in various B cell-mediated indications. As part of this assessment, we evaluate the direct lifetime drug and overall healthcare costs due to the burden from the disease, including the costs of managing potential adverse effects from existing standard of care compared to the potential CAAR T therapy. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We perform this rigorous and detailed conceptual analysis to enable us to be thorough and thoughtful before committing significant resources to a program. We believe this analysis allows us to prioritize and advance potential product candidates through the CABA platform with a higher degree of confidence and a higher probability of success. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Epitope Mapping </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Epitope mapping involves identifying specific sites on the antigen that are responsible for binding to the antibody of interest. This step is required in order to facilitate an understanding of CAAR design and feasibility. An understanding of the locations of the key immunogenic epitopes on the antigen heavily informs the potential feasibility of a CAAR. With an understanding of these epitopes, we then leverage our cell therapy expertise to design the CAAR construct. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">CAAR Construct / Design </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our scientists and collaborators design and create multiple CAAR constructs following completion of epitope mapping, which are tested against the antibody or antibodies of interest. The goal in CAAR design is to maximize the inclusion of known immunogenic epitopes on the antigen while also optimizing the size of the construct to improve the ability of the CAAR to bind to the antibody. Determining the location of antigen expression and if there are other antigens that may unintentionally cross-react with the CAAR will also inform CAAR design and feasibility. The size of the antigen will also determine whether a CAAR can be designed based on the size constraints of the delivery system. Once we have designed and developed optimal CAAR constructs, we test them in a variety of <font style="font-style:italic;">in vitro</font> and <font style="font-style:italic;">in vivo</font> studies. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Vitro <font style="font-style:italic;">and</font> In Vivo <font style="font-style:italic;">Testing</font> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">In vitro<font style="font-style:normal;"> preclinical testing is focused on establishing the specificity and activity of the potential CAAR T cell product candidate against B cells expressing known pathogenic target antibodies. Specificity is evaluated against non-target membrane proteins that may be expressed on other cells, with specific focus against any proteins that are known to bind to the antigen presented on the CAAR. CAAR T function is tested in the presence and absence of soluble, or free, antibodies isolated from patients, since these antibodies may enhance or inhibit CAAR T cell function. Where relevant animal models exist, the CAAR T cell product candidate is tested in one or more models to address specific questions around safety and the ability of the potential product candidate to reduce disease activity </font>in vivo<font style="font-style:normal;">. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pipeline </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing a portfolio of CAAR T cell product candidates for the treatment of B cell-mediated autoimmune diseases. Our lead product candidate, DSG3-CAART, targets B cells that express pathogenic autoantibodies against the DSG3 protein, which cause mPV. The publication of the first <font style="font-style:italic;">in&#160;vivo</font> evaluation of activity and toxicity of the candidate in an animal model was followed by additional preclinical studies to support our IND submission, which was cleared by the FDA in September 2019 The FDA granted our lead product candidate, DSG3-CAART, designed to treat patients with mPV, orphan drug designation for the treatment of PV in January 2020 and fast track designation for improving healing of mucosal blisters in patients with mPV in May 2020. We initiated our DesCAARTes&#8482;&nbsp;&nbsp;trial in June 2020 and announced the dosing of the first patient in December 2020. Our next PV-directed product candidate, DSG3/1-CAART, targets B&#160;cells that give rise to pathogenic autoantibodies against either the DSG3 or DSG1 protein, which cause mcPV, and could address a broader PV population.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">second </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product candidate, MuSK-CAART, targets B cells that give rise to pathogenic autoantibodies against the MuSK receptor in patients with MG. An additional product candidate, FVIII-CAART, targets B cells that produce alloantibodies against exogenous FVIII in Hemophilia&#160;A patients who consequently require repeated and increased exogenous FVIII administration. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, we expanded our </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payne SRA</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to include CAAR design and optimization efforts in three additional B cell-mediated autoimmune diseases.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exploring additional CAAR T cell product candidates that will focus on patients with B cell-mediated autoimmune diseases with well-defined antibody targets.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Product Candidates </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">DSG3-CAART for Mucosal PV </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidate, DSG3-CAART, is a CAAR T cell therapy expressing DSG3 antigen epitopes as the extracellular domain of a chimeric immunoreceptor, and is designed to enable specific cytotoxicity toward B cells with DSG3 autoantibody targeting abilities. We believe this strategy has the potential to enable direct elimination of DSG3 autoantibody memory B&#160;cells and indirect elimination of DSG3-specific short-lived plasma cells that produce the pathogenic autoantibodies. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Scientific, Clinical and Commercial Assessment </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PV is a potentially fatal, chronic autoimmune disease characterized by acantholysis, which is the loss of adhesion between cells of the skin or mucous membranes. Desmosomes are a collection of proteins that provide the structure for epithelial cells to connect with each other. PV results when specific pathogenic autoantibodies disrupt desmosomes by targeting DSG3 and/or DSG1, which are proteins that are part of the desmosomes. These autoantibodies cause the upper layer of the epidermis to split away from its base resulting in characteristic erosions and blisters. Widespread damage to the skin and mucous membranes increases susceptibility to life-threatening systemic infections. PV has two major subtypes: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">mPV&#8212;Characterized by DSG3 autoantibodies only, affecting only mucosal surfaces&#8212;accounts for approximately 25% of PV </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">mcPV&#8212;Characterized by DSG3 autoantibodies and DSG1 autoantibodies, affecting both mucosal and cutaneous surfaces&#8212;accounts for approximately 75% of PV </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The presence of DSG-specific antibodies is 98% to 100% sensitive and specific in identifying patients with PV, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these antibodies have been deemed both necessary and sufficient to cause the disease. Thus, in the absence of DSG autoantibodies, PV generally does not occur. In mPV, patients will typically develop painful skin blisters on their mucosal membrane surface, including mouth, nose, throat, genitals, and other orifices, often leading to an inability to eat, drink and function normally. The pathogenic DSG3 autoantibody is made by a specific small number of aberrant B cells, which express the DSG3 autoantibody on their surface. An overview of mPV and mcPV is provided in the figure below. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><img src="gaz3apgusshz000005.jpg" title="" alt="" style="width:624px;height:320px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Visual evidence of clinical manifestations of PV. (Left panel) Inside of cheek of a patient with mPV, showing sloughing mucosa and blistering. (Right panel) Back of a patient showing cutaneous skin blistering and sloughing in a patient with mcPV. Image credit: D@nderm. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Like most autoimmune diseases, the current standard of care for PV relies on general immune suppression, which is often transiently effective but can lead to severe infection, potentially resulting in hospitalization and death. First-line therapy for PV typically consists of corticosteroids in moderate to high doses in combination with the anti-CD20 monoclonal antibody rituximab where clinically appropriate. Second-line therapy focuses on the several systemically immunosuppressive medications such as mycophenolate, azathioprine and methotrexate. Additional options used in the acute setting with severe disease presentation include plasmapheresis, or infusions of intravenous immunoglobulin. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B cell depletion with rituximab was approved by the FDA for the treatment of PV in 2018 and is playing an increasing role as part of the standard of care because it has proven to be one of the more effective therapies for PV. However, data suggest that a significant number of patients treated with rituximab will relapse with or without chronic therapy. Despite its recent approval for use as an adjuvant therapy with corticosteroids in PV, rituximab has several limitations in terms of efficacy, safety and convenience. Rituximab treatment frequently results in relapse, which is reduced but still occurs despite chronic treatment every six months in PV. It does not specifically target the pathogenic B cells, but rather it depletes all CD20-expressing B cells, which leads to an ongoing risk of severe infection and death. As such, there remains not only an unmet medical need in PV, but also a need for safer therapies that can provide a reliable, durable and complete remission off of all other medications. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are several emerging therapies also being developed for the treatment of PV, which are being evaluated in late-stage clinical trials. These therapies provide important alternative therapeutic options for patients; however, we believe based on early published data that these therapies are unlikely to be curative and do not specifically ablate autoantibody producing B cells. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Epitope Mapping </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DSG3 consists of five extracellular cadherin, or EC, domains as shown schematically in the figure below. Since T cell activation depends on the intermembrane distance of the immunologic synapse, we tested different combinations of ECs for expression in primary human T cells using DSG3 fragments as the extracellular domain as shown in the figure below. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gaz3apgusshz000006.jpg" title="" alt="" style="width:577px;height:228px;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Image showing the naturally occurring DSG3 protein and the five EC domains. (B)&#160;The CAAR constructs that were evaluated in preclinical studies, containing the whole or subsets of the DSG3 protein. The transmembrane and intracellular signaling domains are identical to those in the CART19 studies published by Penn. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">CAAR Construct / Design </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The DSG3 EC1-5 CAAR was minimally functional, likely due to the extracellular domain being too large to enable CAAR function or aggregation of the CAAR on the T cell surface. The CAAR designs with either DSG3 EC1-3 or DSG3 EC1-4 showed interferon-gamma production after exposure to the target cells, demonstrating specific cytotoxic activity across targets. In addition, no cytokine production was detected after exposure to cells that did not express surface immunoglobulins or other non-target cells. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The DSG3 EC1-3 was not effective against one target cell known to bind to the DSG3 EC3-4 domain. Together, this data suggests that the DSG3 EC1-4 CAAR is the optimal construct to balance activity while retaining the ability to target locations of known pathogenic antibodies, as shown in the figures below. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gaz3apgusshz000007.jpg" title="" alt="" style="width:380px;height:692px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Cytotoxicity assay to assess killing activity of DSG3 CAART. Negative control is a CAR T with an antibody fragment attached to the extracellular domain. * indicates construct that was selected for further development. E:T ratio = effector to target ratio. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Vitro </font><font style="font-style:italic;">Studies</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A variety of <font style="font-style:italic;">in vitro</font> studies were conducted to evaluate DSG3-CAART from a preclinical activity and toxicity perspective. These studies included an evaluation of DSG3-CAART against proteins that are known to bind the DSG3 antigen, a screen of DSG3-CAART against an array of other membrane proteins and a set of studies designed to evaluate the potential effects of soluble DSG3 antibodies against DSG3-CAART. The results of these studies are summarized below. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:10.47%;text-indent:5.24%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of DSG3-CAART reactivity against known DSG3 binding proteins. <font style="font-weight:normal;">The DSG3 antigen presented on the extracellular domain of DSG3-CAART may naturally bind proteins in the body. These proteins may bind to and activate DSG3-CAART, potentially causing toxicity. The native binding proteins for DSG3 are the desmocollin proteins, which are important for cell adhesion in the skin and mucosa. We performed a variety of studies to test whether DSG3-CAART recognizes and activates the desmocollin proteins. Epithelial cells isolated from various primary organ systems that express some level of desmocollin proteins were screened. Potential DSG3-CAART activity was evaluated through the detection of cytokines released against each cell type and cytotoxicity. The data demonstrated an absence of inflammatory T cell cytokines after being exposed to these cells, indicating an absence of T cell activation. No cytotoxicity was detected except at very high, non-pharmacologically feasible doses. Collectively, we believe there is sufficient evidence to suggest that the DSG3 protein in the context of a CAAR does not meaningfully interact with desmocollin proteins. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:10.47%;text-indent:5.24%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of DSG3-CAART off-target binding against membrane proteins.<font style="font-weight:normal;"> A membrane protein array was utilized to screen the DSG3-CAART extracellular domain against 5,300 membrane proteins, which encompass the approximate number of membrane proteins contained in the human genome. The confirmatory screen yielded no off-target signals, except for one weak signal against a protein that is known to bind to glycoproteins, and which was detected in both the test and control conditions. Further evaluation of this protein in cell-based assays indicated that DSG3-CAART does not recognize and activate against this protein. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:10.47%;text-indent:5.24%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of the effect of soluble antibodies on DSG3-CAART function.<font style="font-weight:normal;"> We expect that circulating antibodies may prompt an active immune response against treatment with CAAR T cell therapy. These antibodies can induce proliferation of DSG3 CAAR T cells but may also neutralize the cells. In our preclinical </font><font style="font-style:italic;font-weight:normal;">in vitro</font><font style="font-weight:normal;"> studies, we observed that while DSG3 antibodies may have a variable effect on CAAR function, there was no systematic effect to enhance or reduce CAAR function. These dynamics were evaluated in a series of </font><font style="font-style:italic;font-weight:normal;">in vitro</font><font style="font-weight:normal;"> studies as follows: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.71%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Soluble DSG3 antibodies were added to CAAR T cell cytotoxicity assays, at a range of concentrations likely to be encountered in patients, to assess the impact on CAAR function.</font><font style="font-size:10pt;color:#000000;"> In all cases when the CAAR T cells were tested in the presence of soluble DSG3 antibodies, they retained their killing function. In addition, the presence of antibodies did not demonstrate a systematic effect to enhance or reduce the CAAR T cells&#8217; cytotoxic ability. Therefore, we believe that removal of circulating soluble DSG3 antibodies from patients prior to infusions may not be necessary to enable potential benefit. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.71%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Monoclonal DSG3 antibodies with an enhancing effect were evaluated in combination with PV patient serum to assess their impact on DSG3 CAAR T cell division and stimulation of cytokine production.</font><font style="font-size:10pt;color:#000000;"> Monoclonal DSG3 antibodies were capable of inducing DSG3 CAAR T cell division and stimulated production of moderate levels of cytokine production, as measured by interferon gamma. Therefore, we believe the presence of DSG3 autoantibodies in patients may contribute to the DSG3 CAAR T cell population expansion post-infusion. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.71%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Antibodies purified from PV patients were added to DSG3 CAAR T cells at a range of concentrations known to commonly occur in patients in order to evaluate the extent to which</font><font style="font-size:10pt;color:#000000;"> </font><font style="font-style:italic;font-size:10pt;color:#000000;">patient serum may activate CAAR T cells.</font><font style="font-size:10pt;color:#000000;"> These antibodies induced a dose dependent increase in interferon gamma. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.71%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Off-target toxicity may also be seen due to antibody-mediated bridging of DSG3 CAAR T cell cytotoxicity against hematopoietic cells that express receptors designed to bind to antibodies, known as Fc receptors. </font><font style="font-size:10pt;color:#000000;">To evaluate this, we loaded DSG3 antibodies onto cells expressing antibody-binding receptors, and evaluated the ability of DSG3 CAAR T cells to bind and activate against these targets </font><font style="font-style:italic;font-size:10pt;color:#000000;">in vitro.</font><font style="font-size:10pt;color:#000000;"> No evidence of cytotoxicity was observed, suggesting the potentially low risk of off-target killing mediated by this mechanism. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Vivo<font style="font-style:italic;"> Studies</font> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To evaluate DSG3-CAART <font style="font-style:italic;">in vivo</font>, four murine models were used. These models were designed to directly compare the potency of DSG3-CAART in comparison with CART19 cells; evaluate the potential for on-target skin toxicity; and measure the activity of DSG3-CAART in the presence of polyclonal soluble DSG3 antibodies. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Evaluation of potency of DSG3-CAART in a human B cell tumor line compared to CART19 cells.</font><font style="font-size:10pt;color:#000000;"> This B cell model contained genetically-modified B cells to express DSG3 antibodies on the cell surface in addition to luciferase, a bioluminescence marker, and allowed evaluation of DSG3-CAART&#8217;s ability to engage and kill B cells that express the pathogenic antibody. CART19 cells were used as a positive control in this model as the B cells express CD19 on their cell surface. In this model, DSG3-CAART was found to result in a similar reduction of B&#160;cells compared to the CART19 cells. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Evaluation of on-target skin toxicity mediated by DSG3-CAART.</font><font style="font-size:10pt;color:#000000;"> A human skin-xenografted model was used to evaluate the potential skin toxicity of DSG3-CAART by evaluating if the extracellular domain would react with desmocollin proteins, which are the known target for DSG3. These results were compared directly to a positive control CAR&#160;T expressing a DSG3 specific antibody as an extracellular domain. In this model, we observed the absence of skin toxicity mediated by the DSG3-CAART cells compared to the positive control, which did demonstrate skin toxicity. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Evaluation of DSG3-CAART in the presence of soluble antibodies.</font><font style="font-size:10pt;color:#000000;"> We also tested a model where mice have circulating DSG3 antibodies to mimic the situation in PV patients. In this model, the DSG3 antibodies have well-defined and different epitopes with varying affinities, which may reflect the potential breadth of B cell targets that could be encountered in PV patients. The mice were then treated with DSG3-CAART, which was compared to non-CAAR expressing T&#160;cells, or negative control CAR T cells. In this model, we observed amelioration of disease (see figure&#160;A below), reduction of DSG3 antibody titers (see figure&#160;B below), as well as control of the pathogenic B&#160;cells (see figure&#160;C below), by DSG3-CAART. In this model, DSG3-CAART also demonstrated dose-related activity, particularly in regard to reduction of serum autoantibodies, epithelial-bound autoantibodies (not shown in Figures) and DSG3-CAART engraftment, suggesting that higher DSG3-CAART doses may promote engraftment (see Figures D and E). We believe these results show the functional activity of DSG3-CAART in the presence of soluble antibody. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gaz3apgusshz000008.jpg" title="" alt="" style="width:234px;height:288px;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Histology showing DSG3 CAAR maintaining normal epithelial cell structure in treated animals. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gaz3apgusshz000009.jpg" title="" alt="" style="width:268px;height:274px;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">OD450 is a proxy measure for anti-serum DSG3antibodies in the blood. * indicates statistically significant reduction in DSG3 serum antibody level in DSG3-CAART treated mice. P value is &lt; 0.05. *** indicates statistically significant increase in DSG3 serum antibody level in the negative control CAR treated group. P value is &lt; 0.001. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gaz3apgusshz000010.jpg" title="" alt="" style="width:502px;height:252px;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Total flux is a quantitative measure of cell bioluminescence, which approximates cell activity in this assay. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:51.15%;"></td>
<td style="width:51.15%;"></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">D</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><img src="gaz3apgusshz000011.jpg" title="" alt="" style="width:180px;height:184px;"></p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><img src="gaz3apgusshz000012.jpg" title="" alt="" style="width:180px;height:86px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">OD450 is a proxy measure for the level serum anti-DSG3 antibodies in the blood. Serum anti-DSG3 ELISA was performed on day 10 for all mice with remaining serum samples available, indicating that mice treated with the 3x10<sup style="font-size:85%;line-height:120%;vertical-align:top">7</sup> and 1x10<sup style="font-size:85%;line-height:120%;vertical-align:top">7</sup> DSG3-CAART dose effectively reduced serum anti-DSG3 IgG production compared to mice treated with NTD T-cells or the 3x10<sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup> DSG3-CAART dose.** indicates statistically significant reduction in DSG3 serum antibody level in DSG3-CAART treated mice. P value is &lt; 0.01. * indicates statistically significant increase in DSG3 serum antibody level in the negative control CAR treated group. P value is &lt; 0.05. ns indicates a non-significant difference. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:51.15%;"></td>
<td style="width:51.15%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><img src="gaz3apgusshz000013.jpg" title="" alt="" style="width:198px;height:147px;"></p></td>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><img src="gaz3apgusshz000014.jpg" title="" alt="" style="width:182px;height:147px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Quantification by flow cytometry of CD3-positive T-cells in peripheral blood on day 10 and 17 is shown.&nbsp;&nbsp;The data support dose-related DSG3-CAART engraftment based on increased CD3+ cells with increased DSG3-CAART dose.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Evaluation of DSG3-CAART in an active immune model. </font><font style="font-size:10pt;color:#000000;">An exploratory active immune mouse model for PV was developed to better represent the human phenotype in autoimmune disease. This model involved generating anti-DSG3 B cells in a mouse without DSG3 by repeated immunization with human DSG3. Splenocytes containing anti-DSG3 B cells from the immunized mouse were transferred into an immunodeficient mouse to generate the PV phenotype. These mice produced DSG3 antibodies against multiple extracellular domains of the DSG3 antigen, including EC5, at physiologic levels comparable to those observed in PV patients. Treatment with DSG3 EC1-4 CAAR T cells, in the absence of preconditioning, effectively lowered serum DSG3 antibody levels by ELISA, reduced antibodies against relevant DSG3 domains by epitope mapping and reduced blistering by histology. These mice retained autoantibodies targeting the DSG3 EC5 region, though the mice did not show clinical manifestations of PV. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">See figure F below for a schematic representation of the experiment.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:15.71%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:102.31%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:36pt;;text-indent:0pt;;font-size:24pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:36pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gaz3apgusshz000015.jpg" title="" alt="" style="width:578px;height:93px;"></p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:15.71%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Schematic representation of the PV active immune model. A DSG3 knockout mouse is immunized with DSG3 EC1-5. The knockout mouse develops antibodies against DSG3 across all EC domains. The splenocytes from the knockout mouse are transferred to an immunodeficient mouse where the DSG3 antibodies cause a clinical phenotype consistent with PV. Those mice are then treated with DSG3-CAART (EC1-4 domains only).</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical Development Plan </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA cleared our IND for a Phase 1 trial of DSG3-CAART in September 2019. The FDA granted DSG3-CAART orphan drug designation for the treatment of PV in January 2020 and fast track designation for improving healing of mucosal blisters in patients with mPV in May 2020. We announced that the first patient was dosed in the DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial in December 2020. The DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial is an open-label trial to assess the safety and tolerability of various dosing regimens of DSG3-CAART in the treatment of subjects with active mPV. DSG3-CAART will be administered by intravenous infusion, using a fractionated-dose infusion scheme of escalating numbers of DSG3-CAART cells for the initial cohorts in the first phase. This dosing scheme is designed to reduce the potential risks associated with acute infusion-related toxicities while preserving potential benefit for subjects by </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">allowing a total infused dose that we believe is large enough to be potentially therapeutic based on prior CAR T trials. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that the Phase 1 trial will have three parts: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Part A: Fractionated dose escalation </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Part B: Fractionation reduction at the selected dose </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Part C: Expansion phase at the selected dose and administration scheme </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Part A, the split dose uses dose fractionation to accommodate a low number of cells in the first infusion while still advancing the dose within the cohort up towards and spanning the range of cell doses that have been therapeutic in past gene-engineered T cell therapy trials. In Part B, the dose selected from Part A will be delivered in a decreasing number of dose fractionations to determine the dose fractionation strategy. In Part C, subjects will be enrolled at the dose and fractionation, as determined in Part A and B, to generate additional safety and outcome data to support the rationale for and design of future clinical trials. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients are eligible to be enrolled if they have a confirmed diagnosis of mPV based on biopsy for histology and positive DSG3 ELISA; active disease at screening; elevated DSG3 by ELISA at screening; and previously been inadequately managed by, or refractory to, or relapsed after, or with contraindications to or intolerance of at least one prior systemic therapy. The primary objective of the trial is to evaluate the safety of DSG3-CAART cells, and secondary objectives include evaluating the initial signs of target engagement. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe the risk of cytokine release syndrome, or CRS, a potentially life-threatening toxicity that has been observed&#160;after treatment with some types of immunotherapy, may be reduced with our CAAR T cells, due to its correlation with target cell burdens. In the context of treating cancer, the target cell population consists of all B cells (healthy and cancerous), whereas our CAAR T cells only target the small subset of disease-causing reactive B cell population. While the possibility of cytokine release in a clinical trial resulting from strongly activating soluble antibody cannot be ruled out, to date we have not observed any evidence of it in preclinical studies. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary endpoint of the study is the incidence of adverse events within three months of DSG3-CAART infusion, including dose limiting toxicity defined as occurring within 28 days of infusion. The FDA has requested, and we have agreed, that we will share data from cohort A to inform a discussion on the optimal design of cohort C. According to FDA guidance, the submission of cohort A data is not gating to planned enrollment in cohort B and the FDA plans to provide feedback, if any, in a timely manner. In addition, we plan to report on acute tolerability data on no less than a cohort basis, which is defined to include adverse events within eight days following DSG3-CAART infusion. We believe the eight-day timeframe appropriately covers the period of time when one would expect the onset of CRS in most subjects. We also currently intend to communicate serious adverse events once we have sufficient understanding of the events, if they materially change timelines or the trial design. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also expect to provide updates from time-to-time related to target engagement in subjects receiving DSG3-CAART typically only once data is available for a full cohort. Although possible but not expected in the lower dosing cohorts, we believe target engagement could be observed if DSG3 autoantibody titer falls within six months after DSG3-CAART infusion in addition to other parameters of engraftment and target engagement that will be monitored regularly. Clinical responses, including improvement or resolution of mucosal lesions and absence of new lesions will also be evaluated. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">DSG3/1-CAART for mcPV </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Scientific and Commercial Assessment </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our next PV product candidate, DSG3/1-CAART, is being designed to target DSG3 and/or DSG1 autoantibodies on pathogenic B cells that cause mcPV. mcPV is the most severe and most common subtype of PV and affects approximately 75% of PV patients. While mPV is caused by DSG3 autoantibodies, mcPV involves autoantibodies to both DSG3 and DSG1, resulting in the additional involvement of skin erosion and blistering. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar to mPV, mcPV is typically treated with immune suppression, which has a high rate of relapse and potential for hospitalizations and fatal infections. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Epitope Mapping </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DSG1 consists of five EC domains, with all known pathogenic epitopes occurring in the DSG1 EC1-4 domains. Similar to development of DSG3-CAART, we tested different combinations of DSG1 ECs for expression in primary human T cells using DSG1 fragments as the DSG1 EC domains. Given prior development of DSG3 CAAR, we leveraged those findings in the design of our DSG1 CAAR. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">CAAR Construct / Design </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also tested multiple combinations of EC domains of DSG1 CAAR administered alone and in combination with the DSG3 EC1-4 CAAR to evaluate for cell-surface expression of the CAAR along with the potency and breadth of target cell killing. In this setting, the DSG1 EC1-4 CAAR showed robust and specific cytotoxicity towards all known pathogenic epitopes. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Vitro<font style="font-style:italic;"> Studies</font> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CAAR development for mcPV, based on the targeting of DSG3- and/or DSG1-specific B cells, has shown promising preclinical results. DSG1 CAAR T cells specifically killed DSG1-specific B cells <font style="font-style:italic;">in vitro</font>. In addition, we observed that with a 1:1 mixture of DSG3 and DSG1 CAAR T cells had killing capabilities without synergistic or antagonistic effect. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Vivo<font style="font-style:italic;"> Studies</font> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The activity and toxicity of DSG3 and DSG1-CAAR T cells was evaluated using human skin xenografts in comparison with anti-CART19 cells, which are known from human clinical trials not to cause direct skin toxicity. A 1:1 mixture of DSG3 and DSG1 CAAR T cells did not show off-target toxicity <font style="font-style:italic;">in vivo.</font> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Development Plan </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From a regulatory and clinical trial design perspective, we anticipate that many of the elements incorporated into the planned DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial will carry over to DSG3/1-CAART. We plan to evaluate the initial cohorts of patients from the planned DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial to evaluate for safety and evidence of target engagement prior to proceeding with an IND submission for DSG3/1-CAART. We believe that, because mcPV is the most prevalent subset of PV and the patients are generally followed by the same subspecialists, it will allow for a wider patient pool eligible for a clinical trial. We anticipate the DSG3/1-CAART clinical trial protocol will have a significant amount of overlap with the DSG3-CAART protocol, but it will be informed by clinical data from the early cohorts in the DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial. We further anticipate being able to use the same centers from the DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial to enroll patients for the DSG3/1-CAART clinical trials. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently evaluating advanced manufacturing technologies that would potentially allow us to administer DSG3/1-CAART as a single product rather than requiring separate administration. The size of the DSG3/1 product candidate will likely require us to incorporate additional technologies to accommodate the size of the final CAAR construct. An evaluation of potential technologies to achieve this objective is ongoing. Upon completing the evaluation of these manufacturing technologies, we expect to conduct additional <font style="font-style:italic;">in vitro</font> and <font style="font-style:italic;">in vivo</font> studies using the combined product. While a product that administers a DSG3 CAAR and DSG1 CAAR as two separate products may be feasible, we believe that there would be significant advantages to developing a combined product from a regulatory and commercial perspective.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">MuSK-CAART for MuSK Myasthenia Gravis </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Scientific, Clinical and Commercial Assessment </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MG is an autoimmune disease induced by autoantibodies targeting the neuromuscular junction, or NMJ, which can lead to life-threatening muscle weakness. Generalized MG, or gMG, is characterized by profound muscle weakness throughout the body, resulting in motor impairment, disabling fatigue, shortness of breath due to respiratory muscle weakness and episodes of respiratory failure. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gMG affects approximately 50,000 to 80,000 patients in the United States. The majority of patients who develop gMG have autoantibodies against some part of the NMJ that are known to be pathogenic. 80% to 90% of patients with gMG have autoantibodies against the acetylcholine receptor, or AchR, detectable in their serum. Approximately 6% to 7.5% of patients with gMG have autoantibodies against MuSK, which is a different target on the surface of the muscle membrane. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients diagnosed with MuSK MG have a different recommended treatment course compared to patients with AchR MG. Importantly, many patients with MuSK MG respond poorly to cholinesterase inhibitors, which are often the first line of therapy in AchR MG. In that setting, patients with MuSK MG are typically started on corticosteroids in addition to one or more steroid-sparing immunosuppressive agents. Corticosteroids are tapered to the extent possible to prevent disease relapse, though many remain dependent on corticosteroid despite concomitant treatment with immunosuppressive medications. In the acute setting, plasmapheresis or intravenous immunoglobulin may be used to address severe disease. Rituximab is often considered as a second-line therapeutic option in patients with an inadequate response to initial immunosuppressive medications. Importantly, complement is not thought to be meaningfully implicated in the pathophysiology of MuSK MG, and complement inhibitors are not indicated for treatment of disease. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Epitope Mapping </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The MuSK protein has a similar structure and size as compared to DSG3. MuSK contains four extracellular domains, as shown below. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gaz3apgusshz000016.jpg" title="" alt="" style="width:146px;height:342px;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Figure illustrating the domains of the wild-type MuSK protein. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Studies conducted in patients with MuSK MG have revealed that the autoantibodies may be against epitopes located in each of the extracellular domains for MuSK. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">CAAR Construct and Design </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With an understanding that pathogenic autoantibody epitopes may target any domain of MuSK, multiple MuSK CAAR candidates have been engineered that incorporate all extracellular domains. Each CAAR construct is being or will be tested in preliminary <font style="font-style:italic;">in vitro</font> and <font style="font-style:italic;">in vivo</font> experiments. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Vitro<font style="font-style:italic;"> Studies, </font>In Vivo<font style="font-style:italic;"> Studies and Development Plan </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Data from our initial in vitro and&#160;<font style="font-style:italic;">in vivo</font>&#160;studies of MuSK-CAART was presented at the American Academy of Neurology&#8217;s Science Highlights Virtual Platform in May 2020. The efficacy and safety of MuSK CAAR T cells were investigated using in vitro cytotoxicity assays, in vitro screens for&#160;off-target&#160;toxicity and a mouse model to evaluate the efficacy of human MuSK CAAR T cells against MuSK antibody expressing B cells&#160;<font style="font-style:italic;">in vivo</font>. In preclinical studies, MuSK CAAR T cells containing the native MuSK extracellular domain demonstrated in vitro cytotoxicity towards a panel of B cells expressing anti-MuSK antibodies specific for different extracellular regions of the MuSK protein, but no observed cytotoxicity when anti-MuSK antibodies are not expressed (figure below). <font style="color:#000000;">Additionally, MuSK CAAR T cells did not demonstrate cytotoxicity toward cells expressing LRP4, which is a different protein in the neuromuscular junction that can bind with naturally occurring MuSK in certain configurations.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gaz3apgusshz000017.jpg" title="" alt="" style="width:624px;height:332px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Figure illustrating that MuSK-CAART, which contains the native MuSK extracellular domain, demonstrated selective and specific in vitro cytotoxicity towards a B cell line expressing anti-MuSK antibodies targeting different MuSK epitopes across multiple domains of the native MuSK protein. The specific lysis increases directly with increasing effector to target ratios for MuSK-CAART.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> As illustrated in the figure below, in an&#160;<font style="font-style:italic;">in vivo</font>&#160;mouse model, MuSK CAAR T cells, but not control CAAR T cells, showed biological activity by blocking the growth of B cell lines expressing an anti-MuSK antibody.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><img src="gaz3apgusshz000018.jpg" title="" alt="" style="width:624px;height:292px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Figure illustrating MuSK CAAR T cells are able to recognize and suppress anti-MuSK target cells in a murine model. The target cells express both CD19 and anti-MuSK B cell receptors, and CART19 is used as a positive control in this experimental system.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based in part on these results, IND-enabling studies were initiated for the MuSK-CAART product candidate. An IND submission is anticipated in the second half of 2021 for MuSK-CAART.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">FVIII-CAART for Hemophilia A with Factor VIII Alloantibodies </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our CABA platform is primarily directed towards the treatment of B cell-mediated autoimmune diseases, we believe the approach may be applicable in other instances where B cell antibody production is implicated. Specifically, we have identified an opportunity to apply the CABA platform to develop potential CAAR adjunctive therapies in cases where the immune system has or produces antibodies against potential therapies, which is known as an alloimmune response. These alloantibodies can prevent a particular therapy from being delivered effectively because the therapy is degraded by the immune response due to alloantibody binding. We believe our approach has the potential to address the alloantibody response by specifically ablating the B cells responsible for producing the alloantibodies through a similar mechanism seen in autoimmune disease. With the alloantibody producing cells ablated, the treatment could then be provided. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Scientific, Clinical and Commercial Assessment </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hemophilia A is an X-linked bleeding disorder caused by mutations in the FVIII gene resulting in a deficiency of functional FVIII, a critical factor in blood coagulation. It affects about 1:5,000 male births. Severe Hemophilia A, where FVIII levels are less than 1% of normal, accounts for about 60% of all cases and is characterized by frequent spontaneous bleeds. Currently, Hemophilia A is treated with FVIII replacement via intravenous administration. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The main complication of FVIII replacement therapy is that 20% to 30% of patients with severe disease develop neutralizing alloantibodies against the FVIII protein. These alloantibodies decrease the levels of FVIII and at high titers, render attempts to replace or stimulate the production of FVIII ineffective. The risk of alloantibody development for patients with severe Hemophilia A is highest during their initial FVIII exposures. The standard treatment to reverse alloantibody formation consists of repeated high-dose infusions of FVIII, which has limited efficacy, a high cost and is difficult to titrate to an appropriate therapeutic level for the patient. We believe FVIII-</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CAART could be effective in addressing patients with Hemophilia A who have developed FVIII antibodies that require repeated, high-dose administrations of FVIII. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Epitope Mapping </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following image depicts FVIII, which is a large glycoprotein consisting of six domains that interact with each other to form the full complex. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gaz3apgusshz000019.jpg" title="" alt="" style="width:95px;height:253px;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Studies conducted in patients with Hemophilia A have revealed that acquired FVIII alloantibodies following exogenous FVIII administration are typically directed against A2, C1 and C2 domains of FVIII. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">CAAR Construct and Design </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preliminary FVIII CAAR and CAAR-like constructs have been engineered that target parts, but not all, of the FVIII domains. Dr.&#160;Milone, one of our scientific co-founders, has led the development of one such construct. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Development Plan </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internally, we are conducting additional<font style="font-style:italic;"> </font>studies to optimize our FVIII-CAART development. The focus of these studies will be to fully characterize any additional pathogenic epitopes and construct a FVIII-CAART that includes additional FVIII domains. Given the size of the FVIII protein, this will likely require us to incorporate additional technologies to reduce the size of the final CAAR construct. An evaluation of potential technologies to achieve this objective is ongoing. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Manufacturing Strategy </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to implement a three-stage plan that we believe will ultimately enable us to achieve manufacturing independence. Part of our strategy relies on engaging non-profit and commercial suppliers early and in a staged manner. We believe partnering with proven and reputable manufacturing partners will allow us to efficiently deploy financial and personnel resources. Stage 1 of this plan is in place and utilizes the deep expertise in cell and vector manufacturing from our partners at Children&#8217;s Hospital of Philadelphia, or CHOP, and Penn. This included early development work, support of the DSG3-CAART IND, and cell and vector product manufacturing for our DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial. We believe these facilities will allow us to move efficiently into clinical trials but are not sufficient to support a commercial license. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stage 2 of our plan is designed to engage partners who are qualified for manufacturing of vector at commercial grade and scale and cell therapy products. We are aware that changes in any manufacturing process or facility introduces regulatory and scientific risk to a development program, if the changes result in a product that is not comparable. We plan to mitigate these risks primarily in two ways: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;">By securing contract manufacturing organizations, or CMOs, as partners during Stage&#160;2 of our manufacturing strategy early on for both vector and cell manufacturing.</font> We plan to prioritize potential partners who are qualified to, and have an established track record of, the commercial production of vector and cell products. We believe this allows us to make one change in our supply partners during an early period of clinical development to facilitate <font style="font-style:italic;">in vitro</font> comparability testing and clinical validation, prior to controlled clinical studies.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;">By licensing the cell manufacturing process used for our planned Phase 1 DSG3-CAART first-in-human study from Penn.</font> This is allowing us the time to understand the process used in order to reduce the chance of changes that may impact comparability. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to Stage 2, and contingent on sufficient clinical evidence from our planned DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial, we are further planning to pursue Stage 3 in manufacturing supply. During Stage 3, we plan to build, qualify and run our own manufacturing facility. We believe this additional stage will enable full control of continuous improvement, product development and commercial supply for products arising from our CABA platform. Our Chief Executive Officer and Executive Vice President, Science and Technology have both, in prior roles, built and led organizations that have constructed and commissioned cell therapy facilities. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Vector Manufacturing </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lentiviral vector that we plan to use in the initial subjects in our DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial was manufactured at CHOP. We have also reserved multiple vector manufacturing slots at Penn and CHOP, which we may use in our DSG3-CAART or subsequent clinical trials. In parallel, we are engaging in development work with multiple CMOs with a plan to secure production slots for vector which may be used in our DSG3-CAART or subsequent clinical trials. We believe these efforts will provide us with sufficient clinical-grade vector to move forward with our anticipated clinical trials. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cell Manufacturing </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into a collaboration with the Clinical Cell and Vaccine Production Facility, or CVPF, at Penn, to provide focused scientific, technical and regulatory support for CAAR T cell manufacture. CVPF is accredited by the Foundation for the Accreditation of Cellular Therapy and is capable of and experienced at supporting manufacture for early-phase clinical trials of novel cell therapy products in first-in-man clinical trials. We expect to rely upon CVPF to provide initial Phase 1 clinical trial drug supply for DSG3-CAART. Penn&#8217;s manufacturing process for DSG3-CAART is directly related to the process developed at Penn for early clinical trials of CART19, which subsequently became known commercially as Kymriah. The process was later transferred to Novartis Pharmaceuticals Corporation and further modified for the Kymriah program. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we scale our manufacturing of DSG3-CAART and our other product candidates to meet our expected needs for further clinical trials, we may or may not rely on Penn, but we also expect to rely on CMOs and other third parties for the manufacturing and processing of our clinical trial materials. Any CMO that we select will be subject to cGMP requirements. We believe the use of contract manufacturing for our pipeline programs will be cost-effective and allow us to rapidly prepare for clinical trials in accordance with our development plans. In preparation for this transition, we have engaged multiple third-party contractors to manufacture clinical grade viral vector used to deliver the applicable CAAR gene into the T cells. We have also initiated development work with certain contractors for cGMP and commercial vector production. We expect third-party manufacturers will be capable of providing and processing sufficient quantities of our product candidates to meet anticipated clinical trial demands and commercial need. In January 2021, we initiated a collaboration with WuXi to serve as our cell processing manufacturing partner for the anticipated MuSK-CAART Phase 1 clinical trial.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once we have sufficient clinical data from subjects in our DSG3-CAART study, we intend to begin the process of engineering and then establishing our own commercial scale GMP-compliant manufacturing facility. We believe this will allow us to enhance supply chain control, increase supply capacity and help ensure clinical and commercial demand for our pipeline programs is met in the event that DSG3-CAART receives marketing approval. Informed by our experience in building cell therapy facilities and creating supply chains, we plan to develop a robust supply chain with alternative sources to maintain continuous supply. In parallel with these activities, we are evaluating and executing proof-of-concept studies to test advanced manufacturing and automation technologies to continuously improve the manufacturing process and meet commercial and scalability targets. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commercialization </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our aim is to become a fully integrated cellular therapy company in order to improve the lives of patients with B cell-mediated autoimmune diseases. We have designed a strategic approach to move forward with our lead product candidate, DSG3-CAART, while at the same time having a number of product candidates in development. The product candidates from our CABA platform address clinical indications where there is a compelling opportunity to improve clinical outcomes in comparison with the current standard of care in an easily identified patient population. Our initial product candidates are focused on rare disease populations where we believe there is potential to commercialize independently. This is due to a concentration of treatment paradigms and limited but easily identified patient populations. Our plan is to focus commercialization and launch efforts initially in the United States, and eventually in the European Union and Asia-Pacific geographies. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competition </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong focus on intellectual property. We face competition from many different players, including large and specialty pharmaceutical and biotechnology companies, academic research organizations and governmental agencies. Any therapeutic candidates we successfully develop and commercialize will compete with the existing standard of care as well as any novel therapies that may gain regulatory approval in the future. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Existing treatment options for PV are limited. Rituximab, marketed by Roche Holding AG, is the first drug to have received approval for PV in the United States in over 60&#160;years. In Europe, the approved therapies for PV are corticosteroids, azathioprine and rituximab. Other standard of care treatments include various immunosuppressants, plasmapheresis, and intravenous immunoglobulin infusions given monthly or on another periodic chronic basis. Additionally, multiple biopharmaceutical companies have therapies in clinical development. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competition in the MuSK MG autoimmune space is currently dominated by the current standard of care, rituximab. A second approved approach to treating patients is IVIG, which is available through CSL Behring LLC, Grifols, S.A., and Mitsubishi Tanabe Pharma Corporation. Additionally, multiple biopharmaceutical companies have therapies in clinical development. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Multiple therapies are approved or in development for the treatment of Hemophilia A patients who develop alloantibodies against FVIII. Standard of care is typically immune tolerance induction, or ITI, therapy with higher doses of FVIII. Available treatments for those who do not respond to ITI include anti-inhibitor coagulation complexes, recombinant factor VIIa, and bispecific factor IXa- and factor X-directed antibodies. Companies who market products or are developing product candidates within these categories of medicine include Catalyst Pharmaceuticals, Inc., Novo Nordisk A/S, OPKO Health, Inc., Roche Holding AG and Takeda Pharmaceutical Company. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe we are the first and only company developing CAAR T drug candidates for the treatment of B cell-mediated autoimmune diseases. However, despite the significant differences in discovery, development and target populations between oncology and autoimmune targets, we recognize that companies with an investment and expertise in CAR T cell development for oncology indications could attempt to leverage their expertise into B cell-mediated autoimmune disease-affected populations. We are aware of biotechnology companies that are exploring other methods of engineering T cells for the treatment of autoimmune conditions. In addition, some biotechnology companies are engineering red blood cells to incorporate self-antigens with the goal of tolerizing the immune system to treat autoimmune and alloimmune conditions. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property and Barriers to Entry </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We strive to protect the proprietary technologies that we believe are important to our business, including pursuing and maintaining patent protection intended to cover our product candidates and their use, as well as other inventions that are important to our business. In addition to patent protection, we also rely on know-how, confidentiality agreements, invention assignment agreements and trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection, to develop and maintain our proprietary position. The confidentiality agreements are designed to protect our proprietary information and the invention assignment agreements are designed to grant us ownership of technologies that are developed for us by our employees, consultants or certain other third parties. We seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in our agreements and security measures, either may be breached, and we may not have adequate remedies. In addition, our trade secrets may otherwise become known or independently discovered by competitors. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part upon our ability to obtain and maintain patent and other proprietary protection for commercially important technologies, inventions and trade secrets related to our business, defend and enforce our intellectual property rights, particularly our patent rights, preserve the confidentiality of our trade secrets and operate without infringing valid and enforceable intellectual property rights of others. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions for biotechnology companies like us are generally uncertain and can involve complex legal, scientific and factual issues. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February&#160;1, 2021, our patent estate (all of which has been in-licensed) included one issued U.S. patent, seven&#160;pending U.S. patent applications, and 34&#160;pending foreign patent applications. See &#8220;&#8212;Our Material Agreements&#8212;Amended and Restated License Agreement with the Trustees of the University of Pennsylvania and the Children&#8217;s Hospital of Philadelphia.&#8221; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With regard to our DSG3-CAART and DSG3/1-CAART product candidates, we have one issued U.S. patent with claims directed to a genetically modified cell containing a chimeric autoantibody receptor containing an extracellular domain containing DSG3, DSG1 or fragments thereof, which is scheduled to expire in 2035, without taking a potential patent term extension into account. We also have four pending U.S. patent applications and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">counterpart patent applications pending in Canada, China and Europe, which if issued, would be expected to expire in 2035. This patent family is owned by Penn and exclusively licensed to us in the field of the license. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With regard to our MuSK-CAAR&#160;T cell product candidate, we have one pending U.S. patent application and counterpart patent applications pending in Australia, Canada, China, Europe, Israel, Japan, Korea, Mexico, New Zealand, and Russia, which if issued, would be expected to expire in 2039. This patent family is owned by Penn and exclusively licensed to us in the field of the license. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With regard to our FVIII-CAAR&#160;T cell product candidate, we have one pending U.S. patent application and counterpart patent applications pending in Australia, Canada, China, Europe, Japan, Hong Kong, Korea, Mexico, New Zealand, and Russia, which if issued, would be expected to expire in 2037. This patent family is co-owned by Penn and CHOP and is exclusively licensed to us in the field of the license. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20&#160;years from the earliest date of filing a non-provisional patent application. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the term of a patent covering an FDA-approved drug may be eligible for a patent term extension under the Hatch-Waxman Act as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years beyond the expiration of the patent, but cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval. Only one patent among those eligible for an extension may be extended, and a given patent may only be extended once. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. It is possible that issued U.S. patents covering each of our product candidates may be entitled to patent term extensions. If our product candidates receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved product candidates. We also intend to seek patent term extensions in any jurisdictions where they are available, however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to patent protection, we also rely on know-how and trade secret protection for our proprietary information that is not amenable to, or that we do not consider appropriate for, patent protection, to develop and maintain our proprietary position. However, trade secrets can be difficult to protect. Although we take steps to protect our proprietary information, including restricting access to our premises and our confidential information, as well as entering into agreements with our employees, consultants, advisors and potential collaborators, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our know-how, trade secrets, and other proprietary information. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we plan to rely on regulatory protection based on orphan drug exclusivities, data exclusivities, and market exclusivities. See &#8220;&#8212;Government Regulation&#8221; for additional information. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Material Agreements </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk34812055"></a>Amended and Restated License Agreement with the Trustees of the University of Pennsylvania and the Children&#8217;s Hospital of Philadelphia </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, we entered into an amended and restated license agreement, or the License Agreement, as further amended in May 2020, with Penn and CHOP, collectively the Institutions, pursuant to which we obtained (a)&#160;a non-exclusive, non-sublicensable, worldwide research license to make, have made and use products in two subfields of use, (b)&#160;effective as of October 2018, an exclusive, worldwide, royalty-bearing license, with the right to sublicense, under certain patent rights of the Institution to make, use, sell, offer for sale and import products in the same two subfields of use, and (c)&#160;effective as of October 2018, a non-exclusive, worldwide, royalty-bearing license, with limited rights to sublicense, under certain of Penn&#8217;s know-how, which know-how satisfies certain criteria and is listed on a mutually agreed-to schedule, to make, have made, use, sell, offer for sale, import and have imported products in the same two subfields of use. Our rights are subject to the rights of the U.S. government and certain </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights retained by the Institutions. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The License Agreement was amended in May 2020 to add certain intellectual property relating to one of the three undisclosed disease targets.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the License Agreement expires on the expiration or abandonment or other termination of the last valid claim in the intellectual property we license from Penn. We may terminate the License Agreement at any time for convenience upon 60 days written notice. In the event of an uncured, material breach, Penn may terminate the License Agreement upon 60 days written notice.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penn maintains control of all filing, prosecution and maintenance of the Institutions&#8217; patent rights licensed by us, and we are responsible for all ongoing patent costs during the term of the agreement. We also reimbursed Penn for its out-of-pocket expenses incurred prior to the effective date of the agreement with respect to the filing, prosecution and maintenance of the patent rights licensed by us.&#160;Under the terms of the License Agreement, we were also obligated to pay $2.0&#160;million annually for three years beginning August 2018 for funding to the laboratories of each of Drs. Milone and Payne. See &#8220;&#8212;Sponsored Research Agreements with the Trustees of the University of Pennsylvania.&#8221; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the License Agreement, we must use commercially reasonable efforts to develop and commercialize a product in each subfield.&#160;During the term of the License Agreement until the first commercial sale of the first product, we are obligated to pay Penn a non-refundable, non-creditable annual license maintenance fee of $10,000. We are required to pay certain milestone payments upon the achievement of specified clinical and commercial milestones. Milestone payments are reduced by a certain percentage for the second product that achieves a milestone, by an additional percentage for the third product that achieves a milestone, and so on, for each subsequent product that achieves a milestone. In the event that we are able to successfully develop and launch multiple products under the License Agreement, total milestone payments could be approximately $21.0&#160;million. Penn is also eligible to receive tiered royalties at percentage rates in the low single-digits, subject to an annual minimum royalty, on annual worldwide net sales of any products that are commercialized by us, our affiliates or our sublicensees that contain, use, embody, result from the use of or incorporate, or are covered by, the intellectual property licensed by us. To the extent we sublicense our license rights under the License Agreement, Penn would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits. We have also entered into a subscription and technology transfer agreement with Penn, pursuant to which we owed Penn an upfront subscription fee, which was paid in 2019, and a nominal non-refundable royalty on the net sales of products, a portion of which will be credited toward milestone payments and royalties under this License Agreement. Technology transfer activities would be at our cost and subject to agreement as to the technology to be transferred. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sponsored Research Agreements with Penn </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Dr.&#160;Michael Milone </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, we entered into a Sponsored Research Agreement with Penn for the laboratory of Dr.&#160;Milone, or the Milone SRA, pursuant to which we agreed to sponsor certain research related to the development of (i)&#160;T&#160;cell based immunotherapies for autoimmune and alloimmune antibodies of pathologic significance and (ii)&#160;a clinical grade microfluidic device designed for single step selection and activation of T cells from blood samples to be conducted in Dr.&#160;Milone&#8217;s laboratory at Penn. Under the Milone SRA, Penn granted us a perpetual, irrevocable, non-transferable, non-exclusive license to use all intellectual property resulting from the research sponsored by us for internal research purposes. In addition, Penn granted us an option to include, in exchange for a fee, any intellectual property resulting from the research sponsored by us that relates to CAAR T cell therapies for hemophilia and/or pemphigus within the scope of the License Agreement. Penn also granted us an option to negotiate a license to all other intellectual property resulting from the research sponsored by us. Unless earlier terminated, the Milone SRA will expire on April&#160;23, 2021. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Dr.&#160;Aimee Payne </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, we entered into a Sponsored Research Agreement with Penn for the laboratory of Dr.&#160;Payne, or the Payne SRA, pursuant to which we agreed to sponsor certain research related to the development of T cell based immunotherapies for autoimmune and alloimmune antibodies of pathologic significance to be conducted in Dr.&#160;Payne&#8217;s laboratory at Penn. In May 2020, the Payne SRA was amended to<font style="Background-color:#FFFFFF;color:#000000;"> include CAAR design and optimization efforts in three additional B cell-mediated autoimmune diseases. In August 2020, this agreement was further amended to extend the term of the original research plan. </font>Under the Payne SRA, Penn granted us a perpetual, irrevocable, non-transferable, non-exclusive license to use all intellectual property resulting from the research sponsored by us for internal research purposes. In addition, Penn granted us an option to include, in exchange for a fee, any intellectual property resulting from the research sponsored by us that relates to CAAR T cell therapies for </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hemophilia, MG and/or pemphigus within the scope of the License Agreement. Penn also granted us an option to negotiate a license to all other intellectual property resulting from the research sponsored by us. Unless earlier terminated, the Payne SRA will expire </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in February 2023.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have committed to funding a defined research plan for through February 2023 under both the Milone and Payne SRAs. We have estimated the total cost of the two SRAs to be $11.8&#160;million, which satisfies the $2.0&#160;million annual obligation under the License Agreement. As of December 31, 2020, $7.1 million of cost has been incurred pursuant to the Milone and Payne SRAs.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Master Translational Research Services Agreement with Penn </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk64447888"></a><a name="_Hlk64447888"></a>In October 2018, we entered into a Master Translational Research Services Agreement with Penn, or the Services Agreement, pursuant to which Penn agreed to perform certain services related to the research and development of the technology licensed to us under the License Agreement, as well as certain clinical, regulatory and manufacturing services. The Services Agreement will expire on the later of (i) October 19, 2021 or (ii) completion of the services for which we have engaged Penn under the Services Agreement. Either party may terminate this agreement with or without cause upon a certain number of days&#8217; prior written notice. The services encompassed by the Services Agreement are performed by different organizations at Penn pursuant to certain addenda to the Services Agreement, including the Center for Advanced Retinal and Ocular Therapeutics, or CAROT, Addendum, as amended in May 2020, and the CVPF Addendum. In addition, in July 2019 we entered into an Alliance Agreement with Penn, pursuant to which we will pay Penn a nominal annual fee in order for Penn to provide an adequate and consistent level of support to the services that it provides to us. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The CAROT Addendum </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the CAROT Addendum, Penn manufactures vector that is then to be used by the CVPF in the manufacture of our product candidates. In the event that certain materials owned by Penn are incorporated into a product developed for us, Penn has agreed to grant us a limited license to use those materials. Further, Penn agreed to grant us an exclusive, paid-up, royalty-free, transferable, irrevocable, perpetual exclusive license to any deliverables produced under the CAROT Addendum, except with respect to certain technical information of Penn that is contained or incorporated in the deliverables, to which Penn agreed to grant us a limited nonexclusive license. However, any necessary technology transfer would be pursuant to the subscription and technology transfer agreement described above. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The CVPF Addendum </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the CVPF Addendum, Penn conducts process validation studies and large-scale engineering runs for our product candidates. Under the CVPF Addendum, CVPF will contractually agree to manufacture agreed upon quantities of DSG3-CAART material for use in connection with our DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial, unless the agreement is terminated by either party. Any necessary technology transfer would be pursuant to the subscription and technology transfer agreement described above. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research Agreements with The Regents of the University of California </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:6.85%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2018, we entered into the first Research Agreement, or the First UC Agreement, with The Regents of the University of California, or the UC Regents, pursuant to which the UC Regents agreed to perform certain research projects relating to the toxicity and activity of MuSK CAAR T cells in various models of anti-MuSK MG, or the UC Research. In January 2021, we entered into the Second Research Agreement, or the Second UC Agreement, collectively, the UC Agreements, pursuant to which the UC Regents agreed to perform the same.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The UC Agreements provide that the UC Regents will own all rights to any intellectual property developed solely by UC Regents employees in conducting the UC Research, or developed solely by any of our employees that conduct the UC Research using the UC Regents&#8217; facilities or resources. The UC Regents granted us an irrevocable, royalty-free, nonexclusive, worldwide, nontransferable, perpetual license to use this UC-owned intellectual property for internal research purposes only. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and the UC Regents jointly own the rights to any intellectual property jointly developed by our employees and UC Regents employees in conducting the UC Research, provided that our employees did not use the UC Regents&#8217; facilities or resources in the research. We were granted an option to acquire a non-exclusive or exclusive, worldwide, transferable license, including the right to sublicense, to make, use sell, offer for sale, import and otherwise exploit products embodying these joint inventions. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we exercise our option with respect to certain intellectual property under the UC Agreements, any license we enter into will require us to diligently pursue timely commercial development and marketing of product candidates using such intellectual property, and will be subject to other terms and conditions to be negotiated at the time of entering into any such license. Unless earlier terminated, the term of the First UC Agreement will expire in January 2022. Unless earlier terminated, the term of the Second UC Agreement will expire in 2023.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Regulation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a biopharmaceutical company that operates in the United States, we are subject to extensive regulation. Our cell products will be regulated as biologics. With this classification, commercial production of our products will need to occur in registered facilities in compliance with cGMP for biologics. The FDA categorizes human cell- or tissue-based products as either minimally manipulated or more than minimally manipulated, and has determined that more than minimally manipulated products require clinical trials to demonstrate product safety and efficacy and the submission of a BLA for marketing authorization. Our products are considered more than minimally manipulated and will require evaluation in clinical trials and the submission and approval of a BLA before we can market them. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government authorities in the United States (at the federal, state and local level) and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biopharmaceutical products such as those we are developing. Our product candidates must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in Europe are addressed in a centralized way, but country-specific regulation remains essential in many respects. The process for obtaining regulatory marketing approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">U.S. Biological Product Development </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the FDA regulates biologics under the Federal Food, Drug, and Cosmetic Act, or FDCA, and the Public Health Service Act, or PHSA, and their implementing regulations. Biologics are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may result in delays to the conduct of a study, regulatory review and approval or subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, license suspension or revocation, refusal to allow an applicant to proceed with clinical trials, imposition of a clinical hold, issuance of untitled or warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations or penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our drug product candidates must be approved by the FDA through the Biologics License Application, or BLA, process before they may be legally marketed in the United States. The process required by the FDA before a biologic may be marketed in the United States generally involves the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">completion of extensive nonclinical, sometimes referred to as preclinical, laboratory tests, animal studies and formulation studies in accordance with applicable regulations, including the FDA&#8217;s Good Laboratory Practice, or GLP, regulations and standards; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">submission to the FDA of an IND which must become effective before human clinical trials may begin; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practices, or GCPs, and other clinical trial-related regulations to establish the safety and efficacy of the proposed drug product candidate for its proposed indication; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">submission to the FDA of a BLA, which includes not only the results of the clinical trials, but also, detailed information on the chemistry, manufacture and quality controls for the product candidate and proposed labeling; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the product is produced to assess compliance with the FDA&#8217;s current good manufacturing practice, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality, purity and potency; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">potential FDA audit of the preclinical trial sites and/or clinical trial sites that generated the data in support of the BLA; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">FDA review and approval of the BLA prior to any commercial marketing or sale of the product in the United States. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The data required to support a BLA is generated in two distinct development stages: preclinical and clinical. The preclinical development stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. The conduct of the preclinical studies must comply with federal regulations, including GLPs. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, as well as other information, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human trials. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the IND on clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a drug product candidate at any time before or during clinical trials due to safety concerns, non-compliance, or other issues affecting the integrity of the trial. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that could cause the trial to be suspended or terminated. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the submission of an IND to the FDA before initiation of a clinical trial in the United States, certain human clinical trials involving recombinant or synthetic nucleic acid molecules had historically been subject to review by the Recombinant DNA Advisory Committee, or RAC, of the NIH Office of Biotechnology Activities, or the NIH Office of Biotechnology Activities, or OBA, pursuant to the NIH Guideline</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. On August&#160;17, 2018, the NIH issued a notice in the Federal Register and issued a public statement proposing changes to the oversight framework for gene therapy trials, including changes to the applicable NIH Guidelines to modify the roles and responsibilities of the RAC with respect to human clinical trials of gene therapy products, and requesting public comment on its proposed modifications. During the public comment period, which closed October&#160;16, 2018, the NIH announced that it will no longer accept new human gene transfer protocols for review as a part of the protocol registration process or convene the RAC to review individual clinical protocols. In April 2019, NIH announced the updated guidelines, which reflect these proposed changes, and clarify that these trials will remain subject to the FDA&#8217;s oversight and other clinical trial regulations, and oversight at the local level will continue as set forth in the NIH Guidelines. Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an Institutional Biosafety Committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical stage of development involves the administration of the drug product candidate to healthy volunteers and patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by an IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of certain clinical trials of FDA-regulated products, including biologics, are required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials are generally conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3, and may overlap. Phase 1 clinical trials generally involve a small number of healthy volunteers who are initially exposed to a single dose and then multiple doses of the drug product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action tolerability, adverse effects, and safety of the drug product candidate and, if possible, to gain early evidence on effectiveness. Phase 2 clinical trials typically involve studies in disease-affected patients to determine the dose required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, as well as identification of possible adverse effects and safety risks and preliminary evaluation of efficacy. Phase 3 clinical trials generally involve large numbers of patients at multiple sites, in multiple countries, and are designed to provide the data necessary to demonstrate the efficacy of the product for its intended use, its safety in use, and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. Phase 3 clinical trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of a BLA. In certain instances, FDA may condition approval of a BLA on the sponsor&#8217;s agreement to conduct additional clinical trials to further assess the biologic&#8217;s safety and effectiveness after BLA approval. Such post-approval trials are sometimes referred to as Phase 4 clinical trials. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and further document clinical benefit in the case of drugs approved under Accelerated Approval regulations. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for products. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the biologic, findings from animal or in vitro testing that suggest a significant risk for human subjects, and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated intervals based on access to certain data from the trial and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as interim data suggesting a lack of efficacy. We may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate. Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug product candidate and, among other things, must develop methods for testing the identity, strength, quality, potency and purity of the final product. Additionally, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug product candidate does not undergo unacceptable deterioration over its shelf life. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">BLA and FDA Review Process </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following trial completion, trial data are analyzed to assess safety and efficacy. The results of preclinical studies and clinical trials are then submitted to the FDA as part of a BLA, along with proposed labeling for the product and information about the manufacturing process and facilities that will be used to ensure product quality, results of analytical testing conducted on the chemistry of the drug product candidate, and other relevant information. The BLA is a request for approval to market the biologic for one or more specified indications and must contain proof of safety, purity, potency and efficacy, which is demonstrated by extensive preclinical and clinical testing. The application may include both negative or ambiguous results of preclinical and clinical trials as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval of a BLA must be obtained before a biologic may be marketed in the United States. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee, which is adjusted on an annual basis. PDUFA also imposes an annual prescription drug product program fee. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once a BLA has been accepted for filing, which occurs, if at all, sixty days after the BLA&#8217;s submission, the FDA&#8217;s goal is to review BLAs within 10 months of the filing date for standard review or six months of the filing date for priority review, if the application is for a product intended for a serious or life-threatening condition and the product, if approved, would provide a significant improvement in safety or effectiveness. The FDA has substantial discretion in the approval process and may refuse to accept any application or decide that the data is insufficient for approval, and may require additional preclinical, clinical or other studies before it accepts the filing. Additionally, the review process is often significantly extended by FDA requests for additional information or clarification. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the BLA submission is accepted for filing, the FDA reviews the BLA to determine, among other things, whether the proposed drug product candidate is safe and effective for its intended use, and whether the drug product candidate is being manufactured in accordance with cGMP to assure and preserve the drug product candidate&#8217;s identity, strength, quality, purity and potency. The FDA may refer applications for novel drug product candidates or drug product candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA will likely re-analyze the clinical trial data, which could result in extensive discussions between the FDA and us during the review process. The review and evaluation of a BLA by the FDA is extensive and time consuming and may take longer than originally planned to complete, and we may not receive a timely approval, if at all. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving a BLA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether the facilities comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. In addition, before approving a BLA, the FDA may also audit data from clinical trials to ensure compliance with GCP requirements. After the FDA evaluates the application, manufacturing process and manufacturing facilities, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the BLA identified by the FDA. The Complete Response Letter may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, withdraw the application or request a hearing. Even if such data and information is submitted, the FDA may </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ultimately decide that the BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive, and the FDA may interpret data differently than we interpret the same data. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no assurance that the FDA will ultimately approve a product for marketing in the United States, and we may encounter significant difficulties or costs during the review process. If a product receives marketing approval, the approval may be significantly limited to specific populations, severities of allergies, and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval of the BLA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct post-market testing or clinical trials and surveillance to monitor the effects of approved products. For example, the FDA may require Phase 4 testing which involves clinical trials designed to further assess the product&#8217;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. The FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy, or REMS, to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve the BLA without an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or based on the results of post-market studies or surveillance programs. Additionally, post-approval, many types of changes to the approved product, such as adding new indications, changing manufacturing processes and adding labeling claims, are subject to further testing requirements and FDA review and approval. Such post-approval requirements can be costly and time-consuming and can affect the potential market and profitability of the product. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Orphan Designation and Exclusivity </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug or biologic for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity on the basis of greater effectiveness or safety or providing a major contribution to patient care or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication but that could be used off-label in the orphan indication. Orphan drug exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if our product is determined to be contained within the scope of the competitor&#8217;s product for the same indication or disease. If we pursue marketing approval for an indication broader than the orphan drug designation we have received, we may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expedited Development and Review Programs </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drugs and biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and nonclinical or clinical data </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">demonstrate the potential to address unmet medical needs for the condition. Fast </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rack designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biologic may request the FDA to designate the drug or biologic as a </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ast </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rack product concurrently with, or at any time after, submission of an IND, and the FDA must determine if the product qualifies for </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ast </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rack designation within 60 days of receipt of the sponsor&#8217;s request. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ast </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rack </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">designation</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review, or review within a six-month timeframe from the date a complete BLA is accepted for filing, if it has the potential to provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biological product designated for priority review in an effort to facilitate the review. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, a product may be eligible for accelerated approval. An investigational drug may obtain accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a drug shown to be effective can be safely used only if distribution or use is restricted, it will require such post-marketing restrictions as it deems necessary to assure safe use of the drug, such as: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">distribution restricted to certain facilities or physicians with special training or experience; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">distribution conditioned on the performance of specified medical procedures. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The limitations imposed would be commensurate with the specific safety concerns presented by the product. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast track designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Breakthrough Designation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A product can be designated as a breakthrough therapy if it is intended to treat a serious or life-threatening condition and preliminary clinical evidence indicates that it may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. A sponsor may request that a drug product candidate be designated as a breakthrough therapy concurrently with, or at any time after, the submission of an IND, and the FDA must determine if the drug product candidate qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor&#8217;s request. If so designated, the FDA shall act to expedite the development and review of the product&#8217;s marketing application, including by meeting with the sponsor throughout the product&#8217;s development, providing timely advice to the sponsor to ensure that the development program to gather preclinical and clinical data is as efficient as practicable, involving senior managers and experienced review staff in a cross-disciplinary review, assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor, and taking steps to ensure that the design of the clinical trials is as efficient as practicable. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Accelerated Approval for Regenerative Medicine Advanced Therapies </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the 21st Century Cures Act, Congress amended the FDCA to create an accelerated approval program for regenerative advanced therapies, which include cell therapies, therapeutic tissue engineering products, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">human cell and tissue products, and combination products using any such therapies or products. Regenerative</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> medicine</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">advanced therapies do not include those human cells, tissues, and cellular and tissue-based products regulated solely under section 361 of the Public Health Service Act and 21 CFR Part 1271. The new program is intended to facilitate efficient development and expedite review of regenerative </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">medicine </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">advanced therapies, which are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition. A drug sponsor may request that FDA designate a drug as a regenerative </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">medicine </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">advanced therapy concurrently with or at any time after submission of an IND. FDA has 60 calendar days to determine whether the drug meets the criteria, including whether there is preliminary clinical evidence indicating that the drug has the potential to address unmet medical needs for a serious or life-threatening disease or condition. A new drug application or BLA for a regenerative </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">medicine </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">advanced therapy may be eligible for priority review or accelerated approval through (1)&#160;surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit or (2)&#160;reliance upon data obtained from a meaningful number of sites. Benefits of such designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A regenerative </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">medicine </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">advanced therapy that is granted accelerated approval and is subject to post</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval requirements may fulfill such requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval monitoring of all patients treated with such therapy prior to its approval. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Pediatric Trials </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and efficacy of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDCA requires that a sponsor who is planning to submit a marketing application for a drug or biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or PSP, within sixty days of an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from nonclinical studies, early phase clinical trials, and/or other clinical development programs. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of data or full or partial waivers. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Post-Marketing Requirements </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following approval of a new product, a manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting to the applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities with updated safety and efficacy information, product sampling and distribution requirements, and complying with promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although physicians may prescribe legally available drugs and biologics for off-label uses, manufacturers may not market or promote such off-label uses. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modifications or enhancements to the product or its labeling or changes of the site of manufacture are often subject to the approval of the FDA and other regulators, which may or may not be received or may result in a lengthy review process. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, once a product is approved, its manufacture is subject to comprehensive and continuing regulation by the FDA. The FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMPs. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. cGMP regulations require, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. These regulations also impose certain organizational, procedural and documentation requirements with respect to manufacturing and quality assurance activities. BLA holders using contract manufacturers, laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These firms and, where applicable, their suppliers are subject to inspections by the FDA at any time, and the discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such facilities or the ability to distribute products manufactured, processed or tested by them. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA also may require post-approval testing, sometimes referred to as Phase 4 testing, REMS and post-marketing surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, untitled or warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other Regulatory Matters </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the United States, the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, other divisions of the Department of Health and Human Services (e.g., the Office of Inspector General, or OIG, and Office for Civil Rights), the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&#160;&amp; Health Administration, the Environmental Protection Agency and state and local governments. In the United States, sales, marketing and scientific/educational programs must also comply with federal and state fraud and abuse laws, data privacy and security laws, transparency laws, and pricing and reimbursement requirements in connection with governmental payor programs, among others. The handling of any controlled substances must comply with the U.S. Controlled Substances Act and Controlled Substances Import and Export Act. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities are also potentially subject to federal and state consumer protection and unfair competition laws. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The failure to comply with regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. In addition, even if a firm complies with FDA and other requirements, new information regarding the safety or efficacy of a product could lead the FDA to modify or withdraw product approval. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements; (ii)&#160;additions or modifications to product labeling; (iii)&#160;the recall or discontinuation of our products; or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">U.S. Patent Term Restoration and Marketing Exclusivity </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of the FDA approval of our drug product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. PTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product was created by the Biologics Price Competition and Innovation Act of 2009, or BPCI Act, which was part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA. This amendment to the PHSA attempts to minimize duplicative testing. Biosimilarity, which requires that the biological product be highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times, that the product and the reference product may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product. However, complexities associated with the larger, and often more complex, structure of biological products as compared to small molecule drugs, as well as the processes by which such products are manufactured, pose significant hurdles to implementation that are still being worked out by the FDA. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reference biological product is granted twelve years of exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after first licensure. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. This does not include a supplement for the biological product or a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device, or strength, unless that change is a modification to the structure of the biological product and such modification changes its safety, purity, or potency. Whether a subsequent application, if approved, warrants exclusivity as the &#8220;first licensure&#8221; of a biological product is determined on a case-by-case basis with data submitted by the sponsor. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which attaches to the twelve-year exclusivity period for reference biologics, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Pricing and Reimbursement </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">United States </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of our products will depend, in part, on the extent to which our products, once approved, will be covered and reimbursed by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly reducing reimbursements for medical products and services. The process for determining whether a third-party payor will provide coverage for a drug product, including a biologic, typically is separate from the process for setting the price of a drug product or for establishing the reimbursement rate that a payor will pay for the drug product once coverage is approved. Third-party payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the approved drugs for a particular indication. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to secure coverage and reimbursement for any drug product candidate that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the drug product candidate, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Whether or not we conduct such studies, our drug product candidates may not be considered medically necessary or cost-effective. A third-party payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Third party reimbursement may not be sufficient to enable us to maintain price levels high enough to realize an appropriate return on our investment in product development. In the United States, the principal decisions about reimbursement for new drug products are typically made by the U.S. Centers for Medicare and Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent a new drug product will be covered and reimbursed under Medicare, and private payors tend to follow CMS to a substantial degree. However, no uniform policy of coverage and reimbursement for drug products exists among third-party payors and coverage and reimbursement levels for drug products can differ significantly from payor to payor. Additionally, one third-party payor&#8217;s decision to cover a particular product or service does not ensure that other payors will also provide coverage for the product or service, and the level of coverage and reimbursement can differ significantly from payor to payor. As a result, the coverage determination process will often require us to provide scientific and clinical support for the use of our products to each payor separately and can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The containment of healthcare costs has become a priority of federal and state governments, and the prices of drugs, including biologics, have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. In many countries, the prices of drug products are subject to varying price control mechanisms as part of national health systems. In general, the prices of drug products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for drug products, but monitor and control company profits. Accordingly, in markets outside the United States, the reimbursement for drug products may be reduced compared with the United States. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our drug product candidate or a decision by a third-party payor to not cover our drug product candidate could reduce physician usage of the drug product candidate and have a material adverse effect on our sales, results of operations and financial condition. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside of the United States, the pricing of pharmaceutical products is subject to governmental control in many countries. For example, in the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been approved. Some countries may require the completion of additional studies that compare the cost effectiveness of a particular therapy to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. Other countries may allow companies to fix their own prices for products, but monitor and control product volumes and issue guidance to physicians to limit prescriptions. Efforts to control prices and utilization of pharmaceutical products will likely continue as countries attempt to manage healthcare expenditures. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Healthcare Laws and Compliance Requirements </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers, physicians, and third-party payors will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval.&#160;Our business operations in the United States and our current and future arrangements with clinical investigators, healthcare providers, consultants, third-party payors and patients may expose us to broadly applicable federal and state fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any drugs for which we obtain marketing approval. In the United States, these laws include: the federal Anti-Kickback Statute, the False Claims Act, and HIPAA.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration, directly or indirectly, in cash or in kind, that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by imprisonment, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. On December 2, 2020, the Office of Inspector General, or OIG, published further modifications to the federal Anti-Kickback Statute. Under the final rules, OIG added safe harbor protections under the Anti-Kickback Statute for certain coordinated care and value-based arrangements among clinicians, providers, and others. This rule (with exceptions) became effective January 19, 2021. Implementation of this change and new safe harbors for point-of-sale reductions in price for prescription pharmaceutical products and pharmacy benefit manager service fees are currently under review by the Biden administration and may be amended or repealed. We continue to evaluate what effect, if any, the rule will have on our business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we would not submit claims directly to payors, drug manufacturers can be held liable under the federal civil False Claims Act, which imposes civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities (including manufacturers) for, among other things, knowingly presenting, or causing to be presented to federal programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. Penalties for a False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties for each separate false claim, the potential for exclusion from participation in federal healthcare programs and, although the federal False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. The government may deem manufacturers to have &#8220;caused&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off- label. Claims which include items or services resulting from a violation of the federal Anti-Kickback Statute are false or fraudulent claims for purposes of the False Claims Act. Our future marketing and activities relating to the reporting of wholesaler or estimated retail prices for our products, if approved, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state and third-party reimbursement for our products, and the sale and marketing of our product candidates, are subject to scrutiny under this law. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we may be subject to data privacy and security regulations by both the federal government and states in which we conduct our business. For example, HIPAA created new federal criminal statutes that prohibit among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payment for healthcare benefits, items or services. Like the federal Anti-Kickback Statute a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIPAA, as amended by HITECH, and their implementing regulations, mandates, among other things, the adoption of uniform standards for the electronic exchange of information in common healthcare transactions, as well as standards relating to the privacy and security of individually identifiable health information, which require the adoption of administrative, physical and technical safeguards to protect such information. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to business associates, defined as independent contractors or agents of covered entities, which include certain health care providers, health plans, and healthcare clearinghouses, that create, receive or obtain protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities and business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, certain state laws govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and criminal penalties. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, the federal Physician Payments Sunshine Act, or the Sunshine Act, within the ACA, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain payments or other transfers of value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, physicians, certain other healthcare professionals, and teaching hospitals and to report annually certain ownership and investment interests held by physicians, certain other healthcare professionals, and their immediate family members. Effective January 1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners. In addition, many states also govern the reporting of payments or other transfers of value, many of which differ from each other in significant ways, are often not pre-empted, and may have a more prohibitive effect than the Sunshine Act, thus further complicating compliance efforts. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar federal, state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services. Such laws are generally broad and are enforced by various state agencies and private actions. Also, many states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant federal government compliance guidance, and require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, individual imprisonment, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource- consuming and can divert a company&#8217;s attention from the business. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Current and Future Legislation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in March 2010, the ACA was enacted in the United States. The ACA includes measures that have significantly changed, and are expected to continue to significantly change, the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA of greatest importance to the pharmaceutical industry are that the ACA: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#8217; rebate liability by raising the minimum basic Medicaid rebate on average manufacturer price, or AMP, on most branded prescription drugs and adding a new rebate calculation for &#8220;line extensions&#8221; (<font style="font-style:italic;">i.e.</font>, new formulations, such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability by modifying the statutory definition of AMP; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">imposed a requirement on manufacturers of branded drugs to provide a 50% point-of-sale discount (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of January 1, 2019) off the negotiated price of branded drugs dispensed to Medicare Part D beneficiaries in the coverage gap (<font style="font-style:italic;">i.e.</font>, &#8220;donut hole&#8221;) as a condition for a manufacturer&#8217;s outpatient drugs being covered under Medicare Part D; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">extended a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">expanded the entities eligible for discounts under the 340B Drug Discount Program; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">established a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">imposed an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs, apportioned among these entities according to their market share in certain government healthcare programs, and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. The research conducted by the Patient-Centered Outcomes Research Institute may affect the market for certain pharmaceutical products. The ACA established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potentially including prescription drug spending. Funding has been allocated to support the mission of the Center for Medicare and Medicaid Innovation through 2019. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA. Various portions of the ACA are currently undergoing constitutional challenges in the Fifth Circuit Court and the United States Supreme Court. The former Trump Administration issued various Executive Orders eliminating cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices, and Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. It is unclear whether the ACA will be further amended, and we cannot predict what affect further changes to the ACA would have on our business, especially under the new Biden administration. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect in April 2013, following passage of the Bipartisan Budget Act of 2013 and subsequent legislation, and will remain in effect through 2030 unless additional congressional action is taken. However, pursuant to the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, the 2% Medicare sequester reductions have been suspended from May 1, 2020 through March 31, 2021 due to the COVID-19 pandemic. Proposed legislation, if passed, would extend this suspension until the end of the pandemic. Further, in January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability. Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to request access to certain investigational new drug products that have completed a Phase I clinical trial and that are undergoing investigation for FDA approval. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient assistance programs, and reform government program reimbursement methodologies for drugs. For example, the former Trump administration&#8217;s budget proposal for fiscal year 2021 included a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the former Trump administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Moreover, in May 2018, the former Trump administration also previously released its &#8220;Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs,&#8221; or the Blueprint. The Blueprint contains several potential regulatory actions and legislative recommendations aimed at lowering prescription drug prices, including measures to promote innovation and competition for biologics, changes to Medicare Part D to give plan sponsors more leverage when negotiating prices with manufacturers, and updating the Medicare drug-pricing dashboard to make price increases and generic competition more transparent. In addition, HHS released a Request for Information, or RFI, soliciting public input on ways to lower drug pricing. <font style="font-size:12pt;"> </font>HHS has already started the process of soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs beginning January&#160;1, 2020. This final rule codified CMS&#8217;s policy change that was effective January 1, 2019. It is unclear </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">whether the Biden administration will challenge, reverse, revoke or otherwise modify these executive</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and administrative actions after January 20, 2021.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there have been several changes to the 340B drug pricing program, which imposes ceilings on prices that drug manufacturers can charge for medications sold to certain health care facilities. It is unclear how these developments could affect covered hospitals who might purchase our future products and affect the rates we may charge such facilities for our approved products in the future, if any.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 24, 2020 and September 13, 2020, President Trump announced several executive orders related to prescription drug pricing that seek to implement several of the administration's proposals. In response, the FDA released a final rule on September 24, 2020, which went into effect on November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020 CMS issued an Interim Final Rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement rates will be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita.&nbsp;&nbsp;However, in response to a lawsuit filed by several industry groups, on December 28, the U.S. District Court for the Northern District of California issued a nationwide preliminary injunction enjoining government defendants from implementing the MFN Rule pending completion of notice-and-comment procedures under the Administrative Procedure Act. On January 13, 2021, in a separate lawsuit brought by industry groups in the U.S. District of Maryland, the government defendants entered a joint motion to stay litigation on the condition that the government would not appeal the preliminary injunction granted in the U.S. District Court for the Northern District of California and that performance for any final regulation stemming from the MFN Interim Final Rule shall not commence earlier than 60 days after publication of that regulation in the Federal Register. Further, authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. If implemented, importation of drugs from Canada and the MFN Model may materially and adversely affect the price we receive for any of our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, on December 2, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to an order entered by the U.S. District Court for the District of Columbia, the portion of the rule eliminating safe harbor protection for certain rebates related to the sale or purchase of a pharmaceutical product from a manufacturer to a plan sponsor under Medicare Part D has been delayed to January 1, 2023. Further, implementation of this change and new safe harbors for point-of-sale reductions in price for prescription pharmaceutical products and pharmacy benefit manager service fees are currently under review by the Biden administration and may be amended or repealed. While many of the proposed measures will require authorization through additional legislation to become effective, and the Biden Administration may reverse or otherwise change these measures, Congress has indicated that it will continue to seek new legislative, administrative and/or additional measures to control drug costs.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from product candidates and may affect our overall financial condition and ability to develop product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The Foreign Corrupt Practices Act </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FCPA prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Additional Regulation </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Europe / Rest of World Government Regulation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the United States, we may be subject to a variety of regulations in other jurisdictions that we may in the future select governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval of a product, we would need to obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the EU, for example, a clinical trial application must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the clinical trial application is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain regulatory approval of an investigational drug or biological product under EU regulatory systems, we must submit an MAA. The application used to file the BLA in the United States is similar to that required in the EU, with the exception of, among other things, country-specific document requirements. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our potential collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">European Union General Data Protection Regulation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to EU regulations related to the approval and commercialization of our products, we may be subject to the EU&#8217;s General Data Protection Regulation, or GDPR. The GDPR imposes stringent requirements for controllers and processors of personal data of persons in the EU, including, for example, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories of data, such as health data, and additional obligations when we contract with third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and other third countries. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The GDPR applies extraterritorially, and we may be subject to the GDPR because of our data processing activities that involve the personal data of individuals located in the European Union, such as in connection with our EU clinical trials. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EU member states may result in fines of up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. GDPR regulations </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may impose additional responsibility and liability in relation to the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had 34 employees, 33 of whom were full-time. Of those, 27 were engaged in research and development activities. All company employees are located in the United States. We do not have any employees that are represented by a labor union or covered under a collective bargaining agreement. We consider our relationship with our employees to be good. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate History and Trademarks</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated under the laws of the State of Delaware in April 2017 under the name Tycho Therapeutics, Inc. In August 2018, our corporate name was changed to Cabaletta Bio, Inc. Our principal executive offices are located at 2929 Arch Street, Suite 600, Philadelphia, PA 19104 and our telephone number is (267) 759-3100. Our website address is www.cabalettabio.com. We do not incorporate the information on or accessible through our website into this Annual Report on Form 10-K, and you should not consider any information on, or that can be accessed through, our website to be part of this Annual Report on Form 10-K. We have included our website address in this Annual Report on Form 10-K solely as an inactive textual reference.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We view our operations and measure our business as one reportable segment. All of the Company's tangible assets are held in the United States. Refer to Note 2, Summary of Significant Accounting Policies, to our financial statements appearing elsewhere in this Annual Report on Form 10-K for additional information.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own or have rights to various trademarks, service marks and trade names that we use in connection with the operation of our business. This Annual Report on Form 10-K may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties&#8217; trademarks, service marks, trade names or products in this Annual Report on Form 10-K is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this Annual Report on Form 10-K may appear without the &#174;, &#8482; or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable owner of these trademarks, service marks and trade names.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available Information</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to these reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge on our website located at www.cabalettabio.com as soon as reasonably practicable after they are filed with or furnished to the SEC. These reports are also available at the SEC&#8217;s Internet website at www.sec.gov.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A copy of our Corporate Governance Guidelines, Code of Conduct and Business Ethics and the charters of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee are posted on our website, www.cabalettabio.com, under the heading &#8220;Investors &amp; Media.&#8221;</p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a>Item 1A. Ris</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">k Factors. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Our business involves material and other risks, some of which are summarized and described below. You should carefully consider the risks and uncertainties described below, together with all of the other information contained in this Annual Report on Form 10-K, including "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the condensed financial statements and the related notes. If any of the following risks actually occur, it could harm our business, prospects, operating results and financial condition and future prospects. In such event, the market price of our common stock could decline and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Annual Report.</font> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"><a name="_Hlk50125804"></a>&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Business, Technology and Industry </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk50126080"></a><font style="text-decoration:underline;">Risks Related to Clinical Development </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50125501"></a>We are early in our development efforts. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk36209720"></a><a name="_Hlk52858655"></a>We are early in our development efforts and we <a name="_Hlk36209720"></a>have only initiated one clinical trial to date: <a name="_Hlk52858655"></a>our DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial in June 2020. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. Even if we are able to develop and commercialize a marketable product, we may face challenges generating revenue from product sales. The success of our product candidates will depend on several factors, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">successful completion of preclinical studies resulting in data that is supportive of advancing to an IND submission; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">successful submission and acceptance of INDs or comparable applications; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">successful initiation of clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">demonstration of adequate safety to progress to a therapeutic dose level; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">successful patient enrollment in and completion of clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">receipt and related terms of regulatory and marketing approvals and licensures from applicable regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers for clinical supply and commercial manufacturing of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">making arrangements with various medical divisions across hospitals for administration of our product candidates, including with cancer treatment centers to conduct leukapheresis and with the relevant hospital divisions to perform infusion; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">establishing sales, marketing and distribution and patient administration capabilities and launching commercial sales of our products, if and when licensed, whether alone or in collaboration with others; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">acceptance of our products, if and when licensed, by patients, the medical community and third-party payors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">effectively competing with other therapies targeting the same indications as our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">obtaining and maintaining third-party coverage and adequate reimbursement; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">maintaining a continued acceptable safety profile of our products following licensure. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or be unable to successfully commercialize our product candidates, which would materially harm our business. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50125505"></a>Cellular therapies, including our engineered CAAR T product candidates, represent a novel approach to the treatment of B cell-mediated autoimmune diseases, which creates significant challenges for us. Negative perception or increased regulatory scrutiny of any product candidates that we develop could adversely affect our ability to conduct our business or obtain regulatory approvals for such product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cellular therapies are a novel approach and negative perception or increased regulatory scrutiny of any product candidates that we develop could adversely affect our ability to conduct our business or obtain regulatory approvals for such product candidates. Cellular therapies in general, and CAAR T cell therapies in particular, remain novel therapies, with no cellular immunotherapies licensed to date in the United States or the European Union to treat autoimmune diseases or alloimmune responses. CAAR T cell therapies may not gain the acceptance of the public or the medical community. For example, CAR Ts and other cellular therapies have in some cases caused severe side effects, including death, and their broader use may therefore be limited. Even if CAR Ts and other cellular therapies are accepted by the public and medical community in the short term, long-term adverse events observed in these therapies may increase negative perception and regulatory scrutiny. Although our CAAR Ts are different from CAR Ts and other cellular therapies, they may be viewed in the same vein, limiting their market acceptance. Public perception may be influenced by claims that gene therapy, including the insertion of a transgene, is unsafe, and products incorporating gene therapy may not gain the acceptance of the public or the medical community. The patient populations targeted by our product candidates are also typically not at risk of near-term death, even if they may suffer life-threatening symptoms, so patients will need to deem the benefits of cell therapy to be worth the risk of unknown potential adverse side effects. Our success will depend upon physicians who specialize in the treatment of B cell-mediated autoimmune diseases targeted by our product candidates prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are more familiar and for which greater clinical data may be available. Adverse events in clinical trials of our product candidates or in clinical trials of others developing similar products and the resulting publicity, as well as any other adverse events in the field of cellular therapies, could result in a decrease in demand for any product that we may develop.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing a pipeline of CAAR T product candidates that are intended for use in treating individuals with B cell-mediated autoimmune disease. Advancing these novel product candidates creates significant challenges for us, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">manufacturing our product candidates to our specifications and in a timely manner to support our clinical trials, and, if licensed, commercialization; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">sourcing clinical and, if licensed, commercial supplies for the materials used to manufacture our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">understanding and addressing variability in the quality and quantity of a subject&#8217;s T cells, which could ultimately affect our ability to manufacture clinical supply and, if licensed, commercial supply of our product candidates in a reliable and consistent manner; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">educating medical personnel regarding the potential side effect profile of our product candidates, if licensed, such as the potential adverse side effects related to pemphigus flare from infusion of activated T cells or medication taper, cytokine release syndrome, or CRS, or other unexpected adverse effects of therapy with our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">facilitating patient access to the limited number of facilities able to administer our product candidates, if licensed; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">using medicines to manage adverse side effects of our product candidates that may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">potentially utilizing preconditioning agents in patients to enhance engraftment in advance of administering our product candidates, which may increase the risk of adverse side effects; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">obtaining and maintaining regulatory approval for our product candidates, as the FDA and other regulatory authorities have limited or no experience with development of engineered T cell therapies for the treatment of B cell-mediated autoimmune diseases; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">establishing sales and marketing capabilities upon obtaining any regulatory approval to gain market acceptance of a novel therapy; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">managing costs of inputs and other supplies while scaling production. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, preclinical murine and other animal models may not exist or be adequate for some or all of the B cell-mediated autoimmune diseases we choose to pursue in our programs, and because we are early in the clinical development process, we are unable to predict whether there may be short-term or long-term effects from treatment with any product candidates that we develop. In developing our product candidates, we have not exhaustively explored different options in the method for manufacturing CAAR T cells. We may find our existing manufacturing process may be substantially improved with future design or process changes, necessitating further clinical testing, delaying commercial launch of our first products, and causing us to incur additional expenses. For example, while we have used a lentiviral vector in our manufacturing process, we may in the future find that another viral vector or non-viral vector-based process offers advantages. Switching from one lentiviral vector to another or switching from lentiviral to another delivery system would necessitate additional process development and clinical testing, and this may delay the development of existing product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we do not know the doses to be evaluated in pivotal trials or, if licensed, commercially. Finding a suitable dose may delay our anticipated clinical development timelines. Our expectations with regard to our scalability and costs of manufacturing may vary significantly as we develop our product candidates and understand these critical factors. We may experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our clinical studies or commercializing our product candidates on a timely or profitable basis, if at all. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, our product candidates may not perform successfully in clinical trials or may be associated with adverse events that distinguish them from the chimeric antigen receptor T, or CAR T, therapies that have previously been licensed. For instance, subjects in our clinical trials will be infused with our proposed therapies, and may possess strongly activating soluble antibodies, which, are not present in oncology patients and when they interact with our infused product candidates, could result in potential adverse side effects, such as CRS. Unexpected side effects or clinical outcomes would significantly impact our business. Adverse side effects caused by even one of our product candidates could negatively affect our ability to develop future product candidates based on our CABA platform. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, two of our current product candidates, DSG3/1-CAART and FVIII-CAART, and certain of our future product candidates may require introducing large transgenes into T cells, and lentiviral vectors may have too limited a genome capacity to accomplish this process. We currently use lentiviral vector transduction for transgene delivery. However, lentiviral vectors have a limited genome capacity that restricts the size of the transgene that can be delivered using this vector system. For example, designing a lentiviral vector that will have sufficient capacity to introduce DSG3 CAAR and DSG1 CAAR together into T&#160;cells may not be possible. In addition to reducing lentiviral vector titers that may substantially increase the cost of gene transfer, it may be entirely unsuccessful, thus necessitating use of alternative strategies for transfer of these larger transgenes into T cells. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, the clinical study requirements of the FDA and other regulatory agencies and the criteria they use to determine the safety, potency and purity of a product candidate are determined according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours is less clear, and can be more complex and consequently have higher development risk, be more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. Approvals by the FDA for existing cell therapies treating B cell-mediated diseases, such as Kymriah (Novartis Pharmaceuticals Corporation) and Yescarta (Gilead Sciences, Inc.), may not be indicative of what the FDA may require for approval of our therapies. Approvals by any regulatory agency may not be indicative of what any other regulatory agency may require for approval or what such regulatory agencies may require for approval in connection with new product candidates. As we advance our product candidates, we will be required to consult with these regulatory agencies and comply with applicable requirements and guidelines. If we fail to do so, we may be </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">required to delay or discontinue development of such product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. More restrictive statutory regimes, government regulations or negative public opinion would have an adverse effect on our business, financial condition, results of operations and prospects and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, responses by agencies at the federal and state level to negative public perception or ethical concerns may result in new legislation or regulations that could limit our ability to develop or commercialize any product candidates, obtain or maintain regulatory approval or otherwise achieve profitability. The FDA has expressed interest in further regulating biotechnology products, such as cellular therapies. Agencies at both the federal and state level in the United States, as well as the U.S. Congressional committees and other government entities or governing agencies have also expressed interest in further regulating the biotechnology industry. Such action may delay or prevent commercialization of some or all of our product candidates. Adverse developments in clinical trials of cellular therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of any of our product candidates. These regulatory review agencies and committees and the new requirements or guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50125510"></a>Patients receiving T cell-based immunotherapies, such as our product candidates, may experience serious adverse events, including neurotoxicity, CRS and killing of cells other than the intended B cells that express the autoantibodies. If our product candidates are revealed to have high and unacceptable severity and/or prevalence of side effects or unexpected characteristics, their clinical development, regulatory approval, and commercial potential will be negatively impacted, which will significantly harm our business, financial condition and prospects. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates are CAAR T cell-based immunotherapies. There is a possibility that our product candidates could have adverse side effects, such as neurotoxicity and CRS. In other similarly designed cellular immunotherapies to treat cancer, there have been life threatening events related to severe neurotoxicity and CRS requiring intense medical intervention, such as intubation or medications to support blood pressure, and in several cases, resulted in death. Severe neurotoxicity is a condition that is currently defined clinically by cerebral edema, confusion, drowsiness, speech impairment, tremors, seizures or other central nervous system side effects, when such side effects are serious enough to lead to intensive care. CRS is a condition that is currently defined clinically by certain symptoms related to the release of cytokines, which can include fever, chills and low blood pressure, when such side effects are serious enough to lead to intensive care with mechanical ventilation or significant medications to support blood pressure. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates may have serious and potentially fatal targeting of cells within the body due to unexpected protein interactions with the CAAR. Although we have completed multiple preclinical studies designed to screen for toxicity caused by unintended off-target recognition by the cell binding domain of the DSG3 CAAR, our product candidates may still recognize and react with one or more proteins unrelated to the intended surface immunoglobin target protein to which it is designed to link. If unexpected binding occurs in normal tissue, our product candidates may target and kill the normal tissue in a patient, leading to serious and potentially fatal adverse events, undesirable side effects, toxicities or unexpected characteristics. Detection of any unexpected targeting may halt or delay any ongoing clinical trials for our product candidates and prevent or delay regulatory approval. While we have developed a preclinical screening process to identify cross-reactivity of our product candidates, we cannot be certain that this process will identify all potential tissue that our product candidates may target. For example, a membrane protein array with DSG3-CAART yielded one weak signal against a protein that is designed to bind to glycoproteins and which was detected in both the test and control conditions. Further analysis of this protein in confirmatory cell-based assays repeatedly demonstrated that DSG3-CAART does not recognize nor activate against this protein. However, this further analysis may prove to be inaccurate. Any unexpected targeting that impacts patient safety could materially impact our ability to advance our product candidates into clinical trials or to proceed to marketing approval and commercialization.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results of our studies could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our product candidates could cause us or regulatory </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA. The FDA has requested and we have agreed to provide data on the subjects dosed in Part A of our </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DesCAARTes</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> trial </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prior to dosing subjects in Part B. The FDA has communicated that the dosing of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patients</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in Part B1 is not </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dependent on the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">review of Part A data and that they will provide feedback, if any, in a timely manner. In some cases, side effects such as neurotoxicity or CRS have resulted in clinical holds of ongoing clinical trials and/or discontinuation of the development of the product candidate. Given that the autoimmune and alloimmune diseases we are seeking to treat are, in some cases, less serious than the later stage cancers being treated with other immunotherapy products, we believe the FDA and other regulatory authorities likely will apply a different benefit-risk assessment thresholds such that even if our product candidate demonstrated a similar safety profile as current CAR T therapies, the FDA may ultimately determine that the harmful side effects outweigh the benefits and require us to cease clinical trials or deny approval of our product candidates. We believe tolerance for adverse events in the patient population being pursued with CAAR T cell therapies will be lower than it is in oncology, and the risks of negative impact from these toxicities may therefore be higher for us than for CAR T programs in oncology. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the studies or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from T cell-based immunotherapies are not normally encountered in routine medical care. Medical personnel may need additional training regarding T cell-based immunotherapy product candidates to understand their side effects. Inadequate training in recognizing or failure to effectively manage the potential side effects of T cell-based immunotherapy product candidates could result in patient deaths. Any of these occurrences may harm our business, financial condition and prospects significantly. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to side effects caused by our product candidates, the preconditioning, administration process or related procedures, which we evaluate from time to time as part of our process improvement and optimization efforts, may also cause adverse side effects. For example, severe neurotoxicity has been noted to be associated with the use of certain lymphodepleting regimens. While we believe there are sufficient data from other CAR T programs to suggest that it is reasonable for us to initiate our first clinical trial of DSG3-CAART without a preconditioning regimen, we cannot be certain that a preconditioning regimen, with or without lymphodepleting agents, will not be required. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50125514"></a>Although we plan to infuse DSG3-CAART without preconditioning initially in our DesCAARTe<font style="font-style:normal;">s</font><font style="font-weight:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font><font style="font-style:normal;"> </font>trial, we may in the future use a preconditioning regimen for our CAAR T cell product candidates, which may increase the risk of adverse side effects and impact our ability to accurately assess the efficacy of our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In oncology patients receiving CAR T cell therapy, a lymphodepleting preconditioning regimen is typically used to condition the patient prior to CAR T cell infusion in order to improve tumor immunogenicity and to promote the expansion of the infused CAR T cells. Together, these effects have been shown to enhance the clinical activity of CAR T cells in oncology patients. These regimens often include cyclophosphamide and fludarabine and are usually administered within the week prior to infusion of CAR T cells. Serious adverse events have been observed in some patients following CAR T cell infusion, and these include infection, cytokine release syndrome and neurotoxicity. The preconditioning regimen may contribute to the occurrence and severity of these adverse events due to its role in inducing lymphopenia, or low levels of lymphocytes in the blood, and enhanced CAR T cell activity. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lymphodepleting preconditioning may not be required in all oncology settings for CAR T cell activity. A recent clinical trial in multiple myeloma patients published in 2019 in <font style="font-style:italic;">The Journal of Clinical Investigation </font>showed similar clinical activity of CAR T cell infusions in patients with or without a lymphodepleting preconditioning regimen. Furthermore, the requirement for lymphodepleting preconditioning for potentiating engineered T cell therapy outside of oncology has not been well established. Specifically, the effect on tumor immunogenicity is not relevant in settings outside oncology, and therefore the contribution of this aspect to the potential enhancing effect of preconditioning would not apply. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, a lymphodepleting regimen may eliminate pathogenic B cells targeted by our CAAR T cell product candidates. As a result, any lymphodepleting regimen for preconditioning that we use may adversely affect our ability to use DSG3 autoantibody titers, a standard clinical assay, to assess the activity of DSG3-CAART. An </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inability to use DSG3 autoantibody levels to demonstrate the specific activity of our CAAR T cell product candidates may require us to rely on the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subjective</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> measurement of blister formation in patients, which can be a less sensitive and accurate measurement of CAAR T cell activity. This therefore could delay efficient clinical development. As a result of these factors, including the concern that lymphodepletion may confer a potential increased safety risk to an autoimmune patient population, we believe the inclusion of such a regimen must be justified by clinical data demonstrating the need for it in the setting of autoimmune patients and is therefore difficult to justify in our first-in-human studies. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We initiated our DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial without a preconditioning regimen. If clinical data suggest that a preconditioning regimen is advisable, or if FDA requires that we employ a preconditioning regimen, we may employ such a regimen. If we ultimately use a preconditioning regimen, with or without lymphodepleting agents, prior to infusing patients with our CAAR T cell product candidates, our clinical patients may experience increased or more severe adverse effects specifically related to the preconditioning regimen, some of which may result in death. These undesirable side effects, whether associated with the preconditioning regimen alone or in combination with our CAAR T cell product candidates, could cause delays in patient enrollment in our clinical trials, could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a change to our clinical trial design, a more restrictive label or the delay or denial of regulatory approval by the FDA. Any of the foregoing may increase the duration and expense of the clinical development of our product candidates or limit market acceptance of such product candidates, if approved, any of which could have a material adverse effect on our business and financial condition. Even if we do not use a preconditioning regimen, patients may experience adverse effects related to our CAAR T cell product candidates, and our decision to design our clinical trials without preconditioning does not eliminate the risk of those side effects. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50125518"></a>Our business is highly dependent on the success of our initial product candidates targeting B cell-mediated autoimmune diseases, particularly DSG3-CAART. All of our product candidates will require significant additional preclinical and clinical development before we can seek regulatory approval for and launch a product commercially. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business and future success depend on our ability to obtain regulatory approval of, and then successfully launch and commercialize our initial product candidates targeting B cell-mediated autoimmune diseases, including DSG3-CAART, MuSK-CAART, DSG3/1-CAART and others that may be selected from preclinical programs. Our product candidates are in the early stages of development and will require additional preclinical studies, clinical trials, regulatory review and licensure, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. There is no guarantee that we will be able to advance our product candidates through clinical development or obtain marketing approval for any of our product candidates. The process for obtaining marketing approval for any product candidate is very long and risky and there will be significant challenges for us to address in order to obtain marketing approval as planned, if at all. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our IND was cleared in September 2019, and we initiated our DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial in June 2020. We announced dosing of the first patient in this trial in December 2020. Until dosing of this patient, DSG3-CAART had only been administered in murine models, and the preclinical results we have observed may not be predictive of the results of our clinical trial or any future clinical trials. Because DSG3-CAART is the first product candidate that we are testing in the clinic, we may experience preliminary complications surrounding trial design, protocol establishment and execution, establishing trial protocols, patient recruitment and enrollment, quality and supply of clinical doses, or safety issues. For example, while the majority of oncology CAR T clinical trials have been conducted with a lymphodepleting or other preconditioning regimen prior to infusion, we do not intend to use pre-infusion lymphodepletion or other preconditioning regimen initially in our Phase&#160;1 trial. However, we may determine that use of a lymphodepleting or other preconditioning regimen is necessary for our product candidates to be successful, which could result in delays in clinical development and will expose patients to the associated risks. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, a failure of our clinical trial of DSG3-CAART could influence physicians&#8217; and regulators&#8217; opinions with regard to the viability of our CABA platform more broadly, particularly if treatment-related side effects are observed. The occurrence of any of these risks could significantly harm our development plans and business prospects. If treatment-related side effects are observed with the administration of DSG3-CAART, or if it is viewed as less safe, potent or pure than other therapies, our ability to develop other CAAR T cell therapies may be significantly harmed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50125536"></a><font style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have never successfully completed any clinical trials, and we may be unable to do so for any product candidates we develop.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not yet demonstrated our ability to successfully complete any clinical trials, including large-scale, pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. <font style="color:#000000;">Although our key employees have significant experience in leading clinical development programs, we have no experience as a company in conducting clinical trials beyond our current DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial initiated in June 2020. Otherwise, we currently have ongoing IND-enabling studies for our MuSK CAAR T program, with a planned IND submission anticipated in the second half of 2021. </font>We may not be able to file such IND or INDs for any of our other product candidates on the timelines we expect, if at all. For example, we may experience manufacturing delays with&#160;IND-enabling&#160;studies. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing further clinical trials to begin, or that, once begun, issues will not arise that require us to suspend or terminate clinical trials. Commencing each of these clinical trials is subject to finalizing the trial design based on discussions with the FDA and other regulatory authorities. Any guidance we receive from the FDA or other regulatory authorities is subject to change. These regulatory authorities could change their position, including, on the acceptability of our trial designs or the clinical endpoints selected, which may require us to complete additional clinical trials or impose stricter approval conditions than we currently expect. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be delayed in obtaining marketing approval for our product candidates;</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not obtain marketing approval at all;</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtain approval for indications or patient populations that are not as broad as intended or desired;</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be subject to post-marketing testing requirements; or</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have the product removed from the market after obtaining marketing approval.</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50125540"></a>We may not be able to file INDs to commence clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We submitted an IND to the FDA to initiate a clinical trial of DSG3-CAART targeting mPV in August 2019, which was cleared by the FDA in September 2019. The timing of submissions on future product candidates will be dependent on further preclinical and manufacturing success. We cannot be sure that submission of an IND or IND amendment will result in the FDA allowing testing and clinical trials to begin, or that, once begun, issues will not arise that would cause us or the FDA to suspend or terminate such clinical trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND or clinical trial application, we cannot guarantee that such regulatory authorities will not change their requirements in the future. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to the Current Novel Coronavirus (COVID-19) Pandemic </font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk50120566"></a>The COVID-19 pandemic and the future outbreak of other highly infectious or contagious diseases could seriously harm our research, development and potential future commercialization efforts, increase our costs and expenses and have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Public health crises such as pandemics or similar outbreaks could adversely impact our business, the business operations of third parties on whom we rely and our ongoing or planned research and development activities. In December 2019, a novel strain of coronavirus surfaced in Wuhan, China and has since reached multiple other regions and countries, including Philadelphia, Pennsylvania where our primary office and laboratory space, as well as certain of our CMO partners, are located.&#160;The COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">health safety measures. The extent to which COVID-19 impacts our operations or those of our third party partners will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the pandemic, new information that may emerge concerning the severity </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of COVID-19, the impact of new strains of the virus, the effectiveness and availability of vaccines and the actions to contain COVID-19 or treat its impact, among others. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, timely enrollment in our ongoing and planned clinical trials is dependent upon clinical trial sites which will be adversely affected by global health matters, such as COVID-19. We plan to conduct clinical trials for our product candidates in geographies which are currently being affected by COVID-19. Some factors from the COVID-19 pandemic that have delayed and could further delay or otherwise adversely affect enrollment in the clinical trials of our product candidates, as well as our business generally, include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, including the attention of physicians serving as our clinical trial investigators, hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our prospective clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">limitations on travel that could interrupt key trial and business activities, such as clinical trial site initiations and monitoring, domestic and international travel by employees, contractors or patients to clinical trial sites, including any government-imposed travel restrictions or quarantines that will impact the ability or willingness of patients, employees or contractors to travel to our clinical trial sites or secure visas or entry permissions, a loss of face-to-face meetings and other interactions with potential partners, any of which could delay or adversely impact the conduct or progress of our prospective clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">interruption in global shipping affecting the transport of clinical trial materials, such as patient samples, investigational drug product and conditioning drugs and other supplies used in our prospective clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">interruptions in operations at our third-party manufacturers, which could result in delays or disruptions in the supply of our current product candidates and any future product candidates; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">business disruptions caused by potential workplace, laboratory and office closures and an increased reliance on employees working from home, disruptions to or delays in ongoing laboratory experiments and operations, product manufacturing and supply, staffing shortages, travel limitations or mass transit disruptions, any of which could adversely impact our business operations or delay necessary interactions with local regulators, ethics committees and other important agencies and contractors.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These and other factors arising from the coronavirus could continue to worsen. Any of these factors, and other factors related to any such disruptions that are unforeseen, could have a material adverse effect on our business and our results of operation and financial condition.&#160;Further, uncertainty around these and related issues could lead to adverse effects on the economy of the United States and other economies, which could impact our ability to raise the necessary capital needed to develop and commercialize our product candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to the Industry</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50125523"></a>Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Undesirable or unacceptable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA. Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the drug. Undesirable side effects could also result in an expansion in the size of our clinical trials, increasing the expected costs and timeline of our clinical trials. Additionally, results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licensed CAR T cell therapies and those under development have shown frequent rates of CRS and neurotoxicity, and adverse events have resulted in the death of patients. Similar adverse events could occur during treatment with our CAAR T cell product candidates. For example, activation of CAAR T cells by patient autoantibodies or alloantibodies could stimulate CRS. When CAAR&#160;T cells are infused and the CAAR binds to soluble antibodies in the blood or tissues of treated patients, these soluble antibodies may cause the CAAR T cells to proliferate, resulting in an activation of the immune system that is too high, leading to CRS. Further, it is possible that patients will exhibit acute rejection of the CAAR T cells because of preexisting immunity to the antigen within the CAAR. This could render our product candidates ineffective. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If unacceptable toxicities or health risks, including risks inferred from other unrelated immunotherapy trials, arise in the development of our product candidates, we could suspend or terminate our trials or the FDA, the Data Safety Monitoring Board, or DSMB, or local regulatory authorities such as institutional review boards, or IRBs, could order us to cease clinical trials. Regulatory authorities, such as the FDA, could also deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from T cell therapy are not normally encountered in the general patient population and by medical personnel. We expect to have to train medical personnel using CAAR T cell product candidates to understand the side effect profile of our product candidates for both our preclinical studies and clinical trials and upon any commercialization of any of our product candidates, if licensed. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient deaths. Any of these occurrences may harm our business, financial condition and prospects significantly. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50125527"></a>Our preclinical studies and clinical trials may fail to demonstrate the safety, potency and purity of any of our product candidates, which would prevent or delay regulatory approval and commercialization. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are safe, potent and pure for use in each target indication. Clinical trials are expensive and can take many years to complete, and their outcomes are inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, including in any post-approval studies of our product candidates. In addition, initial success in any clinical trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety, potency and purity profile despite having progressed through preclinical studies and initial clinical trials. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of potency or efficacy, insufficient durability of potency or efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical and other nonclinical findings made while clinical trials were underway, or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or EMA approval. Most product candidates that commence clinical trials are never approved as products. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any preclinical studies or clinical trials that we may conduct may not demonstrate the safety, potency and purity necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future preclinical studies and clinical trials are inconclusive with respect to the safety, potency and purity of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for such product candidates. In some instances, there can be significant variability in safety, potency or purity results between different preclinical studies and clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. For example, because our CAAR&#160;T cell product candidates only target approximately 0.01% to 1% of the B cells in a patient, they may not engage enough of the target to achieve adequate engraftment necessary for elimination of all pathogenic B cells. Insufficient safety or potency in clinical trials may delay product development to enable time to modify the product candidate for next generation approaches or make manufacturing changes or may lead us to discontinue development of the product candidate. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, our ongoing DesCAARTes&#8482; trial utilizes, and our planned trials may utilize, an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">active</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, for DSG3-CAART, MuSK-CAART and any future trials that may be completed, we cannot guarantee that the FDA will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA to support a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50125530"></a>Interim, topline or preliminary data from any preclinical studies or clinical trials that we conduct may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our initial clinical trial for our lead product candidate will be open-label. From time to time, we may publicly disclose preliminary or topline or data from our preclinical studies and clinical trials, which will be based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. Additionally, in our DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial, the product candidate will be administered by intravenous infusion, using a fractionated-dose infusion scheme of escalating numbers of DSG3-CAART cells. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, the topline results&#160;that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from planned interim analyses in our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory agencies, including the FDA, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the interim, topline or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50125543"></a>We may encounter substantial delays in our clinical trials or may not be able to conduct our trials on the timelines we expect or at all. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive, time consuming and subject to uncertainty. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. Even if these trials begin as planned, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our ongoing and future clinical trials may not be successful. Events that may prevent successful or timely completion of clinical development include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">inability to generate sufficient preclinical, toxicology or other </font><font style="font-style:italic;font-size:10pt;color:#000000;">in vivo</font><font style="font-size:10pt;color:#000000;"> or </font><font style="font-style:italic;font-size:10pt;color:#000000;">in vitro</font><font style="font-size:10pt;color:#000000;"> data to support the initiation of clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delays in developing suitable assays for screening patients for eligibility for clinical trials with respect to certain product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delays in reaching a consensus with the FDA and other regulatory agencies on trial design; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delays in reaching agreement on acceptable terms with prospective CROs and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delays in obtaining required institutional review board, or IRB, approval at each clinical trial site; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND submission or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical study operations or study sites; developments on trials conducted by competitors for related technology that raises FDA concerns about risk to patients of the technology broadly; or if FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delays in recruiting eligible patients to participate in our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delays in treating one or more patients, once enrolled, due to a patient&#8217;s inability to accommodate parts of the complex study procedures schedule; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">difficulty collaborating with patient groups and investigators; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">failure by our CROs, other third parties or us to adhere to clinical trial requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">limitations on our recourse in our CRO relationship with Penn as compared to a CRO that is not an academic institution; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">failure to perform in accordance with the FDA&#8217;s good clinical practice, or GCP, requirements or applicable regulatory guidelines in other countries; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">transfer of manufacturing processes to any new CMO or our own manufacturing facilities or any other development or commercialization partner for the manufacture of product candidates; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delays in having patients complete participation in a trial or return for post-treatment follow-up; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">patients dropping out of a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the cost of clinical trials of our product candidates being greater than we anticipate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon product development programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delays or failure to secure supply agreements with suitable raw material suppliers, or any failures by suppliers to meet our quantity or quality requirements for necessary raw materials; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to, or we may elect to, conduct additional trials to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which our product candidates and products, if licensed, have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the DSMB for such trial or by the FDA or other regulatory authority, or if the IRBs of the institutions in which such trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delays in the initiation, conduct or completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. In the event we identify any additional product candidates to pursue, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin in a timely manner, if at all. Any of these occurrences may significantly harm our business, financial condition and prospects. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50125549"></a>Monitoring safety of patients receiving our product candidates will be challenging, which could adversely affect our ability to obtain regulatory approval and commercialize our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For our clinical trials of DSG3-CAART and our other product candidates, we expect to continue to contract with Penn and other academic medical centers and hospitals experienced in the assessment and management of toxicities arising during clinical trials. In the future, we may also contract with non-academic medical centers and hospitals with similar capabilities. Nonetheless, these centers and hospitals may have difficulty observing patients, including due to failure by patients to comply with post-clinical trial follow-up programs, and treating toxicities, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which may be more challenging due to personnel changes, inexperience, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA delaying, suspending or terminating one or more of our clinical trials, and which could jeopardize regulatory approval. We also expect the centers using DSG3-CAART and our other product candidates, if licensed, on a commercial basis could have similar difficulty in managing adverse events. Medicines used at centers to help manage adverse side effects of DSG3-CAART and our other product candidates may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50125552"></a>If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. The enrollment of patients depends on many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the size and nature of the patient population; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the patient eligibility criteria defined in the protocol; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">recruiting an adequate number of suitable patients to participate in a clinical trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">obtaining IRB and other required reviewing body approval at each clinical trial site; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the proximity of patients to trial sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the design of the trial and whether the FDA agrees to the design and implementation of the trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to identify clinical trial sites and recruit clinical trial investigators with the appropriate capabilities, competencies and experience; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the occurrence of dose-limiting toxicity in the clinical trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the efforts to facilitate timely enrollment in clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the patient referral practices of physicians; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the ability to monitor patients adequately during and after treatment; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to obtain and maintain patient consents; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the risk that patients enrolled in clinical trials will drop out of the trials before the infusion of our product candidates or trial completion; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the ability of patients to meet the complex follow-up requirements of the clinical trial. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, some of our clinical trial sites may also be used by some of our competitors, which may reduce the number of patients who are available for our clinical trials in that clinical trial site. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, because our product candidates represent a departure from more commonly used methods for B cell-mediated autoimmune disease treatment, potential patients and their doctors may be inclined to use conventional therapies, such as corticosteroids or systemic immunosuppressive medications, rather than enroll patients in our clinical trial. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing and planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial and additional expected Phase 1 clinical trials for each of our product candidates will be pilot dose escalation studies with a limited number of patients. The activity and toxicity data from these clinical trials of our product candidates may differ from future results of Phase 2 and/or Phase 3 clinical trials that enroll a larger number of patients. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the number of patients that we plan to dose in our DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial is small, the results from such clinical trial, once completed, may be less reliable than results achieved in larger clinical trials, which may hinder our efforts to obtain regulatory approval for our product candidates.<font style="font-weight:bold;font-style:italic;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font>In our DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial, we plan to evaluate the toxicity profile of DSG3-CAART and establish the recommended dose for the next clinical trial. The preliminary results of clinical trials with smaller sample sizes, such as our DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial, can be disproportionately influenced by various biases associated with the conduct of small clinical trials, such as the potential failure of the smaller sample size to accurately depict the features of the broader patient population, which limits the ability to generalize the results across a broader community, thus making the clinical trial results less reliable than clinical trials with a larger number of patients. As a result, there may be less certainty that such product candidates would achieve a statistically significant effect in any future clinical trials. If we conduct any future clinical trials of DSG3-CAART, we may not achieve a statistically significant result or the same level of statistical significance, if any, that we might have anticipated based on the results observed in our DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Sales, Marketing and Competition </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50125561"></a>The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our projections of both the number of people who have the B cell-mediated autoimmune diseases we are targeting, as well as the subset of people with these diseases in a position to receive second or later lines of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these B cell-mediated autoimmune diseases. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. For instance, we expect our lead product candidate, DSG3-CAART, to initially target a small patient population that suffers from mPV. Even if we obtain significant market share for our product candidates, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk50125621"></a><a name="_Hlk50125621"></a> <font style="font-weight:bold;font-style:italic;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biopharmaceutical and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong focus on intellectual property. We face competition from many different players, including large and specialty pharmaceutical and biotechnology companies, academic research organizations and governmental agencies. Any therapeutic candidates we successfully develop and commercialize will compete with the existing standard of care as well as novel therapies that may gain regulatory approval in the future. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Mergers and acquisitions in the biotechnology and pharmaceutical </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">industries may result in even more resources being concentrated in our competitors. We believe we are the first and only company developing CAAR T drug candidates for the treatment of B cell-mediated autoimmune diseases. However, despite the significant differences in discovery, development and target populations between oncology and autoimmune targets, we recognize that companies with an investment and expertise in CAR T cell development for oncology indications could attempt to leverage their expertise into B cell-mediated autoimmune disease affected populations. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, while rituximab is the first drug for the treatment of PV, the target indication of our lead product candidate, DSG3-CAART, to have received regulatory approval in the United States in over 60&#160;years, we are aware that multiple biopharmaceutical companies have therapies in clinical development. We are also aware of other biopharmaceutical companies developing therapies for muscle-specific kinase myasthenia gravis, or MuSK MG, and Hemophilia&#160;A patients who develop alloantibodies against FVIII. While we do not expect these product candidates to be directly competitive to our product candidates, even if we obtain regulatory approval of our product candidates, the availability and price of these other products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50125637"></a>Even if we obtain regulatory approval of our product candidates, the products may not gain the market acceptance among physicians, patients, hospitals, treatment centers and others in the medical community necessary for commercial success. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of engineered T cells as a potential treatment for B cell-mediated autoimmune diseases is a recent development and may not become broadly accepted by physicians, patients, hospitals, treatment centers and others in the medical community. We expect physicians to be particularly influential and we may not be able to convince them to use our product candidates for many reasons. Additional factors will influence whether our product candidates are accepted in the market, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the clinical indications for which our product candidates are licensed; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">physicians, hospitals, treatment centers and patients considering our product candidates as a safe and effective treatment; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the potential and perceived advantages of our product candidates over alternative treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the prevalence and severity of any side effects; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">product labeling or product insert requirements of the FDA or other regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">limitations or warnings contained in the labeling approved by the FDA; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the timing of market introduction of our product candidates as well as competitive products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the cost of treatment in relation to alternative treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the availability of coverage and adequate reimbursement and pricing by third-party payors and government authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the effectiveness of our sales and marketing efforts. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The product candidates we plan to develop and commercialize are premised on offering a potential cure for B cell-mediated autoimmune diseases, which may result in a high degree of uncertainty related to pricing and long-term demand for our product. Our target patient populations are relatively small. Because of this pricing and demand for our product candidates, if licensed, may not be adequate to support an extended period of commercial viability, which could adversely affect our continued ability to successfully produce and market our product or any follow-on products.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if our product candidates are licensed but fail to achieve market acceptance among physicians, patients, hospitals, treatment centers or others in the medical community, we will not be able to generate significant revenue. Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk50125625"></a><font style="text-decoration:underline;">Risks Related to Business Development </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50125566"></a>We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital, we must prioritize development of certain product candidates, which may prove to be wrong and may adversely affect our business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we intend to explore other therapeutic opportunities, in addition to the product candidates that we are currently developing, we may fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional potential product candidates, our business could be materially harmed. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research programs to pursue the development of our existing and planned product candidates for additional indications and to identify new product candidates and disease targets require substantial technical, financial and human resources whether or not they are ultimately successful. Our research programs may initially show promise in identifying potential indications and/or product candidates, yet fail to yield results for clinical development for a number of reasons, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the research methodology used may not be successful in identifying potential indications and/or product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">potential product candidates may be identified but may not be able to be expressed on T cells in a manner that enables product activity;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">potential product candidates may, after further study, be shown to have harmful adverse effects or other characteristics that indicate they are unlikely to be effective drugs; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">it may take greater human and financial resources than we will possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify and expand our product portfolio. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and human resources, we intend to initially focus on research programs and product candidates for a limited set of indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50125613"></a>If we fail to develop additional product candidates, our commercial opportunity will be limited. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One of our core strategies is to pursue clinical development of additional product candidates beyond DSG3-CAART, MuSK-CAART, DSG3/1-CAART and FVIII-CAART. Developing, obtaining regulatory approval and commercializing additional CAAR T cell product candidates will require substantial additional funding and is prone to the risks of failure inherent in medical product development. We cannot provide you any assurance that we will be able to successfully advance any of these additional product candidates through the development process. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we receive FDA approval to market additional product candidates for the treatment of B cell-mediated autoimmune diseases, we cannot assure you that any such product candidates will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize additional product candidates, our commercial opportunity will be limited. Moreover, a failure in obtaining regulatory approval of additional product candidates may have a negative effect on the approval process of any other, or result in losing approval of any approved, product candidate. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific, and medical personnel, including our Chief Executive Officer and President, our Scientific Advisory Board members, our Chief Medical Officer, our Executive Vice President, Science and Technology, and our Chief Financial Officer. The loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#8220;key person&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50125628"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We expect to grow the size of our organization, and we may experience difficulties in managing this growth. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had 33 full-time employees and one part-time employee. As our development and commercialization plans and strategies develop, and as we continue to transition into operating as a public company, we expect to rapidly expand our employee base and continue to add managerial, operational, sales, research and development, marketing, financial and other personnel. For example, we are still dependent on Penn and certain Penn-affiliated entities to continue providing certain research and development as well as manufacturing services under that certain research services agreement. Current and future growth imposes significant added responsibilities on members of management, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">identifying, recruiting, integrating, maintaining and motivating additional employees; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">improving our operational, financial and management controls, reporting systems and procedures. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage our growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including certain research and development as well as general and administrative support, pursuant to agreements which expire after a certain period of time. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, or if we are not able to raise sufficient funds in the future to support our hiring efforts beyond our research and development personnel, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50125633"></a>Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations, Penn&#8217;s operations and those of any CMOs, CROs and other contractors and consultants that we may engage could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We currently rely on Penn to produce and process our first product candidate and anticipate that in the future we will rely on a third-party CMO for the same. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, due to the COVID-19 pandemic, our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business operations. Further, this could increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and other important agencies and contractors.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;;font-size:10pt;"><a name="_Hlk50125642"></a>&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Litigation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">inability to bring our product candidates to the market; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">decreased demand for our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">injury to our reputation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">withdrawal of clinical trial participants; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">initiation of investigations by regulators; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">costs to defend the related litigation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a diversion of management&#8217;s time and our resources; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">substantial monetary awards to trial participants or patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">loss of revenue; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">exhaustion of any available insurance and our capital resources; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the inability to commercialize any product candidate; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a decline in our share price. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since we have not yet commenced marketing of any products, we do not yet hold product liability insurance for commercialization of our product candidates. Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. Assuming we obtained clinical trial insurance for our clinical trials, we may have to pay amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Financial Condition and Capital Requirements </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Past Financial Condition</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have incurred net losses in every period since our inception and anticipate that we will incur substantial net losses over the next several years, and may never achieve or maintain profitability. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We have only recently licensed rights to the patents underlying our product candidates and initiated our DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial in June 2020. We have no products licensed for commercial sale, and we will continue to incur significant research and development and other expenses related to our ongoing operations. Our net losses may fluctuate significantly from quarter to quarter and year to year. We have to date financed our operations primarily through private placements of our preferred stock. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, we are not profitable and have incurred net losses in each period since our inception. For the years ended December 31, 2020 and 2019, we recorded net losses of $33.3 million and $16.9&#160;million, respectively. As of December 31, 2020, we had an accumulated deficit of $66.3&#160;million. We expect to incur significant losses for the foreseeable future, and we expect these losses to increase substantially if, and as, we: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">continue our research and development efforts and submit additional Investigational New Drug applications, or INDs, for our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">conduct preclinical studies and clinical trials for our current and future product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">further develop our product candidate platform; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">continue to discover and develop additional product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">maintain, expand and protect our intellectual property portfolio; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">hire additional clinical, scientific manufacturing and commercial personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain regulatory approval, whether through a contract manufacturing organization, or CMO, or through a manufacturing facility that we establish; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">acquire or in-license other product candidates and technologies, including advanced manufacturing and translational capabilities that we will need for the further development and possible commercialization of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">seek marketing approvals for any product candidates that successfully complete clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">establish a sales, marketing and distribution infrastructure to support the sales and marketing of any product candidates for which we may obtain marketing approvals; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts, as well as to support our transition to a public company. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To become and remain profitable, we must succeed in developing, and eventually commercializing, a product or products that generate significant revenue. The ability to achieve this success will require us to be effective in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, discovering additional product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities and have not yet demonstrated our ability to successfully develop any product candidate, obtain regulatory approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. We may never be able to develop, manufacture or commercialize a marketable product. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we are able to succeed in these activities, we may never generate revenues that are significant enough to achieve profitability. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Our expenses will increase if, among other things: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">there are any delays in completing our clinical trials or the development of any of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we are required by the FDA or other regulatory authorities to perform trials or studies in addition to, or different than, those expected; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">there are any third-party challenges to our intellectual property or we need to defend against any intellectual property-related claim. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses we will incur or when, if ever, we will be able to achieve profitability. Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop, seek regulatory approval for and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability, and we may face significant challenges and expense as we test our product candidates and build our capabilities. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in 2017 and initially acquired rights to license certain patent rights Penn in August 2018. We are early in our development efforts, have a limited operating history and are subject to the risks inherent to any newly-formed organization, including, among others, risks that we may not be able to hire sufficient qualified personnel and establish operating controls and procedures. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our limited operating history, particularly in light of the rapidly evolving cell therapy field, may make it difficult to evaluate our technology and industry and predict our future performance. Our short history as an operating company makes any assessment of our future success or viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer. Similarly, we expect that our financial condition and operating results will fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. As a result, our shareholders should not rely upon the results of any quarterly or annual period as an indicator of future operating performance.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently do not have in-house resources sufficient to enable our <font style="text-decoration:underline;">c</font>himeric <font style="text-decoration:underline;">a</font>uto<font style="text-decoration:underline;">a</font>ntibody <font style="text-decoration:underline;">r</font>eceptor, or CAAR, T cell platform. We are reliant on several manufacturing and support services from Penn through a Master Translational Research Services Agreement, or the Services Agreement, as well as certain research and development and general and administrative services through two sponsored research agreements. We also rely on Penn for access to key technologies for current manufacturing of our product candidates. As we build our own capabilities, and enter into agreements with third parties, we expect to encounter risks and uncertainties frequently experienced by growing companies in new and rapidly evolving fields, including the risks and uncertainties described herein. Our ability to rely on services from Penn is limited to a specified period of time, to specific capabilities, and is subject to Penn&#8217;s right to terminate these services with or without cause. If we are unable to establish necessary relationships with third party partners and build our own capabilities, our operating and financial results could differ materially from our expectations, and our business could suffer. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our programs require additional preclinical research and development, clinical development, regulatory approval in multiple jurisdictions, obtaining manufacturing supply, capacity and expertise, building of a commercial organization, substantial investment and significant marketing efforts before we generate any revenue from product sales. Other programs of ours require additional discovery research and then preclinical and clinical development. In </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition, our product candidates must be licensed for marketing by the FDA before we may commercialize any product. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as an early-stage company, we have encountered and may continue to encounter unforeseen expenses, difficulties, complications, delays and other known and unknown circumstances. As we advance our product candidates, we will need to transition from a company with a research focus to a company capable of supporting clinical development and if successful, commercial activities. We may not be successful in such a transition. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have not generated any revenue from our product candidates and our ability to generate revenue from product sales and become profitable depends significantly on our success in a number of areas. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To become and remain profitable, we or any potential future collaborator must develop and eventually commercialize products with significant market potential at an adequate profit margin after cost of goods sold and other expenses. All of our product candidates are in the early stages of development and we will require additional preclinical studies, clinical development, regulatory review and approval, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. We initiated our DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial of DSG3-CAART, our most advanced product candidate, targeting pathogenic B&#160;cells in patients with mucosal pemphigus vulgaris, or mPV, in June 2020. Our other product candidates, which include DSG3/1-CAART, targeting pathogenic B cells in patients with mucocutaneous pemphigus vulgaris, or mcPV, MuSK-CAART, targeting pathogenic B cells in a subset of patients with myasthenia gravis, or MG, and FVIII-CAART, for potential use as an adjunctive therapy targeting a subset of patients with Hemophilia A who develop alloantibody resistance to Factor VIII, or FVIII, replacement therapy, have yet to complete IND-enabling studies. We have not yet administered any of our product candidates in humans and, as such, we face significant translational risk as our product candidates advance to the clinical stage. Our ability to generate revenue depends on a number of factors, including, but not limited to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">timely completion of our preclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party academic and commercial contractors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to complete IND-enabling studies and successfully submit INDs or comparable applications; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">whether we are required by the FDA to conduct additional clinical trials or other studies beyond those planned to support the licensure and commercialization of our product candidates or any future product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to demonstrate to the satisfaction of the FDA the safety, potency, purity and acceptable risk to benefit profile of our product candidates or any future product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future product candidates, if any; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the cost of manufacturing and processing our product candidates being greater than we anticipate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the timely receipt of necessary marketing approvals from the FDA; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the willingness of physicians, operators of clinics and patients to utilize or adopt any of our product candidates or future product candidates to treat B cell-mediated autoimmune diseases; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability and the ability of third parties with whom we contract to manufacture adequate clinical and commercial supplies of our product candidates or any future product candidates, remain in good standing with regulatory authorities and develop, validate and maintain commercially viable manufacturing processes that are compliant with current Good Manufacturing Practices, or cGMP; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to successfully develop a commercial and competitive strategy and thereafter commercialize our product candidates or any future product candidates in the United States, if licensed for marketing, reimbursement, sale and distribution, whether alone or in collaboration with others; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">patient demand for our product candidates and any future product candidates, if licensed; and </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to establish and enforce intellectual property rights in and to our product candidates or any future product candidates. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of the factors listed above are beyond our control and could cause us to experience significant delays or prevent us from obtaining regulatory approvals or commercialize our product candidates. Even if we are able to commercialize our product candidates, we may not achieve profitability soon after generating product sales, if ever. If we are unable to generate sufficient revenue through the sale of our product candidates or any future product candidates, we may be unable to continue operations without continued funding. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Additionally, even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to research, develop and market additional product candidates. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause you to lose all or part of your investment. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Future Financial Condition </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will require substantial additional financing to develop and commercialize our product candidates and implement our operating plans. If we fail to obtain additional financing or cannot obtain financing at the levels we require due to unstable market and economic conditions or other reasons, we may be delayed in our plans or unable to complete the development and commercialization of our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to continue the preclinical and clinical development of our product candidates, including our DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial, our initial <font style="font-style:italic;">in vitro</font> studies and expected <font style="font-style:italic;">in vivo</font> studies of MuSK-CAART, and our planned studies for DSG3/1-CAART as well as research and development, preclinical studies and clinical trials for FVIII-CAART and any future product candidates, to seek regulatory approvals for our product candidates, to enable commercial production of our products, if licensed, and to initiate and complete registration trials for multiple products. While we currently expect our existing cash and cash equivalents and investments to be sufficient to fund our operations through completion of Part A Dose Escalation of our DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial, we expect to require significant additional financing to complete this Phase 1 trial, and any future clinical trials of DSG3-CAART and our other product candidates. Further, if licensed, we will require significant additional amounts of cash to launch and commercialize our product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2020, we had approximately $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108.7</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million of cash and cash equivalents and investments. On October 29, 2019, we completed an initial public offering of our common stock by issuing 7,275,501 shares of our common stock (including 475,501 shares of our common stock pursuant to the underwriters&#8217; option to purchase additional shares that we issued in November 2019), at $11.00 per share, for gross proceeds of $80.0 million, or net proceeds of $71.0 million. Based on our current operating plan, we believe that the net proceeds from our IPO together with our existing cash and cash equivalents and investments will be sufficient to fund our operations through at least the third quarter of 2022. However, we have based this estimate on assumptions that may prove to be wrong. Additionally, changing circumstances may cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may require substantial additional capital for the further development and commercialization of our product candidates, including funding our internal manufacturing capabilities, and may need to raise additional funds sooner if we choose to expand more rapidly than we presently anticipate. Because the length of time and activities associated with development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. Our future funding requirements, both near- and long-term, will depend on many factors, including, but not limited to: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the clinical development plans we establish for these product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the number and characteristics of product candidates that we may develop or in-license; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the terms of any collaboration agreements we may choose to conclude; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the outcome, timing and cost of meeting regulatory requirements established by the FDA; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the effect of competing technological and market developments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs of establishing and maintaining a supply chain for the development and manufacture of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the cost and timing of establishing, expanding and scaling manufacturing capabilities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the cost of maintaining the amount patient data for which we would be responsible following commercialization of one or more of our product candidates; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot be certain that additional funding will be available on acceptable terms, or at all. As widely reported, global credit and financial markets have experienced extreme volatility and disruptions from the COVID-19 pandemic and related factors, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Until we are able to generate sufficient revenue to finance our cash requirements, we will need to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue our research and development initiatives and clinical development plans. We could be required to seek collaborators for our product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to our product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that significant additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to our equity incentive plans, our management is authorized to grant stock options to our employees, directors and consultants. Additionally, the number of shares of our common stock reserved for issuance under the 2019 Stock Option and Incentive Plan automatically increased on January&#160;1, 2020 and will automatically increase each January 1 thereafter through and including January&#160;1, 2029, by&#160;4% of the total number of shares of our capital stock outstanding on December&#160;31 of the preceding calendar year, or a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We rely heavily on certain in-licensed patent and other intellectual property rights in connection with our development of our product candidates and, if we fail to comply with our obligations under our existing and any future intellectual property licenses with third parties, we could lose license rights that are important to our business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to develop and commercialize our product candidates is heavily dependent on in-licenses to patent rights and other intellectual property granted to us by third parties. For example, we depend heavily on our License Agreement with Penn and CHOP, which was entered into in 2018, amended and restated in July 2019, and further amended in May 2020, pursuant to which we obtained <font style="color:#000000;">(a)&#160;a non-exclusive, non-sublicensable, worldwide research license to intellectual property controlled by Penn and CHOP to make, have made and use products in two subfields of use, (b)&#160;effective as of October 2018, an exclusive, worldwide, royalty-bearing license, with the right to sublicense, under certain of such intellectual property to make, use, sell, offer for sale and import products in the same two subfields of use, and (c)&#160;effective as of October 2018, a non-exclusive, worldwide, royalty-bearing license, with limited rights to sublicense, under certain of Penn&#8217;s know-how, which know-how satisfies certain criteria and is listed on a mutually agreed to schedule, to make, have made, use, sell, offer for sale, import and have imported products in the same two subfields of use</font>. We may enter into additional license agreements in the future. Our license agreement with Penn and CHOP imposes, and we expect that future license agreements will impose, various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with our obligations under these licenses, our licensors, including Penn and CHOP, may have the right to terminate these license agreements, in which event we might not be able to market our product candidates. Termination of any of our license agreements or reduction or elimination of our licensed rights may also result in our having to negotiate new or reinstated licenses with less favorable terms. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may need to obtain additional licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current product candidates or future products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, in many cases, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we in-license from third parties. For example, pursuant to our License Agreement with Penn and CHOP, Penn controls such activities for the patent rights licensed to us under such agreement. Therefore, although we provide input to Penn and CHOP on these activities, we cannot be certain that these patents will be prosecuted, maintained and enforced in a manner consistent with the best interests of our business. If our current or future licensors or collaboration partners fail to obtain, maintain or protect any patents or patent applications licensed to us, our rights to such patents and patent applications may be reduced or eliminated and our right to develop and commercialize any of our product candidates that are the subject of such licensed rights could be adversely affected. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disputes may arise between us and our current and future licensors regarding intellectual property subject to a license agreement, including those related to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the scope of rights granted under the License Agreement and other interpretation-related issues; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">whether we have breached the License Agreement and whether any such breach is subject to a cure period; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our right to sublicense patent and other rights to third parties under collaborative development relationships; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, disputes may arise between us and our current or future licensors regarding the ownership of intellectual property developed by us, such that we may be required to assign or otherwise transfer such intellectual property to such licensor. In the event that the assigned or transferred intellectual property is covered by an existing license agreement with such licensor we may be required to make additional royalty or milestone payments, or both, to such licensor. If the assigned or transferred intellectual property is not covered by an existing license agreement, then we may be required to enter into an additional license agreement to advance our research or allow commercialization of our product candidates, which may not be available on commercially reasonable terms or at all. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If disputes over intellectual property that we have licensed, or license in the future, prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our efforts to protect the proprietary nature of the intellectual property related to our current and any future product candidates are not adequate, we may not be able to compete effectively in our market. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends in large part on our ability to obtain and maintain intellectual property protection in the United States and other countries with respect to our product candidates. If we do not adequately protect or enforce our intellectual property rights, competitors may be able to erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. To protect our proprietary position, we have in-licensed patent rights in the United States and abroad relating to the product candidates that are important to our business. The patent application and approval process is expensive, complex and time-consuming. Our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. In addition, the determination of patent rights with respect to biological and pharmaceutical products commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Assuming the other requirements for patentability are met, currently, the first to file&#160;a patent application is generally entitled to the patent. However, prior to March&#160;16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot be certain that our licensors were the first to make the inventions claimed in the patents or pending patent applications we in-license, or that our licensors were the first to file for patent protection of such inventions. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, the patents or pending patent applications we in-license may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to a third party preissuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or become involved in post-grant review procedures, derivation proceedings, reexaminations, or<font style="font-style:italic;">&#160;inter partes</font>&#160;review in the United States, or oppositions and other comparable proceedings in foreign jurisdictions, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of the patents we in-license or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent or in the same manner as the laws of the United States. For example, European patent law is more restrictive than U.S. patent law in connection with the patentability of methods of treatment of the human body. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict whether the patent applications we in-license currently being pursued will issue as patents, whether the claims of any patent that has or may issue will provide us with a competitive advantage or prevent competitors from designing around the claims to develop competing technologies in a&#160;non-infringing&#160;manner, or whether we or our licensors will be able to successfully pursue patent applications in the future relating to our current product candidates or future products and product candidates. Moreover, the patent application and approval process is expensive and time-consuming. We or our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Furthermore, we, or any future partners, collaborators, or licensees, may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to seek additional patent protection. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is possible that defects of form in the preparation or filing of patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If there are material defects in the form, preparation, prosecution or enforcement of the patents or patent applications we in-license, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if the patent applications we in-license issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patent rights by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may also seek approval to market their own products similar to or otherwise competitive with our product candidates. Alternatively, our competitors may seek to market generic versions of any approved products by submitting abbreviated BLAs to the FDA during which process they may claim that patents licensed by us are invalid, unenforceable or not infringed. In these circumstances, we may need to defend or assert our intellectual property rights, or both, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find the patents we in-license invalid or unenforceable, or that our competitors are competing in a non-infringing manner. Thus, even if we have in-licensed valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, we likely will need to expand our patent portfolio to pursue patent coverage for new product candidates that we wish to develop. The patent prosecution process is competitive, and other companies, some which may have greater resources than we do in this area, may also be pursuing intellectual property rights that we may consider necessary or attractive in order to develop and commercialize future product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting, maintaining, defending and enforcing patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. The deadline to pursue protection in foreign jurisdictions for many of the patent families licensed under the License Agreement with Penn has not yet expired. Prior to applicable deadlines, we and Penn will need to decide where to pursue protection, and we will not have the opportunity to pursue protection unless we do so in applicable jurisdictions prior to the deadlines. Although our License Agreement grants us worldwide rights, there can be no assurance that we will obtain or maintain patent rights in or outside the United States under any future license agreements. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States even in jurisdictions where we and our licensors pursue patent protection. Consequently, we and our licensors may </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not be able to prevent third parties from practicing our inventions in all countries outside the United States, even in jurisdictions where we and our licensors pursue patent protection, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we and our licensors have not pursued and obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates and the patents we in-license or other intellectual property rights may not be effective or sufficient to prevent them from competing. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of the patents we in-license or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights, even if obtained, in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put the patents we in-license at risk of being invalidated or interpreted narrowly and the patent applications we in-license at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We or our licensors may be subject to claims challenging the inventorship or ownership of the patents and other intellectual property that we own or license. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an ownership interest in the patents and intellectual property that we in-license or that we may own or in-license in the future. While it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own or such assignments may not be self-executing or may be breached. Our licensors may face similar obstacles. We or our licensors could be subject to ownership disputes arising, for example, from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. For example, our scientific co-founders, Drs. Payne and Milone, are members of our scientific advisory board and are also employed by and subject to Penn&#8217;s intellectual property policy. Litigation may be necessary to defend against any claims challenging inventorship or ownership. If we or our licensors fail in defending any such claims, we may have to pay monetary damages and may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property, which could adversely impact our business, results of operations and financial condition. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Some intellectual property which we have&#160;in-licensed&#160;was discovered through government funded programs and thus is subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of the intellectual property rights we have licensed, including rights licensed to us by Penn relating to our DSG3-CAART and DSG3/1-CAART product candidates, was generated through the use of U.S. government funding and may therefore be subject to certain federal laws and regulations. As a result, the U.S. government has certain rights to intellectual property embodied in our DSG3-CAART and DSG3/1-CAART product candidates and may have rights in future product candidates pursuant to the Bayh-Dole Act of 1980. These U.S. government rights in certain inventions developed under a government-funded program include a&#160;non-exclusive,&#160;non-transferable,&#160;irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or&#160;non-exclusive&#160;licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii)&#160;government action is necessary to meet requirements for public use under federal regulations, also referred to as&#160;&#8220;march-in&#160;rights&#8221;. The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, such as Penn, fail to disclose the invention to the government and fail to file an application to register the intellectual property within </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with&#160;non-U.S.&#160;product manufacturers for product candidates covered by such intellectual property. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may become involved in lawsuits to protect or enforce our patent rights or other intellectual property rights, which could be expensive, time consuming and unsuccessful. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe, misappropriate or otherwise violate patents, trademarks, copyrights or other intellectual property that we own or&#160;in-license.&#160;To counter infringement, misappropriation or other unauthorized use, we may be required to file claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived violators could provoke these parties to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property, in addition to counterclaims asserting that the patents we in-license are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent we in-license is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that the patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving the patents we in-license could limit our ability to assert the patent we in-license against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we establish infringement, misappropriation or another violation of our intellectual property rights, the court may decide not to grant an injunction against the offender and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our shares. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. Any of the foregoing may have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in either the patent laws or the interpretation of the patent laws in the United States or other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. On September&#160;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. When implemented, the Leahy-Smith Act included several significant changes to U.S. patent law that impacted how patent rights could be prosecuted, enforced and defended. In particular, the Leahy-Smith Act also included provisions that switched the United States from a&#160;&#8220;first-to-invent&#8221;&#160;system to a&#160;&#8220;first-to-file&#8221;&#160;system, allowed third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings. Under a&#160;first-to-file&#160;system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO developed new regulations and procedures governing </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective on March&#160;16, 2013. It remains unclear what impact, if any, the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of the patent applications we in-license and the enforcement or defense of the issued patents we in-license, all of which could have a material adverse effect on our business. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions of companies engaged in the development and commercialization of biologics are particularly uncertain. For example, the Supreme Court of the United States issued its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., or Myriad, a case involving patent claims held by Myriad Genetics, Inc. relating to the breast cancer susceptibility genes BRCA1 and BRCA2. Myriad held that an isolated segment of naturally occurring DNA, such as the DNA constituting the BRCA1 and BRCA2 genes, is not patent-eligible subject matter, but that complementary DNA, which is an artificial construct that may be created from RNA transcripts of genes, may be patent-eligible. Thereafter, the USPTO issued a guidance memorandum instructing USPTO examiners on the ramifications of the Prometheus and Myriad rulings and apply the Myriad ruling to natural products and principles including all naturally occurring nucleic acids. Certain claims of our&#160;in-licensed&#160;patent applications contain, and any future patents we may obtain may contain, claims that relate to specific recombinant DNA sequences that are naturally occurring at least in part and, therefore, could be the subject of future challenges made by third parties. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot assure you that our efforts to seek patent protection for one or more of our product candidates will not be negatively impacted by this Supreme Court decision, rulings in other cases or changes in guidance or procedures issued by the USPTO. We cannot fully predict what impact the Supreme Court&#8217;s decisions in Myriad may have on the ability of life science companies to obtain or enforce patents relating to their products in the future. These decisions, the guidance issued by the USPTO and rulings in other cases or changes in USPTO guidance or procedures could have a material adverse effect on our existing patent rights and our ability to protect and enforce our intellectual property in the future. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of trade secrets, our business and competitive position would be harmed. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect certain proprietary&#160;know-how&#160;that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce, and any other elements of our product candidate discovery and development processes that involve proprietary&#160;know-how,&#160;information or technology that is not covered by patents. However, trade secrets can be difficult to protect and some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our trade secrets may otherwise become known or be independently discovered by competitors. Competitors and other third parties could infringe, misappropriate or otherwise violate our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If our trade secrets are not adequately protected or sufficient to provide an advantage over our competitors, our competitive position could be adversely affected, as could our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent term may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication (or any additional indications approved during the period of extension). However, a patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of the product&#8217;s approval by the FDA, only one patent applicable to an approved drug is eligible for the extension, and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. In the future, if and when our product candidates receive FDA approval, we plan to apply for patent term extensions on patents covering those product candidates in any jurisdiction where these are available. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to the patents we in-license, or may grant more limited extensions than we request. Moreover, we may not receive an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or&#160;know-how&#160;of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. Our licensors may face similar risks, which could have an adverse impact on intellectual property that is licensed to us. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual property rights do not necessarily address all potential threats. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">others may be able to make products that are similar to our product candidates or utilize similar cell therapy technology but that are not covered by the claims of our current or future patent portfolio; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we, or our current or future licensors or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license now or that we may license or own in the future; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we, or our current or future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our licensed intellectual property rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">it is possible that our current or future licensed patent applications will not lead to issued patents; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may not develop additional proprietary technologies that are patentable; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the patents of others may harm our business; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent application covering such intellectual property; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">third-party patents may issue with claims covering our activities; we may have infringement liability exposure arising from such patents. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may become subject to claims that we are infringing certain third-party patents or other third-party intellectual property rights, any of which may prevent or delay our development and commercialization efforts and have a material adverse effect on our business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on avoiding infringing, misappropriating and otherwise violating the patents and other intellectual property and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, and administrative proceedings such as interferences,<font style="font-style:italic;">&#160;inter partes</font>&#160;review and post grant review proceedings before the USPTO and opposition proceedings before foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned or controlled by third parties, including our competitors, exist in the fields in which we are pursuing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may assert that we or our licensors are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, methods of manufacture or methods for treatment relating to our product candidates and, because patent applications can take many years to issue, there may be currently pending third party patent applications which may later result in issued patents, in each case that our product candidates, their manufacture or use may infringe or be alleged to infringe. We may fail to identify potentially relevant patents or patent applications, incorrectly conclude that a patent is invalid or does not cover our activities, or incorrectly conclude that a patent application is unlikely to issue in a form of relevance to our activities. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parties making patent infringement claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, including demonstrating non-infringement, invalidity or unenforceability of the respective patent rights in question, regardless of their merit, is time-consuming, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. For example, in order to successfully challenge the validity of any U.S. patent in federal court, we would need to overcome a presumption of validity. This is a high burden requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, and we can provide no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. We may not have sufficient resources to bring these actions to a successful conclusion. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our shares. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that a holder of any such patents seeks to enforce its patent rights against us with respect to one or more of our product candidates, and our defenses against the infringement of such patent rights are unsuccessful, we may be precluded from commercializing our product candidates, even if approved, without first obtaining a license to some or all of these patents, which may not be available on commercially reasonable terms or at all. Moreover, we may be required to pay significant fees and royalties to secure a license to the applicable patents. Such a license may only be&#160;non-exclusive,&#160;in which case our ability to stop others from using or commercializing technology and products similar or identical to ours may be limited. Furthermore, we could be liable for damages to the holder of these patents, which may be significant and could include treble damages if we are found to have willfully infringed such patents. In the event that a challenge to these patents were to be unsuccessful or we were to become subject to litigation or unable to obtain a license on commercially reasonable terms with respect to these patents, it could harm our business, financial condition, results of operations and prospects. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are aware of third-party issued U.S. patents relating to the lentiviral vectors which may be used in the manufacture or use of our product candidates. If these patent rights were enforced against us, we believe that we have defenses against any such action, including that these patents would not be infringed by our product candidates and/or that these patents are not valid. However, if these patents were enforced against us and defenses to such enforcement were unsuccessful, unless we obtain a license to these patents, which may not be available on commercially reasonable terms, or at all, we could be liable for damages and precluded from commercializing any product candidates that were ultimately held to infringe these patents, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even in the absence of a finding of infringement, we may need or may choose to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, or at all. In that event, we would be unable to further develop and commercialize our product candidates. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. Any of the foregoing could materially adversely affect our business, results of operations and financial condition. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Reliance on Third Parties </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are reliant on a research services agreement with Penn for our nonclinical research and development activities and current manufacturing activities. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Penn and its affiliated entities were to fail to perform their obligations in accordance with the terms of the Services Agreement or terminate the Services Agreement with little notice, we may have difficulty continuing our normal business operations and our business prospects, financial condition and results of operations could be harmed. In addition, the termination of our relationship with Penn and the Services Agreement and any delay in appointing or finding a suitable replacement provider, if one exists, could make it difficult for us to operate our business for that period. Moreover, we will be reliant on Penn to assist us with any necessary technology transfer. Any delays or inadequacies in such technology transfer, or disputes regarding the scope of such technology transfer, could delay our operations, including our clinical trials, require us to expend additional resources and otherwise have an adverse effect on our business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, over time we will need to transition from receiving the services that Penn currently provides to performing such services internally. The Services Agreement is scheduled to expire on the later of October&#160;19, 2021 or completion of all research and development projects, and unless the Services Agreement is amended, Penn will not be obligated to provide any further services under the Services Agreement after that time. In addition, Penn has the right to terminate the Services Agreement in whole at any time with 90 days&#8217; notice and to terminate any research and development project being performed under the Services Agreement if the Penn service provider appointed to lead such project is unavailable and Penn is unavailable to find a replacement within 60 days for such service provider. Penn also has the right to terminate certain manufacturing services being performed under the Services Agreement with 180 days&#8217; written notice. From time to time, we may enter into further addenda to the Services Agreement that provide Penn with the right to terminate such addenda with limited notice periods. If we do not have adequate personnel and capabilities at the time that we assume responsibilities for such services, we may not be successful in effectively or efficiently transitioning these services from Penn, which could disrupt our business and have a material adverse effect on our financial condition and results of operations. Further, we will incur costs relating to establishing our own financial, administrative, information technology and other support functions as well as running and maintaining such functions on a going-forward basis. In addition, the process of establishing such functions may distract our management from focusing on business and strategic opportunities and could result in disruptions to our business. Even if we are able to successfully transition these services, they may be more expensive or less efficient than the services we are receiving from Penn during the transition period. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We depend and will continue to depend upon third parties, including independent investigators and collaborators, such as universities, medical institutions, CROs and strategic partners, to conduct our preclinical studies and clinical trials under agreements with us. Specifically, we depend on clinical trial sites to enroll patients and conduct the DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial in a timely and appropriate manner. If our clinical trial sites do not conduct the trial on the timeline we expect or otherwise fail to support the trial, our clinical trial results could be significantly delayed, thereby adversely impacting our leadership position in the CAAR T industry and our ability to progress additional product candidates. Further, although we intend to transition our manufacturing needs to a CMO and eventually secure our own clinical manufacturing facility, we must currently rely on Penn to manufacture supplies and process our product candidates. As we open additional clinical trial sites, we expect to have to negotiate budgets and contracts with CROs and study sites, which may result in delays to our development timelines and increased costs. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will rely heavily on these third parties, including Penn, to conduct our preclinical studies and clinical trials, and as a result, will have limited control over the clinical investigators and limited visibility into their day-to-day activities, including with respect to their compliance with the approved clinical protocol. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with Good Clinical Practices, or GCPs, which are regulations and guidelines enforced by the FDA for product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our marketing applications. We cannot provide assurance that, upon inspection, such regulatory authorities will not determine that some or all of our clinical trials do not fully comply with the GCP requirements. For any violations of laws and regulations during the conduct of our clinical trials, we could be subject to untitled and warning letters or enforcement action that may include civil penalties up to and including criminal prosecution. In addition, our clinical trials must be conducted with biologic product produced under cGMPs and will require a large number of test patients. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As widely reported, global credit and financial markets have experienced extreme volatility and disruptions from the COVID-19 pandemic and related factors, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. In the event that one or more of our current or future service providers, manufacturers and other partners do not successfully carry out their contractual duties, meet expected deadlines, or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, due to the economic downturn or for any other reasons, then we may not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we may develop and will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines. Our failure or the failure of these third parties to comply with applicable regulatory requirements or our stated protocols could also subject us to enforcement action. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any third parties conducting our clinical trials will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical and clinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our relationships with trial sites, or any CRO that we may use in the future, terminates, we may not be able to enter into arrangements with alternative trial sites or CROs or do so on commercially reasonable terms. Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is often a natural transition period when a new third party commences work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of any </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product candidates we may develop or commercialization of our medicines, producing additional losses and depriving us of potential product revenue. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We intend to rely on third parties to manufacture our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if licensed. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we may eventually secure our own clinical manufacturing facility for any late phase clinical development that we undertake, we currently rely on Penn to supply raw materials and other important components that are used to manufacture our product candidates and intend in the future to rely on CMOs. In the case of any manufacturing performed for us by Penn, the services performed for us risk being delayed because of the competing priorities that Penn has for utilization of its manufacturing resources and any capacity issues that thereby arise. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not yet have sufficient information to reliably estimate the cost of the manufacturing and processing of our product candidates in clinical quantity or commercial quantity, and the actual cost to manufacture and process our product candidates could ultimately materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our anticipated reliance on a limited number of third-party manufacturers exposes us to the following risks: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of FDA questions, if any. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Our third-party manufacturers might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Contract manufacturers may not be able to execute our manufacturing procedures appropriately. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Any contract manufacturers that we engage may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our product candidates. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP and other government regulations. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Our third-party manufacturers could breach or terminate their agreement with us. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, all of our contract manufacturers are engaged with other companies to supply and/or manufacture materials or products for such companies, which exposes our manufacturers to regulatory risks related to the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may affect the regulatory clearance of our contract manufacturers&#8217; facilities generally. If the FDA does not approve these facilities for the manufacture of our product candidates or if any agency withdraws its approval in the future, we may need to find alternative manufacturing facilities, which would negatively impact our ability to develop, obtain regulatory approval for or market our product candidates, if licensed. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our contract manufacturers would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above. Each of these risks could delay our clinical trials, the approval, if any of our product candidates by the FDA or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue. In addition, we will rely on third parties to perform release tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For more information, see &#8220;Risk Factors&#8212;Risks Related to Manufacturing and Supply&#8221;. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety, potency and purity. Any delays in entering into new strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. For instance, our License Agreement with Penn and CHOP requires significant research and development commitments that may not result in the development and commercialization of our product candidates, including DSG3-CAART and our other product candidates. We cannot be certain that, following a strategic transaction or license, we will achieve the results, revenue or specific net income that justifies such transaction. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not realize the benefits of acquired assets or other strategic transactions, including any transactions whereby we acquire or license manufacturing and other advanced technologies. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, we entered into a License Agreement with Penn and CHOP which was amended and restated in July 2019, and further amended in May 2020, or the License Agreement, pursuant to which we were granted licenses to certain patent rights for the research and development of products, as well as an exclusive license under those same patent rights to make, use, sell and import such products, in the autoimmune disease and alloimmune response subfields, in each case, for the treatment of humans. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We actively evaluate various strategic transactions on an ongoing basis. We may acquire other businesses, products or technologies as well as pursue joint ventures or investments in complementary businesses. The success of our strategic transactions, including the License Agreement, and any future strategic transactions depends on the risks and uncertainties involved including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">unanticipated liabilities related to acquired companies or joint ventures; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">difficulties integrating acquired personnel, technologies and operations into our existing business; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">retention of key employees; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">diversion of management time and focus from operating our business to management of strategic alliances or joint ventures or acquisition integration challenges; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">increases in our expenses and reductions in our cash available for operations and other uses; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">disruption in our relationships with collaborators or suppliers as a result of such a transaction; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">possible write-offs or impairment charges relating to acquired businesses or joint ventures. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of these risks or uncertainties occur, we may not realize the anticipated benefit of any acquisition or strategic transaction. Additionally, foreign acquisitions and joint ventures are subject to additional risks, including those related to integration of operations across different cultures and languages, currency risks, potentially adverse </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tax consequences of overseas operations and the particular economic, political and regulatory risks associated with specific countries. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Manufacturing and Supply </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50127784"></a>We currently rely upon Penn for our manufacturing needs, and we intend to rely on other third parties for our future manufacturing needs prior to establishing our own manufacturing facility. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently reliant upon Penn for our cell product manufacturing for our lead product candidate, DSG3-CAART. In parallel with initiating our first clinical trial, we have entered into an agreement with a CMO to help secure the manufacturing supply chain for future product candidates. We will need to develop relationships with suppliers, increase the scale of production and demonstrate comparability of the material produced at these facilities to the material that was previously produced. Transferring manufacturing processes and know-how is complex and involves review and incorporation of both documented and undocumented processes that may have evolved over time. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, transferring production to different facilities may require utilization of new or different processes to meet the specific requirements of a given facility. We would expect additional comparability work will also need to be conducted to support the transfer of certain manufacturing processes and process improvements. We cannot be certain that all relevant know-how and data has been adequately incorporated into the manufacturing process until the completion of studies (and the related evaluations) intended to demonstrate the comparability of material previously produced with that generated by any CMO that we engage for our manufacturing needs. If we are not able to successfully transfer and produce comparable product candidates, our ability to further develop and manufacture our product candidates may be negatively impacted. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to eventually establish our own manufacturing facility. While the addition of our own manufacturing facility would provide us with future flexibility within our manufacturing network, we still may need to identify additional CMOs for continued production of supply for some or all of our product candidates. Given the nature of our manufacturing processes, the number of CMOs who possess the requisite skill and capability to manufacture our CAAR T cell immunotherapy product candidates is limited. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, we may not be able to achieve clinical manufacturing and cell processing through Penn on a timely basis, on our own or at any future </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CMO</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. While our current manufacturing process is based off the validated process developed at Penn for CD19 CAR T, or CART19, we have limited experience as an organization in managing the CAAR T engineering process. Finally, because clinical manufacturing and cell processing is highly complex</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and patient donor material is inherently variable</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, we cannot be sure that the manufacturing processes employed by Penn, any </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CMO</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that we engage in the future, or by us at a manufacturing facility that we establish will consistently result in T cells that will be safe and effective. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50127795"></a>Our product candidates are uniquely manufactured. If we, Penn or any of our third-party manufacturers encounter difficulties in manufacturing our product candidates, our ability to provide supply of our product candidates for clinical trials or, if licensed, for commercial sale, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacturing process used to produce our product candidates is complex and novel, and it has not yet been validated for commercial production. Among the complex processes used in the manufacture of our product candidates is the manufacture of the lentiviral delivery vector used to deliver the applicable CAAR gene into the T cells. For example, the manufacture of our product candidates includes harvesting white blood cells from each patient, stimulating certain T cells from the white blood cells and thereby causing them to activate and proliferate, combining patient T cells with our lentiviral delivery vector through a process known as transduction, expanding the transduced T cells to obtain the desired dose, and ultimately infusing the modified T cells back into the patient&#8217;s body. Notably, the manufacture of both DSG3/1-CAART and FVIII-CAART may be more challenging or require new gene delivery technology due to the need to deliver large transgenes for these programs, and vector delivery systems have size limitations. Because of these complexities, the cost to manufacture our product candidates is higher than traditional small molecule chemical compounds and monoclonal antibodies, and the manufacturing process is less reliable and is more difficult to reproduce. Furthermore, our manufacturing process development and scale-up is at an early stage. The actual cost to manufacture and process our product candidates could be greater than we expect and could materially and adversely affect the commercial viability of our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our manufacturing process may be susceptible to technical and logistics delays or failures due to the fact that each patient is an independent manufacturing lot, and also due to unique supply chain requirements.&nbsp;&nbsp;These include  the collection of white blood cells from patients&#8217; blood, variability in the quality of white blood cells collected from patients&#8217; blood, cryopreservation of the white blood cells collected, packaging and shipment of frozen white blood cells to the manufacturing site in order to enable multi-site studies, procurement of lentiviral vectors that meet potency and purity requirements and shipment to the product candidate manufacturing site, shipment of the final product to clinical centers, manufacturing issues associated with interruptions in the manufacturing process, scheduling constraints for cell manufacturing slots, process contamination, equipment or reagent failure, improper installation or operation of equipment, vendor or operator error, and inconsistency in cell growth. Even minor deviations from normal manufacturing processes could result in reduced production yields, lot failures, product defects, product recalls, product liability claims and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, production at such manufacturing facilities may be interrupted for an extended period of time to investigate and remedy the contamination. Further, as product candidates are developed through preclinical studies to late-stage clinical trials toward approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes and results. Such changes may result in the need to enroll additional patients or to conduct additional clinical studies to evaluate the impact of changes on product safety and efficacy. Penn has informed us that it will be unable provide clinical supply for any late-phase clinical trials of our product candidates that we may conduct. Therefore, we will need to enter into new agreements with CMOs to produce clinical supply of our product candidates for late-phase clinical trials. We cannot guarantee that we will be able to enter into such agreements on commercially acceptable terms, if at all. We will need to transfer the technology to manufacture our product candidates to these CMOs, and these CMOs may decide or be required to adopt different manufacturing protocols or processes, which may require us to amend any ongoing or proposed clinical trial protocols or perform additional preclinical studies to demonstrate the comparability of any such new manufacturing protocols or processes. We cannot provide any assurance that Penn will provide adequate support to efficiently and effectively transfer the technology or that disputes will not arise between us and Penn regarding the necessary scope of technology transfer, that the technology transfer will be successful, or that any CMO will be successful in producing our product candidates in sufficient quantities or of acceptable quality, if at all. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of ongoing and planned clinical trials or other future clinical trials. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we continue to optimize our manufacturing process for our product candidates, doing so is a difficult and uncertain task, and there are risks associated with scaling to the level required for advanced clinical trials or commercialization, including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, lot consistency and timely availability of reagents and/or raw materials. We ultimately may not be successful in transferring our production system from our contract manufacturer to any manufacturing facilities we may establish ourselves, or our contract manufacturer may not have the necessary capabilities to complete the implementation and development process. If we are unable to adequately validate or scale-up the manufacturing process for our product candidates with our current manufacturer, we will need to transfer to another manufacturer and complete the manufacturing validation process, which can be lengthy. If we are able to adequately validate and scale-up the manufacturing process for our product candidates with a contract manufacturer, we will still need to negotiate with such contract manufacturer an agreement for commercial supply and it is not certain we will be able to come to agreement on terms acceptable to us. As a result, we may ultimately be unable to reduce the cost of goods for our product candidates to levels that will allow for an attractive return on investment if and when those product candidates are commercialized. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk50127801"></a>In addition, many of the components which are required to support our cell manufacturing process, such as equipment, media, growth factors and disposables, are highly specialized and it is possible that the supply chain for these materials may be interrupted. If we are unable to promptly remedy such interruption, then there may be delays to our clinical development efforts.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The manufacturing process for any products that we may develop is subject to the FDA approval process, and we will need to contract with manufacturers who can meet all applicable FDA requirements on an ongoing basis. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacturing process for any products that we may develop is subject to the FDA approval process, and we will need to contract with manufacturers who can meet all applicable FDA requirements on an ongoing basis. If we or our CMOs are unable to reliably produce products to specifications acceptable to the FDA, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CMOs will be able to manufacture the approved product in accordance with requirements from the FDA, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, suspension of production or recalls of the product candidates or marketed biologics, operating restriction and criminal prosecutions, delay approval of our product candidates, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our business, financial condition, results of operations and growth prospects. Our future success depends on our ability to manufacture our products, if licensed, on a timely basis with acceptable manufacturing costs, while at the same time maintaining good quality control and complying with applicable regulatory requirements, and an inability to do so could have a material adverse effect on our business, financial condition, and results of operations. In addition, we could incur higher manufacturing costs if manufacturing processes or standards change, and we could need to replace, modify, design, or build and install equipment, all of which would require additional capital expenditures. Specifically, because our product candidates may have a higher cost of goods than conventional therapies, the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50127804"></a>The manufacture of viral vectors is complex and variable, and there are a limited number of manufacturers able to supply us with viral vectors. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our DSG3-CAART and MuSK-CAART product candidates utilize a lentiviral delivery vector and some or all of our other product candidates may require a lentiviral delivery vector, a key drug substance that delivers the CAAR to the target T cells. We do not have the capability to manufacture lentiviral vector and plan to obtain the vector we require from third parties. The manufacturing process for lentiviral vector is variable and still evolving. It is not uncommon for manufacturing runs to fail, whether due to contamination, supplier error, or equipment failure, or to be delayed. To the extent our product candidates use a lentiviral delivery vector, a lack of vector supply will cause us to be unable to manufacture our CAAR T cells as well as a delay in patient enrollment, which may have a negative impact on our ability to successfully develop our product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, there are a limited number of manufacturers capable of producing lentiviral vectors. It can be challenging to secure a relationship with any of these manufacturers, and the manufacturing and release process can take a significant amount of time. We have secured a supply of lentiviral vector from CHOP sufficient for a portion of the patients we plan to enroll in our DesCAARTes</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. We have also reserved additional vector manufacturing capacity at Penn </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and CHOP </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and we have engaged other </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CMO</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s to evaluate their potential capabilities and capacity for additional supply. There is no assurance that we will be able to secure adequate and timely supply of lentiviral vector. Moreover, we cannot be certain that our CAAR&#160;T&#160;cell product candidates produced with lentiviral vector from different manufacturers will be comparable or that results of clinical trials will be consistent if conducted with lentiviral vector from different manufacturers. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vector production also requires the production of high-quality DNA plasmids, for which there is also a limited number of suppliers. Although we have established relationships with multiple suppliers for lentiviral vector and plasmids, we do not yet have our own clinical-scale manufacturing facility established, and are therefore highly dependent on the ability of these suppliers to manufacture necessary materials and to deliver these materials to us on a timely and reliable basis. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50127787"></a>If we are to operate our own manufacturing facility, significant resources will be required and we may fail to successfully operate our facility, which could adversely affect our clinical trials and the commercial viability of our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we establish our own manufacturing facility, our operations will be subject to review and oversight by the FDA and the FDA could object to our use of our manufacturing facility. We must first receive approval from the FDA prior to licensure to manufacture our product candidates, which we may never obtain. Even if licensed, we would be subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMPs and other government regulations. Our license to manufacture product candidates will be subject to continued regulatory review. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cost of goods development is at an early stage. The actual cost to manufacture and process our product candidates could be greater than we expect and could materially and adversely affect the commercial viability of our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50127790"></a>The manufacture of biopharmaceutical products is complex and requires significant expertise, and can be impacted by resource constraints, labor disputes and workforce limitations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacture of biopharmaceutical products is complex and requires significant expertise, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial production and ensuring the absence of contamination. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants are discovered in our supply of product candidates or in the manufacturing facilities upon which we currently or will rely, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability or other issues relating to the manufacture of our product candidates, whether by Penn, by a third-party CMO, or at any manufacturing facility that we may establish, will not occur in the future. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penn, third-party CMOs that we engage or we may fail to manage the logistics of storing and shipping our product candidates. Storage failures and shipment delays and problems caused by us, our vendors or other factors not in our control, such as weather, could result in loss of usable product or prevent or delay the delivery of product candidates to patients. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penn, third-party CMOs that we engage, or we may also experience manufacturing difficulties due to resource constraints, labor disputes or workforce limitations arising from the expanding need for manufacturing in the cell therapy field and the limited number of training programs for technical staff. If we were to encounter any of these difficulties, our ability to provide our product candidates to patients would be jeopardized. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50127792"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are dependent upon the availability of specialty raw materials and the production capabilities of small manufacturers to source the components of our product candidates. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates require many specialty raw materials, some of which are manufactured by small companies with limited resources and experience to support a commercial product, and the suppliers may not be able to deliver raw materials to our specifications. In addition, those suppliers generally do not have the capacity to support commercial products manufactured under cGMP by biopharmaceutical firms. The suppliers may be ill-equipped to support our needs, especially in non-routine circumstances like an FDA inspection or medical crisis, such as widespread contamination. We also do not have contracts with many of these suppliers, and we may not be able to contract with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key raw materials to support clinical or commercial manufacturing. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, some raw materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Further, we may be unable to enter into agreements with a new supplier on commercially reasonable terms, which could have a material adverse impact on our business. We are also unable to predict how changing global economic conditions or global health concerns such as the COVID-19 pandemic&#160;will affect our third-party suppliers and manufacturers. For example, two vaccines for COVID-19 were granted Emergency Use Authorization by the FDA in late 2020, and more are likely to be authorized in the coming months. The resultant demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make it more difficult to obtain materials or manufacturing slots for the products needed for our clinical trials, which could lead to delays in these trials. Any negative impact of such matters on our third-party suppliers and manufacturers may also have an adverse impact on our results of operations or financial condition.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50127808"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may encounter difficulties in production, particularly with respect to process development or scaling up of our manufacturing capabilities. If we encounter such difficulties, our ability to provide supply of our CAAR T cells for clinical trials or for commercial purposes could be delayed or stopped. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Establishing clinical and commercial manufacturing and supply is a difficult and uncertain task, and there are risks associated with scaling to the level required for advanced clinical trials or commercialization, including, among others, increased costs, potential problems with process scale-out, process reproducibility, stability issues, lot consistency, and timely availability of reagents or raw materials. For example, we may find it difficult to establish a manufacturing process that is consistent. If this occurs, we may need to complete more than one manufacturing run for each treated patient, which would impact the availability of adequate coverage and reimbursement from third-party payors. Competitors that have developed CAR T cell therapies have had difficulty reliably producing engineered T cell therapies in the commercial setting. If we experience similar challenges manufacturing product candidates to approved specifications, this may limit our product candidates&#8217; utilization and our ability to receive payment for these product candidates once licensed. Alternatively, these challenges may require changes to our manufacturing processes, which could require us to perform additional clinical studies, incurring significant expense. We may ultimately be unable to reduce the expenses associated with our product candidates to levels that will allow us to achieve a profitable return on investment. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50127810"></a>If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials. We and our suppliers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that we and our suppliers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we and our suppliers cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk50127814"></a>Changes in product candidate manufacturing or formulation may result in additional costs or delay, which could adversely affect our business, results of operations and financial condition. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As product candidates are developed through preclinical studies to later-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods or formulation, are altered along the way in an effort to optimize processes and results. Any of these changes could cause our product candidates to perform differently and affect the results of ongoing and planned clinical trials or other future clinical trials conducted with the altered materials or with materials made with the altered methods. Such changes may also require additional testing, or notification to, or approval by the FDA or other regulatory authorities. This could delay completion of clinical trials, require the conduct of bridging clinical trials or studies, require the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and/or jeopardize our ability to commence product sales and generate revenue. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Government Regulation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug products, including biologics, are subject to extensive regulation by the FDA and other regulatory authorities in the United States. We are not permitted to market any biological drug product in the United States until we receive approval of a Biologics License Application, or BLA, from the FDA. We have not previously submitted a BLA to the FDA, or similar licensure filings to comparable foreign authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the product candidate&#8217;s safety, potency and purity for each desired indication. The BLA must also include significant information regarding the chemistry, manufacturing and controls for the product, including with respect to chain of identity and chain of custody of the product. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA has not previously reviewed regulatory applications for the commercial development of CAAR T cells for treatment of pemphigus, and there is no therapy currently approved by the FDA for the treatment of mPV. Because of this, we have little guidance as to which endpoints will be accepted, how many clinical trials we may expect to conduct, and whether open-label clinical trials will be deemed acceptable, among other things. We may also request regulatory approval of future CAAR T cell-based product candidates by target, regardless of disease type or origin, which the FDA may have difficulty accepting if our clinical trials only involved diseases of certain origins. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety, potency and purity data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials, as the FDA often adheres to the Advisory Committee&#8217;s recommendations. Further, given the rapidly evolving landscape of cell therapy, we could encounter a significant change in the regulatory environment for our product candidates once we have already begun one or more lengthy and expensive clinical trials for our product candidates. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also experience delays in completing ongoing and planned clinical trials for a variety of reasons, including delays related to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">obtaining regulatory authorization to begin a trial, if applicable; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the availability of financial resources to commence and complete the planned trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">obtaining approval at each clinical trial site by an independent IRB; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">recruiting suitable patients to participate in a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">having patients complete a trial, including having patients enrolled in clinical trials dropping out of the trial before the product candidate is manufactured and returned to the site, or return for post-treatment follow-up; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">clinical trial sites deviating from trial protocol or dropping out of a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">addressing any patient safety concerns that arise during a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">adding new clinical trial sites; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">manufacturing sufficient quantities of qualified materials under cGMPs and applying them on a patient by patient basis for use in clinical trials. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could also encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, or based on a recommendation by the DSMB. If we experience termination of, or delays in the completion of, any future clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, was enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to a licensed biologic. Under the BPCIA, an application for a biosimilar product cannot be licensed by the FDA until 12 years after the reference product was licensed under a BLA. The law is complex and is still being interpreted and implemented by the FDA. In addition, as discussed more fully below, since the BPCIA was enacted as part of the ACA, if the ACA is invalidated in its entirety as unconstitutional, then the BPCIA could be considered invalid as well. While it is uncertain when such processes intended to implement the BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that any of the product candidates we develop that is licensed in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The regulatory landscape that will govern our product candidates is uncertain; regulations relating to more established cell therapies and other therapies for B cell-mediated autoimmune diseases are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we are developing novel CAAR T cell product candidates that are unique biological entities, the regulatory requirements that we will be subject to are not entirely clear. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. For example, regulatory requirements governing gene therapy products and cell therapy products have changed frequently and may continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA has established the Office of Tissues and Advanced Therapies, formerly known as the Office of Cellular, Tissue and Gene Therapies, within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee, a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. Although the FDA decides whether individual gene therapy protocols may proceed, review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical study, even if the FDA has reviewed the study and approved its initiation. Conversely, the FDA can place an IND application on clinical hold even if such other entities have provided a favorable review. Furthermore, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which a clinical trial will be conducted. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory bodies to change the requirements for approval of any of our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. For example, in the European Union, a special committee called the Committee for Advanced Therapies was established within the EMA in accordance with Regulation (EC) No 1394/2007 on advanced-therapy medicinal products, or ATMPs, to assess the quality, safety and efficacy of ATMPs, and to follow scientific developments in the field. ATMPs include gene therapy products as well as somatic cell therapy products and tissue engineered products. These various regulatory </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Because the regulatory landscape for our CAAR T cell product candidates is new, we may face even more cumbersome and complex regulations than those emerging for gene therapy products and cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn because of changes in regulations or the interpretation of regulations by applicable regulatory agencies. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States. Before we can commercialize any of our product candidates, we must obtain marketing approval. We have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction and it is possible that none of our product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. We, as a company, have no experience in filing and supporting the applications necessary to gain regulatory approvals and expect to rely on third-party CROs and/or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the drug candidate&#8217;s safety, potency and purity. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of obtaining regulatory approvals is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted IND, BLA or equivalent application types, may cause delays in the approval or rejection of an application. The FDA has substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA may disagree with the design or implementation of our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may be unable to demonstrate to the satisfaction of the FDA that a drug candidate is safe, potent and pure for its proposed indication or a related companion diagnostic is suitable to identify appropriate patient populations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the results of clinical trials may not meet the level of statistical significance required by the FDA for approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA may disagree with our interpretation of data from preclinical studies or clinical trials; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an BLA or other submission or to obtain regulatory approval in the United States or elsewhere; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA may fail to approve the manufacturing processes, test procedures and specifications, or facilities that we may establish or of third-party manufacturers with which we may contract for clinical and commercial supplies; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for approval. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the large number of drugs in development, only a small percentage successfully complete the FDA approval process and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. As a result, our ability to develop product candidates and obtain regulatory approval may be significantly impacted. For example, the general approach for FDA approval of a new biologic or drug is for sponsors to seek licensure or approval based on dispositive data from well-controlled, Phase&#160;3 clinical trials of the relevant product candidate in the relevant patient population. Phase&#160;3 clinical trials typically involve hundreds of patients, have significant costs and take years to complete. We believe that we may be able to utilize the FDA&#8217;s Regenerative Medicine Advanced Therapy designation for our product candidates given the limited alternatives for treatments for certain rare diseases and B cell-mediated autoimmune diseases, but the FDA may not agree with our plans. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, approval of genetic or biomarker diagnostic tests may be necessary to advance some of our product candidates to clinical trials or potential commercialization. In the future, regulatory agencies may require the development and approval of such tests. Accordingly, the regulatory approval pathway for such product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, if licensed, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even though we may apply for orphan drug designation for our product candidates, we may not be able to obtain orphan drug marketing exclusivity. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population of 200,000 or more in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. In order to obtain orphan drug designation, the request must be made before submitting a BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product that has orphan drug designation subsequently receives the first FDA approval of that particular product for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic (meaning, a product with the same principal molecular structural features) for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve other biologics that do not have the same principal molecular structural features for use in treating the same indication or disease or the same biologic for a different indication or disease during the exclusivity period. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product or if a subsequent applicant demonstrates clinical superiority over our product. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have obtained from the FDA orphan drug designation for DSG3-CAART for the treatment of pemphigus vulgaris (PV). We may seek orphan drug designation for certain other of our product candidates, but may be unable to obtain orphan drug designation for some or all of our product candidates in specific orphan indications in which we believe there is a medically plausible basis for the use of these products. Even if we obtain orphan drug designation, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition, or if a subsequent applicant demonstrates clinical superiority over our products, if licensed. In addition, although we may seek orphan drug designation for other product candidates, we may never receive such designations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">A fast track designation by the FDA, even if granted, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our current product candidate and any future product candidates will receive marketing approval. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA fast track designation for a particular indication. Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious or life-threatening conditions and address an unmet medical need. We have received fast track designation for DSG3-CAART for improving healing of mucosal blisters in patients with mPV. We may also apply for fast track designation for certain of our other product candidates, but there is no assurance that the FDA will grant this status to any of our other current or future product candidates. Marketing applications filed by sponsors of products in fast track development may qualify for priority review under the policies and procedures offered by the FDA, but the fast track designation does not assure any such qualification or ultimate marketing approval by the FDA. The FDA has broad discretion whether or not to grant fast track designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even though we have received fast track designation for DSG3-CAART for improving healing of mucosal blisters in patients with mPV, we may not experience a faster development process, regulatory review or approval compared to conventional FDA procedures, and receiving a fast track designation does not provide assurance of ultimate FDA approval. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. In addition, the FDA may withdraw any fast track designation at any time.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Although we may pursue expedited regulatory approval pathways for a product candidate, it may not qualify for expedited development or, if it does qualify for expedited development, it may not actually lead to a faster development or regulatory review or approval process. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we believe there may be an opportunity to accelerate the development of certain of our product candidates through one or more of the FDA&#8217;s expedited programs, such as fast track, breakthrough therapy, Regenerative Medicine Advanced Therapy, accelerated approval or priority review, we cannot be assured that any of our product candidates will qualify for such programs. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, we may seek a Regenerative Medicine Advanced Therapy, or RMAT, designation for some of our product candidates. An RMAT is defined as cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products. Gene therapies, including genetically modified cells that lead to a durable modification of cells or tissues may meet the definition of a Regenerative Medicine Therapy. The RMAT program is intended to facilitate efficient development and expedite review of RMATs, which are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition. A new drug application or a BLA for an RMAT may be eligible for priority review or accelerated approval through (1) surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit or (2) reliance upon data obtained from a meaningful number of sites. Benefits of such designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A Regenerative Medicine Therapy that is granted accelerated approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post-approval monitoring of all patients treated with such therapy prior to its approval. Although RMAT designation or access to any other expedited program may expedite the development or approval process, it does not change the standards for approval. If we apply for RMAT designation or any other expedited program for our product candidates, the FDA may determine that our proposed target indication or other aspects of our clinical development plans do not qualify for such expedited program. Even if we are successful in obtaining a RMAT designation or access to any other expedited program, we may not experience faster development timelines or achieve faster review or approval compared to conventional FDA procedures. Access to an expedited program may also be withdrawn by the FDA if it believes that the designation is no longer supported by data from our clinical development program. Additionally, qualification for any expedited review procedure does not ensure that we will ultimately obtain regulatory approval for such product candidate. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;text-indent:-7.69%;">Disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:-7.69%;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs or biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including most recently from December&#160;22, 2018 to January 25, 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separately, in response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities and products while local, national and international conditions warrant. On March 18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities and provided guidance regarding the conduct of clinical trials which the FDA continues to update. As of June 23, 2020, the FDA noted it was continuing to ensure timely reviews of applications for medical products during the COVID-19 pandemic in line with its user fee performance goals; however, FDA may not be able to continue its current pace and approval timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the COVID-19 pandemic and travel restrictions FDA is unable to complete such required inspections during the review period. On July 10, 2020, the FDA announced its goal of restarting domestic on-site inspections during the week of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 20, but such activities will depend on data about the virus&#8217; trajectory in a given state and locality and the rules and guidelines that are put in place by state and local governments. The FDA has developed a rating system to assist in determining when and where it is safest to conduct prioritized domestic inspections. Should FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, FDA has stated that it generally intends to issue a complete response letter.&#160; Further, if there is inadequate information to make a determination on the acceptability of a facility, FDA may defer action on the application until an inspection can be completed. In 2020, several companies announced receipt of complete response letters due to the FDA's inability to complete required inspections for their applications. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Ongoing Regulatory Obligations </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety, potency and purity of the product candidate. We believe it is likely that the FDA will require a Risk Evaluation and Mitigation Strategy, or REMS, in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and cGCPs for any clinical trials that we conduct post-approval. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application and previous responses to inspectional observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker information. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, we will be required to comply with FDA promotion and advertising rules, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved uses (known as &#8220;off-label use&#8221;), limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet and social media. Later discovery of previously unknown problems with our product candidates through follow-up programs with our clinical trial patients, including adverse events of unanticipated severity or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks, or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">fines, warning letters or holds on clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">product seizure or detention, or refusal to permit the import or export of our product candidates; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">injunctions or the imposition of civil or criminal penalties. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action. For example, certain policies of the current U.S. President&#8217;s administration may impact our business and industry. Namely, the current U.S. President&#8217;s administration has taken several executive actions, including the issuance of a number of Executive Orders, that could, for example, result in changes to the FDA&#8217;s priorities and allocation of resources to respond to the COVID-19 pandemic. It is difficult to predict how these orders will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose restrictions on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. Breach of certain environmental, health and safety laws and regulations could also in certain circumstances constitute a breach of our License Agreement with Penn. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological waste or hazardous waste insurance coverage, workers compensation or property and casualty and general liability insurance policies that include coverage for damages and fines arising from biological or hazardous waste exposure or contamination. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk46390326"></a><a name="_Hlk46390326"></a>We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to comply with the laws of the FDA, provide true, complete and accurate information to the FDA, comply with manufacturing standards we have established, comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws, or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. <font style="font-weight:bold;font-style:italic;margin-left:36pt;"></font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Healthcare</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if licensed, profitably. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Successful commercialization of our product candidates, if licensed, will depend in part on the extent to which reimbursement for those drug products will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drug products they will pay for and establish reimbursement levels. The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford a drug product. Sales of drug products depend substantially, both domestically and abroad, on the extent to which the costs of drugs products are paid for by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. Any product candidate for which we seek regulatory approval and reimbursement will need to meet or surpass our target product profile, or TPP, to be deemed a viable alternative to currently approved therapies. In addition, because our product candidates represent new approaches to the treatment of B cell-mediated autoimmune diseases, we cannot accurately estimate the potential revenue from our product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a covered benefit under its health plan; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">safe, effective and medically necessary; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">appropriate for the specific patient; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">cost-effective; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">neither experimental nor investigational. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide the payor with supporting scientific, clinical and cost-effectiveness data for the use of our products, if licensed. In the United States, the principal decisions about reimbursement for new drug products are typically made by the Centers for Medicare and Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent a new drug product will be covered and reimbursed under Medicare, and private payors tend to follow CMS to a substantial degree. However, no uniform policy of coverage and reimbursement for drug products exists among third-party payors and coverage and reimbursement levels for drug products can differ significantly from payor to payor. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for use in their facility or third-party payors may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, CMS revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payors rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payors, and reduce the willingness of physicians to use our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay regulatory approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain regulatory approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that we, or any collaborators, may receive for any approved products. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2010, President Obama signed into law the ACA. Among the provisions of the ACA of potential importance to our business and our product candidates are the following: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription products and biologic products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for products that are inhaled, infused, instilled, implanted or injected; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">expansion of healthcare fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% as of January&#160;1, 2019) point-of-sale discounts off negotiated prices of applicable brand products to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient products to be covered under Medicare Part&#160;D; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">extension of manufacturers&#8217; Medicaid rebate liability to individuals enrolled in Medicaid managed care organizations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">new requirements to report certain financial arrangements with physicians and teaching hospitals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a new requirement to annually report product samples that manufacturers and distributors provide to physicians; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, various portions of the ACA are currently undergoing legal and constitutional challenges in the Fifth Circuit Court and the United States Supreme Court. Additionally, the Trump Administration issued various Executive Orders which eliminated cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices, and Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. It is unclear whether the ACA will be overturned, repealed, replaced, or further amended, especially under the Biden administration. We cannot predict what affect further changes to the ACA would have on our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further legislation or regulation could be passed that could harm our business, financial condition and results of operations. Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April&#160;2013 and will remain in effect through 2030 unless additional Congressional action is taken. Pursuant to the Coronavirus Aid, Relief, and Economic Security Act, also known as the CARES Act, as well as subsequent legislation, these reductions have been suspended from May 1, 2020 through March 31, 2021 due to the COVID-19 pandemic. Proposed legislation, if passed, would extend this suspension until the end of the pandemic. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient assistance programs, and reform government program reimbursement methodologies for drugs. For example, the Trump administration&#8217;s budget proposal for fiscal year 2021 included a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the Trump administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Further, the Trump administration also previously released a &#8220;Blueprint&#8221;, or plan, to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. HHS has already started the process of soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs beginning January&#160;1, 2020. This final rule codified CMS&#8217;s policy change that was effective January 1, 2019. It is unclear whether the Biden administration will challenge, reverse, revoke or otherwise modify these executive and administrative actions after January 20, 2021. In addition, there have been several changes to the 340B drug pricing program, which imposes ceilings on prices that drug manufacturers can charge for medications sold to certain health care facilities. On December 27, 2018, the District Court for the District of Columbia invalidated a reimbursement formula change under the 340B drug pricing program, and CMS subsequently altered the FYs 2019 and 2018 reimbursement formula on specified covered outpatient drugs (&#8220;SCODs&#8221;). The court ruled this change was not an &#8220;adjustment&#8221; which was within the Secretary&#8217;s discretion to make but was instead a fundamental change in the reimbursement calculation. However, most recently, on July 31, 2020, the U.S. Court of Appeals for the District of Columbia Circuit overturned the district court&#8217;s decision and found that the changes were within the Secretary&#8217;s authority. On September 14, 2020, the plaintiffs-appellees filed a Petition for Rehearing En Banc (i.e., before the full court), but was denied on October 16, 2020. It is unclear how these developments could affect covered hospitals who might purchase our future products and affect the rates we may charge such facilities for our approved products in the future, if any.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 24, 2020 and September 13, 2020, President Trump announced several executive orders related to prescription drug pricing that seek to implement several of the administration's proposals. In response, the FDA </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">released a final rule on September 24, 2020, which went into effect on November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020 CMS issued an Interim Final Rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement rates will be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita.&nbsp;&nbsp;The MFN Model regulations mandate participation by identified Part B providers and will apply in all U.S. states and territories for a seven-year period beginning January 1, 2021, and ending December 31, 2027.&nbsp;&nbsp;The Interim Final Rule has not been finalized and is subject to revision and challenge. Additionally, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Implementation of the amendments to the discount safe harbor have been delayed until at least January 1, 2023. Although a number of these, and other proposed measures may require authorization through additional legislation to become effective, and the Biden Administration may reverse or otherwise change these measures, Congress has indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at containing or lowering the cost of healthcare. For example, in 2016, the United Kingdom referendum on its membership in the EU resulted in a majority of the United Kingdom voters voting to exit the EU, often referred to as &#8220;Brexit&#8221;. Pursuant to Article 50 of the Treaty on European Union, the United Kingdom ceased being a Member State of the European Union on January 31, 2020. A transition period began February 1, 2020 and continued until December 31, 2020, during which most laws of the EU continued to apply to the United Kingdom, including the European Union&#8217;s rules, the European Union&#8217;s pharmaceutical laws. The United Kingdom and the EU have signed a EU-UK Trade and Cooperation Agreement, which became provisionally applicable on 1 January 1, 2021 and will become formally applicable once ratified by both the United Kingdom and the EU. This agreement provides details on how some aspects of the United Kingdom&#8217;s and EU&#8217;s relationship will operate going forwards however there are still many uncertainties.&nbsp;&nbsp;Brexit has already and may continue to adversely affect European and/or worldwide regulatory conditions. Brexit could lead to legal uncertainty and potentially divergent national laws and regulations in Europe, including those related to the pricing of prescription pharmaceuticals, as the United Kingdom determines which EU laws to replicate or replace, which could impair our ability to transact business in the EU and the United Kingdom in the future, if we elect to seek regulatory approval and commercialize any of our products there, if approved. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the demand for our product candidates, if we obtain regulatory approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to set a price that we believe is fair for our products, if licensed; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to generate revenue and achieve or maintain profitability; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the level of taxes that we are required to pay; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the availability of capital. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our relationships with customers, healthcare providers, physicians, and third-party payors will be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we could face substantial penalties. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These laws may impact, among other things, our clinical research program, as well as our proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services is subject to extensive laws and regulations designed to prevent fraud, kickbacks, self-dealing and other abusive practices, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, which may constrain the business or financial arrangements and relationships through which such companies sell, market and distribute pharmaceutical products. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive and other business arrangements. We may also be subject to federal, state and foreign laws governing the privacy and security of individual identifiable health information and other personally identifiable information. The U.S. healthcare laws and regulations that may affect our ability to operate include, but are not limited to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act, or FCA. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. On November 20, 2020, OIG finalized further modifications to the federal Anti-Kickback Statute. Under the final rules, OIG added safe harbor protections under the Anti-Kickback Statute for certain coordinated care and value-based arrangements among clinicians, providers, and others. These rules (with exceptions) became effective January 19, 2021. We continue to evaluate what effect, if any, these rules will have on our business;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">federal civil and criminal false claims laws and civil monetary penalty laws, including the FCA, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment to, or approval by Medicare, Medicaid, or other federal healthcare programs, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim or an obligation to pay or transmit money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing or concealing an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (</font><font style="font-style:italic;font-size:10pt;color:#000000;">e.g.</font><font style="font-size:10pt;color:#000000;">, public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;color:#000000;">can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose, among other things, requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions; the federal Physician Payment Sunshine Act, created under the Patient Protection and Affordable Care Act, and its implementing regulations, which require manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the HHS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Effective January 1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, and may be broader in scope than their federal equivalents; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of individually identifiable health information and other personally identifiable information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from the business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The failure to comply with any of these laws or regulatory requirements subjects entities to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">laws. Any action for violation of these laws, even if successfully defended, could cause a pharmaceutical manufacturer to incur significant legal expenses and divert management&#8217;s attention from the operation of the business. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities, or our arrangements with physicians, some of whom receive stock options as compensation, could be subject to challenge under one or more of such laws. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we may be subject to investigations, enforcement actions and/or significant penalties. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct or business noncompliance, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Data and Privacy</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal information. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to stringent privacy and data protection requirements. The collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the European Economic Area, or EEA&#8211; including health data &#8211; is governed by the European Union-wide General Data Protection Regulation, or the GDPR, which became effective on May&#160;25, 2018. The GDPR applies to any business, regardless of its location, that provides goods or services to residents in the EU or monitors the behavior of individuals within the European Union. The GDPR is wide ranging in scope and imposes stringent operational requirements for processors and controllers of personal data, including, for example, special protections for &#8220;sensitive information&#8221; which includes health and genetic information of data subjects residing in the EEA, expanded disclosures to individuals about how their personal data is to be used, limitations on retention of information, increased requirements pertaining to health data and pseudonymized (<font style="font-style:italic;">i.e.</font>, key-coded) data, implementing safeguards to protect the security and confidentiality of personal data, mandatory data breach notification requirements and higher standards for controllers to demonstrate that they have obtained valid consent for certain data processing activities. The GDPR grants individuals the opportunity to object to the processing of their personal information, allows them to request deletion of personal information in certain circumstances, and provides the individual with an express right to seek legal remedies in the event the individual believes his or her rights have been violated. Further, the GDPR imposes strict rules on the transfer of personal data out of the European Union to the United States and other jurisdictions that have not been deemed to offer &#8220;adequate&#8221; privacy protections. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The GDPR provides that European Union Member States may make their own further laws and regulations in relation to the processing of genetic, biometric or health data, which could result in differences between Member States, limit our ability to use and share personal data or could cause our costs to increase, and harm our business and financial condition. Our clinical trial activity conducted within the member states of the European Union is regulated by the GDPR. In addition, we are subject to evolving and strict rules on the transfer of personal data out of the European Union to the United States. For example, evolution of laws governing the cross-border transfer of data, such as the invalidation of the EU&#8211;U.S. Privacy Shield, creates additional uncertainty around the legality and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mechanics of such transfers.&nbsp;&nbsp;Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with any future European activities. We could be adversely affected if we fail to comply fully with all of these requirements. Failure to comply with European Union data protection laws may result in fines (for example, of up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year (whichever is higher) under the GDPR) and other administrative penalties, which may be onerous and adversely affect our business, financial condition, results of operations and prospects. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, further to the United Kingdom's (UK) exit from the EU on January 31, 2020, the GDPR ceased to apply in the UK at the end of the transition period on December 31, 2020. However, as of January 1, 2021, the UK&#8217;s European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December 31, 2020 but subject to certain UK specific amendments) into UK law (referred to as the 'UK GDPR'). The UK GDPR and the UK Data Protection Act 2018 set out the UK&#8217;s data protection regime, which is independent from but aligned to the EU&#8217;s data protection regime. Non-compliance with the UK GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher. The UK, however, is now regarded as a third country under the EU&#8217;s GDPR which means that transfers of personal data from the EEA to the UK will be restricted unless an appropriate safeguard, as recognized by the EU&#8217;s GDPR, has been put in place. Although, under the EU-UK Trade Cooperation Agreement it is lawful to transfer personal data between the UK and the EEA for a 6 month period following the end of the transition period, with a view to achieving an adequacy decision from the European Commission during that period. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the UK to countries not regarded by the UK as providing adequate protection (this means that personal data transfers from the UK to the EEA remain free flowing).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This lack of clarity on future UK laws and regulations and their interaction with EU laws and regulations could add legal risk, uncertainty, complexity and cost to our handling of EU personal information and our privacy and data security compliance programs. It is possible that over time the UK Data Protection Act could become less aligned with the EU General Data Protection Regulation, or GDPR, which could require us to implement different compliance measures for the UK and the European Union and result in potentially enhanced compliance obligations for EU personal data.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, various jurisdictions around the world continue to propose new laws that regulate the privacy and/or security of certain types of personal data. Complying with these laws, if enacted, would require significant resources and leave us vulnerable to possible fines and penalties if we are unable to comply. The regulatory framework governing the collection, processing, storage, use and sharing of certain information is rapidly evolving and is likely to continue to be subject to uncertainty and varying interpretations. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our existing data management practices or the features of our services and platform capabilities. Any failure or perceived failure by us, or any third parties with which we do business, to comply with our posted privacy policies, evolving laws, rules and regulations, industry standards, or contractual obligations to which we or such third parties are or may become subject, may result in actions or other claims against us by governmental entities or private actors, the expenditure of substantial costs, time and other resources or the incurrence of significant fines, penalties or other liabilities. In addition, any such action, particularly to the extent we were found to be guilty of violations or otherwise liable for damages, would damage our reputation and adversely affect our business, financial condition and results of operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our security measures are breached or unauthorized access to individually identifiable health information or other personally identifiable information is otherwise obtained, our reputation may be harmed, and we may incur significant liabilities. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unauthorized access to, or security breaches of, our systems and databases could result in unauthorized access to data and information and loss, compromise or corruption of such data and information. The systems of Penn, any CMOs that we may engage in the future, and present and future CROs, contractors and consultants also could experience breaches of security leading to the exposure of confidential and sensitive information. Cyber incidents have been increasing in sophistication and frequency and can include third parties gaining access to employee or customer data using stolen or inferred credentials, computer malware, viruses, spamming, phishing attacks, ransomware, card skimming code, and other deliberate attacks and attempts to gain unauthorized access. Because the techniques used by computer programmers who may attempt to penetrate and sabotage our network security or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our website change frequently and may not be recognized until launched against a target, we may be unable to anticipate these techniques.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is also possible that unauthorized access to customer data may be obtained through inadequate use of security controls by customers, suppliers or other vendors. While we are not currently aware of any impact that the SolarWinds supply chain attack had on our business, this is a recent event, and the scope of the attack is yet unknown. Therefore, there is residual risk that we may experience a security breach arising from the SolarWinds supply chain attack.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of a security breach, our company could suffer loss of business, severe reputational damage adversely affecting investor confidence, regulatory investigations and orders, litigation, indemnity obligations, damages for contract breach, penalties for violation of applicable laws or regulations, significant costs for remediation and other liabilities. For example, the loss of preclinical study or clinical trial data from completed or future preclinical studies or clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred and expect to incur significant expenses to prevent security breaches, including costs related to deploying additional personnel and protection technologies, training employees, and engaging third-party solution providers and consultants. Although we expend significant resources to create security protections that shield our customer data against potential theft and security breaches, such measures cannot provide absolute security. Moreover, as we outsource more of our information systems to vendors and rely more on cloud-based information systems, the related security risks will increase, and we will need to expend additional resources to protect our technology and information systems. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have in the past experienced security incidents, and we may in the future experience other data security incidents or breaches affecting personally identifiable information or other confidential business information. For example, in 2019, we believe a phishing incident led to certain employee email accounts being accessed by an unauthorized third party. We initiated an investigation to determine whether further action was required under applicable law. The incident did not have a material impact on our business or financial condition. While we believe we responded appropriately, including implementing remedial measures with the goal of preventing similar such events in the future, there can be no assurance that we will be successful in these remedial and preventative measures or in successfully mitigating the effects of potential future incidents or cyber-attacks. We remain at risk for future breaches, including, without limitation, breaches that may occur as a result of third-party action, or employee, vendor or contractor error or malfeasance and other causes. If, in the future, we experience a data breach or security incident, we would be likely to experience harm to our reputation, financial performance, and customer and vendor relationships, and the possibility of litigation or regulatory investigations or actions by state and federal governmental authorities and non-U.S. authorities. Additionally, actual, potential or anticipated attacks may cause us to incur increasing costs, including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts and consultants. Although we maintain cyber liability insurance, we cannot be certain that our coverage will be adequate for liabilities actually incurred or that insurance will continue to be available to us on economically reasonable terms, or at all.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interruptions in the availability of server systems or communications with internet or cloud-based services, or failure to maintain the security, confidentiality, accessibility or integrity of data stored on such systems, could harm our business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely upon a variety of internet service providers, third-party web hosting facilities and cloud computing platform providers to support our business. Failure to maintain the security, confidentiality, accessibility or integrity of data stored on such systems could result in interruptions in our operations, damage our reputation in the market, increase our service costs, cause us to incur substantial costs, subject us to liability for damages and/or fines, and divert our resources from other tasks, any one of which could materially adversely affect our business, financial condition, results of operations and prospects. If our security measures or those of our third-party data center hosting facilities, cloud computing platform providers, or third-party service partners, are breached, and unauthorized access </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is obtained to our data or our information technology systems, we may incur significant legal and financial exposure and liabilities.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also do not have control over the operations of the facilities of our cloud service providers and our third-party web hosting providers, and they also may be vulnerable to damage or interruption from natural disasters, cybersecurity attacks, terrorist attacks, power outages and similar events or acts of misconduct. In addition, any changes in these providers&#8217; service levels may adversely affect our ability to meet our requirements and operate our business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Ownership of Our Common Stock </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Ownership Generally</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our executive officers, directors, and 5% stockholders beneficially owned, in the aggregate, approximately 71% of our outstanding voting common stock, or 64% of our common stock, assuming all shares of non-voting common stock are converted into voting common stock in accordance with the terms of our amended and restated certificate of incorporation. Accordingly, these stockholders will have the ability to influence us through this ownership position and significantly affect the outcome of all matters requiring stockholder approval. For example, these stockholders may be able to significantly affect the outcome of elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls. The Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting and, beginning with our second annual report following our initial public offering, provide a management report on internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. We have begun the process of documenting, reviewing, and improving our internal controls and procedures for compliance with Section&#160;404 of the Sarbanes-Oxley Act. We have begun recruiting additional finance and accounting personnel with certain skill sets that we need as a public company. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Implementing any appropriate changes to our internal controls may distract our officers and employees, entail substantial costs to modify our existing processes, and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business. In addition, investors&#8217; perceptions that our internal controls are inadequate or that we are unable to produce accurate financial statements on a timely basis may harm our stock price and make it more difficult for us to effectively market and sell our service to new and existing customers. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk34051520"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The dual class structure of our common stock may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65775746"></a><a name="_Hlk65775746"></a>The dual class structure of our common stock may limit your ability to influence corporate matters. Holders of our common stock are entitled to one vote per share, while holders of our non-voting common stock are not entitled to any votes. Nonetheless, each share of our non-voting common stock may be converted at any time into one share of our common stock at the option of its holder by providing written notice to us, subject to the limitations provided for in our amended and restated certificate of incorporation. Entities affiliated with or managed by Baker Brothers Life Sciences, L.P. and Adage Capital Partners, LP hold an aggregate of 4,458,004 shares of our non-voting common stock pursuant to our Third Amended and Restated Certificate of Incorporation. At any time, upon written notice, these entities could convert a portion of these shares of non-voting common stock into up to an aggregate of 19% of our shares of common stock. Upon 61 days&#8217; prior written notice, these entities could convert any or all of their respective shares of non-voting common stock into shares of common stock. Consequently, if holders of our non-voting common stock exercise their option to make this conversion, this will have the effect of increasing the relative voting power of those prior holders of our non-voting common stock, and correspondingly decreasing the voting power of the holders of our common stock, which may limit your ability to influence corporate matters. Additionally, stockholders who hold, in the aggregate, more than 10% of our common stock and non-voting common stock, but 10% or less of our common stock, and are not otherwise a company insider, may not be required to report changes in their ownership due to transactions in our non-voting common stock pursuant to Section 16(a) of the Exchange Act, and may not be subject to the short-swing profit provisions of Section 16(b) of the Exchange Act. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.<font style="font-weight:normal;font-style:normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Certain holders of our common stock have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On&#160;November 10, 2020, we filed a registration statement on Form S-3 (File No. 333-250006) with the SEC, which was declared effective on November 18, 2020 (the &#8220;Shelf Registration Statement&#8221;), in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our&#160;common stock, debt securities or other equity securities&#160;in one or more offerings.&#160;We also simultaneously entered into a Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cowen and Company, LLC, (the &#8220;Sales Agent&#8221;), to provide for the offering, issuance and sale of up to an aggregate amount of $75.0 million of our common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf Registration Statement and subject to the limitations thereof.&#160;The Company will pay to the Sales Agent cash commissions of 3.0 percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. Sales of&#160;common stock, debt securities or other equity securities&#160;by us may represent a significant percentage of our common stock currently outstanding. If we sell, or the market perceives that we intend to sell, substantial amounts of our common stock under the Shelf Registration Statement or otherwise, the market price of our common stock could decline significantly.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also filed a registration statement on Form S-8 registering the issuance of 4.5 million shares of common stock issued or reserved for future issuance under our equity compensation plans. Shares registered under this registration statement on Form S-8 can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates and the lock-up agreements described above. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, certain of our employees, executive officers, and directors may enter into Rule 10b5-1 trading plans providing for sales of shares of our common stock from time to time. Under a Rule 10b5-1 trading plan, a broker executes trades pursuant to parameters established by the employee, director, or officer when entering into the plan, without further direction from the employee, officer, or director. A Rule 10b5-1 trading plan may be amended or terminated in some circumstances. Our employees, executive officers, and directors also may buy or sell additional shares outside of a Rule 10b5-1 trading plan when they are not in possession of material, nonpublic information.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to our Charter and Bylaws</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer, or by a majority of the total number of authorized directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">advance notice requirements for stockholder proposals and nominations for election to our board of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of not less than 75% of the votes that all our stockholders would be entitled to cast in an annual election of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a requirement of approval of not less than 75% of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our amended and restated bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to our amended and restated bylaws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) will be the sole and exclusive forum for state law claims for: (i)&#160;any derivative action or proceeding brought on our behalf; (ii)&#160;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (iii)&#160;any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation or bylaws; (iv)&#160;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (v)&#160;any action asserting a claim governed by the internal affairs doctrine (the Delaware Forum Provision). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act of 1933, as amended (the Securities Act) or the Securities Exchange Act of 1934. In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions. We recognize that the forum selection clause in our bylaws may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware. Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders&#8217; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. The Court of Chancery of the State of Delaware may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could materially adversely affect our business, financial condition and operating results. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Tax </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in tax laws could adversely affect our business and financial condition. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. Prospective investors in our common stock should consult with their legal and tax advisors with respect to potential changes in tax laws and the tax consequences of investing in or holding our common stock. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our ability to utilize our net operating losses and certain other tax attributes to offset future taxable income may be subject to certain limitations. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had U.S. federal, state and local net operating loss carryforwards of $45.6&#160;million, $47.7 million and $38.6 million, respectively. $0.3 million of the federal amounts expire in 2037. The state net operating losses begin to expire in 2037 and the local net operating losses begin to expire in 2039. Approximately $45.3&#160;million of the federal net operating losses can be carried forward indefinitely. Certain net operating loss carryforwards could expire unused and be unavailable to offset future taxable income. In addition, in general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of state law, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change net operating loss carryforwards or tax credits, or NOLs or credits, to offset future taxable income or taxes. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. Our existing NOLs or credits may be subject to limitations arising from previous ownership changes, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and if we undergo an ownership change, our ability to utilize NOLs or credits could be further limited by Sections 382 and 383 of the Code. In addition, future changes in our stock ownership, many of which are outside of our control, could result in an ownership change under Sections 382 and 383 of the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Code</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Our NOLs or credits may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs or credits. Furthermore, our ability to utilize our NOLs or credits is conditioned upon our attaining profitability and generating U.S. federal and state taxable income. As described above under &#8220;&#8212;Risks Related to Our Financial Condition and Capital Requirements&#8221;, we have incurred significant net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future; and therefore, we do not know whether or when we will generate the U.S. federal or state taxable income necessary to utilize our NOLs or credits. Under current law, U.S. federal net operating loss carryforwards generated in taxable years beginning after December&#160;31, 2017 will not be subject to expiration. However, any </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">net operating loss carryforwards </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may only offset 80% of our annual taxable income </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in taxable years beginning after December&#160;31, 2020</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General Risk Factors</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The price of our stock may be volatile, and you could lose all or part of your investment. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section, these factors include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the commencement, enrollment or results of our planned preclinical studies or clinical trials of our product candidates or any preclinical studies or future clinical trials we may conduct, or changes in the development status of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our decision to initiate a preclinical study or clinical trial, not to initiate a preclinical study or clinical trial or to terminate an existing preclinical study or clinical trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">adverse results or delays in preclinical studies or clinical trials of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including, without limitation, the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our failure to commercialize our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">changes in laws or regulations applicable to our product candidates, including, but not limited to, clinical trial requirements for approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">adverse developments concerning our manufacturers or suppliers; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our inability to obtain adequate product supply for any licensed product or inability to do so at acceptable prices; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our inability to establish collaborations, if needed; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">additions or departures of key scientific or management personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">unanticipated serious safety concerns related to the use of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">introduction of new products or services offered by us or our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to effectively manage our growth; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the size and growth of our initial target markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to successfully treat additional types of B cell-mediated autoimmune diseases; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">actual or anticipated variations in annual or quarterly operating results; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our cash position; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">changes in the market valuations of similar companies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">overall performance of the equity markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">sales of our common stock by us or our stockholders in the future; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">trading volume of our common stock; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">changes in accounting practices; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">ineffectiveness of our internal controls; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">significant lawsuits, including patent or stockholder litigation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">general political and economic conditions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">global health concerns, such as the COVID-19 pandemic; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">other events or factors, many of which are beyond our control. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the stock market in general, and The Nasdaq Global Select Market and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are an emerging growth company and a &#8220;smaller reporting company,&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act, or JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an emerging growth company for up to five years following the date of completion of our initial public offering, although circumstances could cause us to lose that status earlier. We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal year (a)&#160;following the fifth </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">anniversary of the completion of our initial public offering, (b)&#160;in which we have total annual gross revenue of at least $1.07&#160;billion or (c)&#160;in which we are deemed to be a large accelerated filer, which requires the market value of our common stock that is held by non-affiliates to exceed $700&#160;million as of the prior June 30th, and (2)&#160;the date on which we have issued more than $1&#160;billion in non-convertible debt during the prior three-year period. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, we are not subject to the same new or revised accounting standards as other public companies that are not emerging growth companies and our financial statements may not be comparable to other public companies that comply with new or revised accounting pronouncements as of public company effective dates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also a &#8220;smaller reporting company,&#8221; as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended. We would cease to be a smaller reporting company if we have a public float in excess of $250 million, or have annual revenues in excess of $100 million and a public float in excess of $700 million, determined on an annual basis. Consequently, even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates or grant licenses on terms unfavorable to us. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. In the event that one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline. </p><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a>Item 1B. Unresolve</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">d Staff Comments. </font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_PROPERTIES"></a><a name="ITEM_2_PROPERTIES"></a>Item 2. Properties. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our corporate headquarters are located in Philadelphia, PA, where we lease 7,672 square feet of office, research and development space subject to a lease agreement that is in effect through 2022. We expect to expand to a new space in 2022 that will both be adequate for near-term needs in addition to providing additional space to grow. We feel that suitable additional research and development, laboratory and manufacturing space should be available in the region on commercially reasonable terms. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_LEGAL_PROCEEDINGS"></a><a name="ITEM_3_LEGAL_PROCEEDINGS"></a>Item 3. Legal Proceedings. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may be involved in lawsuits, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters which arise in the ordinary course of business. While the outcome of any such proceedings cannot be predicted with certainty, as of December 31, 2020, we were not party to any legal proceedings that we would expect to have a material adverse impact on our financial position, results of operations or cash flow.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a>Item 4. Mine Safety Disclosures.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a><a name="PART_II"></a>PART II</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a>Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock trades on The Nasdaq Global Select Market under the symbol &#8220;CABA&#8221;. Trading of our common stock commenced on October 25, 2019, in connection with our initial public offering, or IPO. Prior to that time, there was no established public trading market for our common stock. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stockholders</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 10, 2021, we had approximately 14 holders of record of our common stock. The actual number of holders of our common stock is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees. The number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any cash dividends on our common stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and growth of our business. We do not expect to pay any cash dividends in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects, then applicable contractual restrictions and any other factors deemed relevant by our board of directors. Investors should not purchase our common stock with the expectation of receiving cash dividends.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Equity Compensation Plan</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Issuer Purchases of Equity Securities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not purchase any of our equity securities during the period covered by this Annual Report on Form 10-K.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Securities</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Use of Proceeds from the Initial Public Offering</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 29, 2019, we closed our initial public offering, or IPO, in which we issued and sold 7,275,501 shares of common stock at a public offering price of $11.00 per share, including 475,501 shares of common stock at a price of $11.00 per share pursuant to the exercise of the underwriters&#8217; over-allotment option. All of the shares of common stock issued and sold in our initial public offering were registered under the Securities Act pursuant to a registration statement on Form S-1 (Registration No. 333-234017), which was declared effective by the SEC on October 24, 2019. Morgan Stanley &amp; Co. LLC, Cowen and Company and Evercore Group L.L.C. acted as joint book-running managers for the offering.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate net proceeds to us from the public offering, inclusive of the over-allotment exercise, were approximately $71.0 million, after deducting underwriting discounts and commissions and other offering expenses payable by us of approximately $3.4 million. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10% or more of any class of our equity securities or to any other affiliates.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information related to use of proceeds from registered securities is incorporated herein by reference to the &#8220;Use of Proceeds&#8221; section of the Company&#8217;s final prospectus related to the IPO. T<font style="Background-color:#FFFFFF;">he amounts and timing of our </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">actual expenditures may vary significantly depending on numerous factors, including the progress of our research and development, the status of and results from&#160;non-clinical&#160;studies or clinical trials we may commence in the future, as well as any collaborations that we may enter into with third parties for our product candidates or strategic opportunities that become available to us, and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 20</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, we have not used any of the net proceeds from our initial public offering.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a>Item 6. Selected </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Data. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserved.</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a>Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_Hlk31384891"></a><a name="_Hlk31384891"></a>You should read the following discussion and analysis of our financial condition and results of operations together with the section entitled &#8220;Selected Financial Information&#8221; and our financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K, or this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the section entitled &#8220;Risk Factors,&#8221; our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. You should carefully read the section entitled &#8220;Risk Factors&#8221; to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled &#8220;Special Note Regarding Forward-Looking Statements.&#8221; We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biotechnology company focused on the discovery and development of engineered T&#160;cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B&#160;cell-mediated autoimmune diseases. Our proprietary technology utilizes <font style="text-decoration:underline;">C</font>himeric <font style="text-decoration:underline;">A</font>uto<font style="text-decoration:underline;">A</font>ntibody <font style="text-decoration:underline;">R</font>eceptor, or CAAR, T&#160;cells that are designed to selectively bind and eliminate only specific B&#160;cells that produce disease-causing autoantibodies, or pathogenic B&#160;cells, while sparing normal B&#160;cells. Our lead CAAR&#160;T cell product candidate was designed based on the clinically validated and commercially approved Chimeric Antigen Receptor, or CAR, T&#160;cell technology that is marketed for the treatment of B&#160;cell cancers. By harnessing the power of targeted cell therapy, we believe our CAAR T product candidates have the potential to provide responses that may be a safer and more effective option than current treatments. We believe our technology, in combination with our proprietary <font style="text-decoration:underline;">C</font>abaletta <font style="text-decoration:underline;">A</font>pproach for selective <font style="text-decoration:underline;">B</font>&#160;cell <font style="text-decoration:underline;">A</font>blation platform, called our CABA platform, has applicability across over two dozen B&#160;cell-mediated autoimmune diseases that we have identified, evaluated and prioritized. In order to accelerate product development for our lead program and to access a proven cell therapy manufacturing platform, we have entered into a collaboration with the University of Pennsylvania, or Penn. We hold multiple agreements with Penn to develop CAAR&#160;T cell therapies for the treatment of these diseases. Our goal is to leverage our team&#8217;s expertise in autoimmunity and engineered T cell therapy and our collaboration with Penn to rapidly discover and develop our portfolio of CAAR&#160;T product candidates. Our initial focus is mucosal pemphigus vulgaris, or mPV, which is an autoimmune blistering disease. We submitted an Investigational New Drug, or IND, application for our lead product candidate, DSG3-CAART, to the U.S. Food and Drug Administration, or the FDA, in August 2019 and our IND was cleared in September 2019. The FDA granted DSG3-CAART orphan drug designation for the treatment of PV in January 2020, and fast track designation for improving healing of mucosal blisters in patients with mucosal pemphigus vulgaris, or mPV, in May 2020. Our lead product candidate, DSG3-CAART, designed to treat patients with mPV, is currently enrolling patients for a Phase 1 trial, or the DesCAARTes<font style="font-size:9.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font> trial. <font style="color:#000000;">In December 2020, we announced that the first patient had been dosed in the DesCAARTes</font><font style="font-size:9.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font><font style="color:#000000;"> trial. </font>We expect to report the acute safety data from the first cohort of patients in the DesCAARTes<font style="font-size:9.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font> trial in the first half of 2021, <font style="color:#000000;">with additional topline data from any completed dose cohorts throughout the second half of 2021</font>. Our lead preclinical product candidate is designed for the treatment of muscle-specific kinase myasthenia gravis, or MuSK MG, and is currently in IND enabling studies, with an IND submission expected in the second half of 2021. We are also advancing additional product candidates currently in discovery-stage or preclinical development for the treatment of mucocutaneous PV, or mcPV, and Hemophilia&#160;A with Factor VIII, or FVIII, alloantibodies in addition to three undisclosed targets. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in April 2017. In August 2018, we entered into multiple agreements with Penn to develop the CAAR&#160;T technology to treat B&#160;cell-mediated autoimmune diseases. Our operations to date have been financed primarily by net proceeds of $86.4&#160;million from the sale of convertible notes and convertible preferred stock and net proceeds of $71.0 million from the sale of common stock in our initial public offering, or IPO, in October 2019. As of December 31, 2020, we had $108.7&#160;million in cash and cash equivalents and investments. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Amended and Restated License Agreement with </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">t</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">he Trustees of the University of Pennsylvania</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> and the Children&#8217;s Hospital of Philadelphia</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, we entered into a license agreement with Penn, which was amended and restated in July 2019 to include the Children&#8217;s Hospital of Philadelphia, or CHOP, collectively, the Institutions, and collectively with such amendment, as amended in May 2020, the License Agreement, pursuant to which we obtained (a)&#160;a non-exclusive, non-sublicensable, worldwide research license to make, have made and use products in two subfields of use, (b)&#160;effective as of October 2018, an exclusive, worldwide, royalty-bearing license, with the right to sublicense, under certain of the Institutions&#8217; intellectual property to make, use, sell, offer for sale and import products in the same two subfields of use, and (c)&#160;effective as of October 2018, a non-exclusive, worldwide, royalty-bearing license, with limited rights to sublicense, under certain of Penn&#8217;s know-how to make, have made, use, sell, offer for sale, import and have imported products in the same two subfields of use. Our rights are subject to the rights of the U.S. government and certain rights retained by the Institutions. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the License Agreement expires on the expiration or abandonment or other termination of the last valid claim in Penn&#8217;s intellectual property licensed by us. We may terminate the License Agreement at any time for convenience upon 60 days written notice. In the event of an uncured, material breach, Penn may terminate the License Agreement upon 60 days written notice.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sponsored Research Agreements </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63766298"></a>We have two sponsored research agreements, or SRAs, with Penn for the laboratories of Drs.&#160;Payne and Milone, <a name="_Hlk63766298"></a>who are also our scientific co-founders and members of our scientific advisory board. In May 2020, the agreement with Dr. Payne, or the Payne SRA, was expanded <font style="color:#000000;">to include CAAR design and optimization efforts in three additional B cell-mediated autoimmune diseases</font><font style="Background-color:#FFFFFF;color:#000000;">.&#160;In August 2020, the Payne SRA was further amended to extend the term of the original research plan. </font>Under the amended agreements, we are committed to funding a defined research plan through February 2023. The total estimated cost of the agreements is $11.8 million, which satisfies the $2.0&#160;million annual obligation under the License Agreement. As of December 31, 2020, $7.1 million of cost has been incurred pursuant to these agreements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Master Translational Research Services Agreement </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2018, we entered into a Master Translational Services Agreement with Penn, or the Services Agreement, pursuant to which Penn agreed to perform certain services related to the research and development of the technology licensed to us under the License Agreement, as well as certain clinical, regulatory and manufacturing services. <font style="color:#000000;">&#160;The Services Agreement will expire on the later of (i)&#160;October&#160;19, 2021 or (ii)&#160;completion of the services for which we have engaged Penn under the Services Agreement. </font>Either party may terminate this agreement with or without cause upon a certain number of days&#8217; prior written notice.&nbsp;&nbsp;The services encompassed by the Services Agreement are performed by different organizations at Penn pursuant to certain addenda to the Services Agreement, including the Center for Advanced Retinal and Ocular Therapeutics, or CAROT, Addendum, as amended in May 2020, and the CVPF Addendum. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Components of Operating Results </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sales of products for several years, if at all. If our development efforts for our current or future product candidates are successful and result in marketing approval, we may generate revenue in the future from product sales. We cannot predict if, when or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also in the future enter into license or collaboration agreements for our product candidates or intellectual property, and we may generate revenue in the future from payments as a result of such license or collaboration agreements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Expenses </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development expenses include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">personnel costs, which include salaries, benefits and stock-based compensation expense; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">expenses incurred under agreements with consultants and third-party contract organizations that conduct research and development activities on our behalf; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">costs related to sponsored research service agreements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">costs related to production of preclinical and clinical materials, including fees paid to contract manufacturers; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">licensing fees for intellectual property and know-how;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">laboratory and vendor expenses related to the execution of preclinical studies and ongoing and planned clinical trials; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">laboratory supplies and equipment used for internal research and development activities and related depreciation expense. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not reported program costs since inception because historically we have not tracked or recorded our research and development expenses on a&#160;pre-clinical program-by-program&#160;basis. We use our personnel and infrastructure resources across the breadth of our research and development activities, which are directed toward identifying and developing product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense all research and development costs in the periods in which they are incurred. Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and third-party service providers.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, including investments in manufacturing, as our programs advance and we conduct clinical trials. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with product development, we cannot determine with certainty the duration and completion costs of the current or future preclinical studies and clinical trials or if, when, or to what extent we will generate revenues from the commercialization and sale of our product candidates. We may never succeed in achieving regulatory approval for our product candidates. The duration, costs and timing of preclinical studies and clinical trials and development of our product candidates will depend on a variety of factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">successful completion of preclinical studies and IND-enabling studies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">development of chemistry, manufacturing and controls, or CMC, processes and procedures for purposes of IND applications; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">successful patient enrollment in, and the initiation and completion of, clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the impact of any business interruptions to our operations, including the timing and enrollment of patients in our ongoing and planned clinical trials, or to those of our clinical sites, manufacturers, suppliers, or other vendors resulting from the COVID-19 pandemic or similar public health crisis; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">receipt of regulatory approvals from applicable regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">establishing commercial manufacturing capabilities or arrangements with third-party manufacturers; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">obtaining and maintaining patent and trade secret protection and&#160;non-patent&#160;exclusivity; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">effectively competing with other therapies and treatment options; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a continued acceptable safety and efficacy profile following approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">enforcing and defending intellectual property and proprietary rights and claims; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">achieving desirable medicinal properties for the intended indications. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our preclinical studies and clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. A change in the outcome of any of these factors could mean a significant change in the costs and timing associated with the development of our current and future preclinical and clinical product candidates. For example, if the FDA or another regulatory authority, were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development, or if we experience significant delays in execution of or enrollment in any of our preclinical studies or clinical trials, we could be required to expend significant additional financial resources and time on the completion of preclinical and clinical development. We expect our research and development expenses to increase for the foreseeable future as we continue the development of product candidates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our general and administrative expenses consist primarily of personnel costs, costs related to maintenance and filing of intellectual property, depreciation expense and other expenses for outside professional services, including legal, human resources, audit and accounting services. Personnel costs consist of salaries, benefits and stock-based compensation expense. We expect our general and administrative expenses to increase over the next several years to support our continued research and development activities, manufacturing activities, increased costs of operating as a public company and the potential commercialization of our product candidates. We anticipate our general and administrative costs will increase with respect to the hiring of additional personnel, developing commercial infrastructure, fees to outside consultants, lawyers and accountants, and increased costs associated with being a public company such as expenses related to services associated with maintaining compliance with Nasdaq listing rules and SEC requirements, insurance and investor relations costs. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Income</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income <font style="color:#000000;">consists of interest earned on our cash equivalents, amortization of bond discount or premium and investment gains and losses realized during the period.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations for the </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">years</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> ended </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;3</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">, 20</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">20</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> and 201</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following sets forth our results of operations: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Statements of Operations Data:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,376</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,671</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,705</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,457</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,012</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,445</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,833</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,683</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,150</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,833</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,683</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,150</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">494</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,740</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,246</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,339</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,943</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,396</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $21.4&#160;million for the year ended December 31, 2020 as compared to $11.7&#160;million for the year ended December 31, 2019. The table below summarizes our research and development expenses: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sponsored research activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,062</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,228</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">834</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License of intellectual property and subscription fee</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(125</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing of preclinical and clinical supplies</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,652</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,382</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,270</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,202</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">441</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">761</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,827</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,006</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,821</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development services</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,350</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,146</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,204</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,376</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,671</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,705</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specific changes in our research and development expenses year over year include a:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$3.8&#160;million increase in personnel costs </font><font style="Background-color:#FFFFFF;color:#000000;font-size:10pt;">primarily driven by an increase in headcount to support overall growth</font><font style="font-size:10pt;color:#000000;">, including an increase of $0.7&#160;million in stock-based compensation expense; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$2.3&#160;million increase in manufacturing </font><font style="color:#000000;font-size:10pt;">costs primarily due to vector manufacturing and cell processing capabilities and related activities</font><font style="font-size:10pt;color:#000000;">; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;">$2.2 million increase in costs under our development services from increased outsourced preclinical research activities and lab related expenses;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;">$0.8 million increase in costs under our sponsored research agreements primarily due to an expanded scope of research;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$0.8&#160;million increase in clinical trial costs for the DesCAARTes<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> trial, including outsourced costs and investigator payments to clinical trial sites; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$0.2 million decrease </font><font style="color:#000000;font-size:10pt;">in license of intellectual property and subscription fees and other due primarily to a non-refundable payment made to Penn under a Subscription and Technology Transfer Agreement in the third quarter of 2019</font><font style="font-size:10pt;color:#000000;">.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $12.5&#160;million for the year ended December 31, 2020 as compared to $7.0&#160;million for the year ended December 31, 2019. The increase of $5.5&#160;million in our general and administrative expenses year over year includes: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$2.6&#160;million of additional personnel costs </font><font style="Background-color:#FFFFFF;color:#000000;font-size:10pt;">primarily driven by an increase in headcount to support overall growth</font><font style="font-size:10pt;color:#000000;">, including an increase of  $1.4&#160;million in stock-based compensation expense;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$1.9&#160;million of increased insurance costs, primarily as a result of being a public company for a full year; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$1.0&#160;million of additional services, including legal, audit and accounting, public relations, recruiting and other consulting fees and other general and administrative expenses, </font><font style="color:#000000;font-size:10pt;">primarily as a result of being a public company</font><font style="font-size:10pt;color:#000000;">.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other Income</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income has decreased $1.2 million for the year ended December 31, 2020 as compared to the year ended December 31, 2019 primarily as a result of a significant decrease in interest rates beginning in March 2020.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception in April 2017 through December 31, 2020, our operations have been financed by proceeds of $86.4&#160;million from the sale of convertible notes and our convertible preferred stock and proceeds of $71.0 million from the sale of common stock in our initial public offering. As of December&#160;31, 2020, we had $108.7&#160;million in cash, cash equivalents and investments. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred losses since our inception and, as of December&#160;31, 2020, we had an accumulated deficit of $66.3&#160;million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding prepaid expenses and other current assets, accounts payable and accrued expenses. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the&#160;build-out&#160;of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon our current operating plan, we believe that our existing cash, cash equivalents and investments as of December&#160;31, 2020 will enable us to fund our operating expenses and capital expenditure requirements through at least the third quarter of 2022. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or&#160;in-license&#160;other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">At-The-Market Offering Sales Agreement </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On&#160;November 10, 2020, we filed a registration statement on Form S-3 (File No. 333-250006) with the SEC, which was declared effective on November 18, 2020 (the Shelf Registration Statement), in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities&#160;in one or more offerings.&#160;We also simultaneously entered into a Sales Agreement with Cowen and Company, LLC, to provide for the offering, issuance and sale of up to an aggregate amount of $75.0 million of our common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf Registration Statement and subject to the limitations thereof.&#160;No shares have been sold pursuant to the Sales Agreement as of December 31, 2020.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the scope, progress, results and costs of researching, developing and manufacturing our lead product candidates or any future product candidates, and conducting preclinical studies and clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the timing of, and the costs involved in, obtaining regulatory approvals or clearances for our lead product candidates or any future product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the impact of any business interruptions to our operations or to those of our clinical sites, manufacturers, suppliers, or other vendors resulting from the coronavirus disease (COVID-19) outbreak or similar public health crisis; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the number and characteristics of any additional product candidates we develop or acquire; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the timing of any cash milestone payments if we successfully achieve certain predetermined milestones; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the cost of manufacturing our lead product candidate or any future product candidates and any products we successfully commercialize, including costs associated with&#160;building-out&#160;our manufacturing capabilities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of any such agreements that we may enter into; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the expenses needed to attract and retain skilled personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs associated with being a public company; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the timing, receipt and amount of sales of any future approved or cleared products, if any. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, our operating plans may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials and other research and development activities. We currently have no credit facility or committed sources of capital. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated product development programs. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our cash flows for the periods indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in):</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,770</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,045</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,981</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(693</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119,925</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net (decrease) increase in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,775</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,187</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Activities </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, cash used in operating activities of $26.8 million was attributable to our net loss of $33.3&#160;million, offset by the net change of $1.6&#160;million in our net operating assets and liabilities and non-cash&#160;charges of $4.9&#160;million for stock-based compensation charges, amortization of premium on investments and depreciation.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2019, cash used in operating activities of $16.0 million was attributable to our net loss of $16.9&#160;million, increased by the net change of $1.5&#160;million in our net operating assets and liabilities and offset by non-cash&#160;charges of $2.4&#160;million for stock-based compensation charges and depreciation.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investing Activities </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, <font style="color:#000000;">&#160;cash used in investing activities of $8.0 million was attributable to $11.1 million of purchases of investments and $0.6 million of purchases of property and equipment, partially offset by proceeds of $3.7 million from maturities of investments.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, we used $0.7 million of cash and cash equivalents in investing activities consisting of purchases of property and equipment. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Financing Activities </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, <font style="color:#000000;">cash used in financing activities included $0.2 million in payments for common stock issuance costs from our IPO in October 2019, offset by $0.2 million in proceeds from stock option exercises and purchases of shares under the employee stock purchase plan.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, cash provided by financing activities of $119.9 million was attributable to $48.7 million of net proceeds upon the issuance of Series B convertible preferred stock in January 2019 and $71.2 million of net proceeds from the issuance of common stock in our initial public offering in October 2019. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations and Commitments </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, we entered into an operating lease agreement for office space in Philadelphia, Pennsylvania. The lease term commenced in May 2019 and will expire in July 2022. The initial annual base rent was $0.3&#160;million, and such amount will increase by 2% annually on each anniversary of the commencement date. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commitments include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">The License Agreement. </font><font style="font-size:10pt;color:#000000;">Under the License Agreement, we are required to make milestone payments upon successful completion of certain development, regulatory and sales milestones on a product-by-product and geographical basis. The payment obligations under the License Agreement are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones and we will be required to make development milestone payments and royalty payments in connection with the sale of products developed under the License Agreement. As of December&#160;31, 2020, we are unable to estimate the timing or likelihood of achieving the milestones or making future product sales. We were also obligated to pay $2.0&#160;million annually for three years beginning August 2018 for funding to the laboratories of Drs.&#160;Payne and Milone. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the License Agreement, we must use commercially reasonable efforts to develop and commercialize a product in each subfield. During the term of the License Agreement until the first commercial sale of the first product, we are obligated to pay Penn a non-refundable, non-creditable annual license maintenance fee of $10,000. We are required to pay certain milestone payments upon the achievement of specified clinical and commercial milestones. Milestone payments are reduced by a certain percentage for the second product that achieves a milestone, by an additional percentage for the third product that achieves a milestone, and so on, for each subsequent product that achieves a milestone. In the event that we are able to successfully develop and launch multiple products under the License Agreement, total milestone payments could be approximately $21.0&#160;million. Penn is also </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eligible to receive tiered royalties at percentage rates in the low single-digits, subject to an annual minimum royalty, on annual worldwide net sales of any products that are commercialized by us or our sublicensees that contain or incorporate, or are covered by, the intellectual property licensed by us. To the extent we sublicense our license rights under the License Agreement, Penn would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits. We have also entered into a subscription and technology transfer agreement with Penn, pursuant to which we owed Penn an upfront subscription fee, which was paid in 2019, and a nominal non-refundable royalty on net sales of products, a portion of which will be credited toward milestone payments and royalties under this License Agreement.&#160;Technology transfer activities would be at our cost and subject to agreement as to the technology to be transferred. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Master Translational Research Services Agreement with Penn.</font><font style="font-size:10pt;color:#000000;"> Under the Services Agreement, we have contracted for additional research and development services from various laboratories within Penn. The Services Agreement will expire upon&#160;completion of the services for which we have engaged Penn under the Services Agreement. </font><font style="color:#000000;font-size:10pt;">In May 2020, the Company amended its Addendum with the Center for Advanced Retinal and Ocular Therapeutics (CAROT) to expand access to vector manufacturing. The Company may incur additional expenses up to $1.4 million through the remaining term of the CAROT Amended Addendum.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Sponsored Research Agreements. </font><font style="font-size:10pt;color:#000000;">We have two sponsored research agreements, or SRAs, with Penn for the laboratories of our scientific co-founders Drs.&#160;Payne and Milone. In May 2020, the Payne SRA was expanded </font><font style="color:#000000;font-size:10pt;">to include CAAR design and optimization efforts in three additional B cell-mediated autoimmune diseases</font><font style="Background-color:#FFFFFF;color:#000000;font-size:10pt;">.&#160;In August 2020, this agreement was further amended to extend the term of the original research plan. </font><font style="font-size:10pt;color:#000000;">Under the amended agreements, we are committed to funding a defined research plan through February 2023. The total estimated cost of the agreements is $11.8 million, which satisfies the $2.0&#160;million annual obligation under the License Agreement. As of December 31, 2020, $7.1 million of cost has been incurred pursuant to these agreements.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Manufacturing agreements</font><font style="font-size:10pt;color:#000000;">. In January 2021, we entered into a Development and Manufacturing Services Agreement (Wuxi Agreement) with WuXi Advanced Therapies, Inc. (Wuxi) to serve as our cell processing manufacturing partner for the anticipated MuSK-CAART Phase 1 clinical trial. We have the right to terminate the Wuxi Agreement for convenience or other reasons specified in the Wuxi Agreement upon prior written notice. If we terminate the Wuxi Agreement, we will be obligated to pay an early termination fee of $1.5 million. In February 2021, we entered into a research service agreement with CHOP for vector manufacturing, with a total cost of $0.7 million, expected to be incurred during 2021.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Other Purchase Commitments.</font><font style="font-size:10pt;color:#000000;"> In the normal course of business, we enter into various purchase commitments with third-party contract manufacturers for the manufacture and processing of our product candidates and related raw materials, contracts with contract research organizations for clinical trials and agreements with vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation other than for costs already incurred.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance&#160;Sheet Arrangements </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the periods presented, we did not have, nor do we currently have, any&#160;off-balance&#160;sheet arrangements as defined under SEC rules.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Significant Judgments and Estimates </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our significant accounting policies are described in more detail in Note 2 to our financial statements appearing elsewhere in this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Costs </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate costs of research and development activities conducted by service providers, which include activities under the License Agreement, the conduct of sponsored research, preclinical studies and contract manufacturing activities. We record the estimated costs of research and development activities based upon the estimated amount of services provided and include these costs in the accrued and other current liabilities or prepaid expenses on the balance sheets and within research and development expense on the statements of operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate these costs based on factors such as estimates of the work completed and budget provided and in accordance with agreements established with our collaboration partners and third-party service providers. We make significant judgments and estimates in determining the accrued liabilities and prepaid expense balances in each reporting period. As actual costs become known, we adjust our accrued liabilities or prepaid expenses. We have not experienced any material differences between accrued costs and actual costs incurred since our inception. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based Compensation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure our stock-based awards granted to employees and non-employees and shares issued under our employee stock purchase plan based on the estimated fair values of the awards on the respective grant dates. We use the Black-Scholes option-pricing model (Black-Scholes) to estimate the fair value of its stock-based awards and shares purchased under the employee stock purchase plan. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company accounts for forfeitures of stock option awards as they occur. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Black-Scholes requires the use of subjective assumptions to determine the fair value of stock-based awards. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These assumptions include: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Fair value of common stock<font style="font-style:normal;">&#8212;Prior to our IPO in October 2019, the fair value of our common stock underlying stock-based awards was estimated on each grant date by our board of directors. In order to determine the fair value of our common stock underlying stock-based awards, our board of directors considered, among other things, a valuation of our common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice Guide,</font>&#160;Valuation of Privately-Held-Company Equity Securities Issued as Compensation<font style="font-style:normal;">. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected term</font><font style="font-style:normal;">&#8212;The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method</font><font style="font-style:normal;">, which is</font><font style="color:#000000;font-style:normal;"> the midpoint between the vesting period and the contractual term of the option.</font><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility<font style="font-style:normal;">&#8212;As a privately held company prior to our IPO in October 2019, we have a limited trading history for our common stock and, as such, the expected volatility is estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock-based awards. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate<font style="font-style:normal;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of a stock-based award. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend<font style="font-style:normal;">&#8212;We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we used an expected dividend yield of zero. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will continue to use judgment in evaluating the assumptions utilized for our stock-based compensation expense calculations on a prospective basis. In addition to the assumptions used in Black-Scholes, the amount of stock-based compensation expense we recognize in our financial statements includes stock option forfeitures as they occur.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Emerging Growth Company Status </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an emerging growth company, as defined in the JOBS&#160;Act. Under the JOBS&#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&#160;Act until such time as those standards apply to private companies. Section 107 of the JOBS Act provides that an emerging growth company may take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933 for complying with new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Section 107 of the JOBS Act provides that we can elect to opt out of the extended transition period at any time, which election is irrevocable. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS&#160;Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to certain conditions, as an emerging growth company, we may rely on certain other exemptions and reduced reporting requirements, including without limitation (i) providing an auditor&#8217;s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the consolidated financial statements, known as the auditor discussion and analysis. We will remain an emerging growth company until the earlier of (a) the last day of the fiscal year in which we have total annual gross revenue of $1.07 billion or more; (b) the last day of the fiscal year following the fifth anniversary of the date of the completion of our initial public offering; (c) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements Not Yet Adopted</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the Financial Accounting Standards Board, or the FASB, issued ASU 2016-02, <font style="font-style:italic;">Leases</font> (Topic 842), with guidance regarding the accounting for and disclosure of leases. The update requires lessees to recognize the liabilities related all leases, including operating leases, with a term greater than 12&#160;months on the balance sheet. This update also requires lessees and lessors to disclose key information about their leasing transactions. This guidance was effective for public companies for annual and interim periods beginning after December&#160;15, 2018. For all other entities, including Emerging Growth Companies, this standard is effective for annual reporting periods beginning after December&#160;15, 2020, and interim periods within annual periods beginning after December&#160;15, 2021. Early adoption is permitted. As an Emerging Growth Company, we will adopt Topic 842 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for our annual period ending December 31</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2021</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">yet </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">finalized our assessment of the impact </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that ASU 2016-02 will have on our financial statements or financial statement disclosures. </font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a>Item 7A. Quantitative and Qualitative Disclosures About Market Risk. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. We held cash and cash equivalents and investments of $108.7&#160;million as of December 31, 2020. We generally hold our cash in interest-bearing money market treasury fund accounts and our investments are <font style="color:#000000;">investment grade corporate bonds with </font><font style="Background-color:#FFFFFF;color:#212529;">high credit quality issuers</font>. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term maturities of our cash equivalents and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents. Declines in interest rates, however, would reduce future investment income.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any foreign currency or derivative financial instruments. Inflation generally affects us by increasing our cost of labor and program costs. We do not believe that inflation had a material effect on our results of operations during the years ended <font style="color:#000000;">December 31, 2020 and 2019</font>.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a>Item 8. Financial Statements and Supplementary Data. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The financial statements required to be filed pursuant to this Item&#160;8 are appended to this Annual Report.</font> An index of those financial statements is found in Item 15.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a>Item 9. Changes in and Disagreements w<a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a>ith Accountants on Accounting and Financial Disclosure.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been no change of accountants nor any disagreements with accountants on any matter of accounting principles or practices of financial disclosure required to be reported under this Item.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9A_CONTROLS_PROCEDURES"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9A_CONTROLS_PROCEDURES"></a>Item 9A. Controls</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> and Procedures. </font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has established disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Securities Exchange Act of 1934, as amended, or Exchange Act,&#160;is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and &#160;is accumulated and communicated to management, including the principal executive officer (our Chief Executive Officer) and principal financial officer (our Chief Financial Officer), to allow timely decisions regarding required disclosure. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of December 31, 2020, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective at the reasonable assurance level as of December 31, 2020</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance of the reliability of financial reporting and of the preparation of financial statements for external reporting purposes, in accordance with U.S. generally accepted accounting principles.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal control over financial reporting includes policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect transactions and disposition of assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with the authorization of its management and directors; and (3) provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on its financial statements.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures included in such controls may deteriorate.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2020. In making this assessment, management used the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013). These criteria are in the areas of control environment, risk assessment, control activities, information and communication, and monitoring. Management&#8217;s assessment included extensive documentation, evaluating and testing the design and operating effectiveness of its internal controls over financial reporting.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on management&#8217;s processes and assessment, as described above, management has concluded that, as of December 31, 2020, our internal control over financial reporting was effective.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Attestation Report of the Registered Public Accounting Firm</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm due to an exemption established by the JOBS Act for &#8220;emerging growth companies.&#8221;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the fiscal quarter ended December 31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. <font style="Background-color:#FFFFFF;color:#000000;">As a result of the COVID-19 pandemic, since March 2020, most of our employees have been working remotely.&#160;We have not identified any material changes in our internal control over financial reporting as a result of these changes to the working environment. We are continually monitoring and assessing the COVID-19 situation to determine any potential impacts on the design and operating effectiveness of our internal controls over financial reporting.</font></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9B_OR_INFORMATION"></a><a name="ITEM_9B_OR_INFORMATION"></a>Item 9B. Other Information. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_III"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_III"></a>PART</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> III </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a>Item 10. Directors, Executive Officers and Corporate Governance. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Except as set forth below, the information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2021 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2020.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We have adopted a Code of Business Conduct and Ethics that applies to all of our directors, officers and employees, including our principal executive officer and principal financial officer. The Code of Business Conduct and Ethics is posted on our website at </font><font style="Background-color:#FFFFFF;color:#auto;text-decoration:underline;">http://investors.cabalettabio.com/corporate-governance/governance-highlights</font><font style="Background-color:#FFFFFF;">.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of this Code of Business Conduct and Ethics by posting such information on our website, at the address and location specified above and , to the extent required by the listing standards of The Nasdaq Global Select Market, by filing a Current Report on Form 8-K with the SEC, disclosing such information.</font> </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a>Item 11. Executive Compensation. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The information required by this Item&#160;11 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2020 and is incorporated herein by reference</font>.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The information required by this Item&#160;12 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2020 and is incorporated herein by reference</font>. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a>Item 13. Certain Relationships and Related Transactions, and Director Independence. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The information required by this Item&#160;13 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2020 and is incorporated herein by reference</font>. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a>Item 14. Principal Accounting Fees and Services. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The information required by this Item&#160;14 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2020 and is incorporated herein by reference</font>. </p><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IV"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IV"></a>PART</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> IV </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a>Item&#160;15. Exhibits, Financial Statement Schedules.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) The following documents are filed as part of this Annual Report on Form 10-K:</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) Financial Statements:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;width:94.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:0.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</font></a></p></td>
<td valign="top"  style="width:0.48%;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#BALANCE_SHEETS"><font style="text-decoration:underline;">Balance Sheets as of December 31, 2020 and 2019</font></a></p></td>
<td valign="top"  style="width:0.48%;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_OPERATIONS"><font style="text-decoration:underline;">Statements of Operations and Comprehensive Loss for the Years Ended December&#160;31, 2020 and 2019</font></a></p></td>
<td valign="top"  style="width:0.48%;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_CONVERTIBLE_PREFERRED_STOCK_S"><font style="text-decoration:underline;">Statements of Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity for the Years Ended December&#160;31, 2020 and 2019</font></a></p></td>
<td valign="top"  style="width:0.48%;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Statements of Cash Flows for the Years Ended December&#160;31, 2020 and 2019</font></a></p></td>
<td valign="top"  style="width:0.48%;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_FINANCIAL_STATEMENTS"><font style="text-decoration:underline;">Notes to Financial Statements</font></a></p></td>
<td valign="top"  style="width:0.48%;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) Financial Statement Schedules:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3) Exhibits. The exhibits required by Item 601 of Regulation S-K and Item 15(b) of this Annual Report on Form 10-K are listed in the Exhibit Index immediately preceding the signature page of this Annual Report on Form 10-K. The exhibits listed in the Exhibit Index are incorporated by reference herein.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16_FORM_10_K_SUMMARY"></a>Item 16. Form 10-K Summary</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO FINANCIAL STATEMENTS </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#BALANCE_SHEETS"><font style="text-decoration:underline;">Balance Sheets as of December 31, 2020 and 2019</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_OPERATIONS"><font style="text-decoration:underline;">Statements of Operations and Comprehensive Loss for the Years Ended December&#160;31, 2020 and 2019</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_CONVERTIBLE_PREFERRED_STOCK_S"><font style="text-decoration:underline;">Statements of Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity for the Years Ended &nbsp;&nbsp; December&#160;31, 2020 and 2019</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Statements of Cash Flows for the Years Ended December&#160;31, 2020 and 2019</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_FINANCIAL_STATEMENTS"><font style="text-decoration:underline;">Notes to Financial Statements</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a>Report of Independent Registered Public Accounting Firm </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and the Board of Directors of Cabaletta Bio, Inc. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying balance sheets of Cabaletta Bio, Inc. (the Company) as of December 31, 2020 and 2019, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; (deficit) equity and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ernst &amp; Young LLP</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2018 </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Philadelphia, Pennsylvania </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 16, 2021</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CABALETTA BIO, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="BALANCE_SHEETS"></a><a name="BALANCE_SHEETS"></a>Balance Sheets </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,429</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,204</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,233</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,873</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,348</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,535</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140,552</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">890</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">815</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">299</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,724</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,468</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,243</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">920</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,937</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,227</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,180</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,147</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (see Note 7)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $0.00001 par value: 10,000,000 shares authorized as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020 and 2019, respectively; no shares issued or outstanding at December 31, 2020 and 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Voting and non-voting common stock, $0.00001 par value: 150,000,000</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(143,590,481 voting and 6,409,519 non-voting) shares authorized as of December 31, 2020 and 2019, respectively; 24,062,775 (19,387,160 voting and 4,675,615 non-voting) shares issued and outstanding as of December 31, 2020 and 24,034,022 (17,624,503 voting and 6,409,519 non-voting) issued and outstanding as of December 31, 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175,836</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171,280</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,298</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,959</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,544</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138,321</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,724</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,468</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these financial statements. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CABALETTA BIO, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="STATEMENTS_OPERATIONS"></a><a name="STATEMENTS_OPERATIONS"></a>Statements of Operations and Comprehensive Loss</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,376</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,671</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,457</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,012</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,833</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,683</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,833</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,683</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">494</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,740</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,339</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,943</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed dividend</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,326</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,339</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,269</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net unrealized gain on available-for-sale investments, net of tax</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,333</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,269</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per voting and non-voting share, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.44</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.07</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these financial statements. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CABALETTA BIO, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="STATEMENTS_CONVERTIBLE_PREFERRED_STOCK_S"></a><a name="STATEMENTS_CONVERTIBLE_PREFERRED_STOCK_S"></a>Statements of Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:105%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.74%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.98%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.74%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.74%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional Paid-in Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Other Comprehensive Income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Stockholders&#8217; (Deficit) Equity </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance&#8212;December&#160;31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,393,047</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,921</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,848,320</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,762</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,452</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,690</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of convertible preferred stock,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; net of issuance costs of $1,293</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,963,788</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,707</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon completion of initial public offering, net of issuance costs of $3,408</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,275,501</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock in conjunction with exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,667</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange of convertible preferred stock,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; including deemed dividend</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,326</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,762</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,564</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,326</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible preferred stock into common stock on a 1.5 for 1 basis</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,356,835</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(97,954</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,904,534</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,954</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,954</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,300</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,300</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,943</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,943</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance&#8212;December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,034,022</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171,280</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,959</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138,321</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock in connection with exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,611</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.98%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock under employee stock purchase plan</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,142</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net unrealized gains on available-for-sale</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,388</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,388</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,339</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,339</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance&#8212;December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63256191"></a>24,062,775</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175,836</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,298</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,544</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these financial statements. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CABALETTA BIO, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="STATEMENTS_CASH_FLOWS"></a><a name="STATEMENTS_CASH_FLOWS"></a>Statements of Cash Flows </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,339</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,943</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,388</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,300</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of premium on investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">354</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(524</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,372</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(198</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(101</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">555</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">246</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,875</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,721</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,770</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,045</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(635</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(693</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,097</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from maturities of investments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,751</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,981</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(693</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(192</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,212</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance costs of convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,293</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock in connection with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; the exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the issuance of common stock under employee</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stock purchase plan</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119,925</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net (decrease) increase in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,775</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,187</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents&#8212;beginning of year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,204</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents&#8212;end of year</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,429</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,204</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosures of non-cash investing and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible preferred stock into common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,954</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange of convertible preferred stock, including deemed dividend</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,090</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs in accounts payable and accrued and other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment purchases included in accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these financial statements. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CABALETTA BIO, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_FINANCIAL_STATEMENTS"></a><a name="NOTES_TO_FINANCIAL_STATEMENTS"></a>Notes to the Financial Statements </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts) </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Basis of Presentation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cabaletta Bio, Inc. (the Company or Cabaletta) was incorporated in April 2017 in the State of Delaware as Tycho Therapeutics, Inc. and, in August 2018, changed its name to Cabaletta Bio, Inc. The Company is headquartered in Philadelphia, Pennsylvania. Cabaletta is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal operations commenced in April 2018, when the Company executed two sponsored research agreements with the Trustees of the University of Pennsylvania (Penn). </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 16, 2019, the Company effected a 1-for-1.5 reverse split of the Company&#8217;s issued and outstanding shares of common stock, par value $0.00001 per share (Common Stock). Upon the effectiveness of the reverse stock split: (i) all shares of outstanding Common Stock were adjusted; (ii) the conversion price of the Series A convertible preferred stock (Series A Preferred), Series A-1 convertible preferred stock (Series A-1 Preferred), Series A-2 convertible preferred stock (Series A-2 Preferred) and Series B convertible preferred stock (Series B Preferred; collectively, the Preferred Shares) was adjusted; (iii) the number of shares of Common Stock for which each outstanding option to purchase Common Stock is exercisable was adjusted; and (iv) the exercise price of each outstanding option to purchase Common Stock was adjusted. All of the outstanding Common Stock share numbers (including shares of Common Stock subject to the Company&#8217;s options and as converted for the outstanding convertible preferred stock shares), share prices, exercise prices and per share amounts contained in the financial statements have been retroactively adjusted in the financial statements to reflect this reverse stock split for all periods presented. The par value per share and the authorized number of shares of Common Stock and convertible preferred stock were not adjusted as a result of the reverse stock split.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 29, 2019, the Company completed its initial public offering (IPO) of 6,800,000&#160;shares of Common Stock at an offering price of $11.00 per share. The Company received net proceeds of $66,156 after deducting underwriting discounts, commissions and estimated offering expenses. In connection with the IPO, the Company&#8217;s outstanding shares of convertible preferred stock were automatically converted into 12,904,534 shares of Common Stock. In November 2019, the underwriters partially exercised their option and purchased an additional 475,501 shares of Common Stock resulting in net proceeds to the Company of $4,864, after deducting underwriting discounts and commissions. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Risks and Uncertainties </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not expect to generate revenue from sales of engineered T cell therapies for B cell-mediated autoimmune diseases or any other revenue unless and until the Company completes preclinical and clinical development and obtains regulatory approval for one or more product candidates. If the Company seeks to obtain regulatory approval for any of its product candidates, the Company expects to incur significant commercialization expenses. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. As a result, the Company is unable to predict the timing or amount of increased expenses or when or if the Company will be able to achieve or maintain profitability. Further, the Company is currently dependent on University of Pennsylvania (Penn) for much of its preclinical research, clinical research and development activities and initial manufacturing activities (Note 6). Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. Even if the Company is able to generate revenues from the sale of its product candidates, if approved, it may not become profitable. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then it may be unable to continue its operations at planned levels and be forced to reduce its operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_4"></a>In December 2019, a novel strain of coronavirus surfaced in Wuhan, China and has since reached multiple other regions and countries.&#160;The COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures, which have delayed<a name="_cp_text_1_4"></a> the commencement of non-COVID-19-related clinical trials, among other </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">restrictions. The </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company&#8217;s </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial results for the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ended </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2020</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> were not significantly impacted by COVID-19</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, h</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">owever, </font><font style="color:#000000;">the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic, including </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">new information that may emerge concerning the severity of COVID-19, the impact of new strains of the virus, the effectiveness and availability of vaccines and the actions to contain COVID-19 or treat its impact </font><font style="color:#000000;">will have on its financial condition, operations, and business plans, including its ability to raise additional capital, the timing and enrollment of patients in its</font><font style="color:#000000;"> ongoing and</font><font style="color:#000000;">&#160;planned clinical trials, future financings and other expected milestones of its product candidates.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has sustained annual operating losses since inception and expects to continue to generate operating losses for the foreseeable future. The Company&#8217;s ultimate success depends on the outcome of its research and development activities. The Company had cash and cash equivalents and investments of $108,662 as of December&#160;31, 2020. Through December&#160;31, 2020, the Company has incurred an accumulated deficit of $66,298. Management expects to incur additional losses in the future as it continues its research and development and will need to raise additional capital to fully implement its business plan and to fund its operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company intends to raise such additional capital through a combination of equity offerings, debt financings, government funding arrangements, strategic alliances or other sources. However, if such financing is not available at adequate levels and on a timely basis, or such agreements are not available on favorable terms, or at all, as and when needed, the Company will need to reevaluate its operating plan and may be required to delay or discontinue the development of one or more of its product candidates or operational initiatives. The Company expects that its cash, cash equivalents and investments as of December&#160;31, 2020 will be sufficient to fund its projected operations for at least 12 months from the date the Company&#8217;s Annual Report on Form 10-K is filed with the Securities and Exchange Commission (SEC).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, stock-based compensation and the valuation allowance on the Company&#8217;s deferred tax assets. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Off-Balance Sheet Risk and Concentrations of Credit Risk </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, which are primarily invested in U.S. treasury-based money market funds, and available-for-sale debt securities, which are invested in investment grade corporate bonds with&#160;<font style="Background-color:#FFFFFF;color:#212529;">high credit quality issuers</font>.&#160;These investments have maturities in 2021. A portion of the Company&#8217;s cash is maintained at a federally insured financial institution. The deposits held at this institution are in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held.&#160; The cash in this account is swept daily into U.S. treasury-based and U.S. government-based money market funds. The Company has no off&#8209;balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investments</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments are available-for-sale and carried at estimated fair value. The Company&#8217;s valuations of available-for-sale debt securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than, twelve months from the balance sheet date are classified as current.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors including the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or if more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other-than-temporary, if any, on available-for-sale securities are included in interest and other income, net. The cost of investments sold is based on the specific-identification method. Interest income on investments as well as amortization of discount or premium is included in interest income.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property, Plant and Equipment </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying statements of operations. Expenditures for normal, recurring or periodic repairs and maintenance related to property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful lives for property and equipment are as follows:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk31819364"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Three years</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Three years</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Three years</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Lesser of estimated useful life or remaining lease term</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurement </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2&#8212;Inputs (other than quoted prices included in Level&#160;1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs include costs incurred for internal and external research and development activities and are expensed as incurred in the accompanying statements of operations. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to entities that conduct certain research and development activities on the Company&#8217;s behalf. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers, which include activities under agreements with Penn (Note 6), the conduct of sponsored research, preclinical studies and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided and includes these costs in accrued and other current liabilities and prepaid expenses and other current assets in the accompanying balance sheets and within research and development expense in the accompanying statements of operations. Non-refundable advance payments made for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as expense as the goods are received or the related services are rendered.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with service providers. The Company makes significant judgments and estimates in determining the accrued liabilities and prepaid expenses in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities and prepaid expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based Compensation </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures its stock-based awards granted to employees and non-employees based on the estimated fair values of the awards on the respective grant dates. The Company uses the Black-Scholes option-pricing model (Black-Scholes) to estimate the fair value of its stock-based awards. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company accounts for forfeitures of stock option awards as they occur. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company&#8217;s IPO, the assumptions used in the Company's Black-Scholes option-pricing model represented management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities, which relate primarily to the carrying amount of the Company&#8217;s property and equipment and its net operating loss carryforwards, are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the two-class method required for participating securities. The Company has voting and non-voting common stock. The rights, including the liquidation and dividend rights, of the holders of the voting and non-voting common stock are identical, except with respect to voting. Each share of non-voting common stock may be converted at any time into one share of voting common stock at the option of its holder by providing written notice to the Company, subject to the limitations provided for in the amended and restated certificate of incorporation. The Company also considers its unvested shares of common stock held by the Company&#8217;s founders and, prior to its conversion to common stock, its convertible preferred stock to be participating securities as, in the event a dividend is paid on common stock, the holders of convertible preferred stock and unvested shares of common stock would be entitled to receive dividends on a basis consistent with the common stockholders. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock, which excludes unvested shares of common stock. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undistributed loss for each year is allocated to common stockholders based on the contractual participation rights of the voting and non-voting common stock as if the losses for the year had been distributed. As the liquidation and dividend rights are identical, the undistributed losses are allocated on a proportionate basis. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the year ended December 31, 2019</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> is calculated by adjusting the net loss of the Company for the deemed dividend associated with the exchange of Series A-2 Preferred for Series B Preferred. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted net loss per share attributable to common stockholders is computed under the if-converted method and assumes that all non-voting common stock has been converted to common stock. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company was in a loss position for all periods presented, the effects of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the other </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potentially dilutive securities are antidilutive. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segments </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has one reportable segment. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Related Party Transactions </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company engaged a firm controlled by a former executive (until February 2019) of the Company for professional services related to accounting, finance and other administrative functions. For the years ended December 31, 2020 and 2019, the costs incurred under this arrangement totaled $311 and $601, respectively. These amounts were recorded as general and administrative expense in the accompanying statements of operations. As of December&#160;31, 2020 and 2019, amounts owed under this arrangement totaled $13&#160;and $36, respectively, and are included in accounts payable in the accompanying balance sheets.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Emerging Growth Company Status </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS&#160;Act). Under the JOBS&#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&#160;Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS&#160;Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements Not Yet Adopted</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the Financial Accounting Standards Board (FASB) issued ASU 2016-02, <font style="font-style:italic;">Leases</font> (Topic 842), with guidance regarding the accounting for and disclosure of leases. The update requires lessees to recognize the liabilities related all leases, including operating leases, with a term greater than 12 months on the balance sheet. This update also requires lessees and lessors to disclose key information about their leasing transactions. This guidance will be effective for public companies for annual and interim periods beginning after December&#160;15, 2018. For all other entities, including Emerging Growth Companies, this standard is effective for annual reporting periods beginning after December&#160;15, 2020, and interim periods within annual periods beginning after December&#160;15, 2021. Early adoption is permitted. As an Emerging Growth Company, the Company expects to adopt Topic 842 for its annual period ending December 31, 2021 and has not yet finalized the assessment of the impact that ASU 2016-02 will have on its financial statements or financial statement disclosures. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Fair Value Measurements </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of&#160;December 31, 2020 and 2019, the Company&#8217;s financial instruments included cash and cash equivalents, available-for-sale debt securities, accounts payable and accrued expenses. The carrying amounts for cash and cash equivalents, accounts payable and accrued expenses reported in the Company&#8217;s financial statements for these instruments approximate their respective fair values because of the short-term nature of these instruments.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prices in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active Markets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Identical</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets (Level 1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,429</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,429</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,233</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,233</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,662</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,429</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,233</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk31819366"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in Active Markets for Identical Assets (Level 1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other Observable Inputs (Level 2)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Unobservable Inputs (Level 3)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,204</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,204</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,204</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,204</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level 1. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs. There were no transfers of assets between the fair value measurement levels during the years ended December 31, 2020 or 2019.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For debt securities classified as available-for-sale investments, the Company records unrealized gains or losses resulting from changes in fair value between measurement dates as a component of other comprehensive income. The Company did not hold any available-for-sale securities as of December 31, 2019.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Included in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,429</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,429</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds - due in one year or less</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Included in short-term investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,227</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,233</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,656</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,662</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. Property, Plant and Equipment</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property plant and equipment consists of the following:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">961</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">277</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">277</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property, plant and equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,348</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">919</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(458</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(104</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">890</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">815</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense was $354 and $104 for the years ended December 31, 2020 and 2019, respectively.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5. Accrued and Other Current Liabilities </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities consist of the following: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development services</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,294</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">231</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative services</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,445</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,522</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">177</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,937</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,227</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. <font style="color:#000000;">Collaborations, Licensing Agreements</font> and other Agreements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Amended and Restated License Agreement with the Trustees of the University of Pennsylvania and Children&#8217;s Hospital of Philadelphia</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Company entered into a license agreement with Penn, as amended and restated in July 2019 to include CHOP as a party, and as amended in May 2020 (the License Agreement) pursuant to which the Company obtained (a)&#160;a non-exclusive, non-sublicensable worldwide license to certain of Penn&#8217;s intellectual property to conduct research, product development, clinical trials, cell manufacturing and other activities, and (b)&#160;an exclusive, worldwide, royalty-bearing right and license, with a right to sublicense, on a target-by-target basis, under certain of Penn&#8217;s intellectual property to make, use, sell, offer for sale, import, and otherwise commercialize products for the treatment of autoimmune and alloimmune diseases.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63865623"></a>Unless earlier terminated, the License Agreement expires on the expiration or abandonment or other termination of the last valid claim in Penn&#8217;s intellectual property licensed by the Company. The Company may terminate the License Agreement at any time for convenience upon 60 days written notice. In the event of an uncured, material breach, Penn may terminate the License Agreement upon 60 days written notice.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the License Agreement, the Company was obligated to pay $2,000 annually for three years beginning August 2018 for funding to the laboratories of each of Drs.&#160;Milone and Payne (see&#160;<font style="font-style:italic;">Sponsored Research Agreements</font>). During the term of the License Agreement until the first commercial sale of the first product, the Company is obligated to pay Penn a non-refundable, non-creditable annual license maintenance fee of $10. In May 2020, the Company paid Penn an additional, non-refundable, non-creditable license fee of $33 under the amended License Agreement. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to pay certain milestone payments upon the achievement of specified clinical and commercial milestones. Milestone payments are reduced by a certain percentage for the second product that achieves a milestone, by an additional percentage for the third product that achieves a milestone, and so on, for each subsequent product that achieves a milestone. In the event that the Company is able to successfully develop and launch multiple products under the </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement, total milestone payments could </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be approximately</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,000</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Penn is also eligible to receive tiered royalties at percentage rates in the low single-digits, subject to an annual minimum royalty, on annual worldwide net sales of any products that are commercialized by the Company or its sublicensees that contain or incorporate, or are covered by, the intellectual property licensed by the Company. To the extent the Company sublicenses its license rights under the </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement, Penn would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits.</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> There were </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> amounts due under the License Agreement as of December 31, 2020.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-style:italic;">Sponsored Research Agreements </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has sponsored research agreements with two faculty members at Penn, who are also scientific co-founders of the Company and members of the Company&#8217;s scientific advisory board. <font style="color:#000000;">In May 2020, one of the agreements was amended to</font><font style="Background-color:#FFFFFF;color:#000000;">&#160;expand the scope of sponsored research.&#160;In August 2020, this agreement was further amended to extend the term of the original research plan.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the amended agreements, the Company has committed to funding a defined research plan through February 2023. The total estimated cost of $11,781 under the agreements satisfies the Company&#8217;s annual obligation under the License Agreement (see&#160;<font style="font-style:italic;">Amended and Restated License Agreement</font>&#160;<font style="font-style:italic;">with the Trustees of the University of Pennsylvania</font>&#160;above). <font style="color:#000000;">As of December 31, 2020, $7,090 of cost has been incurred pursuant to these agreements. For the years ended December&#160;31, 2020 and 2019, the Company recognized research and development expense of $2,995 and $2,137, respectively, related to these agreements in the accompanying statements of operations. As of December 31, 2020 and 2019, $1,851 and $1,588 respectively, of advance payments are included in Prepaid expenses and other current assets in the accompanying balance sheets </font>and there was $217 included in Accrued and other current liabilities in the accompanying balance sheets as of December 31, 2020.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Master Translational Research Services Agreement </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<font style="color:#000000;">n October 2018, the Company entered into a services agreement (the Services Agreement) with Penn for additional research and development services from various laboratories within Penn. The research and development activities are detailed in separately executed Penn organization-specific addenda. In May 2020, the Company amended its Addendum with the Center for Advanced Retinal and Ocular Therapeutics (CAROT) to expand access to vector manufacturing.</font> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense related to executed addenda under the master translational research service agreement with Penn recognized in the accompanying statements of operations for the years ended December 31, 2020 and 2019 was $2,474 and $2,355, respectively. The Company may incur additional expenses up to $1,360 through the remaining term of the CAROT Amended Addendum.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:5.94%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Subscription and Technology Transfer Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, the Company entered into a subscription and technology transfer agreement pursuant to which the Company owed Penn an upfront subscription fee, which was paid in 2019, and a nominal non-refundable royalty on the net sales of products, a portion of which will be credited toward milestone payments and royalties, respectively, under the Amended License Agreement.&#160;Technology transfer activities will be at the Company&#8217;s cost and subject to agreement as to the technology to be transferred. Under this agreement, the Company recognized $250 of research and development expense for the year ended December 31, 2019. No expense was recognized under this agreement for the year ended December 31, 2020.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6.73%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6.73%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Collaboration and License Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company entered into a collaboration and license agreement with Artisan Bio, Inc. (Artisan), wherein the Company and Artisan agreed to collaborate to potentially enhance certain pipeline products of the Company at specific targets using Artisan&#8217;s gene editing and engineering technology.&#160;If the Artisan technology </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is applied to any of the Company&#8217;s products, the Company will be responsible for the development, manufacturing, and commercialization of any such products. Under the terms of the agreement, the Company was required to pay Artisan a nominal upfront fee, as well as costs associated with research and development activities. Artisan is eligible to receive future research, development&#160;and regulatory milestones, and is also eligible to receive sales milestones and tiered royalties on net sales of products that incorporate the Artisan technology. The Company can terminate the agreement at will upon advance written notice with payment of a nominal cancellation fee.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. Commitments and Contingencies </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Lease Agreement </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, the Company entered into an operating lease agreement for new office space in Philadelphia, Pennsylvania. The lease term commenced in May 2019 and will expire in July 2022. The initial annual base rent is $261, and such amount will increase by 2% annually on each anniversary of the commencement date. The Company records rent expense on a straight-line basis over the lease term. Rent expense related to this lease agreement recognized in the accompanying statement of operations was $266 and $178 for the years ended December 31, 2020 and 2019.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the future minimum payments for operating leases are as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk31819368"></a>2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">426</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:5.94%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Purchase Commitments</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the normal course of business, the Company enters into various purchase commitments with third-party contract manufacturers for the manufacture and processing of its product candidates and related raw materials, contracts with contract research organizations for clinical trials and agreements with vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Indemnification </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into certain types of contracts that contingently requires the Company to indemnify various parties against claims from third parties. These contracts primarily relate to (i)&#160;the Company&#8217;s bylaws, under which the Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their relationship, (ii)&#160;contracts under which the Company must indemnify directors and certain officers and consultants for liabilities arising out of their relationship, (iii)&#160;contracts under which the Company may be required to indemnify partners against certain claims, including claims from third parties asserting, among other things, infringement of their intellectual property rights, and (iv)&#160;procurement, consulting, or license agreements under which the Company may be required to indemnify vendors, consultants or licensors for certain claims, including claims that may be brought against them arising from the Company&#8217;s acts or omissions with respect to the supplied products, technology or services. From time to time, the Company may receive indemnification claims under these contracts in the normal course of business. In addition, under these contracts, the Company may have to modify the accused infringing intellectual property and/or refund amounts received. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or settlement, may cause a material adverse effect on the Company&#8217;s future business, operating results or financial condition. It is not possible to determine the maximum potential amount under these contracts due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">. Convertible Preferred Stock </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Preferred Stock</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Preferred Stock</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has 10,000,000 shares of authorized preferred stock as of December 31, 2020, none of which is issued or outstanding. The preferred stock is not redeemable and does not have a stated voting, dividend or liquidation preference.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Convertible Preferred Stock</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has issued Series A Preferred, Series A-1 Preferred, Series A-2 Preferred, and Series B Preferred of Convertible Preferred Stock. The Company classified Convertible Preferred Stock outside of stockholders&#8217; equity (deficit) because the shares contained deemed liquidation rights that were a contingent redemption feature not solely within the control of the Company.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A-1 Preferred</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A-2 Preferred</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance&#8212;December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,146,551</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,575</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,372,719</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,994</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,873,777</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,352</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,393,047</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,921</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,963,788</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,963,788</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange, including</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; deemed dividend</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,405,332</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,764</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,405,332</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,090</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,326</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,293</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,293</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,146,551</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,575</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,372,719</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,994</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(468,445</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,588</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,369,120</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,797</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,356,835</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(97,954</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance&#8212;December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2019, the Company&#8217;s certificate of incorporation was amended to increase the authorized shares of Convertible Preferred Stock to 20,762,168 shares, and the Company issued 6,963,788 shares of Series B Preferred, resulting in gross proceeds of $50,000. In connection, the Company issued a further 1,405,332 shares of Series B Preferred in exchange for 1,405,332 shares of Series A-2 Preferred. The Company determined the terms of the Series&#160;B Preferred to be materially, qualitatively different than the terms of the&#160;Series&#160;A-2&#160;Preferred and, as such, applied extinguishment accounting with respect to the&#160;Series&#160;A-2&#160;Preferred received in the exchange resulting in removal of the carrying amount of the&#160;Series&#160;A-2&#160;Preferred received ($4,764), the addition of the Series&#160;B Preferred issued at fair value determined with reference to the contemporaneous issuance of Series&#160;B Preferred ($10,090) and the difference ($5,326) determined to be a deemed dividend recorded to additional&#160;paid-in&#160;capital (to the extent of&#160;paid-in&#160;capital) and accumulated deficit within stockholders&#8217; deficit on the balance sheet. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The shares of Convertible Preferred Stock had various rights, including voting and dividend rights, preferences and privileges, including optional and mandatory conversion rights. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, the Convertible Preferred Stock was converted into 12,904,534 shares of Common Stock. Certain holders of the Company&#8217;s Convertible Preferred Stock elected to have such shares convert into 6,409,519 shares of non-voting Common Stock following the closing of the Company&#8217;s IPO. The non-voting shares of Common Stock have the same rights and preferences as the Common Stock but are non-voting. <font style="color:#000000;">No Convertible Preferred Stock was outstanding as of December 31, 2020 or 2019.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9. Common Stock </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common Stock </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Company&#8217;s Third Amended and Restated Certificate of Incorporation filed in October 2019, the Company is authorized to issue 143,590,481 shares of voting common stock and 6,409,519 shares of non-voting common stock. Holders of voting common <font style="color:#000000;">stock</font> shall have the exclusive right to vote for the election of directors of the Company and on all other matters requiring stockholder action. <font style="color:#000000;">Each share of the Company&#8217;s non-voting common stock may be converted at any time into one share of common stock at the option of its holder by providing written notice to the Company, subject to the limitations provided for in the amended and restated certificate of incorporation. In August 2020, 1,733,904 shares of non-voting common stock were converted to voting common stock.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">At-The-Market</font><font style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> Offering Sales Agreement </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On&#160;November 10, 2020, the Company filed a Shelf Registration Statement in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, the Company&#8217;s&#160;common stock, debt securities or other equity securities&#160;in one or more offerings.&#160;The Company also simultaneously entered into a Sales Agreement with Cowen and Company, LLC, to provide for the offering, issuance and sale of up to an aggregate amount of $75.0 million of the Company&#8217;s common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf Registration Statement and subject to the limitations thereof.&#160;No shares have been sold under the Sales Agreement as of December 31, 2020.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Share-based Payment Awards</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2018, several of the Company&#8217;s founders agreed to modify their shares of common stock outstanding to include vesting provisions that require continued service to the Company in order to vest in those shares. As such, the 2,904,000 modified shares of common stock became compensatory upon such modification. The fair value of the awards on the modification date was determined to be $0.74 per share of common stock, based on the issuance of convertible notes in May 2018, considering the maximum conversion price and the seniority of the notes. The total compensation cost resulting from the modification was $2,126. The total compensation cost is being recognized over the three-year vesting term attendant to the founders&#8217; common shares. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, the Company recognized $495 and $177 of this amount in research and development expense and general and administrative expense, respectively. During the year ended December 31, 2019, the Company recognized $529 and $177 of this amount in research and development expense and general and administrative expense, respectively.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-weight:bold;font-style:italic;font-size:10pt;">2018 Stock Option and Grant Plan </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, the Company adopted the 2018 stock option and grant plan (the 2018 Plan), which provided for the Company to sell or issue common stock, or other stock-based awards, to employees, members of the board of directors and consultants of the Company. The Company generally granted stock-based awards with service conditions only (service-based awards), although there was one grant with performance conditions. As of December 31, 2020, there are no unvested options with performance conditions. Stock options granted under the 2018 Plan generally vest over three to four years. There were 1,959,411&#160;options granted under the 2018 Plan prior to the Company&#8217;s IPO in October 2019. No further grants may be made under the 2018 Plan subsequent to the IPO. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:5.94%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2019 Stock Option and Incentive Plan</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2019 Stock Option and Incentive Plan (2019 Plan) was approved by the Company&#8217;s board of directors on October 14, 2019, and became effective on October 23, 2019. The 2019 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#8217;s officers, employees, directors and consultants. The number of shares initially reserved for issuance under the 2019 Plan was 2,342,288, <font style="color:#000000;">which will be increased </font>each January 1 thereafter by 4% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company&#8217;s board of directors or compensation committee of the board of directors. On January 1, 2<font style="color:#000000;">021, the total number of shares under the 2019 Plan was increased by&#160;962,511&#160;shares. As of December 31, 2020, there were 2,314,303 shares remaining available for issuance.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the stock option activity</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is presented below: </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of January 1, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">971,353</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.01</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,051</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,340,839</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.97</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,667</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.01</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(176,893</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.22</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,129,632</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.12</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,844</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">813,172</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.03</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,611</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.44</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,714</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.30</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,900,479</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.33</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,303</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options Exercisable at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,068,675</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.04</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,059</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of options granted is calculated as the difference between the exercise price of the options and the estimated fair value of the Company&#8217;s common stock. The weighted average grant-date fair value of stock options granted during the year ended December&#160;31, 2020 and 2019 was $8.31 and $5.24, respectively. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each award is estimated using Black-Scholes based on the following assumptions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December 31,</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.28%&#8212;1.48%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39%&#8212;2.59%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7&#8212;6.1 years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3&#8212;6.1 years</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70%&#8212;79%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70%&#8212;76%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Fair value of common stock<font style="font-style:normal;">&#8212;Prior to the Company&#8217;s IPO in October 2019, the fair value of the Company&#8217;s common stock underlying stock-based awards was estimated on each grant date by the Company&#8217;s board of directors. In order to determine the fair value of the Company&#8217;s common stock underlying stock-based awards, the Company&#8217;s board of directors considered, among other things, a valuation of the Company&#8217;s common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice Guide,</font>&#160;Valuation of Privately-Held-Company Equity Securities Issued as Compensation<font style="font-style:normal;">. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected term<font style="font-style:normal;">&#8212;The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method, which is</font><font style="color:#000000;font-style:normal;"> the midpoint between the vesting period and the contractual term of the option.</font> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility<font style="font-style:normal;">&#8212;As a privately held company prior to the Company&#8217;s IPO in October 2019, the Company has limited trading history for its common stock and, as such, the expected volatility is estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock-based awards. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate<font style="font-style:normal;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of a stock-based award. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend</font><font style="font-style:normal;">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based Compensation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has recorded stock-based compensation in the accompanying statements of operations as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk31819371"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,989</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,304</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,399</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">996</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,388</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,300</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, there was $9,809 of unrecognized compensation cost related to unvested option awards, <font style="color:#000000;">which is expected to be recognized over a weighted-average period of 2.8 years</font>. As of December&#160;31, 2020, there was $239 of unrecognized compensation cost related to unvested founder stock awards, which is expected to be recognized over a weighted-average period of 0.3 years. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:5.94%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2019 Employee Stock Purchase Plan</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2019 Employee Stock Purchase Plan (2019 ESPP) was approved by the Company&#8217;s board of directors on October&#160;14, 2019, and became effective on October 23, 2019. A total of 234,229 shares of common stock were initially reserved for issuance under the 2019 ESPP, and will be increased each January 1 thereafter through January 1, 2029 by the least of (i) 234,229 shares of common stock, (ii) 1% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31 or (iii) such lesser number of shares determined by the 2019 ESPP&#8217;s administrator. On January 1, 2021, <font style="color:#000000;">the total number of shares under the 2019 ESPP was increased by&#160;234,229&#160;shares.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee contributions&#160;are&#160;made through payroll deductions of up to 15% of eligible compensation over the offering period. A participant may not accrue rights to purchase more than $25&#160;worth of the Company&#8217;s common stock for each calendar year in which such right is outstanding.&#160;At the end of each offering period, shares of the Company&#8217;s common stock may be purchased at 85% of the lesser of the Company&#8217;s common stock on (i) the first trading day of the relevant offering period and (ii) the last trading day of the relevant offering period.&#160;The first offering period commenced on July&#160;1, 2020 and ended on November&#160;30, 2020. Thereafter, offerings will be six months in duration and will commence on each December 1 and June 1. The Company recognized stock-based compensation expense of $18 during the year ended December 31, 2020 related to the 2019 ESPP.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Income Taxes </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reconciliation of federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected income tax benefit at the federal statutory rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State and local taxes, net of federal benefit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible items and other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35.3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The principal components of the Company&#8217;s deferred tax assets consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal, state and local net operating loss carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,241</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,688</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License fee deductions</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,317</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">452</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation deductions</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,243</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">837</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">457</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,978</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,223</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,978</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,223</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company increased its valuation allowance by $11,755&#160;for the year ended December&#160;31, 2020 in order to maintain a full valuation allowance against its deferred tax assets. Based on the Company&#8217;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December&#160;31, 2020. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company had federal, state and local net operating loss carryforwards of $45,550, $47,735 and $38,645, respectively; $45,301 of the federal amounts do not expire, and the remaining $249 expire in 2037. The state net operating losses begin to expire in 2037. The local net operating losses begin to expire in 2039. As of December&#160;31, 2020, the Company had federal research and development tax credit carryforwards of $1,317, which begin to expire in 2038. Under the provisions of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the IRC), these net operating losses, credit carryforwards and other tax attributes may be subject to limitation based on previous significant changes in ownership and upon future significant changes in ownership of the Company, as defined by the IRC.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the U.S. federal jurisdiction as well as in Pennsylvania and Philadelphia. The tax years 2019, 2018 and 2017 remain open to examination by the jurisdictions where the Company is subject to tax. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&#160;31, 2020, the Company had no unrecognized income tax benefits that would affect the Company&#8217;s effective tax rate if recognized. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">. Net Loss Per Share </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the two-class method required for participating securities. For the years ended December 31, 2020 and 2019, the Company had voting and non-voting common stock outstanding. Since the rights of the voting and non-voting common stock are identical, except with respect to voting, the undistributed losses of the Company have been allocated on a proportionate basis to the two classes. Diluted net loss per share is calculated using the if-converted method, which assumes conversion of all non-voting common stock to voting common stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2020</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Voting common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-voting common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of undistributed losses attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,090</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,249</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares used in basic per share computation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,417,900</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,727,327</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.44</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.44</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted net loss per share:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of undistributed losses for basic computation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,090</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,249</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reallocation of undistributed losses as a result of conversion of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; non-voting to voting common shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,249</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of undistributed losses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,339</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,249</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares used in basic per share computation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,417,900</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,727,327</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Add: Conversion of non-voting to voting common shares outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,727,327</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares used in diluted per share computation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,145,227</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,727,327</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.44</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.44</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2019</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Voting common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-voting common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of undistributed losses attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,693</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,576</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares used in basic per share computation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,345,530</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,123,861</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.07</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.07</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted net loss per share:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of undistributed losses for basic computation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,693</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,576</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reallocation of undistributed losses as a result of conversion of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; non-voting to voting common shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,576</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of undistributed losses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,269</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,576</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares used in basic per share computation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,345,530</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,123,861</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Add: Conversion of non-voting to voting common shares outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,123,861</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares used in diluted per share computation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,469,391</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,123,861</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.07</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.07</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,900,479</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,129,632</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-vested founder stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">465,801</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,388,977</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,366,280</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,518,609</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. 401(k) Savings Plan</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains a defined-contribution savings plan under Section&#160;401(k) of the IRC, or the 401(k) Plan. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. In 2019, the Company made a safe harbor nonelective contribution of 3% of eligible compensation on behalf of all employees. Effective January 1, 2020, the Plan provided for matching contributions on a portion of participant contributions pursuant to the 401(k) Savings Plan&#8217;s matching formula, up to 4% of eligible compensation. All matching contributions and participant contributions vest immediately. Contributions totaled $203 and $74 for the years ended December&#160;31, 2020 and 2019, respectively, and have been recorded in the statements of operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13. Subsequent Events</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, the Company entered into a Development and Manufacturing Services Agreement (Wuxi Agreement) with <font style="color:#000000;">WuXi Advanced Therapies (Wuxi) to serve as the Company&#8217;s cell processing manufacturing partner for the anticipated MuSK-CAART Phase 1 clinical trial.</font> The Company has the right to terminate the Wuxi Agreement for convenience or other reasons specified in the Wuxi Agreement upon prior written notice. If the Company terminates the Wuxi Agreement, it will be obligated to pay an early termination fee of $1,500.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, the Company entered into a research service agreement with CHOP for vector manufacturing, with a total cost of $670, expected to be incurred during 2021.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU13"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU14"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT INDEX</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92.04%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:0.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">3.1</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001759138/000119312519278927/d759120dex31.htm"><font style="text-decoration:underline;">Third Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K (File No. 001-39103) filed on October 30, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">3.2</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001759138/000119312519278927/d759120dex32.htm"><font style="text-decoration:underline;">Amended and Restated Bylaws of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.2 of the Registrant&#8217;s Current Report on Form 8-K (File No. 001-39103) filed on October 30, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">4.1</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001759138/000119312519268040/d686907dex41.htm"><font style="text-decoration:underline;">Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-234017) filed on October 16, 2019</font></a><font style="text-decoration:underline;">)</font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">4.2</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001759138/000119312519258869/d686907dex42.htm"><font style="text-decoration:underline;">Amended and Restated Investors' Rights Agreement among the Registrant and certain of its stockholders, dated January 2, 2019 (incorporated by reference to Exhibit 4.2 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-234017) filed on September 30, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">4.3</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1759138/000156459020013929/caba-ex43_244.htm"><font style="text-decoration:underline;">Description of Securities (incorporated by reference to Exhibit 4.3 of the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-39103) filed on March 30, 2020)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.1#</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001759138/000119312519258869/d686907dex101.htm"><font style="text-decoration:underline;">2018 Stock Option and Grant Plan, as amended, and form of award agreements thereunder (incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-234017) filed on September 30, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.2#</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001759138/000119312519268040/d686907dex102.htm"><font style="text-decoration:underline;">2019 Stock Option and Incentive Plan, and form of award agreements thereunder. (incorporated by reference to Exhibit 10.2 of the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-234017) filed on October 16, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.3#</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001759138/000119312519268040/d686907dex103.htm"><font style="text-decoration:underline;">2019 Employee Stock Purchase Plan. (incorporated by reference to Exhibit 10.3 of the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-234017) filed on October 16, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.4#</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001759138/000156459019045375/caba-ex104_188.htm"><font style="text-decoration:underline;">Senior Executive Cash Incentive Bonus Plan (incorporated by reference to Exhibit 10.4 of the Registrant&#8217;s Quarterly Report on Form 10-Q filed on December 5, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.5#</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001759138/000119312519258869/d686907dex105.htm"><font style="text-decoration:underline;">Form of Indemnification Agreement between the Registrant and each of its directors (incorporated by reference to Exhibit 10.5 of the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.6#</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001759138/000119312519258869/d686907dex104.htm"><font style="text-decoration:underline;">Form of Indemnification Agreement between the Registrant and each of its executive officers (incorporated by reference to Exhibit 10.4 of the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.7</font>+</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001759138/000119312519258869/d686907dex106.htm"><font style="text-decoration:underline;">Amended and Restated License Agreement, dated as of July 23, 2019, among the Registrant, the Trustees of the University of Pennsylvania and the Children&#8217;s Hospital of Philadelphia (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Registration Statement on&#160;Form S-1, filed with the SEC on September 30, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.8</font>+</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex107.htm"><font style="text-decoration:underline;">Sponsored Research Agreement, dated as of April 23, 2018, between the Registrant and the Trustees of the University of Pennsylvania (incorporated by reference to&#160;Exhibit 10.7 to the Registrant&#8217;s Registration Statement on&#160;Form S-1, filed with the SEC on September 30, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.9</font>+</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex108.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Sponsored Research Agreement, dated as of April 23, 2018, between the Registrant and the Trustees of the University of Pennsylvania (incorporated by reference to Exhibit 10.8 to the Registrant&#8217;s Registration Statement on&#160;Form S-1, filed with the SEC on September 30, 2019)</font></a></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92.04%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.10</font>+</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex109.htm"><font style="text-decoration:underline;">Master Translational Research Services Agreement, dated as of October 2018, between the Registrant and the Trustees of the University of Pennsylvania (incorporated by reference to Exhibit 10.9 to the Registrant&#8217;s Registration Statement on&#160;Form S-1, filed with the SEC on September 30, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.11</font>+</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1010.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">CAROT Master Services Addendum to Master Translational Research Services Agreement, dated as of February 4, 2019, between the Registrant and the Trustees of the University of Pennsylvania (incorporated by reference to Exhibit 10.10 to the Registrant&#8217;s Registration Statement on&#160;Form S-1, filed with the SEC on September 30, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.12</font>+</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1011.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">CVPF Master Services Addendum to Master Translational Research Services Agreement, dated as of October 22, 2018, between the Registrant and the Trustees of the University of Pennsylvania (incorporated by reference to Exhibit 10.11 to the Registrant&#8217;s Registration Statement on&#160;Form S-1, filed with the SEC on September 30, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.13</font>+</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1012.htm"><font style="text-decoration:underline;">Research Agreement A19-3095, dated as of October 31, 2018, between the Registrant and The Regents of the University of California (incorporated by reference to Exhibit 10.12 to the Registrant&#8217;s Registration Statement on&#160;Form S-1, filed with the SEC on September 30, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.14</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1013.htm"><font style="text-decoration:underline;">Lease, dated as of February 11, 2019, between the Registrant and Brandywine Cira, L.P. (incorporated by reference to Exhibit 10.13 to the Registrant&#8217;s Registration Statement on&#160;Form S-1, filed with the SEC on September 30, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.15#</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1016.htm"><font style="text-decoration:underline;">Employment Agreement between the Registrant and Steven Nichtberger (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Registration Statement on&#160;Form S-1, filed with the SEC on September 30, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.16#</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1017.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Employment Agreement between the Registrant and Anup Marda (incorporated by reference to Exhibit 10.17 to the Registrant&#8217;s Registration Statement on&#160;Form S-1, filed with the SEC on September 30, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.17#</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1018.htm"><font style="text-decoration:underline;">Employment Agreement between the Registrant and Gwendolyn Binder (incorporated by reference to Exhibit 10.18 to the Registrant&#8217;s Registration Statement on&#160;Form S-1, filed with the SEC on September 30, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.18#</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1019.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Employment Agreement between the Registrant and David Chang (incorporated by reference to Exhibit 10.19 to the Registrant&#8217;s Registration Statement on&#160;Form S-1, filed with the SEC on September 30, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.19#</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1020.htm"><font style="text-decoration:underline;">Employment Agreement between the Registrant and Brian Stalter (incorporated by reference to Exhibit 10.20 to the Registrant&#8217;s Registration Statement on&#160;Form S-1, filed with the SEC on September 30, 2019)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.20#</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1759138/000156459020013929/caba-ex1022_208.htm"><font style="text-decoration:underline;">Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-39103) filed on March 30, 2020)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.21</font>+</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1759138/000119312520153792/d933839dex101.htm"><font style="text-decoration:underline;">Amendment No. 1, dated May 27, 2020, to the Sponsored Research Agreement, dated April 23, 2018, between the Registrant and the Trustees of the University of Pennsylvania (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-39103) filed on May 28, 2020)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.22</font>+</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1759138/000119312520153792/d933839dex102.htm"><font style="text-decoration:underline;">First Amendment, dated May 27, 2020, to the Amended and Restated License Agreement, dated July&nbsp;&nbsp;23, 2019, among the Registrant, the Trustees of the University of Pennsylvania and the Children&#8217;s Hospital of Philadelphia (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-39103) filed on May 28, 2020)</font></a></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92.04%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.23</font>+</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1759138/000156459020037278/caba-ex101_80.htm"><font style="text-decoration:underline;">Amendment to CAROT Master Services Addendum to Master Translational Research Services Agreement, dated as of May 18, 2020 between the Registrant and the Trustees of the University of Pennsylvania (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-39103) filed on August 6, 2020)</font></a><font style="text-decoration:underline;"> </font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.24</font>+</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1759138/000156459020052757/caba-ex101_10.htm"><font style="text-decoration:underline;">Amendment No. 2, dated August 17, 2020, to the Sponsored Research Agreement, dated April 23, 2018, as amended by Amendment No. 1 dated May 27, 2020, between the Registrant and the Trustees of the University of Pennsylvania (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-39103) filed on November 10, 2020)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:13.05pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">21.1*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="caba-ex211_8.htm"><font style="text-decoration:underline;">List of Subsidiaries of the Registrant</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">23.1*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="caba-ex231_13.htm"><font style="text-decoration:underline;">Consent of Ernst &amp; Young, independent registered public accounting firm</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">31.1*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="caba-ex311_10.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">31.2*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="caba-ex312_12.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">32.1**</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="caba-ex321_11.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">32.2**</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="caba-ex322_7.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.INS</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.SCH</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.CAL</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.DEF</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.LAB</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.PRE</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
</tr>
</table></div>
<p style="text-align:justify;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:84.62%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Management Contract or compensatory plan or arrangement.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Confidential treatment has been granted by the Securities and Exchange Commission as to certain portions.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The certifications furnished in Exhibit 32.1 and 32.2 hereto are deemed to accompany this Annual Report on Form 10-K and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</p></td></tr></table></div><a name="_AEIOULastRenderedPageBreakAEIOU15"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized<font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cabaletta Bio, Inc.</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 16, 2021</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Steven Nichtberger</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Steven Nichtberger</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chief Executive Officer and President</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Steven Nichtberger</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Director, Chief Executive Officer and President</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:20%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Steven Nichtberger</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer) </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Anup Marda</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:20%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Anup Marda</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer) </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Catherine Bollard</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:20%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Catherine Bollard</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Brian Daniels</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:20%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Brian Daniels</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Richard Henriques</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:20%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Richard Henriques</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Mark Simon</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Director </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:20%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Mark Simon</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>caba-ex211_8.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
caba-ex211_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 21.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">List of Subsidiaries</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>caba-ex231_13.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
caba-ex231_13.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#333333;font-size:10.5pt;font-family:NotoSans;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#333333;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consent of Independent Registered Public Accounting Firm</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#333333;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the following Registration Statements:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#333333;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)&nbsp;&nbsp;Registration Statement (Form S-8 No. 333-234367) pertaining to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan, the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan, and the Cabaletta Bio, Inc. 2019 Employee Stock Purchase Plan, </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#333333;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) Registration Statement (Form S-8 No. 333-237484) pertaining to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan and the Cabaletta Bio, Inc. 2019 Employee Stock Purchase Plan, and</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#333333;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3) Registration Statement (Form S-3 No. 333-250006) of Cabaletta Bio, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#333333;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our report dated March 16, 2021, with respect to the financial statements of Cabaletta Bio, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2020.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#333333;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ernst &amp; Young LLP</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#333333;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Philadelphia, Pennsylvania</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#333333;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 16, 2021</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>caba-ex311_10.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
caba-ex311_10.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Steven Nichtberger, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2020 of Cabaletta Bio, Inc. (the &#8220;registrant&#8221;);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;  </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.43%;text-indent:-5.43%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 16, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;<font style="color:#000000;">Steven Nichtberger</font></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Steven Nichtberger</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer and President</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>caba-ex312_12.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
caba-ex312_12.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Anup Marda, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2020 of Cabaletta Bio, Inc. (the "registrant");</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.43%;text-indent:-5.43%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 16, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Anup Marda</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Anup Marda</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>caba-ex321_11.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
caba-ex321_11.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of Cabaletta Bio, Inc. (the &#8220;Company&#8221;) on Form 10-K for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 16, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Steven Nichtberger</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Steven Nichtberger</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>caba-ex322_7.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
caba-ex322_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of Cabaletta Bio, Inc. (the &#8220;Company&#8221;) on Form 10-K for the fiscal year ended December 31, 2020  as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 16, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Anup Marda</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Anup Marda</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Accounting and Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gaz3apgusshz000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gaz3apgusshz000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $- C,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0.PH L4444""O&?CC_Q\Z'_U\BO9J\K^+N@:MK4^CG3=/GNA%.&D,2YVCU-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A( R> *
M6N"^)\GB271X[#P]8W$[W#;9I(A]U: -Z[\;^&+"X,%UK=G#*.J,_-:UEJ%I
MJ4 GLKB.>(]&0Y%>-Z9\"!=V*SZMJUS'=L,E$ 8#\36-IL6K_#+XAVFFM=--
M9W1Z$\,G/]10,^AJ*:&!4$D#(S3J!!12$@=2*@OKZVTVREO+N98;>)=SNQX
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M(BD#'UKT7P9\+['P9J;WMMJ-Q<,RE=LB*!^E '=T444""BBB@ HHHH ****
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M@KT=E5U*NH93U!&0:;'%'"NV*-47T48% &5XHT5/$'AR\TUP/WR8&?7K_2O
M]+\4>+/AA))IUQ8^;;ASM2;(4GVQS7TI44EM!,<RP1N?]I : /G&]U;Q7\5+
M^W@%D8[)9?F6/.Q/7)//2OH31=,CT;1K33H?]7;QA!5N.WAA_P!5#&G^ZH%2
M4 %%%% !7BOQY9D&D2*NXI-NQ]!7M51RP0SX\V&.3'3>H- 'S_9_'36;.SBM
MUT2T98UV@EGR:9>_%CQ=XFA>STS3EMY&&&-ODG!^M>__ &"S_P"?2#_OV/\
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MR"DJ@D#L>XKE/C""?AY=@#/[V/\ G7=)&D2[8T5%'91@421I*FR1%=?1AD4
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MAH 6BBB@ HHHH **9YL8_C7\Z<"",@@_2@!:*** "BF[TSC>N?3-.H ****
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M%% &)J?@_P /:RV[4-*MYSG.2"/Y&JMG\/\ PI83B:UT2VCD'1AN/\S72T4
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MME'=0@Y"OG@_A6C10!CS^%M$N=&72)M.B?3U((@).T$=.^:OV&GVFEV:6EE
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M)\MDC=C/7%>R12I/"DL;!D<;E([B@!]%%9VN:K'HNC75_+C$,98 ]"<<#\Z
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MT6_J!Z_7K7K! (P1D4 ?/VK^#O$NNZ-?^(_%%S)%Y*;X;4]1R./IS7<_!/\
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M#LOA[X#U/P9J%_YU[!-8S@"*-<Y7GKTKF/C/K]U<ZA9^%K)BK2E6EVG[P8X
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M*!G;P:98VT AAM(4C'\(05YS\1_AK'J=O'J.@VHBU*.09$8P6Y'/X=:]1H)
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M\0^%[S3SKMH[,A:-?FY8<CMZUC? WQ#Y^GW&B2RY:!M\>>X/7'Y4#-OXV_\
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M7HEU;C1;,&>('RA_&*;J_B72-$M'N+V^AC55S][.?RKQ<? GQ&!@:Y:?F_\
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:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gaz3apgusshz000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gaz3apgusshz000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,4!B$# 2(  A$! Q$!_\0
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MISX^HH ]^!!Z&EKPJS^,>HP3)'/IY&2!DXKV'0]4?5;)9VCV;E!Q0!J4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+QS':2,.PJ>H;I/,M
MG3U% 'RQX]E,_CQV/>1?_0J^E/#$"PZ#9E1]Z(5\W?$&!K;QY(". Z_^A5]$
M^#[Y+O0K8*0=D8!H&=#1110(**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M".%<*!@5/10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/Z"O?9?"6E7-J$DAR"O]*\(\/?\ (^W/_7Q_05]*)_J%_P!W^E SYGUS3?\
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M_ TOAVXD(4*C-GBIOBAK?]E^'_D;#LQ7K72V?B33+UG6*[C9E." :\,^+'B
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M()/#[ZC<$L%QG%>5?%/3+6SOK>2!$4M,,A1[UWGA>2VC\&2-=,JQ#&2W3H:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *SM:YTY\>E:--=%D7:P!% 'RH=1ETCQ==S^7)@39R%/I7<3_%N[
M-OL@,H;&/NFO69?"FE32M(]G"68Y)*TB>$M'1L_88#_P&@9X?X<\/:IXI\0+
MJ%PN467><BO4/'?A8W_A=K>S7]X/\*[2VT^TLQBWMTC_ -T5.R*ZX8 CT- C
MYM\,^*]0\'W<]M<>8%!V\*:T/%7Q%GU[3S9VPD.X]U->T7WA72[T[FM(0QZG
M;4%IX,TJV<,;2%L?[- '"_"7PS<V<=S=7B_Z[YEX^E5OB;X(GN+N35;1!N['
M%>PPV\-N@6*-44=@*66&.=-DJ!U]#0!X'H/Q*U#1X?L=\9,1#:N%-5/$_P 0
M;_Q!;FSM?,*L> 5->UWGA#2KMMWV2%3W^6EL_"&E6A!^R0L1_LT#/-OA=X9U
M&VANIY@ 9?F''TJEXLU/6_#OB62X#'[./[H/K7N$-O#;KMAC5!Z 55O]'LM1
M4BXMXW)[L*!'AOB#XB2ZWIR6-N)=\B;7RIZUUGPH\,SZ?9Q7DRX)&.E=E;^#
M=*@F\S[+"><CY:WX8(K>,)$@11V% $E<AX^\,_\ "0Z*T,:@R EN:Z^D(!&"
M,B@#YMT77M5\"WLML^\1,^#M4]*O>)/B1>ZU:?9;0R98XY4U[=?>'--OLF2T
MB+'N5JI:>#M*MI-WV2%O^ T >5^$]!NM)\/W^IWBGS"-ZD"N>\-Z./&WC"5[
MR)FC9<_,/K7T8^GVSVY@\I!&1@KCBH+'0[#3I?,M[:.-L8RHH Y*/X1>&/+7
M=:'=CGI7F7Q \%6_AJ=;JP@*Q"08P/>OHRJ5_I=KJ,>RXA209S\PH ^<->\5
M7>L65M8Q"3 C"$%37=^"OA?HVH>';>YU"V)F;[QQ7HJ^%-)5@PLX<C_9K7MX
M([:$11*%0= * /-M<^$_AZ'2)Y+6UQ,!\IXKSSP9=3^&_$=Y;R(X01%1@'T-
M?1[HLBE6&0>QK*?P[IS3M-]EBWMU.* /GFQ$DOC^UE\M\-(3G::^B9]/BU#2
MFAE7.5./KBF1^'-.CG69;6(.O0[:U@H48 XH ^9M?TF[\%^*8[F)& +EQM%>
M[^#M<_MG18)7W>:PR<BM*^T6QU%@UQ;QR$=V%366GP6*!((U11T"B@"W1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 54U'_CQD^E6Z1E#KM(R#0!\[V44G_"Q[H[&
MQN'./<U[!XFT"/6_#9BV9E,8 _*M9="L%NC<"WC\P]6QS6EM&T+C@4 ?(%YH
MT^E>)H[5HF^25>BGUKWO7=#?5O!!2-?WIA4#(]JZZ?PYIMQ<>?):1&3.=Q7F
MM);>-8O*V#9C&* /G+POK47A:]EMM4CD(1<#:IZUKIXKNM9\0P0:2'6!NH93
M7KU_X4TN^;<UK#N)Y.VI-.\-:;IQW1VL08=& H&<?XV\-W&M>%+>-P#+""QK
MSCPGXPO/"226+[PF\\*I]:]F\;7-S::8K6L#2XZJOI7ENF>+K3[01?:-"K!B
M,N/_ *] CF?%NK7^K7L%Q.Q\AY04!'O7H<EO<7'PPNDAZD#^1KB_$5\_B/4;
M>WL; )&DH.4';->X^&-)6UT-;>= RLH)5OI0,\,\#ZY8>';R;^T893)C PO>
MJOC35FUS7([Z&.3R47'*GVKWR;P;I<MQYIM8>N?NU:?PQI3)M^Q0]/[M ',0
MQ/=?#J'8#D0'@BO)O!?B#_A']699DD&)6/"GUKZ0CLH8K7[.L:B/&-N.*QG\
M':6]SYPM8@?]V@1YI\6;DZGHVE7,:,0[ ]/>NT^%JLOADA@0=PZCZUT\^AV5
MS!'#+!&R1_=!'2K5G9PV47EP1JB^BB@#QKXP^'VC$-Y;1G>6W$@5D?"W1I[_
M %V#4;E#A#MR1[__ %J]ZO=/M[] MQ$L@'3<*CL=*M-/7%O B<Y^44 8/C?0
MCJNC,D:Y,:'%>,>&-8C\*WAMM2CD,8<DA5/K7TDRAU*L,@]16'?^%-,OF+-:
MQ!CWVT >/CQ==:KK$4>EAUB,@!W*>E>W:1%-%8H)OO$ U4T_PQIM@VY+6+=Z
MA:V0 !@4 (ZAT*GH>*\4^)G@VZ74'U:R3"J/3FO;:BFMX;A"DT:NI[$4 >$:
M/\4+S3+(6=T9,Q+M7"FL#4]0U;QUK(BBW%'_ +P->\W/@W2KB3?]DA'.?NU=
ML/#VG:> 8K6(,/X@M S M/"XB\'&T*?OF@V_C7CVG3W_ (#\1_OU81J2?E!]
M:^E-HV[<<>E9FH:!I^H ^=:Q,Q_B(H$>+^)?B)+X@MH[*Q\W=(-K94UU?PR\
M*RZ9IHNKA,2X/.*["S\'Z5:R;Q:PDYR/EZ5O1PQQ)LC0*OH* /FIHI/^%D ^
M6V/M77;[5[GXP!/AP@ GC^E7_P#A'M/^U?:/LT7F9W;L<YK1GMX[B+RY%#+Z
M&@#POX81NNO:@61A^][CZ5#\7K.8:T]R$8H"#P/>O;K31;*RD9X8(T9CDD"C
M4M%L]3C*SP(Q/=A0!YSX=\81:IX1ELU63=##L.0:XWP3'(/B(Q*,!MZD>]>W
MV'AJPT])%C@C ?K@5/;Z#86UU]HCMXUD_O <T 27]J;W1I;;'^L3%?/M[:WW
M@;Q;)>1JRH.,J#ZU]( 8&*H7VC6.H ^?;1NQ[L* /&]9^*#:GI)L;<2^9*FU
MLJ>M7/A9X4N;>;^U[A,%T(SCVKT2#P7I4,WF?983SG[M;\-M#;Q^7#&J(.P%
M 'S[XNBD/C:R(1B/-ZXKW3001I<>:)]"L;BX6:2WC9U.02.:T(XUB3:H  ]*
M "2-98RC<J>M>%?$3PA>V.LR:Q9IA"W&!SP:]XJ&XM8+I-D\2R+Z,* /#--^
M*MW96/V>X,OF1C:ORFN<GEU?QUK_ ,FXQE@WS ^M>\W'@O2II=_V6$?\!K0L
M-!T_3U'DVL2L/X@* .%\22?\(]X-:S56\V2$ X'>N$^'?@BW\17/VC58"T;+
MGD5[W>Z9;7X GB1P!C#"ELM-M;! MO"B ?W10!QC_"+POM.VTY_"O(M<TF3P
MCXQ;[#&RVX=0,#WKZ<K,O-"L+V3S)K:-VSG+"@#SGQI>?VAX15D5BP@&>/:J
MWP=C947<C#Y.X]J]2?1[22#R6A0IC&"*=8Z5:Z?_ ,>\*1_[HH XKXE^$8]8
MTZ2[6/,T:_*<5Y_\-O$-WH>KFPO0_E*-J@ ]:^@)8TFC*.H93U!K*_X1O31/
MYRVL0?.<A: -6&02PI(.C &GTB*$0*.@&!2T %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!'-"D\;1N,J1@UR]U\.] O)#)+;Y8G/:NLHH YS3?!.C:7)OM
MH-K5T0 50!T Q2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 444C,J*68X [T +152'4K.XN#;Q3HTHY*CK5B65(4+R,%4=2: 'T
M5G+KVEO)Y:WD9?TS5\.I3<#\I[T .HK!U3Q19:?(L7G(92P4KW%2ZCK]O86Z
M.S+YCJ&5?6@#9HK$T7Q%;ZM)Y*LHF R4'45MT %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 444$X&30 454_M.S^U?9OM">=_<
M[U99U5"Y.%'>@!U%9SZ]I:2>6UY&'],U>CE29 \;!E/0B@!]%8NM^([+1H\R
MS('SC::FDUNWBTY;IG4;EW*/6@#4HKF](\66^IW7D;E5L=*Z,$$9% "T444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9O!G_(%B_P!Q?Y4#.CHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !4-UM^S/N^[CFIJCF(6%B1D =* /G;XC
MMHW]KN(X9!=;AEL<=:].^%V/[)?'3:*XSXF:K9.YMELHA,'YD YZUV?PO.=+
M<CT% '?T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M57O$BDM76;_5GK5BJU_;&\LY( Y0L/O#M0!X9\3=/T>V-K+9+BX,Z[N1_>%>
ML>#/^0+%_N+_ "KQ[XC>$9M%FM[Y[YYEDG4!">!\PKV+P9_R!8O]Q?Y4 ='1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?[B_RKR+XD^$6T:2VOC>-*))U&P]OF%>N^#/^0+%_N+_ "H Z.BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^H_$#71//\]G&Y4@CM7M.C:1;Z/81VT"[53I4&@:%;Z-9)''&H;:,D#O6S0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLGTJM\4K^UF\-HL<RLWF=!^%6?AC_P @V3Z4 =[1110 4444 %%%% !1110
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MD5]0  # KDFDI-(U3T,_3-&M-)A$5LFU<8K1HHJ!A1110 52U+48=-M&FF8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4@]ZP-6\9:A?J;9),VX^Z*6P\*:YK,ZF:WG*D_>->D>'_@RGR3W%S@GDJPH
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MCK2V/V7Q1H\5S-"CJQR 16S! EO&$C4*H& !0(EHQ110 4F!Z"EHH ,4444
M%9VNA#I$X<97'-:-4M69ETV4K'YAQ]WUH ^7_%$=DFNH8$82><N21[U]$^#/
M^0+%_N+_ "KPKQO<7,NI0K+I1MD$RXEQUY'O7NW@S_D"Q?[B_P J .CHHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFC5.ZN>2^'/AUJFM2)((QY6><BO:O#7PSTO24266#_2!U-=M:V%M9QA((40
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MP.U<#\-O!9T*%KF?F289*L.E>CUPMW=S8****0!1110 4444 %%%% !1110
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M7I'@S_D"Q?[B_P J^7;XW$.M1VLMP\JI*O4^]?47@S_D"Q?[B_RH Z.BBB@
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M=HJW0(0* , <4;5]!^5+10 4444 %%%% !1110 4444 %%%% !1110 4444
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MQK$>ZS\H><OSXZ\U] >#/^0+%_N+_*@9TE%%% @HHHH **** "BBB@ HHHH
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MNF,7AZX9& ;MS46N^+=/T>%B;B-I /N9YS7E&K>(=:\:7)M;:TFBMVX+KTH
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MH **** "LW5-1L[''VHCGI5Z6>*$9D<*/>N%\<:7'K_E^1J/D[1CY30!J_\
M"3Z)CJ/S%>?>.-<TA[V":U_UR_=QZUE?\*\G_P"@X_Y__6JYIGPSC:^CFN=7
M\P(?NMW_ $H ]0\#7DM]X7MYYOOMU_(5T=4=(LHM/T]+>$@HO0BKU !1110
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M** "BBB@ HIDDB1*6=@JCN:XWQ-X_LM(C9;5TN)0.$4\T =5?:C;V$+2S.
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M0DMK(R1"-BI9#7-6^N:YILRS/>W$H!&5)J'.*=F=$,+5G#GBM#ZIR#THK@O
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M#J***9D%%%% !1110 4444 %>>_$N'6YA:?V00,??S^->A4R2&.7_6(&QZT
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MMI=L(;=,* .U7J** "BBB@"I?:?;ZC T,ZY5NM<W_P *XT#S_.\D[LYKKZ*
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M-:K#!J,,Q5V^])0,]P\*:5)HV@PV4@PR=:VZI:5J":G8)=)C:WI5V@04444
M%%%% !1110 54U&%[BQDB3[S#BK=4]4DDBT^1XE+.!P!0!X#\0M O=.N;>YG
M(\MIU Y_VA7LW@S_ ) L7^XO\J\2\>ZEJMU>P17=K+'")EVLW0_,*]N\&?\
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M73/$/B*4@PW,,!&<<8H&<_I6HK;2R),?F)J]J&K0^00A.:I7OA^_TN<K/;2
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M'@F].%N+R!3CVQ0,][' XI:X?PU\0K/5HU6Z9+:7IM8\UVL4T<Z!XG#*>A%
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MG\BSL9X8R<>8F/\ &@#TC7O'FEZ(K+*Y+C@;3WKSF\\8>(?$\Q@TACY3''S
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M?-'/XUVD=O;:;:D(H"**\I;XO:L?N^'Y3^7^-9>L_$S6[VR:/^QIH0?XN/\
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M2KS7;62 Q/&C]1F@#+U[5[WQ)J<KER4)R.:SXXKS2Y5N86(9.>M/TB:,##$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSQ1X[T[P]^ZFD/FD9&#7&V_QBM/M'[V1O+)KRR;4+G7M1\VZ9LJQ!5JO3Z?
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M:EMX9TF"VCB-E"Q48SCK0!\]:AJ7B+Q5<+#-DY8$\&OHCPY#);Z!912?>6(
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M%/W7_0:?_/X4 =K_ ,)II7_/3]:S]9\>Z?;:7-+#)^\4<<US7_"H+G_H-/\
MY_"J&N?"BZMM)FE74WF*C[GK^E 'G&LZK=>)-3EEE<F,G(YJEY,VFL+FW8AD
M]Z=$K:;>/;3C8R==U27MU&T#(C!F/0"O1ITZ3I7>YA*4N:QU7@S0Y_&-]_Q,
M/G1?FZU[KHWA^RT6V$5M'@8YR*\\^$6ESVZ"[D5E5TXS]*]9KSF;A1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !6=?Z-::C,DLZY9>E:-% $4%O';P"&,845D:EX5TW5)1)<1Y8>@K<HH
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M."A1@# I:!'/:?X,TG3<>1%T]16\D*1J JC ]J?10 8'I1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5'.K-"P3[Q'%24A( R>E 'A/Q+T;78Y3=28^QE^/SKN/A
M>"-*<'K@5#\5K^U;P^L*SH9!)RO?M4_PQ/\ Q+9/I0!WU%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHJO<WUK9X^T3+'GINH L45%;W,-U$)8)%D0_Q"H+K5;&QQ]I
MN8XL]-QH N452M-6L+XXMKJ.4^BFC4]033[22=L':,XH NU'.I>%E7J17*Z/
MXQ?5)PBVI"G^*NM0[D!]10!X9\3/#NI1.;YQ^X9^/SKM?A>,:6X/8"G?%?\
MY%A/^NG^%'PR_P"0;)]* .]HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMXPUJQU*VBNHYT#RA?F/O0!]"T56L9#+90N>K(I_2K- !1110 4444 %%%%
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MU% #=B?W%_*C8G]Q?RIU% #=B?W%_*C8G]Q?RIU% #=B?W%_*C8G]Q?RIU%
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MZ%7^M 'BNEZ1J?B;Q<=0NUS"P'.*]KM(?L]I%%_<7%-@LK:V_P!3"J?058H
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MQIUO_P!<E_E5NJ0U/3XB(A<QJ1P%S5M)$D4,C!E/0B@!U%%% !1110 4444
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MU7G7PCF9O"-JA)Z?T%>BT""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV]-MXQ\-E.T9:UY_.O*OAC(8_B"D(^[SQ^- SZ*HHHH$%%%% !1110 4444
M%%%% !1110 4444 07=U'9VSSRG"(,FO&?'_ ,2XY(3:Z;(=X:O7=:L&U/2I
M[19/+,JXW>E>.>,? L/A[PO'*\@FF#8+D<GI0!TOP?U*XU&PNWG;)S6_\1-5
MDTG0!-$V&+8_E7+_  5&+"] _O58^,(N[K04@MH'=A)GY?PH \]TW_A+-=:6
M6S=2@;N37>> =*\36FM-)JI7R-O&/7FO/M';7M+L7E6RN%4#)P.M>B?#_P =
MG4[O^SKJ#RI47)9NM SU$=*6D!! (Z&EH$%%%% !1110 4444 %%%% !1110
M 4444 <OXVU]]$T.>: D3*,K7D%C%XJ\4M)=(<KC<,YKWV]T^VOXC'<1+(IZ
MAA6)J4^E^&M-E*^5#E" * /*?"_BC6M&\2P:7J$@\MR<C\:[SQ[XP?1]'ADM
MGPTWRBO,M%6?Q1XZANXX66%'92PZ=:T_B?NC:RMB2568#]:!F7%#XHOM,FUA
M2-B-UYKO/AIXON=4FDL+Q\O"O2K^BVR#P-*FT8(&1^!KSSP1(;;QM>JG +8X
MH ^@]XHK.\QO6B@1IT444 %%%% !1110 4444 %%%% !1110 5B^+(3<>'+J
M-1DD5M4R6)9HRC@%3U!H ^?_ (;3II/CB\68[?DQS^-6?B_<I?:Y:PQ'<7C'
M3Z"MKQ7\-KA]3EU'3[IHFD/W4[?I57P_\-;V?5(;W4;R27RCC;)_^J@9Z'X
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MQ:R:A.80=N#TQ^5>M>$O#,7AS2HK8$.Z?Q^M '1T444 %%%% !1110 4444
M%%%% !1110 4444 %>/_ !I_X\+3_KL/YBO8*X/XA>%)/$=M!&CE=D@;CZT
M2_#/_D G\*9KWB_0;'4EM;O/FAP.G?-:_A#1FT;3/(9BQXZUA>-_ ">($$L,
M@BE5MVX#F@#0\77=E-X-G<%-A0$8QZ5YM\(4<^*+QX@?+*\?E35\ :]<G['+
MJ5QY)XYZ8_*O4/!WA&'PY:K@AI=N&;')H ZH=!FEHHH **** "BBB@ HHHH
M**** "BBB@ HHHH P/%/B*'P_I<ES(^W;7@XO+OQSKS><X:UCDSU[5ZGX_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** $(S0 /04M% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ H[444 <)XK\"1:_*C,K'!YP:M>%? E
MAX>*S1QD3+W-=C10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gaz3apgusshz000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gaz3apgusshz000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +)!PL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSM'7Z5YWJ6OZ9%JEM!IEC;W):3#D*/EKTNS_ ./=#L"9 .!0!/1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5GZU>?8-)N+D'!C7-:%<'\2-5^SZ:
M]BI^:=,"@#SS_A8VN+K8E-R?L3L HP?6O=--N/M6G6\V<ET!->(7'A<CX<64
MVT_:%DRQ[\8KT/X<ZO\ VCIC1%LF !: .WHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=:[NB@#CA\/-%PKFV'FCDGBM67PY:3:+)IKQYA?JM;E% &;I.D0:5 L4";5
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M3TN5((;TJ[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** ,;Q)I4VKZ=]GA8!L\YJGX2\,CP]',, -*<G%=+1
M0 5RGBWPI_PD#I(H7S$'RDUU=% &3X<TV72=&BM)2"Z=2*UJ** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS7XG?ZZW^E>E5YI\3O];;_
M $H Z7P'_P BM;_Y["MZ]026DBMT(KG? D\:^%[<%O\ .*N^(-<M-/TN=WF
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M>I0']*\C\9?\A^#_ *[K_.O6K3_CS@_ZYK_*@":BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6?$]GJ4,B".$8(/6NWHH X3Q3X(FUBPB6U*+<1MNW'VK)MO#OC8(('U)/+'
M'M^=>HTF!Z4 >6V?PXU*#4_MSS1F9F!=N.?UK<\0>$+S5=7M+N*1 L,85L_0
M5V]% '&^(?"EUJND6EK$ZAX6!)-;?A_3)=*L?)E8%O:M>B@#A=?\&7FJ:G'<
MQ2(%60,0?K7;0H8X(XSU50#^ J2B@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBL[5-5ATR$R2N%
M &>: -&BJ.DZE%JNGI=PL&1^A%7J "BBB@ HHHH **** "BBB@ HHHH **XF
M7QE<)K\FG[%VHP&:[2-M\:MZ@&FU8!U%%%( HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVRV_Y^(O^^Q2_:[;_GO%_P!]"O)+?P_K<]NDH$WS#/WS4Z>&];#@D3=?[YH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O$OB3=K8_$BPG920L?0?A7MM>*?$:U2\^)>GPN
M<*T?^% '667Q$M([1$-M)P/0U?L_'UK=W*PK;N"W<@U'8^!K![.-B[9(J_;>
M"[&UG65';(H SO'>IO%HJ&,E1,"#5/X5Z=%#HLTI4>892<_B:N^/--:;1T\L
M$B($U3^%=_'<:',F[YA+C'XF@#T C(P:Q9_#.GW&KIJ+P*9E& U;?05S&I>+
M;:PUR/33(!(XR!0!IZIIKWEJ((F"KC!%>6?$#PE9Z1X.NIC$OV@'(8?C7L5O
M*)H%D'\0K@?B]_R)=W_GL: -_P #?\BG8?\ 7*NDKF_ O_(I:?\ ]<JZ2@ H
MHHH *\4\?7:V7C8RL"0%Z"O:Z\6\=VRW?CCRGZ%: .IT_P"(=I%80H;:0[5Q
MT-7[7Q]:W4PC6W<$^QJ/3O ]A)I\#EVR5S5^W\%V-O*)%=LB@"#QGJ1C\,SL
MF1YL7%8/PDT]'\/QW[@&8MC=6_XUTXR>&K@("?*B.*P?A'?HOAR.R8XE#=*
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MR*A'@33\#YVZ5>T_PM::=)OC8DYS0(X?XKWDDEG]D5B!O%=OX1L(;/0+1HU
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M*XW_ (61H(D :\7!/' KI=.U6TU2U%Q:2;XSWH NT5SVJ>,M'TJ01W%R%<\
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MJQKJI;W1O"&E"&>14C4$ E17FANAXL\:V5Y9 -#!)R5X_E0![A1347:N*=0
M4444 %%%% !1110 4444 %>.?$JRNQXUM+^"*1UCC_A7/I7L=1O!%(<R1(Y]
M64&@#R.W\9:E#"J?9;GC_8-2_P#";ZE_SZW/_?!KU7[);?\ /O%_WP*/LEM_
MS[Q?]\"@#-LP=8\/+YR$-*A!#"O,KO0]5\(:F9K-V-KDLT:#.3UKV1551A0
M!V IKQ1R??C5O]Y<T >2R?$&_GA^SI8W2R$8W;#4OA?PG?ZEK4>LZD^_:>C#
MG%>H_8[7.?LT/_?L5*J(@PJJH]AB@!(XUB0(HPHZ"N)^*%C-?^$[F&%2S'H
M,]J[FFLB.,.BL/0C- &%X.MWMO#-E%("&6/!!K?I H484  =@*6@ HHHH *\
M=\?V=VOBAKN&*1@!_"N:]BJ-X(I#EXD8_P"TH- 'D5MXQU*"VCB^RW/RC'W#
M4R^-M2+ ?9;GK_<->J_9+;_GWB_[X%'V2V_Y]XO^^!0!FV3'5M&V3(1YJ<AA
M7FNJ>']3\,ZPU]8NWV8=(T&:]A554850!Z 4UXHY/OHK?49H \F;XA7SP_9U
ML;H2D8W[#UH\.^%]0UG6QJVI.7B8?<<<UZK]CM<Y^S0_]^Q4JQH@PB*H]AB@
M#S'XE/?PV]M9V*2>45VL%7-<KX=U&XT.U54L9Q*/X@AKW=X8I/\ 61(_^\H-
M,^R6W_/O%_WP* /-M*\7ZA<ZE!"]M<!6;!)0XKTY3D5&+6W4Y6"($=P@J6@
MHHHH *\B^(UA=27IFAC=L.#\HSWKUVF/#%)]^)&_WE!H \AMO&.I6]K%%]EN
M?D4#[AJ=/&VI%U'V6YY/]PUZI]DMO^?>+_O@4?9+;_GWB_[X% &3I4S:MIK+
M<1L PY#"O/-;\-ZGX?UN75-/D(B<XV(,G%>O*BH,*H4>PQ2-&CC#HK#W&: /
M)?\ A85\(?(^PW7F8QNV&HM%\,:AXBU<WVH,3 2&5'&,$<UZU]CM<Y^S0_\
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MZ@E>XR*Z'PSX*LM9MWO;B^N0Q.2 YQS^-<QXUMM.T_4+2UM9VDD2X3(;_>%
MSO\ Q\Q;PBK'J8%)_P"^:@L_^2;V7^X:E\=_\B<G_7NG_H-16?\ R3>R_P!P
MT"+WPJ_Y!%W_ -=C_,UZ!7G_ ,*O^01=_P#78_S->@4 %%%% !1110 4444
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MN\DB&Y1PS2'O@UZ110!S.L>&9-3T<61<9"!<GV%+%X::/P[#IFX9C&,UTM%
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MASGM7_"SH?[AH_X6=#_<->*^<_J?SH\Y_4_G1]1B'.>U?\+.A_N&C_A9T/\
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M_P ^\_Y&MC_A&['^Z/RH_P"$;L?[H_*BP7,?_A;%Y_S[S_D:/^%L7G_/O/\
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M "-'_"V+S_GWG_(UL?\ "-V/]T?E1_PC=C_='Y46"YC_ /"V+S_GWG_(T?\
M"V+S_GWG_(UL?\(W8_W1^5'_  C=C_='Y46"YC_\+8O/^?>?\C1_PMB\_P"?
M>?\ (UL?\(W8_P!T?E1_PC=C_='Y46"YC_\ "V+S_GWG_(T?\+8O/^?>?\C6
MQ_PC=C_='Y4?\(W8_P!T?E18+F/_ ,+8O/\ GWG_ "-'_"V+S_GWG_(UL?\
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MPJX_U[_[QKW7QC_R#/P->%7'^O?_ 'C4XC_=V>UD/^]KT9%1117DGVX4444
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M10 4444 %%%% !7(>._^07+_ +E=?7(>._\ D%R_[E=N7_[S'U)EL>1>&/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2B@]*!K<S+G[]0U-<_?J&OE,R_B'OX[^'3] HHHKS3S HHHH **** "BBB@
MHHHH ****:W*C\2*.H?ZEJQ*V]0_U+5B5]5A_@/M7L@HHHK<D**** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M  @&D?W6_*C_ (0#2/[K?E1]?#D1\\_V7+Z&C^RY?0U]#?\ " :1_=;\J/\
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M_P \!^==Y_PI?PYZ24?\*7\.>DE%P.#_ .%BP?\ / ?G1_PL6#_G@/SKO/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KA_B)_R"Y/]RNXKA_B)_R"Y/\ <JH[@6OAK_R)=I_GL*ZZN1^&O_(E
MVG^>PKKJ3W ****0!1110 4444 %%%% !1110!X[<_\ (\W'^^*]>@_X]X_]
MP?RKR&Y_Y'FX_P!\5Z]!_P >\?\ N#^57("2BBBH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?\);I_H_Y4 ;]%4;'58+]0T6<'UJ]0 453OM2AL(R\N<#TK,_P"$MT_T?\J
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M\?Y5+%:P0_ZN-5^@J:B@ IDL,<R[9$#+Z&GT4 5/[,L_^?>/\J<EA:QMN2!
M?4"K-% "  # H*AA@C(I:* *K:=:,Q)MT)/M2?V99_\ /O'^56Z* &HBH,*
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M +-L_P#GW3\JMT4 51IUHI!%N@(]JM=!BBB@!" 1@]#59M/M'.6@0GZ5:HH
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M<8EC5_K4/]F6?_/O'^56Z* (([*WA.8X54^PJ>BB@!KHL@PP!'O5;^S;//\
MQ[I^56Z* *HTZT4@BW0$>U60 HP!BEHH 0C(P:KO86LC9>!"?4BK-% %3^S+
M/_GWC_*K$4,<";8T"KZ"GT4 %0RVL$W^LC5OK4U% %3^S+/_ )]X_P JDBL[
M>%MT<2J?4"IZ* "F21)*NUU##T-/HH J?V;9D_\ 'NGY4JZ=:*<B! ?I5JB@
M!  HP.@I:** *S:?:.V6@0D^U-_LRS_Y]X_RJW10 R.*.(810H]J?110!#-:
M03D&6)7(]147]F6?_/O'^56Z* ((K2"'_5Q*OT%3T44 ,DB25=KJ&![&J_\
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M0!KT5R ^(ND'H'J_8>+]-U"0)&Q4G^\: .@HI%977*D$>H-4]0U.WTZ)I)V
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%(WW3]* *D^J6=LV)IE4^]0_P!O:;_S])7F/CJ[
MEBO%VMCFN-_M*X_OU<O9P2YGN=>'P5;$)NFKV/H#^WM-_P"?I*/[>TW_ )^D
MKY__ +2N/[]']I7']^H]I1_F.C^R,7_*?0']O:;_ ,_24?V]IO\ S])7S_\
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MM%_Y_8Z^=_[+U'_GHM']EZC_ ,]%H^KU.P>TB?1'_"5:+_S^QT?\)5HO_/\
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MXKKZQ,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HZ45FZ[<26VCW4T38=(R0: +_ )J?WJ42*>AKP70+
MCQUXF66:RU)%C60J P]S[ULS:1\1;%#,^IQLJ\D '_&@#V.BO-/"'CB::_32
MM39S=,?O$8%=GK^LQZ5ILDQ/S%"5(H U))HXAEVQ21W$4OW&!KQNS?QAXM+7
M-A?*EMN(VL#_ (T^[LO&_AW;<SWRO"O+!0>GYT >S45S'@SQ&-?TH3,&WYP=
MPJOXR\7Q:#$D*DF:883;S@T =7)/'$/G8"DCN(I?N,#7D%I9>.-?'VF*^5(&
MZ*P(/\Z6\T_QOH(%S)?HT*?,X4<D?G0!['17)>"_%(US3U,@;S>^X5E^-O%5
MU:75O8Z>72:<[0P!(!YH [X2(6V@\T^O(9M/\=V=K]KDU%"!R<#M^==;X&\3
MG78YX)6+36_RN3W- '8T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !116;KNJ)H^E2WD@.U/2@#2HKRD_%JV,K*EO<-C^ZI/
M]*7_ (6O%_SZ7?\ W[;_  H ]5HKCO"?C-/$,\L:P3)L_OJ1_2NDU+4X-,M&
MN)V&U>V: +M%>97GQ/@EG:*TM[C*'!(4D']*;9_%"&"X6*\@N.?XBI _E0!Z
M?1533]0AU&U2>%@5<9 STJR\B1J6=@H'<G% #J*XY_'5DVK"QCR6#[20<UV"
MG*@^HH 6BBF2R+$A=R !ZF@!]%>?ZG\2[*"[:WA@F=D;:2@)_I4^B_$2RO[T
M63Q2I*>[@@?J* .YI&^Z?I21N)(U=>A&12M]T_2@#QCQ_P#\?B_6N)KM_'__
M !^+_O5Q%<^/^R?6\.?PY^H4445YY](%%%% !1110 4444 %%%% !1110A/8
ML6O^L%:Z]*R+7_6BM=>E?;Y9_"/Q#BO_ 'L6BBBO2/E0HHHH **** "BBB@
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M4 %%%% !1110!'/_ *A_I532O];5N?\ U#_2JFE?ZT5C/XT<F(^)&U1116Q
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MNCZ52U#_ )"\OUJZOW1]*YJ.[/H<O_ABT445N=X4444 %%%% !1110 4444
M%%%% !1110 4444 1S_ZA_I532O]:*MS_P"H?Z54TK_6BL9_&CDQ'Q(VJ***
MV("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JE?_ /+'_?'\ZNU2O_\
MEC_OC^=9U?@9,_A9[U\.?^0(?PKLZXSX<_\ ($/X5V=>2>:%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%M;O*03M4G K#\,>)X_$'VG9!+'Y+E3O4C/- '1T444 %%%% !1110 4444
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MK%&W@NT)12?I["NO\F+_ )YK^5<G\-/^1*M/\]A77T ,\F+_ )YK^5'DQ?\
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MK^VTSXG![J38-O\ 6M+XDV;7%_I&J6PWPQ-YC-Z#FNHUGP-:ZEJ/VU(U$O\
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MC=U_R/-Q_P!=!7L$'_'O%_N#^5>/W7_(\W'_ %T%>P0?\>\7^X/Y4 24444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+N'U&?<]X_X6IX?_ .?U?R%'_"U/#_\ S^K^0KP.:P@6)B(QP*KZ?:0RR89
M:EX>2:1E/#2@TFSZ$_X6IX?_ .?U?R%'_"U/#_\ S^K^0KP_^R[7_GD*/[+M
M?^>0J_JDNXOJ\CW#_A:GA_\ Y_5_(4?\+4\/_P#/ZOY"O#_[+M?^>0H_LNU_
MYY"CZI+N'U>1[A_PM3P__P _J_D*/^%J>'_^?U?R%>'_ -EVO_/(4?V7:_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC<;FW=3WI?$?@W5&M?M4D;'R!OR2:]HM+=+:V2-!@!0*;J%N+NPG@/\ &A%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#CO%WAZ6Z<ZE9)
MNO(QA!_GZ5OZ$+E=)@6Z7;,%^85HD C!H  Z4 ! /4 _6F^5'_SS3_OFGT4
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MY0<_/S7:T4 (  , 8K/UO3EU72Y;1\[7ZXK1HH P/#WA^+14Q'GICFM^BB@
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M:I7_ /RQ_P!\?SK.K\#)G\+/>OAS_P @0_A79UQGPY_Y A_"NSKR3S0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK[G8LM@J/L;Z'E.:*]7_ .%<K_ST6C_A7*_\]%KC]C2[F/\ 8U+N>445ZO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "N%^(W_(+D_P!RNZKA?B-_R"Y/]R@"W\-/^1*M/\]A77UR
M'PT_Y$JT_P ]A77T %%%% !1110 4444 %%%% !1110!XW=?\CS<?]=!7L$'
M_'O%_N#^5>/W7_(\W'_705[!!_Q[Q?[@_E0!)1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !11FC- !11FC- !11FC- !11FC- !11FC- !11FC- !11FC- !11FC-
M!11FC- !11FC- !11FC- !11FC- !11FC- !129%+F@ HHS1F@ HHS1F@ HH
MS1F@ HHS1F@ HHS1F@ HHS1F@ HHHH *X7XC_P#(+D_W*[JN%^(__(+D_P!R
M@"W\-/\ D2K3_/85U]<A\-/^1*M/\]A77T %%%% !1110 4444 %%%% !111
M0!XW=?\ (\W'_705[!!_Q[Q?[@_E7C]U_P CS<?]=!7L$'_'O%_N#^5 $E%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%?Q&L:J"F  *XB_15U:0 <9JZJ+M' Z5E##J5SU,-056/,SK/^%L>(_5*/\
MA;'B/U2N4V+Z"C8OH*T^J1[G1]2CW.K_ .%L>(_5*/\ A;'B/U2N4V+Z"C8O
MH*/JD>X?4H]SJ_\ A;'B/U2C_A;'B/U2N4V+Z"C8OH*/JD>X?4H]SJ_^%L>(
M_5*/^%L>(_5*Y38OH*-B^@H^J1[A]2CW.K_X6QXC]4H_X6QXC]4KE-B^@HV+
MZ"CZI'N'U*/<ZO\ X6QXC]4H_P"%L>(_5*Y38OH*-B^@H^J1[A]2CW.K_P"%
ML>(_5*/^%L>(_5*Y38OH*-B^@H^J1[A]2CW.K_X6QXC]4H_X6QXC]4KE-B^@
MHV+Z"CZI'N'U*/<ZH_%KQ&H))3BFQ_%WQ#*<*R5R<Z+Y#\#I572U4R<BLY8=
M*21C5PT8-)'=_P#"U?$OJE'_  M7Q+ZI7.>6G]T4>6G]T5I]4CW)^KHZ/_A:
MOB7U2C_A:OB7U2N<\M/[HH\M/[HH^J1[A]71T?\ PM7Q+ZI1_P +5\2^J5SG
MEI_=%'EI_=%'U2/</JZ.C_X6KXE]4H_X6KXE]4KG/+3^Z*/+3^Z*/JD>X?5T
M='_PM7Q+ZI1_PM7Q+ZI7.>6G]T4>6G]T4?5(]P^KHZ/_ (6KXE]4H_X6KXE]
M4KG/+3^Z*/+3^Z*/JD>X?5T='_PM7Q+ZI1_PM7Q+ZI7.>6G]T4>6G]T4?5(]
MP^KHZ/\ X6KXE]4H_P"%J^)?5*YSRT_NBCRT_NBCZI'N'U='1_\ "U?$OJE)
M_P +9\1))&'*89@*YWRT_NBJ=\B@PX'\8_G4SPRC&XI4$E<^CO"6L3ZSIOGS
MD%N.E=#7&?#G_D"'\*[.N(Y HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7HWC+YFCX<>]=+<6<%S"T<D:L",<UR6F>!/[,U1[N"YVHS[B@H [1F"*68X
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M_P#4/]*J:5_K15N?_4/]*J:5_K:QG\:.3$?$C:HHHK8@**** "BBB@ HHHH
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M@J?$)4<M25'+6]7X2$=[X<_Y T5:U9/AS_D#15K5M3^!'+/XF%%%%62%%%%
M!1110 4444 %%%% '#:A_P A>7ZU=7[H^E4M0_Y"\OUJZOW1]*YJ.[/H<O\
MX8M%%%;G>%%%% !1110 4444 %%%% !1110 4444 %%%% $<_P#J'^E5-*_U
MHJW/_J'^E5-*_P!:*QG\:.3$?$C:HHHK8@**** "BBB@ HHHH **** "BBB@
M HHHH **** "J5__ ,L?]\?SJ[5*_P#^6/\ OC^=9U?@9,_A9[U\.?\ D"'\
M*[.N,^'/_($/X5V=>2>:%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M><G_ 'R:^I?^$:T7_H'0?]\T?\(UHO\ T#H/^^:/K,P^N5#Y:^VO_P \Y/\
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MZ!T'_?-'_"-:+_T#H/\ OFJ^LS%[>1\P?VDW_/.3_ODT?VDW_/.3_ODU]/\
M_"-:+_T#H/\ OFC_ (1K1?\ H'0?]\T?69A[>1\P?VDW_/.3_ODT?VDW_/.3
M_ODU]/\ _"-:+_T#H/\ OFC_ (1K1?\ H'0?]\T?69A[>1\P?VDW_/.3_ODT
M?VDW_/.3_ODU]/\ _"-:+_T#H/\ OFC_ (1K1?\ H'0?]\T?69A[>1\P?VDW
M_/.3_ODT?VDW_/.3_ODU]/\ _"-:+_T#H/\ OFC_ (1K1?\ H'0?]\T?69A[
M>1\P?VDW_/.3_ODT?VDW_/.3_ODU]/\ _"-:+_T#H/\ OFC_ (1K1?\ H'0?
M]\T?69A[>1\P?VDW_/.3_ODT?VDW_/.3_ODU]/\ _"-:+_T#H/\ OFC_ (1K
M1?\ H'0?]\T?69A[>1\P?VDW_/.3_ODT?VDW_/.3_ODU]/\ _"-:+_T#H/\
MOFC_ (1K1?\ H'0?]\T?69A[>1\P?VDW_/.3_ODU%+=/<20J(W^^/X3ZU]2?
M\(UHO_0.@_[YH'AO1@<C3H,C_9J7B)M68.M)JQA?#I671/F!'3K795%!;0VR
M;(8U1?05+6)B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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@H **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gaz3apgusshz000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gaz3apgusshz000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (_ C,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% '@WQ\_Y#>@_P#79/YU[M%_JD_W17A/
MQ\_Y#>@_]=D_G7NT7^J3_=% #Z*** $9@B,S' 49->#^)_B!XI\4>+9O#_A!
M0L4+E'E"Y!]R<<"O<KT%K"Y5?O&)@/R->+?!&_L;'4=6TF]9(]5:<D!P S#C
M@'K^% &5J5A\4O!-L=6:]CN8$P95#>80,^E>L_#_ ,:0>-?#Z7JJL=PAVS1
MYVG_  K7\27EG8^';Z>_9%MUA;=OQCD8'ZUXK^SS97G]J:Q?A'73Y(PB$D[=
MV[)_2@#W^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P \M8_)Z /L2BOC^W'Q!^TQ;HM8V[QG(?UKZ[MMWV6'=G=L&<^N* ):***
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MJQX(YK(^!'BVYU*RNO#]X6>6Q4.LC')VYQB@#V6BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#YZ^/WAO4/[4M-?@BWVB1[9&'
M53DGGVJ;PU^T!!:Z;!:ZM8-NB0+YD66+5[S=6D%[;O;W,22Q.,,K#(->>ZA\
M$?!]YYC16C6[OSN5B<?F: ,?_AH7PWCFVO/^_?\ ]>JM[^T1I"0DV5A-))V$
MB[1_.EN?V??#T$;SRZS<10H,L3&,*/SJEHWP^^%LEX+8>(+>_F8[5C\W!)_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#-IW_?X4?\++\%?]#-IW_?X5YW_PS=I'_0P7W_?E*/\ AF[2/^A@OO\ ORE
M'HG_  LOP5_T,VG?]_A1_P ++\%?]#-IW_?X5YW_ ,,W:1_T,%]_WY2C_AF[
M2/\ H8+[_ORE 'HG_"R_!7_0S:=_W^%'_"R_!7_0S:=_W^%>=_\ #-VD?]#!
M??\ ?E*/^&;M(_Z&"^_[\I0![!I6LZ;KME]LTN]AN[;<4\V)LKD=15ZN;\#^
M#[?P/X>_LBVNI;F/SFE\R10#EL<<?2NDH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "CKUHHH XGQG\,M#\7P%I85M[M00DT:X/
MY=*\2'P'\6PWJD&U:-'!!#GD9^E?4=% $-I&T-G#&WWD0 _E4U%% !1110!Y
M]\5O 3>,]!!M.-0MCNB_V_;]:\G@T_XKV7AYO#D6FWGV,C8&$?1?3.*^F:*
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MWNHNFJ10^9(1C8&],]<58_9]U_4KN;4=(N&:2TMXQ)&[')!R!C\J /=Z***
M/!OCY_R&]!_Z[)_.O=HO]4G^Z*\)^/G_ "&]!_Z[)_.O=HO]4G^Z* 'T444
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MV_ '2I+OQ9J&IM&?(BC.U\<;MPX_(U[CK'C?P_H6HQV&HZA%!<R#*HQY/.*
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M5]%U\J_!?=_PLKC/WCG\S7U50!YW\9O$$^A>!I1;.8Y;H^2KCJ._]*XGX0>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAU3BI(<97/8:***XBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_(;T'_KLG\Z]VB_U2?[HKPGX^?\ (;T'_KLG\Z]VB_U2?[HH ?1110 4444
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M_&@"#_A;O@G_ *#EO^O^%'_"W?!/_0<M_P!?\*G_ .%4^!?^A;L__'O\:/\
MA5/@7_H6[/\ \>_QH @_X6[X)_Z#EO\ K_A1_P +=\$_]!RW_7_"I_\ A5/@
M7_H6[/\ \>_QH_X53X%_Z%NS_P#'O\: (/\ A;O@G_H.6_Z_X4?\+=\$_P#0
M<M_U_P *G_X53X%_Z%NS_P#'O\:/^%4^!?\ H6[/_P >_P : (/^%N^"?^@Y
M;_K_ (4?\+=\$_\ 0<M_U_PJ?_A5/@7_ *%NS_\ 'O\ &C_A5/@7_H6[/_Q[
M_&@"#_A;O@G_ *#EO^O^%'_"W?!/_0<M_P!?\*G_ .%4^!?^A;L__'O\:/\
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MSJ&J0/!?7/R^6W55X//XBLGXG6'C*X\;V4FB0WC6(4>88B-N=W^%>VTF!Z4
M8'BOP\OB?P?=Z5(2LDT("MW5N#_2OG[PY#\2/ 8OK"ST:XEMYP5"/C:I_O#!
MZXXKZAI"JGJH/X4 ?/\ \(_AWKMOXK.O:[:2VWE_/'YN,NQ_^L:[;XR>";WQ
M=X?A?3AONK1S((QU<8Q@?G7I?2B@#YAMKSXEV?@]O"L>AW @(V+)_&J^@YQB
MO2?@OX"N/"^FSZCJ<#PZC=#:R/U5>#C\Z]4VK_='Y4M !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!X%\1/^2]:/_P!>\?\ -J]]
MK&O?"FA:CK$6K7FFPS7\2A4G;.Y0.G>MF@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^&'C/P=K32Z%'<3Q9_=W$! ./0Y[U%I7PN\:>+-;6?6;:XA20_O+J<@Y'X4
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M&?')KIZ** "BBB@ HHHH ****  @'J*, =!110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gaz3apgusshz000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gaz3apgusshz000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $C!Q$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***CGE$$$DK=$4L?P
M% /066:*",R32+&@(!9C@<\412QSQ++$X>-QE64Y!%<O>^(;'5-$N(26@F9,
MJK]"0<@ CCM6IX9<OH%N2" -P7(ZC<<4KF$:ZG/ECJK&O1113-PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!V6B^,;#9?Z/$ML^F7EB9RTD*; RY7:K'D8;:020>.2?"GP_<:G\1-7\;?\
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MD+3&$LQV[3@'./3!/Y4$2G&.[.PHI 00".AI:"PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHKS'QQ\;/#_A;S+/3F75M37CRX7_ '49
M_P!M_7V&3ZXH ],DD2&-I)75(T&69C@ >I->5^+_ (\>'-!$EMH__$XOEXS$
MVV!3[O\ Q?\  <_45YY'I'Q.^,4BSZA*UAHKD,OF PP8[%$^])[$Y^HKU3PA
M\&/"WA41SRV_]J:@O/VB[4%5/^S'T'XY/O0!Y:#\6OBP./,T_1Y?3-M;E3^;
MR#_OH5VWA?\ 9[\/Z9LGUZYEU:X')B&8H0?H#N;\2 ?2O8:* *MAIMCI5JMK
MI]G;VENO2*",(H_ 5:HHH **** "BBB@ HHHH **** "BBB@ IDL4<\+Q31I
M)&X*LCKD,#U!!ZBGT4 >)>/O@3!=,VK>#"MC?(=YL@^V-R.<QM_ WMT_W:H^
M ?C3=:9>'PWX]$L-Q"_E+>RIAD/3;,/_ &;\_6O>Z\S^*WPJ@\<6O]I:>5AU
MV"/:A8X2X49(1O0\G#?@>.@!Z4CK(BNC!D895E.01ZBG5\T_#/XHWW@?43X4
M\6K-'8Q2>4K2@[[)O0^J?RZCBOI.&:*XACFAD22*10R.ARK \@@]Q0 ^BBB@
M HHHH **** "BBB@ HHHH **** "BO,-7U;53=ZW9O>RJ]J5DAV';\H;!_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK3?B?X1\&Z?>6?A3P=H7G^*[R5<I'<32>1'C/.Z3:K'@_," FYCM^4UWFG>
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M!X ^'FE_#_3IX+&:>YNKK8UU<3'&\J, *HX5<EB!R?FY)P* .OHHHH ****
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MGKUJW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUWB?XF77B>SM;5]*2S$%RLX<7&_<5!P"-H]:ZGP]XQ70+62ZDBN;K29P)!'
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MOFK54MM296OH%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% &1K7AG2]>0&[@Q.HPEQ$=LB_CW'L<BN#U;P5K%BK;(X]
M7M!_= 68#W4\'\#^%>IT5+BF:0JRCL>)V>K7FDR^19ZI=V#J?^/:X&5'_ 7'
M'X5MQ>-?$B+CS=,F_P!IHB#^C5Z3=6-I?1^7=VL-PG]V6,,/UK&?P-X:D8DZ
M3"N?[C,H_0BIY)+9FOM8/XD</=^+?$$Z$2ZK;6B'K]GB /YMFLFV@FU:[\RU
MMKW5[G/^N<EU'_ FX'YUZI;>#_#UHX>+2+7<.AD7>?\ Q[-;2(L:!$4*HX
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MC_X#I_A1_86C_P#0)L?_  '3_"M"B@#+N="T]K&YBMM/LXI98F0,(57DCC)
MKS7P=\ M"T41W6ON-7O1SY1!6W0_[O5_^!<>U>O44 ,AABMX4AAC2.) %1$4
M!5 [ #H*?110 4444 9^MZ4FMZ-<Z<\\D"3J%,D>-PY![_2I["Q@TVP@LK5-
MD,*!$']3[GK5FBBW4=W:P4444""H+RRM=0MFMKRWCGA;JDB@BIZ* //=8^'T
MT :70Y1)$>397+9'_ '/3Z'\ZYG3]2U/P_=M;V<TMC*IR]A=KF,_0'I]5->T
M52U/1]/UBW\G4+2.=!]TL.5]P>H_"LW#JC>-=VM/4Y?3_B):';'K%I+92=Y4
M!DB/XCD?B/QKJ;+5M.U% ]G?6\X/_/.0$_E7&7WP\N8<MI&HAH_^?>\&X?@X
MY_,&N:N_"VK0/FY\.O(?^>EJROG\CG]*.:2W17)3E\+L>QDA1DD #N:QM1\6
MZ%IF5GU&)I!_RRA/F.?P7/ZUY7_8MTYV_P!@ZLY_NM$^/UXK4L?".O3X%OI4
M%C&?X[EP"/\ @*Y-'.WL@]C!;R*GQ#^(U[/H36>F6DUG#=OY37,C 2%,9( '
MW<CC.>]>4V\2H%45[AJOPI.J:)/'<:J\FH ;[<A L2./4<D@].O>O#S'/9W4
MME=Q-#=6[F.2-NJL.HHUZF<N6_NENBD5@PR*6F2%%%% !1110 44QI .%Y8U
MNVOADFT^U:E>M:J1D+P"/KG^5#=AQBY;&%)*D2;I&"KZFEC+W$L,%M%)//.P
M2*)%^9V/05);Z5<:UJGV#2H)-4E5_D,:8 _VF/11[FO<_!'PYMO#5L+N]*7&
ML2KAY0/EA4]4C_J>I^G%-:B>AN^$="70-#C@,HEFEQ)*RG*YP!@>PQU[UO5'
M%'Y88=B<@>F>OZU)32L2VV[L****8@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** ,K7U)TY6'194)^F<?UK!KKKFW2ZMI()/NNN#[>]<G+');3&"
M<;9!T/9QZC_/%>9CH/F4^AWX2:Y>4YRY1H[B17Z[B?K5G38#(SN<A0.&'4'V
MK6>-'^^BMCU%* =RQ1)ND;A$7O\ _6]ZX$M3T95KQL0QO,6D4Q^8$;!9#@GC
MT-.=Y50LMM(<#O@5N3Z0\-C"8AOFC4^8!_'DY./?-9RL&^Z<XZ^U;SH.F[2.
M2%53U1ALSS2;G.Y^@ Z#V%;$2,EO&G\8V@?7(Q4@50=P4 ^N*NZ7;&YN5F(_
M<Q'(/9F[8^E.E3<I)(JK57*=!1117M'D!1110 4444 %%%% !1110 4444 (
M0",$9!ZBN1UCP#8W<C7.ER?V=='DA%S$Y]T[?48_&NOHI-)[E1DXNZ/&=3T'
M4M+E\S4--D&SE;VR)8#WR.5_$"IK'Q5K4"[;375N$'\%T@<C\>#^M>P5F7OA
M[1M18M>:9:RN>KM$-WY]:CD:V9NJZ?Q(X,^-O$A3&[2U_P!H1M_\56/J'B'4
MKP;-0UZ3:>/)ML1@^WR\G\Z]%_X03PSG/]E)]/,?'Y9K2L=#TK3"#9:=;0,/
MXDC ;\^M'+)[L/:TULCQ34_">K:SX?G_ ++T694CQ/YDHV-+MYPH/+$_2O,P
MVX U]CUX)\6_!)T?4F\0Z?#C3[M_])51Q#*?XO96_0_6LZU'FA9'9EV8?5L3
M[22T>C/-**<$+#*\T];>5NB_B:\[V<[VL?;1Q^%E'G516]2-5+N%'4FM0# Q
MZ5%# (N>K>M35W8>DX*[W9\AG.81Q=11I_#'\0HII=5ZD4VW::^N/L]A;37<
MQ_@@C,C?D*Z#QAY( R3@"I+6VN[YBMI:O+CJ>@%:#>$/$<2P3W^D7-I;22K'
MYDH'!/3*@DC\1[5WMCX.\07=D(-(BATVW0X\^]5M\GJRH!G\3BD[]"XQ3U;T
M/*KZ*YBW6[J]M,#\VX<@>W^-==X$^'MQXIV7MX'318V')SNNB#R%_P!GU;\!
MWKO]'^#^F07(O->O9M8N,[BCC9%GW4$EOQ./:O1HXTBC6.-%2- %55&  .@
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MG1?QY'I7O'A7X?>&O!L0_LG3D%QC#7<WSS-_P(]/H,#VKIZ* "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5POC;X9:;XL=KZ"3[#JN,&=5RLN.@=>_U'/UKNJ* /FO4/AGX
MSTIRHTP7L8/$EK('!_ X8?E5%/"GB]FVCPWJ6?>+ _,U]144N4=SYUL?AAXU
MORN^Q@LD/\5S<#C\%R:Z[2O@?#E7UO6IIO6&T3RU_P"^CDG]*]<HHL@NS!T7
MP7X=\/X.FZ3;QRC_ );,N^0_\";)K>HHIB"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **X+Q)?W,?C>W@BN98XDMC(Z*Y )"N:T_ -U=7F@-/=SR3/YQ52YS@
M#_Z]!E&JG/E.JHHHH-0KRWXI_#R;6O\ B?Z+#OU&-<7$"];A!T*_[8_4<=A7
MJ5% 'R#%<;6*OE'4[6##&#Z$=C5M95(]*^C/$7@#PYXGD,U_8!;HC'VFW;RY
M#]2/O?CFN-F^!.G%R;?7;^).RO&CG\\"ILRKH\GWK_>%1O/&@RS 5[%:_ S1
MT;-WK&I3CT0I'G]#73:7\,_".DLKQ:/%/*O22Z)F/_CV1^E%F%T> :;8ZIK<
MFS2-,NKT]"T49V#ZL?E'YUV^E?!OQ#?8?5+ZUTY#U1!YTG]%'YFO<XXTBC6.
M-%1%& JC %.IV%<\J3X,Q6-S:7%IJKW#H^91=J I&."H4=0<<'K726_PVT.0
M+)K$9U2X!SNF)$:^P0'&/KFNQHHLA\[M8K66GV>FVXM[&T@MH1TCAC"+^0JS
M16-X@U"\M;-DTKR)=0&'$#M\Q3N0N>:9$G97-FBN8T#QE::HPM;L?9+X<&-^
M Q]O\*Z>@49J2N@HHHH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *CGMX;F/9/$DB^C#-244-7W!.QF-H-B2"%E4#LLK8_G5NVL;:SSY$*H6Z
MMU)_$\U8HJ(TX1=TBW4FU9L*KSV-K<G=+ C-_>Q@_F*L4532>C)3:U12&DV(
M8'R-V.S,6'Y$U<      '0"EHI*,8[(')O=A1115""BBB@ HHHH **** "BB
MB@ HHHH ***X_P ::G>V=]I-O9W#Q&XD*OMQR-RB@F<U"-V=A17)>#]7OM4U
M#5EN9_,A@EVQ# X!9OZ 5UM 0DIJZ"BBB@H*BN;:"\MI+:YB2:"52DD;KE6!
MZ@BI:* /%?$WP4N(YWNO#%TAB)R+.Y<@K[*_<>S?G7%3^"O&5G(4D\.WKD=X
M@'!_%2:^GZ*5D.[/F2W\%^,[I@L?AV\7/>7;&/\ QXBNAT[X.>*+T@ZA=V6G
MQ]P"9G_(8'ZU[U118+GG>D?!KPW8E9-0:YU24=?/?;'_ -\+C]2:[NRT^RTV
MW%O8VD%M".B0QA!^0JS13$%%%% ",RHA9V"J!DDG %(CI(@=&5E/0J<@US7C
M+5DL+1+6ZL)9[&Z4I/+&V-@]O>N6L+K4?#T7VS2+C^TM&)^=/XHO9A_"?TH,
M95E&5CU"BLC1?$>GZY!OMI,2 ?/$WWEK(?XC:(DC)MNB5)&1&.WXT%NK!*[9
MUU%<WI7C;3-8U%+*VCG$C@D&0 #C\:Z2@<9*2N@HHHH*"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "N5\9ZHT-O'IL+$/<#,I'9/3\3^@
M-=57FNLS&\\47;'HCB(?11C^>:BH[+0[L!34ZO,^FI7GT476E-(I*30@R1L%
MSVY!'H1_*MOPH%CMO[/+!VB7>CXQO!))X]B?R(J]81@*HQVJQ8:59:3.UVUP
M57:502L $!Z@>O05,N=.*B]#HJU8R4D]^AJ) ,=*H:[&R:)=&-224P<#D*2
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV96,<JE8E9<\@LL4G0< D$\\^TUYS\)/AU>> -/U/^TKF":^OID)^S.6C$:
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M/11^5<CH?@35[?XP:QXSU<Z5+;W,+16:0%VDBQL1&(9<*WEJ02#U8@<&O1J
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLTGXQ3-XPL?#GB7PK=:#/?I&;=Y)C+N:3&P%=BD G*YYVL,$##8]3H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R72=6\.?&VWU'1/$6@/IVJ
M:6[;(6N/W\6059D.%8%6&&4J5SLSGH.-L=9U_P #^-O$'AK1?$D^LZ59Z5<R
M*TNZ?^SS# [1CD;59'"H<?(=P! ;Y5]=UGX6^"O$&H-?ZCH$#W3YWR0R/#O)
M))9A&RAF))RQY/K7*?$'P7IGAKX5ZMI'A+PW=//JD\*LEE')<295P^YR26V
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MK"5&9HR4)&]1GYB,8[<>J^)? 7ACQ?<07&NZ3'=3P(4CD$CQL%)S@E&!(SG
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MXU^+?BO1/B7/X4T33M*N<RP0VPG1][O(B$ MYBK]Y\=J /;J*\%LOB[X^O\
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M@ZQX$O+G4]$TV]G74I$66YM4D8*(XR "P)QDGCW->Y4 %%%% !1110 4444
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MA0, 9/)X'>HIRE)NYPY?B<3B:DE*2M'RW_JQ+1116Q[84444 %%%% !1110
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M*-;ZC;-!*I'J#P01@@@D<XZ@@:E !1110 4444 %%%% !1110 4444 %%%%
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6)XQ@FNO
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MZ]10!\\V?@/QW?G0]+/@_P .:%;VT0AO-2>SLKIIL?\ +1@V]BVT 8'5B22
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M#R_+QNW[NFW'.>F*J6?B30M1M[FXL=:TZY@M%WW$D%TCK"N"<N0<*, \GT-
M&G1679^)-"U&WNKBQUK3KF"T7?<2072.L*X)RY!PHP#R?0U7@\9^%KJXBM[?
MQ+HTT\KA(XH[^)F=B<  !LDD]J -RBL_4]=TC1/*_M75;&P\[/E_:KA(M^,9
MQN(SC(_,5)IVK:=K%NUQI>H6M] K[&EM9EE4-@'&5)&<$<>XH N4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/L]W[I#GY\;G$BYP/E(QAN&(Q7#?#C4H=8_:(CU2W618+R\O;B-9  P5XY6
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M8GS,[#/&5QN0\YQ7+ZM\5_B?X6M]/U'Q%X2TVWTZZ=<81U9A@,4)\QO+<C.
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MVHZUIGB37-;FB4VL^FP>:D,QR090/NK\JJ !@+NP 0I !]BT5\M?V7\4=?\
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M .Q^$_Q:T?2O"MS#XP\2W3Z@UZ[QFZ6>X;RMB ?, V!N#<9]?6O9/^$IT/\
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M]Y06)*D #))P.I%?,VKW.H?#K5O&?A&W:=+6^ @4F5=_EB0/&Y91SNB9E*C
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M%]I?2TGFNKCA[J[97D"<?("% "Y&>!R<9S@8 .OHHHH **** "BBB@ HHHH
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M)/L5%% 'C&H_ B\N?%M_XAL/&<^G75U=37"&WM"'B\QB2H<2@]&(SQFKFB?
MFQA\0?VUXGUV[\1W*NCJMQ'M5RHQ^]W,Y<#Y<#('RX.0<5ZW10!YIXW^#ECX
MLU]?$%AJ]WI&L;XV>>,>8I*#"L!E2KC"<AL?+TR<U3\._!"WT_Q1'XAU_P 1
M7VNW\$L<T+2J8_G0?*7)9F?&$(Y&-N#D<5ZO10!P'Q$^%&E?$"2*\ENY['4X
M8A#'<(-Z%-V[#(<9QEL8*_>YS@"N37]G^:]>RAUWQQJ6HZ?:(4BMA$5,:[<
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M1(.%'\R2<DD\DDD\FKE%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=0<<'!'(JQK_ ,-/!_BC5#J6L:+'/>,@1I5FDB+ =-VQ@"<<9/. !T KJZ*
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M-_\ 8*M?_12UQ?Q'^*=_X<\2:=X7\,V-K?:U=.@?[0V8T+G:D> RD.20?F(
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MJFGOF.\BA#L5SD#@JV5894[N,MQSD=W10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '*?$+P;-XZ\-+HT6K/IJ&X665UB,
M@E50?D*[ER,E6Y/51Q6WH>C6?A[0[+2+!-EK:1+$F0 6QU9L  L3DDXY))K0
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gaz3apgusshz000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gaz3apgusshz000016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0O <D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1ONGZ5Y#\0?\ D+P_
M2O7F^Z?I7D/Q!_Y"\/TKHPW\1&=7^'+T.>3[HIU-3[HIU?41V/SVI\;"BBBF
M0%%%% !1110 FG?\A6/_ 'Q_.O>K7_CTA_W!_*O!=._Y"L?^^/YU[U:_\>D/
M^X/Y5\WCOXA]_@O]WCZ$M%,E<11/(>B@DUSMAXOL;[4!:1R@N6(Q7$=1TM%%
M% !1110 44UW6-&=CA5&356SU.UOPQMWW8.#0!<HHHH **** "BBB@ HHHH
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MZ2#!,I/ZF@#N:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS@5+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH **** "BBB@ HHHH **** "BBB@!&^Z?I7D/Q!_Y"\/TKUYONGZ5Y#\0?\
MD+P_2NC#?Q$9U?X<O0YY/NBG4U/NBG5]1'8_/:GQL****9 4444 %%%% ":=
M_P A6/\ WQ_.O>K7_CTA_P!P?RKP73O^0K'_ +X_G7O5K_QZ0_[@_E7S>._B
M'W^"_P!WCZ$M%%%<1U!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2HTCC(.._P"=4(-0UKPEXI@L+RX!MV&XJH^GO[T >TT57LKE;NT2=>C#-6*
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MOQ*OUF^Z'&W->V0@""/TVC^5 'ANB>(-3'B)K"YWKY; <FO7+C0[?49(;F4
ML$'4>U>6W4<2^.IV7&XR#->P/=Q6>GI+*P"J@SDX[4 .S%86G)"H@S7C?B*]
M'B/QY;1V8$D>TJ77L>*O>(_%UYK]\=,T@R)AMKL02"*ZKP;X+BT:$7%TBM=$
M[@P]^: .HTFW-KID,+9RH[U=HHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=Q99)B,-)CDUTM 'G<WPIT@S%D$F">>:W]!\%:9H.&MD.X'.6KI:* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!&^Z?I7C7Q-_X_4^E>RM]T_2O
M&OB;_P ?J?2M\-_$0'E$O^L-,I\O^L-,KWUL8,**** "BBB@ HHHH Z[PM_Q
M]0?[PKZ-M?\ CTA_W!_*OG+PM_Q]0?[PKZ-M?^/2'_<'\J\7&?$;K8EHHHKC
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 C?=/TKRKQE_P C%:UZJWW3
M]*\J\9?\C%:T_LR]&..YT-A_QZ)5FJUA_P >B59K\VJ_Q&=R"BBBLQA1110
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M ",/_;0?SKV*U_X](?\ <'\J_1\-_NU/T.*?Q$M%%%:D!1110 4444 %%%%
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MB_E1_;-7L']FP[GD.DV&S6(H;A,CS%!!^M?2=GX'\/O90,VG1$F-2?RKPRY
M'BI< #]ZO\Z^E;'_ )!]M_UR7^5>[0JRJ4U)GD5H<DW%&'_P@OA[_H'14?\
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ML?QH ]4+J!DL *%=7^ZP-<A?)XC:,+%&O%8-MXBUO2O$MOI]\%6&09;]/\:
M/3B0.II#(@."P!K@?'_BJ\T6TLI; C=/(%Y^M9EU?^+WT[[<L2Y"@C\J /4L
M\9IKS1QG#N!]:XWPUXHGOM/G6Y(^TP1EF ]<5S]KK6K^(;QO( **Q7K[T >I
MAU89# CUI#+&%W%P .]8 >^L=%GDG #1Q$BN"\/:UXE\26\Y@16A64J3GW-
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M'\S77^*D4^$\$<;!_*F^)_#*ZY=V4I7/V=PU:^J:<+[2_LI&1@#]* .'T/\
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M=/EKC--\):<_A$3LA\QH22:H?#QFLIC9H?W9D/'XT >H4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 C?=/TKP+XJ?\C?8_2O?6^Z?I7@?Q3_Y&ZQ^E14^!ET_C1JZ;_P >25;J
MIIO_ !Y)5NOBY_$SZF/PH****@84444 %%%% ' 77_(U+_UU7^=?2EC_ ,@^
MV_ZY+_*OFNZ_Y&I?^NJ_SKZ4L?\ D'V__7)?Y5]CA/X,3YG$_P 5G.^-T=]-
M78I.#VKGO"&OQZ=I\T<@ ;>>#]37HEU:17D?ERC*UB?\(5H^\OY)R3FNDP..
M\0:YJ6ORQVEM9R",. 77N*UK[PCY?@FYL(N9)@&.!SG!_P :["RTNVL!B!,5
M=H \T\+:_<:+9#3;FW*B!<*S=ZH2B\\2^-;6[^S.D"#:3V[5Z)>>'K"^DWS1
MY;.:MV6GV]A'L@7 H \W\2:?,FH6J1QEE64<CZUU/C2&27P1+&BEGV+P/I70
M3:?!.X9UR0<U+/;QW$'DR#*'M0!RG@V&2+0$5T*MY?0USWV2X_X3JWD$;;0#
MS^(KTN&UCMX]B#"XQ48L(!<"?;\XZ&@#R?2VDM/&&I/J5L9(2?W?F=/PJ&Z\
MV[\?VL]O8>7 $P64<=J]5O-!L;YP\T>2#FGPZ-9P,"B8(Z4 >=>-K*YGGTDQ
M0LVV8$X[<UH>-;2XFLHQ'$S'REZ?2N\EL89=N]<[3D4Z6TBF&'&>U &/IL3K
MX/6,J0_DD8KE/!]G<0ZMNDB91O/)^M>CK$JQ>6!\N,5'%9Q0MN1<&@">BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***IZH
M\T>G3/;G$H'RF@"Y17D%UK?C);AA'<87MP?\:@_MWQK_ ,_/Z'_&JY0/9J*\
M9_MWQK_S\_H?\:/[=\:_\_/Z'_&CD ]FHKQG^W?&O_/S^A_QH_MWQK_S\_H?
M\:.0#V5ONGZ5X#\4R/\ A+K'GM6PVN^-=C?Z3V]#_C7F/BS4M5NM4CEOI-TR
M_=-34@W%HJ#M),]*TZ6/[$GS"K?G1_WA7DD.KZV(@(W;;VX-2_VQKW]]OR-?
M/2RBJW>Z/968TTK6/5O.C_O"CSH_[PKRC^U]>_OM_P!\FC^U]>_OM_WR:7]C
MU>Z'_:5/L>K^='_>%'G1_P!X5Y1_:^O?WV_[Y-']KZ]_?;_ODT?V/5[H/[2I
M]CU?SH_[PH\Z/^\*\H_M?7O[[?\ ?)H_MC7O[[?]\FC^QZO=!_:5/L;-RZGQ
M4A!_Y:K_ #KZ6L?^0?;?]<E_E7QZ-0OCJ:.S?OMX_/->OVVN^,Q:Q!+CY=@Q
MP>F/K7O8>DX4U%]#R*TU.;DCVNBO&?[=\:_\_/Z'_&C^W?&O_/S^A_QK;D,C
MV:BO&?[=\:_\_/Z'_&C^W?&O_/S^A_QHY /9J*\9_MWQK_S\_H?\:/[=\:_\
M_/Z'_&CD ]FHKQG^W?&O_/S^A_QH_MWQK_S\_H?\:.0#V:BO-/#>J^)[B\VW
MTVY,^AKTI,[%)ZXYI-6 6BBBD 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %(5##!&0:6B@" V5L3DP)^5)]
MAM?^>"?E5BB@"O\ 8;7_ )X)^5'V&U_YX)^56** *_V&U_YX)^5'V&U_YX)^
M56** *DMC:^3)^X3[I[5\X_$"*-?$\*J@ )/%?2TW^HD_P!T_P J^;/B%_R-
M,'U- '3Z+8VK:7$6@0GUQ6A]@M/^?>/\JKZ'_P @J*M&J$5OL%I_S[Q_E1]@
MM/\ GWC_ "JS10!6^P6G_/O'^5'V"T_Y]X_RJS10!6^P6G_/O'^5'V"TQ_Q[
MQ_E5F@]* /'-4C1/&BHJ@+YZ\#ZU]4:=96ITRU)@3_4KV]A7RSJW_([K_P!=
MT_G7U=IW_(,M?^N*?R%2,7[#:_\ /!/RH^PVO_/!/RJQ10!7^PVO_/!/RH^P
MVO\ SP3\JL44 5_L-K_SP3\J/L-K_P \$_*K%% %?[#:_P#/!/RH^PVO_/!/
MRJQ10!"EK!&<I$H/L*FHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9
M-_J)/]T_RKYL^(7_ "-,'U-?2<W^HD_W3_*OFSXA?\C3!]30".OT/_D%15HU
MG:'_ ,@J*M&J$%%%% !1110 4'I10>E 'CVK?\CNO_7=/YU]7:=_R#+7_KBG
M\A7RCJW_ ".Z_P#7=/YU]7:=_P @RU_ZXI_(5(RS1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,F_P!1)_NG^5?-GQ"_
MY&F#ZFOI.;_42?[I_E7S9\0O^1I@^IH!'7Z'_P @J*M&L[0_^05%6C5""BBB
M@ HHHH *#THH/2@#Q[5O^1W7_KNG\Z^KM._Y!EK_ -<4_D*^4=6_Y'=?^NZ?
MSKZNT[_D&6O_ %Q3^0J1EFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 9-_J)/\ =/\ *OFSXA?\C3!]37TG-_J)/]T_
MRKYL^(7_ "-,'U- (Z_0_P#D%15HUG:'_P @J*M&J$%%%% !1110 4'I10>E
M 'CVK?\ ([K_ -=T_G7U=IW_ "#+7_KBG\A7RCJW_([K_P!=T_G7U=IW_(,M
M?^N*?R%2,LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% #)O]1)_NG^5?-GQ"_P"1I@^IKZ3F_P!1)_NG^5?-GQ"_Y&F#
MZF@$=?H?_(*BK1K.T/\ Y!45:-4(**** "BBB@ H/2B@]* /'M6_Y'=?^NZ?
MSKZNT[_D&6O_ %Q3^0KY1U;_ )'=?^NZ?SKZNT[_ )!EK_UQ3^0J1EFBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9-_
MJ)/]T_RKYL^(7_(TP?4U])S?ZB3_ '3_ "KYL^(7_(TP?4T CK]#_P"05%6C
M6=H?_(*BK1JA!1110 4444 %!Z44'I0!X]JW_([K_P!=T_G7U=IW_(,M?^N*
M?R%?*.K?\CNO_7=/YU]7:=_R#+7_ *XI_(5(RS1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 ,F_U$G^Z?Y5\V?$+_D:8
M/J:^DYO]1)_NG^5?-GQ"_P"1I@^IH!'7Z'_R"HJT:SM#_P"05%6C5""BBB@
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MQC-'/RBR KGZUZQ;@"VB Z!!_*@#E]'\.6_AV=Y1)(4(XW&NDM+R&\C+0MD
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M8]T]B8P3$<JAZ5PGA339-2U7,\F^#><QGH>: /1+#Q9I6I+(;>;=Y8RU0?\
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MZ3F_U$G^Z?Y5\V?$+_D:8/J: 1U^A_\ (*BK1K.T/_D%15HU0@HHHH ****
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MC0=+NWW3V44C>I%26NDV%D0;:V2,C^[0!=HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** &3?ZB3_=/\J^;/B%_P C3!]37TG-
M_J)/]T_RKYL^(7_(TP?4T CK]#_Y!45:-9VA_P#(*BK1JA!1110 4444 %!Z
M44'I0!X]JW_([K_UW3^=?5VG?\@RU_ZXI_(5\HZM_P CNO\ UW7^=?5NG?\
M(+M?^N*?R%2,M45P^K>.+_3K^6!-(DECC_C'0_K67%\4KF=ML6D,QSC _P#U
MT >DR1B6-D;HPP:HZ?HUKIN[R5^\VXDBL_P]X@N=88B>Q>WP,_-70T %%9>M
M:K)I<*O' 92QZ"LJ]\3R1>&KC4FMBC1G&WUZT =316%X:UDZQ81SE-NX9Q6[
M0 54;3H&O%N2O[Q>AQ5NB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!D
MW^HD_P!T_P J^;/B%_R-,'U-?2<W^HD_W3_*OFSXA?\ (TP?4T CK]#_ .05
M%6C6=H?_ ""HJT:H04444 %%%% !0>E%!Z4 >/:M_P CNO\ UW7^=?5VG?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!DW^HD_P!T_P J^;/B%_R-,'U-?2<W^HD_
MW3_*OFSXA?\ (TP?4T CK]#_ .05%6C6=H?_ ""HJT:H04444 %%%% !0>E%
M!Z4 >/:M_P CNO\ UW3^=?5VG?\ (,M?^N*?R%?*.K?\CNO_ %W3^=?5VG?\
M@RU_ZXI_(5(RS1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R;_42?[I_E7S9\0O^
M1I@^IKZ3F_U$G^Z?Y5\V?$+_ )&F#ZF@$=?H?_(*BK1K.T/_ )!45:-4(***
M* "BBB@ H/2B@]* /'M6_P"1W7_KNG\Z^KM._P"09:_]<4_D*^4=6_Y'=?\
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M+-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M110 4444 %!Z44'I0!X]JW_([K_UW3^=?5VG?\@RU_ZXI_(5\HZM_P CNO\
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M4_D*D99HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** &3?ZB3_ '3_ "KYL^(7_(TP?4U])S?ZB3_=/\J^;/B%_P C3!]3
M0".OT/\ Y!45:-9VA_\ (*BK1JA!1110 4444 %!Z44'I0!X]JW_ ".Z_P#7
M=/YU]7:=_P @RU_ZXI_(5\HZM_R.Z_\ 7=/YU]7:=_R#+7_KBG\A4C+-%%%
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=110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gaz3apgusshz000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gaz3apgusshz000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ', FL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HKRCX\2/'X6L2CLI^T]5..U?/GVJX_Y[R_
M]]F@=C[:HKXE^U7'_/>7_OLT?:KC_GO+_P!]F@+'VU17Q/'=7'F+^_EZC^,U
M]FZ7SI-F3_SP3_T$4"+=%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \F^
M/?\ R*MA_P!?/]*\-\.Z,WB'Q!9Z2DPA:Y?8)&7<%_"O<OCW_P BK8?]?/\
M2O)/AK_R431?^N_]#0-'>?\ #/=[_P!##!_X#'_XJC_AGN]_Z&&#_P !C_\
M%5[Q10%SQWPS\%+KP_XDL=5?6X9EM91(8Q;D%L=L[J]BHHH$%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M>3?'O_D5;#_KY_I7STK,C!E)!'0@U]JWFGV6HQK'?6=O=(IR%GB5P#]"*I?\
M(MX>_P"@#I?_ (!Q_P"% [GQY]JN/^?B7_OLT?:KC_GXE_[[-?8?_"+>'O\
MH Z7_P" <?\ A1_PBWA[_H Z7_X!Q_X4!<^//M5Q_P _$O\ WV:^MO +%O 6
MALQ))LX\DGVJ[_PBWA[_ * .E_\ @''_ (5I0P16T*0P1)%$@VHB*%51Z #I
M0!)1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M /6:*\ N-9\8?"SQKI=GJVN-KEC?[0R/P1EMO&<D$?K73_%KQSJ&G7.F>%]
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MKWP]9W%SJ"B.:Y VQ=U ]?>N_I,YL5&G&JU3V"BBB@YPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O,]=9_P#A??AY0S;?[*D. >/OM7IE4)KC
M2UUJWMYI+<:DT;-"C8\PIW([XH OT444 %%%% !1110 4444 %%%% !1110
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M;5 )&/7/% '04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &3KFH:9X?T:YU2^CB6
MWMT+-\HR?8>]>*_\+BUZ]U&SN+7PY!;Z+=7J6L=Q+%G.2,C/3.#FNS^.FEW^
MI?#Z0V2-(MO*)ID7KL'?\*\^\0^.O#6I> /!^GV=TL=Q87MJ]S!L(\L("&;I
MCKS^- 'HY^)6G6?Q'_X1:\L%C$C1I;W"IUD;L?Q[UZ/7S]XQ\5Z)XQ^(7A&W
M\/D74\%W'YEPD9'&X<<]N]?0- !1110 5X1\9]&FTWQIHOBYK5KG3XI(UN55
M<XVL" ?J*]WIDT,5Q$8IHDDC;JKJ"#^!H ^=?B/XOTOXD7/A_3?#5O<7%TL^
M6/DD%<XX_#&:N?%?0[O0O%WA?Q8\3RV=J;:.<H,D-$P;I[@&O<['1-)TPDV&
MF65H3R3;VZQY_(5:F@AN(C%/$DL9ZHZA@?P- 'SOXXUZ+XK^+M!TSPQ'-.D)
MWR2/&5"\Y.<]@*N?%?2KOPY\2=$\7+;22::@A2:5%SM92<@_5>GT->Z6.D:;
MIF[^S].M+3=][[/ L>?R%6)X(;F%H;B*.6)OO)(H8'\#0!\[>,=3M?C!X_T'
M3M!,QM8E(FF>,J%&06//H :^C ,# [54LM)TW3 18:?:6@/400JF?R%7* /&
M/C#_ ,E'^'?_ %_C_P!'0U[/7C'QA_Y*/\._^O\ '_HZ&O9Z "BBB@ HHHH
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M%QKNFQ7RP27#H0DNQ=PQG"XX'.:T?CU-?1?#TBU:18GG59RG]WT/M6O\+8=
MTSP%IXTJXB"SQB:?=+R92 &R">.1C\* .>\!'X?>'?&>H>'M*CFBU9)?+$EX
M0^\CLC=J];KY[\?6N@6GQ?\ #<NA&(7\MY&]T(&R-V\8/'&:^A* "BBB@ HH
MHH **** "BBB@ HHHH \8^,/_)1_AW_U_C_T=#7L]>,?&'_DH_P[_P"O\?\
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M_P"O_P#I7L->/?L_?\@77O\ K_\ Z5[#0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4C,J(S,0%49)/84M-DC66)
MXW&5=2I^AH IW5MI_B#1Y+>7RKNQNH\$JP964]P1_.O&[O\ 9X,=S(=(\3W%
MM;,>(I(R2H]V##/Y"K.I_";Q-H=X9_!'B*XMX&Y-M+,1CV![BLN[U?XX:,P@
M-F;O'1XK99L_B* .R\#_  :TGPGJ']IWET^J:BIS')(FU8SZ@9.3[DUZ,US
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M;XE>%_"5XMGJE_BZ(R88D+LH]3CI6QH'B/2O$^G+?Z1=I<P$X) (*GT(/(H
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MUOPS8:C(NV2:/YA[@D']16O2/,E%QDXOH%%%%!(4444 %9TVI:5'KMOI\T\
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M?^2C_#O_ *_Q_P"CH:]8URYFL]"OKBW7=-' S(/<"O)_C#_R4?X=_P#7^/\
MT=#7L5Q)%%;2R3D")4)?/3&.: /$?A3;^&X_!6I>,?$/DW%V]TZW5Q.-YC'R
MX&.V2V?R]*Q[+QCX9\-?%R.]T+41%H%Y&3=HN?+5\'H.W.*Q-*\+Z_XOU379
M_!&;70)KAE=+N8&*4YSPNW'H1D<9ZUSFE> -4OOB$GA*\DBM+MF;S),!E"@$
MD@?0<=* /K[3=2M=7TZ"_L91+;3J'C<=Q5NO#-9\-:W\(K6SU[1]?O;_ $NV
M81W%A=RDIM/]U1P/RKVC3+Y-3TJUOHQA+B)9 /3(SB@"W1110 4444 %%%%
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M_P"O";_T$UD?!;_DEFD_63_T,T =_1110 4444 %%%% !1110 4444 %%%%
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MV;92:C,Q0A(\JC_W6.>I]LUN:MX1\$Z+I%UJ5WH%IY%M&9'VIR0.PR>M><?
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M "BBB@ HHHH **** "BBB@ HHHH \8^,/_)1_AW_ -?X_P#1T->SUXQ\8?\
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MT444 %%%% !1110 452&K61UIM($P^VK!YYBQSLSC/YU=IM- %%%%( HHHH
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M-.BLS_A(M#_Z#.G?^!2?XT?\)%H?_09T[_P*3_&@#3KS+X\9/PWFQ_S\1?\
MH0KNO^$BT/\ Z#.G?^!2?XU!=ZKX8OX/(O+_ $BYA)SY<TT;KGZ$T >9?%7P
ME<-I%CXRTB1X]1L+=%D5!]Y,=?PSBO+8/$36_P ';C1(ANNM4U0EU YV*%;_
M -"VU]2-KOA]XC$VJZ88R-I0W$>"/3&:S5C\"(RLB>'%9#N4@0 J?44 >=0_
M"WQK_P (D-&7Q3;+ISP;3;>4W0CI5CX!:I<)INL>&KL_O-,N3L!/0,2"![!E
M)_&O4?\ A(M#QC^V=._\"D_QJI;7OA*SN9+FUNM$@GE),DL4D2L^3DY(Y/-
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M#_Z#.G?^!2?XT?\ "1:'_P!!G3O_  *3_&@LTZ1F"(68X4#)-9O_  D6A_\
M09T[_P "D_QK#\8:S;7OA>]M-)U?33=SIY:[KQ%P#P3G-.*N[ >3^*QJ'CR\
MUCQ%;QI]BT@BWC4#/F(&//OUS^-<KI6A:[J0:^T[0Y+R$DKE+?>@/IBNVT5O
M%F@:2=,L-2\/):L275KF)BY/7)/6NF^&4LOAU;ZTU;4M(2UF;SHS'>H=K]P!
MZ'^E>FZRIP?+9VV,[79S&CVWB33?&MIK%EX-NK&$*(IH8H6"D'@GV]:]\K,_
MX2+0_P#H,Z=_X%)_C1_PD6A_]!G3O_ I/\:X*M7VC3L6E8TZ*KVE_9WZLUG=
MP7"J<,89 X!]\58K(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP3Z:C_X$C_XFO4J* /+?^% >"?34?_ D?_$T?\* \$^FH_\ @2/_ (FO4J*
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MSRW_ (4!X)]-1_\  D?_ !-'_"@/!/IJ/_@2/_B:]2HH \M_X4!X)]-1_P#
MD?\ Q-'_  H#P3Z:C_X$C_XFO4J* /+?^% >"?34?_ D?_$T?\* \$^FH_\
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MEDN4WF+).WGUP*W*9##';PI#$@2-%"JH'  I] !1110 4444 %%%% !1110
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M;[MAD.6^9BQS^)H UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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-10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gaz3apgusshz000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gaz3apgusshz000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -9!YX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *S]2U1=.:,&$R;P>C8QBM"N=\3?ZRV^C?TH V;&[%[:+.$*!B1@G/
M0U9K-T'_ )!,7U;^9K2H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD0 A0 8 48H ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%RTTJKCS')Y/]/PKYQ\,?\C7I'_7Y'_Z$*^JJ "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &#
M??\ '[+]?Z4EK=/;29'*G[R^M+??\?LOU_I5>@#HXI4FC#H<J:?6!:W3VTF1
MRI^\OK6Y%*DT8=#E30 ^BBD=UC1G<@*HR2>PH Y_Q=XOL?"6F_:+G]Y<29$$
M"GES_0>]> ^(O&FM^)9F-Y=,EN3\MO$=J ?U_&F^,?$,WB7Q+=7KL?)5C' G
M94!X_/K6#0 =.E%%% !1110 4444 %203S6LRS6\KPRKT>-BI'XBHZ* /6O
M_P 5K@7,.F^(7$D;D)'>8P5/;?ZCWKV0$$ @Y!Z$5\@U] _"CQ))K?AIK.Y<
MO=6!$98GED/W3^A'X4 =]1110 4444 %%%% !7.^)O\ 66WT;^E=%7.^)O\
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M_M.V]6_[YH_M.V]6_P"^: +E%4_[3MO5O^^:/[3MO5O^^: +E%4_[3MO5O\
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ML,8KRSD&<QR(5;VR.: /D9<[1GKCFEJ2X4)=3JO196 ^F34= !1110 4444
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M4AT^5T88W ]0:ZXW^A:P5<W"P2GEED&*O:EI5MXGT9[B-%3481E9,\-WP?\
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ML$%U<M(V<#SB,X&>YK;TNTUJ+4HGNVF, SNW3AAT..,^N*R?#W_(<MO^!?\
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M9GC0X50"Q)*D+N!X'S_B0#MJ*** "BBB@ HHHH **** "BBB@ HHHH ****
M"GI-)$DBHV-ZE3FF44 ?.FL:;=Z3JD]K>Q&.4.6]F!/!![BJ!. 37O\ XE\-
M6GB33_)F 2X3)AG Y0_U'J*\2O-$O-/UE=+O(BDS2*@]&!. 0>X- %GQ1H;:
M!K'V8D&.6))HL'^%AG!]ZQ:[OXLPM#XMA4C ^QQ@?@,5PE !1110 4444 %:
MFIZ/)IFG:7<2D%KV(S #LN< ?I64WW3]*[[QW8M;^$_"$Q7K:LI_0C^= '!5
MZM\$)MNI:M#_ 'HD;\CC^M>4UZ!\'KQ;;QLT+''VFV9 /4@AOZ&@#W^BBB@
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M2"%"N3N7G.,#/)P.<X/97FH_%N_L;BSNO".CR6]Q&T4J><!N5A@C(GR.#VH
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MELHH8-;M8]LD,H;R1*0=C9'.PD'CJ,$<\$]E##%;P1P01I%#&H1(T4*JJ!@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M36.I6MVAPT$R2#\"#7U=-(LNGM(IRKQ[@?8B@#"HHHH **** "BBB@ HHHH
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MCFU"-U8_NU=X0A;J=N<#/<X^OO6[X1N6>UN;1MQ$+AT.T!0K9X&.2=P8G/\
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M2=JJ, 9/)X'>OGSX':(U_P",I=497\G38"0RL /,D!101U(*^8>.X'/8_15
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^S[K_GE_X\/\: *U%6?[/NO^>7_CP_QH_L^Z_P">7_CP_P : *U%6?[/NO\
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MY15NA$TWL4HYI[B[RI8ACT S746Q>Y\,WUO<Q[&\IMJOW.,_SYK&GO8=+4I
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MDU]9VL"VMI#;I]R*-47Z 8H \D^.!7_B4#<-V7./:O(*]&^,U[Y_BZWM<_\
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MADMKB2"48DB<HP/J#@U[Y\'(?+\#^9_SUNI&_D/Z4 >@4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !139'6.-G8X4#FL^6:1U+LS+_=13C\Z -*
MBLX/+"H?S6<K]X'H16@I#*&'0C(H 6BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH ***Q?%NJ2:+X3U/4(CB6& E#Z,> ?S-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3+/&'7\1Z4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXJR7T:8BC$LQ_+:#^9JG\4-,:+XBS(HVB]$;J?<_*?U%6,Q_#CZ^=T>EJSP
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MRL<;ES-ON*639UY]*:<D#+'%0ND@?&U<TTJZ=Q^= B["X) (^0=JF>2-6VD
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M$TJ7^Y<L/S7_ .M0!YSJD9:SA,9^78,5@B.5&7'!SC@UVD6E+;:#:)>R9,B
MX/\ #GD#\*JQZ3IJL7%TASR?F'%81G%['7&49JZ9!;;VT>Y#L-C#')XZ5?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O&/CA9[;_2;
MT#[\;PD_0@C^9KV>O-OC3:B7PE:W/\4%VH'_  ($4 >$T44JC<RKG&X@9]*
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MD$=Q3E"4=Q0J1G\+%HHHJ2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXF_UEM]&_I715SOB;_66WT;^E &AH/\ R"8OJW\S6E6;H/\ R"8OJW\S6E0
M4444 %%%% !1110 4444 ?-WQ-L_L?C[4,#"S;95_%1G]<UR->C?&A-OC&U;
M'W[)3_X\PKSF@#8\+:;)JWBG3;.-<[YU9O95.3^@KZF    X Z5\\_"5'?Q[
M 4Z+"Y;Z?YQ7T/0!Y%\;=)=H=.U>-"5C)@E/IGE?ZUX[7T3\5T=O %Z4Z*Z%
MOIG_ /57SM0 =J^G/ =G]A\#Z3"5P_D!F^IYKYCVE_E'5N!7UMIZ"+3;6,#
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MSS7@E?2WPYM/L?@#2$Q@O#YI_P"!$M_6JITE#8(Q2.IHHHK0H**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X3
MXO)O\!3'^[<1M^M=W7F7QJU+R/#EGIZMAKJXW,/]E!G^9% 'AM7-(L9-3UFR
ML8ER\\Z(!^//Z53KN_A% DWCV)G4-Y5O(ZY'0\#/ZF@#Z"1!'&J+]U0 *'42
M(R-T8$&G44 ?)FKV,FF:S>V,R[9()W0C\>/TJG7<_%N-$\?W!10-T$3-@=3C
MK^E<-0!]&?"J'ROA]I[8_P!8SO\ ^/$?TKLZ\]^#NIF\\'-9L<M93-&/93\P
M_F:]"H **** "BBB@ HHJ.>0Q0LX'(Z?6@!7E2(9=POU-0F_M@>7P/4@XJN8
M\'<QW.>K&JMRO [\]/6@"U=SP3QC8^70Y'RG!]JCAVNH93_]:H4=%ZMCV[U(
M3&3NRZ'^\ 10!(%$<WHK GZ$5<LP1:KGOD_F:IP1),N9'WR*<#/3\!5K[4(B
M5E&-HZJ.* +##<I&<9&*\3N+5K>]N89 =Z2LISUX->Q&[?\ A@./]IL&N0\5
M:(;^4WUFFRXQB6,]']P?6NC#S479G)BJ<I13CT.*5)7W+&A?:I9MHZ =3]*L
M:-JU]H]U]HMF&&X>,CY7'H:IQ-,)'PQ0\J0...XI^[9P>E=C2>YYR;B]#U/_
M (2"&]TU)K5MID7YL]4/<?6L9 DLCJR^8".AYS]:YOP_,9)+BVSA2 _7H1Q7
M40%;8?*,Y]*\^I'DE9'KT9\\$V4Y= L-^YHL[N2N>*M^2L<:0HH10.@'04CS
MDMPF6J"26;?DXR>PJ&V]S112V+JMY2$CL.*SRQ=BV<G/<TVXN_+^5G#$CH.@
MK.N+TH %(_"D,TP=O7%!F4=/TK(6^)'.*F6Y4C[@_ T 7C*H&&R?2DW/G<JG
M%58[I2VWYJL_:$4[2XH R;_3I7=IK<;F8Y9">E1VFE3EP]P0H'\ /)K9."VY
M6%/ W=JOVDK6,G1BW<Z:RO(I;1#N^<#!0=<U(Y6"%Y9V5!]YB3TKEE>6VD$L
M1*L.XJAXCU*5K&-6E8^8V#SV':E"/-*Q52?)%R'ZEXQN=TJ::@C5OE\YOO$>
MWI7,12;LL^=S')).<TX.K+@4Z2Y>.R%MY<>P/OW!1N/MGT]J]&,%!:'DSG*H
M_>(Y%+#(XKT+X>374NDW*3R,\<<H6+<<XXY KB=-L;K5KE;:TB+,?O-V4>I-
M>M:3IL6DZ;%9P\A!EF_O-W-8XB24;=3?"0DY\W1%VBBBN(](**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /!/C+=Q3^,(8$^_;VP#GW8Y%>=UN>,KTZAXRU:XSE3<,J^R
MC@5AT >O?!+2HV.I:L_,BD6Z#'08R37L->8?!-U/AW4$'WEN>?Q6O3Z (;JV
MCO+2:VF ,<J%&!]"*^3]1M!8:I>688L+>=X@Q[[6(S^E?6Q.!D]J^3]=D$OB
M'4Y <A[N4CZ;S0!GM]T_2OJGPO=17GA72YX#^[-K&!^ P?U%?*]?0/P?O3=>
M!UA8\VT[Q >@X/\ 4T =]1110 4444 %%%% !1110 5SOB;_ %EM]&_I715S
MOB;_ %EM]&_I0!H:#_R"8OJW\S6E6;H/_()B^K?S-:5 !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3=7SWSV&3V%?4WA33!H_A;3;$#YHX%W'U)&30!LT444 %%%% !1110 4444
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MM[R/[\$JRC\#FOK.UN$N[2&YC^Y*BNOT(S7R+7TU\/[DW?@+1Y6.6%N$)/\
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M5\,--&G> [ D8DN=UP__  (\?IBNQJO8VJ66GV]H@ 6&)8P![#%6* "BBB@
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M'?A.];?C73K?39K6]L8T6TN$P-GW=W4'\1_*MCPUHECJOA1)7@07,A8";'S
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M6^B#=_2K'Q+C$7Q"U4#HS(WYH*W/@O:";Q;=7)'_ ![VIQ]68#^E 'N]%%%
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M?03^*],A>)IE-RGRKPW6L\1",Z;4D;8.I.G54H,^E:***^9/M0HHHH ****
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M#U+OJ%Y_W^;_ !H ](W+ZT;U]:\_31+_ +WUW_W^;_&K":->CK>7/_?UO\:
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M==A*IQ^HIID2B6&\?^)X8PJWT851@?N5KG]7UG5O$$R2:E=O/Y?W%P JYZX
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-K&/XID'_CPH ^JM'1X]#L$D^^MM&&^NT55\4I+)X4U9(,^:UI(%QZ[36L
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M1+E6'"-\I-0:%&^$EO,"!\KC-9\H68Y!VGO727MLSP #ED/YBL"Y@*/N P*
M(44(I#'/& :GL]1NM*NX[JW894;2AZ,/0U696Y!S3=Q'7GZT ;<WCR"VE>XM
M]"B6]<8,VX<_7 S6+HGBR;2-4O=0N8#=378^?YMN#G-0O:K.,BJILU4\C- &
MT_C31]V3X4MB2>N5_P#B:K>'_%::--J++I@>*]DWB(/@(.?EZ<CFLMH(E^9E
MS[4L?DGMC\* -R;Q?I4EO+$OAFWB9U*A@5X)'7I4MCXVM[?1;73KG2%N4@4+
MEW&"1WQBL%K(2<J/RJ%K*1?X>* -'7/$%EJMHD%KHL5FX<,94(R1Z<"JEKT!
M/:HTM21TJY#9RB,N4(0#J: +*WAV%5XJQ:[EP1RS53MK9Y#P..]:UG$ V[&0
MO3W- &DTDBA8MQZ<FL/Q*\AAMT*GRF);=[UMQH6.YSFBZMX[JT:.5=R=O4'V
MJZ<E&5V9U8.<&D<7&&5>QIX@CDAEF:X19(R-L3 Y?/<'VK4?0+X%5ME$^X\!
M3AOR-4[G0]6M/WUQ83I'Z[<_RKO4XM:,\ITYQ?O(K;AMZ&NM^'VH7/VZ>PW%
M[8H9 ,_<.?ZUS$=K=7#".&UF=ST58R:[7P9X7NM,N7U"]_=R,FU(L\C/<_X5
M-9KEU+PT9.::.UHHHKSSU@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH BG^Z/K5>K$_W1]:KT %%%% !1110!"+JV-VUH)XS<*NXQ
M;OF ]<42SV\#QI+*B-*=J!C@L?05YOK]O?\ _"P]2U+3&)NM.LX9_+'_ "U3
MHR_E6IJ^J6^MW'A*_M3F.6Z)QW4XY!^E7RD\QW.Q?04FQ?05RBZ_KVL75Z^@
MVEF;*TD,?F7+',[#J%QTK8\/:TNO:4+L1&&57,4T1.=CCJ*EIH=R_,]O;0M-
M.T<<2#+.YP!1&()XUEB*O&XRK+R"*Y?QFPU.\TKPVK8%[+YMQSTB7K^M)X,N
MFL[?4M"E;,NERMY>3UB/*T^72X7UL=7Y,?\ =%(8X0P4[0QZ#/)KA[?Q9XFO
M="FUJWTVR%G;EO,#N=\@4X.WT_&F37VIZCXWT.[M%MECGM?,B21FX4XW9]_2
MCE8N8[,W>FA68W,("R>4QW='_N_6K/DQ_P!T5YEKE\LNB7SP6,4<D&MHNV//
M[UAW/O73KKVMZ=JMC!KMI:I;W[[(Y+9B3$_96SU_"AQ#F.F\E/[M.\M/[H_*
MN337]?UB>\ET*SLS96DACWW+'=.PZ[<=*8/&LU]9:?%IMDIU2\D>(PRM\L)3
M[Q8^U'*QW1U1EMA<K;&1!.R[A'GD@=\5+M7T%<!'<:R?B"HOK>V6^ATV7RFB
M),<O<'GGVK77Q?GP0=<,*_:A^Z-O_P!-<XVT.+"YU.T>E&!5:UN=UM#]JDA6
MY*#S$5N W<"K52,**** "BBB@"2'_6?A6-XF_P!9;?1OZ5LP_P"L_"L;Q-_K
M+;Z-_2@"_H?_ "!X_JW\S4U0Z'_R!X_JW\S4U !1110 F!1M'I2T4 -V+Z"C
MRT_NBG44 1^2G]T5'*+:!=TS1QJ3C+L /UJQ7GWQ?R?"EL%)R;H 8/M0!W+Q
MVZ1F1V18P,EB0!CZTJ06\B!TVLK#(93D&O(K?Q'-=_#+7=!U$LFHZ?" H8\M
M'O7^7\L5TUEXKMO"WPUT">:-[BXGMU2&!#RYY[^E '<?98O[M'V6+^[7&Z;X
M^NUUVVTKQ#HLFER7>/(D+9!ST!JE:?$;5=2U.>PT[PX]S)!<>7*RN<(F<;CZ
M&@#O_LT7]VE%O'_=%<$_Q%U*74=4L-/\/FZFL';<RR?*$4G)/Y56_P"%IWMQ
MI)U*R\.R26UO@7<C/\J$]EH ]'\B/^X*1DAC0NY557DLQP!7)ZAXUNOLFF/H
MNBS7TM_'Y@#?*D8]"WKUK$N_&4GB+PEXGL+NQ^QW]E;$R(K[EQG'!^M 'I""
M&5 \95T/1E.0:=L7T%<W\/<GP'I.23^[;K_O&NFH 3:/2EQ110 4444 %%%%
M !5P=!5.K@Z"@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ JGJ.FVVJ6_DW,88 Y5NZGU%7*J:G>KIVF7%VW_+)"P'J>U)
M[:CC>^FYY!K-N]E?36I^5D?!]A69D>8,CE1R/6II;B6\NY)[AC))*Q9B3ZT!
M(FB C4B0?>S7,I*2NCV)TI4GRRW&B*$D2#)).:U)(PR @D$5G00-(X*'&TY<
M5J!6(PSC'J!5HRF465)3AHP".I'>HFT]7Y0U?DAVMOC8$]QZTP N00N&]J9E
M8R);*2+^'CU%5&B;-=2;5F3+-FF+91,<[-QIW$X&':6L3<.2#5ORT@/! 'TK
M1>U1%+!5]P131%:R*"R'<.HHN/E,^>Z*D"%OQQ4<=S>.V%^;/M6PMK!MRD(Y
MZ<9J7B&/[@'IQBD%BBD%Q-'MEBVYIUO:3)(=J84>O>M&.96^7^+TILUP(C@Y
M^@H*LB.:*<P$ #-9T5K+EGQD^IK3%X)'V+&>F35B!)KB588;61W8X 49H!V,
M8-Y388>Y^M=/X:\/2:M*MY<H\5JARO8R?_6K9TSPB#*DVHHFU>1$#G)]ZZU5
M"J%4 *!@ #I5J/<YZE6VD3AO$/@1IV,VD,D:DY:W( !/J#_C7(R>&=:BDV-I
MLY/JJY'YU[116<\/";N;T,RK48\JLUYGE$GAK7;+2DN5@*LC;B$;YT';]>:T
M]"\>3Q%;75(VF).U95&&_$5Z$[K'&SL<*HR3[5Y#KFJ6NI7DE[;V,<15]BG/
MWA_>(]:B<?96<6=%"I]<O"K"_FM+7,Z[5KN\FG242^8Y;+-AOQ!JDUDKSHD]
MU#;JS8+,V<?@*LLT5RYWA8I&/##[I/OZ5'<Z!K ( TZX;=]TJN0?Q%<J5W=*
MYZ[FH14)2M]W_#?@1^)]'M],N(K9-3MGMU0,I3+,2>I('<URLJ62N&2^GCD4
MY5_(P ?7ALUNZMI6I0QV\$UE<FX4$-B,G [#/>FZ5\/_ !#KLZJMD]K 3\TU
MP-H ^G4UK9N6B.+GC&G[T_R/;_!U[+J'A+3KB>YCN9FB >5#D,1Q^=;M9?A[
M0[?PYH=OI=L6:.$<LW5F/)/YUJ5W+;4^?E9R=M@HHHIDA1110 4444 %%%%
M!1110 5\K>*+N*_\6:M=P_ZJ6[D9?IG']*^HKTN+&X*??$3;?KBOD?)/)ZF@
M#UCX(:D5OM4TMF^5T6X0>X.T_P Q7L]?//PC=U^(%NJYVO!*&^F,_P Z^AJ
M.*^*FIG3? EVBMB2[9;=?H>3^@-?.A&5(]17LOQQED%IHT(!\LRR,3ZD 8_G
M7C= 'U'X.OHM0\':1<1?=-JB8]"HVG]16Y7"_"(N? %ONS@3RA?IN_QS7=4
M%%%% !1110 4R658D+MT]NII]4;M\W*KV1=WXF@"N#(9,",!@=W+<#FM&&<3
M \%67[RGM6>KXFD]P#3XY-MU&P_B.P_CT_6@#2HHHH **X_QQXQ_X1VW6ULP
MKZC,N5W<B-?[Q_H*\E/BWQ-%/),NL77FR#!^;@#V'05V4<%4JQY]D>=B,RI4
M9^SW9]%45PWPW\5W6OV,]IJ+[[RVP?,Q@NA[GW!KN:YJE.5.3C([*-:-:"G'
M9A1114&H444A(523T S0!!/<>6WEQ@&0C//11[U6$UQYNU9LX&6RHP/I56.X
M#NS$G<YSR*EB?[Y]6- %^WF,FY7 #KUQT(]:GJC:'-VW^YS^=7J "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KWD!FA^7[
MZG*^_M5.,!AD?EZ5J5#);)(V\$H_<KWH SF&R.9.RC(]@:E.U8@W\.*E-I&L
MR9W.QR3D^E1BT)D9XPN V KYX]Q0! $(0LW!)R?:K-A; $SNOS'[F>P]:E2S
MR0TS!L=% X_^O5J@ K.US1;3Q!I$^FWREH9AU!P5/8CW%:-% 'B&H?!35(KC
M&GZC;SP$@9F!1P.YXXXK/M_A7XAC\5):>3BRBF5OMNX!2@.<@=<^U>_T4 %-
M==Z,I.-PQQ3J* /GZ/X4^(9O$LEE+#Y=F79OMH(*[>2#CKGIQ6GI7P5U*6?.
MJZA#;PC.1!\[GGCKP,BO;J* *>E:9:Z-I=OIUDFRW@3:@)R?J??-7*** "BB
MB@ HHHH SI8_(RKKF+/RMC./8U5F*JA*JO/'2MOJ,&J[V5LYR8ASZ<4 9D:!
ML%R7(&,MS5@0QD?= ]QQ27,"6V!'(V]NBGG%,P-F99"0.H' H GM1(5D<2#D
MXSCJ!3)U9F;87=ARK#G%-0&-A+Y8$8',>>OO6HN-HV@8/3% &7CS!S,2.X Q
M4%P L>%P,'./6MAX8I#EXU)]2*$MX4.5C4'UQ0!EPQSL!B%N>[<"C4=.EDL&
M*MF9>0!TQZ5L$@#). *Y?7?&=KIK?9[,)=7)ZX;Y$^I'7Z548.3LB)U(P5Y%
M*&59E\H'$D?WZ9<,74Q*<;>M<R^KWTUW-=F2.-VP2J+@5?TR_DOKSRYBNXKP
MPXS[5<J4H[D0KPGL;L#>; &/WAP:RKV%HY-P&5)_*KUO)]GF>)_NDY^E6KB-
M)H0RD5D;'.M'@<XYJC/'M;(^Z:V9HEY [5G3H5/S#B@"B,C)% ^?AA4KQC P
M>M*D1P"#R: *<UJW;\J6VM59L$8]36U%9EU!?!(]*2Z_<1;3&H)[B@"J\T<2
M>4@'N:;;HK2_O#\G4GUIJV[2\H"P]A0\+P\'\J -!1;,"1& %Z57N+TS#RE7
M:@JQ:V.8O,9LY_AJ6VTEYI=S+M7- %>SM99<A!A>YK42V"NJ(>%%79!%;Q"&
M/@XYQ388&)'/N30 "W*$9&%/ I%4*A!YVC.*DN9 (_O8"]R:K6TA>4*N&+*2
M<<Y]* .CT>Q"1"ZD'[R09 (^Z*UJCMPZV\8D^^%&:DH **** "BBB@ HHHH
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M2V]D&5]^3D,/7IUJ/3-'OX%\7HFAWMK%=V!%K"8V;^($+GN<5[=D^M+D^IH
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M@)_4UR'A>>]LM8BO+2UGGC1MDXBC+?*>N<?G^%=Q\\>S44@.0".]+0 4444
M%%%% !1110 4444 %%%1S2B%,D$DG  [F@#SWXK^+I-$TI-)LI"E[>J=[J>8
MXNA(]ST_.O!J]J\?> -0\3:N=6L[F)9/*6,P2'CC/0^^:\MNO"FNV0O#<:;.
MB6:!YGVY4*3@$'O0!V?P4MUD\47TY7)BM,*?3+#_  KW2O%O@A;W/]I:I="(
M_9#"L?F$<%]V< _3/Z5[30!YG\:[=7\+65P1\T5X%!]-RG_"O#*^@OB_:W%U
MX&)@B:00W,<LFT9*J 03^9%>&6NB:G?:?)?VEE-/;1R")GC0MACTX% '=_"/
MQ7)IVL#0;F0FSO&S#D_ZN7T'LW\\5Z7XV\81>%[)(T4O?7(80CLO^T?;->7>
M"OAOKUSK5EJ%] ]A:6\PE)EXD8J>@7J,^M=%\6[5CJ^FW# ^6T+(#[@Y_K73
MA*<:E51D<>/K2HT)3AN<G9>-?%,=Q]H_M>=VSDI(=R_D>*]5\'^.8?$7^AW:
M+!J*KG:#\L@]5_PKQ4*0X"*26. HZDTD%]<Z;JT%S"K)/;N'&>"".U>Q7PE.
M<+6LSYW"X^M3J7O>/5'TW161X<\06WB324OK?Y6^[+&3RC=Q6O7S\HN+Y7N?
M60G&<5*.S"LK4-PNQL.,H,\5I22QPH7D=44<DDUC+J%MJ%\X@+':N,L,9^E0
MY).S>H[H9E]W+?/T48X8=_RI\0<7,.YR1O&<U-*F$#?W6%#;(Y8B[J@+CEC@
M<50S6HJM<:A:6L8>>X1%/0YSG\JR_$VHB'P?J-Y:RAL0$(ZGIGC/ZTX6G)13
MU(G-0BY=CQ3Q/JPU'Q9J,YE#@RE8\'^%>!^@K,R-X)!&X9&1VJ+[.NS=WZU9
MU2[N]3>.6=U!CB6) BA0%48'2OJ(J4$HK9'Q$Y1J2<F]6=Q\* S>(KUD^XMM
MAO\ OH8KU^N%^%>E1VGAC[>5/GWCDL3_ '5.!C]37=5X&-FIUFT?69;3=/#1
M3ZZA1117*=P54OV/DK&/XVP?I5NJMZ.(W/16Y]L\4 9LL6(R<=.::R-RP.S/
M(5>@JU.,J(Q]YSC\.]1S8^X@+-WQV% %S3HV6#S7^])S]!VJY68;^2-,+ H
M& -U$=W<2 ,'4 ]MM &G151+IE($RC:>-Z]/QJW0 4444 %%%% !1110 444
M4 %%0_:X,X\P?7M^=2@@C(.0>XH 6BBB@ HHHH ***@N[RWL+5[FZE6*%!\S
M-1N)M)79/17G]Q\191?LMM8H]JIP"S$,P]?:NJT3Q!9ZY"3"3',OWX7^\/?W
M'O6DJ4HJ[,XUX2=DS6HHHK,U"CH,FBJM\^(UC_OG!^G>@""XN/,=61&*#@$'
M&3[5/:28!B<%7R2,G.151F'FQ>@S_*G22;=KCJAR* -.BBB@ HI&944LS!5
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MKCR;N=H%51E@5]N]267BN.\OVTV\TV\T^X>%I(EF _>*!S@CH:X_3E+>'_"
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M)Y7RQGT)_P *Y2[8?\+$\7C(R--D[_[*U7E2)?@%&X5 6N5);WWCO0!WEO\
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M>(M1DL+7SXKE%+".=-I<#N*XSQM# -0\"Q;$"$HNW Y&4XK1G")\?8E4*O\
MH/0<?P4 >CT444 %7!T%4ZN#H* %HHHH **** "BBB@ HHHH **** "BBB@
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M11Y:?W13Z* &>6G]T4>6G]T4^B@!GEI_=%'EI_=%/HH 9Y:?W11Y:?W13Z*
M&>6G]T4>6G]T4^B@!GEI_=%'EI_=%/HH 9Y:?W11Y:?W13Z* &>6G]T4>6G]
MT4^B@!GEI_=%'EI_=%/HH 9Y:?W13Z** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH S]<TJ+6]%NM.FX6>,J#_ '3V/YU\
MZ2>%M;M-?_LN:QG,B/RZ(2I4<E@?I7TW28&<XYK.=-3W.FAB9T4TNIXOX$\$
M7^I^(#K>JVKVUG%,98XI5PTC9R./05[31151BHJR,ZU:565Y!1115&04444
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M "LC6M/GOGA,(4[ <Y./2M>B@"EI=M):6"0RXW@G.#[U=HHH **** "BBB@
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MA<R"7+!\]?6GN$2'<#R.@KYNHY.3<MSHYN;4BGD*YYQN-95W,0?))VJ?F?\
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M%J#,;D0C=NZ@=@?PQ6W117@RES2;[GU<(\D5'L%%%%24%%%% !1110 4444
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MV4%ORSBN\C?:I3NO'X5Y9\:P#::))Z3R*?\ OD5MATG5C<RKNU-GFZ$+'@=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HID<T4I81R(Y4X8*P./K0)8S*8A(AD R4##(
M_"@!]%1FX@5F4S1AD&6!894>IJ/[?9_\_<'_ '\% [,L44PS1"+S3*@CQG?N
M&/SI(;B&X3?!-'*OJC!A^E K$E%,DECA3=+(D:YQEF %*SHB%V=0@&2Q/&*
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M?+SAD_ XQ]36=*W-J=&,4E3T/7Z***ZCR HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YV\86\EMXXU5#,9&,Q?+<'
M!Y _6LUMQ3D8^E>V>+O =KXDD%Y#)]FU!5QYF,JX[!A_6O/KKX=^)H6V):13
M#/WXY1@_GBO?PV*I.FDW9GRF-P%>-5N,;KR.:NETY)8O[-DN'W1@RB90-K]P
M,=156X9U3D BNF_X5OXIMG!%DDH;GY95X^O-76^'U[:6GVS6IXK>$$ 11G<S
M?CT%5+%T:=-RE+8Q^IUY5-(,@\,J(M"A<RL!+(V W;MBM.2)%7[^%S42B%K
M"!=L2'"+Z"H6E+CRQUKXG$5/:UI5%U9]'1I^SIJ+Z%B6*UBL9'>3C')K2\#+
M;WVF>*+8S+;P26R1M,_1 5D!8\C@=>M<[> +9.DF<9R*?X7UBPT_1/$]M=S^
M7->VOEVZ[&.]ML@QD#CEAU]:K#V4KLWAN=KX+T32=,UB66P\1V6HR&W*&& K
MN4;E.[ASQP!T[UR7PG876C^+$%[]BW6\8^UYQY&5E^?.1C;UZCIUK)^&^K:?
MX=\3W5WJ=QY$#VC1*VQFRQ=#C"@GH#2?#K5]#TK3?$6G:]>O:1:C"D*LD;,Q
M7$@;&%."-PZUUQ<=+&BL;-WILECI]U=Q?%E[N2&%Y$@6[YD(!(4?OCR>G0TG
MPLM'@AUGQ$+>6=K: Q01QJ6:1\;B !WX4?\  JH?V+\*A_S,VK?]^V_^,TJ>
M-[?PW\/=.T_PYJ _M9Y/,NV^SD[,Y)'SKM)^Z,C/2GI>['UN7O'EK>ZO\/-$
M\07UO<0:A9_N+M)X_+8@G;N(([LH(_WZS];.[X$>'C_U$6_]"GJUH'CB77M
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ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2,=A6-X)U*]U'XF:J^HQ1Q7GV1UECB^ZK(\:$#D^GK1*&MD#1YI>O#)(R(
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M^4?LJ/\ S\_!GI%%>;_\*JN>_B_5OS_^RI/^%43=_%VK?G_]>CFG_*'LJ/\
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MW,4<(O9/EF=<;RHD&,^U2ZDG]S+CAZ<=-WS+\3U'3O$-K:Z%I4NM:M9?:;M
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MP4?\*<L^WB#5O^_@HYI]OQ#V=#^?\#TNBO-/^%.6O_0Q:M_WV*3_ (4[;?\
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M[>IHA3YY)($KLZ:"%8($B3[JC J2HH[B*8X1P3Z=ZEKUTK*QTA1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV&ILVDWGP!C]X<-]:GK)L]UM,OS$JYPWU[&M:@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$YX_#\*O&>-81(QPI_//I0!+157[:!_RQEQZX%2Q7$4W"-\PZJ>#0!+1110
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M-/"__0PZ7_X%I_C61_PJ?P/_ - */_O])_\ %4?\*G\#_P#0"C_[_2?_ !5
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M/"__ $,.E_\ @6G^-9'_  J?P/\ ] */_O\ 2?\ Q5'_  J?P/\ ] */_O\
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MVL1@;AS]T80_:Z[>1[O7.^(_%UKX<U+1=/EMIIKC5KE8(2A 1/G16+'KP'R
M <XQQUKYTL+;0=*MVTWQEH&MVETS?:(KFW/ES&/ 41^5* NW(<[NN1CIFO0?
MB!I>E:AK?PZ=7FOK>_\ *MGN)Y'\RYM]T6TL>#N(D8DX!RWTPR/:MQ;1Z==:
M]?V_C.QT2/0[F:QN(#+)J:[O+A8!_D/RXS\@_B'WA^.]7E&H6D&G_'KPE96J
M>7;V^DF*),D[55+@ 9/)X'>L#PWX+L_&/CSQK'J5U<K96VH2DV\+;0\CO,J.
M3TR@W$<=6],AD4JCO;S/=J*^;O"7@JSU_P"'>OZ_J-U<O)I\$T5E$K86$QKY
MQ/.<@EB-O ^9CU(*WO$,TLW[/7AEI9'D8:@4!=B2%4W"J.>P   [  4Q>VTO
M;I<^@ZY>Q\8_;?B)J?A/[!L^PVPG^U>=G?D1G&S;Q_K.N3T]ZY;X\?\ (CV7
M_823_P!%RT:'_P G$>)?^P:G_H-O2*E-\W*OZW/4:YWQ'XNM?#FI:+I\MM--
M<:M<K!"4(")\Z*Q8]> ^0 #G&..M>":G_P (Q=VNKIH/A_7M:=-TTVN7%PV^
M%B2=[*J%2AVELOACENF 1<?3K;4]*^&+7J/.UY/)93EY6RT"7(54Z\ !V QC
MC [##(E6?0^D:*\<^,J2V>F^%_#.GW<=CIEPS0,LTA6(+'Y2QF1SD[5W9.<]
M,G) K+U/P]%\//BIX830-0>.*_:&">%I@\I4R*C[UQC8XP1_M!L;=JX1;J6>
MVQ[O17@7A[P-9^,_B5XP;4G<65I=W"D1/M?S))'"$<$8 5C]0O!&15V?4W^&
M_P 7]>ED1WL=2M)KR-)KH(LCE3*.@(SYB21*",C?WS\P"JNUVM#W"N7\>>,?
M^$)T.'4OL'VWS;E8/+\[R\95FSG:?[O3'>N6^"&ESQ>'=0UV[>9[C5;G.^20
M/YBID;_7<7:0')YP#[D^/'_(CV7_ &$D_P#1<M 2F_9\R*MU\:+_ $J>W76?
M!-_I\4S?>FF96*@C<5#1KN(!'&1U'(S7J.FZE9:QIT&H:?<)<6DZ[HY4/!']
M"#D$'D$$'FL#XC_8/^%=ZY_:/^H^S';][_6Y'E?=Y_UFSV]>,UXMJMS>2?"O
MP/HT-_':VFH3W0G,S[(B5N!M:1L9"J6)/;OC(&&2YR@[-W/I*BO"-3\/1?#S
MXJ>&$T#4'CBOVA@GA:8/*5,BH^]<8V.,$?[0;&W:N%\-^"[/QCX\\:QZE=7*
MV5MJ$I-O"VT/([S*CD],H-Q''5O3(9#]J[\MM3W:BOF[PEX*L]?^'>OZ_J-U
M<O)I\$T5E$K86$QKYQ/.<@EB-O ^9CU(*]0EQI$OP"T4^);[55M#.8U6Q<&2
M8K)($C.[*[%5<X. /+7'( H"-6^ZZ7/::P=!UZ_U;5=9M+O0[G3X;"?RH+B7
M=MNUW.-ZY4<84'@G[P_'P2P>%/'?A*^TSPU?^'8KB[A"E[F21+E&=061G4$@
MJ^#@D$,.!DYZ[0?^:P_]O'_MS3$JK;_KL>UT5\_:-\/K'4_@]=^(;JZFDOUM
MI9;0N6*6L<+NS(J[L'>0^2>!OR!D$MZ=\*)I9OAEHS2R/(P65 78DA5E=5'/
M8   =@ *1<*CD[-=+G9T444&ASQ\=^$P2#XCTP$=?])7_&C_ (3SPE_T,>F?
M^!*_XUG'X4^"&8L=!C))R?WTO_Q5)_PJCP/_ - &/_O_ "__ !5!G^\\C2_X
M3SPE_P!#'IG_ ($K_C1_PGGA+_H8],_\"5_QK-_X51X'_P"@#'_W_E_^*H_X
M51X'_P"@#'_W_E_^*H#]YY&E_P )YX2_Z&/3/_ E?\:/^$\\)?\ 0QZ9_P"!
M*_XUF_\ "J/ _P#T 8_^_P#+_P#%4?\ "J/ _P#T 8_^_P#+_P#%4!^\\C2_
MX3SPE_T,>F?^!*_XT?\ ">>$O^ACTS_P)7_&LW_A5'@?_H Q_P#?^7_XJC_A
M5'@?_H Q_P#?^7_XJ@/WGD:7_">>$O\ H8],_P# E?\ &C_A//"7_0QZ9_X$
MK_C6;_PJCP/_ - &/_O_ "__ !5'_"J/ _\ T 8_^_\ +_\ %4!^\\C2_P"$
M\\)?]#'IG_@2O^-'_">>$O\ H8],_P# E?\ &LW_ (51X'_Z ,?_ '_E_P#B
MJ/\ A5'@?_H Q_\ ?^7_ .*H#]YY&E_PGGA+_H8],_\  E?\:/\ A//"7_0Q
MZ9_X$K_C6;_PJCP/_P! &/\ [_R__%4?\*H\#_\ 0!C_ ._\O_Q5 ?O/(TO^
M$\\)?]#'IG_@2O\ C1_PGGA+_H8],_\  E?\:S?^%4>!_P#H Q_]_P"7_P"*
MH_X51X'_ .@#'_W_ )?_ (J@/WGD:7_">>$O^ACTS_P)7_&C_A//"7_0QZ9_
MX$K_ (UF_P#"J/ __0!C_P"_\O\ \51_PJCP/_T 8_\ O_+_ /%4!^\\C2_X
M3SPE_P!#'IG_ ($K_C1_PGGA+_H8],_\"5_QK-_X51X'_P"@#'_W_E_^*H_X
M51X'_P"@#'_W_E_^*H#]YY&E_P )YX2_Z&/3/_ E?\:/^$\\)?\ 0QZ9_P"!
M*_XUF_\ "J/ _P#T 8_^_P#+_P#%4?\ "J/ _P#T 8_^_P#+_P#%4!^\\C2_
MX3SPE_T,>F?^!*_XT?\ ">>$O^ACTS_P)7_&LW_A5'@?_H Q_P#?^7_XJC_A
M5'@?_H Q_P#?^7_XJ@/WGD:7_">>$O\ H8],_P# E?\ &C_A//"7_0QZ9_X$
MK_C6-+\-/A]#GS-)MEQU!N9/_BJRKSPA\.K?*PZ#'.X]+B15'XEJ3E%;D2J2
MCNT==_PGGA+_ *&/3/\ P)7_ !K)U'XH^'+9S%9ZC:7+CJ_G (/Q[UQ4G@SP
MO.SR1Z7!#&.H260A?Q+5EW'A/PX3B&P( [AVY_,UFZB>Q@\3)Z(ZF]^*JL=E
MOJ.G)G^)7! _.L&;Q18W#L\VLV[.YRQ$H&?QK,'A'12?^// _P!]O\:=_P (
MGH0X%D"?^NC?XU+<7N92E*6Y,^IZ&>3JEOD^DHI(]4T.-MRZA:D^K2BFIX1T
M/^*P'_?QO\:E_P"$/\/D<6:*?=V_QI>Z3=DPUO1V'.KV8/O)2?VUI*L"-6LB
M/:85!_PANB?\^49'M(W^-/3PAH.X Z6I&>29'_QH]T+F+X&E*V>HE!NW760?
MPKK3%,0LLA"KD87N>:YKX?R_9['4T2,'%WQGMQ7522&5=S=<C^=17VD53^)'
M1WW_ ""4_P ]JXS1WN/L4JI(%3[1)CCWKL[_ /Y!"?Y[5R6B;#IK@]?/D_G7
MEY?NSMQ7P$XMF8Y?YCZXJ9+<Q\A:>+@1L ?F'ZU;^T1[?_K5ZEV>>VRK@8I5
MC#"GRLI&Y0:K"["'G- $WD$\=JHW6DRL-]N[ _W2:U;>XCE&,\U8)"K2NT+F
M:9C627/V?#L5D4XYJ5;JYB<$,VX'TK2MW RAP>>,U'.J^8"C%"?3BBX7U.BT
M;Q?B)8;]'XX$@&3^-==!<17,0E@D5T/0J:\KD2;'^O<CWIVF:U?:-=[TD\V%
MC\\3=_\ Z]:PJ-;G32KM:2V/5JXW7_BEX5\/7#6T]\UU=(VUX+-/-9#[]A^=
M<%\4/B'J4T*Z7I"RVMA-'^_NU.&D)ZQJ1]W'<]37D42A<!1@4Y54MCVL-A?:
MQYV]#H/&&L6_BCQ3J&LVRS103;-BSKAAM0#H/<&N;W>E;]]J%O+X?@LDM4%Q
M&^1,!\[9[?3VKW/1_A'X2L3'<2V,MW(5!VW<I=5/^[P#^-91BYNYVU*L<.E$
M\B\!?#R^\8WJ3W"26VC1G,LY&#-_L1YZY[GH*^EK6VALK6*UMHUB@A0)&BC
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<("<[=N: ,^2$^63P7SDFI+6":=0WW$/\1ZGZ5=6Q4G,KF3VQ@5:  & , 4
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MP/ \2(/^ G_"DX+N0T=V;=-N326NV.4J!UKC!HOC,C'_  E"?]\G_"HQHGC
M28_X2= ?7:?\*GE7<5CT48S5'4(AL#XY'6N3'A_QN4W#Q5'_ -\G_"HV\/\
MC212&\41MZC:?\*.5=R4K/<Z:V(28$=#6LR&1<J?F_G7G4>@>+_,V#Q&B\]U
M/^%7/[!\;J<?\)6@_P" G_"AQ7<<D=TOW 2,'H172^&YQY<L&>AW ?SKQF73
M/&D1PWBE?^^3_A5VTTCQTH$UOXQC7/!(0\?^.U44HN]RZ4O9S4CW>BO*E\'_
M !-=0R^.X2I&01&>?_':7_A#?B=_T/4/_?L__$UTGI\[['JE%>5_\(;\3O\
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M'_OV?_B:/^$-^)W_ $/4/_?L_P#Q- <[_E/5**\K_P"$-^)W_0]0_P#?L_\
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M',?O$88>XZU:K!\.W(*R0$\_>']:WJZX2O&YZU&?/!,****HU"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH IW<95Q,!D8P^/3UJO*R!8SN'+ @UJ4Q8HU8LL:@GJ0* *]K&3(9B
M"!C:N?YU;HHH **** "BBB@ HHHH H3)LNFSTDY'U[U&P'GCT523[5H21I*N
MUUR*C%G;@Y\O)]R3F@"*SCRS3$<$87Z>M7*** "BBB@ HHHH **** "BBB@
MK'U[4OLEMY$1_?RC'^Z.YK5EE2"%Y9#A$&2:X&^NGN[B2X?JQX'H.PK*K*RL
M<V)J\D;+=E<HCQ%3SUK'N;%%.-V,FM*2988\N<9Z#N:S9V>6Z3/ /:N='GQN
M/MK6+?SSBM(*H7ITJ&",(N:L%28RWM0Q-W(@OGDD?+COZU7DW*2K#&>]6 _E
MK@4_ D3YAFHE%,11^SY3IFECF:'Y).4Z ^E3,K1_=RP].]5+J9(T)?CV/>I5
MTP;+CR(D>XL,5ERWK,YP<*.@K"GNYA,65R/;M4L-ZLORO\K^G8ULD5"S+4\A
MD-1C@9IC-36?Y*LWL-,F&J3.]:J\LU3IE>#0.Q&P :D+ <TZ8<9%5R:8T3/-
MNX XJ-I"1BD3D4UA@T ).S?991GJAJ./_CP_ 4Z;)MY /[IJ&*538@ ]1657
MH>'G*=X%?1GV:K>'UC4?K6CJ$Q;3KH?],G_D:R=).[4;UNP51_.M*Z0R6DT:
MXW.C*,GN16D=D>IA5^YCZ&=X9_Y 4/\ O-_.M@#UK-T6UEL=,CMYMN]22=IR
M.36L%4CFJEN;K1!Y?<&G*L8/S4GF+&IP*K&4LU(9H*(NU6$=0.*R5D/K4B3'
M/6E83B;-I)BX^M:C;77@X(KG;>?9*&K0-YSE34M&<HZEHW&U]A/S?SJ"2=U?
M-5IF\WGO4T$F\;9!^-%A6-RRN/-A [BIWC#'(X-4[)$7H:T!Z5#,GN5_)!<-
MW'6I",Y'<=*;(WE!B:SY[]ARH(QWHM<$FR:XA+,<\CJ*DM4,!R!\K<$56M[L
MSKC@MZ5=MY0<QL,'T-,;OL=CX<O!-9F M\T1X!]*VJ\^CDD@G$L+E&]0>AKI
MM.UPR;8KQ0KG@2#H?KZ5M3J*UF=M#$1LH2-NBBBMSM"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \2\4:K<> OC8WB"\29M
M,U&VPPMXPS2((PA3+8&X2(C'!Z%?7%;&K_''3(=1CL] TFYUAG8('W&$.QQM
M"+M9F))(P5'(XSFO3KRRM=0M7M;VVAN;=\;XIHPZ-@Y&0>#R ?PJK8:!HVE3
MM/IVD6%G,R[#);VR1L5R#C*@'&0./:@RY))^Z]#RMO$6E>&?CUXBO=8NOLUN
M]E'$K^6SY8I 0,*">BG\JHZKXH/Q$^*'AJ'0+2::RTJY69Y&CVDJ)5,DAYX3
M:B8R <G&,D"O7[OPUH.H73W5[HFFW-P^-\LUHCNV!@9)&3P /PJ;3]&TO2/,
M_LW3;.R\W'F?9H%CWXSC.T#.,G\S0+V<MKZ7N<%XH\>>$-0&N>'?$%C>PFRB
MDRT]O'N9_N*8,DG>0^Y6P!C+$@9K!^'5IXNN_A9Y?A[4$L;D:J[127BDQFW\
ML;@F488\PD\#J&YSFO6+_0-&U6=9]1TBPO)E78)+BV21@N2<98$XR3Q[U>AA
MBMH(X((DBAB4)''&H544#   X  [4#Y&Y7;/'?&GB7QCX.\%QZ?JVJPSZUJ5
MS(([RU0 16RHFX A4VON;@[3P3R#C!\/?$/P_P#!&D21GQ#Y^H76UKN46L^S
M*YPJ#9]T;CSU.23C@#UC4-&TO5O+_M+3;.]\K/E_:8%DV9QG&X'&<#\JH_\
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MC4M:N510 6:W=F/'<DDD]R2:V_B5#%;>,?AS!!$D4,6H;(XXU"JBB2   #@
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M2NT39!RI(^4Y Y'H*0_9.S7>WX%JBBB@V"BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%%%%6;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY;Q5=.9X;13\@7>P]3VJ9RY5<SJU.2',<[+*TMP[G[TCEC^)IA39M8<Y;FI
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M "BBB@ IDDT4./-D1,]-S8S3ZP/$WW+;ZM_2@#=21)5W1NKJ>ZG(IU9F@?\
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M+;Q;>6WAJ;09;>&ZM),[?-SNCSZ?0\BN?4<4F3*S=SI? _\ R.6E_P#74_\
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MB@ HHHH *P/$WW+;ZM_2M^L#Q-]RV^K?TH N:!_R"8_]YOYUIUF:!_R"8_\
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M[UF6-^8R%S@G_P"O4*+5F=_UBE6<X6MS=;]MO0T-$@D71;BX$B1RW *1O(<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!,48SUI:*
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M%%% !1110 4444 %%%% !1110 4F*6B@!",]:0H">E.HH C,2GM33 G:IJ*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBB@ HHHH **** "BBB@ HK"\1^(_[ ^S?Z+Y_G[O^6FW;MQ['UK#_P"%B_\
M4*_\F/\ [&NB&%JU(\T5I\C">*I0ERR>OS.YHKA1\1OWB Z5\A8;R+CD#/)
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M1X9_LO[1_:/D_P"D?:-GE^9*8_N[3G&,]1FNXJI0<4F^HDT]@HHHJ1A1110
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M8/L7E7+6_E^=YF<*K9SM'][ICM5.G))MK82DF=51114%!1110 4444 %%%%
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MI5T-0G4A%KI_F9IRC&33ZGKGB/Q'IOA;1IM4U2;RX(^%5>7E<]$0=V./T).
M"1Y<WQZEE2\N;+PA<SV-JP#W!NB BL<(7Q&0A;TR>> 34'[0\TJP>'H!*XA=
MKAVC#':S*(P"1T) 9L'MN/K7K?A_1XM \/:?I,)0K:0+$72,()& ^9]HZ%CE
MCUY)Y-<RC"%-2DKMFC<I2:3M8X?0/C!9>)/&]KH&GZ8YM;E2RWDDVUE(A,C
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M8^]\GWNOY5H^,II;G]GB.>>5Y9I-.L'DDD8LSL6B)))Y))[UL_!__DEFC?\
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MJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI661%%V @(;D +MP/3&.*?LXJ4))6=UI>XN=M-;Z&EX3_P"3<;C_ +!FH?\
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M9RA=W6YV4,4J<73FKQ9\[^,_B7JOBZ'['Y:6.FA@QMXW+-(0!_K&XW $$@
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M%IES<R8WS36D;NV  ,DC)X 'X4]_#^BR3VL[Z/I[36BHEM(;9"T*H<J$.,J
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M&=8AOFA)RDD8W!>61<\G'S#J.-WXJ?$BP\5Z,=&\/+>SV\,JW%W=A62-HQ@
M%>I7>Z\L  RKC.0:]TU#2]/U:!8-2L;:\A5MZQW,*R*&P1D!@1G!//O56+PQ
MX?@M;BUAT+3([>YV^?$EI&$EVG*[AC#8/(STJ_;P<E.2U1/LW9Q3T.<^#_\
MR2S1O^V__H^2O!OB+H,_A'QYJ$$!\B"YWW%L8 (QY,NX% %/"C+QXXR!TP:^
MG[A]/\,>'KF>&S2"QL())S!:QJH"J"[!5X&3SZ<FOGSQ1<_\+;^*%M;Z%!,+
M5(DMC<E,XB5V+3E3C:HWG )R< <%MHO#S;J2GTUN*HO=4>IZS\']#;1?AW9M
M*KK-?NUZZLRL 'P$QCH"BH<'G)/3H.\J.""*VMXX((DBAB4)''&H544#   X
M  [5)7).3E)R?4V2LK&-XO\ ^1*U[_L'7'_HMJ\:^!W_ ".MY_V#G_\ 1D=>
M]S0Q7$$D$\:2Q2*4>-U#*RD8((/4$52L="T?3)VGT_2K&TE9=ADM[=(V*Y!Q
MD#ID#\JRE&\DSKI8A0HRIM;G*_%/PB_B?PV)[09O].WS1*%9C*F/GC '\1PI
M'!Y4#C)->6_"OQC_ ,(YX@%G?7?E:1>963S'Q'%)_#)T..FTG@8().%%?1E8
MO_"(>&0,#PYI&/3[#'_\32E"\N9%4L2HTG2FKI_@>)?%W2]2\-_$>V\70Q>;
M;S2P3Q2.G[M)H@!Y;8.>1&&[9!('W2:[+4OCMX<CT;SM.BO9-0EBD\J&6 8A
MD'">;\P!4G!^0DXSG!KU&>"*YMY()XDEAE4I)'(H974C!!!X(([5C_\ "%^%
M?^A9T;_P B_^)KL]K"44IK8\_DDF^5[F5\.]=\3^)-&DU3Q!8V5G!/M-DL".
MKNG.78,Q^4_+MZ9Y/0@GQOPWJEQ\'?B#J%GK-O>S64D31_NL+YR;LQS*A;:W
M0C[WR[F&<@@_2M5-0TO3]6@6#4K&VO(5;>L=S"LBAL$9 8$9P3S[THU4F[K1
M@X-I:ZH\/\=_$;4/%^NZ?H/@2ZU#&[F6U9H6N7(X Z,J*-V22!R21A0U;'QC
M\(ZE/X(T2ZCGFU"71(C'=R%,O(A10TS98G@Q@D<_>))PI->HZ?X>T32;AKC3
M='T^SF9=ADMK9(V*Y!QE0#C(''L*TJ?ME%QY%L')=/FZGC'@[XS:#IG@FTL]
M62Z6^T^". 1009$Z@[5V$MC(0*6W%><XSTK9\">//$_C;Q)=/#IME%X9@ED!
MN7C=92.?+0'>5+\J6P, 9Z97/:S>$?#5S/)//X>TF6:5B\DCV4;,[$Y))*Y)
M)[UI6=E::=:):6-K#:VT>=D,$81%R<G ' Y)/XTI3IV?+'5@HRZL^<O'>HW6
MD?':[U.SBFEELY8+AHX6*L\:0(S@D X4H&R<8QG/%=CXK^-'AO4?!EY9V$-[
M+>:A:S6_DR1A/(W#9EVR1T)8!=V<8.W-4?\ FZ;_ #_SY5ZQ#X1\-6T\<\'A
M[28IHF#QR1V4:LC Y!!"\$'O6U24$H<ROHB(*3YK/J</\#O#4NC^%)M6N0Z3
M:LRND;9&(4R$." <L68YR05*D=ZX?PQXHTOPI\:O$UYJ\KPVL\]Y!YJQEPC&
M<,,@<X^0C@'DCMDCZ)K*O/#'A_4+M[N]T+3+FYDQOFFM(W=L  9)&3P /PK)
M5TY2<UN4Z>B2Z'BOQITN?6K31/&ME%,VFW-C&D@9!FW#$NA?!/WO,(] 5 S\
MPKJO^%\^&_["^U_9+W^T?N_8=H^]MSGS.FS=\N?O=]E>I0PQ6T$<$$210Q*$
MCCC4*J*!@  <  =JQO\ A"_"O_0LZ-_X 1?_ !-"JP<5&:V'R23O%[GDWP"\
M.7D=Y?>(Y4>*S> VEON3B8EP68'.<*4 Z8)8\Y4BI/AM_P EV\7_ /;Y_P"E
M*5[C5&VT72K*_FO[73+."\GW>;<10*LDF3D[F R<D9.>]#K\SDVMQ>SM:W0O
M4445SFH5\T?"G_DI>D?]MO\ T2]?2]9EIX<T.PN4N;/1M.M[A,[)8;5$9<C!
MP0,C@D5$H\S3['50Q"I0G%KXE_F:=%%%6<IP?Q>\.7OB3P*\6GH\MS9SK=+!
M&FYI@ RLHYZX<MQDG;@#)KBOAW\7]&T?PC#I.N&]6XL8I/*E \T3J#E$'=6P
M=H!^4!1\PZ#W&LJ\\,>']0NGNKW0M,N;B3&^:>TC=VP,#)(R> !^%;0J1Y.2
M:T(<7?FB>3_#34_%/C7X@7?B"XOM0AT.!I&^S&8F#<R[4A RJDJK!BP4_=!.
M"P-<AH%Y<?"#XF7$>K6TTML(I(&=8AOFA)RDD8W <LBYY./F'4<?2MG96FG6
MB6MC:PVMM'G9#!&$1<G)P!P,DD_C4>H:7I^K0+!J5C;7D*MO6.YA610V",X8
M$9P3S[U?UA7>FCT)]F[;ZGE?B7XX6V^.R\'VSZA?-.B*\]LQBE5@>$4,KE]Q
M48*^O7BM7X@R:O+\$+^37H;:'5'6%IXK4DQH3<)@#)/(& >2,YP2,5VMGX8\
M/Z?=I=V6A:9;7,>=DT-I&CKD8."!D<$C\:O7EE:ZC:O:WMM#<V\F-\,\8=&P
M<C(/!Y /X5/M()QY5L/EDT[L\R\)_P#)N-Q_V#-0_P#0IJ/@%_R(E]_V$Y/_
M $5%7I,6F:?;Z:=-AL;:.Q*LAMDA41%6SN&T#&#DY&.<FC3],T_28&@TVQMK
M.%FWM';0K&I; &<* ,X Y]J)54XR5MW<%"S3[%NBBBL#0**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "L/_A"_"O_ $+.C?\ @!%_\36Y133:
MV"R9'!!%;6\<$$210Q*$CCC4*J*!@  <  =JDHHI %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4R:&*Y@D@GB26&52DD<BAE=2,$$'@@CM3Z*
M*FGZ9I^DP-!IMC;6<+-O:.VA6-2V ,X4 9P!S[5;HHHO< HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M&30Q7,$D$\22PRJ4DCD4,KJ1@@@\$$=JJ:=HNE:/YG]F:9967FX\S[- L>_&
M<9V@9QD_F:O44[O8 HHHI %%%% !1110 4444 %%%% !1110 4444 4?[%TK
M^U?[5_LRS_M'_G[\A?-^[M^_C/W>.O3BKU%%-ML HHHI %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% #)98X8GEE=8XT4L[N<!0.I
M)["L-_&WAY)'0ZB"48J2L,A!(]"%P1[C@U@^.)[R_P!;T[P_ 9$AGV/(4&_<
M6<@$J.<)M+=<<Y.-H-;UIX+T&TMY(A8B4RQA)))G+,< C(Y^0G)Y7;^@H T]
M,U2RUBS^U6$XFAW%"=I4@CJ"" 1Z\CH0>A%7*X_2?"E_HOBE[JRN8X])<D-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 1W$$=U;2V\R[HI4*.N2,@C!&1533-&T_1XY$L+9
M81(VYSN+$XZ<DDX]O<^M7Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
B*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gaz3apgusshz000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gaz3apgusshz000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +N!Y\# 2(  A$! Q$!_\0
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M_P#']-_O57IB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQE&)212* .>HK5\26T-IXAO(+>,1Q(^%5>@K*H **** "BBB@ KH$_Y%&?\
MZZ)7/UT"?\BC/_UT2@#GZ*** "BBB@ HHHH **** "BBB@"9+.YD4,EM,RGH
M50D&G?8;S_GUG_[]FO2+/5GT7P#:7D<2R,J@;6.!R:HZ=\0);R]CM[BQ18WX
MS'EC^5 ' B"5I/+6)S)_="G/Y4UT>-BKJRL.H88(KU22Q@M?'%E+#&%::%V;
M'<US.L^'=1UCQ-J#6L0VK)U<[0>* ./HK2U70K_1V47<8&[H5.1^=/TOP]J.
ML*S6D0VKW<[10!E45T-WX,UBSA,LL<6T#)VOFLK3]+NM4N?(M8]S>IX _&@"
MG1722^!M;AB:1HHBJC)Q)DUC6FF7=[=_9H8CYG<,,8H J45T4_@G6;> RO%$
M5 R=KY-<\RLC%6!!'4&@!*DC@FE!,<3N%ZE5)Q5W1-,.KZFEH'V;@23]*]/T
MK3;'2])N[:T8/(L9$K\9)P>M 'C]%.?[[?6FT %%%% !1110 4444 %36G_'
MY!_UT7^=0U-:?\?D'_71?YT :GBG_D.3_6L6MKQ3_P AR?ZUBT %%%% !111
M0 4444 %%%% #HXWE;;&C.WHHR:F^P7G_/I/_P!^S6YX%_Y&B'_<;^5='K7C
MJYTO5KBS2RA=8FP&9CDT >>R6UQ$NZ2"5!ZLA%)'!-*"8XG<+U*J3BO4K6_M
M_%>@W#W%J%9%)((.,XSP3UK)\!C_ (EFK*!Z@?\ ?)H \_HKH+;P?J]_#]HA
MB0(W(WOM/Y5EW.EW=K??8Y8F\[., 9!H IT5TJ>!-;DC#B.'!&>9*R-1TF[T
MN8172 .W3:<YH HT5OV7@[6+^V6>&) C#(WOM/Y53U70;_1RHNXP W0H<C\Z
M ,RBM/2]!O\ 5R?LD8('=C@5/J/A;5-+A\VXB79_L-NH Q:?'#+*<1QN_P#N
MJ33*]#\/SZ9HOAH:A)Y;3L!E0<MGZ4 <&UG=(,M;3 >IC-05Z?H?BI?$<[V5
MU9JFX';MR1CWKA/$5I'9:[=6\*A8T;  H RZ*** "BBB@ HHHH **** -_0/
M^/2Z^G]*P6^\?K6]H'_'I=?3^E8+?>/UH 2BBB@ HHHH **** "G)&\K;8T9
MV]%&33:Z3P-_R-$/^XU &']@O/\ GTG_ ._9IDEM<1+ND@E0>K(17H>M^.KG
M2M6GLTLHG6)L!F8Y-7K2_M_%>A7#7%J%=%R00<9QG@GK0!Y;'!-*"8XG<#J5
M4G%1UZ!X#'_$NU90/4 ?\!-8%MX/U>_B-Q#$@1CD;VVG\J .>HJY<Z7=VE[]
MDEB/G9Q@#(-;,?@36Y(PZQPX(SS)0!S5%7M1TF[TN98KI &;IM.<UHV7@[6+
M^V6>&) C#(WOM/Y4 8%%:>JZ#?Z.5%W& &Z%#D4:7H-_JY/V2,$#NQP* ,RB
MMK4?"NJ:7#YMQ$FS_8;=6+0 ^.&67_5Q._\ NJ34ALKI1EK:8#U,9KKO#WB#
M1M'TL#RF:](Y^0X)^M='H>NW.O&6.\T\0Q#C)!Y'XT >48). .?2E=&C8JZE
M6'4$8-=Q:6.GQ>);R)K:U-K&^0[O@K@9X'>D\5+8S1K=VD-M*96!>1GPXYZ8
M]* .($;E"X1BHZL!P*;7IMG%I(TK[++#:12SC>T2/E21TR<UY]JBA-1F4111
M 'A(FRH^AH IT444 %%%% !1110 =J[KX7?=U/\ ZZ+_ "KA>U=U\+ONZG_U
MT7^5 'C%%%%=AS!1110 4444 >K?"[_D4O$'X_\ HLU8^$+*FA:NS_<64%OI
MMJO\+O\ D4O$'X_^BS1\+_\ D4_$'X_^BS6,NIJNA>A^)=E#KB:;#:(MFS>7
MYBYSD\#C\:P_B7I-G;^*M,$$*H;PYEP/O'<!7!:7_P A>S_Z[I_Z$*])^*KB
M/Q/H4C<!5R?P<57*HR5A7NM3H==UJW\ :);P6=K$\Q PC$@$9P3Q5S1-<AU_
MPI?7B0I%,T#&94.0&VFLWQGX<?QEIEK>:88I+A5 7<X VD\\U;\->'6\.^$+
MZ"79]IDA9I@C9 8*:STMYE:W\CG-<_Y(EIO_ &R_F:I_"S3+22"_U6YB5S:D
M@$CH-N?Z5<US_DB6F_\ ;+^9J+X4W,+:=JFFR2*CW)XR>VW%5]ED_:1HVWQ6
MTN>ZN(+V QV>2(G1"688[CM7%6=]H<WCV>\FBEETUF+QJL19L\8^7ZUT%O\
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M(9(D'RDC[PR14]/(K\RQX,\91^*-1?[39PP7: B/82<KCGK6'HO_ "6W4/\
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M#.8, EAWZT 4]4D7PYX1CM4(,S*%.3@D=Z\T[UU/CG45O=9\E?\ EWRE<M0
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MY7^8H ] \0ZU;:-%'-)$LDVWY :J6>I6OBS0;DSVZ[HE)9<' ."1BL+XD?\
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M(>I;UJO10(O:GK.HZS)&^HW<ERT8VH7/051HHH **** "BBB@ HHHH ****
M"BBB@#T2_P#^17\.?]>A_P#0JR*U[_\ Y%?PY_UZ'_T*LBN26YT+8****0PH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH D@*+/&9!
MF,,"P]L\UZ$WB_0;'3Y(=+B:-F7 'ED#I7G-% $DTTEQ,TLK%G8Y)/>HZ**
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M/^/2Z^G]*P6^\?K0 E%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !VKNOA=]W4_P#KHO\
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MF_[Y%'M(AR,\MHKU+_A4B?\ /]-_WR*/^%2)_P _TW_?(H]I$.1GEM%>I?\
M"I$_Y_IO^^11_P *D3_G^F_[Y%'M(AR,\MHKU+_A4B?\_P!-_P!\BC_A4B?\
M_P!-_P!\BCVD0Y&>6T5ZE_PJ1/\ G^F_[Y%'_"I$_P"?Z;_OD4>TB'(SRVBO
M4O\ A4B?\_TW_?(H_P"%2)_S_3?]\BCVD0Y&>6T5ZE_PJ1/^?Z;_ +Y%'_"I
M$_Y_IO\ OD4>TB'(SRVBO4O^%2)_S_3?]\BC_A4B?\_TW_?(H]I$.1GEM%>I
M?\*D3_G^F_[Y%'_"I$_Y_IO^^11[2(<C/+:*]2_X5(G_ #_3?]\BC_A4B?\
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M]$_Z[)_.D]@6YUUI_P >L?TJ:H;3_CUC^E35D:A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!A?\ ,0N_]_\ I5A:K_\ ,0N_]_\ I5A:U6QDR6EI
MHIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% %>\_X]_Q%20_ZE?I4=Y_Q[_B*DA_U*_2@"2B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ JF?^0@OT-7*IG_D(+]#0!<HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *;)_JV^AIU-D_U;?0T 5[#_CU7Z5:JK8?\>J_2K5 !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!4N_P#61U;[54N_]9'5OM0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 !Z57TC_ (^KS_?'\JL'I5?2/^/J\_WQ_*E+8<=R>BBBJ$%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:0TII
M#0! ]8FN?\>B?]=D_G6V]8FN?\>B?]=D_G2>P+<ZZT_X]8_I4U0VG_'K']*F
MK(U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#"_YB%W_ +_]*L+5
M?_F(7?\ O_TJPM:K8R9(*=313J "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *]Y_Q[_B*DA_U
M*_2H[S_CW_$5)#_J5^E $E%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5,_\ (07Z&KE4
MS_R$%^AH N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %-D_U;?0TZFR?ZMOH: *]A_QZ
MK]*M55L/^/5?I5J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J7?^LCJWVJI=_ZR.K?
M:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH #TJOI'_'U>?[X_E5@]*KZ1_Q]7G^^/Y4
MI;#CN3T4450@HHHH **** "BBB@ KS7XF:[JVE:GI\.G7LMNLL1+!#U.[%>E
M5Y7\45W^)M#7^\,?^/BM\.DZFIAB&U#0ZO2=5NV\%K-<REKU82K.3R7(.#7'
M^ _$&N7OC 6.HZA--&(G+1N1C(%-O]1GLY=4TE9'#G4HA$ .B<9Q[4[PU"+;
MXO7D(Z()!^@K;D2C+3<Q<VY1\CU1;FW:8PK/&91U0.-P_"A;FW:8PK/&91U0
M.-P_"O,M%_Y+1J/_ &T_D*-%_P"2T:C_ -M/Y"L71\^ES95O+K8]/DFBA&99
M$0>K,!1'-%,NZ*1'7U5@:\]FO&U[XC/HUR6-G"D@:,CAB,$5U>D>'8]&N9GM
M[F3[.YREO@;8QCH*B4%%:O4N,W)Z+0UY)HH1F61$'JS 41RQS)OBD5U/=3D5
MY_<W9U[XB-HUP6-I#'(&C(X8C!!IOAV_ELO%>K>'X"WD1E_(7'RH O _,U7L
MM//<GVNOX'?27MK$^R2YA1O1I #4RLK#*D$>H->0"2*VU*\3Q+8R3R.^8K@1
MLYBX[8XZ\UZ)X6$(TE?L]_+>1X&'D !'X"B=+E5PA4YG8UY;B" 9FFCC'^VP
M'\Z@NKI&TVZEMYT9EA=E9&!P0#7-:U+I-QJYTVZ07]Q+EU@=<JF.V1TKE-#N
M[BT\6:OI 40VRP3$0H?E3"=!3C2NKBE5L['0_#+6-0UC3K^34+N2X:.954N>
M@Q7=UYO\'_\ D%:E_P!=U_\ 0:](I5TE4:15!MTTV%%%%8FHAI#2FD- $#UB
M:Y_QZ)_UV3^=;;UB:Y_QZ)_UV3^=)[ MSKK3_CUC^E35#:?\>L?TJ:LC4***
M* "BBB@ HHI"0H))  Y)- "T54_M33O^?^U_[_+_ (U)%>VLYQ#<PR'_ &)
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M_4'_ '\%'VZS_P"?J#_OX*^:?MUS_P ]FH^W7/\ SV:CZGYA];\CZ6^W6?\
MS]0?]_!1]NL_^?J#_OX*^:?MUS_SV:C[=<_\]FH^I^8?6_(^EOMUG_S]0?\
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MZ"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 'C7&UV7Q,_Y&VX_WC7&U[E#^&CQ:W\1A1116ID%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &SX;
MU^YT#4DGA8^63ATSP?>OH'3-0AU33X;N!LI(N17S+7K7PIU9I+6>QE;.PCRQ
MZ#%<F*IIQYT=6%J-2Y6>F4445YQZ 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %-D_U;?0TZFR?ZMOH: *]A_P >J_2K55;#_CU7
MZ5:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** *EW_K(ZM]JJ7?^LCJWVH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU7Z5:JK8?\>J_2K5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK3_CUC^E35#:?\>L?TJ:LC4**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /GSXF?\ (VW'^\:XVNR^)G_(VW'^\:XVO<H?PT>+6_B,****U,@HHHH
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M^E6JJV'_ !ZK]*M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_J5^E $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !5,_\A!?H:N53/\ R$%^AH N4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2IJAM/\ CUC^E35D:A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A
M?\Q"[_W_ .E6%JO_ ,Q"[_W_ .E6%K5;&3)!3J:*=0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!7O/\ CW_$5)#_ *E?I4=Y_P >_P"(J2'_ %*_2@"2BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ JF?^0@OT-7*IG_D(+]#0!<HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;)_
MJV^AIU-D_P!6WT- %>P_X]5^E6JJV'_'JOTJU0 4444 %%%% !1110 4444
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MY[_6@":BH3"Y##SF&3D'TH,3Y)\YN?TH FHJ(1."#YS' Q2"%P%'GN<#GWH
MFHJ'R7QCSVZT&%R6_?,,G(]J )J*A\I\Y\YJ!"_R_OFX&#[T 345#Y,F //?
MZT&%R&'GL,G(]J )J*A\I\D^<W/;TH$3@@^<QP,8]: )J*A$,@"_OW.!S[T>
M3)C_ %[=<T 34V3_ %;?0U&87);]\PR<CVI'B<*Q\UB-IXH 98?\>J_2K54;
M.-F@C(D8 #&!WJQY,F //?ZT 345"87(8><PR<@^E'E/DGSFY_2@":BH1$X(
M/G,<#&/6@0R +^_<X'/O0!-14/DR8QY[=<T&%R6_?,,G(]J )J*A\I\Y\YJ/
M)?Y?WS<#!]Z )J*A\F3 'GO]:#"Y##SF&3D'TH FHJ'RGR3YS<_I2B)P0?.8
MX&/K0!+14(AD 7]^YQU]Z/)?&//;KF@":BH3"Y+?OF&3D>U'E/G_ %S4 345
M#Y+_ "_OFX&#[T>3)@#SW^M $U%0F%R&'GN,G(/I1Y3Y)\YN?TH FHJ$1."#
MYS' Q0(9 %'GN<=?>@":BH3#)@CSWY.<TIB<ECYS#)X'I0!+14/E/G/G-TH$
M+@+^^8X&#[T 345#Y+XQYS4>2_S?OFY.1[4 345#Y3Y/[YJ!"X*GSF.!@^]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O>?\
M'O\ B*DA_P!2OTJ.\_X]_P 14D/^I7Z4 24444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M4S_R$%^AJY5,_P#(07Z&@"Y1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %-D_U;?0TZFR?ZMOH: *]A_QZK]*M55L/^/5?I5J@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH J7?^LCJWVJI=_ZR.K?:@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH #TJOI'_'U>?[X_E5@]*KZ1_Q]7G^^/Y4I;#CN3T4450CC/BC_P B7)_U
MWC_G6+\,V_L^QE5Y,?:5,X!/916U\4?^1+D_Z[Q_SKCGDDTG2] U"-<I)I\D
M#'_:<D"NRFN:ER]V<E1VJ\W9&3KT9/C.&\W[EN[A9%/MN KVK6=9L]"T\WU\
MSK"&"DHN3D]*\>UJS:R/A*-QB3REW#W\RN^^*"EO!D@4$GSX^@]Z=5*3@A4V
MXJ;-JX\4:9:^'XM;E>064N-I"?-STXJ[9:G:W^EQ:C"Y%O*F]6<8.*\XUMA_
MPIC3AD9_=\9]S5Z>6YB^$%@UJ,R&-0?IDYK+V2M\[&BJN^O:YT__  F&D_:U
MM]\V6Z2>6=A_X%TK4NM0MK.U^T32@1GH<]:YOPQ9:9=>!-+2_CA:,QJQ\QL#
M<"<?C6-\0C)%/I%O;HOV$R)N(/ .\8I*$7/E0W.2AS,[#3?$FG:I</! TBR(
M<;94V9^F>M:LDB11L[L%51DDFO.O%YDMO&NBG3T4N8B& /;<,UT/CV6YB\*S
MM:C,A90?ISFDZ:O&W4:J.TK]"Q_PF&D_:UM]\V6Z2>6=A_X%TI^J^*]+T>ZM
M;>[DD\RZ_P!5L3<#SCK]:S/#%EIEWX%TM+^.%HS&K'S&P-P)Q^-<Q\1HDC\1
M>'Q"H$*@ ;>@^<54:<)3Y295)*',=YK'BC3-#O;:TO7D66Y_U85,CKBL_P :
M^*_^$;L5\J%Y+F3E,J=@'0Y;L:Y7XF,#XJT'!!QC./\ ?%=!\4?^1+D_Z[Q_
MSHC3C>%^H2J2M.W0T/"WB2/6/#\=W-YBRQ@"4NI +?[)/6E/C725NS;.+I&!
MQO> A,_7I63I^HVNE?##3KN[B\V-8EVK@GYLG%8/BFYO-3\ 0ZK,XB65T9(5
M;(ZG\::IQE)]KV$ZC4?.UST35-=L='TO^T;IV^S;@NY%W=>E5/\ A+])^R6M
MR7E$-R 8V\OCKCGTKB]==I/@U8.Y)8^7DGZFH]714^#>GR* ')B.?Q-$:4;*
M_>P.K*[MVN>H"YA-M]HWCRL;MV>U8D'C/2+B^^R(\P;. [1$(?HW2N;NKBZ'
MPCLI8,M*T:AC[9.:QX++7=3\$V%M#96$=NNQTN'N=K'!R,@]*4:4;:OK8<JL
MKZ+I<]3N[ZWL;?SYY J>N>M4=-\2:=JEP\$#2+(AQME39GZ9ZUP?BYM2CLM
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &%_P Q"[_W_P"E6%KE-<UV?3=9N8XT!!?N
M:H#QC=C_ )8K_P!]&NZ&$J2BI(X9XNG&3BSOA3JX#_A,[S_GBO\ WT:7_A-+
MS_GBO_?1J_J54GZ[2.^HK@?^$TO/^>*_]]&C_A-+S_GBO_?1H^I50^NTCOJ*
MX'_A-+S_ )XK_P!]&C_A-+S_ )XK_P!]&CZE5#Z[2.^HK@?^$TO/^>*_]]&C
M_A-+S_GBO_?1H^I50^NTCOJ*X'_A-+S_ )XK_P!]&C_A-+S_ )XK_P!]&CZE
M5#Z[2.^HK@?^$TO/^>*_]]&C_A-+S_GBO_?1H^I50^NTCOJ*X'_A-+S_ )XK
M_P!]&C_A-+S_ )XK_P!]&CZE5#Z[2.^HK@?^$TO/^>*_]]&C_A-+S_GBO_?1
MH^I50^NTCOJ*X'_A-+S_ )XK_P!]&C_A-+S_ )XK_P!]&CZE5#Z[2.^HK@?^
M$TO/^>*_]]&C_A-+S_GBO_?1H^I50^NTCOJ*X>+QQ.,![6,CN=QK;T_Q397K
M"-F*2'L1Q^=9SPM6"NT7#$TI.R9NT4BLK#*D$'N#2USG0%%%% !1110 4444
M %%%% %>\_X]_P 14D/^I7Z5'>?\>_XBI(?]2OTH DHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *IG_D(+]#5RJ9_P"0@OT- %RBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ILG^
MK;Z&G4V3_5M]#0!7L/\ CU7Z5:JK8?\ 'JOTJU0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4 %%%% %2[_UD=6^U5+O_61U;[4 %%%% !1110 4444 %%%% !1110 4444
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M\JX+2-7F/B;[1-;FV2;)9<$ GH.M;WC*^>#3!#"Q\V0@@+U(SS15H-UTN_\
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MW'^\:PJW?%W_ "'[C_>-85?1X?\ A1/G<1_%D%%%%;F(4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 444<DX% !7?^$-.-M8FX<<RX*Y["
ML+0/#TM[,L\ZE81SSU->@1HL2!$&%'05YN-KJWLXGHX.@[^TD.HHHKS#T@HH
MHH **** "BBB@"O>?\>_XBI(?]2OTJ.\_P"/?\14D/\ J5^E $E%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !5,_\A!?H:N53/_(07Z&@"Y1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4V3_5M]#3J;)_JV^AH KV'_'JOTJU56P_X]5^E6J "BBB@ HHHH ****
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MG\Z3V!;G76G_ !ZQ_2IJAM/^/6/Z5-61J%%%% !1110 4444 %%%% !1110
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MV'_'JOTJU56P_P"/5?I5J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J7?^LCJWVJI=
M_P"LCJWVH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ****  ]*KZ1_Q]7G^^/Y58/2J^D?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 'I5?2/^/J\_WQ_*K!Z57TC_CZO/\ ?'\J
M4MAQW)Z***H04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 AI#2FD- $#UB:Y_QZ)_UV3^=;;UB:Y_QZ)_UV3^=)[ M
MSKK3_CUC^E35#:?\>L?TJ:LC4**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** ,+_F(7?^__ $JPM5_^8A=_[_\ 2K"UJMC)D@IU-%.H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH KWG_'O^(J2'_4K]*CO/^/?\14D/^I7Z4 24444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %4S_ ,A!?H:N53/_ "$%^AH N4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-
MD_U;?0TZFR?ZMOH: *]A_P >J_2K55;#_CU7Z5:H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** *EW_K(ZM]JJ7?^LCJWVH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*KZ1_Q
M]7G^^/Y58/2J^D?\?5Y_OC^5*6PX[DGFQ\?.O/3FCS8_^>B]<=:>-'M%5%$8
MP@P.*&T:T9&4QC!<.>.XI<X^4;YB#.77C@\]*/,3^^OKUJ1M)M7:1C&/WC;F
M^M TFU#;O+&=I7\#1SARD7FQG'SKR,CGK1YL?]]?SJ1=(M%$0$8_=(47CL:3
M^Q[3:%\L8!!HYPY1GFQ\_.O!P>>E+YB?WU_.GG2+1A*#&/WCAVX[BE.DVI9F
M\L9;K1SARD?F(2 '7D9'/:D\V/CYUYZ<U(NDVJNC",91"@^AI!H]HJHHC&$&
M!Q1SARC/-CQGS%ZXZTOF(,Y=>.#STIS:-:,C*8Q@N'/'<4YM)M6:1C&/WC;F
M^M'.'*1^8G]]?7K2>;&<?.O(R.>M2C2;4-N\L9VE?P-(ND6BB(",?ND*+QV-
M'.'*1^;'_?7\Z/-CY^=>#@\]*?\ V/:;0OEC (-*='M&$H,8_>.';ZBCG#E&
M>8G]]?SH\Q"0 Z\C(YJ0Z3:EF;RQENM"Z3:H\;B,91"@^AHYPY2+S8_[Z\^]
M'FQX)WKP<'FGC1[0*J^6,+TH;1[1D=3&,.X<_44<X<HWS$Y^=>.O-'F)_?7I
MGK4ATFU9G8QC+G)H72;575A&,JA0?0T<X<I%YL9QAUYY'/6CS8_[Z_G3UT>T
M58U$8Q&NU>.U!T>T*[?+&-P;\11SARC?,C&?G7@X//2CS$_OK^=/;2+5C*3&
M/WKAV^HI?[)M=Q;RQD@BCG#E(O,CX^=>1D<]::98\??7\ZF&D6JF(B,?NT*+
MQV-1G2+0(J^6,+TXHYPY2O)(F"=Z\'!YK$UQU^RH-PR)DSS[ULSZ7;%)%V##
MN'/U%86N6<2P;@.7F3/YT.0*)V-I)']FC&]<[<]:F\V,@$2)SR/F'-4;33H!
M#"^T9$90?0T]=*MD6)0HQ&NU?I4%EOS8\9\Q.N/O"CS8QG]XO!P>>E5#I5L5
MV[1C<&_$4K:9;L9B5'[UP[?44 6O-CSCS%_.CS8^/WB\C(YZBJW]FV^\MM&2
M"*1=,MU,1"C]U&8U^AH M>;'C/F)S_M"CS8P"3(G!P?F'6J@TJV"*NT87I0V
ME6SI(A48>02'ZB@"WYL>2/,7CKS1YL9.-Z],]:K-IMNS2,5&7.30NFVZNK!1
ME4*#Z&@"SYL9 (D3GD?,.:/-C_YZ)Z?>%5%TJV18E"C$:[5^E!TJV*[=HQN#
M?B* +?FQC.9%X.#STH\V/_GHOYU5;3+=C,2H_>N';ZBE_LVWWEMHR010!9\V
M/C]XO(R.>HH\V/&?,3G_ &A55=,MU,1"C]TAC7Z&D&E6P55VC"]* +?FQ@$F
M1.#@_,.#1YL>2/,7CKS51M*MG212HP[B0_44YM-MV:1BHRYR: +/FQDX#KTS
MUH\V,@$2)SR/F'-5ETVW5U8*,JA0?0TU=*MD6)0HQ&NU?I0!;\V/&?,3T^\*
M/-C&<R+P<'GI50Z5;%=NT8W!OQ%*VF6[&8E1^]<.WU% %KS8\X\Q?SH\V/C]
MXO(R.>HJM_9MON+;1D@BD73+=3$0H_=(47Z&@"UYL>,^8G/^T*/-C ),B<'!
M^8<&J@TJV"JNT87I0VE6SI(I48=PY^HH M^;'DCS%XZ\T>;&3C>O(SUJLVF6
M[,[%1ESDT+IMNKJP495"@^AH L^;&<8D3GD?,.:/-CQGS$]/O"JBZ5;(L2A1
MB-=J_2@Z5;%=NT8W!OQ% %OS8QG,B\'!YZ4>;'G&]?SJJVF6[&8E1^]<.WU%
M+_9EOO+;1D@B@"SYL?'[Q>1D<]11YL>,^8G/^T*JKI=NIB(4?ND*+]#2#2K8
M*J[1A>E %OS8P"3(G!P?F'6CS8\D>8O'7FJC:5;.DBE1AW#GZBG-IENS.Q49
M<Y- %GS8R<;UY&>M'FQG&)$YY'S#FJRZ;;JZL%&50H/H::NE6R+$H48C7:OT
MH M^;'C/F)Z?>%'FQC.9%X.#STJH=*MBNW:,;@WXBE;3+=FF)4?O7#M]10!D
M)=POJE\BN-R28/Y5>1D.,.O(R.>M4H],M%U"[80KN9^3Z\5<CT^V4QD1 >6I
M5?8&JYF3RHG!7&=Z<_[0I?EP3O3@X/S#@U$NGVP55$0PO2G-I]LRNIC!#N';
MW(Z4<S#E1)@<_.G'7YJ, G&].F?O4PV,#,[&,9<Y/O2K90*RL$&54H/H>M',
MPY4.^4XPZ<]/F'-)\H&?,3KC[PIBZ?;*L:B, 1KM7V%!TZV9-IC!&X-^(HYF
M'*B3 !(+IQU^;I1@?WT]?O4QK&!VD8H,R'<WN:464 ;=Y8SM*_@:.9ARH=P<
M?.G(R/F'-'RXSO3_ +Z%,6PMU$8$8 C4JOL#2?V?;;0OEC .:.9ARHDXY^=.
M#@_,.*,#.-Z<?[5,-A;L) 8Q^\<.WN11]A@+,VP9;K1S,.5#\ D .G(R/FH^
M7 .].>GS"F+8VZLC", HA1?8'K2#3[8*BB,808'M1S,.5$GR@9+IP<?>%& "
M073CK\W2HVT^V964QC#,&/U%*UC [2,4&9#N;W-',PY4/P/[Z>OWJ.#C#IR,
MCYAS318P!MWEC.TK^!I%L+=1&!& (U*K[ T<S#E0_P"7&=Z?]]"CCGYTX.#\
MPXJ/^S[;:%\L8!S2FPMV$@,8_>.';W(HYF'*A^!_?3_OJC ) #IR,CYAS3/L
M,!9FV#+=:%L;=71A& 40HI] >M',PY4/^7 .].>GS"D^4#)=.N/O"F#3[951
M1&,(, >E#:?;,K*8AAF#'ZBCF8<J), $@NG'7YNE&!_?3_OJF-8P,TC%!F0[
MF]S2BQMPV[RQG:5_ T<S#E0[@XPZ<C(^8<T?+_?3_OH4Q;"W41@1@"-2J^P-
M)_9]MMV^6, YHYF'*B3CGYTX.#\PXHP/[Z?]]4PV%NPD!C'[QP[>Y%'V& LS
M;!ENM',PY4/P"0 Z9(R/F%'RX!WIST^84Q;&W5T81@%$**?0'K2#3[9511&,
M(, >E',PY40:C(D5H79UP& .#4UN5:W4AUZ<_-TJ&^L+9K5E:)2K.&(]Q4D-
MA;>4<1CYSD^]',PY43X']]/^^J.#C#IR,CYAS3190!MWEC(4K^!I%L+=1&!&
M (U*K[ T<S#E0_Y?[Z?]]"CY>?G3@X/S#BH_[/M]NWRQC.:4V%NPD!C'[Q@[
M>Y%',PY4/P/[Z?\ ?5&!D#>F2,CYA3/L,!9FV#)ZT+8VZLC", HI13Z ]:.9
MARH?\N =Z<]/F%'R@9+I@''WA48T^V5541C"# ]J&T^V9&4Q@AF#'ZCI1S,.
M5$F "1O3CK\W2C SC>G_ 'U3&L8&:1B@S(<M[FE%E &W>6,A2OX&CF8<J'?*
M<8=.1D?,.:/E_OI_WT*8MA;J(P(P!&I5?8&D_L^WV[?+& <T<S#E1)@<_.G!
MP?F'%&!_?3_OJF&PMV$@,8_>,';W(I?L,!9FV#+=:.9ARH=@$@!TY&1\W6CY
M< [TYZ?,*8MC;JR,(P"BE%]@>M(-/MPJ*(QA!@>U',PY42?+C.].#C[PHP 2
M"Z<=?FZ5&VGVS*RF,89@Q^HI6L8&:1B@S(<M[FCF8<J'X&<;T_[ZHX.,.G(R
M/F'--%E &W>6,A2OX&D6PMU$8$8 C4JOL#1S,.5#_EQG>G_?0HXY^=.#@_,.
M*C_L^WV[?+&,YI386["0&,?O&#M[D4<S#E0_ _OI_P!]48!(&].1D?,.:9]A
M@+,VP9;K0MC;JR,(P"BE%]@>M',PY4/^7 .].>GS"CY0,[TX./O"HQI]N%11
M&,(,#VH;3[9E93&"&8,?J*.9ARHDP 2"Z<=?FZ48&<;T_P"^J8UC S2,4&9#
MEO<THLH V[RQD K^!HYF'*AW!QATY&1\PYH^7^^G_?0IBV%NHC C $:E5]@:
M3^S[?;M\L8SFCF8<J)..?G3@X/S#BC _OIQ_M4PV%NPD!C'[Q@S>Y%!L8"S$
MQC+=:.9ARH?QQ\Z<C(^8<UGM/%_:T<6]=Q4D<\5=%A;J8R(Q^[4JOL#5$Z;:
M#4(SY*Y4'!HYF'*C1X )WIP<'YA1@9(WIQU^:F-86[*ZF,$.P9O<CI0;&!F9
MC&,L<GWHYF'*A^ 3C>G(S]ZCY2 0Z<]/F'--6R@5E8(,JI4?0TU=/ME5%$8
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M0_Y?[Z?]]"CY0"2Z<'!^85'_ &?;[0OEC Z4K6%NRNIC!#L&;W(Z4<S#E0_
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M.\_X]_Q%20_ZE?I0!)1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 53/\ R$%^AJY5,_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KWG_'O^(J2'_4K]*CO/\
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MN_\ "9>(?^@I/^8H_P"$R\0_]!2?\Q1[9!_9<_YD?47FQ_\ /1/^^A1YL?\
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M%%% !1110 4444 %4S_R$%^AJY5,_P#(07Z&@"Y1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4V3_ %;?0TZFR?ZMOH: *]A_QZK]*M55L/\ CU7Z5:H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** *EW_K(ZM#I56[_UD=6ATH 6BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M /2JFF?\?=W_ +P_E5L]*J:9_P ?=W_O#^5 &G1110 4444 %%%% 'D?Q<C\
MWQ!H\?\ ?C*_F]:]MJMMIWA6[L"2!:SI:$8[L/\ Z]9OQ1Y\6: /I_Z&*@UK
M3I_^$WFTY&(AO+D71'^X16ZUBC)[LJ> [06'Q/EM0,"*.1<?@*]#E\3SP>+X
M]&FMHU@D1F67<<G'M7':$ OQLU$ 8 \W^0K4^)4363V6M0DH]NZHS#T+<BD]
M9:C6B-W5/$\]GXFM-(MK:.7SD9G9F(*X-6M3U;48VDCTNSAGDC;#>>YC'X&N
M.\%2_P#"1^+;[6W):.-RD0/\((JS=:K?7OQ";3+MS;Z=&CXP>),8P3FIY5>P
M[Z%VU^(,2O<V^HPI#=V^0R1$LN0,\&DA\9ZH]O#J#Z9 =,F("/$Y>3DX&5'2
MN&B@TYOB5J<5PC&S DP$3<1\H[5I.LWA_3X=1T35YI;=W55M6 5@"<<KU%5R
MHGF9Z-K%]?#PY+=Z7 LDQ0L%E;9M7!R?J*X'P#JVLZEIFLFYVW%L8W,D[O\
M.K;#@ >E>@)/->>%9)I4*RR6KDKZ'!K@/AE^[\+^((G^63GY&X/^K/:I7PLI
M[HK?#/4;FPT/5&M;=9G64.0Q(& O/->B>&?$,7B/3?M4:A6& ZCL:X/X7_\
M(I^(/Q_]%FK?P;_Y!.I_]=U_]!IS2U8H]#I=;\4RVFIII>EVT=U?,I8I(Q4
M#KS3]*\4_;;>^CN(5BO[-6\V%22NX+G />N*U'3;N/XF2S-J,UA',KLEP@'R
MCCCGCFKVDZ990:OJUQ%K%Y>W/D2B8R1 (Y*==PZT<JL.[N:'A_QW?Z[I-[=Q
MZ="LELP^4.<%<9)S6OHWB6#Q#X=NKQ8E/EQ-YD?;[I.*XSX7?\BGX@_'_P!
M-+\+O^13\0?C_P"@&B45J";T-OX;ZI9W^EZA+:Z7!8+'(-R0DG?\O7FM+4=?
MUF%?M%EI]K):*"S--,48#Z5R_P )':+P_K,B#+I(&4>I"&ET2_FURTUR?69"
MKQEA%;GHOR'IWZT./O,2>B.U\,^(H/$FGFYA&"A =?0FMNO,_@W_ ,@K4_\
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M%%%%2= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA76T44));!.<IVY@HHHID!1110 4444 ?-_Q7_Y'"?\ WC7"UW7Q7_Y'"?\
MWC7"UQ3^)GT^%_@Q"BBBI.@**** "BBB@ HHHH **** "BBB@ HHHH ****
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M+8EA*$@>F>M4_&7B&#1+FRC6V$M].0L18$ *6P>:XKQ[%<P>)M%\^<L\H 8
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MZB UE#X(V!_YC%S_ -^UKTI?^/ZZ_P!^K:U#IQ>MCICBZT5RJ6AY8/@A8?\
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MU3_KLG\ZZ.;I7.:]_P >J?\ 79/YT =9:_\ 'K']*FJ&U_X]8_I4U !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!CK_Q_77^_5M:J+_Q_77^_5M:
M 'BG4T4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@"O>?\>_XBI(?]2OTJ.\_P"/?\14D/\
MJ5^E $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !5,_\A!?H:N53/_(07Z&@"Y1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4V3_5M]#3J;)_JV^AH KV'_'JOTJU56P_X]5^E6J
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"I=_P"LCJT.E5;O_61U:'2@!:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ****  ]*J:9_P ?=W_O#^56STJIIG_'W=_[P_E0!IT444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (
M:8U/-,:@"I-TKG->_P"/5/\ KLG\ZZ.;I7.:]_QZI_UV3^= '66O_'K']*FJ
M&U_X]8_I4U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!CK_ ,?U
MU_OU;6JB_P#']=?[]6UH >*=313J "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *]Y_P >_P"(
MJ2'_ %*_2H[S_CW_ !%20_ZE?I0!)1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 53/_(0
M7Z&KE4S_ ,A!?H: +E%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7=O.-P7IW-*VHVZF0%C^[8*W'<T'3K0KM\A<9#?B*5M/M6,A,*DR,&?W([T
M9J2JUY<L#P7R*MK*GR\]1D542)!>7*A0 'P*MK$G'RC@8% #A,F,YZT[SDP3
MGH<&D$,>,;1Q2^3&01L')R: %\Y,GGIUI!,A.,]1FE\I"2=HYZT>5'G.T<#%
M ""9" <]1D4&= ,Y[XI1#&  %'' I/)C(QM'7-  9D!(ST.#2^:F<9[9H\J,
MDG:.3DT>5'G.T=,4 )YR';S]X9%'G)C.:40QC;A1\HP*/)CQC:* $\Y!NYZ'
M!I?-3.,]*/)C.?E')R:/*CSG:.:  3(2!GJ,BD$R$ YZTOE1@@[1P,"D\F/
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M@SST.#1Y,>,;1ZTODQY/RCDY- !YR9QFD\Y#CGJ,BE\J/.=HH\F,8^4<# H
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MOG)GK1Y,9S\HY.31Y4><[10 GG(2!GJ,B@3(0#GK2^5'D':.!@4>3'@#:.*
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M10 4444 %%%% "&F-3S3&H J3=*YS7O^/5/^NR?SKHYNE<YKW_'JG_79/YT
M=9:_\>L?TJ:H;7_CUC^E34 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% &.O_ !_77^_5M:J+_P ?UU_OU;6@!XIU-%.H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M KWG_'O^(J2'_4K]*CO/^/?\14D/^I7Z4 24444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%4S_ ,A!?H:N53/_ "$%^AH N4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-D_U;?0TZ
MFR?ZMOH: *]A_P >J_2K55;#_CU7Z5:H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *E
MW_K(ZM#I56[_ -9'5H=* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TJIIG_'W=_[P
M_E5L]*J:9_Q]W?\ O#^5 &G1110 4444 %%%8MOXITRZ\0RZ'%)(;V+.Y2G'
M'7FBP&U16+K'BG3-"O;6TOI)%FN?]6%3(/./YUM46 **** "BBB@ HHHH **
M** "BL76/%.F:%>VMI?22+-<_P"K"ID'G'\ZVJ+ %%9^LZU9Z#IYOKYF6 ,%
M)5<G)Z5ES^.=$MTT]Y)90+]0T&(SR,XY].:=FQ71TE%8NL>*=,T*]M;2^DD6
M6Y_U85,@\X_G6U2L,**** "BL[6=:LM!T\WM\[+"&"Y5<G)]JAT'Q+IOB2&:
M73I'98F"MO7;SUIV=KA<UC3&IYIC4@*DW2N<U[_CU3_KLG\ZZ.;I7.:]_P >
MJ?\ 79/YT =9:_\ 'K']*FJ&U_X]8_I4U !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!CK_Q_77^_5M:J+_Q_77^_5M: 'BG4T4Z@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@"O>?\>_XBI(?]2OTJ.\_P"/?\14D/\ J5^E $E%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !5,_\A!?H:N53/_(07Z&@"Y1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
MV3_5M]#3J;)_JV^AH KV'_'JOTJU56P_X]5^E6J "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ5H+'H "?^^Q5KQ>IUKQGHHL'8F.,ERH^[A@<'TIJ*L@;=RK\4VV^*=!;K@
M_P#CXKJY_&$EEK=O8WELD45R"T3Y.2,XY';FN5^*/_(V>'_P_P#1@H^*'_(V
M>'_P_P#1@II)I)B>C;.O^(%[;V'A9Y[JQBO8Q*@\F4D G/7BO./$UQ%=/X/G
M@MDMHWB4K"AR$'F=!7<_%7_D2)/^N\?\Z\^U?_CU\$_]<%_]&44]@EN=MX\U
M2RL?$.CPW.D6]Y)+C9+(Q!C^<#C'YUV.I7\MKMBMH1+.ZDJ&X7\37G'Q1_Y&
MSP_^'_H8K=^(&LZEI\UA:V>Z.&=U\V9>J_-C'Y5-KI#ON2IXUO++58;#6[.W
MMWG_ -689=_?'/XUVM>,^.X;:#Q-H8MGWDE=[_WCO%>RLP1&8] ,FE-))6'%
MGGOQ"D?4[ZQT* !FF82.#Z*W-0>%H?\ A&?&EWI!4);W!:2''<  53CEUC5/
M'MWJ.EVD%REFS0A99-HY --\2R^(+;6M/UJ_T^VM5B80GRIMV=S"K2TY2/,]
M7-,:D@F6X@29#E7&12M6)J5)NE<YKW_'JG_79/YUT<W2N<U[_CU3_KLG\Z .
MLM?^/6/Z5-4-K_QZQ_2IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% %2[_UD=6ATJK=_ZR.K0Z4
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M\BQ\ZY*CM7S57J/PGU-A)<6#L3O.Y1Z "E)'HY?7<9^S>S/5J***@]T****
M"BBB@ HHHH KWG_'O^(J2'_4K]*CO/\ CW_$5)#_ *E?I0!)1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 53/_(07Z&KE4S_R$%^AH N4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%-D_U;?0TZFR?ZMOH: *]A_QZK]*M55L/^/5?I5J@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH J7?\ K(ZM#I56[_UD=6ATH 6BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2JF
MF?\ 'W=_[P_E5L]*J:9_Q]W?^\/Y4 :=%%% !1110 4444 %%%% !6?K5]-I
MNERW4$*RO&,[6.!BM"H;J$7%I-"PR'0K^8IK<&<_;>+%F\()K<D<:.4RT>[@
M'GC/X4[2/%2:CX8;5I(TC=8RS1@\!L$@?I7ET@O?[2N?"*1![?[6C#<<;57&
M0/SJ?7'O= U"Z\/6\82SN[I&B*GD(,#&/QK7D1GS,[NU\07FO>'H;@VR0R32
M(556)!7/-=A%&L,2QK]U1@5S.D:>MO=V-K'Q#9PM&Z#INZBNIK.5NA43RCXI
M$#Q7H!)  QDG_?%>FB_L"0!=VQ)Z 2+7F'Q4C67Q1H4;C*.-K#U!<5W,?@GP
MY%(DB:5"'0AE//!%4[<JN)7NSG?'$;Z7K^FZS!V(B<>NYA6IXZU8VWAD>1@O
M<.J#GLQQ5SQIIPU'P[,N/GC(D4^FWFO,K#49_%U[HFEF>3_1H]TW'WF5LTXJ
MZ3[">CL;WBC3O[,^$EO;D?.'BW?7)J'6_P#DB6F_]LO_ $(UT'Q34)X&D51@
M">/'YUS^M_\ )$M-_P"V7_H1IIW2]0>AS^K_ /'KX)_ZX+_Z,KW>O"-7_P"/
M7P3_ -<%_P#1E>[U-39#@%%%%9EA1110 AIC4\TQJ *DW2N<U[_CU3_KLG\Z
MZ.;I7.:]_P >J?\ 79/YT =9:_\ 'K']*FJ&U_X]8_I4U !1110 4444 %%%
M% !7AM_K5QH/Q3U2^M;3[5*KNHCYZ$#GBO<J\GT4 _&[4<C_ )Z?R%-'%C$W
MR).VI/:_$_6I[N&%O#Q59)%4MA^ 3C/2O0]7LDU#2KBW<?>0X^N*N[5]!^5+
M0;TZ<TFIRYKG"_#W4'BM+O1[G"O8-Y:\]1C)-4['=XD^(4UPZC[-8%HE(.<Y
MP163XXEN?"GB;[=8H<7L;^8!TR>/SKK/AWIAM/#R7DH/GW@$CEASGI3\SCIM
MRFJ#^SO^AS&B_P#);M0_[:?R%'Q2_P"1K\/_ (?^ABC1?^2W:C_VT_D*/BE_
MR-?A_P##_P!#%'4RE_N\_P#%^J#XH_\ (U>'_P /_0Q7JDDT<$>^61(U_O.P
M KROXH_\C5X?_#_T,5W_ (ET%/$FBMITD[P*SJ^]!D\4NAU4FU5JN*N]/R+-
MU?VSV5SY%S#)(L+L%20$\ ^E<-\*I#>C5[R5,3-<+U[?+5_P_P##>WT#4S>I
MJ$TY,3Q['4 ?,,5A6>HR^!/$]]#=6S_V=<N9%D12V,# Z4$SG-3A4JJR5SU1
MT61"K@%3U!JO((--L)&11''&A; ]A7&7WQ/TJ6V9=+$\UP>%!B(J#5]>U$>"
M(WNXPEU<LB!=W.&.#18VEB:>KB[V1!X-DL]2U?6-8FGA47$A$?F. =I7!X-2
M^$+F#2?%^IZ2LB%+B0R1;&!& *S['X0P7%E%-+JD\<CKEE"# JGJ'A1O >IV
M6HVMU)<(SB-RX QN(':GH<2]K!1E*-K.][]ST3Q?JL>D^'KB5V(WCRQCU;(K
ME]"TRP_X5\;>6XMA--'YC*95SN ..],\;2MXBU2PT.!\13H9'9>HP:B_X4W:
M8_Y"]Q_WP*1K4=2=5N$;I*QM_#C4DN- 6PW9DLL1-CIZ\5P&H:S<:#\4]3OK
M6T^U2J[*(^>00.>*Z#PS9/X.\9G2#*9+:X5G61N"<<"H=& /QNU#/_33^0IF
M4G*5.G%Z-.PR3XL:MN6)M$2)G.U2[,.3]:W?!OAZ^_MRZ\0:I%&EQ.Q*;'W<
M$<UK^,/"T.O::QC'EW4?SHX'/'.*QO 'B&X+2:)JAVW4!VH6/4 <T=-#51E&
MLE6=^WJ=MJ?_ "";S_K@_P#Z":\\^#?_ "#-4_Z[K_Z#7H>I_P#()O/^N#_^
M@FO//@W_ ,@S5/\ KNO_ *#2Z&M7_>:?S/3:***1V!1110 4444 %%%% '@7
MQ*_Y&N?_ 'C7&UV7Q*_Y&N?_ 'C7&UHMCYC%?QI!11108!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5VOPO9O\ A,(U'W3$^?RK
MBJ]'^$^GM)J4M]CY8LIGZBA['1A$W6C;N>P4445F?3!1110 4444 %%%% %>
M\_X]_P 14D/^I7Z5'>?\>_XBI(?]2OTH DHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MIG_D(+]#5RJ9_P"0@OT- %RBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX_G6U2L,**** $-,:GFF-0!4FZ5SFO?\>J?]=D_G71S=*YS7O^/5/^NR?SH
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M-.T6.1-.M4MUD.YPG<U?HH#E3=PHHHH&%%%% !1110 4444 >!?$K_D:Y_\
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MKVA^+/[2UJYTFZ@2&\@)!53D<#)KC]#_ .2VZC_VU_\ 011HG_);=2_[:_\
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M5M:+F;I4V[N*,$>!O#7_ $"8/UIW_""^&?\ H$0?D:WQ3J+B]C2_E7W'/?\
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M1110 4444 %%%% !1110 4444 5+O_61U:'2JMW_ *R.K0Z4 +1110 4444
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M %%%% !1110 4444 %%%% !1110!4N_]9'5H=*JW?^LCJT.E "T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 !Z54TS_C[N_\ >'\JMGI533/^/N[_ -X?RH TZ*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M $-,:GFF-0!4FZ5SFO?\>J?]=D_G71S=*YW7O^/5/^NR?SH ZNU_X]8_I4U0
MVO\ QZQ_2IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'7_C^N
MO]^K:U47_C^NO]^K:T /%.IHIU !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>\_X]_Q%20_Z
ME?I4=Y_Q[_B*DA_U*_2@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JF?\ D(+]#5RJ
M9_Y""_0T 7**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "FR?ZMOH:=39/]6WT- %>P_X]
M5^E6JJV'_'JOTJU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 5+O_61U:'2JMW_ *R.
MK0Z4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 'I533/^/N[_WA_*K9Z54TS_C[N_\
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MI1YR%QE#Q0=;B$>_RI?OA/N'O6I@>E&!Z4 9KZS&C7 ,4G[B41GY#R3Z4O\
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MX><U5^S>U'V;VH N-XDM%>1=LGR''W#S0OB2T9U7$GS(7^X>U4_LWM1]F]J
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M[Q"X^0]!4D,"J20.O6KD:>U %%=3B**VR3#=/D-.;4HE21RDF(Y A^0]36D
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MZ8*?D/4^E:N!Z48'I0!EG4(P[+LD^7_8-"ZC&SQJ$DS(I8?(>@K4P/2C ]*
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M+LDX_P!@UJ8'I1@>E &6NHQL\:A),R*6'R'M2#4XBJ,$DPW3Y#6K@>E&!Z4
M9+:G$J,Q27"L%/R'O3GU"-'D4I)F,@'Y#6I@>E&!Z4 98U",L%V29*D_</:D
M74HF6(A)/WJEA\A[>M:N!Z48'I0!E?VG%MW;).N/N&AM2C42Y23]TP4_(>_I
M6K@>E&!Z4 9?]H1AV79)Q_L&A=1C9XU"2?O%+#Y#VK4P/2C ]* ,G^TXBBL$
MDPPX^0TS1KA9KN]VAQM<9W+CM6Q@>E(J*K,RJ 6Z^] #J*** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "48I
M:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&
M*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q
M1BEHH 3%&*6B@!,48I:* $Q12T4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gaz3apgusshz000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gaz3apgusshz000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +D!P\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN?[:MH[F,P]@/6O5HF#QAAWK6$N9'!BL/[&20^BBBK.4**** "BBB@ HHHH
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M>S(>20RL/[W-=-'$L2!4   [5I'FZG?0]L]:@^BBBK.D**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FLZ(/F=5^IQ6+J
MGB2UL@R)(IF' 7WKEWN]6UYS%/$T$;?Q*<4KEJ#>K.POM=M;%-S$/[*<U@R?
M$*Q0X^RW'_?)_P *KV7A=+=][W,DGLQ)K96PM0,&",_\!HU'[B\S)_X39)N8
MX9@/=3_A1_PF!_YYR_\ ?)K8%I;CI"G_ 'S2_9H/^>*?]\T68<T>QC?\)@?^
M><O_ 'R:/^$P/_/.7_ODUL_9H/\ GBG_ 'S1]F@_YXI_WS19AS1[&-_PF!_Y
MYR_]\FC_ (3 _P#/.7_ODUL_9H/^>*?]\T?9H/\ GBG_ 'S19AS1[&-_PF!_
MYYR_]\FC_A,#_P \Y?\ ODUL_9H/^>*?]\T?9H/^>*?]\T68<T>QC?\ "8'_
M )YR_P#?)H_X3 _\\Y?^^36S]F@_YXI_WS1]F@_YXI_WS19AS1[&-_PF!_YY
MR_\ ?)H_X3 _\\Y?^^36S]F@_P">*?\ ?-'V:#_GBG_?-%F'-'L8W_"8'_GG
M+_WR:/\ A,#_ ,\Y?^^36S]F@_YXI_WS1]F@_P">*?\ ?-%F'-'L8W_"8'_G
MG+_WR:/^$P/_ #SE_P"^36S]F@_YXI_WS1]F@_YXI_WS19AS1[&-_P )@?\
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M_P#?)H_X3 _\\Y?^^36S]F@_YXI_WS1]F@_YXI_WS19AS1[&-_PF!_YYR_\
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MH_X3 _\ /.7_ +Y-;/V:#_GBG_?-'V:#_GBG_?-%F'-'L8W_  F!_P"><O\
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MX3 _\\Y?^^36S]F@_P">*?\ ?-'V:#_GBG_?-%F'-'L8W_"8'_GG+_WR:/\
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M32U_Y]I_^^3_ (5O_8K;_GA'_P!\T?8[;_GA'_WS1=!J<_\ \)I:_P#/K/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZN<56FZ<^5G+:Q9O9ZE;WEN=D:'=(/6NUTJ_34K%+E/NM6-JT'VC39HP.67
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M*![>3<#13:M8YZ.'J4::4U8T*0D 9-&<UDZ[JT.FV3N[X(JV[(<YJ$>9G(V
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "N5L?^1]G_W?\:ZJN5L?^1]G_P!W_&DS2GU/0E^Z*6D7
M[HI:9F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &
M5KO_ !XO_NFN<\*_\>,W_70_S-='KO\ QXO_ +IKG/"O_'C-_P!=#_,TNII]
M@WZ***9F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 4444 %%%% !1110 4444 %%%% &5KO_ !XO_NFN<\*_\>,W_70_S-='KO\
MQXO_ +IKG/"O_'C-_P!=#_,TNII]@WZ***9F%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !61XG_Y
M %S]*UZR/$__ " +GZ4GL5#XD:'@O_D5[7Z5T%<_X+_Y%>U^E=!0M@G\3"BB
MBF2(2 "3T%11W<,IPDBD^@-22+OC9?48KA=2M=2T>Z-Q:C]R#DYJ9.QC6JNG
MK:Z.\HKF='\5VUX!#*_[X?>%=*K!@"".::DGL53J1J*\60W<ODVLDG]U2:^>
M_&VN-J>L'#':N5(KW+Q'<>1I4YSU0U\R74YDOI3G^-OYUA6>ECVLJ@N=R99B
MJ];X+"LV)JNPOM.:XI(^MH2T-Z%5"]JANMNT]*J)=X'6HIKG=WJ#11L[LJ3X
MR:HR5;D;-5)*UB<M=ILS+I>M;GP^UQ])\2P%G(B'4=NM8MQT-9BS&WG$BG!%
M=-)ZG@XZ*<3[.L+@7=E%.O1QFK-<%X6\7V,'ARR6XD(81UL-XWT@#_6FNCGC
MW/G)5J<79LZ1F"C+' %8][X@M[5_+0K(WH#7+77BJZU64P::P92<'-7]'\+$
MRK=7P;SOKQ4\[?PG,\1*H^6BOF==;R^?;I+C&X9Q4M,C011JB] .*?6AV+;4
M****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %(2 ,DX J.>=+>(R2'"CK7G^O>-9;N=K#16WS@X<'TH @^).JSK:2#3;
M[$VWA$/)KS'P<FOZYK0CN+F?]VP9@U>K:#X':YE%]JZM]HSD#M@UT^E^%;#2
M=0EO+=,22=>* ->TB\JUB3N$ /Y5-110 4444 ,E95C);I7DJV']I^*;E8^%
M5^?>O2/$5S]ET>67TKD_!%MYNIW-RX^_R#64]6D>=C$JE6%,[/3M-@L8%6*-
M5.!TJ]116IZ$8J*L@HHHH&%(2 ,DX I:Y[Q1J4]C;!(/O2#%)NRN14FH1<F9
MOC'78TLGM82'D/\ =KE-'_M*'>\4,J>9W K7T#P[/J=R+V^4XS7H,-M%!$L:
MHN%&!Q62BYN[/-C1J8F7M9.RZ'G?]E:Y>'_C]E0'M5ZQ\'ZFDZ32:DQP<D&N
M[VJ/X1^5+5*FCHC@8)WDV_F0VT3Q1!7;<1WJ:BBM#L2LK!1110,**** "BBB
M@ HHHH **** "BBB@"*X_P"/:7_</\JX#P?_ *_4/^NI_G7?W'_'M+_N'^5<
M!X/_ -?J'_74_P Z3W-(_ SJZ**AN9UMXF=N@H;MJ9-V5Q+J?R(B^,U6TO41
M?I(0N-IQ63=^([-HF1G.<&H_"EU&4G&?O.<5C[1.:2.;VZ=513T.JI&95&6(
M%9U_K-M8J=[X:N7O-?O+IRL!!0UVTZ$YFTZL8[G8R7UM'UF3\ZJOK5LAX=3^
M-<5]GN;@YD)_.I%THGJ6_.NB.%BMV<\L3V.O77;<G[R_G5B+5+63_EL@_&N)
M.D_7\ZB.G21G*EN/>F\+![,2Q+/1$FBD^XX/TJ2O.H]0U"Q;Y?NCUKH--\3P
MR8CN'Q(:QGAI1U6IO"M&1T;ML1F]!FL^UU1;B;RP.^*GN+A&LG=3P5.*X[2M
M6M[2=VG8@AS_ #KAJ3Y9)$U:RA-*^YWE%9=CK=M?2%8F)Q6IVK2,E)71M&2D
MKH****905#=,RP,4!)]JFHH8FKHX^?6+V"5E-O(P^E4+.^,OB".:6,Q@#^*N
M[:%'ZJ/RK"UG1$EC:6%?WG;%<TZ<EK<XJM&HO>3O8WHG#QJRG(-/KF-%U9E<
MVLYP4X%=#-=1V\?F.<+6].2FM#JI55.-T345R>H>*T1BMN^2*RV\4:FWW-M=
M4<-4:N)UHH] HKS[_A)=7]%IR>)]4'W\57U29/UB!W]%<A:>+!N"W#8KI+34
M(+Q 8FSFLIT90W1I&<9;%NBBBLBRO>R>3:2..JKFLK1;][LC=G%6M;N$AL)0
M3R5XKDM(U@6D(&?FKGJ5.6:..M64*J39Z!16!I^L2W4H!Z9K?K:,E)71TPFI
MJZ"BBBJ+"N5L?^1]G_W?\:ZJN5L?^1]G_P!W_&DS2GU/0E^Z*6D7[HI:9F%%
M%% !1110 4444 %%%% !1110 4444 %%%&: "BBB@ HHHH **** ,K7?^/%_
M]TUSGA7_ (\9O^NA_F:Z/7?^/%_]TUSGA7_CQF_ZZ'^9I=33[!OT444S,***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BD)P,FF),DCE5/(HN!)11
M10 4449'K0 44F1ZBER/6@ HHHH ***;O7.,T .HHHH **** "BBB@ HHHH
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MHWW6!I]<#'JM[">&XK;T[Q"LA"3-\U2Z;W0U46S.CHID<JRJ&4T^LS0****
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M4IC<NQW 2=L]J[J*&.! D2!5'0"I.@HH *P_$6J-IJ6Y5<[W"_K6Y7)>-_\
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MCAXN+ON70M3E<],HJIIUT+NV#@YJW7"TT['J)W04444AA1110 4444 %%%%
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M"2\6.73Y KQ\Y)H [\$$<45Y5HOQ$>RN%M-6E+R#J17I5AJ$.H0++"?E89H
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MRK=:7($D0<$FFM@G\3/2@01D4M>0:%\4/L-P+/6)&DE'!(]:]2TW4X-3MQ-
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MM%?K6I4,H**** "BBB@"*X_X]I?]P_RK@/!_^OU#_KJ?YUW]Q_Q[2_[A_E7
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M-PQFN7_X0=,_\?;_ )UU]%<QTG'?\(*O_/X_YTA\"H 3]L?CWKLJ0@$$'H:
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MM=3"UW0(]4$; [&0YR*N:/:/9VGE.Q8YZFM&BCE5[@J45/G6X4444S0****
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MJ<4Z*=)AE&!'L<T"NKV)J*0D 9-0?;8/,V"12WH&% -I%BBD!R,BEH&%%%%
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MBR=V%)2T4Q";1Z"EHHH **8TT2,%:1%8] 33@01D'- "T444 %%%% !1110
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M*\G\$^(+6TN)#(0-WJ:],M=2MKM0T<J'/8-2I-<IRX3#U*-%*:L7:1F"KDT
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M** "BBB@ HHHH BN/^/:7_</\JX#P?\ Z_4/^NI_G7?W'_'M+_N'^5<!X/\
M]?J'_74_SI/<TC\#.KHHHIF84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5RMC_P C[/\ [O\ C755RMC_ ,C[/_N_XTF:4^IZ$OW12TB_=%+3,PHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RM=_X\7_W37.>
M%?\ CQF_ZZ'^9KH]=_X\7_W37.>%?^/&;_KH?YFEU-/L&_1113,PHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYK6TN1I+-2W6N7+N>E)T)^IKB.6:YT7:***]<Y0HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N5L?^1]G_W?\:ZJN5L?^1]G_P!W_&DS2GU/0E^Z*6D7[HI:9F%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &5KO_ !XO_NFN<\*_
M\>,W_70_S-='KO\ QXO_ +IKG/"O_'C-_P!=#_,TNII]@WZ***9F%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^"_'\6I;+6X.V3U8UZ/&ZR(&4@@]"*Z4TU<\.I3E!V8^BBBF0%%%% !1110
M4444 %%%% !1110 4444 17'_'M+_N'^5<!X/_U^H?\ 74_SKO[C_CVE_P!P
M_P JX#P?_K]0_P"NI_G2>YI'X&=71113,R%K6)G+%02?:FBR@SGRUS_NBK%8
M?B/7!HME)/Y9?:,X% &LMM$C$A%Y]JA.F6QE$GEKD?[(KS^#XAW,MLMP-.F,
M9[XXKK_#/B)/$-J\J1[-AP10!K26D,BA61< Y Q2O:Q.ZLRC*C XJ5F5!EB
M/>JZZA:.^Q;B,MZ9H <UI$QR47\J;/8P7 P\:_7:*?+=00KNEE5 >Y-1/?P?
M9VDBD60#^Z: )(;2&!-J(HXQG%+';1Q'**!]!7+VOBY9[ZZ@\HCR5+9]:O\
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M"!]Q0X:KM>=>$KA[+6+Z)V+!Y3CVKT6@ KE;'_D?9_\ =_QKJJY6Q_Y'V?\
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MK:K57MJ>G2<G&\U9A1113- HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]!6Y72>&]PHHHH$%%%% !1110 4444 %%%% !1110!%<?\>TO^X?Y5P'@_\
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M]: -# QC I/EZ?+]*QK;Q)87@=8[B,L%)X-<?<^(+A?$,4 =MC'UH ]( 3/
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MC/:N$DBO?#5[L"O/!(V2YZ(*6QK\:\SK:, ]15.RU*WO4'ER*6]!5RF9M6#
M]****!!1110 4444 )M'H/RI:** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "L_5=3ATVV+R'KP /6H]1UF"TC8(
MZO+CY4[DUEZ3I-UK=X+Z\#1QM_RR;H*39I&/5[%GPWI$U[</>WPSAMT7TKN*
MB@@2")8T  48XJ6A(F4N9A1113)"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K(\1::=3TJ6!!EFZ5KT8H&G9W."\/WXCF?37X:
M8YKI*P_$^BR12+>6@(;=N?;WJ;1]7COH0KD+(/EVTEV+FK^\C6HHHIF84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %,>)9,;ATI]% !VQ5633X)9
M-[+R#FK5% #54(N!TIU%% !4:Q*C%@.3UJ2B@ HHHH **** "BBB@ HHHH *
M*** "FR(LL;(WW2,&G44 5;>QAM3^Z7%1W^DVNI;?M";MO2KU% &-:>&=.L[
MCSXHL/ZUL !0 .@I:* "FLH=2IZ&G44 ,CC6) JC %/HHH R+WP[87UPTTT>
M7;J:ET[1++3 WV9-NXY-:5% !1BBB@"G%IMO%>M=JO[UA@FKE%9NK:I'80,
M09B/E3UH&DV[(S_$>IO#$D-N?G9@K >AK>\,Z2FF61*K@R_.?QK#\-Z/)>WS
M:G=@XD'$;=!7<* JA1T'%)=RY.RY4+1113,PHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_.C_ (0";_H*R_G1=ARQ[F[YL?\ ST7\Z/-C_P">B_G6%_P@$W_05E_.C_A
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M645DP^(+(J!-,J2=UJ_#=P3C,<@:F9N+1/1110(**** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "HYH(YXRD@RI[5)10!SUSX-TB9FD%O\ O#SFLJ?PSJD/
M%A*D8[9__77;44K(M3D<!_8?BW/_ !^QX^G_ ->E_L/Q9_S^1_E_]>N^HHL/
MVC[' _V'XL_Y_(_R_P#KT?V'XL_Y_(_R_P#KUWU%%@]H^QP/]A^+/^?R/\O_
M *]']A^+/^?R/\O_ *]=]118/:/L<#_8?BS_ )_(_P O_KT?V'XL_P"?R/\
M+_Z]=]118/:/L<#_ &'XL_Y_(_R_^O1_8?BS_G\C_+_Z]=]118/:/L<#_8?B
MS_G\C_+_ .O1_8?BS_G\C_+_ .O7?446#VC[' _V'XL_Y_(_R_\ KT?V'XL_
MY_(_R_\ KUWU%%@]H^QP/]A^+/\ G\C_ "_^O1_8?BS_ )_(_P O_KUWU%%@
M]H^QP/\ 8?BS_G\C_+_Z]']A^+/^?R/\O_KUWU%%@]H^QP/]A^+/^?R/\O\
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M?446#VC[' _V'XL_Y_(_R_\ KT?V'XL_Y_(_R_\ KUWU%%@]H^QP/]A^+/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0M;:X61&VL.<FJY17-Q]<F&@176\[F;&:W8M1B6TA=V!++GK7%3?\B;#_O\
M^%-N(+UX+<VP9TV_-STHL%ST*&=)T#*P.?>I:YCPY(BR"%Y#YX'*DUT]2U8H
M****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\
M]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_Y
MZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/
M.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\
MWT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_G
MH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\
MZ7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[Z
MKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SW
MB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::
M;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'
M_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7
M_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?
M^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X
M333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=S
MZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^
MSH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&C
MVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\
M]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_Y
MZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/
M.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\
MWT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_G
MH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\
MZ7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[Z
MKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SW
MB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::
M;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'
M_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7
M_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?
M^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X
M333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=S
MZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^
MSH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&C
MVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\
M]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_Y
MZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/
M.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\
MWT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_G
MH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\
MZ7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SWB_[Z
MKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::;_SW
MB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'_"::
M;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7_?5'
M_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?^>\7
M_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X333?
M^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=SZ>_X
M333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^SH=S
MZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&CVK#^
MSH=SZ>_X333?^>\7_?5'_"::;_SWB_[ZKYA\Z7_GH_\ WT:/.E_YZ/\ ]]&C
MVK#^SH=SZ>_X333?^>\7_?5/A\7Z=,X19HR3_M5\O>=+_P ]'_[Z-:6B2R?V
MC'F1^H_BH]JQ/+XI7N?5T4@EB5U.0PR*?5'1O^0/:_\ 7,5>K<\EJSL%%%%
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MN8\63/%)9JI(#. :Z>N>\3V;W)MG09$;;C36XF4=90*R1D8A9 3Z5T%C%#_9
MB+@>7MY^E4;JV35]*(BY< +68L7B*.'[*D2^2!MSWQ3Z 2>)X[2+PS<+:[ N
M?X?QK7T:-&T&W#@8*<UCR^'[A_#TMM@F9SG!-101>(X+1;9(E\M1BCH+J1^5
M%_PED<"J/LY'([5H:K>PQ+]DM8@YD^4[?X:9!H]Y':FX*?Z8#Q67::7KUI>2
MS)"#O.3FF 1:>]B/L\IW(QW<U;U]40:85 X/'ZU>N;"_N]-+2(/M78"J8TK4
M[V6W%Y& D)^7%%P-4:TT3+$8&/'6JOB >:]G-TP<X_.MO[#$2"1R!6)XB)%S
M91)T+8/ZTEN,V["8S6P8U:J"UA$,"J*GJ1A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7BOQ;_P"/Q_\ =KVJO%?BW_Q^/_NU%3X3KP7\5'D=
M%%%<Q[P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%=OX+\+VFM6<T]T"0A[5OCP;H$\SP0;C*!TJE%LPEB(1E9GE-%;OB;0)="O
M%B=<!^5^E8XMY"N[:<?2IL:QDI*Z(J*7:V<8.:>(9&) 4\>U!1'12E2IP015
M[2+-;V]2%NC,!0)NRN4**]9OO!?A_2Q"MWN#N@;\Q65K/@FV_L\7.FJ2N,\^
ME5R,PCB8,\[HISJ4D93U4D4BJS' !-2= E%2/"Z?>4_E351F. ": &T4]XG0
M_,I'X5V=AX5M[G2/M3*=VPM0E<B<U!79Q-%=O9>%+>X\(76J%3YD4FT'\_\
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M,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %S%7JHZ-_R!K3_KF*O5UK8^9ENPHHHIB"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O%?BW_
M ,?C_P"[7M5>+_%I':\?:K'Y>PJ*GPG7@OXJ/(:*?Y,O_/-_^^31Y,O_ #S?
M_ODUS'O#**?Y,O\ SS?_ +Y-'DR_\\W_ .^30 RBG^3+_P \W_[Y-'DR_P#/
M-_\ ODT ,HI_DR_\\W_[Y-'DR_\ /-_^^30 RBG^3+_SS?\ [Y-'DR_\\W_[
MY- #**?Y,O\ SS?_ +Y-'DR_\\W_ .^30 RBG^3+_P \W_[Y-'DR_P#/-_\
MODT ,HI_DR_\\W_[Y-'DR_\ /-_^^30 RBG^3+_SS?\ [Y-'DR_\\W_[Y- #
M**?Y,O\ SS?_ +Y-'DR_\\W_ .^30 RBG^3+_P \W_[Y-'DR_P#/-_\ ODT
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M3_\ ?)I&BLARW$R+M61@/04HN[A591*P#=1GK3/)E_YYO_WR:/)E_P">;_\
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M /?)H\F7_GF__?)H 913_)E_YYO_ -\FCR9?^>;_ /?)H 913_)E_P">;_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "J5YI5G?'-Q CG_ &A5VB@:;6QB_P#"+:3_ ,^4/_?-'_"+:3_SY0_]
M\UM44K(KGEW,7_A%M)_Y\H?^^:/^$6TG_GRA_P"^:VJ*+(.>7<Q?^$6TG_GR
MA_[YH_X1;2?^?*'_ +YK:HHL@YY=S%_X1;2?^?*'_OFC_A%M)_Y\H?\ OFMJ
MBBR#GEW,7_A%M)_Y\H?^^:/^$6TG_GRA_P"^:VJ*+(.>7<Q?^$6TG_GRA_[Y
MH_X1;2?^?*'_ +YK:HHL@YY=S%_X1;2?^?*'_OFC_A%M)_Y\H?\ OFMJBBR#
MGEW,7_A%M)_Y\H?^^:/^$6TG_GRA_P"^:VJ*+(.>7<Q?^$6TG_GRA_[YH_X1
M;2?^?*'_ +YK:HHL@YY=S%_X1;2?^?*'_OFC_A%M)_Y\H?\ OFMJBBR#GEW,
M7_A%M)_Y\H?^^:/^$7TG_GRA_P"^:VJ*+(.>7<Q?^$6TG_GRA_[YH_X1;2?^
M?*'_ +YK:HHL@YY=S%_X1;2?^?*'_OFC_A%])_Y\H?\ OFMJBBR#VDNYB_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM$M?VMJ'_/W+_P!]4?VMJ'_/W+_WU5*BBX^5=B[_ &MJ'_/W+_WU1_:VH?\
M/W+_ -]52HHN'*NQ=_M;4/\ G[E_[ZH_M;4/^?N7_OJJ5.6-W^XC-]!FBXN6
M/8M_VMJ'_/W+_P!]4?VMJ'_/W+_WU5;[/-_SQD_[Y-,*E>H(^HHU#EB7/[6U
M#_G[E_[ZH_M;4/\ G[E_[ZJE11<?*NQ=_M;4/^?N7_OJC^UM0_Y^Y?\ OJJ5
M%%PY5V+O]K:A_P _<O\ WU1_:VH?\_<O_?54P">@S2F-P0"C GH,47%RQ[%O
M^UM0_P"?N7_OJC^UM0_Y^Y?^^JIE67[RD?44 %C@ D^@HN'+'L7/[6U#_G[E
M_P"^J/[6U#_G[E_[ZJF593AE(^HH ). "3[47#E78N?VMJ'_ #]R_P#?5']K
M:A_S]R_]]53*,OWE(^HI*+ARKL7?[6U#_G[E_P"^J/[6U#_G[E_[ZJE11<?*
MNQ=_M;4/^?N7_OJC^UM0_P"?N7_OJJ5%%PY5V+O]K:A_S]R_]]4?VMJ'_/W+
M_P!]52HHN'*NQ=_M;4/^?N7_ +ZH_M;4/^?N7_OJJ5%%PY5V+O\ :VH?\_<O
M_?5']K:A_P _<O\ WU5*E ). ,T7%RKL7/[6U#_G[E_[ZH_M;4/^?N7_ +ZJ
MJ8I ,F-P/7::14=ONHQ^@HU#EB6_[6U#_G[E_P"^J/[6U#_G[E_[ZJHR,GWE
M(^HIM%PY5V+O]K:A_P _<O\ WU1_:VH?\_<O_?54J*+CY5V+O]K:A_S]R_\
M?5']K:A_S]R_]]54\M\9V-CUQ3:+BY5V+O\ :VH?\_<O_?5']K:A_P _<O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8#ZFE!!&01B@!:*IWVHQ646]B#SC&:EM[E+B-7!QD9H GHI,CUID\RP0M(Q
M"C- $E%9<VMP16*77!5C@8-7X;B.:)75A\PSC-%@):*1F5?O$#ZTTRH$+;@0
M/>@!]%58;Z*>8QHP)'H:M$@#)H **H:CJL.GQ*[$-N;;@&K:2J\2R9 ##/-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1VHH[4 >*?&?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %':BCM0!XI\9_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% #'B60@L,D=*=C I:* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gaz3apgusshz000017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gaz3apgusshz000017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0.!YX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3_$?P_X4NOL=Y+-<7@VE[>U0,R @D%B2%'0<9S\P.,'-8!^./AH#_CPU<_\
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MA11169H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B@D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-BIY!4Y<!L<87([BO4[_ $VPU2!8-0LK:\A5MZQW$2R*&P1G# \X)Y]ZS_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH Y?P[_ ,CAXN_Z^K?_ -)TKJ*Y?P[_ ,CAXN_Z
M^K?_ -)TKJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBL&V\7Z3>^,+CPQ:RM-?VUOY\Y
M3!2/Y@-A.?O<@XQ0!O45S'BWQYHW@XVT5_\ :9[RZSY%G:1>9+(!U('I]32^
M$O'>C>,?M,=A]H@N[4@3VEW%Y<L>>A(]/I0!TU%>?ZO\8?#>DZK=6"P:G??8
MV*74]E;>9% 1U#-D=.>F>E=EH^KV.O:3;ZIILZSV=PF^.0#&?J.Q!X(H O44
M44 <OX=_Y'#Q=_U]6_\ Z3I745R_AW_D</%W_7U;_P#I.E=10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%>/_  @_Y*'\3O\ L*C_
M -&W%>L7M]9Z;:27=_=06MM'C?-/($1<D 98\#D@?C0!8HK(L?%?AS4[M+2P
M\0:5=W,F=D,%Y'([8&3A0<G !/X5;TW5M-UFW:XTO4+2^@5]C26LRRJ&P#@E
M21G!''N* +E%>:?$/XQZ1X+>ZTNUC>]UZ-,"$H1%"Q564R,<9&ULX7.<8)7.
M:X/X-ZQJOB#XS:UJVM1^7?7>E&5D$?E@(7@\O:/[NS;@G.1@Y.<T ?0]%%%
M!1110!Q?Q,\4MX9\,,+:79?WA\J CJH_B;\!^I%?-Q))))R3U-=M\5-:;5_&
M]U$K$P6/^C(,\9'WS_WUD?@*XF@ HHHH **** "BBB@ KTOX0>*GTW7/[#N9
M3]CO3^Z#'A)NV/\ >''UQ7FE/BED@F26)RDB,&5E."".0: /L*BLSPYJRZYX
M<T_4QC-Q"K,!V;HP_ @UIT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!F66@:?I^MZGJ]O&ZWFI>7]I8N2&\M=JX'0
M<>E<G/\ !OPA<7EQ=O#?B:YE:65EO9!N9CDGK[UW]% '-V'@3P_I_ANZ\/BT
M>XTRY<R2Q7,K29)QW)R/NC&.AYJOX<^&_A?PKJ!O],L&%WL\M)IIFE:-?1=Q
M.*ZRB@ HHHH YK_FIH_[ _\ [6KI:YK_ )J:/^P/_P"UJZ6@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ"[O+;3[26[O+B
M*WMXEW22RL%51ZDFL_5_$^B:#I":KJ>HPV]E(!Y<K'/F9&1M Y.1SQ0!KT5C
M>'O%FA>*[9Y]$U**[6,XD"Y#)Z94X(_*MF@ HHHH I:QIQU;2+K3Q=W%I]H3
M89[9]LB ]=I['WKS/POX?TWPS\;KK3=*M_)MUT%&.6+,[&7EF)Y)/K7K-<-;
MZ1J"_&N[U=K20:<^C) MQQM,@DSM^N* *.E1K=_'S7YI@&>RTJ"*#/\  '.Y
ML?CG\ZAUT_V;\<-.NK9=LEWH=PLVW^/82RD^IX'Y5+XITWQ'H'CR/QAX;TL:
MM%<6@M+^Q$HC<A6RKJ3W[=^GOP>%M*\0^(/'$_B_Q-I:Z7'%9FRL+ RB1PK-
MEG8COV[=?;D F^"]K$OPNT^8JK27CS33L1R[&1@<^O  J'X.?N-)\1:?& +>
MRUVZA@4=%3(.!^9_.L;2#X[^'=K<^&].\*C6K%9Y'TV[CN @1'8D"0>Q/MWY
MKM?AUX:N_"_A46^I.CZG=W$EY>%.1YKG) /?  % &OK&D7.J-$8-:U#3O+!R
M+3R_GSZ[U;I[>M9G_")ZC_T.6N_G!_\ &JZBB@#CO!MK)9>(O%5O+>3WCI=0
M9GN-N]OW"==H ]NE=C7+^'?^1P\7?]?5O_Z3I744 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 444$@=3B@ HJ-KB%?O31CZL*A;4[!/OW
MMLOUE7_&FHMB<DBU16<^OZ1'][4K7\) :@;Q5H:]=2A/TR?Z52IS>R9+J06[
M1L45@/XST)/^7PM_NQL?Z5 _CO1%Z/.WTB/]:I4*K^RR77I+[2.FHKDV^(.D
MC[L-TW_ 0/ZU ?B)9_P6%PWU915+"UG]DEXJC_,=G17G<OC_ ,[5[.50(+6-
MB)HS*"6!XS^%>A1R)-&LD3JZ,,JRG((^M34I2IVYNI=.K&I?EZ#J***R- HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH \?^$'_)0_B=_V%1_Z-N*Y77;.;XQ?&VZT)[N2
MTTC1$>-UYWE8W"RE1DKO9S@-Q\JJ2"1@]5\(/^2A_$[_ +"H_P#1MQ63X"UC
M_A%_CMXPT+57@M1J]TTL!D.2\AD+PJ&!P-R2L<'G.T<'@@$GC?X(Z1HWAN37
M/"]W=Z?J.D6XN"SSDB7R@69\]4D.,@KA<J!M&<C2_9Q_Y)YJ'_85D_\ 145>
M@^-/$UMX1\)ZAJ\\\$4L<3"U6;)$LY4[$P.3DCG'8$\ $CS[]G'_ ))YJ'_8
M5D_]%14 =ZO@3P[_ ,)7=>)I].CN=6N'1A-<?.(MBHJ[%/"D>6#NQNR3SCBN
M"\/?\G0^+/\ L%)_Z#:U[!7C_A[_ ).A\6?]@I/_ $&UH ]@HHHH *:[B-&=
MCA5&33J@O06L+@*<$Q, ?P- 'R1>W3WM_<7<F=\\K2-GU8D_UJ"BB@ HHHH
M**** "BBB@ HHHH ^A/@W>&Y\"^22?\ 1;J2(?0X?^;&O0:\Q^" /_"*7[=C
M?$#_ +X2O3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT8!V!_$"G?V_XMD^YH@3ZQM_4U7U6:WLOF+ZU![7?R.VHKB?M_C>7[MC$G_
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M1_C1]>ETC^ ?V6OM37_@1T?_  A>JO\ ZW7I#_WV?_9J4?#\M_K-7G)_W/\
MZ]<V/#'Q2O#F?Q)%;YZA9L?^@I0?ACXLNC_IWC*4@]0KRM_-A1]>K]%^0?V;
MAE\4U^+.E/@#3D&9]1F_':/YU _AKPE:_P#'QK*+C^_=1K6&GP4CDYO/$=W-
MZ@1#^I-78/@GX<3_ %UUJ$O_  -5_DM)XO$L:P.!6\K_ "_S'R'X=6A_>ZU
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M(2*968@>P-?/GC;Q-KGB-+,ZS96]M'$S&$1J1DG&<Y)]!5KX1[?^%@V^,?\
M'O+_ "K-U6I\K1TK!1=!U>:^^VJ^\^AZ***W/."BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *Y#XE#Q,?"+CPEYW]J^>FWR2H;9SN^]Q77T4 >,
M:\GQ5_X0+PT-,-[_ &V#-_:6UHMWWODW9XZ>E<EY?QZ]=3_[Z@KU;XJ_$-O
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!B
M>+/#L/BCP[<Z9*P1W :&0C/ER#H?Z'V)KY?U+3KK2-1GL+V(Q7$#['4_T]0>
MH-?7=<5X]^']MXNMQ<P,MOJL28CE/W9!_=?V]#V]Z /F^BK>I:;>:1?RV5_;
MO!<1'#(X_4>H]Q52@ HHHH **** "O;OA#X,DL83XCOX]LT\>VUC8<JAZO\
MCV]OK6+\/OA;)J#1:OK\31V@(:&T88:7W;T7VZGZ=?<  H    X % "T444
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MVV%%S_.H=;"KO]YJL'C9=/P_S9TS?$'3_P#EG9W;_@H_K3/^$\W']UHUV_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@"*XN(;2VEN;B18H8E+N[' 4#J37SGX\\?WGBR\>V@9H=)C?
M]U".#)CHS^I]!V^O-=7\9O%3&:+PW:3$*H$MYM/4GE4/_H7XCTKR"@ HHHH
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MM;06=M';6T210Q*%2-!@*!V J6B,+:O<5:MS^[%6BMD%%%%68!1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP&F:'8V0 !AA56QZXY_7-7Z**[4K*Q\]*3DVWU"BBBF(**** "BBB@ HHHH
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MOFWD5M&D\F[=ND"@,<GKDYYJ]0 4444 %%%% !1110 4444 <U_S4T?]@?\
M]K5TM<U_S4T?]@?_ -K5TM !1165XAUE-$TM[@X,S?+"A[M_@.M5&+D^5$RD
MHKF9@^*[R75=0@\.V!R[L&G;LO< ^PZG\*G\':+=:;&;HW,;V]R@)C"$$$=#
MG\Z9X9T+4+>!M2>YCCN[L;G\V'>P!YZY'7J:VK/3]0LX(H%OXFBC &#;\D?7
M=774G&,/91>AR4X2E/VLEJ:M%%%<1VA1110 5SGB_P 9Z=X1T_S;D^;=R ^1
M;*?F<^I]%]ZH^-O'MKX6B%I;*+O6)@!%;+SMST+8_0=36/X0\!75QJ'_  DO
MBYC=:I*0\=O)RL/ID=,CL.@^M9RDV^6.YTTZ,5'VE7;HNK_X'F4_#O@_4O&&
MIKXF\99,9YM; C "]1D=E]NIZFO5%544*JA548  P *6BJC%11G5K2J/79;+
ML%%%%49!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 >:_&+Q_>^"]&L[;2%7^U=1=DB<KN\M5QDA
M>[98 ?6M_P -GQ%+\-;<:G'*OB V3JRRN YEPP4D] 3\I]JX/X^Z3J"PZ#XI
ML(3,-(G)F&,A02K*Q'IE<'ZBBV_:/\.-9*]SI.I1W6WYHXPC+GV8L./PH J?
M"_Q[XHL_&C>!_&?F/=%3Y,D^/,1@N[!8?>4KD@_KS7N5?.?@>[O_ (F?&_\
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ME3:VF@ZI*L6H7A#0$C8KD8/?/'6M*23FKK0SJMJ#MN8/P_MK>6[NKJ1]UU&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "L3Q5XIT[P=HC:MJGG?9ED6,^2FYLMTXR*VZ\X^-
MFJV6E>!8WO\ 2HM3AEO(T^SRR/&IX8YRA!SQ0!:U3XL^%]/\,Z7K5VEXUCJP
MD6!1 "2$.&W#/%><W'C+X(W5R;B7PS+YA.3LM-@)_P!T.!^E:?B^_P# >G^$
M?"%G<Z!%J5C,";>&WU!@+4OM9LMG+#+=_2NE_P"%5?"W_GPM/_!A)_\ %T /
M\$_$[P3JNHVOAOPY9SVC2!C%$+58XQM4L>A]!7I%<1X>\ ^ ]#UJ'4-$M+>/
M4(PPC9+QY" 00>"Q'0GM7;T %%%% !1110!3U+2M/UFT-IJ=E;WEN3DQSQAU
MSZX/>FZ7HVF:):_9M+L+:R@)R4@B" GU..IJ]10!C:CX2\.ZO>K>ZCHEA=72
MXQ+-;JS<=,DCFM=$2*-8XU5$4!551@ #L!3J* "BBB@#E_#O_(X>+O\ KZM_
M_2=*ZC ]*Y?P[_R.'B[_ *^K?_TG2NHH 3 ]*6BB@!&^XWTKY#G"B>;@#YV[
M>YKZ3^('B27PQX8DN[?RS<2MY,>]L$$@_,!CDCK7#^ /!^LV-M:ZTMA83M<Q
MNVV[F8,5;&W(V$#H3[[JYZRYY**/4P,_8TY5)==CM?AWH>G:7X3L+FTME6XN
M[=)9YCRSDC/7T]JZVL[2VU,JZ:A9V=LB@"(6TQ?ZYRHQVK1K:*LK'GU9.4VV
M%%%%49A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!J^LPZ1X<_MW2=3O'OK=H;E8G@D?&Y'#?PY'!KU"B@#R=OA_KZ>"/M"?9O\
MA)QK?]OB$/\ NA-G_5;O3;QGU[]ZM+%XL\<^)="DUGPW_8>EZ1<"]E\VY65Y
MYE!"!0O8$YR:].HH **** .:_P":FC_L#_\ M:KGB;5O[(T:25&Q/)^[A_WC
MW_ <U3_YJ:/^P/\ ^UJT-6\/V6M/$UYYI\H$*$D*@9ZUI2<5-.>Q%12<&H;F
M)X&LTFAN-7FE\Z\F<HS'JGK^)_EBNPK,TG0;/13+]C\T"7&Y7<L..]:=.O-3
MFY+8FA!P@HO<***@N[RWL+26[NYDAMXEW/(YP%%9&J5R5W2*-I)&5$4$LS'
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M-<RIQVCI_F%%%%:'*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJLORH.5MP>H'JWJ?P'J>L\2>)+/PMIBZA?1S/"THB_<J"02"<\D<<5L5S'Q
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M\9R,8YX)+,5+%TJLN6+U.HHHHI'2%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7@WQ2U+6?!GQ;TSQ=!ISWMDMEY*@[@A/SAE)'0
M_,",U[S7&>(?B-IGA[QGI?A>YLKJ6YU'R_+DC"[%WN4&<G/4>E '@_ASXT:S
MHNOZWJ,EC-J":A+O2UENW*VOS,=JY!X^;'0=*Z?_ (:/U/\ Z%./_P "6_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \X^+WQ!NO ^BVL6EHC:IJ#LD+,NX1JN-S
M8[GD #WK<\-S^(;GX:V\NI0S+KYLGW)+A7,N&VD]@3P?;-<#\?M,OHE\/^*+
M.$S)I4Y\Y<9"Y964GVRN#]15JV_:*\)R6*R7-EJ<5QM^:%8U89]FW#(_*@"A
M\+OB+XD'BYO!7C))#?;6\F690LBL!NVMCA@5Y!_GFO;J^<_!E]=_$OXZKXIA
MLFMM/L4W-GG:H0H@)Z;B3G'H#Z5]&4 %%%% !1110!@^+?$B^&]($L4/VG4;
MF06]A: \SS-]T?0=2>P!KD/A+<ZJ(_%BZ[?O>7=KJKI+(6)4$*-P4'HN<X J
MEJZ>/8/B1>:W!X1BU:WMT^SZ8SWT<2PH1\[!2<[F/4G' Q6=\+KWQ'>Z]XLL
M[G08[>UN]0N&O9Q<J3;3%/\ 5@?Q=N10!)X<\-:M\3-+F\6:AXIUC3WNIY/[
M/M[*;9';QJQ"Y7^+D>WUKLOA?KU_KGA22/5I1-J6FW<MA<RX_P!8T9X;ZX(K
M'^$.NZ;9_#B*POKVWMKK29)H;R.60(8B)&.2#VP>OUJ;X-J9] UK5E!\C4]9
MN;J D8S&2 #^8- '9:OXBTW0FB6_DF4R@E/+MI)>G7.Q3CKWK,_X6#X=_P">
M]Y_X+[C_ .(KJ** ..\&W]OJGB+Q5>6K.T$EU!M+QLAX@0?=8 C\J[!ONGZ5
MS'AW_D</%W_7U;_^DZ5T[?=/TH P_!G_ ")VE_\ 7$?S-><^))&^('Q/M=!A
M);3--8^>1T.,>8?Y(/QKI)/$:^&/A-:WP8?:&@$5N#WD;./RY/X4SX2^'3IG
MAUM6N5)O-2/F$L.1'_#^?+?B*Q?O6@=\/W7/6>]VEZGH*(L:*B*%51@ #@"E
MHHK8X HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCCQ7>1B1PCV+,R!CM8ATP2.Y&XX/;<?6AF6'3A4IN6MUIY'ME%%%2>T%%%%
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M,HEO-IZC^%#_ #/_  &O&ZN:KJ4^L:M=:C<L3-<2&1O;/0?0#C\*IT %%%%
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M]GA88$>,(O!]!D_4YKVJHI^\^8Z,3^[BJ2]7_7D%%4Y]06"9HS;73X_BCA+
M_C44.L0SJC1VUXR/T;R&Q6IQ&C1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO_LUI4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"0002".A%)10!]<Z1=_VAHMC>YS]HMXY<_[R@_UJY6+X0!'@O0]QR?[/@_\
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M>>%K4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3*"$5 .P)SF@#TJ[DGBM)9+: 3SJI*1%]@<^F[M]:P?[7\4_]"K#_P"#1?\
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M[9ZCW![5R$^CZOX9F:ZTF5KBUSEXB,G'N._U'-=Q10!AZ+XHLM6"Q,?(NO\
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M#1O@)X+TC4$O)$OM2V8*PWTJM&&!!!*JJ[NF,-E2"<@UZ?110 4444 %%%%
M!1110!YK\6_!TFM:;'K-C'OO+)")44<R1=>/=>3CT)KP2OL6O%OB+\+Y(9)]
M:T"(O$Q+W%F@Y3U9!W'MV[<= #R.BBB@ HHHH ***?##+<3)#!&\DLC!41%R
M6)Z #O0 0Q27$T<,,;22R,%1%&2Q/  'K7TO\/O"G_")^&TMY@IOKAO-N6'8
M]ESZ ?KFL#X=?#4: T>KZN%?4R/W4(P5@S[]V_0?K7I5 !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %> ?%YKGPG\6O#_C)[5Y[%516V_W
MD+;ESV.ULC_ZU>_U7O;&TU*U>UOK6&YMWX:*9 ZGZ@T ?,UYJ,GQF^,6FFRM
M)TTNW$882 92%#N=FQP,DD#GN*Z'XY>/+35H_P#A"-+MIYKY+M/M#;,#</NH
M@ZL22/\ Z^:]PTK0M)T*%HM)TVULHW.6%O$$W?7'6JL'A+0+;7Y]=CTNW_M2
M=MSW3#<^< <9^[P.V* %\):7)HG@_1]+F_UUK9Q12?[P49_7-;-%% !1110
M4444 %%%% !1110!S7_-31_V!_\ VM72US7_ #4T?]@?_P!K5TM !1110!Q>
MH(WA;Q$FHPJ?L-V=LJ#L>I_Q'XBMKPYJ5G=Z9'##,#)"H$BG@C_ZU4_&>EW>
MH6=O):HTIA8EHUZD'N!WQ_6N=T#PM/JA:6Z$MO:[?E8<%S[>U,#OY=1LH/\
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M? NCG_GX'_;3_P"M7344 <N? FF?PS72_P# Q_A3#X#L_P"&]NA^(_PKJZ*
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M8.#@YP: '44W>N_9N&_&=N><4,ZH5#,%W' R>IH =12,RHI9B%4<DD\"@$,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *\^\;_$2^T'7(/#WA[09M9UB2'[0\:YVQ1YP"<#GI[8X]:]!KSWQO\
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M+<3VDXPZ9(((.001T(/.:Y[P_P##30_#VKQZJD^HW]["AC@EU"Y,WD*>"$&
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M<5OT4@(8+2WM5VP01Q#T10*FHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_"@#T:BBF2S1P1F25U11W8X% #Z*\J7XBZOI/B"XBUFR(MF?B(##1KV*GO\
MUKTC2]6L=9LUNK"X66,]<=5/H1V-;5</.FDY;&-*O"H[+<NT445B;!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '-?\U-'_8'_ /:U=+7-?\U-'_8'_P#:U=+0 4444 5)M1A@E,;1W!8=T@=A
M^8%4=*OD@T^VMY(;I9%4*0;=^#]<5LT4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R_AW
M_D</%W_7U;_^DZ5U%<OX=_Y'#Q=_U]6__I.E=10 4444 %%%% !1110 4444
M %%%% !1110 4444 %9^K?<M/^ON+^=:%9^K?<M/^ON+^= &A1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?/G
M@K5/C#X[T:;5-+\6:;#!%<-;LMU;QJQ8*K9&V!AC#COZUT?_  CWQS_Z'/0_
M^_*__(] 'L%%<WX*L_%=CHTT7C#4[34-0-PS1RVJA5$6U<*<(G.X,>G<<UTE
M !1110 4444 %<5\5M0-AX O54X>Z9+<'ZG)_P#'0:[6O*?CE<E-%TFTSQ+<
M/)C_ '5Q_P"ST >(4444 %%%% !1110 4444 %>D?!;4#;>,)K,GY+NV8 ?[
M2D,/TW5YO73_  \N3:>/]&D!QNG\O_OL%?ZT ?3U>>_$[3-;O[>&2S7S-/A7
M=)&GWM^3R1W&,?K7H5%:4:KI34T9U::J0<6?/UEXA62V73M<@-Y9CA&SB6'W
M1OZ'BK:6NI>'&&L^'[XW5@3S+&/N_P"S(G;\>/2O0?%7P\LM:#W5AMM;[KT^
M20^X['W%>6YUKP?JK(RO;3#AD8921?<=&!KV:56%9>Y\TSR*M.=)^_\ )H]=
M\'>,H_$\3Q/ T-W"N9 /ND>H_P *ZJO%]/\ B*-*23[!HEE \IW2%2WS'\^G
MM4[_ !:U=ONV=FO_  %C_6N*I@JDIMP5EZG93QL(Q2F[OT/8:*\5D^*6OM]T
M6Z?2+_&J[?$OQ,W2ZC7Z0K_A4K+ZWD4\?2\SW*BN/^'>OWFO:1=/?RF6XBGQ
MNV@#:0,#CW!KL*Y*E-TY.#Z'53FJD5)=0HHK'\1ZXFAZ:95,374G$$3D_,<C
M)XYP <GIV&1D4HQ<I**W8Y244Y/8V**YOPIX@N]=^U_:HX4\G9M\I2,YW9SD
MGTK4UW4?[)T.[O0R"2./$6]2RF0_*@('."Q _J.M5.E*$^1[DPJQG#G6QH45
MYPOQ"U16!:ULW Y* ,I(],Y./K@UZ)%+'-$DL3K)&ZAD=#D,#T(/<55;#SHV
MY^I-&O"K?EZ#Z*YGQ5XJ.B,EI:(KWSJ)/WJDHB9(R<$9)P0 #QU/8' M_B!J
M G@>XMK9K5B2_E(P9ER5)4EL<,#_ -\D<=14,+5G'FBB9XJE"7*V>BT5%;SQ
MW5M%<0MNBE0.C$$94C(X/(J6N<Z HHHH **** "BBB@ HHHH **** "BBB@
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M]0^(K23Z;=6#+I.T1W)3<P\X<C:Q&*[.@ HHHH **** "BBB@ HHHH ****
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MQ;P>(+I(0.BK\O H ](HK*UBQUB\:(Z7K*:>%!\P-:+-O].K#&*S/[%\6_\
M0WP_^"I/_BZ #P[_ ,CAXN_Z^K?_ -)TKJ*X[P;#=P>(O%45]=K=W*W4&^=8
MA&&_<)CY03C\Z[&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S]6^Y
M:?\ 7W%_.KLL@BB:1@Q"C)"C)_(5C:AJ,=PMN(X+L[+A';_1WZ \]J -RBJ=
MOJ4-S,(DCN%8C.7A91^9%7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT7_3]%;GF*4?D5_QH \DHHHH **** "BBB@ HHHH *U?#+F/Q7H[CJM]"?\
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M[21YLH/WV/4#H*]LHH \V\0KK?C/PC:ZI8:!=:=J^CZG'>6MC?81I_+ZC/0
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M*?\ V6O6ZX+XP6)N_ 4LRC)M+B.;\.4/_H= 'SO1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 <7JE_=V/Q(C:UTFYU!FTC!6!XU*_ONIWL
M*T?^$BUC_H3]4_[_ -M_\<IO_-31_P!@?_VM72T <Y_PD6L?]"?JG_?^V_\
MCE'_  D6L?\ 0GZI_P!_[;_XY71T4 <Y_P )%K'_ $)^J?\ ?^V_^.4?\)%K
M'_0GZI_W_MO_ (Y71T4 <Y_PD6L?]"?JG_?^V_\ CE'_  D6L?\ 0GZI_P!_
M[;_XY71T4 <Y_P )%K'_ $)^J?\ ?^V_^.4?\)%K'_0GZI_W_MO_ (Y71T4
M<Y_PD6L?]"?JG_?^V_\ CE'_  D6L?\ 0GZI_P!_[;_XY71T4 <Y_P )%K'_
M $)^J?\ ?^V_^.4?\)%K'_0GZI_W_MO_ (Y71T4 <Y_PD6L?]"?JG_?^V_\
MCE'_  D6L?\ 0GZI_P!_[;_XY71T4 <EI_C*_P!4L(;ZS\)ZK);S#<C>=;C(
MSCH9*M?\)%K'_0GZI_W_ +;_ ..4WX?_ /(B:3_UR/\ Z$:Z6@#G/^$BUC_H
M3]4_[_VW_P <H_X2+6/^A/U3_O\ VW_QRNCHH YS_A(M8_Z$_5/^_P#;?_'*
M/^$BUC_H3]4_[_VW_P <KHZ* .<_X2+6/^A/U3_O_;?_ !RC_A(M8_Z$_5/^
M_P#;?_'*Z.B@#G/^$BUC_H3]4_[_ -M_\<H_X2+6/^A/U3_O_;?_ !RNCHH
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M$_5/^_\ ;?\ QRC_ (2+6/\ H3]4_P"_]M_\<KHZ* .<_P"$BUC_ *$_5/\
MO_;?_'*/^$BUC_H3]4_[_P!M_P#'*Z.B@#G/^$BUC_H3]4_[_P!M_P#'*/\
MA(M8_P"A/U3_ +_VW_QRNCHH YS_ (2+6/\ H3]4_P"_]M_\<K4T758=<T>V
MU*".2..=<A) -RD$@@X)'4&K]<UX _Y$C3OI)_Z,:@#I:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \_LM;N--\:^*XXM#U.^#7,!+VJH5
M'[A.#N85L?\ "77O_0H:_P#]^X?_ (Y1X=_Y'#Q=_P!?5O\ ^DZ5U% '+_\
M"77O_0H:_P#]^X?_ (Y1_P )=>_]"AK_ /W[A_\ CE=110!R_P#PEU[_ -"A
MK_\ W[A_^.4?\)=>_P#0H:__ -^X?_CE=110!R__  EU[_T*&O\ _?N'_P".
M4?\ "77O_0H:_P#]^X?_ (Y7444 <O\ \)=>_P#0H:__ -^X?_CE'_"77O\
MT*&O_P#?N'_XY7444 <O_P )=>_]"AK_ /W[A_\ CE'_  EU[_T*&O\ _?N'
M_P".5U%% '+_ /"77O\ T*&O_P#?N'_XY1_PEU[_ -"AK_\ W[A_^.5U%% '
M+_\ "77O_0H:_P#]^X?_ (Y1_P )=>_]"AK_ /W[A_\ CE=110!R_P#PEU[_
M -"AK_\ W[A_^.57N_'CV*PM=>%M>C$TJPQYBB^9V.%'^L[FNPKF/&W_ ![Z
M'_V&K3_T.@!/^$NO?^A0U_\ []P__'*/^$NO?^A0U_\ []P__'*ZBB@#E_\
MA+KW_H4-?_[]P_\ QRC_ (2Z]_Z%#7_^_</_ ,<KJ** .7_X2Z]_Z%#7_P#O
MW#_\<H_X2Z]_Z%#7_P#OW#_\<KJ** .7_P"$NO?^A0U__OW#_P#'*/\ A+KW
M_H4-?_[]P_\ QRNHHH Y?_A+KW_H4-?_ ._</_QRC_A+KW_H4-?_ ._</_QR
MNHHH Y?_ (2Z]_Z%#7_^_</_ ,<H_P"$NO?^A0U__OW#_P#'*ZBB@#E_^$NO
M?^A0U_\ []P__'*/^$NO?^A0U_\ []P__'*ZBB@#E_\ A+KW_H4-?_[]P_\
MQRC_ (2Z]_Z%#7_^_</_ ,<KJ** .7_X2Z]_Z%#7_P#OW#_\<J"S\=O?Q/+:
M^%=>D1)7A8B*(8=&*L.9.Q!%=?7+^!/^0-?_ /86O?\ T>] !_PEU[_T*&O_
M /?N'_XY1_PEU[_T*&O_ /?N'_XY7444 <O_ ,)=>_\ 0H:__P!^X?\ XY1_
MPEU[_P!"AK__ '[A_P#CE=110!R__"77O_0H:_\ ]^X?_CE'_"77O_0H:_\
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MKNR?^!"N'H **** "BBB@ HHHH *]Q^"6CFWT6^U:1<&ZE$4>?[J=3^))'_
M:\2AADN)XX(4+RR,$1%ZL2< 5]7>'=)30O#MAIB8_P!'A56([MU8_B230!IT
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !114%Y=P6%E/>74@BMX(VEE=NBJHR3^5 #?L%M_:?\
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M 345F3^)-#MM1&GW&LZ?%>G@6[W*+)_WR3FM.@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!Q_Q(\+'Q/X8D6!-U]:$S6^!RW'S)^(_4"OFH@@X(P17V+7A_Q7\"-9
M7,OB+3(LVLK9NXE'^J<_Q_[I[^A^O !Y51110 4444 %%%;?A;PS>^*M9CL+
M-2J_>FF(RL2=R?Z#N: .R^#WA5M1UEM=N4/V6Q.(<]'EQ_[*#GZD5[Q5+2-*
MM-#TJWTVRCV6\";5'<^I/N3R:NT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R'Q3\S_A5_B'
MRL[OLASCTR,_IFNOJ"^L[?4;"XL;J,26]Q&T4J'^)6&"/R- '#^-A;?\*.O@
M OV<:3'Y?I]U=OZXKK]"\P^'M-\W/F?9(M^>N=@S7!1?"2X:&WTJ_P#%^I7O
MARW=632WC4;E4Y5&D'+*,=,?3%>F    # '04 +1110 4444 %%%% !1110
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M$#OGOCM74_"6SN_["U36[VWDMY-;U*:^2*0898VP%S^6?QH ] HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*Y;6OB/X1\.ZI)INK:S';7D84O$8I&(!&1R%(Z&L[_A<?P__ .ACB_[\2_\
MQ% '=45G:)KNF>(],34M)NENK-V*K*JLH)!P>" >M6KV]M].L+B^NY1%;6\;
M2RR$$[549)X]J )Z*X7_ (7'\/\ _H8XO^_$O_Q%'_"X_A__ -#'%_WXE_\
MB* .ZHIL<BRQK(ARC@,I]0:=0 4444 %%%5(M4L9]2FTZ*[BDO($$DL*MEHU
M/0L.V<=Z +=%8 \:^'3XI_X1H:FG]L9Q]E\M\YV[^N,?=YZUOT %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $,%I;6V[[/;Q
M1;CEO+0+GZXJ:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1E#*58
M J1@@C@TV.*.&-8XD5$4855& /PI]% $+6EL]PMP]O$TR_=D* L/QZU-110
M4444 %%%% !1110 4444 %%%% !1110 5#<6EM=A1<V\4P7[HD0-C\ZFHH I
M#2-,!R-.M 1_TP7_  JS-!#<1F.>))8SU5U##\C4E% #8XXX8UCB1411A548
M _"G444 %%%% !1110 4444 %%%% !1110 4444 %0S6EM<.KSV\,K)]TN@8
MK],U-10 5"EI;1SM/';Q),WWI%0!C]34U% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4R.&*)G:.)$:0[G*J 6/J?6GT4 0S6EM<.CSV\4K)]TN@8K
M],U-110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 ?'M_<2W>H7-S.Y>665G=B<DDG)JO3YO]?)_O'^=,K@/
MKEL%%%% PHHHH **** "OJGP+<2W7@7199F+.;506)Y..!_*OE:OJ3X>_P#)
M/]%_Z]Q_,UM1W/,S3^''U.FHHHKI/#"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^8_B.FE
M2?M"HFN&,:66M_M/F,0NSRQG)'-=G]@^ W]_2_\ P)F_^*KDO'FEVFM_M(6^
MF7\9DM+E[:.5 Q4E3&.XY%>H?\*,^'__ $")?_ R7_XJ@#HM(_L+0/ [W7AF
M&)M*A@ENH$BD8J^ 6."<GDBL+P!XVB^*>@:LE]HZVMNI^S2P^>7$JNISSA2.
M.*[/2=)LM"TBWTRPC\JSMDV1HS%L+]3R:MQ>5@^5LQWV8H \)^,?P\\*>&O
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M//34(Y8+^-@7^S1A7#MD$=".">QZ5Y[\#M;\3Z??FQTC15O-+N[V%;ZZ*,3
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MQJ _[>G_ ,:S:*5V;\D>QI_\)'KG_09U'_P*?_&D_P"$BUO.?[8U#/K]J?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME,FH2JXSNVL B_097CVIWCL)IWCJ[>U18BHM)QL4#YMQ&?TIWP]?[#XWL[8
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 45XIJ_Q,\1ZIK;V_AX[+=9'6W2VMO-EG0=&(
M92>BEL # )!SC--F\>^-O#.M?9];"3,JJS6T\2*&4D'<KQCK@$9^8 YR"1BG
M8XGCJ2>SMWMH>VT5#:W4-[9P7=N^^">-9(VP1N5AD'!Y'![U-2.T**X?XA>.
M?^$:MQI]CDZK<1[U<KE8$)(W\\,V0<#D<9/& W#_ /"2_$G^Q_[4WW?V+/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH \N^+&IB.ZLK$V<$JQ0/>%Y"P. =I08(QD'DU9\;W-E'X%T6RCL6
MC^U>4UJD;[5@94W#).<C''O61\6^=:3U_LN0?FXK8\>6X7P/H,Q^]!-;J/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M##(OPM\4W94A+@S&/_:"H%R/Q!'X5R,VGK/#!&UU=_Z/%Y4)\XGRU]!VKM]
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M ".OA#_KO=?^D[4 =11110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#+20@ G'\(P  !V'<Y)VJ*&RJ6&A3DY7;?=A1112.@**** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *>
MJZ9::UI5SIM]&9+6YC,<J!BNY3U&1R*I:GX6TC5_#2^'KRW=],5(XQ$LK*=J
M8VC<#GL.];-% 'G7_"C?A_\ ] >7_P #)O\ XJNFU+P5X>UCP_:Z'J&G)<6%
MJBI CLVZ,*NT8;.X''?-;]% '/\ AGP3X>\'QRKH>FI;--_K)"S.[#L"S$G'
MM70444 %<OX@_P"1U\(?]=[K_P!)VKJ*Y?Q!_P CKX0_Z[W7_I.U '44444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R'
MK-_-JFM7E]<.S2SS,Y+'/?@?@./PJC3YO]?)_O'^=,K@/KDDE9!1110,****
M "BBB@ !(.0<$5]7>#K^;4_!ND7EPQ::2U3>S')9@,$GZXS7RC7U)\/?^2?Z
M+_U[C^9K:ANSR\T2]G%^9TU%%%=)X@4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+^(/\ D=?"'_7>Z_\
M2=JZBN7\0?\ (Z^$/^N]U_Z3M0!U%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3X9[N"[CG8?O(Y&VX/?MTKLEAZ<(IS>OD<<<14G)J"T\S:E\6:'%UU"-C_L
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M]/TRWTR-TMVG8.VX^=.\IS[%B<4J=+D=R\5BU7BEV+E%%%;' %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7 >./B
MA;^"?$.FZ1+I<MTU\BL)$F"A,OMZ$'-=_5&\T;2]1GCGOM-L[J:(8CDG@5V3
MG/!(R.: /*?'7QCT71?$MYX?U/PL-2^Q.HWRNA4DJ&R%93CK6'=?M!Z#?6/V
M&Z\&F:T&W]Q),A3Y2"OR[<<$#\J]*UO4? T?C2RT+4=,T^ZUO43GYK-)&7Y3
M@NQ'&<8'4].U<3XN^(7P\\*^(9=''@ZROI;=MMQ)%9PJJ-W49'S$=^E '?\
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M<?4Z:BBBND\,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?'$W^OD_P!X_P Z93YO
M]?)_O'^=,K@/KPHHHH **** "BBB@ KZD^'O_)/]%_Z]Q_,U\MU]2?#W_DG^
MB_\ 7N/YFMJ.YYF:?PX^ITU%%%=)X84444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY]*]\C1(HUCC4*B *JJ,  = *WHQ:U9Y.98B$TH1=QU%%%;GE!1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI]^B3?O&R2A5SCCT-<U53<K+8];!2HPI<TK<Q[K:6D%C9PVEM&L<$*!(T7H
M.E3445TGDMW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KF/$7C_ ,/>%=5M--U:ZDBNKM0T*K"S@@MMZ@<<UT]>._$&Y\.7
MOQ>\/:-K6DK,[P*5O6O7A\GYW(&!PW*]_6@#6\<^./AO)>7'A[Q6OVB:U8;H
MVM9&V$@'*LHXX(Z&N&L=0^ MA=BX2VFE=3E5GBGD4'_=/!_&MB^TSX?>+_BW
MJVCZCI%P=05!++>_;BL3X5.  >."/R-;G_"F?AK_ ,^__E0?_P"*H [3PIXI
MT7Q;I37FA2M):0R>1S$8]K  X ('&"*W:P/"7AC0_"FERV.@)MM9)C*X\XR?
M.0 >23V XK?H **** "BBB@#'C\*>'H=5_M2+0]/2_SN^T+;('SZYQU]ZO:A
MIMCJUHUIJ-G!=V[_ 'HIXPZG\#5JB@"AI6B:5H=NT&E:=:V43'++;Q! Q]\=
M:OT44 %<OX@_Y'7PA_UWNO\ TG:NHKE_$'_(Z^$/^N]U_P"D[4 =16#X;_X^
M=>_["C_^BXZO7NNZ3ILX@O=1MK>4KN"2R!3CUP?I7.:!XET."?6C+JUF@EU%
MW0M,!N78@R/;@_E4MJZ-H0DX/0[.BHK>XAN[>.XMY4EAD&Y'0Y##U!J6J,0H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***@
MN;5+I CM*H!S^[D*']* )Z*P_P"SH_[9%OY]WY7V??C[2_7=CUK5MK5+165'
ME8,<GS)"_P#.@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA_UZ?^SUH5G_ /,Q#_KT_P#9ZT* "BBB@ HHHH **** "BBB@ HHHH ****
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M6TM$;*0(>WNQP,MWQV  '>_LZ2:*/%]]%>PQG5FMPVGRR$?*!GS57)^^00>
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,0 0P';(/3U!KN:\P^!?A>]\.>!Y)M1B>&XU"?SQ"XPR)M 7([$X)_$5Z?0
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M3/6N]KE_$'_(Z^$/^N]U_P"D[4 =11110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!G_ /,Q#_KT_P#9ZT*S
M_P#F8A_UZ?\ L]:% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7R!\;?^2O:[_V[_P#HB.OK^OD#XV_\E>UW_MW_ /1$= '1
M?%O1/^+>_#_7HK?II<-G<3[_ /IDKQ+MS_UU.0/J>E<UJOBZ&\^"F@>&5AC$
M]KJ4[NPF!;:H+*2F,@,;A@#G_ED>N>/>/B+X-6;X)/I'F)//HEE%-#.^Y 3
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M#$\[0*^JM2TG3=9MUM]4T^TOH%?>L=U"LJAL$9 8$9P3S[F@#YL_X:.\8?\
M0-T/_OQ-_P#':ZB]\6ZQ\1?V>_%&H7MG +J&Z2(1V43X\M&@D+$%F/ +$GH
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M?B;_ +"MU_Z-:OM^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH \U^)OQ1T/PB/[(N-/35[Z9 [6;X\M%/0N2#U[#'Y5
MQ7A7Q[H<?A?7?%3^"-'M9M+GMTC2VB57<R-@_,5X(Z\5#;ZAI&@?M&ZW<^+
MD:2 FSN+A<I&Q";&]OE!&>QH\'>*/"FGM\19-;N[.:RO+YGA@)#_ &E<R8V+
MWZCD=,B@#VSPOXFT[Q=H%OK&F.S02Y!5QAHV'56'J*V:\;_9SM[B/P9J<[JR
MV\U^3"#T.$4$C]!^%>R4 %%%% !1110!4O-+L=0EM9;RTAGDM)1- TBY,;C^
M)?0T:CIEAJ]FUIJ5G!=V[=8IXPZ_D:MT4 9^DZ%I.@P-!I.G6ME$QRRV\03<
M??'6M"BB@ KE_$'_ ".OA#_KO=?^D[5U%<OX@_Y'7PA_UWNO_2=J .HHHHH
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M444 <QXV\!Z/X]TZVL]6,\7V>7S8YK8HLBY!!7<RM\IX)'<JOI6?X(^%VC^
M=0N;O2=0U67[3%Y4D-S,C1G!!#;51?F'(![!F]:[>B@#S?Q3\%/#?B[Q'=ZY
M?WNJQW5ULWI!+&$&U%08!C)Z*.]=YI.FPZ-HUCI=NTC065O';QM(06*HH4$X
M &<#T%7** "O//%OP9\,^,=?EUJ]GU&WNYD59?LLRA7*C:&(96P< #C X'&<
MD^AT4 <IX'\ :;X!MKRVTN^U*>"Z=7:.[E5E1@",J%50"01D]]J^E=7110!Y
M7JWP#\*ZSK-]JEQJ&LK/>W$EQ(L<T04,[%B!F,G&3ZFO5*** "BBB@ HHHH
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M!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT %%)N'J/SH!!Z&@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHJG<ZMI]F/\ 2+R&,^A<9_*L:Y\<:5#D1>=.W;:N!^9H Z6BN-_X2G6K[C3M
M'8*>CN"W^ H_L_Q;J/\ Q\7J6J'LK8_]!_QH ZZ6XAMUW32QQKZNP%9%SXLT
M:VS_ *6)6':)2WZ]*S(? L+MOOK^>=N^./U.36O;>&-'M<%+)'8?Q2?.?UH
MQY/'!F;9I^F33-V+?X#-,^T>,-1_U<$=FA[D!3^N377QQ1Q+MC147T48%/H
MXX>$-2O3NU+6'?U5<M_/C]*T+7P7I%O@O').?^FC\?D,5T-% %:VTZRLP!;V
ML,6.ZH ?SJS110 4444 %%%% &?_ ,S$/^O3_P!GK0K/_P"9B'_7I_[/6A0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU9V!\EK[">F0BY_I7M%8_A?PW8>$O#]MHVFJP@@!RS<M(QY+-[DUL4 %%%%
M!4%W96NH6[6][;0W,#$$QS1AU..G!XJ>B@#'_P"$2\-_]"]I/_@%'_A6@]A9
MRV0LI+2![0*$$#1@IM'0;>F/:K%% %>SL+/3H?)L;2"UBSG9!&$7/T%6***
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MBBB@ HHHH **** "BBB@#/\ ^9B'_7I_[/6A6?\ \S$/^O3_ -GK0H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0_Z]/_9ZT*P_[1C_ +9%QY%UY?V?9G[._7=GTK5MKN.[5FC650IP?,C*?SH
MGHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X?QS\+]%\
M<2I>SRW%GJD2!(KR!N0 <@%3P0"3Z'WKN*\>^*&LZU>^.=,\'V/B&/P]:3VA
MN);UY/+\QLL H;(_N],C.?I0!1^W_$_X:#9J5N/%6@H,&9,M*B^YP6'']X,/
M>N?T?P;\,O'U^TNC:Y?:-=3ME]+D95()ZA,]1[ G\*LI)K_PX\2Z&8?'D?B&
MWO[U+::P,QD;:QP6VEFQUZ\<XZ\UZ9XM^$OA?Q87N'M?L&H$Y%W9X1B?5AT;
M^?O0!L>#O!>D>!]);3])C?$C;YII6W/*V,9)_H*Z*N(^'WAWQ3X9.H:?KNM?
MVK8+Y?V"9F)=1\VX-GD?P]R*[>@ HHHH **** "O,?&]J?%_Q'T?P;<W,\6D
MK92:A>Q02%#/\VQ5)';/\_I7IU>8>+]0MO"/Q:T7Q+J9:+2[O3Y-.EN-I*Q2
M!]Z[L= ?Z'TH KZ9HUO\.?BGI&D:/-<IHNNVTP-I+*76*:,;@RYY&1Q^)_#U
M"]NDL;.6ZD25TB7<5AC+N?HHY)^E>8KK6G^.OC%H4VAS_:['0K6>6YN8U/E[
MY!M50>Y[_GZ5ZK0!S'_"<Z?_ - W7/\ P53_ /Q-9-SKUOK/C?PJL%M?PF.:
MY)^U6DD(.8&Z;@,_A7>UR_B#_D=?"'_7>Z_])VH WM1O4T[3YKN1&=8ER50<
MFET^]34+"&[1&195W!6ZBK) (P1D&@  8 P!0!F6&M0W^I7EDD,J/;'#,PX;
MG%&J:U#I=S:0R0RR&Y?:"@X7I_C6D  20 ">I]:9-)##&99V1$3DLYP!0!FZ
MS<K9S65RZLRQ-(Y51DG$;=*M:7J*:KI\=Y'&\:OGY7'/!Q5"\U.P?4-/87EN
M561RQ$@P/D(YK3M[VTN24MKB&0J,E8V!P/PH J6VM0W.M7.F+#*LD"Y+D?*>
MG^-&L:U%HZV[2PRR>=)L&P=*TL#).!D]300#U .#D9H 9-,L%O),P8JBEB%&
M2<#-5-'U6/6+ 7<44D:EBNU^O%7Z0 *,  #T% &:FM0OKSZ3Y,HD5-_F8^7U
MIVLZQ%HMHEQ+%)(&<( @K0P-V[ STS00&&" 1[T -$@,/FX;;MW8QS5#1M8B
MUJU>>**2,(Y0AQUK2I  HP  /:@#,EUB :XFD/!(SR)NW[<KW/\ 2J'B.RT:
MTTZ2ZN-.5CD*#"NU@3WXKHL#=NP,],T$!A@@$'L: /*E\/:F]Q%"EN6,J>8C
M$@ KQR?3J*ZKPM9Z1=6S[=/S/;L$DDF3.YO49Z?2MR3_ )#]O_U[2?\ H2U?
M  S@ 9.3BF!ESZO;V.KVNEBWDW3C*LB_*O7_  JSJFH)I>GRWDD;NL>/E3J<
MG%6\ D' R.AH(!&" 0>QI 0V5TM[90W2*RK*@8*PP1FJ>F:U#JEU=P1PRHUL
M^TEQPW7_  K3Z4@ !)  SU]Z ,W4-:AT_4;.S>&5VN6P&4<+SBK5_>)I]A-=
MNC.L2[BJCDU8(!() )'3VI2 1@C(- %73KY-2T^&\C1D649"OU'.*K66M0WV
MJW=@D,JO;=78<-SBM,  8 P!28 )( R>I]: ,W5=:BTF6UCEAED-P^P%!TZ?
MXU=NKA;2TFN'5F6)"Y"C).*E(!QD XY&:6@"EI6I1ZMIZ7<<;QJY(VOUXJ&#
M6H;C7)]+6&420KN+D?*>G^-:0 48   ["C W9P,GO0!FZSK,6C10R2PRR>;)
ML C'2M"6410/,0Q5%+$ <\#-.(#=0#@YYI: ,_1]6CUFQ^U1121J'*[7'I3!
MK4)U\Z3Y,OF"/?YF/EZ9K2 "C   ]!1@;MV!G&,T 9^LZO%HUF+F6*212X3"
M#UJ\DH>!90&"LNX CGIZ4X@,,$ CT-+0!FZ-K,6M02RQ0RQB-]A#CK22ZU##
MKL.E&&4R2IN#@?*.O^%:0 7H /I1@;MV!D=Z *6K:G'I&GM=R1O(JD#:G7FK
M-M.MS:Q3JK*LB!P&&",CO4A 88(!![&EH S-)UJ+5VN1%#+']GDV'>.O^<47
MFM0V>KVFG/#*SW/1U' K2  S@ 9.3BC )!(&1T- %74K]-,T^:\D1W6,9*IU
M/.*?8W:W]C#=(C(LJA@K#D5.0",$9![&EZ# H S-.UJ'4KZ\M8X94:U;:S..
M&Y(_I1J.M0Z;>V=K)#*[7+;0R#A><?UK2  )( !/7WH(!() )'3VH @OKM;&
MQFNG5G6)2Q51DFF:9?IJ>GQ7D:.BR#(5QR.<5;ZC!I  !@# '84 9MIK4-YJ
M]UIRPRJ]N.78<&C5]:BTAK82PRR>?)L'EC./\YK2P 20!D]300#C(!P<C- $
M=S.MM:RSLK,L:%R%&2<"JVD:G'J^GK=QQO&K$C:_7BKU( %&   .PH S8M:A
MEUV72A#*)(TW%R/E/3_&EUG68M%MXYI89)!(^P",=*T<#=NP,^M! 88(!^M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !151-4T^6[-
MI'?6KW(ZPK,I<?\  <YJQ--%;PM-/*D42#+.[!54>Y- #Z*AMKNVO8?.M+B*
M>(G&^)PR_F*FH *Y?Q!_R.OA#_KO=?\ I.U=17+^(/\ D=?"'_7>Z_\ 2=J
M.HHHHH **** "BBB@ HHHH **** "BBB@ HHHH *AN(#<1;!/+"<YW1$ _J#
M4U% &8='S,LQU"]\Q5*AMZ\ ]?X?85<MK9K8,&N9YMW_ #U(./I@"IZ* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKHJI_:FG_P#/];?]_E_QH_M33_\ G^MO^_R_XT 6Z*J?VII__/\ 6W_?Y?\
M&C^U-/\ ^?ZV_P"_R_XT 6Z*J?VII_\ S_6W_?Y?\:/[4T__ )_K;_O\O^-
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M\O\ C0!;HJI_:FG_ //];?\ ?Y?\:/[4T_\ Y_K;_O\ +_C0!;HJI_:FG_\
M/];?]_E_QH_M33_^?ZV_[_+_ (T 6Z*J?VII_P#S_6W_ '^7_&C^U-/_ .?Z
MV_[_ "_XT 6Z*J?VII__ #_6W_?Y?\:/[4T__G^MO^_R_P"- %NBJG]J:?\
M\_UM_P!_E_QI?[3T_P#Y_K;_ +^K_C0!:HJI_:FG_P#/];?]_E_QH_M33_\
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M:/[4T_\ Y_K;_O\ +_C0!;HJI_:FG_\ /];?]_E_QH_M33_^?ZV_[_+_ (T
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M"_\ T+FD_P#@''_A6Y10!A_\(9X7_P"A<TG_ , X_P#"C_A#/"__ $+FD_\
M@''_ (5N44 8?_"&>%_^A<TG_P  X_\ "C_A#/"__0N:3_X!Q_X5N44 8?\
MPAGA?_H7-)_\ X_\*/\ A#/"_P#T+FD_^ <?^%;E% &'_P (9X7_ .A<TG_P
M#C_PH_X0SPO_ -"YI/\ X!Q_X5N44 8?_"&>%_\ H7-)_P# ./\ PKG8_"?A
MW_A8]Q;?V#IGD#2(G$?V5-H8S2#.,8S@#GVKOJPTTZZ'CN?4S&/LC:9';A]P
M^^)78C'7H1S0 ?\ "&>%_P#H7-)_\ X_\*/^$,\+_P#0N:3_ . <?^%;E% &
M'_PAGA?_ *%S2?\ P#C_ ,*/^$,\+_\ 0N:3_P" <?\ A6Y10!A_\(9X7_Z%
MS2?_  #C_P */^$,\+_]"YI/_@''_A6Y10!A_P#"&>%_^A<TG_P#C_PH_P"$
M,\+_ /0N:3_X!Q_X5N44 8?_  AGA?\ Z%S2?_ ./_"C_A#/"_\ T+FD_P#@
M''_A6Y10!A_\(9X7_P"A<TG_ , X_P#"C_A#/"__ $+FD_\ @''_ (5N44 8
M?_"&>%_^A<TG_P  X_\ "C_A#/"__0N:3_X!Q_X5N44 8?\ PAGA?_H7-)_\
M X_\*/\ A#/"_P#T+FD_^ <?^%;E% ' :5X4\.R>._$<#Z%IK0Q6]F8XS:H5
M4D2YP,<9P/RKH_\ A#/"_P#T+FD_^ <?^%-TW3KJW\8Z[J$L8%M=PVJ0ON!W
M%!)NX[8W"MZ@##_X0SPO_P!"YI/_ (!Q_P"%'_"&>%_^A<TG_P  X_\ "MRB
M@##_ .$,\+_]"YI/_@''_A1_PAGA?_H7-)_\ X_\*W** ,/_ (0SPO\ ]"YI
M/_@''_A1_P (9X7_ .A<TG_P#C_PK<HH P_^$,\+_P#0N:3_ . <?^%'_"&>
M%_\ H7-)_P# ./\ PK<HH P_^$,\+_\ 0N:3_P" <?\ A1_PAGA?_H7-)_\
M ./_  K<HH P_P#A#/"__0N:3_X!Q_X4?\(9X7_Z%S2?_ ./_"MRB@##_P"$
M,\+_ /0N:3_X!Q_X4?\ "&>%_P#H7-)_\ X_\*W** ,/_A#/"_\ T+FD_P#@
M''_A61#I&FZ1\2]-33=/M;-9=)NC(+>)8P^)8,9P.<9/YFNSK"N-.NI/'.GZ
MDL8-I#IUQ [[AP[R0E1CKT1ORH W:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=6EU58K5+ZQNYQ^],9.UE8]R#C]?H/1: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@!/A3936'POT""=2LAM_,P1R [%A^C"NRI%4*H50 H&  .E+0 4444 %%%%
M!1110 4444 %%%% !1110 5Y[\;/^287W_7Q;_\ HY:]"K.UO0].\1Z7)INJ
MV_GVDC*S1[V7)4AAR"#U H XOXOJT?@W3=1VL8M-U2UNYL#.$5L$_P#CPJO\
M7=;T[4/AP]A87UO<W.KRP0V<<4@8RDR*<@#M@5Z/<VEO>6<EI=0I-;RH8Y(I
M%W*RG@@@US&C_#+P=H&JC4].T.&*[4[DD9W?RSZJ&)"_A0!U,$?DV\<6<[$"
MY^@J2BB@ HHHH **** "BBB@ HHHH **** "CH,FBHYX8[FWE@E!,<J%& )&
M01@\B@#S34/$-Y\0[JYT;0+Q=.\/12&&^U<N \^/O1P ]NQ?\O>+Q_9Z;X:T
M3P;=6"1QZ/HNL0>9L.Y8XSD%B>_)Y/J:T_\ A27P^_Z 1_\  N;_ .+KI--\
M&>'])\.RZ!:Z;'_9<Q8R6TK-(K$XSG<2>PH X[XM:G8ZGX?TG1;&[@N;S4]2
MMA!'#(')4-DOQ_#TY]Z].KE=!^&_A'PUJ)U#2M&B@N^=LK.SE,]=NXG;^%=5
M0 4444 %%%% !1110 4444 %%%% !1110!#=W"V=G/<NCNL,;2,L:[F( S@#
MN:\ZU./X?_$KPVGB2_N%B6&!@EP]QY4MI@D\J&P&SSSG/%>EUQMW\*?!%[JK
M:E/X?MFN&;>V&948^I0':?RH \X@UN_FT#X:^*?$$S&*VU*:":[E&,QOE4D;
MTX7K^-=9\3-0L]5O?".AV5U#/>7.LP7 2)PQ6),EG..V/ZUW]_HVF:GI+:5>
MV,$U@RA#;L@V #I@=L8XQTK&\._#WPKX5NVN]&TB*WN6!7SF=I& /4 L3C\*
M .GHHHH **** "BBB@ HHHH **** "BBB@ K@OBE:^)-1T>RT_0M*;4;6>?.
MHPI<+"TD2X/E[B> QX..<#'>N]HH \$U#7?&:_$KPQ*W@:*VO;:TN([2P6_C
MVR1[<,=PX7:.U=?I%W;Z-\;_ !)!J$T=N^JV5K/;>:P ?8I5@">ISGCVKN[C
M0M.NM<L]:FM]VH62/'!+O8;%<888S@Y]Q5/Q)X-\/^+8HX]<TR*[\K/EN25=
M,]0&4@X]LT <EI5S!K?QXU*]L9DGMM.T9+262,[E\UI-VW(XZ _D:]*K*T#P
MUHWA>P-EHMA%9P%MS!,DN>F6)R2?J:U: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBN9\4^/O#O@R:VBUR\>W>Y5FB"PN^0,9^Z#CJ
M* .FHKSG_A>G@#_H+3?^ <O_ ,36SX:^)?A;Q=JC:=HU_)/=+$92C6[I\H(!
M.6 '<4 =;117'>(?BEX2\+:O)I6KZA)#>1JK,BV\C@!AD<@$4 =C17G/_"]/
M '_06F_\ Y?_ (FMGPS\2O"_B_4GT_1;Z2>Y2(RLK0.GR@@$Y8 =2* .MHHH
MH **** "BBJ":WIDNM/H\5[%)J$<7G26Z-ED3(&6QTY(ZT 7Z*Y?7/B%X;\.
MZ];Z)J=Z\5_<!#'&('8$,Q5>0,=0:ZB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYV_:6_Y"GA[_KC-_Z$
MM?1-?.W[2W_(4\/?]<9O_0EH Z+3M#^"C:9:-<S:%]H,*&7=J)!W;1G(W^M=
M=X+T3X=VVIS7G@\:<]Y'%LE>TNC*51CW&XXR5_2N5TW]G_P==Z7:7,D^K!YH
M4D;%PF,E03_!79^"OAMH?@.XNYM(DO':Z14D^T2*PPI)&,*/6@#'OOBNME\4
MHO!7]C[R\T<7VO[3C&]0V=FWW]:Z#6OAUX3\1:F^HZMHT5U=NH5I6D<$@# Z
M,!TK>;3;![P7;6-LUT"")C$N_(Z?-C-6J /E#2_#&C3_ +04GAV6Q1M)%[/$
M+;<V-JQN0,YSP0.]?1>@^ ?"_AB_:^T;2([2Y:,Q&19'8E202/F)[@5X5HO_
M "=-+_V$;G_T4]?3- !7CVL?'NST3Q+K.D7>BO\ Z TD<<JW&?.=3A1MV_*#
MZY.,=Z]AKYBT?3K?5/VG+J"ZC62)-1N92C#()169>/J!0!Z'X4^-']I^%M;U
M_7=+2RM=-9$4PR%C.[9P@!QST[]ZPC\<_%5S92ZM8^!I'T>,G-P3(R@#KEPN
M/\*]&^(GB#1/"'A2>_U/3(+Y9952.U:-2)I2.,Y!' !YQT%>5Q:Y\3?$_@^=
M]%T;2]"\-_9I-NQ%0&( [@H;)]>0HH ] T;XL6^N_#[4?$FGZ3/->:>56;3E
M;+%B0!M8 Y&"3G'8UX3\./&U[X8\7ZGJD.AW.J37<;*\,;MNCRX;)(4D],=*
M]$_9H!_L[Q$<\>;!Q^#UD_ //_"R_$7_ %[R?^CEH Z3XC^(/#5A\3=)L]4\
M))J6H2QVYCO3>-&8P9&"C:!@X.3^->B>-O&^E>!=%_M#4B[O(VR"WC^_*WH/
M0#N>U>)?&7_DMV@_]<[7_P!'-3_CZS7'Q(T"SNF(LOL\?4\ -*0Y_(#\J -C
M_A>WB2*V35[CP/*NANV!<!G (_WRNT_E7K?A/Q9I?C+0HM6TJ0F)CMDC<8>)
MQU5AZU;U.PLI?#UW83PQBQ-LT31X 4)MQCV %>%?LU3SC4/$%N&8VWEQ.1VW
M98 _EG\J /H:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *\@^-/P]\0>-[[2)=%A@D2UBD63S)@F"Q7'7Z5Z_10!\_1
M>&/CG!"D,>L*L<:A547,? ' '2NG\":/\5+/Q5!-XJU(3Z2$<2)YZ-EMIV\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
0* "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gaz3apgusshz000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gaz3apgusshz000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" AS!*8# 2(  A$! Q$!_\0
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M^)6C:+-Y4^]F_P!DUH;KV;PX-T;+.P(([]*\PTOX=W6HZG/<:D\BKYA(W^E
MCO=&^)FBZU.(8=ZM_M'%=FCK(BNIR",BOF;Q=I4?A_7P+"Z.X2*,+QWKWWPG
M<37&C0&8$$1CKWH WJYKQ)XUTWPQ(J7H;+#(Q72UXA\;O^/V'_<_I0!TX^-'
MAT]$F/\ GZ4?\+G\/?\ /.;\O_K5R'@GP%8ZQHD%S-.%9QR,5U'_  JK2_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %>/?&/\ X\)?K7L->/?&/_CPD^M (T_A#_R#Y/\
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M?_Y!<W^[_2N2^'?@VW\0QD:C&)(@N5%=1\5Y!+H;.#G=&#^E6OA&!]@7_<H
M\U^(OARW\*ZZG]G((D"9_E7J<.FPZ]\/+=[E=[1P%A7%?&O_ )#(_P"N?^%>
MA^&?^2<K_P!>QH \,\*Z#:ZKXTCTZ>/=$S$$?C7M/BC1H-'\--# FU5B( KR
MCP3<Q67Q(BEG<(@=LD_[U>Q^.;N&ZT!VA<,#&>10!P7PA_X_A_UT/\Z],U#Q
MYI>FW#0S9W*<'FO,OA#_ ,?P_P!\_P ZZ#Q'\,GU?4)+@7<B;FS@$T".NTSQ
MMINM7/V6VSO8<<U\^M_R5%_^OO\ I7K7A/X=-X?U9;TW4DFT=&->17$T=O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \B^,]HQTN"3!*F89P/<54
MT/0M%E\&7,CI'YH4=6%>F^)= A\0:=]GFXQDCZUY2? &J6QEM(3.8)&.3N-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*T-SQ_QIJNO2^-[72=,O/)$J]_P_QJX/"7CP_P#,93_/XUB^,KUM/^)]A<*
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MS0!F^%_$NIV'B&32M7G:9XQR>V>:]31M\:N.A&:\@T&QU#7_ !;-J,T&RW<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"R)\JC- CKVT33V15:W4A3D"KL4*0IMC7 %/HH **** "BBB@ HHHH ****
M.)\61ZK;RM=6DS^7G[BBL_1?B&3(+:]LY(B#M+N,5U'B+Q)IVA6IDO751G'(
M%>:7_BCPUK\XBGN!&&. 4 % #?$>FF7Q)/K5E<+*)> B')[_ .-06.C:CK&K
MVTDB2(J'G<*NIH>I:;"MWX=C-U;]C*2>/UK<T3QRL%PEIJZQ0W#' "J* ._T
MZU^Q6:0$YVU:J*">.YA$L1RIZ&I: "BBB@ HHHH **** /#OC;_QZ1?[_P#6
MO)_#?_(;AKUCXV_\>D7^_P#UKR?PW_R&X:!H^M/#?_("MO\ =K5K*\-_\@*V
M_P!VM6@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,;3^->GV[F2VC=NK*": ):*** "BBB@ HHHH \.^-O\ QZ1?[_\ 6O)_#?\
MR&X:]8^-O_'I%_O_ -:\G\-_\AN&@:/K3PW_ ,@*V_W:U:RO#?\ R K;_=K5
MH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 45GWNLV>GKF>3:!7(ZM\1K&$,+28,W;-:0I
M3GLB7)+<[MYHXAEW"_4UBZOX@LK6V?$\;-@\ UY-JGQ U*]+)E=G08-<M<7L
M]RY=Y&Y_VC793P+WDS*59="WJ6I3RZE<.DIVLY(JJ+ZYS_K35:@=:])125CG
MN>R?"Z:2:TN3(Q;%>AUYQ\*O^/2Y_P ^E>CUXF)_BL[*?PH****P+"BHIKB.
M#[YQ5?\ M2U_OT6'9EVBJ7]J6O\ ?K/;Q3IZ7C6[2_,.U-1;&HMF[15$:K:L
MH(?K2_VI:_WZ+,5F7:*@ANXI_N-FIZ0@HHIDO^J?Z4 5I]5L+5]D]W%&WHS8
MJ+^W])_Z"$'_ 'W7D/B?3AK/Q#L[":618I%YVL1Z5U'_  J+2?\ GXN?^^C_
M (T =U!J^GW,@CANXG<] K<U;>1(UW.P4#N:XW1/AWI^B:A'=PS3LZ= S''\
MZR_&WB6Z\^*PTXAG9]D@] : .VDU[3(VVM>P@_[U3V^IV5UQ#<QN?137G]E\
M,+.^@$]]-<+*PS@,>_XUF7N@:AX1U"W;2][Q22 ,78]* /7JBEN(8,>;(J9Z
M9-9SZQ%9Z/\ ;;MMJJ!N/X5Y+XL\4ZGJ6HVJV^/LPDX(/:@#VY)$D7<C!AZB
MG5A^%69M(4L23Q6Y0 C,J#+$ >]4FUC3D8JU["".H+51\67AL=$DF!QBO.-&
M\(+KEQ/<7$LP#G*X8T >L0:E97,GEPW,<C>BM5NN-\/>";?1=16[CDE8CLS'
M%=E0 =*I3ZO86YQ+=Q*?0M6+XU\1?V#H[3QL!)G'-<=I'@Z;Q2#>ZJTJ(_S1
ME&/- 'I$.N:;,VU+R$MZ!JOJ0RAE.0>AKRO6?AZ-%@^UZ1),\P/1F.*Z_P '
MW]Y=VC178 :(8H Z*:>*W3?+(J+ZDTRWO;:[S]GF23;UVG.*X3XF:FXTHVEJ
MW[_=T!KGO -_/HMR(+MSNNFX#'- 'L=-DD2)"\C!5'4FG5R/CC5?LVGO9*V)
M)UPM '2P7]I=-M@N(Y&]%.:L,P5<L< =Z\+\"W5YHWB _;680D8&23S7LFHR
M^9HTDBG[R9!H =)K6FQ.4DO858=06IO]O:4?^7^#_ONO'=+\-0>)/&%Q#=3S
M!0N?E8^_O76R?";2T0F.XN2W;YC_ (T =_!>6]S_ *B9)/\ =-3UX]X9OKO0
MO&5QI3,?L\:X4L>>]>OQMOC5O49H =1110 4444 %%%% !1110 4444 <;XO
M\%'Q*A42A,G/-<D/@_= 8&H# KU^B@#R'_A4%W_T$!1_PJ"[_P"@@*]>HH \
MPT3X62:7J'VI[H.>*],A3RH4C_NC%/HH *K75];6:YN)DC'^T:FFD$43R-T5
M2:^??B;XOFU&Y:&RD)B7*N0: /?[>ZANH1+#(KH>A4\5!<ZOI]HVV>[BC;T9
MJXOX?W1A\!12NQ)$3$$G_9KSJ&*[\<ZY()7?RTD9/E8]CB@#WRUU&SO?^/>X
MCD/^R<U:KP7P]?W/A7QA/IY=O)4A5W&O:;G6+6QLTGN7VJ4#'\J /'_C;_QZ
M1?[_ /6O)_#?_(;AKT7XM:]8ZM;1K:R;B'S^M>=>&_\ D-PT#/K3PW_R K;_
M ':U:RO#?_("MO\ =K5H$%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 44R258E+,>!6!J/C+2M/!$DV&%5&$I;(
M3:6YT6<#)JM-?VL _>3HN/4UYAJWQ+E^9;)U*FN*U'Q/?ZD3YKXSZ&NNG@IR
M^+0RE62V/7]5\=6>GAMFV7'H:X35OB+/>;A;AXL^E<(7D<\LQSZFM"QT*^U$
M@6\>[-=D,+2IZLR=24MAMUK=_=L?-N78'L:II%-.WR(SD^@KOM)^&]W*0;R$
MA3Z5W&F> ],L K!3N'J*4\52AH@5.4MSR#3O#%_?. 89$![D5VVD_#)QMEFF
M!']TUZ?#:PP(%2-<#VJ; '05QU,;.6VAM&BEN<BG@6P5 #%&2.]/_P"$'T__
M )XQUU=%8>VGW+Y(F;I.CP:4C+"BJ&ZXK2HHK-MMW96P4444@/._B3>W%HB>
M1*R?+VKR/_A(-4_Y^Y*]X\5^'3K@4!2<#%<1_P *N?\ YY&NNE."C9G?0J4X
MPLSSW_A(-4_Y^Y*A.J7K2F0SMO/>NF\0>"Y],E1(XSR*P?[ OO\ GG6Z<6KH
MZ8R@U=#1K^J 8%W)1_PD&J?\_<E:^C>$KB^G6.2,Y)KJ_P#A5S_\\C2<X+<F
M52G%V9)\-]2N[L_OYV?YN]>MUQ/A3PBVAGE".<UVU<55IRT//KR4IWB%,E_U
M3_2GTR7_ %3_ $-9F)X7XLN)K7XB6<D"LSA> O7M71?\)%K/_/K<?E67K%S#
M:_%"PEGQL .<_A7I/_"3:-ZI_P!\B@#,\-:K?W<RBXAE09_B%<=:CS_'EXLW
M*K(-N:]+M/$&F7,ZPP,N\], 5YWXLMI=!UM-25<)-*"Q]J /6HA^Z3_=%1W$
M-O+M\]5..F:Q-,\7:7>V:/'-G"@'ZURWBKQNLEW;6NE2;I#(%<&@#T&:SMKJ
MV,#QJT1ZKVKS[X@:=:V7V 6\*QY;G%=SHGVG[ INAAR :Y#XE==/_P!^@#H_
M"[JFCJS$ <=:LR>(M+CD*/>PAAU!:J7AV!;C0Q&V<''2L2[^%6C7=W)</-.&
M<Y.&/^- %WQI_P 3OPI*MA(),G@IS7(:=X%U]K(/%JTD/R_=XKIM2A_X07PP
MXL,M&IZR<UJZ-XJL;[3$F9P'5,N!0!QGAW6=0T7Q,FBZA.\YQDR-7JL;B2,.
M.A%>17$R:W\1U:T^:,KU_&O6K9#%;1H>JC% 'F'Q,)D)B?\ U>X=>E>@^'45
M- L@HX\H5RWQ*T:6]T5I;9<S!LTGA'QE8O8)8S2XFMUV,/>@#NI$1UPX!'O5
M=?LMI%))$%&.6Q7,>)O&UCIMB3'+^\S@5@6FMWX\/ZE/>_+YJ9@]^E &;<:C
M;:I\1IHKBX1;;;D;CQU-'C-["VUG2[BRNXML)RP0]>M,\(> [3Q+IR:I?M(L
MK]2IK6UOX5Z3!I-Q/"\S3(N5R3U_.@#N]"U1-4T=;Q2"",UYGXJU2'4_&&GJ
M;A8XHGPX)XI?!_B/^Q=&&E7#XD1#P?I53PKX,M_%-[?W6I%QMD)C*GM0!?\
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M$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_6NKMM(L;4#RK=%QZ5>HKCE5G+=FJBEL(  ,#I2T45F4%%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV4%M'LC08^E<]3'):01<:/<\MTCX9.^V2:?'?:17<Z;X2TZR0![>-V'?%=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&59:!8V<846\9([XK22-(QA% 'M3Z*Y7)O<TM8****0PHHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "N0\6^*H-$NH8&6-I)/NA@#77'H:\7^)9\KQEI$MPI:%6^;Z8H
MTO$GC[^S]"CGAMH3<LV"FT>U9_A?X@7<VI0VNHV<,7GM\ORCD5RFKR0Z[XND
MM;1/]&0A@HY'6M76?LC>*M#BLXL,@ 8CUQ0,]XCB@(W)&@]PM2U6L%9;10_W
MJLT""BBB@ HHHH **** /#OC;_QZ1?[_ /6O)_#?_(;AKUCXV_\ 'I%_O_UK
MR?PW_P AN&@:/K3PW_R K;_=K5K*\-_\@*V_W:U:!!1110 4444 %%%% !10
M2 ,FLK5=>M-+@:21U;'8-S346W9 W8TI)4B0NYPH&2:XWQ%XZMM.C9;617D'
M8UQ7B/Q[<7KM%9NZ+T-<8XGO)=\A)8]S7;3PT8KFJNQS5*Z6QH:SXCN]6F+.
M[*,] U9"H\C<9)K0BTT]6P:NQVL<?1>:57,Z-)6IZGGU,7%;:DFE:5;#$MPY
M5EY ]:Z3_A(#:P^1!#'@?Q #-<^ S< $_2KEKI=S=.%6-QGN5KQZ^-K5V<[Q
M-2>D1EQJ%Q<,2TCC/;=4*)).^%RQKL=.\#7$F'D9=O7!KK+'PM86R@O""P[U
ME&A.6Y<,%5J:RT/.++PW?W3#]P=I[UU>G>!8>'F9@?2NVAMXX%VQK@5+71##
MQ6YZ%+ 4X[ZF=9:-:V:[5C5O<K5]45?NJ!]!3J*W22V.R,5%604444R@HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?%/4L?Z^2@5CZ;HKYF'Q4U$=9I*</BMJ'_/62@+'TO17S3_PM>__ .>LE/\
M^%L7O_/22@=CZ3HKYN_X6U>8^_)3A\6[L#EI* L?1]%?.0^+EUZR4H^+MSGK
M)0%CZ,HKYU_X6_<?]-*=_P +@G])*!6/HBD9@BEFZ"OGH?&*7TDI'^,$KQE2
MLG(Q0%CVJ7Q=H\,K1O<X93@BF_\ "9Z)_P _7Z"OE:^\07MS>2S+,P#MG%10
M:IJ$TR(LSDD@<4#L?8&GZM::HK-:R;PO6KM<1\.-+N;#2?,N'+&90PS7;T""
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH H:O<_9M-N'SC]VV/RKPKPEI:^*
M=;GDO)'PD[*,'MFO;/$D;2:1.%[1M_*O)/A9(L6I72.0";ANO^\: *$.[PSX
M^N(H';RRX49/O7L.L>(X-%TM+B=PH\L,3^%>/>(OW_Q!E6/DB52<?6NR^),,
MDGA@!$9CY"]!_LT#/-OB+XOM?$<");RAR&SQ7'^&_P#D-PUFRV\T/,D;+]15
MC3+P6-]'<$9"]J /J-S_ ,4='_US->&3J/M,O ^^?YUT<7Q7@FTE-/\ LK A
M=N:YIW\QV?\ O'->I@?A9S5M&-Z5CZGJ!B;RT/:M=ONFN7U7_CZ_"M<9-QAH
M315Y&UI?CG4-* \J*)L?WA_]:NKL/C-JR866*!1[ ?X5Y717C79V'JVK?&+4
MY$3[.(R>_P#G%9/_  MS7?[D?Y__ %J\_HH$>G:7\7=4%TGVD1K'NY.:[:7X
MPV2H/+G4G'M7SW10![C<?&>4?ZIXS65<?&W5QGREB/\ GZ5Y'10%CTB;XS^(
M)<@QQ?G_ /6K/F^*&MS_ '@H^AKAZ* .GG\<ZK/]YR/HQK-F\0W\_P!Z9Q]'
M-95*#@\T 3O?73G)N)?^^S3#<SGK/(?^!FK$%U!']^+=6K;ZSID>-]B&H P/
M.E/65_\ OHTF]V/WF/XUVEOXHT&/&_25:M6#QOX6C^]H*G\Z //H[*XF^ZN:
MN1>'=2F^Y#FO04^(OAB/[N@J/SJPGQ2T"/[NC8_.@#@HO!&N3?<ML_G5V+X:
M>)ION66?S_PKN$^,&D1_=THC\ZL)\;K&/[NGL/SH X^W^$WB1O\ 661'Y_X5
MJV_P?U-L>;;,/SKH/^%ZVO\ SXO^M'_"]K;_ )\G_6@-3-D^#LJVK,(G\P#@
M<U7T;X23W-ZZ7L3K&!P1FMD_'6U(P;%_UIJ_'&S4Y6P8'\: U)S\%K/_ *:4
MS_A2UIZ24G_"]K7_ )\7_6C_ (7M:_\ /B_ZT!J)_P *7MO[LE(?@O;_ -V3
M]:=_PO:U_P"?%_UH_P"%[6O_ #XO^M :D9^"\/99/UIA^#$?9)/UJ?\ X7M:
M_P#/B_ZT?\+VM?\ GQ?]: U*Y^#*=D?]::?@R.T;_K5K_A>UK_SXO^M'_"]K
M7_GQ?]: U*?_  IH_P#/-_UII^#3_P#/)_UJ]_PO:U_Y\7_6C_A>UK_SXO\
MK0&IGGX-R=HG_6FGX-S=HG_6M+_A>UK_ ,^+_K1_PO:U_P"?%_UH#4S#\')_
M^>+_ *TT_!RY[0O^M:O_  O:V_Y\7_6C_A>UK_SXO^M :F1_PIV[_P">#_K3
M/^%/7O\ SP;]:VO^%[6O_/B_ZT?\+VM?^?%_UH#4Q#\'K[_G@WZTT_!_4/\
MGW;]:W?^%[6O_/B_ZT?\+VM?^?%_UH#4P#\']1[6[?K3?^%0:G_S[-^M=#_P
MO:U_Y\7_ %H_X7M:_P#/B_ZT!J<Y_P *@U7_ )]F_6FGX0ZO_P ^K?K72_\
M"]K7_GQ?]:/^%[6O_/B_ZT!J<R?A#K'_ #ZM^M-/PBUKM:G]:ZC_ (7M:_\
M/B_ZT?\ "]K7_GQ?]: U.5/PBUSM:']::?A'KO\ SZ']:ZS_ (7M:_\ /B_Z
MT?\ "]K7_GQ?]: U.1_X5'K_ /SYG]:;_P *D\0?\^9_6NP_X7M:_P#/B_ZT
M?\+VM?\ GQ?]: .-/PD\1=K(_K_A33\)?$G_ #Y']?\ "NT_X7M:_P#/B_ZT
M?\+VM?\ GQ?]: U.)/PE\3=K(_K_ (4G_"IO$_\ SX_J?\*[?_A>UK_SXO\
MK1_PO:U_Y\7_ %H#4X;_ (5-XI_Y\?Y_X4W_ (5/XJ_Y\?U/^%=W_P +VM?^
M?%_UH_X7M:_\^+_K0!P7_"J/%?\ SX_J?\*3_A57BK_GQ_4_X5WO_"];7_GQ
M?]:/^%Z6G_/B_P"M ' GX6>*O^?']3_A2?\ "K/%7_/C^I_PKOO^%YVG_/@W
MZT?\+RL_^?!OUH \_P#^%7>*?^?']3_A2?\ "L/%'_/C^I_PKT#_ (7C9_\
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M_P"$8T?_ )\8Z/\ A&-'_P"?&.@+GR1_8E[_ ,\Z/[$O?^>=?6__  C&C_\
M/C'1_P (QH__ #XQT!<^2/[$O?\ GG1_8E[_ ,\Z^M_^$8T?_GQCH_X1C1_^
M?&.@+GR1_8E[_P \Z/[$O?\ GG7UO_PC&C_\^,='_",:/_SXQT!<^2/[$O?^
M>=']B7O_ #SKZW_X1C1_^?&.C_A&-'_Y\8Z N?)']B7O_/.C^Q+W_GG7UO\
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MTS_>= 35NJ6CH8M'M488*Q@$5=H$%%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&ZM>B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** &31K-$T;?=88->7>(OA_=MJSW^EJQD/'6O5** /(]%^'%W+J,5WJT9W
MQ-N6NQ\4^$+?6]*^S!,D'(P*ZNB@#Q-/AQK4MRL,T9^R@XZGI7JGAO1(=!TF
M.RA7"I6Q10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIUK!\"WVHW-_?+=F7:K_ "[OPH ]&HIKNL:[G8 >IJ!;^T9MJSH6],T 6:*
M0>E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHKEO%WBH^'+-IP%.#WH ZFBO&O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F
MZIH.GZS$8KZ 2(>H-:5% 'DGCSP3H6FZ5)):V:HX3(-<A\+_  [IFL72K>VX
MD!]:]0^)?_(%E_ZYUPGP;_X_4H&>KZ=X/T32'\RTM%C.<YK)\2_$33_#LS0R
M1M*Z]DYKL9D$D3(3@$=17D_B3PWX;AUR2\U'4I%?NA)(_G0(='\:;#S0'LKA
M5)ZE2/Z5W^A^([77=.%W!PI&<9YKQ+Q;=^'Y;#9ITR.47&0H%;?PAN)&M/++
M$J(SP3[4 =9J/Q5TO3M1%G+ ^XMMSS58?%FP;5/LJ6LS<@;@#C^5>3^)[7[;
MXP2WR1OE(R*];\/?#^QMM,%P[%I%4GYAGH*!F_K?C2QT6QCN)AG>FX*#S7)V
MGQDL)YO^/*XV>NTX_E7G_BR>35_%-KI[2,(U;9@&O4--\ :>/#FP\,J,<XYZ
M4"'P_%;2YM2@LEA??+T/I78W.K6]K8_:I6"I@GDXKYHL[ Z?X]@CW,1YIQDU
MW?Q1UB6/0(;='* 28)4XXR* -F]^,>GP7#1QVD[A3@E%)'\JW_#7Q"T_Q#+Y
M2(8GQG#G'\Z\L\&3>%X=/D_M&\42,<_,,U@:CJ-G8>*A-I-R7C>50,' QF@#
MU+XK^+(]/L'TX1N7F3*N <#BN$^&_C6#1K]1/!)(TF$RH/?BNS^(%A!J/A-=
M08YD2!>WM7,_"GP_;:G=!INJC<.*!GL.M^*[;1--%[-$S(4#X'N,TSPSXOM?
M$R;K>)TXS\U3:YX8MM<L/LDSE4VA>*C\.>$[7PXNVWD9N,<T".AHHJ*ZE\FU
MEE_N*30!Y?\ %W7Q;:;-IRM\TBYP/I_]>O&)M#NM,MK+57R5=@PP*Z/QQJ\6
MO>+X_,DQ$H*G'X5UVLW6@W7@RVM%N%,D*''% SM_AOKG]LZ )&?+*0N":Z'6
MM:AT6U,\REE SQ7AWPF\0?9M733=_P CR$_K7J7Q 8-H;D="AH$9L'Q:TJ>U
M>9()#M;&WG-9R?&;3OMBQ/:3H&; +*0/Y5P/PW\/QZKK(:5VV>801GCK6_\
M%;PM::59VTMOPW7(&*!GJC>*K4:$VJ(A>,=EY-?.6L^)/M/C!;QE<Q1S[PN.
M:]6^%,/]J>"VMIV+*7ZGGUKRO5M.B7QX+4?<-P%H ]RT_P 8Z?KF@++):R"(
M  JP([5B>&=8\,7&MW$=EI[1SA\,Q[G\JW;[0K?2?"^V'^Z#T]J\M\ ?\C;>
M_P#7;^@H$?1"_=&/2@]*Y'Q#XUM= F\F:15('>LO3_B=8W][%;I,A:1MH'%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPJLM4U![V.65)&[(2/Y4 <OXMT[PYIVA@6EO&TSQ\LC X-2?"!E\G&>?*/\
M*M^S^$5D+22.>[N&W#^)B<?K6WX5^']IX:G+P2R-E=N&)H&>0:G_ ,E!MO\
MKN:^A[%<Z65'=2/TKC;CX96,^N1ZD99-Z/N YKNX(1;6^P= *!'SIXULY="\
M607C1L4WEL@5Z+IWQ(L/^$=!*DNR$8SSTJOX\OM&NIUMM2E6+=P" ,U@:7X.
M\*K:M=)JDS+M) +''3ZT#.)L-0.H>/8)2K &4D9%=U\4M*E;0X;A4+J9.0!G
MN*XW38X9O'=HEH=R+(1G%?15SHT.HZ6+6X48P>HS0!XOX&L/#5]I\AOK>,2*
M<?.P%6#=^$(-=^Q1:29'1QADY'7Z5M7WP=M1<,]M=7"ACDA7(_K6UX9^&%AH
MUS]J:2224]?,R?YT"$\?0HO@B8PQE4,0('IQ7#?"36K:PN]DS!25P,G%>U:S
MHT.KZ3)82\(ZXR*\SB^#MK;ZBLL5Q.JHP888CI^- 'HNL^([;1K(W,HW*%#<
M5'X?\46WB!<P*5XSS5?6_"<.L:4+.21PNP+D$YX&*3PKX2@\-IMAD=N,?,:
M.GKE/'>M+I&BR$M@R*5'-=77+>,/",/BJVC@GE=%0Y^4F@#P'PWX1OO%E[)/
M#(%S(V"?K7:O\'-9\LC[9'C'3BO2_"'@^T\+6300,7RV[+=:Z>@#Y5N=,N?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %!Y&*** .'\8^ 8?$9#QJBR <$UQ:?"
M37XE\J/446(?P\5[910!YYX4^&\>B3BXN@DDX.0PKT.BB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVVS?3VD:VJG);/;\J />**PO"VO)KND0W)8>8XR0*W: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ^] SW6BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW6BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !15::]@@^^V*SYO$VFP??FQ4N26Y$JD8[LV
M:*Y.Y\;Z>N?*F!K'N?'DPSY+*:AUH+J8RQ=*/4]"+JO5@*B:[MU^],@^IKRR
MX\:ZC-D';BLR?7+NX^\Q'T-9/%1Z'-+,8+X4>NSZS9PC/GQG\:RKGQA:P9P
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M!\0$2WC4V;<(!^E6K;QVEQ.D7V1AN.,UH_\ "'Z=[_E4D7A2PAD5USD'(XH
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MQASTI/ OAF'4+O4;C4[?S=TA9-XZ5Z9<Z?!<VXA90$!Z 4ZULXK-=L0 S[4
M8\_@_0S!)MT^(':<<5Y99RW7A&ZOHXXG*2N2H4=!7N?45DWWAZROW#2KR/04
M >=^$]!BUW7'U74+;>LB]''UKNIO!FAR1,JV$0)[UJV.GPZ? L4(PH]JMT >
M,Z?!-X<\>7R1Q-]E\O:H X[U8L8IG\5V\OE,%+YSBO3;C1K:YF,KK\QZG%$>
MC6T4JR*/F7IQ0!9O+6.[MGBD4,"I S7D,EK>^$/%D*0J[6TSEV"CBO9JHWNE
MV]\P:51D=\4 365T+RU2<#&[M5BH;:W2U@6)/NKTJ:@ HHHH **** "BBB@
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MHHH *1F51EB!2UQ/CG7[C2K-C;D;@:N$'.7*A2=E<[/SH_[XH\V,]'%>#_\
M"?ZOZK^=7M*\<:I<7BHY7!([UTO!32N9^V1[;14%E(9;*&1NK*":GKC9J%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %9FO?\ ((FK3K,U[_D$34 ?
M)?BG_D8;K_>KU+X,?<7_ '_ZUY;XI_Y&&Z_WJ]2^#'W%_P!_^M SW6BBB@04
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 44A8#J156;4K>#[[4FTA-I;ENBL.;Q7ID&=TO2LJY
M\<68SY,E0ZL%U,I8BE'=G8TQI$3[S 5YS<^.[GGR6%9,_C'49_O$5F\3!'/+
M,*2V/5VOK5/O3H/J:ISZ[90CB>-OQKR*?5[J?[SGGWJF9)&.2S?G6;Q79'-+
M,G]E'J=SXTMX,X0-]#61<_$$-D) 1[UP7S'N:GAL)Y_N+G-9.O-[&$L;6EL;
MUSXPN9L[&9:RI=<U"4_\?+XJQ#X7U*?[D6<UJ6W@>_.#+%Q2M4D1RXBIW.9>
M^N9/OS,:BQ)(>A8UZ';>!(./.4UK0>#--AP0#FJ6'F]S2.!K2W/*ELKE_NP.
M?PJU!HE[,>8)!^%>O0:+:0?=4<>U7EAC08"+^5:+"]V=$<M_F9Y3;>#;F?&6
M9?J*U[;X?.,,UP#[5Z#M4=A^5+6JP\$=$<!26YRUMX-MXL;PK5JPZ#I\0_X]
MD)^E:E%:*G%;(Z(T*<=D5DT^UC^Y"HJ=45!A1BG455D:));!1113&%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(6"C)(K+OO$-A89\^
M3&*:BWL%[&K37D1!EF 'O7!:G\2+",$6LV6%<;J/Q$U.X)1&78:Z(82I(S=6
M*/8KC6;&W4E[F,$=B:Y?4_B':V.X(BR8]#7CUYJMU>MND=OP-4_G8XRQKKA@
M8KXF9.L^AW6J?$6>[W"!7B^E<C?:M>7Y/GSNX/8U8LO#M_?X\B/.:Z*V^'&J
MO&#)#S6Z]C2(]^1P]:>A_P#(03ZBNL_X5KJ/_/&KFF_#Z_MKI9'BP 12EB*;
M6X*G*YZCIO\ R#;?_<%6JAM(S#:11GJJ@&IJ\9[G8@HHHI %%%8M_P")]-TZ
M9HKB3:R]::BY:(3=C:HKEY?'6CB,E9N:X?4_B7J$=_(MJRF$?=K:&&J3V1+J
M11[!17B?_"SM8_O)71^'?B()Y"-2D 7'&*J6$J15Q*K%GI-%<U_PG6B_\]JV
M;'4K?4(A) V5/2L7"4=T6FF7*Y77/&MKHLFR55)SCDUU5?/GQ0 DUJ.-F(5I
M@#@^]0,]"'Q2LO\ GFOYU:L?B+:7MPL2HN6..M<QH_@+PS<V*2322;BH)Y]J
MW=,\!>'+:Z66W>0NIR.: .ZENX8+<3S2*B8SDFN+U+XEV-C.T<827!QD&N=^
M*_B*6QA.DP/C<@QS[5#X.^&EEJ6F1WU_YF9ESG- '8:-\0[#5)UB<QQ$^IKL
M(Y$EC#HP93T(KQ7Q'\+;JUO_ #="1S@<9)KO+>YU+1/#$:7(Q.D7ZT ;&N^(
MK30[1I973<O\)-2:-K46L0"6,  C/%?/'C*_U[6();ZY&+=202":]:^%Q)TA
M,G^"@#T*BBD9@JECT% %>]O(K&W,TSA5'<U@Z3XQM=6O);>(+^[;&0:X;XF^
M*9)VDT:S?,A&<"N9^$IE_M:Z$I.\/SS]* /H8=*1F5%+,0%'4FA?NCZ5RGCK
M7#I&C3!6P[Q\4 &M^.M/TAV0/'*P[ UEV7Q0L;FX6.1%B!.,DUY[X(\)GQ?<
MK?ZB7,3]P:ZKQ'\)K3[+NTP2&55XY[T#/3[.]@OH!+!(KJ>ZFG7EREG:R3N1
MM09.:X?X=Z1K>CZ?';:@F$7W-2?$K71INCRVP;#3)@4"+-I\0+"ZO_LP*?7-
M=?$XEB5UZ,,BODJULM1L+.#6/F$;N!G)]J^F?"6JQZGHMN5;+)&-U &\3@$^
ME<IK/CFRTBZ6%RA)]ZZ#4[N.RL99)#@;#C\J^8M;2^\0WE[=1DLD$A&0: /I
MO2=3BU:P2ZB(*OTQ4&LZU%H]NTL@&%&>:\X^$6O-)#'I$C_-$N2"?;_ZU;'Q
M3)&BS8)'R4 .'Q3L3T1/SJS:_$K3YY51S&F>Y->??#WP/I>NZ?%+>.^YER<&
MIO'G@32-#L))[1Y/,5<CF@#VFUU*UNK99TF0HW0@UCWOBVTM-:@T\%&\W^+/
M2O/_ (>7%S>>'Q$Y)2.)F!S[5QVI37DVMF^@R88'(8^E 'T?'<13?ZN16^E2
MURG@H//IL5XQ)$B]ZZN@ HHHH **** "BBB@ J*XF6W@:5NBC-2UGZU&TVD7
M$:?>*\4 <[=?$+3[6<Q,\>1[U#_PLK3?[\?YUPVF?#H:OKTC:@K^61V/UKI/
M^%.:'Z2_G0!J_P#"RM-_OQ_G1_PLK3?[\?YUD_\ "G]!]7_[ZK.U[X2Z9;:-
M<367F&=5^7F@#TS2-9AU:W6:$@AO2M.N"^&NFW.GZ+!'<@A@.?RKO: "BBB@
M HHHH *S->_Y!$U:=9FO?\@B:@#Y+\4_\C#=?[U>I?!C[B_[_P#6O+?%/_(P
MW7^]7J7P8^XO^_\ UH&>ZT444""BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *0L%&2<"EKGO%FJ-INGAHS@L<5,I**NR*DU
M"+D^AI2ZQ91/M-Q'GZU)'J5I(NX3I^=>(W%U+/*SLYY.>M2Q:E<0IM5CCZUR
M_6M=CS%F3OJCV:35K*,9-S'GTS69<^*[6#.UD;Z&O)I+F64Y9C^=1Y<]VJ7B
MI=$1+,IO9'HUS\0(X\A;?/TK'N?'$LV=B,M<I'#)*<*#5^'0;V?[B=:CVM21
MB\57J;$MQXCOIB=L[K^-47U.]D^]<.:VH/!>IR$$QC;6Q;>!6X\]*7)4D)4<
M1/>YPS2RR'YF+4JVT[_=C8_05Z?;^!M.7!=3FM.#PU86_P!Q?TJUAI/<UCEU
M1_$SR2/2[V0\6TGY5I6WA>[GQN1U^HKUJ*SAA&%0?E4^U1T4?E6JPJZLZ(Y;
M%;L\UMO ,LN"TY7ZUL6W@6.'&^0-79X'I16BH070Z(X*C'H8=MX9LH<;H4;\
M*T$TJQC^[;(*N45HHQ70Z%3@MD1I!$GW4 J2BBJ+L%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 444=* "BHY9XXE+,PP/>
ML*^\8Z789$LN"*J,)2V0FTMSH:BDN(8?]9(J_6O-=4^)2C=]BE!],UQ]_P".
M-4OLAW&#Z&NF&#J2W,W5BCV>^\2:?:(2+B-B.V:Y#4_B;%!N2* -[@UY/-=3
M3N69V)/O38X9)GVJ"2:ZX8*$?BU,G5;V.GU/QQ>WI/E221 ^AKGIM4O;C_6W
M#OGUK7L/!NJ7Q!CBRIKKM+^&C''VV/'KBM'4HTT+EG(\T2WGG/R1LY/I6I9>
M&]0NW -O(JGOBO9K#P/I=B 40[O<5T$-I# FU$7 ]JYYXY?91:H]SR?3/AC+
M/MDDN"O?!%=GIG@>QLP/-CCEQZBNKP!T%+7)/$U)[LU5.**D.EV5N!Y5NBX]
M*M  # I:*Q;;W+"BBBD 4444 %%%% !7B/Q!DD76IPK$<U[=7.:IX,TS5KAI
MKA26;K71AZD:<KR(J1<E9'@'G2_WS3"23D]:]OE^&NC>6=B-N[5P^I_#K5%O
MI!:19A_AS7I0Q5.7D<[IR1P].5W7[I(KJ_\ A7>N_P#/$5T7AWX<%I3_ &K&
M0N.,54L13BKW$H29YKYTO]\U[?X"9FTJ$L<_+2?\*TT/^XU='I>D6VE0K%;@
MA5&!FN+$8B%2-HFU.FXN[-"OGKXJ(TNKHBG#-* #Z<U]"U\_?%$.FKI*JGY)
M0>GO7 ;(ETSP!KUS:))'K,R*0" ,?X5U?ACP7K.F7IDN=5EF7/1L?X5SFF?$
M][.T2$GH .E:UA\4GN;V&'=]]PO2@9SGQ=1D\70,V2@BP3^5>Q^#71O"UCM(
M^YVKD_B-X3DU_3#>6Z;K@QC;^5<5HGCS4?#$/]GWQVB(;5&* /<KO4K*R;_2
M9XX_]XT\?8]1A!&R:,CBOGO5=8U?QSJ:PVI)C<8[U[EX6TQ]-T2VBESYBIAL
MT".%^+%E;6GABX6"%8QZ#Z5I?#!MNBJV.D=5_B]&S^&[@*,__JJW\,8R-'16
M&,I0!#XE^*#>']4-F--:; SN'_ZZRW^+!U+2[M39&W8(=I/_ .NNWU/P5I6J
MW7VBX0E_I61??#3298MD2-R,&@#S'P_=65V&U2_N8VFR1M<\TG@+5+6U\47Q
M,B*LDWR\_2NHU#X2:?;6K2(L@(]ZXGP=X42Z\2SHZOB"7"T#/I.WF2>)70@C
M':O-/B\DC6$93. O./QKT73K1;*U6)<X [UE^*]$76=(GCVYDV86@1R'P=DB
M_P"$8A3(WYKTBXN(;:)GF=54#))KYZTS4-6\ Z@8)QLA2K6N_$'4/$,2V5BQ
M/FC:U SW.UU2RNXBUM<1R #/RFO"/B9KZ:CX@M80X"1OM89KJ?"VGW7ACPJM
MU=[A*5(//M7&^&_"P\7Z]>37:L8Q*>?:@"WK&K:9+X*BTZ+R@Z-G(/TK9^#_
M (@"BXM97R2V%R:Z.3X.^'O*;"R9 ..:\S6PD\'>+K=44K;F7]* /3/BQK@T
M_0 D;_O"^" >>U>=^"M6T^UTJ^CNO+9YSGYC2>+[^;Q7XC>U@RT!8']:[[3_
M (0:!)8022+()&0%L>M 'F>A:[%I'CB6:%@(GPHP>.IKTWXC3"X\,>:#G="#
M^E<7X^^'UKX;MXKVP1L"4<GZBK=[JLFK^#9E.28H@O2@#D_#>F:[-IXEL+V>
M-=I("8]*@MEU;5-92QU74)41FVGS:]7^$\'_ !)XE=.J$'(]JR_B=X0>.7^U
M+&/ B&21ZT >A^%=!M-+T:.&$I(-I!=>_%6U\-Z:L4B?9(_G.3Q7%_"[Q.]_
M91Z?,3YD:Y.?I7IE B"TM8K.W6&% B+T J>BB@ HHHH **** "BBB@ IDSQI
M$S2D!!U)I]5K^U6\LI+=NCC!H BM;C3I7S;21LW^S6=XLU-].T2XEC!W!<@B
MN)U#0O$&A7#3:1CRQ_>/:HI_&$%[8R:9K1/G2#;P* .8@;5=5@_M!=;EB4\^
M7D=OPKNOAWK<NIVT]O=$S;&VDMWKFK/PC?31JNG!?LIX&3VKT#P=X430+>3*
MX=SN/UH ZB.&.%<1H%'M4E%0W4PM[=I3T6@"IJ&MV&FKFXN8XSZ,:J6'BK2[
M^3RX[N(N3@ 'K7C&L7+>)_&5U8W#G[-&=PP?K6M8^$((-<M;C12=J#Y]S=Z
M/9KB]M[6+S)I51?4FL6/QEI$EQY0O(<YQUKS[XEZQ=0:;:6>_$C2A&P?4BL+
M4O \6F^%Y=93>)E4.#GU&: />X9HYXQ)$X=#T(JAKW_((FKD?AKKKWNA11RM
MGRTR?RJ;Q1X]T:TMI+260B4]!0!\Y^*?^1ANO]ZO4O@Q]Q?]_P#K7D^O74=Y
MK$\\1RC'BO6/@Q]Q?]_^M SW6BBB@04444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%9^J:K!IMN9)6QZ4FTE=BE)15V/U#48;"!I
M'9<@=#7E?B/76U29D&0@.0*;KNOS:E.?FR@X%9-K:R7<P1!DDUPU:SF^5'B8
MK%.J^2.Q"JLW09K5TK0KC4IMFUD7UQ7:Z)X-@6W#W:?,>1756>G062XB7'X4
MZ>&;UD71R^3LY['&VOP^V@,]QGVK8MO"-K#C>J-^%=+174J,%LCT8X6E'9&?
M%HMA$/\ CVCS]*LI96R?=A45/15V2-E"*V0@4*.!BEHHIE!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444F
M0.I% "T54NM0M[1-TCC'UKF]0\?Z5:@J)#O[5<:<I;(3DEN=?T%5I;^T@_UL
MZ+]37E&I_$J[)(LY!@^M<G?^*-0U#/G2=?0UU0P4WN9.LEL>SZCXRL+($I+'
M(1Z&N-U3XGE]T<5N5]P:\S9Y)#DECFK%KI]Q>,%C0DGVKJCA*<-69NK)[&G?
M^*M1O&)6YD0'MFLB6[N+@_O)6?/K74:?X U6Z(8QC978Z9\-;0;3=QG/?%4Z
M]&GL)0E(\HBT^[GQY4#MGT%;NF^#;^](\R*2+/J*]FL?#&GZ>!Y*=/45L+&B
MC 4?E7-/'/[*-%1[GF>E_# 1[9);@-GG!%=C8>%=.M$ :VC=AWQ6[17+.O4G
MNS502((K2W@XBB5?I4]%%8W*"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ I-H]*6B@!-J^E  '04M% !1110 50NM%TV].;FSCE/^T*OT4 8_P#PBNA?
M] R#\C3D\,Z+&X=-.@5@<@@=*UJ* &&-&385!7&,5EW'AC1[E]\NGPLQZDBM
M>B@#-M- TNQ8-;V44;#H5%:(  P*6B@"O=6%K?1F.Y@25#U#4MM96UFNVWA6
M-?1:GHH **** &NBR+M=01Z&JD&D:?;2M+#:QH['+,!UJ[10 E!&12T4 9UW
MH6F7Q+7-G%(Q[L*@@\+:+;OOCT^%6'0@5L44 5Y+*VE@\F2%6C_NGI4=II5C
M8EC:VR1%NNT=:N44 ':J%QHFFW4@DGLXI''0D5?HH S4\/Z3'+YJ6$0?^\!6
MBJA5"J, =!2T4 5[NQM;^/R[J!94!SAJK+H6EI$T2V40C;JN.M:-% %:UL+2
MR0+;0)$HZ!:DN+6"ZC,<\:R(>H-2T4 4;31M.L)"]K:1Q,>ZBKU%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*\EOI7H-9VE:+9Z/ L-HFU%Z5HT 0S6L%PN)HE<>AID.GVEN<PVZ(?859HH
M:Z*ZX8 CWJJNE6*R;UM8PWKBKE% "!0HP!@5FZ]_R")JTZS->_Y!$U 'R9XI
M_P"1ANO]ZO4/@Q]Q?]_^M>7>*?\ D8;K_>KU+X,?<7_?_K0,]UHHHH$%%%%
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M<)&N#CFK]=E*BH+7<]3"X6-)7>X4445L=@4444 %%%% !1110 4444 %%%%
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M **** "BBB@ KG=4\)VVIW#2R;<MZBNBHIIM;#4G'5'%M\/[(+D;/RKA-9\
MW#:C)Y*-L[8%>WTF!Z5I&M)&L*\XL\!_X5_>_P!R3\JZSP[X"4KMN4Q@=6%>
MI8'I2TY5Y-%2Q,VK'&?\*^LO]C\JZ33-+CTV!8H\8 QQ5^BLW-O<R<Y2T85X
M[XX%S!K$<T<#.!*#Q]:]BK/O-&M+XYF3-20<=#X^N$@C3["?E4#]*M6OCF>X
MN$C-F1N.,UN?\(KIG_/*GQ^&M.B<.L?(.10!SGCK09+^Q;4+92;@*-H7KTK,
MT'QK>65HEG=V3(8AC<W>O30H"A>P&*R+SPUIU\Y>:/))S0!YYXE\2ZGX@B;3
M+.TD59!_K4[5WOA739;#2(!.[-)MYW=:MV&A66G$&"/&*TZ .-^)T$EQX-N$
MB0LQ/0?2K?@N%D\/VT<J8_=X(-=!=6L5Y 891E#VIT%O';QA(QA1TH J2Z'I
MD[[Y;*%F]2*S=;TM;?2YFTZ,0NJ9 C&,UT5(0",&@#S/PQXLO;&R-OJ$#B0,
M>7ZUF:@+SQEXALY3;/'':2Y![$?Y->D7OAO3K^7S)H\M5RQTRVT]=L"8% %B
M&,10JH["LKQ)I2ZGI,\>/G*84ULT4 >/^'=9U+PFPTN:SD>%.?-:M?6O'-U/
M9/;VEF7>5<97M7<WVCVFH@^>F<U4M?"VF6DHDBBPP.: .&T.VU&PT8:E<^9Y
MS@J8VZCBI? /AQ)KK4+C4;<2>8Y9?,'2O1[BSAN8?*D7*TMO:QVR[8Q@4 9\
M_AW26@D L(<E3CY?:O)$%]X4N[U((7*3.2 .U>Y5FWFB6=\P:9,D4 >>^#=#
M&J:PVJW]L&\Q?NN*[Z;PWI,D3(+"$9[[:O6EE#90B*%<*.E6* /'+6TN?#_C
MV^:*%OLICVJ!T[U/86UP_BFWF,3!2^2:]/GTNVN9"\B98T)I=M'(KJGS+TH
MGN;>.Y@>.10P92.:\AO-.O?"OBV VB.]O(Q=]O05[)52[T^WO#^^7- #K"Z-
MY9I,5QN[59J*W@2VA6*,84=*EH **** "BBB@ HHHH **** "BBH+NY6TM7G
M?.U!DXH H^(+5KO3)$7.0I/'TKY^.J:AI=MJFF"Q;-PY /XU[)9^/].O]0FL
MD63>B%CD=N:XC4?&7A%]2=I[68RQL1D#O^5 &?I,4_AKP9!?-;%IILQE3UY
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGMBN'WJLCQ6ZF*J$/AKPN]U(LTZE54Y />O2K:UBM8@D:@ >E.@@2WB6-!@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC:/XBCU5V5<<,5XID&NVVM:%/-!GYHF.">>E<9\//^/J;_KLW\S0!ZG1110
M4444 9VLV7V[3Y(^^TX_*OGRYM=?TY[_ $Z*QE:.Y<\U]#:K++%9.\)PP!->
M,CQ_-9:O)_:D<\BI(0N%/2@"2'2M0\/^!K66*V9KF0E&3N <#^M==\+]$N-*
ML;J2X1D:=M^#[U/I_CK0]>B2)D90#D;SC^E=E;7%L\2^5+&1C@!A0!9HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM&5F'GB0;U[CFO8)+.*^TQ+>9<HR#(_"O!/%WAV_TKQ'#)&I-N\PVA5S@9H
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ME@+13,/NC&[K6MX0US2=#L6@N[*=I]YY"G_"J'B"\N-2\2:5*D4GDB8%05/
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MU?XCW5E*VZ! & /3J?\ "O0=0T6Q;1&C^SQCY,9VUP_B72+C0=>DUJW4[9"
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M6 %L<]*M0> =,AE61;< J01TJ'C:8_92,W1_AO:Q11S/*6+*&P:Z^ST&QM$
M$$;$=]M:4:".-4'10 *=7FSK3GNSH44B-(8H_N(J_05)116104444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 8%%%% !1110 5"UI;NVYH4+>I%344
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ME64W=F\8J.P4445F4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(==)"''/:@#G]?N8[O6;B>%MR,>#7JWP8^XO^_\ UKQ8@@X->U?!C[B_[_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ=)XC_P*@#K**X2;XFZ='T,9_&L^;XNV,?2%3^- 'I=%>2S?&VTBZ6>?Q_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !29'K7+>-/%:>&M/63
M8)'<[0*\U3X@ZM;R&\ELIO(4YYZ8H ]TK,U[_D$35!X:UV/7=)ANEPK.,E?2
MI=?=1I,H+"@#Y-\4_P#(PW7^]7J/P9^XO^__ %KR[Q1SXANO]ZO4O@Q]Q?\
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M3^KP#ZI3,5+*XP=SOG_>-.A@O;>=9(W;*D$?,:U:549CA033^KP*^JPL:O\
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M_"K-(_N-5S3OAWING7(FB#!A7;457M)]RW6F]+C(D$<2H.BC%/HHJ#(****
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M3^\*/,3^\* '44WS$_O"CS$_O"@!U%-\Q/[PH\Q/[PH =13?,3^\*/,3^\*
M'44WS$_O"CS$_O"@!U%-\Q/[PH\Q/[PH =13?,3^\*/,3^\* '44WS$_O"CS
M$_O"@!U%-\Q/[PH\Q/[PH =13?,3^\*/,3^\* '44WS$_O"CS$_O"@!U%-\Q
M/[PIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4_YX2_E0!/\ \+<\2_\ /9?UH_X6YXE_Y[+^M0?\*XU3_GA+^5'_  KC5/\
MGA+^5 $__"W/$O\ SV7]:/\ A;GB7_GLOZU!_P *XU3_ )X2_E1_PKC5/^>$
MOY4 3_\ "W/$O_/9?UH_X6YXE_Y[+^M0?\*XU3_GA+^5'_"N-4_YX2_E0!/_
M ,+<\2_\]E_6C_A;GB7_ )[+^M0?\*XU3_GA+^5'_"N-4_YX2_E0!/\ \+<\
M2_\ /9?UH_X6YXE_Y[+^M0?\*XU3_GA+^5'_  KC5/\ GA+^5 $__"W/$O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7E7QINIK;2K/R6P6?'ZUZK7D7
MQSR-(LR.N_\ K0!RGAGPEK&O:>;F.:, '')_^O706OPYUJ*ZB=IX2%8$\_\
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M5?0?%=EX@FDCME8%.N:63PW')HCZ:93M;^*H/#GA*'P]/))%*7+CO0!K:O\
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MWQWCH=^\J,T".'^*3B?6RZ D%A_.NG\6Z5-?>![*6,9\NV!(Q72:K\/K759
M\LQ!!!KI4TR%=+2Q8!D5-G(H \E^&7B^TTO0XM/N5=9$&3GBL7QWK,?BOQ-I
MT5FCG8^TG&1WKOM3^%5G?7+317309[)Q6AH'P\LM$D\PR>>X.06&30!L^%+%
M].T**WD^\M;=( %& ,"EH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HH)P,TSS4]: 'T4SS4]:/-3UH ?1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !132ZJ<$TH.1D4 +1110 4444 %%%% !132ZJ<$TX<C-
M!112%@.M "T4SS4]:56#=* '4444 %%0RW44'WVQ1%<Q3_<;- $U%%% !14,
MUS% ,NV*2*\AF^XV: )Z*** "BF>:@;;GFGT %%%% !13#*H/6CS4]: 'T4P
M2H3UI] !136<(,MTJ!+ZW=]BODT 6:* <C-% !13&E13@GK3\YH **** "BB
MD9@HR: %HIB2*^=ISBGT %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ$T[SX@H;S%VGH<U\]6FO>+?%5U)-I\(>-'(&&/^%2:WXR\3Z-;Q6=Y$J,C
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M.4QG:*!G%?#SQ\-:V6-QGS@,EFK;\=>*%T+37"_ZQURI%>*:1G0O'+QQ$@#
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M679\OVDG-?30Y3% V<%X^\3:9H^Q+FT6XD8?+ZBN+@US4]6T]A86\UM 5)
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M?H%NK>&[&.10<1 $$4 >!+XK\5^:!Y=YC=_=KJ?%5U=77AI'N@X<Q<[J]?\
M[*M/^>,?_? KA?B;9,^F[(4'W,<"@1@?!O\ X]XOI7JNMSI!I%P[L!A>]?-W
MAOQ!KWAI%6TB3"],ULW_ (S\7:_"UF84Q(-O!_\ K4#,R ?VIX]=H?F'!X^M
M>UZIXBL]%TRUMKV-65XP"&-<=\-/ 5SI]TNHW\1$C+@YK<^)?A&;7+19K=6+
MPI\N* $'A+0_%-@+NT@AC:3TKS[QA\-I-!C:]AN578-P JEHWBGQ%X.46;HH
M6,8^8TNL^+O$'BT"U6-&#C;Q_P#JH ZSX3ZY=7\+V,KLRB$]?H:XSQ!"VD^-
MH9I1A3(3S7I_PP\(3:+:1W-S&5E9<-^5-^)/@5];7[7:QDS1KQB@#L/#UW'J
M/AU3$XRZ$#!]J\J\3> M7A^T7W]J%4#%MO%8&E^)_$W@Y1:/&H5!CYC_ /6J
M34O'_B/Q!"UHD<95Q@X__50!#X"O+R/Q*\$MR7"XYKZ$_M2RMHHDGNHT<J.&
M:O&/AYX(U:/5&OKV K&XX/-:WQ,\,ZE)/#?6 <K#& <,?2@#KM?\):;K-M/>
M[(V8H6#_ (5Y%X,U2ZT?QE'IR3LT+2ME1TZU9M?B'KEEI0TPA=VTH<GGGBK'
MP_\ "&H7NO1ZO=1$*'+$_4T >^0R>9&'QC-5-7_Y!TE7$4(H4=!535E+:?(!
M0(^9;BP34/'%Q$X!!D YKUV'X6V#P1L8X^5!_2O(]7CU'3_%MS<V\8)#Y&:Z
M=/B?XK2-4$46%  _SB@9Z3I7P^L],N!*B("#GBN8^+]BYTV28 [43'Z5CV/Q
M-\4SWT,4D4>QW /T_*O4=9TH>)?#;6\ZY:503CZ4".'^#^HPR0M"74,J^M>K
MS3QV\1DD8*H[FOF]]-U_P)JTLMK%B$MP6)Z5:U#XC^(M7M#9!4^88X/_ -:@
M9ZO;?$*SN=7DL%091MN[/6NHN-3L[509[B./(SACBO&?AYX(OYM0;4-21E#'
M>I!/-=-\3/#%YJ.G/-9;_,5<  D=J!'1ZYX?TWQ!9/(PCE^7*MZ5XO'<7'A/
MQHEK!,3".=J].M3Z=XYUS1+-].F"@JNP9/-'AGP_JOBCQ)'J-Y#^Y/5A]:!G
MH'C76=3AT+3[BP64M(F6V#ZUYO;^*_%1FPT=WC_=KZ$@TZ)+&&W= 1&N!D9I
M?[*M/^>,?_? H$?-_B7Q+>ZE/8BX20K$?G5AUZU?U?QK:2>$O[*@L#%SG=7K
MMY\.-&O9VED#!F.>!7(^.?AWING^'WFLPQE![B@9R'PJ\7)H=_-;M;F0W38!
M';I_A7T3;S?:(1)C&:\+^%/@Z"\N[F>\4AH6RF/PKW:*)88PB]!0(?1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444F:
M%HHHR/6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ I"0!DG%+5'5YC!ILLB]0* //_%O
MQ"DL[Q["RMFFE1L'9UK/T+QYJ2:M#9WEA,HEYW/VKAX=4,/CF]G;EFZ9YYYK
MK[7Q%!<:];1ZMA92/DVCMQ0,[7Q;XTCT'3(YEC$CRG:%':N @^(VIVMP+BXL
M9A #G+=,?G5#X@7:7.H6441)A^T+C\Z[#QSIL,7P_>54 ;R4.<?[- '>:#J\
M>LZ7#=I@>8,[?2M(NHZL*\Q^&5[)_P (_C/^KB)'Y5QOBOXF:[IFJM! ZA03
M0(^@ ZGH13J^>O#GQ>O_ +7_ ,324"+/:O9M \6Z;XAA5[.0MV/UH WZ***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[91110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:[K&,NP
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M'^_0,]LHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MEH9)1SZULZ[\.I_[+FD.H-(RKP/\BN_T32H=&TU+.!=L:=!5Z6-98RC=#UH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_&#5I"K6&[Y=PXKI?A_X4LK72([@Q?-*@8F@#F-,^*VH6UVMOJ&GF$9P2_\
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M*>WN(;V6/]S(XP .>M>Z:18PV-A&D*[04&?RH OT444 %%%% !1110 4444
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M-:OY-157N9",C@M7,5K^'?\ D)I]171.$>5Z$1;N?1%DQ:RA8GDH*GJO8?\
M'A!_N"K%>$]SM05SGC*&2;2=L:ECSP*Z.HY84F7:XR*<)<LDQ-75CYPGT>_,
M\A^S/]XU5N+"YM5W31,@/<U]&G1K,G/EUCZ]X1M=3MEC2,9!SS7HQQR;LT8.
MB> TJJ68 #)->M?\*TC_ .>:U+!\.(HIE<QKP0:V^MTR/92/+1H]^1D6SX-=
M-X-TR\AU/=) RC(ZUZ_'H=FD2+Y?0 5/%I=K"VY$P:YIXWFBU8T5&SN68O\
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M4SS8RVWS$W>FX4 /HI"P49) ^M,$\).!+&3Z!A0!)61XE_Y <U:_6LCQ+_R
MYJ /DOQ%_P AVY_WJ]?^"W_'D/\ ?KR#Q%_R';G_ 'J]?^"W_'D/]^@9[911
M10(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5CY)=C7HK-_MRS_YZI_WT*DAU6VG?:DBD^S"E9BY67J1B%4L>@ZTN<BH;O\
MX])?]TTA&7=^+-%L9?+N+Y$?T-5_^$Y\._\ 02BKS"31[+6/&T,-Z@=&)R"?
M<5W'_"LO"_\ SZK_ -]"@#H['Q+I.I2B.TNTD<] *T9[F*VC+S.%4<Y-<_H_
M@W1M'G6:R@"NO0@BN/\ %NMWNJZHFFZ?+MV2;90>XH [.7QMH,3[6OXP15^P
MU_3=3XM;E9".N*YBQ^&FAR6RO?6@>9@"2"*P=1\,7OAO5+9]'Q% \@W #/%
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M]35>PUBPU/?]CN%EV'#8[5Q7Q.U)VTO[%:MB;?@US/A*>;PSJ%M;3'!O#DT
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MC(QU- ST6L[7+5[W29H(R0S#C%:-% CPBX^'NH0W4]U&9@Q4Y()KC;+2;O\
MX2R"V#R>:2<'/-?5#*'0J>A&#6&GA+28]22_6V N$.0U 'D/C?0+JPL=/G=6
M9DE#,6]B*G\2^,K?5_"S:9!(KS&-5VCV&*]FU/2;35H/)NX]Z]A7-6WPUT"W
MNA.MDH;.>U %+X>:,]MX:C,BE6DB(/Y5QGC+X<-/+)?9?C->W6]O':P+#"NU
M%Z"LWQ+_ ,@.:@#Y OK;[)>20?W3BO:O@M_QY#_?KR#Q%_R';G_>KU_X+?\
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MIU@B3[L:CZ"I**SNR@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,DBCE&)$5A[BGT4
M0?8K7_GWC_[YH%G;*<B",?\  :GHHN.[ # P****!!367>A4]",4ZB@#E;_P
M39WUUY[/M;VJO_P@%M_S\/\ G7944 <WI?A*#3+Q+A)F8KV-;5[807T1CFC5
MLCC(SBK5% '%3_#VVED++<N@/9216QI'A>STKD*LC?WF'-;M% !T&*S-4T:'
M5'A:7_ED<CBM.B@"*W@6WB$:]!4M%% $%U:Q7<)BE164]B,URL_@"VEN#(MR
MZ*3G:IXKL:* ,S2M%MM*A"1JI8?Q8YK3HHH :Z+(I5U# ]B*YC4O!5G?R%U;
MR23SL&*ZFB@#DM/\"VEE*'>0S8[/S6S>Z);WD2QD!548P!Q6I10!4TZPBTZT
M6WB "KTP*M,H=2K#(-+24 <S=^#;2YU![L-M9NH K7TO28=*C9(0/FZX%:%%
M "$9!'K6)<^&K:XU**]X5XSD8%;E% &+!X<MX-8DU$'][(,'BMD# Q2T4 8V
MK^';75@GF *RL&W <UHVEL+6%8PQ( Q5BB@ HHHH **** "BBB@ HHHH ***
M* "H+RY2TM7G<X5!DFIZKWULMY:20.,JXP10!S=OXST^]FD@$J,54DBN+O/$
M7ADZB9'> ,C'(V"NPM/ UE:7$DRQ*"ZD$YK#E^&6C3S22;(22Q)^84 4K_QE
MX>U"TBM6FA"(P8 **[OPOJ=GJ5CFS*%$X^48K@7\!>'HKGRF%N&!_P">BUW_
M (9T2UT6S:.U"[6Y^4YH W:*** "BBB@ HHHH *R/$O_ " YJUZR/$O_ " Y
MJ /DOQ%_R';G_>KU_P""W_'D/]^O(/$7_(=N?]ZO7_@M_P >0_WZ!GME%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M48 &!3J\FI4E4E=G3&*BK(****S*"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!" >H!H  Z "EHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4E*=F==.*2"BBBN8T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHI"0.M "T4FX>M&X>M "T444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM7?1?#N\D^\'7\*OQ?"^9_O3,/PHYJ:%STD>:B!!VIP0#M7JT7PCW_>O"/\
M/TJEK?PRETZUWP2M,P/0"A587L@5>E>R/.5.U@17N?PVUB.?2(;+=^\49(KR
MAO#5PC;75@?2NM\#Z;J&FZH)A'(T9&/:IJN,H[D5Y4YQLGJ>TT4R(DQ(6&"1
MR*?7">:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,!\6[8C(1/SJ:U^*UI<3K&P103C.: /2:*R!XGT?RU9KZ(9 /6H9?&&AH/\
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M "BBB@ HHHH **IZAJ5KIL/FW4RQKV+5S]OX]TB>Z$/VN(9..M '65D>)?\
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MR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#SGXC^$9]8MX9[( 2QOO)/L:X.>V\2ZS!_94DF8R-N"IQQQ7T"RJXPP!'O4
M"V-JC;E@0-Z@4 8?A'0!I&@PVTJCS FUL5E^*O!>BRZ?-=/;YE'?BNX  &!6
M1XE_Y <U 'R/K<"6^KSQ1C"*W KV+X+L!9C) ^?UKR'Q%_R'+G_>K3\.>,;C
MP['LACW<YH&?2'B#PQ;:X )@K8.1R*X*7X:R?\)%&%\O['CYER*Y#_A<&H?\
M\/UI/^%O7^<_9^?7-6JDDK(TC5G%63/9M"\'V>C2F2)44GKR*ZT,@ &Y?SKY
MN_X7!J'_ #P_6C_A<&H?\\/UJ7)MW9$I.3NSZ1WI_>7\Z:_ER+M9E(^M?.'_
M  N#4/\ GA^M'_"X-0_YX?K2$>_/H>FNY9D7)Z\BF_V!IG]Q?S%>!_\ "X-0
M_P">'ZT?\+@U#_GA^M/F8^:1]%V\%O:KMB*@?6IMZ?WE_.OF[_A<&H?\\/UH
M_P"%P:A_SP_6D+4^D=Z_WE_.C>G]Y?SKYN_X7!J'_/#]:/\ A<&H?\\/UH%8
M^D=Z?WE_.C>G]Y?SKYN_X7!J'_/#]:/^%P:A_P \/UH"Q]([T_O+^=&]/[R_
MG7S=_P +@U#_ )X?K1_PN#4/^>'ZT!8^D=Z?WE_.C>G]Y?SKYN_X7!J'_/#]
M:/\ A<&H?\\/UH"Q]([T_O+^=&]/[R_G7S=_PN#4/^>'ZT?\+@U#_GA^M 6/
MI'>G]Y?SHWI_>7\Z^;O^%P:A_P \/UH_X7!J'_/#]: L?2.]/[R_G1O3^\OY
MU\W?\+@U#_GA^M'_  N#4/\ GA^M 6/I'>G]Y?SHWI_>7\Z^;O\ A<&H?\\/
MUH_X7!J'_/#]: L?14EO;RMN8J3]:E3RXUVJRX'O7SA_PN#4/^>'ZT?\+@U#
M_GA^M%@Y3Z1WK_>7\Z-Z?WE_.OF[_A<&H?\ /#]:/^%P:A_SP_6@+'TCO3^\
MOYT;T_O+^=?-W_"X-0_YX?K1_P +@U#_ )X?K0%CZ1WI_>7\Z-Z?WE_.OF[_
M (7!J'_/#]:/^%P:A_SP_6@+'TCO3^\OYT;T_O+^=?-W_"X-0_YX?K1_PN#4
M/^>'ZT!8^D=Z?WE_.C>G]Y?SKYN_X7!J'_/#]:/^%P:A_P \/UH"Q]([T_O+
M^=&]/[R_G7S=_P +@U#_ )X?K1_PN#4/^>'ZT!8^D=Z?WE_.C>G]Y?SKYN_X
M7!J'_/#]:/\ A<&H?\\/UH"Q]([T_O+^=&]/[R_G7S=_PN#4/^>'ZT?\+@U#
M_GA^M 6/I'>G]Y?SHWI_>7\Z^;O^%P:A_P \/UH_X7!J'_/#]: L?2.]/[R_
MG1O3^\OYU\W?\+@U#_GA^M'_  N#4/\ GA^M 6/I'>G]Y?SHWI_>7\Z^;O\
MA<&H?\\/UH_X7!J'_/#]: L?2.]/[R_G1O3^\OYU\W?\+@U#_GA^M'_"X-0_
MYX?K0%CZ1WI_>7\Z-Z?WE_.OFW_A<&H?\\/UI?\ A<&H?\\/UH"Q]([T_O+^
M=&]/[R_G7S=_PN#4/^>'ZT?\+@U#_GA^M 6/I'>G]Y?SHWI_>7\Z^;O^%P:A
M_P \/UH_X7!J'_/#]: L?2.]/[R_G1O3^\OYU\W?\+@U#_GA^M'_  N#4/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM?6JW
MEJT+C(:K-% '@'CKX<R_:C/91@,[<\5Q?_"OM7]/_':^KY((I?\ 61JWU%1_
M8K7_ )X1_E0.Y\GW/@;5+6%I7'RJ,GY:YEAM8J>H.*^N_%%A VB7(C@3=Y9Q
M@5\K7&CWWVJ7$#8WG^= %C2_#%]JJDVXZ#/2M+_A7VK^G_CM>M_";3=EN_VB
M!?N]Q7I_V&U_YX1_]\T!<^5?^%?:OZ?^.T?\*^U?T_\ ':^JOL-K_P \(_\
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M_/"/\J N?*O_  K[5_3_ ,=H_P"%?:OZ?^.U]5?8;7_GA'^5'V&U_P">$?\
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MRK_PK[5_3_QVC_A7VK^G_CM?57V&U_YX1_E1]AM?^>$?Y4!<^5?^%?:OZ?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU"/3]1A$,SG@'K7J ((R* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "DWKG&X?G7->,O%"^&],$Z[6=FV@&O,SX\\4,KW
MJZ83;H<[NV* /<J0D#J0/K7&^#_&8U[3]\P5)E0LRCM@9KD=>^(NIS:D;72K
M43X)4X]: /8 0>A%+7EW@_X@7=WJKZ9JD(@DC'(/7->H(P= PZ$9H 6BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** .=\5:+=ZS!'%;.JJ/O@]Q7B?B;PW%H'B-(@@#%<DC\*^CJ\1^)
MO_(X1_[G^% 'K'AK_D7K/_<K6K)\-?\ (O6?^Y6M0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 8'B;1[K5[-X('"AACFO"O%OAF
M/0KJS+*//\]0S#OR*^E*\.^*G_(2M?\ KX3_ -"% 'H>H2M#X&WJ>1"O\J\[
M^&,2W7BC4I)!DM&?Y&O2+FV:[\%B%!EFB7C\*\N\":C;Z%XJU*.]<180@9^A
MH 36E6Q^)UB8AMX)_E7N6G2&6QC<]2*\*GG37OB392VQWQ@$$C\*]WLHO)M4
MC/84 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#(UKP[I^N0K'>PB15;<,^M<AXTO]+T#P[/IL"@O(F%"'-=!XS\31^'=)
M:;<-S97FO$]'O['Q#K1O-7O3$J2'"DY!% '2>!K"XL])EU$@JDD+  CG[I_Q
MJO\ #*W2XUB[E<987#?SKT>"XT>^T66RTR9)-D3$!1[5Y?X$U.#0];NH[UQ%
MNG8C/UH&,\0G['\1)I(^"TB@_G7O5B=UA;GUC7^5>"7KKKWQ#N/LA\Q ZL"/
MK7OEFI2R@4]1&!^E B>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH H:CHUEJH NXM^.E>3_$/5(=+MO[#LK:58T?@A3C^5>A
M>*/$CZ"$8*"A&23VKE]6\3Z%K/AW[1,T/GMGG:,]* ,_PG:C3_!>IS*Z[I$W
M<'FL?X9HMSXHGG<99HCD_@:C\$QW=WI&M1IN>-F.WGMFH_ ]_!H7BVYAO7$0
M6(]?QH&-UQ%L_B'IYB&,R$FO>+.0RVRN>IKP.[G37/'UC):G?&DAR17OUO'Y
M4(3TH$2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7)
M>(/!Z:SJ8NV520,<UUM% %:PM19V,5N/X!BK-%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5R/B+P='K<\<C*IV.'Y]C7744
M5K:T6&T2 CA5 _*N(U[X<P:C=O<VT:)*Y^8G'->@44 <7X8\!VNB2">2)3.I
MR&%=I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% '*>*_"G_"1P>4^TIG.#7)I\(XT'RI&/Q%>KT4 <AX8\'+H4K-A<,I
M4XK.U_X<6^H77GVD:(W4DD=:] HH XSPQX%MM$N#<R1J9R,%A79 8  [4M%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9
M>M:):ZS:/%<1AB1@9K@#\*R) BA!;@\+D5ZG10!BZ)X;LM%LS!!$%WCY\=ZY
MK7_AU!J-\]W;1HDK]6..E=_10!Q7AGP%:Z,YEEB4R@Y#"NUHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMIO*EE"OZ57'B/3#,L0N!O8X H U:*HW>K6=BNZXE""JL'B?2;F01Q7(9B<
M4 ;%-#H3@,#^-8OB/7DT?3&N0PS[UPG@7QR=6U.\2[<)B3">] 'J3W,$;;7F
MC5O0L!4@((R""#T(KRGQA;RW'B R13RJNX<*Q ZUZ5IG[O2;?<2<1C)- %VB
MLJZ\1:99R&.>X"L.U6;/4[2_4M;RAP* +E%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;>KJ%DEPG1JMUD>&K5[/18H9 0R]<UKT""BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFTA;&9 RA-A%:=% 'EM]\*R;IGL&2%#VK7\.?#NTTJ;S[F-))@<AA7=T4 (
M ,"EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gaz3apgusshz000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gaz3apgusshz000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -9 T@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BN6\:^*
MV\*Z7]K6(2'=C!KS/_A=>I79(@TS=CTQ0![ID>M+7A:_%_683E]*./?%=#H/
MQ<AU&98[Q$@R<'- 'J=%5K.]@OH%FMY Z-T(JS0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'E7QL_Y%?_@?^%>2^#]?U?1XI5TU
MV4,?FPI->M?&S_D5_P#@?^%87P0L[:YL[PSP))AN-PS0/H8.H>/_ !>L) FE
MYX^XU86E:C'JNL1MKZ/(2W<8_G7T[)HFFR(5-E!S_L5YE\0?A_;K8RZC:GRV
MB7("#% 'H/A=--BTB)-."K$.BY!K<KYY^%7BBZM]8^QW+L4"\;C]:^@XG\R)
M7_O#- A]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!Y5\;/^17_X'_A63\"?^/.\_P!Z
MMCXUJ3X8X'\?^%>:?#WQK_PBL,\953YA[T#Z'T]7->.+R&W\+WH=UR4X&:\_
MG^,\@0^5#&S>G%<9K?B'7_&<PCCM75#QA3P:!%#P+&U[XI+0@XP#T^M?4%FI
M6SA4]0@KS/X9>!#HP2_NE(F9<%&'2O4@,# Z4 +1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 9NKZ%8:Y;?9[^'S(\YQ7./\+/"Q.18#\Q_A7:T4 <9%\+_"\9S]@&?J
M/\*V;#PII&FL&M;?81TK:HH 0  8%+110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 451U35+?2[-[BX<(JC))KSRZ^*@^T,
MMILDC'?B@#U&BN%\._$2RU:=;>:5%F8X"BNY5@PR#D4 +1110 4444 %%%%
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M;W$A 5>IH M45Y];?$NTFU4V?F)][:*[^-@\:N.C &@!U%%% !1110 4444
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MDV8(_*@#G)=$O--AT_6&)(E<,<"OH?P7K(UG15E#9V +7C&HZ_/=>'(+!H$
MA7 .!FMSX0:^82-+D;YI)"<'Z_\ UZ /;Z***!!1110 4444 %%%% !1110
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M\;075H"L*@G"CW%>V4PQ1LVYHU)]2* (K)F>TC9\[B.<U8H  & ,44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%8VK>)+#1WV74P0XS0!LT5!9W<=[:1W
M$+;HW&0:GH **P+?Q;IESJ,MDEP#-&VUE]*W@<@'UH 6BJ.I:I;Z7 9;A]B@
M9S4>BZU::W9_:;2021YQD4 :5%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&O>?[#L?^>$?_? H_L.Q_P">$?\ WP* /!O^$\\1_P#/"[_[X-'_  GGB/\
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M31K)&RL,8/\ N"@";3I&ETZ"1\[F0$YJU2*H50HX I: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#A_'W@V
M]\5VT45O=>5L/.>]<!!\$]6MSF+4PI]L5[O10!Y)HGPRUK3KZ.:;5-ZJP)'%
M;7B_P-?Z_=++;WGE (%Q7H-% &%#H"MX<CTVY(D=8]FXUYG>_"O5K6\:73M0
M\E<D@+7M-)@'J* /+?#'PPFLKW[9J4ZW#[MP)[&O48T$:!5& !BG44 %?/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS1@FM&L?PS;&VT*T5NOE#-;%>6= 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M96YW4 1ZO:ZQ>:4\DES+#&1T-2_#Q&C>_1GWD1'YO7BK.H2^)=:L#:11(8V
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M&%^E2T4 -9%<889I0H4<#%+10 4$9&#110!7>RMG;<T*DU*D:1#"*%'M3Z*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>O*/C#_R")_]W^E &O\ ##_D"0_[E>@5Y_\ "_\ Y D/^Y7<S7<4#8=@#]:
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MHHH **** "BBB@ HHHH *Y/QKXH'A_3Y&5=S[<@5UE><?%'2'O+%[KC9&G-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M% !1110!SGBZPN=0LUAMI'0MP2M>(^,/!3Z-I<UQ/<M+(.?FZU](UY1\8?\
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MJ, GM95EC/1EKQ,?!N\!^XE>I^#="?P_H:64@ 93VH$=%1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,JL,,
M 12T4 53IUFS;C;1D^N*GCB2)=J*%'H*?10 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!R_C7Q.OAO2O/ #,YV@&O$+S7/%'B"5Y+*WGV
M9X*-7H/QFLYI=%@=5+*)02 ,\9%9/@CQWH>DV7D312+)T/;^E SAO[*\;YW>
M7>?]]5>L]<\4^'7$]Y;W!1.3O:O7O^%GZ'CHWYUQOCGQ[H6JZ1/:PQ2&=QA3
MU_I0!Z'X-\3KXATR*0X$A&2OI745Y3\(K&>&V6=P0C)QD>U>K4""L?Q/?G3=
M!GNAU2MBN4^(V1X*O<=<?T- 'COAO2YO&_B6^\ZX=47D#-)JEK-X(\;6L4=P
M[1[=Q&>.U;?P3Q_;5X3UV?TJC\8_^1R@(Z^7_A0,]PT.[-[H]O<'^-<UHU@>
M"\_\(I8YZ[*VIPYB(C.&H$?.?C"X_M/Q9+:/<F)%EP3GH*Z"S^&^C7FQ8O$!
M9V . 34=_P#"_6;_ ,275YYD1CD?(_SFLKQ)HFL>#9/MD$JHL8[4#/4=<D'A
MCPG]FCE+XB*AZ\Q\%>&)/%<C75S=/@N1R?>MCQ!KKZOX0M2[%I!%\QK5^#8'
M]BGUWG^M CB=-NKGPQXS-FLSM&\X09/:OHR!Q) C ]5%?.7BK'_">6^.OVD5
M[7JFHSZ9X9%S%NWA1T'M0!TU%>!W'Q0UJ.X=!Y^ ?[C56;XMZJC;6ED5O0@T
M ?0M%?/R_%/6FP09R#_L-7KG@C6+C6] CN[G=YA/\0Q0!TM%%% !1110 444
M4 9NKZO%I5NTLK  #/-<A_PM#3?^>\==/XAT--:LW@=00PQS7GG_  IVT_YX
M)^E &Y_PM#3?^>\='_"T--_Y[QUA_P#"G;3_ )X)^E'_  IVT_YX)^E &Y_P
MM#3?^>\='_"T--_Y[QUA_P#"G;3_ )X)^E'_  IVT_YX)^E &Y_PM#3?^>\=
M'_"T--_Y[QUA_P#"G;3_ )X)^E'_  IVT_YX)^E &Y_PM#3?^>\='_"T--_Y
M[QUA_P#"G;3_ )X)^E'_  IVT_YX)^E &Y_PM#3?^>\='_"T--_Y[QUA_P#"
MG;3_ )X)^E'_  IVT_YX)^E &Y_PM#3?^>\='_"T--_Y[QUA_P#"G;3_ )X)
M^E'_  IVT_YX)^E &Y_PM#3?^>\='_"T--_Y[QUA_P#"G;3_ )X)^E'_  IV
MT_YX)^E &Y_PM#3?^>\='_"T--_Y[QUA_P#"G;3_ )X)^E'_  IVT_YX+^E
M&Y_PM#3?^>\=:.D^.['5)_*BE0G..*Y+_A3MI_SP7]*V/#_PVM]&NO.2)0<Y
MXH ]$!RH/J*6D484#T&*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.JZ+#=DY+UI&2DKHXJU&5&;A+=&O1115&04444 %%%% !1110 4444 %%%%
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M7R?.3'T_^O7/5H<[N>U@,V>&I\C5SG96_M+6;:&'YB6QQ7TMX,LWL/#5O;R
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MBBB@ HHHH **** "BBB@ HHHH *^?_B/_P E#/T_K7T!7S_\1_\ DH9^G]:
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M1.<M&I^HIRQH@PJ@?04ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R
M3XTL3I%LN>//'\Q6]\-(88-%R%4$@'I6)\9;2>YT:+R(W=A)GY5)[BO*['6?
M%NG1>5;/.B>GEM0,^J?-3UK@OBA%#)X9NI-JE@O!Q7CW_"5>-O\ GM<?]^VJ
MG?ZQXLU.V:"Z:X>-N"/+- 'K'PA=C81J2<!/Z5ZK7F'PHM)K:S02QLOR?Q+C
MM7I] @HHHH **** "BBB@ HHHH **** "BBB@ KY_P#B/_R4,_3^M?0%?/\
M\1_^2AGZ?UH ]NT#_D V?_7,5I5FZ!_R ;/_ *YBM*@ HHHH **** "BBB@
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M?;5=%@BE8M*JY)KO*!!1110 4444 %%%% !1110 4444 %%%% !7S_\ $?\
MY*&?I_6OH"OG_P"(_P#R4,_3^M 'MV@?\@&S_P"N8K2K-T#_ ) -G_US%:5
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MG&60XH ]"^#<4BH';.TIQ^5>P5S/@SP^NAZ+!"P'FJ,,1734""BBB@ HHHH
M**** "BBB@ HHHH **** "OG_P"(_P#R4,_3^M?0%?/_ ,1_^2AGZ?UH ]NT
M#_D V?\ US%:59N@?\@&S_ZYBM*@ HHHH **** "BBB@ HI"0!DG%1_:8,X\
MU,_[U $M%("",@YI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5U/T- #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(4 >$?VQXV_Y\A_WU_\ 6JM>WGC*^@,4ED-I]_\ ZU?0']F6G_/(4?V9:?\
M/(4 ?(U[:ZEH\Y:ZBV,YS5?^VI_3]:^J-:\&:7J\1#VR%\<$]JXT?"" 7.\B
M/9Z5+A%ZM'1#%58+EC*R/$[&TU/5IUFM8=Y0UW%G?>,[*V6".R&U>G/_ -:O
M:-&\':7I,.V.V0-W(K7_ +,M/^>0II)*R,ISE-\TMSPC^V/&W_/D/^^C_A1_
M;'C;_GR'_?1_PKW?^S+3_GD*/[,M/^>0ID'A']L>-O\ GR'_ 'T?\*/[8\;?
M\^0_[Z/^%>[_ -F6G_/(4?V9:?\ /(4 >$?VQXV_Y\A_WT?\*ZKP/J/B6XU)
MUU&V"1XX.?\ ZU>F_P!F6G_/(5)%96\+9CC - $ZYV+GKBEHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OG
M_P"(_P#R4,_3^M?0%?/_ ,1_^2AGZ?UH ]NT#_D V?\ US%:59N@?\@&S_ZY
MBM*@ HHHH **** &M&CC#HK?49JN=.M"^[[/%G_<%6J* &)%'&,(BK]!BG,H
M92IZ$8I:* //O%?PUL-<8SJ&$HZ!1BN'B^#TYN,.DGEYZY->\T4#NSD/"O@3
M3_#D0\H$N>26'>NOHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !15/4=2M]-@\VXD5%SC+'%9/_"8Z5_S
M]0_]]4 =%17._P#"8Z5_S]0_]]4?\)CI7_/U#_WU0!T5%<[_ ,)CI7_/U#_W
MU1_PF.E?\_4/_?5 '145SO\ PF.E?\_4/_?5'_"8Z5_S]0_]]4 =%17._P#"
M8Z5_S]0_]]4?\)CI?_/U#_WU0!T5%<[_ ,)CI7_/U#_WU1_PF.E?\_4/_?5
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH Y;QOX=?Q%I(M4+@AL_*2*\X
M_P"%13_WI_\ OHU[A10!X?\ \*BG_O3_ /?1H_X5%/\ WI_^^C7N%% 'A_\
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MB@ HHHH **** "OG_P"(_P#R4,_3^M?0%?/_ ,1_^2AGZ?UH ]NT#_D V?\
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M'%?-*6=Q?#SKB8NS>M*/MFD2":WG9=O/RUL\/44>:Q//&]CZUDM[:2,NT49
MYSM%>,?$_P 6O;70TVP"!'7G P<UUO@#Q,VLZ!]GD8M,L1)8]>E>/^.$DB\4
M+Y^>IQFLHJ\DBGL82V5Q<?O)'DR?]HU:TS5K_P .7Z3QNVU>?F8U=B93&-O2
ML[5V3R&'&[%>E5PU-4[HYXU).5CZ9\(:ZNMZ+!,S9E9<M6Q>V,%] T4R J?:
MO._A-',NF1L^=A3C->FUY9T'&S?#71)IO-93N)SP*WM+T"RTF+9;H..Y%:E%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1137=8U+.0%'<T .HKSS7_
M (HP:/=O;PVPN&4X.TU-X;^)5OKMRD$L MW8\!C0!WM%(K!U#*<@]Z7I0 45
MPWB7XC6N@R^5'$L\F<%0>15'0OBI!JE\EM<6HMBW=C_]>@#T>BJS7D2V1N=X
M\L+NS7GFK_%J&PO#!;V?VG'=?_UT >F45QOA?Q_:^(79&18'7^$GFNR'(S0
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MU5<%!BMBBBLQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^=?.'F^,?^GW]*/-\8_]/OZ4 ?1^Y?[P_.C<O]X?G7SAYOC'_I]_2CS?&/\
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M':HM<U.X\=:W%!:@LK)@Y'TKZ"OM#T[4!_I-I'(?]H5#9>&M*L'#PV42..C
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M]% #/*C_ .>:_E1Y4?\ SS7\J?10 SRH_P#GFOY4>5'_ ,\U_*GT4 ,\J/\
MYYK_ -\T>5'_ ,\U_*GT4 ,\J/\ YYK^5'E1_P#/-?RI]% 'C'QAC41VFU /
MWZ]![BNY\!QH=$7*+T'45:\1^%(M?$8D8#8P;FM72M-73+40J00!VH N>5'_
M ,\U_*CRH_\ GFOY4^B@!GE1_P#/-?RH\J/_ )YK^5/HH 9Y4?\ SS7\J/*C
M_P">:_E3Z* &>5'_ ,\U_*CRH_\ GFOY4^B@!GE1_P#/-?RH\J/_ )YK^5/H
MH 9Y4?\ SS7\J/*C_P">:_E3Z* &>5'_ ,\U_*CRH_\ GFOY4^B@!GE1_P#/
M-?RH\J/_ )YK^5/HH 9Y4?\ SS7\J;+%'Y+_ +M?NGM4M(PW*1ZC% 'SC<H/
M^%C6PV\?:?3VKZ+6*/:/W:]/2N1?P' ^LIJ&]=ROOQBNR' H 9Y4?_/-?RH\
MJ/\ YYK^5/HH 9Y4?_/-?RH\J/\ YYK^5/HH 9Y4?_/-?RH\J/\ YYK^5/HH
M 9Y4?_/-?RH\J/\ YYK^5/HH :(T!R$4?A13J* "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHK,UG6K;2+1III57 /!H TLCU%+7C6F>.]1UOQ-'';VLAMUDP67IBO
M8T8LN2,4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN-\>^
M*I/#-K%(D)DW^G:@#LJ*X+P/X]M]?MPDK+',3]TGFN\!##(.0: %HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "DR!WILLR0QL[L% &<FO+/%GQ'
M-MJ2V>G1?:&;CY#WH ]6HK&\,7D]]HD$UQ$T<C#E6ZBMF@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZU\3Z*R(^7>/#9-,\1^#K/6M*-ML1)-H ?'/2O&()-6\"Z_Y165X&DPI/3%
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MI;I:W;".;ON/- '&^(YH] \4)+-Q'+-EOI7,^*EB\3>(9'TI&P5SG%>K^/\
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M/UQHS=Q[O+.16W10!3TW3+?2K46]LNU!VJY110 4444 %%%% !1110 4444
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MHUFV^SW&XRQ#:<CO7HE<]H?A2TT2XGEB5?WIS@#I70T %%%% !1110 4444
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M]BD%_:>1+ N S=2:[3X0^)1):QZ8[Y<G/)YH ]AHHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7%>-? MOXDMWD2,?:B,
M*QKM:* /GQ/A_P"*[*5K>"XC6%OEQCM^=>F^!O"$F@VBM>!3<9SN%=F8T)R5
M&?I3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gaz3apgusshz000019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gaz3apgusshz000019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,8 2H# 2(  A$! Q$!_\0
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MIHK:"2>>5(H8E+R22,%5% R22>  .] #Z*^5--,OQ(^+$$EZB;=0O/,EB=R
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M )'JQ_[!D?\ Z-EKV_P9_P B+X>_[!EM_P"BEH \L_:'_P"9;_[>?_:5=O\
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M<IA9_+=,. "1A@#T8?G0!JT444 %%%1SSPVUO)<7$J10Q(7DDD8*J*!DDD\
M =Z )**RM)\3Z%KNP:7J]E=R-$)O*BF4R*G'+)]Y>H!R!@G!K5H **** "BB
MB@ HHHH **** "BBB@ HHHH *\*^(?\ R/6I?]LO_125[K7A7Q#_ .1ZU+_M
ME_Z*2NC#?&-%:BBBOKS\L"BBB@ HHHH **** "BBB@ K,U'_ (^%_P!S^IK3
MK,U'_CX7_<_J:Y<9_"/;R#_?5Z,]^\-_\BMI'_7E#_Z *TZS/#?_ "*VD?\
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M=7S)\%M>_LCQ]%:2R;;;4HFMFW3;$$GWD)'1FR"@'7]X<>A^FZ 85Y5\?O\
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M+2W9]@%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=:\*^(?_ "/6I?\ ;+_T4E=&&^,:.%HHHKQC]%"BBB@ HHHH **** "BBB@
MJY:?ZH_[U4ZN6G^J/^]79@?XQY6<_P"ZOU1](>&_^16TC_KRA_\ 0!6G69X;
M_P"16TC_ *\H?_0!6G6TMV?'!4%]>V^FZ?<WUW)Y=M;1--*^TG:B@DG Y/ /
M2IZ\P^./B)])\'1:9;3^7<:I+Y; ;@Q@49DPPX&244@]5=ACKA >$,-;\=>*
MI&AB^U:OJ,KR"(2!1P"Q52[<*JJ0 3P% KI_@WXD30O'4-O.[BUU1/LA =MH
MD)!C8J =QW?(.F/,)R!G/0? /0?M.N:CKLT>8[.(6\!>'(,C\L5<]&55P0.<
M2]L\\5\2?#;>&?'&HV>Q%M;AC=6HC14412$D*%!. I#)V^[G !% SZTJO?7M
MOINGW-]=R>7;6T333/M)VHH)8X')X!Z5E>#?$!\4^$--UEH_+DN(OWJA< 2*
M2C[1D_+N4XR<XQGFM:^LK?4M/N;&[C\RVN8FAE3)&Y&!!&1R.">E CY+O[[6
M/B-XW5OG>[U"<16\3DNMO&2=J_*OW$!))"]F8\DU]%:%\+O".@VK0KI,-_(W
MWY]019W;!)'!&U>N/E S@9SC-3Z1\-_"6@ZK!J>F:3Y%Y!N\N3[1*VW<I4\,
MQ'0D=*ZJ@9\Y?%OX<6/A)+;6-';RM/N)1;M:.S,8Y-I(*L<DJ0ASDY!Z9!PO
M8_ OQ5/J>D7F@WMQYDNG[7M?,E!<PGC:%QG:A YR<>8HX %)\>?$26GAZT\/
MPSXN+Z433QKM/[A.1NSRN7VD$#G8PSP0<3]GW2=^I:SK+I./)A2TB;'[M]YW
MN,XY8;(^AX#<CD4!T/>****!!1110 4444 %%%% !1110 4444 %>%?$/_D>
MM2_[9?\ HI*]UKPKXA_\CUJ7_;+_ -%)71AOC&CA:***\8_10HHHH **** "
MBBB@ HHHH *N6G^J/^]5.KEI_JC_ +U=F!_C'E9S_NK]4?2'AO\ Y%;2/^O*
M'_T 5IUF>&_^16TC_KRA_P#0!6G6TMV?'!7RY\7_ !$^N^/KR!)]]GIO^B0J
M-P 8?ZTD'^+?E20!D(O7&:^C?$VO0>&/#5_K-RNY+6+<J9(\QR0$3(!QN8J,
MXXSD\5\H>&]%NO&'BRTTLWFVYOI6:2YG)<\ N['NS8#'D\GJ1UI#1[]\-M6\
M*^'? 6EVC^(=&2YEB^TW :XBB?S)/FVN-V=R@A,GGY!TZ#D?C<^A:Y8:?J^E
M:SI-U=6C-#-%!<1-*\38*GAMQ"L/N@'_ %A/ !J;_AGC_J:?_*?_ /;*/^&>
M/^II_P#*?_\ ;* *WP"\1)!>ZCX=N)]OVG%U:H=H!=1B0 _>+%0A YX1CQSG
MWBOC;3;R]\)>++>YDC=+S2[S]]"DVTDHV'CWKD8.&4D9!!/45]A6-[;ZEI]M
M?6DGF6US$LT3[2-R, 0<'D<$=: 9/7,>,O'6D>#-.DENYDEOB@,%@D@$LI.0
M#CJJ94Y8C'!QDX!H_$/XAV?@C3@B!+C6+A<VUJ3PHZ>9)CD(#VZL1@="5\ \
M/>']>^)?BN9FG>661A+?7\PRL2G@$XP,X&%08Z8&%!(!#+6#6?B9X]RZ[KR_
ME5[B2&(;+>(84MC(^5%  R<G &2QY^H?#GAS3?"NC1:7I</EP)\S,W+RN>KN
M>[' _( 8  "^'?#NF^%M&ATO2X?+@CY9FY>5SU=SW8X_0 8  &K0,****!!1
M110 4444 %%%% !1110 4444 %>%?$/_ )'K4O\ ME_Z*2O=:\*^(?\ R/6I
M?]LO_125T8;XQHX6BBBO&/T4**** "BBB@ HHHH **** "KEI_JC_O53JY:?
MZH_[U=F!_C'E9S_NK]4?2'AO_D5M(_Z\H?\ T 5IUF>&_P#D5M(_Z\H?_0!6
MG6TMV?''C'Q\\1K%86'AJ%W$T["[N-KLH\L95%(QA@S9/7@QCCD&H?V?M$7R
MM7U]U0L6%E"0S;EP \F1TP<Q8/)^4]._HVM_#WPQXCU)M0U?3GNKIE";VNI@
M HZ *' 4=3@ <DGJ36SH^CV&@:5#IFF0>19P[O+CWLV-S%CRQ)ZD]Z0%ZBBB
M@#YK^-OAU-'\:)J%O!Y=MJL7G$C:%,RG$F .1P48D]6=CGKCL_AAXZ6U^%FJ
MR7\R2S: K%(Y)&0O&5S"A=LC)<-&H'0!1CIGTS7_  WI/BBQCLM9M/M-O'*)
ME3S'3#@$ Y4@]&/YUA0_"KP5;PW,46B[4NHA%,/M4QW('5P/O\?,BGCT^M '
MS%J6IS:]K]QJ>J3.)+N?S)WC4N4!/1%9N0HX52PX &17LWASXL^ _"NBQ:7I
M>DZS' GS,[0Q%Y7/5W/F<L<?A@    #L?^%0>!/^@%_Y-S__ !='_"H/ G_0
M"_\ )N?_ .+H&<SJ'[0&BQP*=-T:_N)M^&2Y9(5"X/(*E\G..,=SSQSK^ ?B
MK_PG&OS:7_8OV+R[5KCS/M7F9PR+C&P?W^N>U7_^%0>!/^@%_P"3<_\ \76K
MH'@/PUX7U![[1M-^S7+Q&%G\^1\H2"1AF(ZJ/RH#0Z.BBB@04444 %%%% !1
M110 4444 %%%% !7A7Q#_P"1ZU+_ +9?^BDKW6O"OB'_ ,CUJ7_;+_T4E=&&
M^,:.%HHHKQC]%"BBB@ HHHH **** "BBB@ JY:?ZH_[U4ZN6G^J/^]79@?XQ
MY6<_[J_5'TAX;_Y%;2/^O*'_ - %:=9GAO\ Y%;2/^O*'_T 5IUM+=GQP444
M4@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KPKX
MA_\ (]:E_P!LO_125[K7A7Q#_P"1ZU+_ +9?^BDKHPWQC1S.UO0_E1M;T/Y5
M/167U^78^9_M^I_(B#:WH?RHVMZ'\JGHH^OR[!_;]3^1$&UO0_E1M;T/Y5/1
M1]?EV#^WZG\B(-K>A_*C:WH?RJ>BCZ_+L']OU/Y$0;6]#^5&UO0_E4]%'U^7
M8/[?J?R(@VMZ'\J3!'458J*3[WX5M0Q4JL^5H[<!FL\36]FXI'T-X;_Y%;2/
M^O*'_P! %:=9GAO_ )%;2/\ KRA_] %:=<\MV>P%%%%( HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\*^(?_(]:E_VR_P#125[K
M7A7Q#_Y'K4O^V7_HI*Z,-\8T8%%%%>6?G04444 %%%% !1110 4444 %12?>
M_"I:BD^]^%=6"_BGK9+_ +TO1GT-X;_Y%;2/^O*'_P! %:=9GAO_ )%;2/\
MKRA_] %:=7+=GUP4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KPKXA_\CUJ7_;+_P!%)7NM>%?$/_D>M2_[9?\ HI*Z,-\8
MT8%%%%>6?G04444 %%%% !1110 4444 %12?>_"I:BD^]^%=6"_BGK9+_O2]
M&?0WAO\ Y%;2/^O*'_T 5IUF>&_^16TC_KRA_P#0!6G5RW9]<%%%%( HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\*^(?\ R/6I
M?]LO_125[K7A7Q#_ .1ZU+_ME_Z*2NC#?&-&!1117EGYT%%%% !1110 4444
M %%%% !44GWOPJ6HI/O?A75@OXIZV2_[TO1GT-X;_P"16TC_ *\H?_0!6G69
MX;_Y%;2/^O*'_P! %:=7+=GUP45Y1^T!_P B-IW_ &%8_P#T5+7BOA'PE?\
MC36)-,TZ:VBFCMVN"UPS*NT,JD?*"<Y<=O6D!]@T5\Z?\*#\5?\ 00T;_O\
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M_P"O*'_T 5IU<MV?7!1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O"OB'_R/6I?]LO_ $4E>ZUX5\0_^1ZU+_ME_P"BDKHP
MWQC1@4445Y9^=!1110 4444 %%%% !1110 5%)][\*EJ*3[WX5U8+^*>MDO^
M]+T9]#>&_P#D5M(_Z\H?_0!6G69X;_Y%;2/^O*'_ - %:=7+=GUP4444@"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KPKXA_P#(
M]:E_VR_]%)7NM>%?$/\ Y'K4O^V7_HI*Z,-\8T<WYC>@H\QO05A_VM/_ '(_
MR/\ C1_:T_\ <C_(_P"-=W]GQ_E1P?4L'_(C<\QO04>8WH*P_P"UI_[D?Y'_
M !H_M:?^Y'^1_P :/[/C_*@^I8/^1&YYC>@H\QO05A_VM/\ W(_R/^-']K3_
M -R/\C_C1_9\?Y4'U+!_R(W/,;T%'F-Z"L/^UI_[D?Y'_&C^UI_[D?Y'_&C^
MSX_RH/J6#_D1N>8WH*/,;T%8?]K3_P!R/\C_ (T?VM/_ '(_R/\ C1_9\?Y4
M'U+!_P B-SS&]!368L<FL7^UI_[D?Y'_ !K0L;A[F!G<*"&Q\OT%'U14O>2L
M:T<-AZ<N:G&S/I+PW_R*VD?]>4/_ * *TZS/#?\ R*VD?]>4/_H K3KRI;LZ
M0HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7A7Q#_Y'K4O^V7_HI*]UKPKXA_\ (]:E_P!LO_125T8;XQH\PHHHKZ0Y@HHH
MH **** "BBB@ HHHH *V=)_X]6_WS_(5C5LZ3_QZM_OG^0K#$? 73^(^F/#?
M_(K:1_UY0_\ H K3K,\-_P#(K:1_UY0_^@"M.OFY;LU"BBBD 445S&M_$/PI
MX=U)M.U35TANT4,\2Q22%0>F=BD XYP><$'H10!T]%96@>)-)\46,E[HUW]I
MMXY3"S^6Z8< $C# 'HP_.M6@ HHJAJ^M:;H-@U]JM[#:6ZY&^5L;B 3M4=6;
M .%&2<<"@"_17#_\+?\  G_0=_\ )2?_ .(K<T#QCX>\4>8-&U2&YDCSNBP4
MD &,ML8!MOS ;L8R<9H W**** "BBB@ HHHH **** "BBB@ HHHH *\*^(?_
M "/6I?\ ;+_T4E>ZUX5\0_\ D>M2_P"V7_HI*Z,-\8T>84445](<P4444 %%
M%% !1110 4444 %;.D_\>K?[Y_D*QJV=)_X]6_WS_(5AB/@+I_$?3'AO_D5M
M(_Z\H?\ T 5IUF>&_P#D5M(_Z\H?_0!6G7S<MV:A1112 CGGAM;>2XN)4BAB
M0O))(P544#)))X  [U\>ZSJ.I^-/%5YJ$=G/<7M]*7CM8$\QPH'RH H&[:B@
M9QSMR>]?07QG\2-H?@:2TMW076J/]D +KN$1!,C!2#N&/D/3'F YSBO.?@/H
MBW_BZ\U:149-,M\)EF#+++E0P X(V+*#G^\..X!HJ_!'Q$FC^,WT^XG\NVU2
M+R@#M"F93F/+'D<%U '5G QTQ]*5\B>,]"N/!_C>^LH%>T6&?S[%XF<;8B=T
M95SR2O SD_,IY.,U]2^&=>@\3^&[#6;9=B746YDR3Y;@X=<D#.U@PSCG&1Q0
M!K5\E^*_$VJ?$/Q:A0N\<L_V?3+0X0(KL @()P';Y=Q)Z]\  ?5E]96^I:?<
MV%W'YEM<Q-#,FXC<C AAD<C@GI7.Z/\ #?PEH&J0:GIFD^1>0;O+D^TRMMRI
M4\,Q!X)ZB@1RFA? S0+;16BUIYKS4IHL/-%*42!^>8AQG&1RX(.T' R17DGC
MSP?=> /%$<,%Q,UN^+BQNU!1QANFX8'F(0,E?53QG ^L*^<OC=XJTWQ!K>FV
M6EW$-W#80NSW,$N]&>3;\H(&#@(IR"?O8X*F@9[%\.O%/_"7>#;2_E;=>Q?Z
M/><?\M5 RW0#Y@5; &!NQVKJZ\[^"FD2Z7\.X9IBX;4+A[L(\90HI 1>O4$(
M&!XR&'U/HE F%%%% !1110 4444 %%%% !1110 5X5\0_P#D>M2_[9?^BDKW
M6O"OB'_R/6I?]LO_ $4E=&&^,:/,****^D.8**** "BBB@ HHHH **** "MG
M2?\ CU;_ 'S_ "%8U;.D_P#'JW^^?Y"L,1\!=/XCZ8\-_P#(K:1_UY0_^@"M
M.LSPW_R*VD?]>4/_ * *TZ^;ENS4***H:UJ]IH&BWFJWS[;:UB,CX(!;'15R
M0"Q. !GDD"D!\[?&KQ(VL^-WTZ-T:STE?)38ZL#(P#2'(&00=J%23@QGH217
ML7PGT1=$^'6F\)YU\OVV5D9B&\S!3KT(CV @<9!Z]3\VZ;I^J>,O%*6L3)-J
M>I3O([N0BECEW<XX  W-@#MP#P*[W_A0?BK_ *"&C?\ ?Z7_ .-T#.@^/OAU
MY8--\1V\&X0YM+MQN)"DYC)'W0H8N,\<NHYXPOP"\1/+;ZEX=N)]WDXNK5#N
M)"DXD /W0H8H0..78\\XY[_A0?BK_H(:-_W^E_\ C=<+X;U6?PIXPL-1E2>&
M2QNA]HB\L>8$SME3:W1BI9><8)[=: /L6BH/MUI_9_V_[5!]B\KSOM'F#R_+
MQG?NZ;<<YZ8K&M_''AF\UVWT6TUFVNK^Y4M$EN3*I #$_.H*@X4G!.>GJ*!'
MG'C7X>>,_&OB/4KB.^2UT@7"_9;.^NV*_)&JF143>J@G?C.&Y.0,UY?J6@ZI
M\/M=C&N:'9W><M;_ &K=);R[6'S#8R[N@RK=F&Y>17UO7G_QIM(+GX97\TT>
MZ2UF@EA.XC:YD6,GCK\KL.?7UQ0%S9\$>-]/\<:5)=VD3V\T#+'<6\C*61BH
M.1@Y*$Y 8@9VG@8KIZ^=O@%-*OC74(!*XA?3F=XPQVLRR1A21T) 9L'MN/K7
MT30-A1110(**** "BBB@ HHHH **** "O"OB'_R/6I?]LO\ T4E>ZUX5\0_^
M1ZU+_ME_Z*2NC#?&-'F%%%%?2',%%%% !1110 4444 %%%% !6SI/_'JW^^?
MY"L:MG2?^/5O]\_R%88CX"Z?Q'TQX;_Y%;2/^O*'_P! %:=9GAO_ )%;2/\
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M #PC_P"^!3T1(QA$51UPHQ5VH)OOCZ54:SF[''CLF^J4?:\]_E;]3Z%\-_\
M(K:1_P!>4/\ Z *TZS/#?_(K:1_UY0_^@"M.O.ENSP@HHHI %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A7Q#_ .1ZU+_ME_Z*
M2O=:\*^(?_(]:E_VR_\ 125T8;XQHPZ***D_4 HHHH **** "BBB@ HHHH *
M@F^^/I4]03??'TK6C\1XV>_[F_5'T+X;_P"16TC_ *\H?_0!6G69X;_Y%;2/
M^O*'_P! %:=<LMV?#A1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_!>F^"=&%E9#S;B3#75VRX>=Q_)1DX7MD]223TE ,*^<OCY_R/UG_P!@N/\
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M$****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5X5\0_\ D>M2_P"V7_HI*]UKPKXA_P#(]:E_VR_]%)71AOC&CU&BBBOR(](*
M*** "BBB@ HHHH **** "O-/B'_R'X/^O5?_ $)Z]+KS3XA_\A^#_KU7_P!"
M>OH>%_\ D8+T9E6^$]<\-_\ (K:1_P!>4/\ Z *TZS/#?_(K:1_UY0_^@"M.
MOM9;LX0HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7A7Q#_ .1ZU+_ME_Z*2O=:\*^(?_(]:E_VR_\ 125T8;XQH]1HHHK\
MB/2"BBB@ HHHH **** "BBB@ KS3XA_\A^#_ *]5_P#0GKTNO-/B'_R'X/\
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M?-_C6"6W\>>(4FB>)SJ5PX5U*DJTC,IY[%2"#W!!KZD\$?\ (@^'/^P7;?\
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MO=:\*^(?_(]:E_VR_P#125T8;XQH]1HHHK\B/2"BBB@ HHHH **** "BBB@
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MFR\Y0)+V9@LJ#G<J*I(!QCY]V1DX .&H$'C/XOZ_I/Q OK;1[FVDTRQ?[/\
M9Y+?Y9'"X?<3A\ARP^4@?(.O)/L7A+4-0U?PGIFI:HMJMW>0"X(M0PC"O\R8
MW$G.TKGGKG'%?.7P[^'.H>+=5MI[BU>+0HF$D\\JLJSJ&(,<9&"Q)4J2#\O)
MSG /TGXAUB+P_P"'=0U>8(5M(&E"/((Q(P'RIN/0LV%'!Y(X- SG?B'\0[/P
M1IP1 EQK%PF;:U)X4=/,DQR$![=6(P.A*^ >'O#^O?$OQ7,S3O++(PEOK^89
M6)3P"<8&<#"H,=,#"@D8FHZG-KVOW&IZI,XDNY_,G>-2Y0$]$5FY"CA5+#@
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M6/\ OS%_\<H_X7QX7_Y\-8_[\Q?_ !RCDEV ]1HKR[_A?'A?_GPUC_OS%_\
M'*/^%\>%_P#GPUC_ +\Q?_'*.278#U&O"OB'_P CUJ7_ &R_]%)72?\ "^/"
M_P#SX:Q_WYB_^.5YMXJ\;Z;KGB2[U&V@NTAFV;5E10PPBJ<X8CJ/6ML.G&5V
M-'NU%>>?\+D\/?\ /GJG_?J/_P"+H_X7)X>_Y\]4_P"_4?\ \77YG_8^/_Y]
M,[O:0[GH=%>>?\+D\/?\^>J?]^H__BZ/^%R>'O\ GSU3_OU'_P#%T?V/C_\
MGTP]I#N>AT5YY_PN3P]_SYZI_P!^H_\ XNC_ (7)X>_Y\]4_[]1__%T?V/C_
M /GTP]I#N>AT5YY_PN3P]_SYZI_WZC_^+H_X7)X>_P"?/5/^_4?_ ,71_8^/
M_P"?3#VD.YZ'17GG_"Y/#W_/GJG_ 'ZC_P#BZ/\ A<GA[_GSU3_OU'_\71_8
M^/\ ^?3#VD.YZ'7FGQ#_ .0_!_UZK_Z$]6/^%R>'O^?/5/\ OU'_ /%UR'BK
MQUIFN:I%<VT%XB+"(R)44'(9CV8^M>YP_E^*P^-52K!I69G5G%QLF?0?AO\
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M_DA_]LH_X9]_ZF?_ ,D/_ME%%'M)=P#_ (9]_P"IG_\ )#_[91_PS[_U,_\
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K*/\ AGW_ *F?_P D/_ME%%'M)=P#_AGW_J9__)#_ .V5[7112E)RW __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gaz3apgusshz000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gaz3apgusshz000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ', CL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXJSXJO;"+X>,^LJ'$MLH"'[S.0,8]\UYO\)O(TOQ)Y>N0/%>W$(-D\QR-G'
MST.* /5?$>G:YJ^B0VEE>)9SR8$\B]AWQ7FGAWP[#X:^,EO8Q323-]E9GDD.
M2QR.:]OKRJ3_ )+W#_UZ-_,4"+?QCD>70K+3D<K]KN C$>G'^-=?%X<TS_A'
METT6</DF$+C8/3K7'_&(>1I.FWY!*6UTK-CTR*[R'4+8:,EZ)D\D1!MV>.E
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M]W_"NUKBOA3_ ,D\TW_=_P *[6@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HW@AD;<\2,WJ14E%
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M4W?REDD 95!..OT% 'MEI=17MI#=0-NBE0.C#N#3-0O8=.T^>\G;;%"A=CZ
M5P7P@ULWOAR33)I ]Q8/Y9P<Y';^5-^+^L&WT"'2(I%2:_DV<G'R]_YT 5/
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M;\.:;XA2%-1@\T0N'3DC!'TH TXO]2GT%>>_&O\ Y)Y)_P!?,?\ )J]$ "J
M.@KSOXU_\D\D_P"OF/\ DU &A\*?^2>:;_N_X5VM<5\*?^2>:;_N_P"%7/$O
MC_1/"EW';:E*ZR.NX;4)X_ 4 =##?V=Q<R6T-U!)/$,R1I("R?4=JL5X'X7^
M(FA:7XZU[5KF606MZB"(A"2<'Z5[)X<\2:?XHTXWVG.S0AMN64CG\: )M?OI
M=-T&\O(0#)#&67=TS63X U^[\2^%(-2O0@F=W!"# X8BKOB__D4M3_ZX&O&_
M!.C^,/$7A6*#2M2CTVQMV?:Q&3(230,]_HKRKX>ZWKHUS4O"FN3^=-!&62;N
M.W]:T?A_J-];:]K/AW4[IYYK67=$\G5DR>:!'HE<=X5\37NL^)-<L+E8Q%93
M;(MH.<>]9,FKWVM?%E=.M+AUL-/BW3!3PS9Z'\JXRSB\1ZEXW\2:7H$JVIDN
M-TURP^Z,<?UH&>]45XY:WGBSX?\ B*QM]<U!=0TZ]D$7F@?=8G'U[U+XXUO7
M(?'MGIVCW)5KN':BG[HSGYOP% CTGQ"^L)I,C:'%%+?<;%E;"_SJYIYNCIUN
M;Y56Z,:^<JG(#8YQ^->5ZOI?B7PCX%U.XU#7C=7+LIC:,8V#(SU%:7B'QC>Z
M-X'T2.S_ 'NJ:C#$B,W8E1EJ /1KF0Q6LTB_>1&8?@*Y7X<^)+WQ3X:&H7RQ
MB8N5Q&"!7$G0/B!H5E)K,VKI>KL)FL\<X(YJ;X=ZXGAWX37&IN-WE,VU?4]J
M!GK]%>*V6@_$+Q=9_P!L'7%L$E^>* CJ.W3^M;_@/Q3JYU>\\+^(2&U"W7='
M+_?'?^5 CTNBO"/#MSXQ\57.J:7I^I_9XX[ABUS*,[1V4?Y[U+INL^--(UR[
M\'O<K=WTP'D7+=$[D_3&: /<J*\/N9/&'P_\0Z;-J>KKJ%K>3"-U P!N.*[G
MQU=^)II;33/#D)3[1S+=GI&/2@#MZ*\*U[2?&W@NT.K2^*8;D1D;X0<'!]C7
MKWAC57UKPY9:A( 'FB#,!TSB@#7HHHH **** "BBB@ HHJ":]MH+B*"694EF
M.(U)Y:@">BBB@ J*.Z@FE>*.:-Y(_OJK E?K7*^,_$.K:?)%I>AZ>]Q?7*9$
MN/DC!)&37(_"!+V/7O$":A+YMV)!YC9SSQ0!Z[16+J'BG3-+UBVTR\E,4]S_
M *HL/E;\:DUWQ)IOAV".74)PGFL$11R6- &M4)N[=;D6QGC$Y&1'N&XCZ5A>
M(O$LVE:+%=V-A-=SSX$42CN1WKR_PN=<?XQPRZ\P%U);,PC!X0$CB@#W(D 9
M)P!W-4?[:TOS?*_M&U\S.-OFKG^=<G\5]9NM+\)F&Q=DN+M_)4J<'GT_.L%/
M@QI3:!YS7%R=6,6\7'FMPV,],T >JR7$,,)FDE1(@,EV; _.J::]I$CA$U.T
M9F. !,I)_6N)^&E^=?\ "MWI&K?Z0UE,UNV_G>HYR?SJAI_AC1]7^(#BRL8H
M+'2<;BB@>9*>WX9'Y4 >J]1FJMUJ5C8LJW=Y! S#*B20+G\ZM 8&!T%>.?%3
M3;?5_B!X;L;M2T$R.K@$@XR.] 'J(\0:.3@:I9DG_ILO^-7XY8YD#Q.KJ>A4
MY%>>2?!3PB8V$4%Q')CY7$[G:?SK#\,76I>!?'__  BUW=/<Z?=#,#R')'I0
M!Z_+-% A>6144=2QP*IIKFE22>6FI6C.?X1,N?YUYKX[,^O>/]/\-7%^]EIK
MQ^8SJVW>?3-7Y?@MX:-J39/<P76/EN%G8\^O6@#TD$, 000>A%1S7$-NF^>5
M(U]78"N2\#V^NZ+H=U;Z^Q=;8L8I6;)* =ZX:RT_5/BKK]Y=7=[-;:);2&-$
MB8C?CZ4 >N1ZWI4K[(]1M7;T$RD_SJ\"",@Y'M7FMW\%?#PM6.G275I=@965
M9F)S^=:/PYGUZ&QO=,UJ*1VLY"D$[?\ +5>: .QNM0L[(#[5=0PYZ>8X7^=.
MM[RVNTWVUQ%,OK&X;^5>8S> )_$VOZAJ7B^:2.R5R+> 2E5"YX)P?2LOP]9Q
M>'?BE%IGAZ^EN=,>/,T>\LL?XT >TT45SOC;Q'_PB_AFYU!0#*!MC!_O'I0!
ML7.HV5G_ ,?-W!#_ -=) O\ .EMM0LKS_CVNX9O^N;AOY5Y/X;^&[^++1=;\
M5WES.USETMQ(RA1VZ&G:U\/;OP?/;ZOX/DN28Y!YEF9"P9<\]30!Z_5>:^M+
M:9(I[F*.23[BNX!;Z"DLYWFT^&>>,Q2-&&=#_"<<BO"/%TE]XL\2ZKK-D[>1
MH>!%M]00#^?- 'T!16+X4UQ/$7ANSU%2-TD8\P#LV.:C\9:XOA[PO>W^1YB(
M1&#W8]* ->"]M;IW2WN(I7CX=4<$K]:GKP+P2]]X0\4:7=WKM]FUQ,R%O[W;
M\LU[V2"F1T(H H'7]'5BK:I9@@X(,R\?K2QZYI,KA(]2M&8] )E/]:\=\!?#
MSP_XIM=1O-3@E>9;R105E9>,^QK7\2_"7PSI>AW5]8SS6%Q!&9$D,[') SCD
M]Z /4[F^M+.)9;FYBAC8X#2.%!_.JO\ PD.C?]!6S_[_ "_XUP/A'2K;XA?#
MNQA\0K),()"4(<J3C(SD>U<C\2/AYH'AJWTY].@E0SW"QONE9L@_4T >VIKV
MD2.$34[1F)P )ER?UKB_C7_R3R3_ *^8_P"35-8?"#PG:3P7<5K,)8R'4F=S
MS^=0_&H8^'<@':XC_DU &A\*?^2>:;_N_P"%=7<Z987KA[JQMIV' ,L2L1^8
MKE/A3_R3S3?]W_"NUH \K\'^'X/^%C^)?M6DQ?9?+3R?,MQLSGG;D8_*O3K>
MTMK./R[6WB@3.=L2!1^0J:B@#$\7_P#(I:G_ -<#7._![_DGMI_UTD_]"-=K
M?64.HV,UG< F&5=K@''%5-"T*R\.:6FG:>C);H20&8L>3D\F@#S_ $/_ )+A
MJW_7M_44WQY(_A+QKI_BB,$6\RFWN"!V./\ "N[@\,:99^(+C7HXW%[,FUVW
MD@CZ=.U>;?$'Q1:^+S#X5TF%Y[EKH"5MG^KQD'^= SH/A5IQ?3KSQ#< _:-3
ME+\CH@Z?S-8/A#Q%I^D_$?Q):7\JP?:+C]W(_"DXZ9KU/1]/32M(M;&,86&,
M+6%=?#KPY>O?-<69D:\??*2YSGV]/PH$<=\1=:L_$6LZ+H6E2K=7 NDDD:+D
M(H8=_P *?JD>SXUZ!&>=MNP_)&KM/#W@/0/#$IETVS"RG^-V+$?B:MW'A?3+
MGQ';Z[)&YOK=2L;!S@ @CIT[T 8'Q9_Y$.\^J_S%<9XPBEM-$\%:V8V>VM(H
MEEP,XRG6O6];T2R\0:;)87Z,\#_>"L5/YBE_L:Q;1DTJ2!9+-(Q$$?GY0,#K
M0!@:MX[T%/#$U[%>Q3F6(B.%#EF)'3'6O-M"L9]0^!=Y';H7D23S-HZG&:]%
MT_X7>%M-OVO(+$^:<_><L!GT!-;F@^&M-\.:6=.L(B+8DDJ[%OYT#.>\%^-M
M#NO"MJ9+Z&WEMXPDL4C;2I'UZURWARY3Q/\ %^]UJQ!:QM;=H_- P&)SBNJU
M'X3^$]2O&NIK%E=CDB.1E'Y UTVDZ%IVAV7V33[9(8N^T<GZF@1YY\'?]?KY
M_P"GMOZ4T?\ )?%_ZX'_ -!-=YH/A?3/#C7+:?&Z&Y<R2;G+9/XT?\(MIG_"
M3#Q!Y;_;PNW=O.,8QTZ4 <+\8_O^'_\ K]C_ )TWQSK]R_B_3_#DFHOING31
MAI9UX+<>O:N]U[POIGB,VIU&-W^S2"2/:Y7##ITJ+Q#X.T7Q1#''J=J)#&,*
MX)5A^(YH \@\>:9X5T?P])'#J]QJ6HR?ZLM<M)CW/.*]2^&Y!\!Z7@Y_=#^0
MJO9?"SPI8VLT$>G[EE7:Q=RQ ]B>E='HNC6F@:7%I]BK+;Q#"AF+$?B: -"B
MBB@ HHHH **** $) !). .M?//Q!\9RS^.XY;*8^5ILF(R#P6!Y-?0%[;&\L
MIK<2-%YBE=Z]17FK?!'1F8L;ZX)/)./_ *]=.&G3@VYDRN]CO] U6+6]$M;^
M%@5E0$X[&M*L#PKX8C\*V#V4%W)-;EMRJX^Z>_>M^L)VYGR[%"8&<XYKS#X;
M_P#(Y^*?^N_^%>H5YUX!TN^LO%GB.>YM9(HIILQLPP&''2I V/B#X>M];\.R
MRO(L-S:#SH9CQM(]Z\Y\">?\0_$4-[KERDBZ6@6.'/WSP-V*[#Q^FL:_?VGA
MS3K>9+25@;NYQ\H7KC^59GB'P=<^$[[3-:\*P.QMPL-Q!&.9$QU/KTH&>J[1
M@# XZ5Y7)_R7N'_KT;^8KTVRN3=V4-P8FB,BABCCE?:O/I-*OS\:HM0%K)]C
M%JRF;'RYR.*!#?BZ-L.BRL<1K>+N/8<BO1H646D;$_+L!_2N8^(?AJ7Q1X6F
MM+;'VI#OBSW([5PB^+?B#'I']BGPVYNMOE"\R<8Z=,4 :?PB&Z^\1N/NF\8
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M/T%5]$\8:'XA<QZ;?QRR#^#.&_*@#=HHHH ***S7U[3DUM-'-P/MSH7$8]*
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M44A.!D]J %HK(TGQ+I6MW5U;6%TLLML<2J.W^<5K]!0 45QDOQ3\)0RO$^I
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M+0=&MM+;3M,AMS+=*CE,_,,].M>Q:;#9P:= E@J+:[!Y83IBO-_C/_QZ:/\
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MM6@T&#:9Y]Z_O,#[H&<_I3/%_@BYBDTW5O"\(6^L-J"%"%\Q ,8YX_.O1J*
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MGT)KT2B@!KHLD;(X!5A@@]Z\W\&>&M:\+^,=6A^RDZ+<MOBE#C /TSFO2J*
M.)^&VA:CH6F7T6HVQ@>6Z>1 6!RI/!X-;7BSPW;^*-!GL)U&YES&_=6[5N44
M <5\.;7Q!IFD2:7KEHT8MF*P3%U82+GCH<U5^)_A[5-?M]-73+4SM#<J[@,!
M@ ]>37?T4 -C!$:@]0*XWXI:)J/B#P8]CI=N9[DSHP0,!P <]?K7:44 <O\
M#W2KW1?!EC8ZA"8;F-<.A(./RKJ*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:9$4X9U!]":R/
M%.KOHGA^YO8@#*HPF?4UQUCX*U;7+)-2U/7+F*[F&\(F<)GMUH-Z=%2CSSE9
M'I5%<#X.UW4H=?NO#.K2>?);C,<QZL/>N^H)JTG3ERLXGQC\1+;PS<I86MJ]
M_J+C/D1_PCWJCX:^*<.JZG'INK:=+IMW+_JP_*M[9K;N/#^C:!?:AXI\B:6\
M,99RS[N@[#M7F5[XBM_'7CO2HIX1IB6L@=6F&&D/4"@S/=J*X;QMXAUOPO?6
M-_ 8Y=%+!+E#'\R>^:I^)?'UQ)?:9I7A9HI[R]VN7*[@B$9Z4"/1&944LQ
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MXCMH\6$3E83V9B>H_*O8Z!!1110 4444 %%%% !1110 4444 %%%% !1110
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MU/X4 >]T5Y5IV@_%!;VWENO$BR6X8%TV)R/RKU09VC/6@!:*0D 9)Q0&5NC
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MN4101HY=R#@#/M0"/7Z\A\:QK9_%WP_=0#;+-P^WO@BNLE^*G@R.)G76XI&
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MK3ZU\$_MER<S-& Q]<-BF>)K2]C^'7AW6;&:9&L8H6E5'(!3:,Y Z]15)O\
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MR%SR?Y5Z=2*H4 *  .@%+0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
=10 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gaz3apgusshz000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gaz3apgusshz000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '.!YX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L#Q!K%QITL4
M< 4;EW$D9[__ %JWZX_QA_Q^0?\ 7/\ J: .GT^Y:[L(9V #.O('3-6:H:)_
MR![;_=/\S5^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HI"0!DD #J30"" 0<@]"* %HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&M6T\5VDQ"SHT+'O]X?XUI2Z5I\ZG=:Q<]U&T_F*Q[WPE$X+6<I1O[C]/SH
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M&K;,XCC'^>M=+I&A0V$&Z=$DG8?-D9"^PH Y"QO;C3Y#) H#D8W%<X_.K_\
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M>'GRR^\?1115G,%%%% !1110 4444 %%%% !7$SVB7WBI[>5F"N[9*]>A/\
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M .OFK^N1";1KE3_"N[\CFN>\(2[;Z:+^]'G\B/\ $T =C1110 4444 %%%%
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M'45[!X+\;0>)[9K:Y5;;5X!_I%L3U_VT]5/Z?D2J56_NRW*QF#]FO:TM8O\
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MQ@]*V/[5T_\ Y_;?_OX*\WR?6C)]: /2/[5T_P#Y_;?_ +^"C^U=/_Y_;?\
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MV:5=-_TR8#\1BN5\**6U=FQP(R?Y#^M ':T444 %%%% !1110 4444 %%%%
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MO$G_ "+UY_NC^8H XWPY_P C!:?[Q_\ 037H]><>'/\ D8+3_>/_ *":]'H
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M@.VXG/3A!_,_TJIXJO//OUMD.5A&#_O'K_2NCT2T^QZ5"A&'8;V^I_\ K8H
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M)_B#?3Z<Z/;/I\>]H^@<-@#Z[0*M?VY!X?\ !T-].C22,2!&.LDI))_7))H
M7Q)IEBUG!$L"P&*)]D\2#?$B+T7\2 !TI_AS4;Q6.FZF0;B,;5;U('(_K7+V
MM]J&NN;][I6D^Z(0Q$0'!VX[=!SU^M79=5N(;B2XN+257WYRB[LD],8ZT =A
M-I%E/.9GB(=OO['90_\ O '!_&KB(L:!$4*JC  [5GZ-J3ZG;22/"\?ER% S
M1L@<8!R P![X^H-:5 !1110 4444 %%%% !1110 4444 %<?XW\;Q>&H%L[-
M5N=9N%_<P=D']]_0?S_.CQMXWB\-PBRLE6YUF=?W,&>(Q_??T'MWKR;2M*U3
MQ)KLUI:3-<:C.=^H:C)RL(/]>P ]/;C&I4M[L=ST<'@U)>UK:17XAINF:KXC
MUV2TM)FN=4G.^^U"3E8%_P \ #T_+W+PWX;L/"^DI86"<?>EE;[\K]V8_P"<
M4OAWP[8>&-)CT_3X\*/FDD;[\K=V8]S6M3IT^75[F>,QCKOECI%;(****U.(
M**** "BBB@ HHHH **** "BBB@ KD?#W_(UZG_P/_P!#%==7(^'O^1KU/_@?
M_H8H ZZB@G R>E<M<:GJ&N7DEGH[>5;QG$ESTS]#_AS0!TSRQQ_?D1?]Y@*<
MK*XRK!AZ@UY_KFB1Z9!'(UX;BX=\,&[<9SZUE6UW<6<@DMIGB8?W3_3O0!ZM
M16#X?\0#4P;>X"I=*,\=''J/?VJ/2);V3Q+J OLADC 0#[H7/&* .BHHHH \
M^\6?\A^3_KFG\JK>'_\ D/V?^^?Y&K/BS_D/R?\ 7-/Y56\/_P#(?L_]\_R-
M 'I597B3_D7KS_='\Q6K65XD_P"1>O/]T?S% '&^'/\ D8+3_>/_ *":]'KS
MCPY_R,%I_O'_ -!->CT %%%% !1110 4444 %%%% !1110 4444 %%%% !5>
M^OK73;*:]O9TAMX5W22.> *2_O[72[":]O9T@MH5W/(YX _Q]J\+\6>+9O%<
MZW%PDD&C1/\ Z)9?QW#=F8=R>P[?J<ZE101UX7"2Q$M-$MV'BWQ;-XKN!/<"
M2#1(7_T6T_BN&[,P[^P[?F3VO@7P&\4L6O>((1]LQFULV'RVP[$C^_\ R^O0
M\"^ Y8)X]?\ $$0^W8S:VAY6V'J?]O\ E]>GI%13IMOGGN=.*Q<8Q]A0^'J^
MX4445N>6%%%% !1110 4444 %9?B+_D!W'_ ?_0A6I67XB_Y =Q_P'_T(4 >
M?T444 %%%% !1110 4444 *GWU^M>G6W_'I#_N+_ "KS%/OK]:].MO\ CTA_
MW%_E0!+1110 4444 %%%% !1110 4444 %%%9VMZY8>'M+EU#49A%"G '\3M
MV51W)H&DY.R#6];L/#VERZCJ,PC@C'_ G;LJCN37A>O:_J'B?58KV_AD8L^S
M3=+CYP3T)'=CW/\ ]84:_K^H>)=6AOKZ%WD9MFFZ8G.W/0D=V/&3_P#6 ].\
M"^!1H0_M75=L^M3+R>JVZG^!/?U/^3S-NJ[+8]F$(8&'M*FLWLNP>!_ JZ'C
M5M6V3ZU*O7JMLI_@3W]3_P#7SV]%%=$8J*LCR:M6563G-ZA1113,PHHHH P_
M%7_(('_70?R-</7<>*O^00/^N@_D:X>@ HHHH ,XZ5JV.OWMCA1)YD8_@?FL
MJB@#I_\ A,9/^?1/^^C1_P )C)_SZ)_WT:YBB@#I_P#A,9/^?1/^^C6+J>H'
M4KLSF,)P!@'-4J* "BBB@ HHHH **** "BBB@ KT+0?^0);?0_\ H1KSVO0M
M!_Y EM]#_P"A&@#2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "HYX4N+>2&0?*ZE34E% 'GT;3:'K/(YC;!'9A_^JNX=(-2
ML"OWH9EX/^>XK+\1Z3]MM_M$*_OXQR /O+61X>UG[%)]DN#B%CP3_ ?\* *,
MD=UH.J9!PR'(/9A7:V-];ZK9[E (88DC/./:DU/38=4M=CX#CE'';_ZU<6RW
MV@WW=&'0]F']10!HZOX;DMV:>R!>+J4'5?\ &H=/\27=D!%./.C'9CR/QK=T
MWQ':W@"3$0S>C'Y3^-6[S1[&_P#FEB <_P :<'_Z] %6#Q/ITH&]WB)[,N?Y
M5:.M:<%S]J3'T/\ A6--X/4G,-U@>CK_ %_^M4 \'SYYN(\?C_A0!IW'BFPB
M'[K?,WL,#]?\*Y^^UR^U0^2@*1MQY:=_KZUK0>#XE.9[EF]D7'ZG_"MJUT^R
MTY"T4:)@<NQY_,T 86C>&BK+<7R^ZQ'^O^%:NL:O'IEN0I!G8?(GI[FJ6I^)
MX8 T=GB63^__  C_ !K#L-,N];NS+*S>63EY&_I[T /T;3I=7OS/.6,2MND8
M_P 1]*ZW4[Z/3;!I3@,!MC7U/:I$2VTRRP,1PQCDG_/6N)U._GUK4%2-24SM
MC0?YZT .T6R?5-5\R7+(IWR$]_\ ]?\ C7>U0TG3ETVR6(8,AY=O4U?H ***
M* "BBB@ HHHH **** "BBB@ HHHH *\R\>>/)/.F\/\ A^<+< ;;R]4\6X[J
MI_O>_;Z]$\=>/9'GFT#P_,%F7Y;R^4\0#NJG^][]OKTY+P?X/D\5S".,/;Z!
M _[^<</=-W53_,UA4J-ODAN>IA<+&$?;U]NB[AX0\'R>*W\J'S+;087Q/<?Q
MW3=U4_S->Z6=G;:=9PV=G"D-O"NV.-!@**6TM+>PM(K2TA2&WB4+'&@P% J:
MKITU!'+BL5/$2N]NB"BBBM#E"BBB@ HHHH **** "BBB@ HHHH *\PUK_D-7
MG_79_P"9KT^O,-:_Y#5Y_P!=G_F: -OP3_Q]W'_7/^HJ/QK_ ,A.#_KB/YM4
MG@G_ (^[C_KG_45'XU_Y"<'_ %Q'\VH R] _Y#=K_P!=!_.O3*\ST#_D-VO_
M %T'\Z],H **** "BBB@ HHHH **** "BBB@ HHHH ***X?QQX[&AG^R=)"S
MZU*O?E;93_$_OZ#\^V5*2BKLTI4IU9*$%J+XZ\=#0A_96E;9]:F7@=5MU/\
M&_OZ#_)\PT#0=0\3:K-8V$[M(S;]1U23YMN>H![L><#_ .N0:#H-_P")]6FL
M;&9V9FWZEJDG)&>H![L><#_ZYKW71-$L/#VE1:=IT(C@C'_ G/=F/<FN=)U7
M=['K3G# P]G3UF]WV$T+0K#P[I46G:=#Y<*<DGEG;NS'N36E1173L>,VY.["
MBBB@04444 %%%% !1110 4444 %%%% ",RHI9F"J!DDG  K%\,$2:?<W,9S!
M<WDTT)]4+G!^AY(^M7[_ $NRU1(TOH!/'&V\1L3M)]QT;\<U#K-U)IVD.UI&
M/..(H%4<!CP./;KCVH S_$&H1VMW'YUT5MX[>65X8IMCNZ[2H]>1G ]:X;1-
M)NIFEO=6LS"]RV^-G #2 ]6/?OU->A:/H,%C 'GAC>X8#)8;B/J3U.>2?6JW
MBZ*<6<-W!$TGDL0X49(4]_S _.@"[HEI!86#>7M5&.]CTQP/\*XV6_O=;O[R
M2.\F%H9E,<.<KA2"IP?< U%+XC-QH-Q8VS'S)5.6![#^'\:H^&;]8I)HF!(P
M"3C@'T^IH [^WUI[>!?[2AF48XN%0%&/7''(/X<UST7BJ?Q#J#6D#&TA!^6/
M.'D'KG^@_6KAU>X>^LE61?L0#"=,#YB/N?Y]JY_6(XM!N9;ZPQMG4I%E<F%C
MU_3./K[4 =R6CL=)> .3MC*@#MQVKA](TR5?%%O$I*G<665!PRXS_D5:TF]U
M'Q%$R6D(62,#S9';"+G]>QXQ5:]ANM'2.5YI6D2X>*;9A5C88*L.^"AS0!V&
MH:J;)65AL=>H-,\*V,2V<E\T;&YGD8EY26<#/0D\\]?R]*O6=O\ VC903:G:
M6[S#YDRH/'8\]#[5*)8[746@9U'V@>8JYYR, _TH L75K#>VLMK<QB2&52CH
M>X-<?9^%8XW^TV]U<S6MK(P@BGP^1C!(/7 );'KBNOO9!%9S.6"_*<$G'-/@
M$:V\8BVF,*-NWIB@#S_4_%XT.]AACA!20?O74#<%[8]Q5G6+S2=>\,VT6FW$
M9,;@QQR':Q(!!'/4\UN:MX.T?6;@3W,3K)W,3[<_ATJ#5O#&F0>&)K6U@6!8
M4+JP&XY')SGDYQ_*@#(\%6OS7EG=0,F0'0E<$$<'!_$?E6Y'H$Z:Q!*TJ/:1
M'?\ [18=!CZ\Y]J9X=T.ZL9S=7,N/DV)"/\ T(_X?Y'24 %%%% !1110 444
M4 %%%% !1110 5QWCCQQ'X;B6PL%6YUJX7]U#U$0_OO[>W>F^-_',?AU%T_3
MU6YUF=?W<7\,(_OO[>@[UY5I&D:GXEUN:RLIFFOIFWZCJ4G(B!_KV 'I[<8U
M*EGRQW/1PF#4E[:MI%?B&CZ1J?B36YK.RF:>_F;?J&I2#(A!_KV 'Z8X]R\.
M^';#PQI,>GZ?'A1\TDC??E;NS'N:7P_X?L/#6DQZ?I\6V->7<_>D;NS'N36K
M3ITU#5[F>+QCKOECI%;(****U.(**** "BBB@ HHHH **** "BBB@ HHHH *
MXM)QH/BZX>Z!$$^XA\= QSG\#Q7:54O]-M=3A\JZB#@?=8<%?H: ,[Q-?>3H
M#/"^?M&$5E/8\DC\*S'OHM'\*0Q64T?VF4#<48%E)&2?PZ5O7NC6]]IT-E(\
M@2+&Q@>>!C^597_"%6/_ #\W'_CO^% '%$EF+,26/4DY)I*[?_A"K+_GYN/S
M7_"C_A"K+_GYN/S7_"@#DM-\_P#M.V^RL%G\P;"W3/O[5W-IK$HU0:;J$,<=
MRR[D:)B5;VYZ'BJL?@ZUAD62.\ND=3E6!&0?RJQ%X<B34(KV2]N9IHR"#(P.
M?;I0!MT444 >?>+/^0_)_P!<T_E5;P__ ,A^S_WS_(UU>O\ ATZK(MQ!(L<Z
MKM(;HP[?0U%H7AEM.NA=W4J/*H(14Z#/?- '25E>)/\ D7KS_='\Q6K65XD_
MY%Z\_P!T?S% '&^'/^1@M/\ >/\ Z":]'KSCPY_R,%I_O'_T$UZ/0 4444 %
M%%% !1110 4444 %%%% !1110 56O[^UTNPFO;V=(+:%=SR.> /\?:DU'4;3
M2=/FOKZ=8+:%=SNW;_$^U>$^*O%5QXJNTNKM)(M*C?%C8#EIF[,P[D]AV_GG
M4J*".O"826(EV2W8OBWQ9-XJN5N;I9(=(B?_ $.Q_BG;LS#N3V';\R>Y\">!
M)+:6/7M?C!U C-M:G[MJOJ?]O^7UZ.\"^ WM)8]>U^,-J1&;>V/*VH_J_P#*
MO1*BG3;?//<Z<5BXQC["AI%?B%%%%;GEA1110 4444 %%%% !1110 5E^(O^
M0'<?\!_]"%:E9?B+_D!W'_ ?_0A0!Y_1110 4444 %%%% !1110 J??7ZUZ=
M;?\ 'I#_ +B_RKS%/OK]:].MO^/2'_<7^5 $M%%% !1110 4444 %%%% !11
M69KVO6'AO2I-0U"79$G"J.6D;LJCN31L.,7)V0NNZ[8>'=*EU'49O+A3@ <L
M[=E4=R:\+US7-0\2ZQ#>WT+R3NVS3M,CYV9Z$CNQXR?_ *P!K>MZEXFUB&\O
M8'DN)&V:;I<?/EY[GU;U/_U@/4? W@9?#Z'4]3*W&M3K\[]5@4_P)_4_Y/,V
MZKLMCV80A@8<\]9O9=@\#^!UT!3J>IE)]:G7YF'*P*?X$_J>_P#/M:**Z(Q4
M59'DU:LJLG.;U"BBBF9A1110 4444 4M5L!J5BT&_:V=RGWKFO\ A$+S_GM!
M_P!]'_"NCU?4&TVR$Z(')8+@_0_X5S__  F$_P#S[Q_K_C0 S_A$+S_GM!_W
MT?\ "C_A$+S_ )[0?]]'_"G_ /"83_\ /O'^O^-'_"83_P#/O'^O^- #/^$0
MO/\ GM!_WT?\*/\ A$+S_GM!_P!]'_"G_P#"83_\^\?Z_P"-'_"83_\ /O'^
MO^- #/\ A$+S_GM!_P!]'_"C_A$+S_GM!_WT?\*?_P )A/\ \^\?Z_XT?\)A
M/_S[Q_K_ (T ,_X1"\_Y[0?]]'_"C_A$+S_GM!_WT?\ "G_\)A/_ ,^\?Z_X
MT?\ "83_ //O'^O^- #/^$0O/^>T'_?1_P */^$0O/\ GM!_WT?\*?\ \)A/
M_P ^\?Z_XT?\)A/_ ,^\?Z_XT ,_X1"\_P">T'_?1_PH_P"$0O/^>T'_ 'T?
M\*?_ ,)A/_S[Q_K_ (T?\)A/_P ^\?Z_XT ,_P"$0O/^>T'_ 'T?\*/^$0O/
M^>T'_?1_PI__  F$_P#S[Q_K_C1_PF$__/O'^O\ C0 S_A$+S_GM!_WT?\*/
M^$0O/^>T'_?1_P *?_PF$_\ S[Q_K_C1_P )A/\ \^\?Z_XT -7PA=[ANGA"
M]\$G^E=7:6RV=I';H2508R>]<M_PF$__ #[Q_K_C71:5?'4+!+AD"$DC ]J
M+M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9F@D<8:2WD,;'\JN6\$=K;16\*A(HD"(H[ # H RTT;0K^TCFM[6V9&7]W/
M &Y[AASFO-O$:#2GOM/AG0!+D3O*JA6)V#&0.,__ %S7H^I12:3YFJ61C6)
M7NK=VVI(HZL#T5Q^1[^M>47I'CSQ<D.G636ZS2[IY-Y.8Q@;F&< @ ].Y H
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M@MQK4Z_NX^JPK_??^@[UV=?.'A;3=5\8WDD5H[_:9V,FH:C+D^6"3@9[L1T
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M,VZ6 .WJT2DTW^U] _Y]$_[\K6C_ &#IG_/J/^^V_P :/[!TS_GU'_?;?XT
M9W]KZ!_SZ)_WY6C^U] _Y]$_[\K6C_8.F?\ /J/^^V_QH_L'3/\ GU'_ 'VW
M^- &=_:^@?\ /HG_ 'Y6C^U] _Y]$_[\K6C_ &#IG_/J/^^V_P :/[!TS_GU
M'_?;?XT 9W]KZ!_SZ)_WY6C^U] _Y]$_[\K6C_8.F?\ /J/^^V_QH_L'3/\
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M/UK3HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXP<L #G<JG('(INIV6A,<"FDI2M)[(^EZ*Q?"6N_\)+X5T_5VC\N2>/]XNW
M#J2KX&3\NY3C)SC&:VJU3N<,HN+:?0****!!1110 4444 %%%% !1110 444
M4 %%%% !1110!Y9\0OBK_8ES)I&@-#+?)N6YN6&Y8#@C:HZ%P>3G(&,$$Y"\
MQ_;_ ,7OL/VOR=2\OS?*Q_9D?F;L9SL\O=M_VL;<\9S65\*K";6?B-;W5PR7
M'V99+R=K@EV<XVAAD'+;W5LGT)SFOH^L8WGK<].M*GA6J:@F^K9Y9\/?BK_;
M=S'I&OM#%>OM6VN5&U9S@#:PZ!R>1C .<  X#>IU\W_%6PFT7XC7-U;LEO\
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M?%7_ &]_^DZ4G+WOD7&DE0=TKJ5K_<=EX"_X37_B8?\ "8?],_LO^I_VM_\
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MR=#U#4A%YWV2VDG\O=MW[%+8S@XSCKBM5L>=->^TNYY__P 71'C3UT'^TO\
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MTZKUTV,XX&+4;SMS+30^A_%?]M_\(U=_\([_ ,A;Y/(^Y_?7=]_Y?N[NM4O
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MI?X=QZCI6#\#O^1UO/\ L'/_ .C(Z]7\)^ ]&\'?:'T\32W$_#7%RRLX7CY
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MH **** "BBB@ KP'XX_\CK9_]@Y/_1DE>_5R'BKX<Z/XOU2+4-0N;Z*6.$0
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M9.8C&4HI=#JK5J-&O*>O-^&QXAXBL[:V^*&I6^NK+#9R:B[S-"XWI%(VY7!
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M7"*H!(!SC=&PQP>/H:])\0_%O0M+TFTO=*DBU:2XE*_9UE,3(HSEF!4E><
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M25F@6(I24Z<]F[IE'3OC%_:WBJ#1[#06GAGN_(CN5N6R8]V/-V>7D#;\Q!/
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M%.A>&]<M=6L[O47GMMVQ9I$*'<A4Y 0'HQ[TG3=DC:.+CS5)RW:LCAOCK?\
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M0HR;O+H$ZU&%*5.E=\V]RU1116IP!1110 4444 %%%% !1110 4444 %%%%
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MMM6L[O49+BWW;5FD0J=RE3D! >C'O5SQ/\./#_BN[^V7<4UO>G:'N+5PK2
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M(?\ ]-/M7^I_V=G^L_X%T_'M2;LKETX<\N6Z7J=G15+2/MO]BV']I?\ '_\
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M$V[O,S]T#/W1U]*],IQES*Z(K4G2FX2W04444S,**** "BBB@ HHHH ****
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M9W>TM6B>")ND9?S-V/0$J#CIG)ZDYY[X'?\ (ZWG_8.?_P!&1UL_ 7_F8/\
MMV_]JUC? [_D=;S_ +!S_P#HR.A?9'423KI>7Y'OU%%%=!XH4444 %%%% !1
M110 4444 %%%% !1110 4444 ?+FKK>W'Q'UC3[&Z>WEU#5)K,D2,BN))BNU
M]O522,C!^E/\3>%-:^'VI64AO-CS1%H+JSE9"&V@2*#PPQNQGN".G('1>%_^
M2_S_ /81OO\ T&6MGX]?\R__ -O/_M*N7E]UR/?]JU7A2Z-:_<_\CDY_"/B7
MQ/X3F\:W>I)?85W$<DA\P1(\GF8R JA2"0B\8)Q@@ ]5\'-2U<^&_$EI9M]I
M>SB62PM92-@E82'&<C 9E7(R!U/&2:[3_FBO_<N_^V]>5> =9O/#_@GQEJ=@
MR+=1+9K&SKN"EG=,X]0&R,\9QD'I5649)F',ZU&<;+1I+[R23X;^)M4FU/6?
M%=];:4VSS#=7T\9664G"J2K81>@SVRH53VK?":ZO=/\ B-;6$=QLBN?-BNHX
MW5TEV1NPY&0<,,A@?7!P3G/\.6_AW7KB_OO&/B._@F1%.=I>2;E5!$AWEB.A
M7;G&"#A6Q;^&?V;_ (6OI_V+SOLOF7'D^?CS-GE2;=V.-V,9QQFI5KIHWES.
MG4C/6R[62TZ&O\;)98/'>GS0R/%+'81LDD;%65A+(001R"/6L/5?A_J]OX.7
MQ?=W]K/%<*ES(I=VD992FTDD<L2YW9Z8SDYXV?CC_P CK9_]@Y/_ $9)73^(
M?B=I5]\-)5AOK9]9O;402VPAD 5V""8#/0 .VTDX)'!;!%4TG*5S.,ZD*5+V
M:WW-'X1^+M1\2:5>66I'SIM.\M5NBV7E5MV WJPV?>[Y&>02?$O#FGZEKVIK
MX?TZ\\@ZAD/')*R12>6I<;PH.<;3C@X->H? :*41:],8G$3- JR%3M9AYA(!
MZ$@,N1VW#UKA_AMXDM_#'C".[O94BL9H9(;B1HV<JN-PVA><[E4=#P3]0GJH
MW'!<DZWLUM8=J-GK/PJ\91&VOH9+@1>:C(#MEA9V4+(IQUV9(!..,'(!J]\6
M-0.K:SH>I&+R3=Z+!/Y>[=LWL[8S@9QGK@5+\7?%5EXBUNSMM-N8;FSL8W!E
M16'[UFPXR>&7"(01P<GD]J'Q'BE@E\,0SQ/%-'X?M5>.12K(PW@@@\@@]J4M
M$TMC2C>4J<YKWFF>D_''_D2K/_L(I_Z+DKS32_"6O>-?#]YKJWB3KID'V6&W
M(9I6$2(1&BJN -C'&.2W4?,6KTOXX_\ (E6?_813_P!%R5L_"G_DFFD?]MO_
M $<]:.*E.S..G6E2PBE'>YYY\#;^[7Q'?Z:L[_87M&N&@_A\P.BAAZ'!(..O
M&<X&.;OM3UKXJ>,;:V,D$$DN];.WD=O*@4*7(R 220O+8Y..@  W/@=_R.MY
M_P!@Y_\ T9'6/X!UH>"?'C_VL4MH56:TO2RM(8\<X79G)WHHR,C!/UK-.\4G
ML=4HJ-6I."]Y)6*7B[1-4\&W#^&[F_2>SF9;Y$CSM/+QJY!'RL0#D D=.3@8
M^BO"'_(E:#_V#K?_ -%K7B?Q=\567B+6[.VTVYAN;.RC<&6-6_UK-AQD\,N$
M0@CCD\GM[9X0_P"1*T'_ +!UO_Z+6M*=N=V.3%N4L/"4U9LV:***V/,"BBB@
M HHHH **** "BBB@ HHHH *\,^,/C.__ +;E\/6=Q-;6=M$/M00[3,SID@D'
ME-C 8XR2V0<#'N=?.WQ,DO-#^+$FJ+$F\-;WEMYARKA%4 D YQNC88X/'T-9
MU6U$[LOC&5776RT]0UOX5^(?#6GV&HVLC7U[Y^'BTZ*1G@899'5@,D?+R<+@
MD 9ZUUW_  FWB'0OA']IU*UO8-:6Y^P037L)W-D;Q*P8#.$W*"=V64$YR:V_
M$/Q;T+2])M+W2I(M6DN)2OV=93$R*,Y9@5)7G  (&<Y&0*Y7QKK]YXV^%"ZS
M_9+64-MJB[@TV\-&$*;P2JY&^0+@ \@^AQ%E&_*S=2JUN7V\=+[[?(Y+PSX&
MU[Q_]LU3[<A5&,3W-Y,SO+($RJ]S@?("3T#<;L8HTC6=;^&7B]["YF<06\X%
M[:1OYD<J,%)=5R!N*;2IX/0'C(KM/A?\1-'TOPU_8VLW2VDEHTCP.8V*R1G,
MAY&?F!W<8&<J!DYKC/&NKS?$#QV%T6V>X7:MK9JJ;7E5<DL<G@9+')QA<9 P
M:G1136YT)SG5G3J1]Q&]\9;N>P^(6EWEL_EW%O912Q/@':RRR$'!X/([US6M
M^!M7L/"EIXJNKA+N/4&6639O=T610ZO(Q'4DD'/<KR=W&_\ ''_D=;/_ +!R
M?^C)*]+^*W_)--7_ .V/_HY*;BFY7(C5E3A14>N_]?,YOX>:UJ0^#VM7)O',
MVFK<)9NX#&%4A5E'(Y ). <\8'0 5YAX?ATCQ#JUT/%.O7=K<31!;>[D!E#2
M\*IE<DG:!CK@8!RRX&?1OAAKMKX9^%NJZO>1S26]OJ)W+" 7.Y85&,D#JP[U
MS]Q:_#;Q5)?SV5W>>&[B*+SMMPBF%_F);8@8DM@X"*R]MJG!H>J00:A4J*S2
MONEL=+\-_!GB30M4M;Z'7M-NM!E\SSXK*[>6.4[2N5&S;N#*N6!!PI'J#YMJ
MGA'^S?B!'X6^W>9ON((/M/E8QY@0YV[NV_IGG%;'PFO;FP^(MM86]YNM;KS8
MYQ'GRYPD;LIPP!ZC() ."1QDBI_&EW!8?'(WMR^RWM[RSEE?:3M54B).!R>!
MVI.SBO4N'M(8B2;O>-]ON.Y\5Z#_ ,(Q\#[O1_M/VG[/L_>^7LW;KE6Z9./O
M8Z]J\F\+>$-9\;S306,T(CL8E!>ZE(6,,S$(H )Y.\\#'7/)Y]I^(VHV>K?"
MC5;RPN$N+9F1%E3[K%;A5.#W&5/(X/49%9GP-AB7PC?SB)!,]^R-(%&YE6-"
M 3U(!9L#W/K52BG-+R,*5:=/#2J?:YO\CAOB]81:5X@T?3H&=H;31X8(RY&X
MJKR*,X &<#TKU7XK?\DTU?\ [8_^CDKS/XX_\CK9C_J')_Z,DK8^(/Q%TS7/
MA_;6EA/";W4/*>ZMBKL8%!+,-V -PD11SU!R!@@T72<A\LIJ@TK_ /#H7X=Z
M[_PC?P@US5A'YDEO>OY:[<@NR1*F1D?+N89YSC.*Y+PUX;UGXH:S=W-[K'-M
MM\^:?,CJ'WE1&G V[@?ERH&>/2MKPY:SWGP$\2QVZ;W6],I&0,(@A=CSZ*I/
MX5:^#GC#3M(MK[1]5O;:T26836SRY4,Q4A]S_=4 (F,XY)Z\"DM;)[&DKP56
MI37O7_#0H>![7QAX1\:061T[57TQKLV]RL<,OV9PQ"&8$KC PK!L D+C(!-<
MSJGA'^S?B!'X6^W>9ON((/M/E8QY@0YV[NV_IGG%>IZ=\8O[6\50:/8:"T\,
M]WY$=RMRV3'NQYNSR\@;?F()X .3QFN+\:7<%A\<C>W+[+>WO+.65]I.U52(
MDX')X':E)1Y=.XZ,ZOM7S1LW&_KYGMGA30?^$8\-6FC_ &G[3]GW_O?+V;MS
MLW3)Q]['7M5S6=0.DZ'J&I"+SOLEM)/Y>[;OV*6QG!QG'7!I^GZC9ZM9K>6%
MPEQ;,SHLJ?=8JQ4X/<94\C@]1D5R7Q:U%;#X>7R?:'AFNWCMXMFX%R6#,N1T
M!17SG@C([XK=V4=#R(J52K:6[9P?P)T_?KFJZ@)<?9K5(/*V_>\QMV<YXQY6
M,8YW>W/N=>:_!/3FM?!MQ>26Z(UY=LT<HQNDC4!1DCG <28!]SWY]*I4U:*-
M<;/FKR/F_P ;ZQJOBWX@SZ,;EX[<:@MC;6TDI\E'#F,.0!U)+'."0&QD@"J7
MC+PEK'@JVLK&]U))[.[9ID@AD?8)55 [%" ,C=M#=2!VSBKT]_-X3^--Q?7:
MI$L>J2/*7!<+!*3EL*<Y\N3<!ZXR.U;GQ<\:Z7KVGZ;INCWD5U")/M,["-P4
M.P>6 3@<AWR.2",'!!%8.S3;W/4BYQG3A!>[8Z?PMKO_  C?P*AU98_,DMXY
MO+4KD%VG94R,CY=S#.#G&<5YKX>\(:]\1[W4M5>\0.&S+<W0;][(5.U5PN,#
M"@@8VJPP#P*[>VM9[S]FYH[=-[K&\I&0,(ER78\^BJ3^%<'X(TKPCK,DUKXC
MU.YTZXW#[/(LRI'(,$D$LA"D;>I89W  9'-/7E3[$4DHJK..CYGTOIZ&OX"U
MC5/ _CT^&[S?]EN+O[-/ $)'F$[4E3=C )V\]T.<'"XA^*^J7=UX_O--O+^Y
M_LRW:'9 GS+&#&I+!,@,WSMR2#SC(&,;6A:5\+H_$&ER:?XCU66]6[B-O&\3
M!7DWC:#^Y& 3CN/J*N>-/%7@'Q!J\VG:WI^JPWEG.UH;^!$!C"R88\,=RY!X
M*D@$X )HL^6UR5./MU-0;TUT_&QA6O@!-1U=;OP%XLLW01%XQ-<O#>1?P/D*
MFX+S]["\-C'<Z7QG2\BTKPG'J,J37R02K<2)]UY L6XC@<$Y[#Z"N%\3Z9IW
MAW7E70?$":@D;>8DL&0\# [E^<?*Q *_,IZ@Y"XY['XK7<U_X6\$7ES)YD]Q
M9-+(^ -S,D))P.!R>U*ZY6C11E[:G*]UKNK/8Z_6_%%YX3^$&@W>GQH;JXM;
M:V21^1%F'=OQ_$1MX!XR03G&#YCX8^'NK^.=/OM5@OK4$3M&QNG<O++\C,6.
M#P5<G/))&,<Y'<>/+6>X^"'AV6)-R6T=G+,<@;5,)0'GK\SJ./6D^&/Q T72
M?!QT[6;^*UDLY7,2B*0EHF93G@$,V]VX'.!G& 35.SDE+:QA!RIT93I+WN;4
MY#X;ZC=ZK\5=)O+ZX>XN'1U:5SEF"V[*N3W. .3R>IR:/B1J-WI/Q5U:]LKA
M[>X1$594X90UNJG!['!/(Y'4<T?#F^FU/XNV>H7"HLUU-<S2",$*&:.1CC))
MQD^M:/BC_DO\'_81L?\ T&*H^Q\SJ>F(U7V-OF<[XO\ A_J7@VUL9+UX)X[D
M,K-;JQ2-P>%)('5<$=#PPQ\N3[M\-]0O-4^'^E7=_</<7++(K2R'+,%D95R>
MYP!R>3U.37._''_D2K/_ +"*?^BY*V?A3_R332/^VW_HYZTBN6;2.&O4=7"Q
MG+>_^9V=%%%;'FA1110 4444 %%%% !7D/Q'\->-_%OB,6=K:(=#@=/L[F=$
M3<5&Z1QNW$@EA]W@#@<G/KU?-GC;7[KQ!XXO-/UG5);72K:]>!!#$9(X0C,J
MOY>X;FY.3G."<=EK.HU:S.W PDYN4>B]?N\S)\4>'SX2UY8;36+:]\I]T=Q:
MS 212(>0RABT;JW3GZ'(('I7Q-NI[[X1>'+RZD\RXGDMI97P!N9H').!P.3V
MKSCQC8>%M-OHK;PSJ-[?[-XN99RIC!!P A"KNZ$D\@@K@GFO0?B%_P D5\*_
M]NG_ *3O6*TYD>C/WG2D][]K'&Z7X2U[QKX?O-=6\2==,@^RPVY#-*PB1"(T
M55P!L8XQR6ZCYBU=#\#;^[7Q'?Z:L[_87M&N&@_A\P.BAAZ'!(..O&<X&/0_
MA3_R332/^VW_ *.>O-/@=_R.MY_V#G_]&1U25G%KJ93J.I"M%[1V.<ENM:^)
M?C%+9KO;+=RRM:PW,Q,5NNTML&%X^5 ,A>2,GGFHO&>@:EX4U.#1+[4/M<$4
M9FM51V*)&[L,[3PC$KD@9^IK0\ ZT/!/CQQJQ2VA59K2]+*9#'CG"[,Y.]%&
M1D8)^M:/Q=\567B+6[.VTVYAN;.RC<&6-6'[UFPXR>&7"(01P<GD]HT<6WN=
M"<XUXTXKW+'MGA#_ )$K0?\ L'6__HM:N:SJ']DZ'J&I"+SOLEM)/Y>[;OV*
M6QG!QG'7%4_"'_(E:#_V#K?_ -%K6#\6M16P^'E\GVAX)KMX[>+9N!<E@S+D
M= 45\YX(R.^*Z;VC<\3EYZW+W?ZGEOP8L(;KQ\DKLX:RM))XPI&"3MCP>.F)
M#TQR!4/Q?OI;OXB7<,JH%LX8H(RH.2I42<\]<R-Z<8KK/@1IS"/6=3>W3:QC
MMX9S@MD9:11W YC)['CKCCB]/1?&'Q>5DE2[MKK4VG4W08K);HQ?:0PSCRUV
MA2/0<"L+>XEW/74E]:G-[11'XE\%:YHGA?2M9U>]\X2[+:.WE:0R6Z%-Z(=P
M^7&'!7HI QG)QZO\&-0N[_P1(EU</,MI=M;P;^2D81"%SZ L<9Z# Z "N9^.
M^HJUUHVF)</O1)+B: ;@N&(5&/8GY9 .XYZ9Y[GX7:<VG?#S2UEMTAFG#W#[
M<9D#L2C$CJ2FSKR  .V*N*M-V.:O4<\)&4MV]#I-8T_^UM#U#31+Y/VNVD@\
MS;NV;U*YQD9QGIFO"?@IJ*6WC22UDN'1+VT=(XAG;)(I#C('&0HDP3ZD=^?H
M.OF+79+SP/\ $G4Y-.%M#/;SRM;"-,I$DJ';A< 95)!QC ([CJZFC4C/!+VD
M*E+NC=^(NHW/C;XBV^@::-Z6DALXLJ<>:2/-<X7<%!&#U&(RPZUSWQ!M(-'U
M^'0X$PFD645LTN3^_8@S-)@YVY:5OER<?H.Z^"/A?FX\27,/"YM[+<O_ 'VX
MR/HH93_ST!KC+3_BJ_BTCP_\3&WN]6,H$_(>V$F[!#_PB)?NGL,8[5FU=7?4
M[:4E";A':"_$W?C'H,6C7'AWR9W>%-/%C&D@&X+"1ABPX)(D'8=/?CN+KQLN
ME?!RPUF&Z>>^FM8[2&5]Q9KG:5=B64Y*E';YN&VXSR*;\:=+^V^"DOD2'?87
M*.SN/G$;?(54X[LR$C@?+["O%K635?$[:)X;A",MNSPVB*A^4R/O=W(!..Y/
M0*F<=2:D^63MU,:,%7H0<OLMW]-SK_ASI<>@:3?>/]13_1K"-X[*$AU,LIP@
M8,!C:2WEYPPRS$XVUE:;IFN_%?Q9<7$]PBNJJTLSHWEP1[L!$ SS@L0I(SAB
M3G)KUGQWHL6E?!^]TK3H':&UAA"A4!8A94+.VT 9X9F./4UPOPB\5^'_  ];
MZK#JDJV=Q,5D6=B["5$5CLP 0"OS$=V+@#) I.*347L.-64X3KP5Y7LO)'.2
M-K7PN\;M!'<S,D,J2,L9,<=[#VR""#P67.&VMNP<C-?35?,7B2\N/'_Q%F&F
MEY!=3K;68=G95C7Y0^,953@R$8^7+=>37T[5TNMMC#'[0<OB:U/ ?C1H/]G^
M)8M8^T^9_:F?W7EX\KRDC7KGG.<]!CWKI?#&G?\ "N/AWJ/BA;K[9)?V5M/'
M"8,")V!" _/\R[I1G&#@'%4_CU_S+_\ V\_^TJO7VI6?B'X'S6&DSK<W5CIE
MJUU&/E,01ANSG R!#(<=2 ".&7,V2FS;FE+#4T]F[/TN<!X>\(:]\1[W4M5>
M\0.&S+<W0;][(5.U5PN,#"@@8VJPP#P*TO 6L:IX'\>GPW>;_LMQ=_9IX A(
M\PG:DJ;L8!.WGNAS@X7&1X(TKPCK,DUKXCU.YTZXW#[/(LRI'(,$D$LA"D;>
MI89W  9'/5Z%I7PNC\0:7)I_B/59;U;N(V\;Q,%>3>-H/[D8!..X^HJ8K9HW
MKR2YH23:MHN7;YF+\5]4N[KQ_>:;>7]S_9ENT.R!/F6,&-26"9 9OG;DD'G&
M0,8LVO@!-1U=;OP%XLLW01%XQ-<O#>1?P/D*FX+S]["\-C'<[OC3Q5X!\0:O
M-IVMZ?JL-Y9SM:&_@1 8PLF&/#'<N0>"I(!. ":\Z\3Z9IWAW7E70?$":@D;
M>8DL&0\# [E^<?*Q *_,IZ@Y"XY)63;W)H\TH1@KQ=NVC.Z^+WAV\BTK1]>U
M&^2:^2"'3[A$C^5Y LCM(&XX)SQM'X=*U_@YX1^QVD7BG[=O^VV\L'V;RL;,
M2@9W;N?]7TP.OM4'Q-NYK_X1>'+RYD\R>XDMI9'P!N9H').!P.3VK<^$>NZ9
M/X/T_1HKM6U&!9WE@ .Y5$N<GC&,2ICUR<?=.*27M#GG.HL';SM\CA/@=_R.
MMY_V#G_]&1USVIO?R?$37--T^Y^SR:IJ,U@Y)P&62?&TD D*2!G'49'()!Z'
MX'?\CK>?]@Y__1D='A?_ )+_ #_]A&^_]!EJ%K%>IUS?+6J2[1.6\5>$]3\#
MZM:13S9=HDN(;JWW*%<?>"M@?,K#J.<%3QG ]C\3>,]3T+X6:/J\.R74K^&W
MC:=P $=XB[2;0,$_*<#@9/<#!Y[X]?\ ,O\ _;S_ .TJF\>6L]Q\$/#LL2;D
MMH[.68Y VJ82@//7YG4<>M5\+DD8-JM&E*IU9P_ACX>ZOXYT^^U6"^M01.T;
M&Z=R\LOR,Q8X/!5R<\DD8QSD6/AOJ-WJOQ5TF\OKA[BX='5I7.68+;LJY/<X
M Y/)ZG)KK_AC\0-%TGP<=.UF_BM9+.5S$HBD):)F4YX!#-O=N!S@9Q@$UR'P
MYOIM3^+MGJ%PJ+-=37,T@C!"AFCD8XR2<9/K2LERV-7*I+VJFM$G8^CZ***Z
M3P@HHHH **** "BBB@ HHHH R/%4LL'A#6YH)7BFCL)V22-BK(PC8@@CD$'O
M7D/P-TF.YU[4=4D*,UE L<:-&"0TA/SAOX2 C+[AS^/M&L:?_:VB:AIHE\K[
M7;20>9MW;-ZE<XR,XSTS7S[X&UZ7X>>-+BWUR"Y@B=?LUU$#_JFR"LA4<.!S
M@C^%R5ST.4]))L]#"IRH5(1WT/HB]M(-0L;BRND\RWN(FBE3<1N5A@C(Y'![
M5BZ'X(\.^&[][W2=/-O</$8F?SY'RI()&&8CJHK#\2_%'P[9Z#<_V;JZRZC-
M:%[001%RKL"$+9&U2#R5;D =.@.3\*/$/BOQ-?WUWJU^;C3((O+4&W1,S$@C
M:509PH.1GC<O'/%<T>:Q@J-54G/9?F<IX7_Y+_/_ -A&^_\ 09:/%'_)?X/^
MPC8_^@Q4>%_^2_S_ /81OO\ T&6CQ1_R7^#_ +"-C_Z#%6/V?F>I_P OO^W/
MU)OC+=SV'Q"TN\MG\NXM[**6)\ [6660@X/!Y'>N:UOP-J]AX4M/%5U<)=QZ
M@RRR;-[NBR*'5Y&(ZDD@Y[E>3NXW_CC_ ,CK9_\ 8.3_ -&25Z7\5O\ DFFK
M_P#;'_T<E-Q3<KD1JRIPHJ/7?^OF9_P8O[N]\#NEU</,MK=M;P;^2D81"%SZ
M L<9Z# Z "N$^!W_ ".MY_V#G_\ 1D==E\#O^1*O/^PB_P#Z+CKC?@=_R.MY
M_P!@Y_\ T9'3_E(:25=+R_4RM3U?6?BAXR73H+ORK>>5_L5M.Q2*-45V4LJ[
MOGV[LMSR<=, 3:KX,\6>!O$@.@G4KLB)9$O+"UDP1GE' !'WDR5)((VD]<56
M\ :T/!/CQ_[6*6T*K-:7I93(8R.<+LSD[T49&1@GZUZ3XG^,EAH>KFRTVSAU
M>)8E9[B*\VH'.?E!",&P-IR#WQU!J5RM7D]36I*K":ITHWC;Y%GQVOC#Q%X4
MTNWT'37B74(-^HPF58Y(@54B(ERIP<L&XR=N#@$@^3>)? 5SX8T:SN;W4; W
MTJA[C3O.430J3A2HS^\&002HX/3< 6'5?%?Q=K4@TK3E,NG6]WIL=W<VJLRO
MNDW*T;G@E0 1MP,DG(Z8Y75-+\%V?A.WN+'6]0O=;G566'R5CCC!<@^8N#M(
M"D8#DDX8?*<TYV;9.%4Z<8]$WT5_O9Z!X'O[N^^"7B%+JX>9;6&ZMX-_)2,0
M A<^@+'&>@P.@ JO\!?^9@_[=O\ VK1\/?\ DBOBK_M[_P#2=*/@+_S,'_;M
M_P"U:<=XD54E2K)=U^A[+7SG;:=_PD/QOGL[R7S$.K3,_G+YH>.)F;RR"?NE
M4V>@';C%?1E?.7BZTU'P/\4&U@I,T,EZ;Z"16\L3J6W/'N&<?>*'/8Y(PPJJ
MO1G/@-7.*W:T/HVN8_X5YX6_MK^V/[,/V_[3]K\W[3+_ *W=OW8W8^]SC&/:
MJL/Q2\'RZ7'?OJRPJ[B,PO$YE1BN[!103@=-PRN>,UY_X<\=>+O%/Q!BL]/U
M&0:6]VTQBDM8ODM0V[:S!"0=N%SG[Q'/.:IRCH94Z%:TFO=MOT&_&#Q-J&H^
M(/\ A$[(3?9HO+\V&-,M<3, RC@DLH!3 P/FSP<*1S_B7X;ZYX-TVVUF2ZAE
M\N50SVADW6\FYBK!MHPO"?-P=S 8Z$R?%>V:U^)EW-=P.;>X6&9%20*TD814
M.#@[3E&'([9P1UUI/#GPGBMH+AO%6I%)]VP+\S#:<'<HAW)[;@,]1FL7JW<]
M.FU3I4^79[V5[AXJ\3S^*_@[I]Y><WD&K"WN'"!5=A$Y#  ]U9<].<X &*ZW
MPO\ \D G_P"P=??^A2UQ_BFW\.6OPICC\,7]S>V1UP&22X0JPD\ALCE%XQM[
M=^M=AX7_ .2 3_\ 8.OO_0I:J-^;7L85>7V*Y59<YC? 7_F8/^W;_P!JU[+7
MC7P%_P"9@_[=O_:M>RU=+X$<N/\ ]XE\OR04445H<84444 %%%% !1110 44
M44 %%%% !1110 4444 %?-'Q0T'^P?&MS_I/G_;]U]_J]OE^9(_R]3G&.O'T
MKZ7KP'XX_P#(ZV?_ &#D_P#1DE95E[IZ&6R:K6[H[^U\(_\ "&?##Q)IWV[[
M9YMO=3^9Y7EXS#MQC<?[O7/>O#_#7A[5/%VI)H^GR)^[1[@^?(1'$/E#-CGD
MG8. 2>,\#(^A=6UW3-?\ >(+K2KM;F!+"=&=00 Q@WXY YPZY]#D'D$#@/@-
M#$T^NSF)#,BP(LA4;E5BY(!Z@$JN1[#TJ913DET-J%:<*-2H_BNCD/B'H7_"
M-7>AZ07WO;Z4GF,#D%VFE9\' ^7<QQQG&,UZ]\3K/Q7JFDV^F>&[;S+>YWB^
M9941MOR[4RS#Y6RV<=<8Z$@^=_''_D=;/_L')_Z,DK5^-7B35;75+;0[:Z:"
MQDM/.F6(E6E+,Z%6(/*X'W>AR<YXPM%S%M2J>Q:M?5Z_(XOQ+X"N?#&C6=S>
MZC8&^E4/<:=YRB:%2<*5&?W@R""5'!Z;@"P] \#W]W??!+Q"EU</,MK#=6\&
M_DI&( 0N?0%CC/08'0 5Y_JFE^"[/PG;W%CK>H7NMSJK+#Y*QQQ@N0?,7!VD
M!2,!R2<,/E.:[CX>_P#)%?%7_;W_ .DZ4HZ2T+K-RHIRU:DNE@^ O_,P?]NW
M_M6N+\3:C_;'Q'NX/$6J7G]F0:E+#N0;_L\0?;\B=!PJY(!/&<,>#VGP%_YF
M#_MV_P#:M4]5\0_#?QWK%NU]:ZKIEW.RHU^!'&N "%$GS,,<@;MN1@9(44[7
M@B7+EQ4W9O1:KIH5='\ :H=6FU'P+XLTV2%-KQN+EEF6-L,JS(J$=5P588.W
ME1R![W7R?>[?"OB42:%KJ7C6C9BO;>-DPPR&&&R".HX+*RD<G) ^L*NDUJCE
MQ\9+EDW=/RL_F%%%%:GGA1110 4444 %%%% !1110 4444 %%%% !1110 4R
M:&*Y@D@GB26&52DD;J&5U(P00>"".U/HH \VE^"/AB2:1TNM5B5F++&DR$("
M>@RA.!TY)/J33KKX)>%;BXDDBDU*VC?I#%.I1> ."ZLW/7DGKZ<5Z/14\D>Q
MT?6JW\S.0\5?#G1_%^J1:AJ%S?12QPB "W=%7:&9NZGG+&MSQ!H=MXDT.XTF
M\>:.WN-N]H2 PVL&&"01U4=JTZ*?*C/VL]-=MC#\*^%;'PAI<NGZ?+<2Q23&
M<FX96;<55>P'&%%86O?"?PYX@U>74Y6O+6:;F5;5T5';NY!4_,>^.O7J23W-
M%+E5K#5:HI.:>K/.9/@IX5>VAB6748Y(]V^99UW2Y.1N!4J,=!M ]\UZ-113
M44MA3JSJ?&[C)H8KB"2">-)89%*/&ZAE92,$$'J".U><R_!'PQ)-(Z76J1*S
M%EC29"J GH,H3@=.23ZDUZ310XI[A3K3I_ ['-^%O VA^$5=M-@=KF1=DEU.
MVZ1ER3CL .GW0,[1G)&:K>)_AQX?\5W?VR[BFM[T[0]Q:N%:0 $ ,""IZCG&
M?E S@8KK:*.56L'M:BESWU//-/\ @SX8L-1@NVDO[L0MN\BYD1HW/;< @)&>
M<9P<<Y&171^)/!VF>)M$MM(N3+:VEM(LD2VFU-NU2H4 J0% ;H!V%=!12Y4E
M8<J]64E)RU1F>']#MO#>AV^DV;S26]ONV-,06.YBQR0 .K'M6'X5^'.C^$-4
MEU#3[F^EEDA,!%PZ,NTLK=E'.5%=?13Y4+VL]==]SD/%7PYT?Q?JD6H:A<WT
M4L<(@ MW15VAF;NIYRQH\5?#G1_%^J1:AJ%S?12QPB "W=%7:&9NZGG+&NOH
MI<J92KU(VL]MC,\0:';>)-#N-)O'FCM[C;O:$@,-K!A@D$=5':JWA7PK8^$-
M+ET_3Y;B6*28SDW#*S;BJKV XPHK<HIV5[D>TER\E]#D+#X<Z/I_C!_$T-S?
M->M-+.8W=#'ND#!N-N<?,<<^E)XH^&N@^+-134+O[3;707;)):LJ^:.,;]RG
M) X!X..#G QV%%+E5K%>WJ<RE?5'GFG_  9\,6&HP7;27]V(6W>1<R(T;GMN
M 0$C/.,X..<C(KI_%7A6Q\7Z7%I^H2W$44<PG!MV56W!67N#QAC6Y10HI*P2
MKU)24G+5&9X?T.V\-Z';Z39O-);V^[8TQ!8[F+')  ZL>U87BCX:Z#XLU%-0
MN_M-M=!=LDEJRKYHXQOW*<D#@'@XX.<#'844^5-6$JLXRYT]3S_3/@YX5TZ]
M6YE6\O@N"L-W(ICR"""0JKNZ8P<@@G(-;7B[P/IGC/['_:,]W%]DW^7]G=5S
MNVYSN4_W17344N6-K6*=>JY*;EJCF-8\!Z+KGARQT6\68QV$:1VURC*)HPH
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M!FC>9 ' /0[4!P?8@^XJQ9?!WPWI^LV^I6UQJ2/;W*W,41F4HI5]P7E=Q48
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MJ>>:?\&?"]CJ$%VTE_=B%MWD7,B-&Y[;@$!(SSC.#CG(R*W?%W@?3/&?V/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^9]GG:/?CR\9VD9QD_G7%7]_\0-1T2Z\9/J=Y;Z9)*H M[TQH 6,?R1AN K
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MIT!G*HH +- 68\=R223W))KR#PO%+-\-_'"Q1/(P6R<JBDD*LK%CQV !)/8
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MT1698KIEM@=S'=@'YEY*'[@_"SX9M?B-\6;:^\0)XSDTF")Y((+>UDDB7S
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M'UI=:]J5W?7>H,;Q#=3&5HXF "+N+'(*@/VQO(QD&@#NZ*** "BBB@ HHHH
M**** "BBB@#P'XX_\CK9_P#8.3_T9)7I'Q0ABMOA;J<$$210Q+ D<<:A511+
M&  !P !VJMXX^&?_  F>M0ZC_:_V/RK=8/+^S>9G#,V<[Q_>Z8[5TWBO0?\
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MV#K'_P!"BK/7X%6@TMX3K3F]:8.+G[-\JQA2"@3?U)()8G^$  <Y[;5/"/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)>6'A_2K2ZCSLF@LXT=<@@X8#(X)'XUKT >8?'O1;S5_ALTEFGF?V?=)>2H
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MCO+WPIX<U.\>\O\ P_I5W=28WS3V<<CM@ #+$9/  _"M.""&UMX[>WB2&&)
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M_P"BEKS_ /9Q_P"2>:A_V%9/_145>N000VMO%;V\4<,$2!(XXU"JB@8  '
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^</@YK>G7_@37_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2EFDC9D8@-C<$5'.SE>3@_-@@4 >QU077-+DUQM%COH'U-(C,]JC[GC0;.6
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\2?#_P"%=O%_PF.JW]]+K2M]N\Z2*01F%_W>=[';E,XSC)Z5K^(?^3H?"?\
MV"G_ /0;JC]H[_DGFG_]A6/_ -%2T <CXNL_BII.AIX]N_$D\&^6.>;3;>:2
M-+-&V>6#$V%.&.QD(/8DMEB&7VF_%'7O!]YX_/B6ZLXY$-VFFVUS+;[;==VY
ME7(4 *JLHY+J2<EOO>H_&W_DD.N_]N__ */CH_YMZ_[E3_VTH U?AIK]]XH^
M'FD:QJ3(UY.CK*Z+M#%)&3=CH"0H)QQDG  XKEOCYJVI:-X%L;C2]0N[&=M3
MC1I+69HF*^5*<$J0<9 X]A6I\$O^20Z%_P!O'_H^2N?_ &CO^2>:?_V%8_\
MT5+0!S5_H/Q,UKP?<^.Y?&$]@\L37XTRWN98HTM1&64KL8@,0!A2.ARS;LBJ
MOB'XD>(->^!]AJZWD]AJ<&M+8SW-E,T)G @9]QVXQG*Y XRN1C@#H?\ A?NC
M_P#"OO\ 7WW_  DWV7R,?95_X^/*_P!=_<\OS.W7_8Q7GVJ:+>:1^SGILEXG
ME_VAX@%Y$A!#",P.BD@@==FX8R"I4]Z /1;-/&/@/P=J/C[7_$%UJEY/9!AH
M]UYBQ6\LTJ;206 !4'E BXR5! YK#\/^&?B9X^\.'Q0OCV>UDN_^/:V2XEB1
MMKF-MPCPL?W,C:K;L\X.37J_Q2T:\U_X::WIU@GF73Q+*D8!)?RW60JH )+$
M(0!W)%>;^ _C?X>T;P!9V&N27S:EIT*PB..W4^>@8A A! ^5 N=^W..-QH W
M?A7\3[O7?!6NWOB$O<7>AJUQ/+%"BF6$JS# ! WC8XZ*,;>^37%^%=/^(GQ4
MBU3Q'%XTGTJ'S9(HK:"XF1!*JH50(I 2/# ;LLW&2&)S6I\(M!UGQ!X*\=:G
M=.@F\2K)##+*I0/+MEW2'"XV;I<97/*L,<53^%GQ6TKP9X7NO#GBC[=;W6GR
MS-#']FZ#()AXY$A<R'YP ,X+#@4 3_"F]U2^^._B1];D@EU.'3Y+6YD@7"2/
M#)!$6 XZ[,]!UZ#H.K^ >K:EK/@6^N-4U"[OIUU.1%DNIFE8+Y41P"Q)QDGC
MW-<Q\+]<F\2?'OQ'K$UK);"[TPO#')&4;R=T B)&3R8PC9!P<Y'&*Q_A%\2M
M(\ Z-K&@^(X+JTGBN)+E,1%F>0*J-"5QE7RG&[ Y.2N.0#O]"U;4IOVC?$^E
MRZA=OI\.F(\5HTS&)&VV_*IG /S-R!W/K7"Z!>^./C+XGU*]LO$\_A[3;,HA
M@M9Y!Y:-OV852HD;*G<S$=>. %&G\,-<F\2?'OQ'K$UK);"[TPO#')&4;R=T
M B)&3R8PC9!P<Y'&*S/A9X[MOAE/JOA+QA!/I["[\T2>27\MRF&W[225(2/:
M54YW$YP0: .D\+>%?BF]IKGAS7M:NK2SG0/:ZR+KSY8Y4E3_ %9$@D".@;AL
M8]B2#C?L^^&]2N81X@B\0W<&GVM[+%+I*AO*G8PJ-[?.!D;UZJ?N#GT[3X:?
M$/Q!X]\0ZM(VEP0^&K?>MM=")DD+[QL1B7(+;"2VT<''3(SR?[/'BS2+73;C
MPK<3/'JMS>O<6Z&,E95\I<@,. 0(F)SCJ,9YP >]T444 %%%% !1110 4444
M %%%% !7C'PCLK>3XI_$B_:/-S#J#PQON/"//*6&.G)C3\O<U[/7'^$/ O\
MPBGB'Q/JW]H_:O[<N_M/E>1L\CYY&VYW'=_K,9P.GO0!Y3J?]J?\-.ZE_8G]
ME?VKY*?9?[3\[R\_9DW8\KG=LW_>^7&>^VK?Q+\->+O$EOIT?BO6/ >EO"[M
M:RF\G@9@0-ZCS,AA]PGC(P.1DY[SXA_"G2_B!+#>R7D]CJ<$0ACN$&]"F[=A
MD)&<9;&"OWN<X KG]&^!%O#XH36_$WB&X\1,F&,5S"1YCC 4R,SL74 ?=[X&
M>,@@&1\1OLG_  T9X,^W>?Y/E6VWR<;O,\^7R\Y_AW[=W?&<<XK?_:%^Q_\
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M'$@4OMXW;1GVZ5ZGH_@S0]$\)OX9M+3_ (ELL3Q7 9COGWKM=G88)8CN,8X
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M) Z-@D'##@\@C\* +%%%?/FC:-XJ\>>.O&MO;^/=9TF#2]3=(XXYI74JTLH
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MS$G YP,X&3ZFMNBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&003YV?VB?!HMDE%IK!=G93"+>/<H &&/[S&#D@8)/RG('&8_P!G'_DGE_\
M]A63_P!%15E_LY>'].?0-0U^2WCEU 7IMXI9$5C"JQJ?D.,J6\U@<'D ?B >
MB>"/B5X?\>BY32GGAN;?E[6Z54D*<?. "05R<<'@XSC(SS>J_'_P;I>J7%BJ
M:C?"!]AN+2*-HG(Z[2S@D9XSC!QQD8-<6ME;^&_BQ\2H=%C^P1V_AJXF@6W8
MIY3F.%\IC[OS$D8Z=L "ND^ .B:++\/;B[,-K=W=U<3079DM1N1"$!@+$?.A
M4*^.GSXQD&@"OX)U6QUO]HWQ)J6FW,=S9W&CQO%*AX8;;;\00<@@\@@@\BNK
M\%ZIX._X2+QJ^CV,^G75I=DZQ=74F(Y'#RY<$NP501(>B\$<>G$?#C3+/1_V
MB/%MC82P26J6DS((%"I'NEA8Q@ D#86*8_V>@Z#FYYYK;1_C9)!*\3G4H4+(
MQ4E6NY58<=BI(([@D4 >B?\ #0O@K^T?LOEZKY/F^7]K^SKY>W.-^-^_;W^[
MG';/%9_P@OK3_A,_B=J'VJ#[%_: G^T^8/+\OS+AM^[IMQSGIBN@^$_AWP_)
M\*-,06EC?QWT.^\>2S4><XD8['##Y_+;*@G/W<C -<'\&;/2=/@^)5E?7:7>
MBVZK%/<QYVS6Z_: SC82<%03\I)YX- '67W[0O@JTO)((8M5O8UQB>WMU"-Q
MGC>ZMQTY Z>G-;EM\6_#-YX(OO%5N;J2VL'1+FT"+]HB+N$7*EL8.<@[L8![
M@@<!X2U/4KS2KNT^''PTM+32;VXVSWVL7#217$)W)\P8AF P<JK.%^88);)G
M_9\A6WUKQO AM2L=Q @-G(SP$!IQ^[9B2R>A))(QF@#/_9^\;:=90CP?+#=M
MJ-_>RW$4JJIB"B%3ACNSG]VW0'J*]$\6_&/PGX0U!;"XFGO[KYO-CT\))Y!!
MQM<E@ V0?EZC'(&1GGOV<?\ DGFH?]A63_T5%7"_!R[UF-]5UG3O!Z>)=4>X
M!EO9]4@BE@)5N0) 7!?<^7SAL8_A- 'M_@WXB^'?'4;C2+EUNHDWRV=PFR5%
MW$9QR&'3E2<;AG!.*ZNO$/"_@_Q/;_&.U\2)X2_X1O2)(7CN[:"_@DB_U3 8
M6/;\I81G&#\PW9]/5/&<\UKX&\07%O*\4\6FW+QR1L59&$3$$$<@@]Z .'U7
MX_\ @W2]4N+%4U&^$#[#<6D4;1.1UVEG!(SQG&#CC(P:Q_!.JV.M_M&^)-2T
MVYCN;.XT>-XI4/##;;?B"#D$'D$$'D58^ .B:++\/;B[,-K=W=U<3079DM1N
M1"$!@+$?.A4*^.GSXQD&LOX<:99Z/^T1XML;"6"2U2TF9! H5(]TL+&, $@;
M"Q3'^ST'0 '<>+?C'X3\(:@MA<33W]U\WFQZ>$D\@@XVN2P ;(/R]1CD#(S<
M\-_$_P .^+-+O+K2&NIKJSMWN)=-\G_22JYX5<X<G QM8\LH.":\8^#EWK,;
MZKK.G>#T\2ZH]P#+>SZI!%+ 2K<@2 N"^Y\OG#8Q_":ZOPOX/\3V_P 8[7Q(
MGA+_ (1O2)(7CN[:"_@DB_U3 86/;\I81G&#\PW9] #TSP5XUTWQWHTNJ:7!
M=0P17#6[+=(JMN"JV?E9AC##O5>/Q_ILWQ#E\%16.HOJ$*>9+.L2F!%\L/EF
MW9 ^95R5^\0.]>:>#9;+X7_%SQ3X?N6^S:/=6IO[:1X)"=D:F3:IYW*J-,">
M<F+L>#0^'=E?S^$OB%\0[B/[+?:A:W9M)H6DC*':\DC)_L[]@#9)!C89&#D
M[KQ!\=/!N@ZHU@)+K4V50S3:<L<L0)_AW%P"<8SC(YQG(('6>$_&>A^-=.:\
MT6[\WR]HGA=2LD+$9 93^(R,J2#@G!KQ/X2-JUEX.EDTCX=VNO"[>6*YOI-4
MMD9E. T)1EW*F%4[&)SG=T85U'PP\(^)-"^(VN:K=Z"^B:+J%N[):"]AF1)3
M(A"@1X& #)M^4;0<9]0 _9XGAM?AIJEQ<2I##%J<KR22,%5%$,1))/  '>KE
M]^T+X*M+QX(8]5O(UQBX@MU"-P#QO=6XZ<@=/3FO-_#O'[+_ (LQ_P!!5/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&RJ&+ KA"8B2<L$;G."371_"OX9Z_P##[Q#JKW.IV-SI%W%M58MPE=U?]V[
MK\ORE\@,>6[X!KU>B@#R#X<_#;QIX#\1E!KUC-X:DE=Y[92V^7Y&5&"LA"-G
M83M;^'&6P*@O_A'XHT+Q1=:Q\/O$D&FQ7DK2RV<X*1QYSA0JJR.H+/M!4;1C
M&3S7LU% 'E/P[^$]_H/B.;Q/XKU7^U-;&4MW2>20*"FTLS. S-MRH!X ]21M
M]2G@ANK>2WN(DFAE0I)'(H974C!!!X(([5)10!X3!\(?B!X9O-0MO!WBZ"VT
MBYW!(YYG5PK 9)41LHD& /,7#<9&W.!T?@+X6:EX,^(6HZW-JD=_9W-D8?-E
M=C<23,8W=W!& "RN?O$X(R2<FO4Z* /&;_X1^*-"\476L?#[Q)!IL5Y*TLMG
M."D<><X4*JLCJ"S[05&T8QD\UH?#OX3W^@^(YO$_BO5?[4UL92W=)Y) H*;2
MS,X#,VW*@'@#U)&WU:B@#RSXM_"JZ\>SZ?J&DW%I;ZC;H8)3=,X62+DKRH."
MI+?P\[SD\ 5W'AWPQ8^'_!]GX<6-+BTAMS#*)$RLQ;)D)5B>&)8[<D<XZ5MT
M4 >&I\(/'7ABXN[?P5XQC@TNZ5PT5T[QLFXX. JLN\*J?O%VMUQBNK^&/PQ?
MP9+>:QK%]]O\0WVY9IUD9D5"VX@%L%F8@,6(]AW+>CT4 >:> OAC-HGPYU;P
MIXC>TN$U"XD=FM27"JT:*"-Z##J4W X." :Y2'X3_$S0K2XT?P]XW@31WV[
M\LL+K@[CM 5O+^8MG8PW=_2O=J* /,+;P!9_#[X0>*[&"X^V7-QI]W+<730B
M,O\ N6"J ,D*!T!)Y9CQG%><?#[P+\0)_!]OJGA+Q3!8V6IQ3+-;S2NFQO,:
M-BH"L V(U(<;6'0=,GZ*U;38=9T:^TNX:18+VWDMY&C(#!74J2,@C.#Z&J?A
M;PY9^$?#EIH=A)/):VN_8\[ N=SLYR0 .K'M0!RGPP^&\W@J._U'5[U+_7M1
M?,]P,N%7<3@.P#$L3N8G&2%X^7)G^$W@K4O GA6ZTO5)[2:>6]>X5K5V90I1
M%P=RJ<Y0]O2N\HH X/P)X*U+POXJ\8ZI>SVDD&M7OVBV6%V+(N^5L/E0 <2#
MH3WJ.Q\!WD?Q=\0>*+TV,^D:IIXM!;,2SGY85(=2NW:?+;N>HXKT"B@#PU/A
M!XZ\,7%W;^"O&,<&EW2N&BNG>-DW'!P%5EWA53]XNUNN,5U?PQ^&+^#);S6-
M8OOM_B&^W+-.LC,BH6W$ M@LS$!BQ'L.Y;T>B@#@_ G@K4O"_BKQCJE[/:20
M:U>_:+9878LB[Y6P^5 !Q(.A/>C5?!6I7WQET/QA%/:#3["R:WEC9V\TL1,,
MJ-N,?O%ZD=#7>44 >0:?\-O&F@_$Z_U_1M>L8](U+4!<7D#E@\L+2;W3849=
MPRRA@0>>JY(KU^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
(@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gaz3apgusshz000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gaz3apgusshz000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /K!Y\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*?\ H-W7YC_"C_A._%/_ $&[K\Q_A7.T4>SAV0>TGW9T7_"=^*?^@W=?F/\
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M44<D>P<\NYL_\);K_P#T%+C\Q1_PENO_ /04N/S%8U%')'L'/+N;/_"6Z_\
M]!2X_,4?\);K_P#T%+C\Q6-11R1[!SR[FS_PENO_ /04N/S%'_"6Z_\ ]!2X
M_,5C44<D>P<\NYL_\);K_P#T%+C\Q1_PENO_ /04N/S%8U%')'L'/+N;/_"6
MZ_\ ]!2X_,4?\);K_P#T%+C\Q6-11R1[!SR[FS_PENO_ /04N/S%'_"6Z_\
M]!2X_,5C44<D>P<\NYL_\);K_P#T%+C\Q1_PENO_ /04N/S%8U%')'L'/+N;
M/_"6Z_\ ]!2X_,4?\);K_P#T%+C\Q6-11R1[!SR[FS_PENO_ /04N/S%'_"6
MZ_\ ]!2X_,5C44<D>P<\NYL_\);K_P#T%+C\Q1_PENO_ /04N/S%8U%')'L'
M/+N;/_"6Z_\ ]!2X_,4?\);K_P#T%+C\Q6-11R1[!SR[FS_PENO_ /04N/S%
M'_"6Z_\ ]!2X_,5C44<D>P<\NYL_\);K_P#T%+C\Q1_PENO_ /04N/S%8U%'
M)'L'/+N;/_"6Z_\ ]!2X_,4?\);K_P#T%+C\Q6-11R1[!SR[FS_PENO_ /04
MN/S%'_"6Z_\ ]!2X_,5C44<D>P<\NYL_\);K_P#T%+C\Q1_PENO_ /04N/S%
M8U%')'L'/+N;/_"6Z_\ ]!2X_,4?\);K_P#T%+C\Q6-11R1[!SR[FS_PENO_
M /04N/S%'_"6Z_\ ]!2X_,5C44<D>P<\NYL_\);K_P#T%+C\Q1_PENO_ /04
MN/S%8U%')'L'/+N;/_"6Z_\ ]!2X_,4?\);K_P#T%+C\Q6-11R1[!SR[FS_P
MENO_ /04N/S%'_"6Z_\ ]!2X_,5C44<D>P<\NYL_\);K_P#T%+C\Q1_PENO_
M /04N/S%8U%')'L'/+N;/_"6Z_\ ]!2X_,4?\);K_P#T%+C\Q6-11R1[!SR[
MG4Z)XHUN;5[>.34IV4N 02/6OHF(DQ*3UP*^7] _Y#=K_OC^=?4$7^I3Z"O.
MQJ2:L>A@FVG<?1117"=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#Q7XR?\AFP_ZY-_.O-*]+^,G_(9L/\ KDW\Z\TK
MVL-_"1XV(_BL****W,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "K6F?\ (5L_^NZ?^A"JM6M,_P"0K9_]=T_]"%)[#6Y]
M322B&%6/3(%>7_&#21+;6VIJQ'E#80.AR:[WQ'<&UT-Y@<;"":Y[68D\6_#E
M9$=EW*)<@<_+DUX]!\LE/S/7K+FBX'%?"321<ZU)J+$X@!3;VY%>TQS+(\BC
M^ XKS[X:Z<ND>$KG4&<G[0OF\CI@&NA\&ZE_:UC-=@DJ[ C-5B7SS<NQ&']R
M"CW/$_'W_(\ZM_UV_H*ZC1OAC9ZGX3BUA]1G21X&E,808! /'Z5R_C[_ )'G
M5O\ KM_05[%X3_Y)C;?]>3_R-=56<H4H.+['-2A&=62DNY\]$8)'I7I>C?#&
MSU/PG%K#ZC.DCP-*8P@P" >/TKS1OO'ZU]"^$_\ DF-M_P!>3_R-7BJDH13B
M^I&&A&<FI+H?/]O:S7=TMO!&TDCM@!1FO4=+^#GGV<;ZC?2P3$99(PK 4WX/
MZ9!/<7E^\:F6%]BL>H!%6_B-XYOM.O/[-TR<P.I^>1#\P([5%6K4E4]G3T+I
MTZ<:?M*FI'>_!J&.!FM-1FDD R ZJ :\OU/3+K2;Z2SNX]DL9P?0_0UZ)X5^
M*<EJABUV668 <2X+,:PO&'B"R\5>(+)[6+:F\(Q*D%LL*JDZT9<L]5W)JJBX
M\T-&5/"?@F^\3REU!BM5X:0\'\,]:[M?@O8[,MJMR&]-BUV1>U\)^%0RHJ)"
MF .@)[5X_<?$[7Y=1%PDS1Q _P"H5OE-9*I6K-N#LC5PHT4E-78OBSX=WOAZ
M'[3 S7%L.&;^(?@*XZWMY;J=((49Y'.  ,U]%>&=;C\6^'#),B>8R;94!R 2
M*\X\-6-MIGQ:GLRJK#%O51V' JZ5>5I*>Z(J4(WBX[,M:;\)$>RCFU346M78
M98*5('XFK0^$>DS@_9==>9AV78?Y5UOC3PWJ&OP)]AOI(=B$&($!7/OFO,;;
M2/%?@>8WBP;X\_-'$Q;=^0K.%2=174[/L:3IP@[.&G<R_%'@G4/#3O)*%>UW
M823=R?J*?X1\$WGBB5GYBM$X:3H<]L9ZU+XH\=ZEXAM6LKJV6W4,"4!/4>QJ
M]H'Q)O\ 2-(BTNTTJ&8HFT.&;<?? KH;K>S\SG2H^T\CH&^$FBQ$)-X@>.0_
MPML!_G6/XD^%TVDV+75C<M<HO)WX'\JQUTOQ)XIU-[_[.XD1PP$N5QWXR*]J
MM8KO_A#2FHJHN1;/Y@!R,X/>L)U*E-KWKF\*=.HG[MCQ[X5?\CS#_P!<9/Y5
MN?&G_D):7_UQ;^=8GPL_Y'N+_KE)_*MOXT_\A+2_^N+?SJY?[TO0B/\ NS]3
MRVK6F_\ (5L_^NZ?^A"JM6M-_P"0K9_]=T_]"%=CV.1;GOWQ"U*\TKP=)=6-
MP\$XD0!TZX->-+X]\4!@3K5T0#T)'/Z5[SXBT"+Q+H9TV:=X49E;>@!/'UKB
ME^"^G*P)U:Y(!S@QKS7F8>K2C"T]_0]&O3JRG>&Q)\/_ !W>:[?'3[U"TA!*
MR<GH.YK%^+<<=GX@TNY4?,09&_!A7H>E>']%\*PM)%Y41_BD8A2:\A^)6OP:
MWKB+;MN2V!0'UR<U5&TZW-!:"K7C1M-ZGK5G<1^*/!@DP&,L).#ZX.*^>-0L
MIM/OYK2X4++&V& ->I?"+6F(GTV>8MDYB4GH .U9'Q8T86>N17<,)_TD%G91
MU.<#-:4/W55T^YG6_>4E4[%3X8:-)J'B-;ID#6T((<D]&QQ76?%W64BTZ+2E
M.6EPY]L&MGX=:9'I/A%+QH_+DG3S),C!XSUKR'QGJTFK>)+J4REX0Y$8[*/:
ME'][7OT02_=4+=6<_1117><04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!)!_K/P-1U)!_K/P-1T %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!]&^ 3M\!Z:?2'/\ZFU^WAUSPO<12*'
MPI<@^H!-5O O_)/K#_KW/]:I>#]2:_FU?3Y@-L;[%&>H*\UXTD^>4ET9[":Y
M8Q?5'D_@C3HM2\6P6TJ!E&7P?45]"_:5%Y';J1]TY%<#X-\.V]AXNU>=;<)]
MEDV1G'0%><5H:-JKW_CK4(CCRX'*J0>O%:XA^TE=;)&6'7LXV?5G+_&G_C^T
MS_KDW\ZV/#'A/0;SP%!>W&EP27+6S,9&!R3@\UC_ !I_X_M,_P"N3?SKL?!_
M_),[?_KT?^1IRDU0C;N3&*=>5SY\D $C = :]J\,>$]!O/ 4%[<:7!)<M;,Q
MD8').#S7BTO^M?ZFOH+P=_R32V_Z]'_D:Z,7)J*MW,,)%.3OV/ ([>2XNQ!"
MA9V?:H ]Z]F\+?#/3K+3EGUN..:9QED?&U/H:X7X<PK/XYA1AD;7-=[\5=?F
MTNPAL;>5XWN%SE?0'FIKSG*:I1TN50C",'4EJ;0\&^#KI2EO8V!;UC8$C]:\
MS\?^!AX?D^VV9S:.>0>-A[ 5RVBZ]>Z%>BYM9#URRYP&K;\1_$'4/$EB;.:!
M(HB02$8GI3A2JTYJSNA3JTIPU5F1>#/!MQXFO=S9CLXS\[]S[#/6O78_ WA*
MRB5;FRLR>FZ4[2?UJ/P!&EGX$M[D#!,)=O?&:\=\4>)KS6]5FD-S(;??F.,]
M%K-^TKU&D[)&BY*---J[9ZOK7PUT/4;%SIL45M(!E3" 0?QKQ34]+NM)OY+.
MZC*RHV..A^E>D?"SQ1=3:B=*NIY)=X+1ANB@"E^*EJD?B72' &96!;W^855*
M4Z=3V<G<FK&%2G[2*L5O GPZ&HPKJ>K+B!AF.(C[P]_2N]'A#P8&\G[!I_FC
MC&\;ORS4WB74?^$>\(/<1DKM4(I';-?/?]J7G]I&_P#/<W!;<7[FH@JE=N7-
M9%S=.@E&USU/QK\-K2.P:^TA!&T8R8E&%(KBOA[IMIJ?B^&TO[=)X2CDH_3(
M%:,OQ3U:73/L1@090JTF\Y-0?"X[O'4!/>-_Y5JE4C2DIF+=.56+@:'Q5T/3
M-%N]/73;.*V62-BXC'4YK%^'NG6>J>+H+6^MTG@:-R4?H2!75?&G_C^TS_KD
MW\ZY[X6_\CQ;_P#7)_Y4X2?U:_D$XKZQ;S-CXDZ#I.D:SH\5C90V\4I_>A>
MWS#K7J>@Z=HNGV[C1XK:,/@R>0P.3[\UYK\:?^/W3/\ KDW\ZN?!;_CRU/\
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MRWQ1T(Z=KYO5W%+HENG"]JY[PIJHTGQ);WC9Y.TX]Z]F\>:8VN^$GDM0KRJ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /%?C)_R
M&;#_ *Y-_.O-*]+^,G_(9L/^N3?SKS2O:PW\)'C8C^*PHHHK<Q"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *M:9_R%;/\
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M%% !1110 4444 %%%% !1110 4444 20?ZS\#4=20?ZS\#4= !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?17@<@?#RQ)Z"W/]:X/PAK'D_$*Y
MA0@PSLQ)SWQ5[P]\0M!TWP7#I=Q).+E+=HR%B)&2#WKS"POI+'5(KJ*1DVR
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ML.DX0DW*=[G#?#/_ )'Z+_<DK?\ C3_Q^Z9_US;^=<[H.NZ-HWCUM2C,BZ:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"2#_6?@:CJ2#_ %GX&HZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH TM _Y#=K_ +X_G7U!%_J4^@KY?T#_ )#=K_OC^=?4
M$7^I3Z"O-QVZ/1P.S'T445P'<%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI"6S"5.<=T4:*ZS4?AQXBTRT%S/;Q,A=4Q%)N.3TX%61\+/$[1>8(;?;C/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /%?C)_R&;#_KDW\Z\TKTOXR?\ (9L/^N3?
MSKS2O:PW\)'C8C^*PHHHK<Q"I[.UDO;N*WB1F:1@N%&3R>M1(ID=47EF.!7M
MW@#PA!H.F?VQ>1E[ID+#Y<E!CD"L:U54XW-:-)U)6-KPKX9L_"6DEY"HF*[I
M'.!SBN!OO&]G)\0UO+P'[%:*\<;(-Q;.#TJ/QAXQUK6WFM+*PNXK+=\KB)P7
M'N,5RGA_P^-3UR*PU%Y;))%)#NFTDC_>KFITM'.H]6=%2KJH4UHCTW5?B]I<
M<*G386N),C(F0J .]=!97&E^/O#SF:!'RO*D?<;M7F_BOX:-H5C'<V,\]WN(
M5EV#()/M7<?#;0YO#N@7$UV=K3D2E3_#@5E4C2C3YJ;U-:<JKJ<M1:'EL%P_
M@;QO,(_WOV9S&2W&0<9Z5Z*_Q-\+JCW4$4IOV4\^2>3]:\O\9727OB[4KB,@
MI)+D$'VJIH&FSZMK5M:VZAF+AB"?X01FNN5*,XJ4^QRQJRA)QAW/8/"S&VTC
M4?$MX DU]^]56/0[< ?I7"OX*\2^*99=:2VA1;D[]KR;3^1KKO'^HP6,.E>'
MXNC31L1Z8<5I>,?$.H:#JND6>GQ,T,X ?;GCY@*YH2FG>*U?Y(Z9QBU:6R_-
MGB6I:;=:3>R6EW&4E0X/H?H>]5*]-^,L:KJNFLH +PL6_.O,J[J4^>"D<56'
M)-Q.G\ Z9#JWBRWMIT#(%,F#ZCFO5/B%XM?PQ90VEGE;F9<H1V .#S7F7PVN
MX[+QE!+*P53&RY)QR:]!^*/ABXUNVM]0M,N]NA78.X)S7)6LZ\5/8ZJ-U0;A
MN5_AQXXN=8N?[*U*1IK@J661N<@#G-8GQ)23PUXHMM0TJ0VMS<1LS21]3SBK
M?PM\*7=MJ(UFZ5H@J%51AC(([YJA\8;R*YUJSCC=6:&-E;!Z'-**C]8M';J$
MG+ZO>6_0]'\.7]U=_#^WOIYWDNFM&<RGJ6P>:\ U76M2UF5'U&\DN6C!5"YZ
M"O=O"G_),+7_ *\G_D:^>F^\?K585+GGZBQ3?+#T$KZ&\*?\DPM?^O)_Y&OG
MFOH3X?SP7W@>UM-ZL5A\MUSTSFJQOP)^9.#^-KR/GQOO'ZU['\%O^09JG_79
M?_0:R=<^$VHMJ9?2O*:U=LD.X7;]!7H/A'PW%X3T>2-F'F.-\K<<D"HQ%>$Z
M5HO<O#T9PJ7:V/%/'W_(\ZM_UV_H*YNM[QG<I=^+]2GC8,CRY!!Z\5<LOA[K
MVH:.FJP1P&U>,R F4 [1[?A75&2A!<SL<LHN4WRJYD^'M9DT'6(K^)02ORD$
M]CUKW+3/&/A[Q-:,DKJ,?*Z3#:/PR:X+X7:5H>JK>0:K9P7$^\>7YG4#'.*U
M_%7PJ^TRF?0HXXR3_J2P51^-<M=TISY9:/N=5!5(PYHZKL=!=_#WPSJ4#&R@
M@B+#AH<'^M>.>*?#5QX9U0VTIW1MDQ-GEA7K7@;PCK.@R))?WSB-5*_9E8,E
M<G\8[B&;6+%(W5FCB97 /0YI4)R57D4KH=>$72YVK,\THKJK+X>Z]J&CIJL$
M<!M7C,@)E .T>WX5RIX.*[HSC+9G$XRCNBUIG_(5L_\ KNG_ *$*^D/$^MIX
M?\/R7[C.W"CCN>E?-^F?\A6S_P"NZ?\ H0KZ*\8Z*VO^&);%'*L2'!'J.U<6
M+MSPYMCLPE^27+N>9^&_B9J/]O :C,\EM.^%3.=A/  KI_BSI=O+X>&I^6OG
M1NJ!^^":X'PUX(U.\\0+%/$\*6\@+.1U(P>,]:]$^+%Y%'X3-F77S'D1@,\\
M&E-05:/(.#DZ,N<L_#K2HK+P=#=VT*?:;F+?GIN;D#-4;:T^(B:]]LF:!K1F
MYMOM(VJ/;C-:G@"[2Z\#6MO#*!-% 4)4\J><5QP7QL?%']E'6+X0DDB8 8P/
M?&*R2;G.]OF:-I0C:_R-WXM:7!+X=&HM&OGQ,J!NX!/-;G@F40?#W3YCTCMB
MQ_#)KBOB'IEWIF@E+KQ->7K.ZD6\P4 \]>.>*Z_PG_R3&V_Z\G_D:4E^Y2O?
M4<7^^;M;0\]_X65JLOBF)K>5C9-((Q"3@$$@9KU7Q5K,>A:!+J+@[EPJD#N>
ME?..G_\ (8M/^NZ?^A"O<_BG_P B)+_UUC_G6U>E!5(12,J%63A-MG-_#WQM
MJVK^)VL;V5IHIE9UW-]S Z"D^*D2IXJT)E&"Y!/_ 'V*YSX5?\CS!_UQD_E7
M3?%;_D9_#_U'_H8IN*CB$EV$I.6';?<[[Q-K:>'_  _)?N,[<*..YZ5Y;X<^
M)FH_V\!J,SR6T[@*N<["> !7IGC#16U_PQ+8HY5B0X(]1VKQSPWX(U.\\0+%
M/$\*6\@+.1U(P>,]:SP\:3IOFW-*[J*HN4[[XLZ7;2^'1J?EKYT;*@?O@FMW
MP1*(?A[I\K#*I;%C^&:R/BO>11^$S9EU\QW1@,\\&M'PE_R3&V_Z\G_D:S=W
M05^Y:LJ[MV/,M:^).KSZINTVZDMK2-OEC0X##WKU>QO3X@\!K>W4:AIK9G*@
MY .#7S@WWS]:^A?"7_),;;_KR?\ D:Z,53C",>5=3##5)3E+F8[PK_R32W_Z
M\W_D:\@\!:;!JOC"&VN$#H SX/J.17K_ (5_Y)I;_P#7F_\ (UY-\.;N*R\:
MPRRL%4HZY)QR:FE>U2PZMKT[GIGQ!\6/X8LH;2S!6XF7*$=@#@UE?#CQO<ZO
M>#3-1D::Y*EDD;DD <YJS\4/#-SK=M;W]IEVMT*[!W!.:QOA;X4N[?4QK%TK
M1!5*HC#!(([YJ8JE[!M[ER=3VZ2V)OBO_P C/H'U'_H8KHOBE_R(<O\ UUC_
M )USGQ8./$V@$]L?^ABNR\;::VN>#Y;> DGY9!COCFI3LJ;?]:C:NZB1\^:;
M_P A6S_Z[I_Z$*]T^*7_ "(<O_76/^=>6^$O!^H:KJ\320RP0PR!F9U*G(.>
M]>I_%,8\"3#TEC_G6]>2=:"1C0BU1FV3_#MH&\%6:P.OG>5A\'D'GK6#J">/
M-*UJ:\CG^U6*DE(6EX(^@%<QX-T/Q?;VBZAHTD/V:8;VC,X&[ZBNLTCQIXC?
M71I=[HX&#AY06(_/&*RE!QG)QLS6,U*$5*Z.)\6^.K[7[#[%?:/':MD$/\V[
MCZUQ%>X?%?3;%O#9OFB07:.JJW?!/->'UUX:490O%6.3$1E&=I.YL>%]6ET7
M7[:[B4,V[8<G'!.#7LOQ"THZ[X4^T6JJ\R893G^'J:\#!*L"#@@Y%>\_#K6(
MM<\+FQE8O) GE2;AUR#6>*BXM5%T-<,U).F^ID_"717M;&XU*X11O.8FS_#C
MFNP\/:V^K:KK,.!Y5K.$C(/48S577+FU\'^#F2+Y%1?+0*.><US/P=N3-;ZJ
MTK[I'F4\]3Q7+->TC*JSI@_9RC31P'Q _P"1YU7_ *[?T%=[\%O^0=JG_75?
MY5S7Q&\.WJ^+)KB&"65;M]PV(2!T':O0?AKX<G\/Z1,;D_O;A@[+_=P*WK3C
M]72OV,*,)>W;]3F]*_Y+C??]M/Y"J_QI_P"0CI?_ %Q;^=6-*_Y+C??]M/Y"
MJ_QI_P"0CI?_ %Q;^=*/\:'H.7\&?J=5\.]/MM,\&QZBL2B26(RNPZG -<+J
M'Q0U-]?\ZVE=;%6QY6<!AZFO0/ 4\5_X#@LT==ZP&-@#R"0:\HU#P+JEMX@_
ML](7=';Y9,<8[Y/2E24'4G[0*KFJ<>0]PM=2CU?PDU_""(YK9V (QV->,>!-
M9U'3KZ>#3=,BNYY22'D8C9^(KV/3=,.C>"_[/+[_ ";5UW'OP:X?X.)$8]29
ML>:)1M]<8K.FXQA-VNC2HI2G!;,V+?1O%MW+]JO==FL0S!O(BD4JH].1757E
MN)/#T\<TOGX@8ESSN.#S7G7C23Q9<^*!8V;RQ6KD^68SD%??C@UWEA9SV'@\
MVEQ(99H[9PS'J3@U%1.T977R+IM7<4G\SB_@S_QY:M_UV7^59OQ!\<:C9^(3
M9:9>S6XMB5E5> QK3^#:LMIJRL"")UR"/:N ^('_ "/.J?\ 77^@KIA",L1*
MYSRDXX>-CT?X47\NJ#6;R?\ UDLZEN?]FO/_ !EM_P"%DW>[[OVM<Y],BNU^
M"W_(/U3_ *ZK_*N%\>1M+X^U*-<;GG"C/J<55-+ZQ)>1-1OV$7YGO$R/<Z#M
MTF8(Y3]VZ,*\[35O'?A6.6;4H1J2%N 9"Q'_ 'R*CT;3_'?AS30T?D7%FBY6
M,7&<#V %=/X.\5ZKX@EEAO\ 2_LR)QN(89X]ZY^7D3VDCHYN=K>+/(?%GB6;
MQ)?)-<6$=I+&"&52<GZYKGJ]%^+>G65EK-K):QHDDR,TNWN<]Z\ZKT*+3@G%
M61Y]9-3:D%%%%:F9)!_K/P-1U)!_K/P-1T %%%% !1110!+;0-<W44*@DNX7
M@>IKZ#M;:'PAX(V%\,D14N>"6(.*\?\ A_;+=^+K:-AD!6;\J]*^+-V(O#BV
MNX R,K 9Y.#7%B7SU(TSMPZY:<JAXRU[)/JJW=U(TC&4.['J<&O8Q\5?#]MI
MHCM_.>5%PJM$0#^->*0(LMQ%&S;5=PI/H":]-N?A1;?V,U]9:E+.^W<J[5P1
M]15UXTG93,Z$JJNX'6>%/&MKXO1[*ZMHXY2"#&,D$8YZUYU\0?#]OX8\0P3V
M8VQ3-YJ1@8"X/05L_"_PO>P:R-5N(WB2-64*PQG(]Z@^,%[%<ZO9PQLI:%&5
ML'IS65-*-?EAL:U&Y4.:>YMZ=\3/#USI\!UB%_M<:]%C+ 'ZU+HM\/&7BHZM
ML*65BK)&2,;@1G)S7B\:-)(L:_>8A1]37M4)'@WX<!IU"W,L>UU'J<BG5I1I
M_#NQ4JLI_%LC!\3Z7K/CKQ!.NG0Q-;VC%$=GP&!YXKB]=\+:KX<D1=0A4;AD
M,AW#\Z]1L]2N-%^%%IJ%BA:X.W@9R<DU#XKNY=5^$\&H7:;;ARA(/4<FBG5E
M%J*VO8*E*,DY/>USQJIK2,2WL$;='D53^)J&K%BP34+9ST652?S%=KV.);GT
M+=W%KX+\'"5(]J1*$ 4=STKSGP]\3-2_M[&H3/);3/A4SG9G@ 5Z-X@T]?%?
M@UK>"4?. ZE2#G%>1^&_!&I7GB%89XGACMY 6<CJ1SQGK7G4%3<).>YZ-9U%
M.*AL>@_%/3H6\/KJRH!<0.NR3N,FF_"G6]2UFSOVU&\DN3'(H3>?NC%3_%2[
MBB\(M9EU\QW0@9YX-9/P6_X\=3_ZZK_*I2OAFV4W;$)(Y;XB:]JDGB/4=+>]
ME-BLHVP$_*,5P]=-\0?^1XU3_KK_ $%<S7?125-6."JVYNY[#\%O^/'4_P#K
MJO\ *N%^(/\ R/&I_P#77^E=C\&[R*(7ULS@/(X*J3UP*T_'/PYFUJ\?4-,V
M?:9#EU9@H/XURJ:AB&Y=3J<'/#I1Z'$?"S_D>+?_ *Y/_*N@^-/_ !_:9_UR
M;^=;O@/X?S>'KG[?J&S[4 0 K @9Z\US/QAO(KC5;.*-U9H496 /3FA34\2G
M$'!PP[4CS2GQ2&&9)5ZHP8?A6WX>\'ZMXFCFDTU(F6$A7WR;>36AX<T:WT_Q
MR-,U^&&18PRR(S97=VYKKE4BKKJCDC3D[/N>A^%OB/IFI6L-CJ!,=R5YR/E/
MXFMB?PKX3UMGE2WM&E?EG1@3G\ZS?$/PTTG4;,'2;:*UE X\OHWYU@>&/AUX
MCTR]\R:\^QQA@3Y$@;=CUKSOW;3E"7*>C^\349QN87CKP&WA[_3+1M]HQYS@
M;?3BN$KWKXJ7$,?@^2W:1?.9T*@GDX->1^'_  AJWB:.:334B982%??)MY-=
M>'JMT^:;.2O22J<L$8-%7-4TRYT?4IK"["B>$[7"MD9^M4ZZ4TU=',TT[,^B
MO D@A^']C*>B0%C^&:\WU'XGZF=?$MI*Z62-CRLX##WKT?P-%Y_P]LHLXWV[
M+GZY%>1:GX&U.V\0?88HGDC=OEDQQCW/2O.HJFZD^<]"LZBIPY#V&Y^R>+O!
M?VIX@T<D1D4,.F :X7X1Z3;7%W>WLD2M);OL0GL"*[JVMT\,^!A:3R#]U R9
M8@9)!KC/@_>PQOJ-NSJ'ED#*">N!41NJ4^78N23J0YMS?\2V?CJ[U?=H\D4%
MG&WR@3@&0>XQQ6SJ&FSZMX0>'68(OM(B+NJMN4, 3P:Y#QRWBRPUD2Z9J5Y]
MEG< 1QC(3G'I5ZYT76+;P^]WJ'B[4(V,9W1X3!..E+E]V+NE^8[^])6?Z%#X
M-#%MJH':9?Y55\?>/+_3];?3]-F>$P/B0J<9]JM?!G_CUU7G/[U>?PKA/B%_
MR/&I_P#77^E;QA&6(E<QE-QP\;'N'AW5GU7PE;ZG<J [1&1@#GIG_"O+I?B5
MJDGBF,VLS?8C($$). 02!FN_\&_\DTM_^O5_Y&O!K3_D,6__ %W7_P!"%30I
MQ<IW6Q5>I)1A9[GN/Q019/ \LI'S!TP?QJ[X$D$/P_L93T2 L?PS53XF?\B#
M+_OQU:\#1>=\/;*+.-]NRY^N:P_Y<?,V7\9^AYQJ/Q/U,Z^);25TLD;'E9P&
M'O7I=Q]D\7>"_M+Q!XY(C(H8=" :\>U/P-J=MX@^PQ1/)&[?+)CC'N>E>PVU
MNGAGP,+2>0?NH&3+$#)(-;5U32BZ>YE0=1N2GL<I\&AMM]5 [2K_ "JM\0/'
M=Y8:I-INER/;RQMB25>#FK/P;.8-6/K,O\JX7XA?\CQJ?_73^E7&"EB)<Q$I
MN.'C8]0^&?B2^\1:7<QZ@WF/ 0GF,<E\CO5SPG$D'B?Q)'&,*MPN!_P&N;^"
MW_'GJ?\ UT7^5=1X9_Y&SQ-_U\K_ .@UA52C.:7];&])N48-GDOC=!+\1;R-
MAD/<*I'UQ7L%Y<6O@SP?YT405(E"@*.YZ5Y!XU8)\1[ICT6Y4G]*]>U^P7Q5
MX-:WMY!\X#J5([5K6^&FGL94;\TVMSSC0/B7J)U[&HRO):S. J$Y"9X&*[OX
MGMN\"3L.\B']:\O\.^"-2N_$"P3Q/#'!("SD=2.>,]:]/^)R[? DZ^CH/UHJ
MJ"K0Y I.;I2YB3P;_P DUM_^O5_Y&OGZ;_7/_O&OH/P+MN/A]:PJ?F-NRGVS
MFO'+CPCJ1\12:=';RG#_ .L*$+CZ]*O#R2G.Y&(BW"%CV'P9_P DUM_^O5_Y
M&N5^$+6PGU$2,@G,@V GDC'-=WI.EG1O!@L&;<8K9QG\#7B7A;1-=U'4I;K0
MY8XYH7P2TH4\UE32FJFMC2;<'#2YZGXOLO%[WT<^AWK);CEX_,"Y]NE<KK'Q
M"URVM9M.U+0XFP-C2LSX)]<XQ6E/XK\8^'[B&UOM+2Y9SC>CL_YX%=EJ=M;Z
MUX8D?4[:,$Q%]I[$ XJ4U"W.DUY%-.=^1M/S/FMCN8G&,FG0R&&:.4=48,/P
MI) !*P'0'BFUZIYA]$:-=CQ5X(4S*IE>([E!S@X.*\W\#^%[H^,W2YB7R[4D
M2<]#U%7OA-KRP7LFES2,?-^:,8X  KU)+"TTF34-14!6F_>.?H*\N<G1<H+J
M>G&*K*,WT*-WKC1>,+#28L%)(G,G/((Z5P7QH_X^],_ZYM_.JOAO6_[7^*?V
MQI#Y3!]@;MQ6]\6M%N+^UM;V!'D\@;2J+DG)IP@J=:*?8F<G4I2:[G$?"_\
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M91'-B"#O$C9!_.N89MSEO4YI*VC1II\R6IBZTVN5O0ZKPCXXN?",5Q'!9Q7
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M<B)?OC^=?1$7^J7Z"N/%554:L=^#C9,?1117(=H4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 >6?%<_\ $QT\?],6_G7G)7->C_%;_D(Z?_UQ
M;^=>>8%.QZ-!^XBG(,<BJTDY Q5V5.#6?.E*QJV9MRQ8GFJR#YJGGZU .*A[
MF,MS1MN6%:*KD9K,MB !6I$W%25)D$P*\U'#=X;DU;G7<AKG[ES!(23Q18SE
M*QU$-SG%7HYN<BN/M=648!-;MI>K(HP:'&Q,9IFXDX[U)YF3Q6>F6< =*T8X
MN@K-W9=TB5$#<T]H<]*DC7:N#4NW(K2,=#-R,V2'\ZI75N=N&K;,8W\BJDZ!
MF*M^%-Q'&1S;QNK@AN!6M:'A:J7EOA24X-)I[/&H#UFUH:IG6V9X%:4?-8]B
M^<5L1<UI YZA.%P/6DE&!Q4BK@4CKD5L8F7< X)QS6#?6X.7Z,*Z>:/*UCWD
M!(:H<;[FD)69RYUY]/D^<G:*W])\66]X!NROOBLF?1+;4875Q\Z\].M8"":U
ME:". "-#@$\4E314I.YZU%=*^"K9!JXLH/>O);+Q!>V4NZ0DQCL#FNNTWQA8
MW2@.6C;W6KLXF4DF]#LU;-.W5A+K]B.?/7\ZCG\5:;"N6G''84<PN1G1B3BL
MG6M>MM(LWEED&X#Y1FN/U/XD6L*LEJNY\8!P:\ZU76+S5YS)<R%ESPN<XHNV
M3)I#]<UB?6M1>XE<E2?E!K,Y/8G\*L6=G)=SA$'UKL;3P\GD &,9QR<4-V)A
M!S.)CCD9N$/Y5:CL;A^1&W'M7:)HRQL!LQ^%;^EZ8@7F,'/K4*=W8T]BDKGF
MB:9<3#"QOG_=JS;>%[^X?[A4>M>PVFE0 A5A0$U=FT[R%Z*,^AK9*Z(:2/*H
M?!QC \TY-))HT%JX4+DDX'%>DRV87+ <FN0U1UM]4C9QE5.2/QIM)&M*S9E7
MEB^D"&7H6YQ6YIVM!D0_G6+K^I?VG=@J,1KP!5&,M'PK8%9MZG;&CSH].M-1
MCD3[PR?>I7G'=A^=>:I>W$)RLAI[:Q>M\HD;'UJE-(AX"3>C.IUO74M86AC(
M+GCBN(.6D9VY)J7:TK>9*Y9O>I$1?2HD[GH4*"I*R*VPD]*<J'/-6@!Z4OE\
MYQ2N=%B$)@T]%SR.U2;:>%"T(3(RM59QSC%7]O>JLJ98DTS&9GNE,5<&K3KF
MH2N#D4C-QU'K$'95-7V0!51>HJ@LH4\]:FCN#YF30:)&Q812L>.U:B,T7WES
MBLJQU%+7YF%2SZW$YRJ\_2E<J4&Y6L7IYXY!_JP#5(VL<I.#@UGOJC.W*\4]
M;Q  RG!IG1"#2T+,EC+&,QL3563S(_OY'TK0MKPR <U?2*"48E4'-*QNJKC\
M1SOF*5R22:<'&W(K<?089<^4V">@ JG/H-S;C)R#Z'BD:QK4Y.US.56D;BKJ
M1!, C!HBC\GW([422.91@8H--]BY;-ME",>M=!;YM664#/%8L%L)$1S]X5N0
M_-& >>*B3.6LUL6#)]HR.F[DU#%$4D*GD5 1)')Z5HQPEHP^>:ELP:Y4#Q@)
M54+A\,,BK3R+MVGM566=5Z5FQ)OH3?(JX Q4FF:6^I7.YN(E/YU5LXI=4O%A
M3..YKO[&Q2TMU1.W7WI'+7J<N@6UHD"!47 %7$0BG!<C-2+\IYZ4U$X)38!>
M*=T%&<].* <<$<52,FQ'C5ER*B3*-@]*ME RY'%1[,]>HH<-;H%/HQJOCK4J
MR>M1B/C)I&P%Q3NT#29-G)XI3R<5$C<"IC@\BK6I#T#GM0:0,:=UH3$8GB<8
M\/WG_7-OY&OBN^_X_IO]ZOM7Q0?^*?O >OEM_(U\57W_ !_3?[U:0V(GN1+U
MIZ_>J->M2)UK1$$RBIT%1+4ZTC)DB"K""H4%64%!DR5!4JBF(*E4<T(EC@*E
M4&D4"I%IDDBBG@<TU:E49/% 68X"E'6EQQ3=RKUHT+46R2EWJO4U 9&8X44J
MVY9OF-#D:1HMCS<$G:HJ41[L9&1WIT=O@X(J['%Q@5#D=<*!%% HJ=5"MD"I
MH[;Y?>IHH01SVJ;FZ@1Q_+R1UJ1A(1A:ERH.-M!;CVHN:JG<H-;RS'!8@9K2
MMX(88P%Y8]3BFKG. .#4JKZ#I2;1:IV)-H4BG[E ]ZC^9L<8J00@$$T7*Y1N
M6Y(H0,W#=ZL;!MYZ=J0 ;<G\*+BL57PI (J0(-I(Z4\X(QC)IRIN]J5RDA$S
ME=M6E4 Y%1J"" !QZU*%^;;Z]*+EI#ER6-3I&2%!]*9'$<[<\U<6,X4@]*+C
ML1K#M/'&.U2"!6&\_E4C*01FI57CD=:$%RH(%SD-CVIRJ%'2K/EJ#TI"NWEA
MFJ'<A'S<YHE0N/3'I4BH2< "G[/E-#07*95MH[^E2C>%&]<'M5A%$:[L=:5E
M,F*5AW& /\HQD=ZN;22,#BDBCPN#G-6%P!CO5)&;9$4;'%.C0GD]JE526R*?
MM!;:1B@S; 1*HR.AI!&L1\S%2',<6 ,BFN-RC'XTQ7&+(9VR:9([*I4#(J;8
M(ER.].VCRR#U-2QHJI(-H4CDT#=N*D?C4T5JH!9CS3;AB  HH'<KL"I.*2)L
M2G-2[6 P1UJ-H\DXZT#%#M)*PP,?6E/[ME Y/>F+UW#J*!*"22,$T%)$ZG.X
M9_"F%% Y.34()W9!^M.SY3Y."#3!HD$8:,^HH5%8#/WA2[E/>EQABV>#THLA
M78\Q*4'/'<57D@3^ @?C4V[J%Y]:RIK2Z-P9%F(4GA<U-QQ++Q#;\OXTL:Y&
M#G%/MXW  =@?7FK!0!MJGBFF#96:W5N6'%1?9\%E"#95W>%?9S2R*$&[=G/:
MG9$W,2ZTN.8 @;2.]00PM:9RWXUN/B4@;?PJ&2U6=61@!CH:B4$T4I&+<2.V
M!_6GB.9(PV>#[TDUI-'DYS@^M68'W(%9AD=B:YW=&C>A6<7#)\F0*(1C"RC(
MJ^RR*,A1M^M0;?-?:!BDMR$4Y[2$MT&#2+"L8PO2K4D:QG#]J9\DB?)U^E6Q
M-#%C##L:;+"N #@?2I88RO4\5'.F6X8XHBAJ)5= KX'*U#("I^49!J5G9#M/
M-*<%:M:#=.,E9E*:W4@;>M5VMFQTK153W'%(8F!SFM85FF<-7 Q>J,O8R]0?
MRH(!K1.]>L8-1/;JZ;Q\K>E;QJW/,K8.4=BCBDZ=JF9"IP0*85K3F.24)1W&
M4HXI.<XI>*9%AP/-!]:;D9IW44!8N:-SJUO_ +X_G7T%'_JE^@KY_P!&&-6M
M_P#?'\Z^@(_]6OT%95#KPVS'T445F=04444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ4@YZ41P^O-6HK? HYC6- A&?2GKN)XJTD(/:GK;8;/:ES&JH(JK"[=34BP
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'A7Q[_Y#&D?]>[_^A5X^:]@^/?\ R&-(_P"O=_\ T*O'
MS29:V(VX--X-.;K28I (W I%8GM3J4#/% "!2:EC8QD4 8HHO<I:'2Z9<"1
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MC!P13!@5-S0D,N.E/5MRY8U79P!ZTY"-N>GM18I%@N .*3EQN%1[U(PHJ9"
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M<*]$7[H^E.)Q8G="T4459RA1110 4444 %%%% !1110 4444 %%%% !1110
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M )+L3 ('-69)2J%0@P.N.]4UD$8W%MI/I5BVGBC3]XQ8'I2N:63*[* X>(;
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C
M7QJ&=5TO_K@W_H5>5E?:O5OC/_R%=+_ZX-_Z%7EY%4MCT*,?<1#MXIRQYIQ
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M9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQQ0T"8HP5]Z.: N>]!.1B@0Y2II_45",9J;^&K3T)D)GM2 $TF,=:<#BEUU
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4@N'TIV".:0<'I4I*[* &G.W-(&P,D9HR6XZ"D4'..U!5QRLI'(J0 !<@4T
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MEE)MX@K-D8H=PK;A56X?S1MSBM$]!)-ZE7<&F9A^53P3A&W.,D#@5#&HR=Q
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M355/E3WJ<2%4![U29G(M0$+(H PQJX[A9BC'ITK/M<27(+$UH/&OF[FYJF9
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M/$F3TIK]#0-:%$1@2K]:Z$=!7/%B;A1[UT(Z#Z4#J=!:***#,**** "BBB@
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M>L:ZN,MM!IFU.%R*[?/0UGE=OS$U.S9ZFH'^8XI'5'16$W%STXJ6./!H1 %
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MEIQ/.,4G?!I6U*N.SQBA>>#2D<4@4[O:GL297BC/_".7@_Z9M_(U\;R?\?\
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MK4S>MTI)_BKK%^Z/I7(#YKQ!GO77K]T?2@NMT%HHHH, HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH \F^+O\ R$M._P"N+?SKSCFO2?BW_P A
M+3O^N+?SKS<C!I,]K#+]R@S36&13J=MIIER13=,FHB,=:NNF*K2=*!H@+<TY
M#S49!S3T/-.X%J'[U3L !56-\-4[.".*D+$+O@X% EXYJO(YS3-YH3*:)WDJ
M(FDZBFG-#8T(#S4H]ZBVFI![TD,L)TI^<'BF1C-2%<4%)CU?BI ^:@P<4JFB
MY=KD^0:4*,U&I%+WXHN"1.#02:C7-.ICL*O)J8'%0C@T\GB@=B=6IP?!J!3Q
M4B=:5Q-%D8ZU(IJ'M1DYZTT*URXIS05J*-JG)S5&+5F-"T[[M)030(AEYJC<
M*>U7GZU6GQCI4FT#.8,.0:C.3UJR_2JIR#29LA$<J^:UH9!)&"#6487*EL5/
M9.5;::#*25BW-;K*.15!XO+?%; (VUFW6WS.M-$1;!'P *69_EQ42>M)*W%6
MC.:(<_-3AR>:A##=TJ134,187&*F0\53$@%2+)CG-*YK8N!]M(T_&*KF<;:K
MF7)ZT[EJ)8DD8#-0LQ8TIRR\G%-0'/-(T6@]5]:L*H I(U&,FE+#-4*]QSG
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M9E<BH5RS=.E30LVW::=#;R22%HQP*>I-[%:<[4R!\U5A*Q7YLU<G(+D$8(J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKR:A;S++:_9I03N&1E>.!7DS?\A&;_>KT3P+J5T;FXM6F8Q/;R$J>G"FO/6
M_M";_>K-FM(T[8<"K>=HQ5:VQ@58<@C/>LV=G0Q[\_-6::T;[KS6<:J)$@7[
M]7EZ"J(^\*O1GBFQ19(*LP=:K FIX/O9J62S3C1FQBK*#!P1S5:*7Y<9J97)
M-*P)EI<T]ONU"'&*E!!3WI6*N3)VJU'S^%58QQ[U-NYI%)D\:[Y,U9WA.HR:
MJJY7 6IP"XR34R+1,&+$$<5.K\\U64D5(I^;FLWH6D60JDY'%2HBC@\YIBJ"
MM+M;&1VI%H<$"G%->+<,BIXD#KD]:#&>W2J-$BF%(-2"G;1SGM2Q#+8/X542
MD.1:21P%QWJ4 J=H&2:AF94;YNM-RT+W16E7*\]ZIY^SMU^4U=DE.P[>]8LL
MLANPD@PG/2LK7*C*QL+(OE;5?@]J+?\ >3XQ@"J:1+%$)3(<,> :U(HF2!6"
M@EJ7*R^9,F3.]E["I(E#H1MQ3U"1/SC+=JE?"#KUK2*,GH4G1D;!;BH"@R=U
M7I8@R[\\U3<<YZT/0N+N0MA?E4=:D0J$-*!GD=JB8Y; J#<<3GI3U/'%,;)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?_O@T?\ "P=,]'_[X- '7T5R'_"P=,]'_P"^#1_PL'3/1_\ O@T =?17(?\
M"P=,]'_[X-'_  L'3/1_^^#0!U]%<A_PL'3/1_\ O@T?\+!TST?_ +X- '7T
M5R'_  L'3/1_^^#1_P +!TST?_O@T =?17(?\+!TST?_ +X-'_"P=,]'_P"^
M#0!U]%<A_P +!TST?_O@T?\ "P=,]'_[X- '7T5R'_"P=,]'_P"^#1_PL'3/
M1_\ O@T =?17(?\ "P=,]'_[X-'_  L'3/1_^^#0!U]%<A_PL'3/1_\ O@T?
M\+!TST?_ +X- '7T5R'_  L'3/1_^^#1_P +!TST?_O@T =?17(?\+!TST?_
M +X-'_"P=,]'_P"^#0!U]%<A_P +!TST?_O@T?\ "P=,]'_[X- '7T5R'_"P
M=,]'_P"^#1_PL'3/1_\ O@T =?17(?\ "P=,]'_[X-'_  L'3/1_^^#0!U]%
M<A_PL'3/1_\ O@T?\+!TST?_ +X- '7T5R'_  L'3/1_^^#1_P +!TST?_O@
MT =?17(?\+!TST?_ +X-'_"P=,]'_P"^#0!U]%<A_P +!TST?_O@T?\ "P=,
M]'_[X- '7T5R'_"P=,]'_P"^#1_PL'3/1_\ O@T =?17(?\ "P=,]'_[X-'_
M  L'3/1_^^#0!U]%<A_PL'3/1_\ O@T?\+!TST?_ +X- '7T5R'_  L'3/1_
M^^#1_P +!TST?_O@T =?17(?\+!TST?_ +X-'_"P=,]'_P"^#0!U]%<A_P +
M!TST?_O@T?\ "P=,]'_[X- '7T5R'_"P=,]'_P"^#1_PL'3/1_\ O@T =?17
M(?\ "P=,]'_[X-'_  L'3/1_^^#0!U]%<A_PL'3/1_\ O@T?\+!TST?_ +X-
M '7T5R'_  L'3/1_^^#1_P +!TST?_O@T =?17(?\+!TST?_ +X-'_"P=,]'
M_P"^#0!U]%<A_P +!TST?_O@U)!X[TZXG2)0^YR /D- %CQ*,W$'^X?YU@,*
M[BY@MIV4SQ!R!QFH/L&G_P#/LGY5G*#;N>C0QD:<%%HXIEJ)@*[G^S]._P"?
M5/RI/[-TS_GT3\J7LV;+,:?9G!4TBN^.F:6?^71/RH_LO2_^?./\J7LV/^T:
M?9G TPK7H']E:5_SYQ_E1_96E?\ /G'^5/V;#^T:?9GGA%,Q7HW]DZ5_SYQ_
ME2?V1I/_ #Y1_E1[-B>84^S/.QUJ1CTP.*] _L?2?^?*/\J=_9>E[=OV./'I
MBFHM&,L73?1GFDN"#D5AZG9)=Q%645[(=&T@];&/\J8= T0]=/B_(U23,WB*
M;Z'SN?#K98*F3VJI)X5NL;O+S7TF-!T1>FGQ#\#3_P"QM('_ "Y1_E579C*=
M-[(^69=!N87/RD>U7=-AGMGRV<>E?24GAO0)3F3386/N#4?_  B?AO\ Z!,'
MY&C4SYH]#QBUN1(./O#K6U9R;CR*].3PIX;C;<FE0 ^N#4XT#1%Z:?$/P-4F
M)R// >E2J_'6O0?[%T?_ )\8_P C0-&T<=+&/\JKG1)Y[NSTJ)S7I']CZ1_S
MY1_E2?V-I'_/C'^1I.28T['DU_$)8R#7/%3&Y3TKW=M!T5OO:?$?P-0GPMX=
M8Y.EP$_0U*=CIAB%%69XFI&/>G<GH*]I_P"$5\._] J#\C3O^$9\/_\ 0,A_
M(TW(OZVNQXY#"[D8&*NI:.>!7K*^'="7IIT(_ U(-$T9>EC$/P-+F(>)?0\@
MFMI8^<<54)]:]K;1='88-C&1]*@/AK0&ZZ;"?P-.Y<<7;XD>,;N:E3EJ]A_X
M1CP__P! R'\C3AX;T =--A_(T<Q;Q<.QY,H IK. <5ZY_P ([H7_ $#H?R-)
M_P (YH/_ $#8?R-/F1'UF/8\<=AGBJ[GK7M7_"-:!_T#(?R-(?#'AX]=,A_(
MTKEK%P70\+=JKEB37O1\*>'#UTJ#\C3?^$1\-?\ 0)@_(TKE?78=CP8@XS5.
M?KDU]"_\(EX:_P"@3!^1II\'>%VZZ/;G\#1</KL.Q\Y9 -+#\TE?1/\ PA/A
M3_H"VWY'_&E'@KPJIR-&MQ^!_P :0OKD.Q\^3+L2J/>OI-O!OA=OO:/;G\#3
M/^$(\*?] 6V_(_XU+17UZ'8^<-V#3@QZU]&?\(/X3_Z EM^1_P :7_A"/"G_
M $!;;\C_ (T),?UZ'9GSD6+'FGX"KZU]%?\ "$>%/^@+;?D?\:/^$)\*?] 6
MV_(_XT6?4O\ M"GV9\Y]> *E5<+BOH@>"O"HZ:+;?D?\:7_A#/"W_0&M_P C
M_C32%_:$.S/G8IQ0!@5]$_\ "&>%L8_L:W_(T?\ "%^%O^@-;_D?\:9+Q\.S
M/G8=:0@YXKZ)_P"$*\*C_F#6_P"1_P :7_A"_"W_ $!K?\C_ (TQ?7H=F?.A
M.*EAZYKZ%_X0KPJ?^8+;?D?\:4>#?"X&!H]O^1I#^O0[,^?'/K44AXKZ)/@W
MPN>NCV_Y&F_\(7X5_P"@-;_D?\:&)8Z"Z,^=PVP5(A+#ZU]"'P5X5/71K?\
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M^LAX,\+CIH]O^1H/@SPN>NCV_P"1J+&WM4?'%Q'*6_U3_P#?)JOY$N?]4_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JYI?_(3M_P#K
MHO\ ,53JYI?_ "$[?_KHO\Q0![7-]X5'4DWWA4= !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5,O^J-0U,O^J- $-%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 ^+[XJU56+[XJU0!YO\2O
M^0A8_P#7)OYUP]=Q\2O^0A8_]<F_G7#T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %7-+_Y"=O\ ]=%_F*IU<TO_ )"=O_UT7^8H ]KF^\*CJ2;[
MPJ.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *F7_5&
MH:F7_5&@"&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ?%]\5:JK%]\5:H \W^)7_(0L?^N3?SKAZ[CXE?\ (0L?^N3?SKAZ "BB
MB@ HHHH **** "BBNM\$Z':ZE--<WB"2&'*E&''3K0!R5%=QXRT&PMK"+4-/
MC2*+A2$Z-D]:X>@ HHHH **** "BBB@ HHHH **** "BBN@NKG0F\+PPP08U
M0;=[[#SSSS0!S]%%% !1174W&@6]KX(CU3)>>9D(R/N@YX% '+4444 %%%%
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M%_F*IU<TO_D)V_\ UT7^8H ]KF^\*CJ2;[PJ.@ HHHH **** "BBB@ HHHH
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MQ^[,^=N>V *]<\%^*H/%NA17T>T28'F(#]TT =)1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4
MR_ZHU#4R_P"J- $-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45
MY)\9?'%[X>AM['2;R6WO)AG='UX/2N>^$WQ$UF_\1-I>OZA<7#R E!,/NX%
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MY'0;3TH \Z[TJJ68*.I.!2=ZT] L#J.L0P XP=Y_ T =Q;)%X=\$F9UV23J
M^.Y.13=!:#7/!\EBZ[S;KC!'< D5HZWK/A^W T_4D,@7^ )N Q4&CZ[X8CF-
MMIT9A:7K\A - 'F$T+P3-%(,,IP17HNG>&-+O_"EE/)$D4S*'>8#DX/(_&N8
M\9Z=]AUR1P?EG)<#TKHKZ:2#X8V;Q.58A!D>A)H GMH_!]U>FPBM$,XS\Q0X
M_/-<SXHT6VT36H-O-O*V\IC@*#R*Q--D>+4K9D8J3(HR/J*Z[XE?\?\ 8_\
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD)"J6/0#)H
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MXS\?9XK_ ,3Z/:Q."RH8VVG."6%>I:'?V?@/X9Z;)J1F,%O&L;&.,LV23V%
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MM C$Y)4$U\I?$/\ Y+'=_P#7]'_,5[U\2;_5=-^'\ESHLD\=ZK1A6@7+8[T
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M#XDEN]5\5W+R1112-&&8$G@D<5Z?\)O^2:Z/_P!<OZFNJU7_ ) ]]_U[R?\
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M)7F]% '2^!9$B\3HTCJB^6_+' KK-2L]$\1WLR-<I%-;OM9^/F[]2>:\NHH
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M-]X5'0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM[USGQ7^&UWXD>/4])*_;(N2A( ;GKFO6:* /E.XU+XF>'&2R6]U!%Z*(5+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5<TO\ Y"=O_P!=%_F*IU<TO_D)V_\ UT7^8H ]
MKF^\*CJ2;[PJ.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]4:AJ9?]4: (:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@!\7WQ5JJL7WQ5J@#E?%6J:=87-NE]:).S(2I8'@9KG_P#A(] _Z!D7
MY&G?$K_D(6/_ %R;^=</0!VW_"1Z!_T#(OR-'_"1Z!_T#(OR-<310!VW_"1Z
M!_T#(OR-'_"1Z!_T#(OR-<310!VW_"1Z!_T#(OR-'_"1Z!_T#(OR-<310!VW
M_"1Z!_T#(OR-'_"1Z!_T#(OR-<310!VW_"1Z!_T#(OR-'_"1Z!_T#(OR-<31
M0!VW_"1Z!_T#(OR-'_"1Z!_T#(OR-<310!VW_"1Z!_T#(OR-'_"1Z!_T#(OR
M-<310!VW_"1Z!_T#(OR-'_"1Z!_T#(OR-<310!VW_"1Z!_T#(OR-'_"1Z!_T
M#(OR-<310!VW_"1Z!_T#(OR-'_"1Z!_T#(OR-<310!VW_"1Z!_T#(OR-'_"1
MZ!_T#(OR-<310!VW_"1Z!_T#(OR-'_"1Z!_T#(OR-<310!VW_"1Z!_T#(OR-
M'_"1Z!_T#(OR-<310!VW_"1Z!_T#(OR-'_"1Z!_T#(OR-<310!VW_"1Z!_T#
M(OR-'_"1Z!_T#(OR-<310!VW_"1Z!_T#(OR-'_"1Z!_T#(OR-<310!VW_"1Z
M!_T#(OR-'_"1Z!_T#(OR-<310!VW_"1Z!_T#(OR-'_"1Z!_T#(OR-<310!VW
M_"1Z!_T#(OR-'_"1Z!_T#(OR-<310!VW_"1Z!_T#(OR-'_"1Z!_T#(OR-<31
M0!VW_"1Z!_T#(OR-'_"1Z!_T#(OR-<310!VW_"1Z!_T#(OR-'_"1Z!_T#(OR
M-<310!VW_"1Z!_T#(OR-'_"1Z!_T#(OR-<310!VW_"1Z!_T#(OR-'_"1Z!_T
M#(OR-<310!VW_"1Z!_T#(OR-'_"1Z!_T#(OR-<310!VW_"1Z!_T#(OR-'_"1
MZ!_T#(OR-<310!VW_"1Z!_T#(OR-'_"1Z!_T#(OR-<310!VW_"1Z!_T#(OR-
M'_"1Z!_T#(OR-<310!VW_"1Z!_T#(OR-'_"1Z!_T#(OR-<310!VW_"1Z!_T#
M(OR-'_"1Z!_T#(OR-<310!VW_"1Z!_T#(OR-3VGB#0Y+N)(]-C5BP .#QS7!
M5<TO_D)V_P#UT7^8H ]O=E!Y%-\Q/[HILWWA4= $WF)_=%'F)_=%0T4 3>8G
M]T4>8G]T5#10!-YB?W11YB?W14-% $WF)_=%'F)_=%0T4 3>8G]T4>8G]T5#
M10!-YB?W11YB?W14-% $WF)_=%'F)_=%0T4 3>8G]T4>8G]T5#10!-YB?W11
MYB?W14-% $WF)_=%'F)_=%0T4 3>8G]T4>8G]T5#10!-YB?W11YB?W14-% $
MWF)_=%'F)_=%0T4 3>8G]T4>8G]T5#10!-YB?W11YB?W14-% $WF)_=%'F)_
M=%0T4 3>8G]T4>8G]T5#10!-YB?W11YB?W14-% $WF)_=%'F)_=%0T4 3>8G
M]T4>8G]T5#10!-YB?W11YB?W14-% $WF)_=%'F)_=%0T4 3>8G]T4>8G]T5#
M10!-YB?W11YB?W14-% $WF)_=%'F)_=%0T4 3>8G]T4>8G]T5#10!-YB?W11
MYB?W14-% $WF)_=%'F)_=%0T4 3>8G]T4>8G]T5#10!-YB?W11YB?W14-% $
MWF)_=%'F)_=%0T4 3>8G]T4>8G]T5#10!-YB?W11YB?W14-% $WF)_=%'F)_
M=%0T4 3>8G]T4>8G]T5#10!-YB?W11YB?W14-% $WF)_=%'F)_=%0T4 3>8G
M]T4>8G]T5#10!-YB?W11YB?W14-% $WF)_=%'F)_=%0T4 3>8G]T4>8G]T5#
M10!-YB?W11YB?W14-% $WF)_=%'F)_=%0T4 3>8G]T4\,NS..*K5,O\ JC0
M;T_NBCS$_NBH:* )O,3^Z*/,3^Z*AHH F\Q/[HH\Q/[HJ&B@";S$_NBCS$_N
MBH:* )O,3^Z*/,3^Z*AHH F\Q/[HH\Q/[HJ&B@";S$_NBCS$_NBH:* )O,3^
MZ*/,3^Z*AHH F\Q/[HH\Q/[HJ&B@";S$_NBCS$_NBH:* )O,3^Z*/,3^Z*AH
MH F\Q/[HH\Q/[HJ&B@";S$_NBCS$_NBH:* )O,3^Z*/,3^Z*AHH F\Q/[HH\
MQ/[HJ&B@";S$_NBCS$_NBH:* )O,3^Z*/,3^Z*AHH F\Q/[HH\Q/[HJ&B@";
MS$_NBCS$_NBH:* )O,3^Z*/,3^Z*AHH F\Q/[HH\Q/[HJ&B@";S$_NBCS$_N
MBH:* )O,3^Z*/,3^Z*AHH F\Q/[HH\Q/[HJ&B@";S$_NBCS$_NBH:* )O,3^
MZ*/,3^Z*AHH F\Q/[HH\Q/[HJ&B@";S$_NBCS$_NBH:* )O,3^Z*/,3^Z*AH
MH F\Q/[HH\Q/[HJ&B@";S$_NBCS$_NBH:* )O,3^Z*/,3^Z*AHH F\Q/[HH\
MQ/[HJ&B@";S$_NBCS$_NBH:* )O,3^Z*/,3^Z*AHH F\Q/[HH\Q/[HJ&B@";
MS$_NBCS$_NBH:* )O,3^Z*/,3^Z*AHH F\Q/[HH\Q/[HJ&B@";S$_NBCS$_N
MBH:* )O,3^Z*/,3^Z*AHH F\Q/[HH\Q/[HJ&B@";S$_NBCS$_NBH:* )O,3^
MZ*/,3^Z*AHH G1T+8"U-56+[XJU0!YO\2O\ D(6/_7)OYUP]=Q\2O^0A8_\
M7)OYUP] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5S2_P#D)V__
M %T7^8JG5S2_^0G;_P#71?YB@#VN;[PJ.I)OO"HZ "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ J9?\ 5&H:F7_5&@"&BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ?%]\5:JK%]\5:H \W^
M)7_(0L?^N3?SKAZ[CXE?\A"Q_P"N3?SKAZ "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "KFE_\A.W_P"NB_S%4ZN:7_R$[?\ ZZ+_ #% 'M<WWA4=
M23?>%1T %%%% !1110 4444 %%%%  2 "2< =2:K?VC8_P#/[;_]_5_QHU'_
M )!EW_UQ?_T$UXUX-\&P^*+>ZEFO)8##(% 10<Y&:N,4U=DMM.R/9EO[-SA;
MN!CZ"0&IP0PR""/45YVGPKBM3YMMJ]R)0/E.P5<\'ZM=Q:Q=Z%?3F66!L*S'
MG %#BK:,+OJ=S136=4&78*/4G%0B^M&;:+J MZ"09J"BQ40N8&F,(FC,HZH&
M&X?A4H((R#D5R]IX:LH/&4^LIJ.^YDW9M\KQD?G35A,ZBBHI+F"%E66:-&;H
M&8 FB2YMXCB2>)#_ +3@4ADM-9U1=SL% [DXH$B,NY74J.<@\5YW\0]><3V.
MG6=T@BN>)'C<';\V*<5=V$W9'H,5U;SG$,\4A']QP:EKC_"WAK3_  [YES'J
MJSJQ^8LRX!^M=<CI(@>-E=3T93D&AI+8$.IDDL<*;Y9$C7^\S8%-DN8(6599
MHXV;H&8 FN4^)G_(FR_]=4_G0E=V!NR.N1TD0/&RNIZ,IR#3JY_P1_R)NF?]
M<?ZFN@H:L[#6Q$+F!IC")HS*.J!QN_*I:\OTL_\ %X[[GC]Y_(5Z6+JW9RBS
MQ%QU4.,TY1L).Y+40N8&F,(FC,HZH&&[\JEKR_2C_P 7DO?^VG\A0E<&['I8
MN8&F,(FC,HZH&&[\JEKE[7PU90>,I]974=]S)NS;Y7C(_.NG) &20![TG8$+
M14'VZTW[/M4&[^[Y@S4H=2NX,"HYSGBD,7(SC(SZ4M>=V?B.>;XF36DMZHL8
M@X4%QM/ QS7H22)(@='5D/1E.0:;5A)W'45"]Y:QMMDN84;T9P#4JNKC*L&'
MJ#FD,6BHI+F"%E66:.-FZ!F )H-S )/+,\8?^Z7&?RH EHIKR)&,NZJ/4G%1
M)>VLAQ'<PL?19 : )Z*.O2B@ HI"0!DD >]0B]M2^P7,)?\ N^8,T 3TUG5%
MW.P4#N3BEW#;NR,=<UYU\0]>=9[+3[.Z01W/$CQN#MYQ3BKNPF[(]!BNK><X
MBGBD([(X-2UR/A+PI9Z([S6VHFZ+?> ((''M77$@ DG '4FAI)Z A,C.,C/I
M39)8X4WRR*B_WF.!7GUIXCGF^)DUI)>J+&(.%!<;3P,<UI_$B1)/!4KQNK*9
M4PRG(/-/EU2%S:7.O1TD0/&ZNIZ,IR#3JYSP7+'%X,TUI)%0>5U9L=S6_'/#
M,,Q2HX_V6!I-68TR2BBHY+B"$9EFCC_WF I#)**CCGBF&8I4<>JL#4E !102
M "2< =2:B2ZMY%9HYXG5>I5P0* ):*CCN(9O]5-&_P#NL#39+JWA8++/$C'H
M&< T 344@(89!!![BHY+B"%E66:.-FZ!F )H EHHJ(7,!F,(FC,HZH'&[\J
M):**A>\M8VVO<PJQZ!G H FHI P894@CU!I'D2,9=U4>K'% #J*ACN[:8XBN
M(G/^RX-3$@ DG '4T %%1Q7$,X)AFCDQUV,#C\J626.%-\LBHO\ >8X% #Z*
M:DB2H'C=74]&4Y!ILEQ#",RS1QC_ &F H DHJ*.Y@E_U<\;_ .ZX-2T %%%%
M !1110 4444 %%%% !4R_P"J-0U,O^J- $-%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 ^+[XJU56+[XJU0!YO\ $K_D(6/_ %R;
M^=</7<?$K_D(6/\ UR;^=</0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5<TO_D)V_\ UT7^8JG5S2_^0G;_ /71?YB@#VN;[PJ.I)OO"HZ "BBB
M@ HHHH **** "BBB@"MJ/_(,N_\ KB__ *":\F\ >*]+\/6E[%J#R*TL@9=B
M;N *]9U'_D&7?_7%_P#T$UYA\-M!TO6+*_?4+..X:.4!2_88K2-N5W(E>ZL=
M,WQ+T%E(@:X>3'"^2:H>#K*34?$M]X@D@,8D<[-P(."/>NGM_".@VLHE@TR!
M''1@#6PD:Q($10JCH!2NDM!V?4XS6='\2:QK;Q_:OLFEC(#1N"S>F0:R+OX>
M0V$<U[;ZW*;B-2W.T9P*O:WKU]JGB4^'M*G:WD3/F2 X/'UJO?>#;R.RGGO=
M=GX0L0=OS''2J3:)=F:OP\UN?5]'D6XD:22W8(6/?BL#2O\ DLE]_P!M/Y"K
M/PC_ .0?J7_79?Y56TG_ )+)??\ ;3^0HM9L.B&_%+?_ &[H_EG#[?E^NX5I
MS>!+O6HQ<ZAJUPLS?,(P 0IK/^)G_(R:'^'_ *&*].7[H^E)MJ*L-*[9YMX5
MO+F#7[_PS=74DHVLJLW8;?\ Z]<OXK\(P^']5L+2.ZDF6Z/+,H!7YL5T6E?\
MEDOO^VG\A2_$S_D9-#^H_P#0Q5IVD2]A/$7A>+PQX$O8H;J2?SKB-B7 &,5V
M'@C_ )$W3/\ KC_4UG_$E2W@R4*"3YJ=![U?\#LI\':: 1D1<^W)J&[QN4E:
M1R/Q,_Y&30_J/_0Q6]\2O^1+D_ZZQ_SKGOB1-')XFT548$H0&P>GSBNA^)7_
M ")<G_76/^=-?9#N:/@C_D3=,_ZX_P!3705S_@C_ )$W3/\ KC_4UT%9RW92
MV/'Y5NW^*=^EDVV5F==P/0$#-;%]X'O=+BDU.TU:XDN1\[A@!G'6JFGRI#\8
MKUI&"KEQDGV%>C:K/'#I-TTC@*8F )/L:TE)IHA).YF^$=:;6M$BFD(,R@"3
M!SS7':5_R62]_P"VG\A6A\*[2:WTJ\ED7"32!D.>HQ6?I7_)9+W_ +:?R%%K
M-CO=(-+_ .2R7O\ VT_D*V/B%K=WIZ6MG:N\/V@C=*H^Z,X^E8^E?\EDO?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@!\7WQ5JJL7WQ5J@#S?XE?\A"Q_P"N3?SKAZ[CXE?\A"Q_ZY-_.N'H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2^2_UB\>ZN$&%#X.,_2NPHH<V+E1Q'C7PSJ6MZQI=S9)&T=OCS-SX(^8&NV
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MM55B^^*M4 >;_$K_ )"%C_UR;^=</7<?$K_D(6/_ %R;^=</0 4444 %%%%
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M@ HHHH ?%]\5:JK%]\5:H \W^)7_ "$+'_KDW\ZX>NX^)7_(0L?^N3?SKAZ
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MD C!Z5YIHKRQ_%B_AB)%N2Y8#IG Q1\2#9ES3];U*7XHW6FO=R-9IOVPGH,
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M(R_\A5)+\"7<LW;>.X6-^Q1;=028EFR,?E74^%->/B#2/-;"S*,/M.<&M?4
M#IMT#_SQ?^1K@?A+_P >FI_]=E_E2WC<>S+\^KZCH'BE8+ZXDGL;@DHS=$[
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MIV@PJSQ';)(S;<&LV"3QSHH:XORMU"#E@9<X'X"N8\/P>*]0N+V32+HQOO\
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M3+P0<@\5D44 =YX'GABT#5EDE1&;. S $_*:R/ DB1>)D:1U1?*?EC@5S5%
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MAQZ/9L&"D$;>@P:X/)]:2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+VYN+5T,=Q VUUQP?H>] &E1110 5,O^J-0U,O\ JC0!#1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 /B^^*M55B^^*M4 >;_$K_
M )"%C_UR;^=</7<?$K_D(6/_ %R;^=</0 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** 'Q??%6JJQ??%6J /-_B5_R$
M+'_KDW\ZX>NX^)7_ "$+'_KDW\ZX>@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH<#^,/[6@B$3Q*R2D#_6$]ZZ2I=N@U<Y#XE_\B;-_P!=4_G5[P/_ ,B;IO\
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M-17^B:;JDT4U[:1S20_ZMF_A[U=9%>-HV&48;2/44F]$AI:L\Y^$O_'IJ?\
MUV7^50_$W_D8-$^H_P#0Q7H&FZ/I^D+(MA:I )#EPG<TE_HFFZI-%->VD<TD
M/^K9OX>]/F7-<7+[MBZG^K7Z5R7Q#;S-!6UQDRS1\>V:Z[@#T KEI(O[=\39
MW/\ 9[+*.I7Y68\@CUI1WN-[6-K1+-;#1[:V50JQI@ =JT*.@HJ1A4R_ZHU#
M4R_ZHT 0T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% #XOOBK558OOBK5 'F_Q*_Y"%C_ -<F_G7#UW'Q*_Y"%C_UR;^=</0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5<TO_D)V_P#UT7^8JG5S2_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M#XOOBK558OOBK5 'F_Q*_P"0A8_]<F_G7#UZOXIBT:2YMSJ;LKA#LPN>,U@?
M9O"?_/5_^_?_ ->@#AZ*[C[-X3_YZO\ ]^__ *]'V;PG_P ]7_[]_P#UZ .'
MHKN/LWA/_GJ__?O_ .O1]F\)_P#/5_\ OW_]>@#AZ*[C[-X3_P">K_\ ?O\
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M /KT?9O"?_/5_P#OW_\ 7H X>BNX^S>$_P#GJ_\ W[_^O1]F\)_\]7_[]_\
MUZ .'HKN/LWA/_GJ_P#W[_\ KT?9O"?_ #U?_OW_ /7H X>BNX^S>$_^>K_]
M^_\ Z]'V;PG_ ,]7_P"_?_UZ .'HKN/LWA/_ )ZO_P!^_P#Z]'V;PG_SU?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "KFE_\A.W_ .NB_P Q5.KFE_\ (3M_^NB_
MS% 'K>I?ZX?2J57=2_UP^E4J[(?"CDG\3"BBBJ)"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "M"'_ )![_A6?6A#_ ,@]_P *B>Q<-S/HHHJR
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH L67_'TM;U8
M-E_Q]+6]7/6W.BEL>;_$K_D(6/\ UR;^=</7<?$K_D(6/_7)OYUP]8FH4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5<TO_D)V_P#UT7^8JG5S2_\
MD)V__71?YB@#UO4O]</I5*KNI?ZX?2J5=D/A1R3^)A1115$A1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !6A#_ ,@]_P *SZT(?^0>_P"%1/8N
M&YGT4459 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 6+
M+_CZ6MZL&R_X^EK>KGK;G12V/-_B5_R$+'_KDW\ZX>NX^)7_ "$+'_KDW\ZX
M>L34**** .@\&6-MJ'B!(+N%98C&QVMTR*I>(K>*T\07L$"!(DDPJCH!6KX
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M=Q)M?&\'J.YH RZ*])DTGPUH%HBZE&LT@X)VY)/T%-ET'0==T]I-)587 W#
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M9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBB@ HHHH L67_'TM;U8-E_Q]+6]7/6W.BEL>;_$K_D(6/_7)OYUP]=Q\2O\
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M^Y<C'%9U6+^2"6^F>VC$<+-E%'857H ]1M]7?1/ %C>)$LK!57:QP.2:Q_\
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MXDNUE+%$<B,$< >U4=&U)M)U2.Z49QP?H>M>A7UCHOBF&*Z^U+"V,[C@']:
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MQX7TZ6:](^U7!#%0<A>,8KT*KIJT2:CO(\(^/W_(6T?_ *X/_P"A5Z7\-/\
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M3244 +D^M)110 4N3ZTE% "Y/K2444 %&:** "ER?6DHH **** %R?4TE%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU<];<Z*6QYO\2O\ D(6/_7)OYUP]=Q\2O^0A8_\ 7)OYUP]8FH4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5<TO\ Y"=O_P!=%_F*IU<TO_D)V_\
MUT7^8H ];U+_ %P^E4JNZE_KA]*I5V0^%')/XF%%%%42%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %:$/_(/?\*SZT(?^0>_X5$]BX;F?1115
MD!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!8LO\ CZ6M
MZL&R_P"/I:WJYZVYT4MC(UCP]::U+%)<_>C4J.*S?^$$TST_\=KJ:*Q-3EO^
M$$TST_\ ':/^$$TST_\ ':ZFB@#EO^$$TST_\=H_X033/3_QVNIHH Y;_A!-
M,]/_ !VC_A!-,]/_ !VNIHH Y;_A!-,]/_':/^$$TST_\=KJ:* .6_X033/3
M_P =H_X033/3_P =KJ:* .6_X033/3_QVC_A!-,]/_':ZFB@#EO^$$TST_\
M':/^$$TST_\ ':ZFB@#EO^$$TST_\=H_X033/3_QVNIHH Y;_A!-,]/_ !VC
M_A!-,]/_ !VNIHH Y;_A!-,]/_':/^$$TST_\=KJ:* .6_X033/3_P =H_X0
M33/3_P =KJ:* .6_X033/3_QVC_A!-,]/_':ZFB@#EO^$$TST_\ ':/^$$TS
MT_\ ':ZFB@#EO^$$TST_\=H_X033/3_QVNIHH Y;_A!-,]/_ !VC_A!-,]/_
M !VNIHH Y;_A!-,]/_':/^$$TST_\=KJ:* .6_X033/3_P =H_X033/3_P =
MKJ:* .6_X033/3_QVC_A!-,]/_':ZFB@#EO^$$TST_\ ':/^$$TST_\ ':ZF
MB@#EO^$$TST_\=H_X033/3_QVNIHH Y;_A!-,]/_ !VC_A!-,]/_ !VNIHH
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M^SH?\BC^SH?\BKE%'/+N')'L4_[.A_R*/[.A_P BKE%'/+N')'L4_P"SH?\
M(H_LZ'_(JY11SR[AR1[%/^SH?\BC^SH?\BKE%'/+N')'L4_[.A_R*/[.A_R*
MN44<\NX<D>Q3_LZ'_(H_LZ'_ "*N44<\NX<D>Q3_ +.A_P BC^SH?\BKE%'/
M+N')'L4_[.A_R*/[.A_R*N44<\NX<D>Q3_LZ'_(H_LZ'_(JY11SR[AR1[%/^
MSH?\BC^SH?\ (JY11SR[AR1[%/\ LZ'_ "*/[.A_R*N44<\NX<D>Q3_LZ'_(
MH_LZ'_(JY11SR[AR1[%/^SH?\BC^SH?\BKE%'/+N')'L4_[.A_R*/[.A_P B
MKE%'/+N')'L4_P"SH?\ (H_LZ'_(JY11SR[AR1[%/^SH?\BC^SH?\BKE%'/+
MN')'L4_[.A_R*/[.A_R*N44<\NX<D>Q3_LZ'_(H_LZ'_ "*N44<\NX<D>Q3_
F +.A_P BC^SH?\BKE%'/+N')'L5H[&*)PPZBK-%%)MO<:26Q_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gaz3apgusshz000018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gaz3apgusshz000018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .2!YX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@_\ (O:9_P!>D7_H H X_P#X6;_U"/\ R9_^PH_X6;_U"/\ R9_^PK0^(_\
MR+UO_P!?:_\ H#UH>"/^10L?^VG_ *,:@"O<>,/L_A>TUK[!N^T2F/R?.QMP
M6YW;>?N^G>L?_A9O_4(_\F?_ +"M#XC_ /(O6_\ U]K_ .@/6AX(_P"10L?^
MVG_HQJ ,K3?B/9W-T(;^T-E&[!5F\T.B]>7X&T=.>>O. ,UVM>8>//#MMI<U
MM>Z?:B"WFS',D>%C1P!MVKVR-V<<?+V).>U\)7D]_P"%[&XN6W2E60MDDL%8
MJ"22220 2?7- &U1110 4444 %%%% !1110 4444 %%%% 'D^K_&O^RM:O\
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M8WRQ=P3EE)Z**OVBY>8YUA)NLZ-U<].UW6K3P]HMUJU\7^SVZ@L(UW,Q)
M]22!S@<\D#FO+9?CS&)Y!#X<9X@Q$;/>;69<\$@(<'';)QZFMGXWQ22>"+9T
MB=UBOXV=E4D(-DBY/H,D#)[D#O7$_#7QWX?\+P/;ZGI/EW4DFT:C!&'<QL1D
M29.X*NT'"9!_NY&6F<GS6O8WP^'@Z+J./,[['>^$OBWI?B/4(].N[5]-O)F*
MP[Y0\<AXPN[ (8DG QC@<Y(%=5XKU[_A&/#5WK'V;[3]GV?NO,V;MSJO7!Q]
M[/3M7ET_@7PEX^UBXO/#/B*WM$*@/81V6W9M"@LJ$H0ARO."-Q//8=O\5O\
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MZ).EM%"+JYSF1!)M$:XXR<'D\<>G/'&<R#XBV_G 7>GR10=Y(I/,*\CDK@<
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M!Z5I-4:3Y&KD0=:HN=.QE^$?'&F^+HG2!7M[Z)0TMK*03C RR'^)03C/!Z9
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[J^C0V]C#YLJW"N5W!>-K#/)'J*YNQL?'>G6<=I:1^7!'G:NZ XR23R>>I-
M%OXE:B@@LM,4(TCL;A\.-R #:N5]&W-@_P"P>O;>\$JZ^$+ 21LA^<@,I!(+
ML0?H1@CV-<;9^"-?U.]7^UY98H4PK33W'G2E.3A.6YS_ 'L ;LX."*].CCCA
MB2*)%CC10J(HP% Z #L* 'T444 %%%% !1110 4444 %%%% !1110!\Z:;81
M:K\;-0TZ=G6&[O-1@=HR P5HYU)&01G!]*YUKNZTOP[J_A^YN9H+C^T8?,M!
M(2G[M9EDSCY3\WE?7:IYV\>O>$?!VK:?\4M;UO4=-1;*9KE[2=GC<[GE!! !
M+*2A;G X)'>L'Q!\,]4O_B9+=P:/YF@W%]%+._VI1N1MIF."^\<E^GX=JYN5
MV/:C7I^TM)Z63^:..\>:,WA^XT'3)%=9HM&B:978,5D>69W7*\$!F('L!R>M
M?0OB_P#Y$K7O^P=<?^BVKB?BUX.U;Q+/I4^BZ:EQ-$LJ3R!XT;;E2@)8@D9W
MX';)]:]%U*QBU32KS3YF=8KJ!X'9" P5E*DC((S@^E:1C9LY*U92ITFWJKW^
M\\@^ TT2SZ[ 94$SK ZQEAN95+@D#J0"RY/N/6L/XTWD%SX[2*%]SVMG'%,,
M$;6)9\<]?E=3QZU-;_#SQ_X5\0RW'A]/,\O*1W<4T2B5".Z.WTR"" 1D9P#5
M6_\ A;XVNX(-0N8GO=0N&<3QRW2-)&J[0A9V?YB1G@$X"CGG S?-R<MCMBZ7
MUGVW.K,]?\:^,]'\*0VUOK%E<W<.H+(GEQ1HZE5"A@P9AD$/TY[UR4'PX\(^
M.-)77](6_P!)6[63RXAMV*X=AN*<\9'W58# &,5UOCWP;'XRT(6R2)#?6[&2
MUF901G&"C'&0K<9QW"G!Q@^6Z1X1^*/A>>>/1HWCB+,#LN86BDY WA';&2%'
M)4-CCCI6D[WU5T<6'4?9WA/EEYO0YCQAX3O/ NO00#4$F)59[>XA;RY%(/4J
M"60A@<'.#C@Y! ]=\974]]\"_MEU)YEQ/96<LKX W,SQ$G X&2>U<9IGPK\7
M>(-6CE\4W,T-O%M5Y;B[%Q,Z<G;'RV.?[Q &[(#<BO3/&GAZ:\^'-SH.B6N]
MUB@BMX/, ^5'3C<Q[*O<]JF,79Z&]:M!SI)R3:>KZ;GCOP\^'3^,GFO+R=[?
M2H&,;-"P\R23 .U<@@  @DD=P!W*P:%JVI_##QQ-;WP=HXF$=];V\@*S(5RK
M#/!(#!AG![$KDUZ[\*_#^J>&_"]S9ZM:_9[A[UI53S%?*E$ .5)'535'XI^
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MN4K*T6CS7X+ZN"FI:*Y0$$7<0"G<V<*^3TP,1X'!Y/7MT'C+X=_\)=K$-_\
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M1[[<GZXKK='M;BQT:RM;RY>ZNHH56:>0Y:1\?,?Q.: +;ND4;22,J(@+,S'
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ML!R:=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<M6.G>=<6VFB<AL*D4F,@<?QT >[45\[/\>O%*J"+#1_^_,O_P <J[J_QO\
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M@$PRY_\ 1E3Z9\>/$]Y#=/+8:.#$N5VPR\_7]Y0!]#45\Z#X^>*2,_V?H_\
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M#:_&_P 2SW,<;6.DX89.(I/_ (Y0![[17AFJ_&?Q'8WGDQ6.EE3&'&^*3/\
MZ'3M$^,OB'4K*^FFLM+5H%RNR*0 _7+F@#W&BOG _M >*]K'^S]%X_Z8R_\
MQRM5/C;XE;PVNHFQTGSF?;CRI-N/^_F?UH ]ZHKYX7X\>*#'N-AH_P#WYE_^
M.5T^L?%C5]/T"UO8;?36N)E#%&1R,'V#Y_6@#V"BO +7XY>)I]4AMGL=($;]
M2(9,_P#HRJNH?'KQ1:ZC-;QV&CE$/!:&7/\ Z,H ^B:*^>M)^._B>^>Y6:PT
M@>4FY=D,OZ_O*B7X^>*23_Q+]'ZX_P!3+_\ '* /HJBO&9?BWKZ>$O[5%GIO
MGX4X,;[.<]M^>WK7/I\>/%#74$9L-'VR, 2(9<_^C* /H:BOG_4?CGXFM-0D
M@CL=)*+T+0R9_P#1E5?^%]^*O^?#1O\ OS+_ /'* /HJBOG3_A?GBH?\N&C?
M]^9?_CE?1= !16/>Z5JEQ=R2V_B*[M(FQMA2W@8+QV+(3[\GO7 ?$#Q5>^ Y
M-(CN/%5[*]]<A9%%K;YC@'WY/]7U&1@=^?2@#U>BN=31]8EC62/Q?>LC ,K+
M:VQ!!Z$?NZV[.&6WM(XI[I[J51\TSJJE_J% 'Y"@">BBB@ HHHH **** "BB
MB@ HHHH *\$\8OXB^)_Q.OO!NF:B=/TG3$S.V3AB,99@,;CEL 9QQFO>Z\0\
M=^$O%_ACQY-XW\$QM<_:UQ=6R)O(. #E.K*< \<@T <QX3\+ZI<_#CQGI.D7
MHCN]/U4.)<F,R"$'[I'W2< BO6OA#XIO/%O@&WO-1?S+RWE:VEEQS(5 (8^^
M&&?>O"]#F^)LL&LZ1I6AWD']M7#2W<ILVC*EOO .V HY/O[U]"?#CPB?!/@R
MUTF619+K<TUPZ?=,C=0/8  ?A0!UE%%% !7+Z-X8NM-\>>)-?EGA>WU5;=8H
MUSO3RTVG=VY]JZBB@#SW5O!?B:S\47^M^#M<M;+^TPIO+6\A+QEU& ZXS@X]
MJW/!/A-O"FF7*75\U_J5]<-=7MVR[?,D;T'8#%=-10 5D:KX8TG6KE;B_@ED
ME5-@*7,L8QDGHK =ZUZ* .:_X0'PY_SZ7/\ X'3_ /Q=4?"&FVND^+/%=I9Q
MLD*RVI :1G.3",\L2?UKLZY?0?\ D>/%O^_:?^B10!U%%%% !1110 4444 %
M%%% !7(^(_B7X6\*:K_9NKWTL-UY8DVK;2.-IZ<J".U==2%%)R5!^HH \[_X
M7CX!)P-5GX_Z<Y?_ (FNN\.>)=+\5Z7_ &EI$[36OF&/<T;(=PQGA@#WK@_A
MJBGXC?$4%00+^/''^_7J0  P !]* %HKCO&_C.Z\/W.F:/HVGKJ&O:HY6V@=
MMJ(J_>=SZ#\.A]*Q!XC^(/AG4]/'B?3-.U'3;V98&ETA)#);,>A93U7_  Z^
MH!Z917GFI^+O$VM^)K_0?!5G8$::0E[J.H,WE)(>?+55Y)'?_.9O#OC#7;?Q
M4GA3QA96D&HSPM-9W=DQ,-RJ_> !Y##D_A],@&Y#XWT&?PY?:_'=N=.L9'BN
M)?)?*LI (VXR>HZ5M6=W#?V-O>6[%H+B-98V((RK#(.#[&O#=*_Y(!XT_P"O
M^Z_]"2O8?"?_ ")VA_\ 8/@_]%K0 _5?$>EZ+J.F6%].8[C4Y3#:J$9M[#'&
M0..HZUJUQOC'Q$^C>)_"5BMA:7 U*]:$RSKEX<;>4]#S^E9.I^._$;_$#4_!
M^A:1:7%U%!%+!<3NRQQ*5!=I<=0"0 !R<T >D5DZ-XETO7Y]0@TVX,LFGW!M
MKD%&79(.HY'/3J*XS1?&'BC3/'5IX4\8VNG-)J$32V=[IY8(Q4$E2&^A].W7
M-6O"_C6&9/&5W?V=I8VNBWLJ/);IAI57)W-ZL<4 =_17E]GKWQ0\1V*:YH^F
M:'9:;*/,MK.^=S/-'U!)' R.G3K5Z#XK62^ ;_Q!?V,EO?:?,;2ZT[=EA<YP
M$!]"><]AGTH ]"JI=ZG8V,]K!=744,UW)Y5O&[8:5NN%'>O-Y]=^*]GI;>()
M]'T1[-$\U]*C:0W*QXR>>FX#M^G:N;\:ZSXFU7QWX)U&PTFTC21GDTR*[9DD
M9C&AD68?PX.0,=: /8I_$>EVWB6U\/2SD:E=PM/#%L8AD7.3NQ@=#6K7"-XD
MOHOB-X=T*_TRP%U>:8UQ<3H"SPR -N1&_NY%9\WC+Q5XH\0:CIG@>STY+/39
M?(N-2U$L4:4=515YX]>?PXR >ET5P'AGQMK!\33>%/%NGV]IK*P&XMIK5B8;
MI!U*YY!X/Y'IBL/P[XX\>^.]&-QH&F:18F"5XY[J]9S&[@\+&HR>%QDGN>*
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M":]Q@TN[31?LAFCV;, E>17D_BO0Y])N?-;]XCG)<#@4 86M2QSZEOB<.@C
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MC!^7>O7\*]!DL]1,+67[@V\:?(X7'X4 >-W",D@C;@JV#1K<D<]Y;^2X<)$
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MU2_CM8V"E^K'L*]M\'>&]/L+-DB^:8?><UXGIFH3:?,SP "60;0YZJ/:O?\
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M2W1GN(W^7[H%<WI$;SZC%'$ 6W9KVK1+20LBJ-N!S@4 6/L:FV56C& ,8Q7
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M ,HV[,NP<9]:\]\<^%;@ 7<41^4?,%%>TRZ,T;*2:PO$KSV5KYB1B3 PP]J
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!\\76&NYB .7-0XJ64%;F53U#&HS0 TU]O5\0FOMZ@ KF_%WW_#_ /V&(/\
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M/,-M*O7(R-W!R.E8_P -.-<\="3_ %W]O2EO7;M&W\.M'@/GX@?$$Q_ZG[=
M!CIO\L[OQS0!GZ5<ZAJ'A_PYI=WJE[(+[6+R&[NEF,<LJ1&9@NY>5!*+]W'
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MG(XKKFMDV$8'2L/4+<D$=1C&* /EG7X?L_B&Z0C'S$UG(AENH8QU9@*Z;Q[
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MZ*BKYU-?17P#_P"1%OO^PG)_Z*BH [?QI_R(GB'_ +!ES_Z*:OCH5]B^-/\
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MWGX?V:+X=M[A\%BHKO[2;*X)SSQ7"^$HDMX[2V5R59%R,^U=Y';B*=E'W0*
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M\*(,[3N- 'T;X-U$S6L*OUP*[TC]WQP"*\K\,JT#1JO3KCTKTQ+@+8&0]%%
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MG/S?+0 R]/G[CCD\"N.U:W4,\. 0 <UTFH:@L#?*,_+P*Y74[M+:PENKEP,
MD\T >)>*(((-;F2!=O=A[UB&KFIW9OM0GN3_ !L2/I5(]* /HKX!_P#(BWW_
M &$Y/_145=QXT_Y$3Q#_ -@RY_\ 135P_P  O^1%OO\ L)R?^BHJ[CQI_P B
M)XA_[!ES_P"BFH ^.A77>!HVAUE)Y8CY+#:'/3-<B*OVFJW=F4\N4[%/W3TH
M ^AM*=+:\Y P1\M=+-<,UH\"G@UX]I/C.UGL$^T2!73OGD5Z+HNI+?68?<&!
M'!S0!N:=&=B[FRHZ"O//C.\:Z5!C&X-75W7B"TTZ187E597.%4GDFO(OB;XA
M_M.]6P"L#$=S$]Z ,WP#$KZYSUV5[]X9(CC*'C!KYFT+5FTC68)P?E'#?2OH
M#1]7A>&&XC<%7&>* /0)YC$J-U'>LF-S<:CC^'O5B*^2>V5MP(Q5)[R* ELA
M3[T <M\4K.-?"\[K@X%?/ND*)-6L@>AD%>O?%/Q.L^EKIMN2\DAY"C/%>.(D
M]C<V\LD4B;&#<J10!]0:%$T)7"?*4 !-=1"RQCC%<5X3\26>HZ)'(94^50#S
MT-;2:JH4A3N!]* -Z55E7=VK%OHRX920%Q44VKF.+[W'I63-KD;Q2.TBA4!)
M.>E '@?CBW%MXJND7OS7H/P>MMMK.Q&":\U\3WRZEXBN;E&S&6P#7KOPLV+;
M,,8!48H ]1MH%*#(S5\QJ(]HJDDGEE?[M2RW ) &* ,+58=TK#K7C/Q4L"D$
M$^/NMBO:+R8-<$ ]!7DOQ;ND_LZ&(8+LW2@#G_A5:"?Q,K_Q*.*^B%M!-&!G
M:^,5\W_#'4!8>+H1(VU9!C)]:^DWF 595/!% %9-'1 S3'<W8UE7MBJJP[-T
MK;:[!0DG.17.ZGJ,:1N2W7@4 >7_ !"TY1IWVCC<C5Y@:]1\7Z[;H LN'_NI
MC.37F5Q*)YVD"! QSM'04 0&OM^OB U]OT %<WXN^_X?_P"PQ!_Z"]=)7-^+
MOO\ A_\ [#$'_H+T =)1110 4444 %%%% !1110 4444 %%%% '+^.O&)\#Z
M(FK2:7/?6HD$<IA< Q9Z$Y[$\?4BO$++X\W4/CV^U:X2_ET.:';!IOF+^Z?"
M?-G'J&_[ZKZ2N;:WO+:2WNH(YX)!AXY4#*P]"#P:\B\6Z;\-OAWXAF\0ZG:F
M>]OHBL6DI%&\6,*-RQE0%^[U)[G% &+JW[1=C=Z/>VUCHU];7<L+I#,)E'EN
M1@-T['FNX^"NK:SK7P_%[K=Q-<S/=R"*:8Y9XQCOZ;MP_"N%TKXM?#6[OTAO
M?!=O81,V!.;.&15]V &0/IFO=[&2TEL8)+%HFM'C#0F'&PJ1QMQQC% $]%%%
M !1110 4444 %%%% !7+Z#_R/'BW_?M/_1(KJ*Y?0?\ D>/%O^_:?^B10!U%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<_XWT";Q1X,U
M/1;::.&:[B"H\F=H(8-SCGM705D^)M>@\+^&[[6KJ*26&TCWLD>-S<@ #/N1
M0!7\%Z%-X9\':7HMQ+'--:0['>,':3DDXSSCFMZLKPWKL'B;P[8ZS;1R10W<
M?F*DF-R]B#CW%:M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45B>(/%NC>&H=VHW:B
M4C*0)\TC_1?ZG KSJ7Q-XQ^($K6WA^U;3M-)VO<;L''O)_1>:VA1E-7V7<QG
M6C!VW?8[CQ+X^T3PR&CGG^T7@'%M 06'^\>B_C7"&7QO\23B(?V5HK'KRJL/
MK]Y_T%=1X:^%VCZ,RW.H?\3*^SN+2C]VI]E[_4YKN@   !@#H!5^TIT_X:N^
M[_1$>SJ5/XCLNR_5G*>&?AYH?AL)*D/VN]'_ "\3@$@_[(Z+_/WKK***PE.4
MW>3-XPC!6B@HHIKABC!&"L1P2,X/TJ2AU%<SJVM3:0ZQ2ZG \Y(S&MJ20I/)
M/S>E:>F3S7T:74>HPW%N<@A8-ISZ?>X- &G1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'AW[1'
M_,M_]O7_ +2KR?1-8328YR(LRN/E?N*]8_:)_P"9;_[>O_:5>'4 ;O\ PE6K
M>9N$Z9[90<59TCQ9?66J+<3RF16;YAVKFP>>*>* /;]>\9I:>&([NV7+3 *I
M]Z\PL?$5\NHO)/,TD<QQ(I/:M0-]N^')!Y>VEZUR(.#F@#KXXV\+:];:O"6D
MLY&SUY7/8UZ3)\3-/GGM[1G7+ %9%.0/8UY8-9LY/"[VD\CO<$8"E>/;FN:Y
M# C@CH: /JZQU&.:,;VW9&0>U/N[^VME+32JB]\FO$/!/BG4);C[#)+N54)0
MM6#XB\3ZIJ&HR12SE5A?@+TXH ]C\2>)K6WTV0"8+&1U]:\FN/%_E2;K&"/W
M,R Y%<Y=:C=WI!N9VD Z G@?A5;.>U '86?CB.V#,-*B29NK1-M!_"KFD?$6
MZCU3_2ABV8\#.2OXUP6:#R* /=]?\96UKHRW0^8L/D]S7G,'Q OUGE:XB$L<
MG 4-C:*34R;CP'9R=2C8KD,T =;%J'A28L]UI]SYK\EM^1FNE\%^*]-TV[.F
MV(E5)FR,C&*\MW5UWARP2WTV;5)&&\@K'GL* /7+;QEIEWJ4NGCB>,]2>M=1
M%J,<D*JK@ #O7RO]LFBOGNHI&$F[.[->@7GB34+/PG;71ES)*,4 >GW7B#3[
M6[$#SH)"V ,\FN-^)'BN*'3#8POF>48_"O()=1O)[P73W#^<#D-GD5OV?B"/
M466WUJWBN1T$K<,/QH YM()KB:-80SS,?E ZYKT%O%NH^%],M[)[D7%Y@%T[
M(/0^],BT^RT".XU2WDRK18A63JI]JX*XG>XG>60EF<DDT >Y:%\0;;5M.9V4
MK+$OSC'2N3\0?$2'=(MBA>0G&YAP*Q/#F+3PIJEV>"_R"N-/KW/- '=7GB)O
M%NGI8?:GMY .589#5R.J:/=:5(JSJ"C?<=3D&J22O%('1BK#D,#6MJ'B%[_2
MH[*2(%U.6E/4T 8E?17P#_Y$6^_["<G_ **BKYTKZ+^ 7_(BWW_83D_]%14
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MR,&NAH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@6-=,8$2(_,R?PL#Z^U7(;F[DE59+!XD/5S*IQ^ -,"Y1112 **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#QSX\:+JNL?\ "/\ ]F:9>7OE?:/,^S0-)LSY6,[0<9P?R->.?\(7XJ_Z
M%G6?_ "7_P")K[&HH ^.O^$+\5?]"SK/_@!+_P#$TX>#/%7_ $+6L_\ @!+_
M /$U]AT4 ?-.A^%_$"^$M4MIM#U-)&Y1'M) 6^@QS7+_ /"&^*?^A:UC_P
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M<:EF=C&P  '))/:OE'_A"O%7_0LZS_X 2_\ Q-?8]% 'QR/!?BK_ *%G6?\
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M /CYO!OBG_H6M9_\ 9?_ (FF?\(9XJ_Z%G6?_ "7_P")K[$HH ^.SX+\5?\
M0LZS_P" $O\ \333X+\5?]"SK/\ X 2__$U]C44 %>!_&_P]K6K>-+.?3='U
M"\A73D1I+:V>10WF2'&5!&<$<>]>^44 ?'(\%>*O^A9UG_P E_\ B:7_ (0O
MQ5_T+.L_^ $O_P 37V+10!\=CP9XJ_Z%G6?_   E_P#B:ZK6_#'B&?PQI4,>
MA:H\L8(=%LY"5^HQQ7TU10!\@?\ "&>*?^A:UC_P!E_^)I?^$-\4?]"WK'_@
M#+_\37U]10!\@_\ "&^*?^A;UC_P!E_^)I?^$.\4_P#0MZQ_X R__$U]>T4
M?-6K>&?$-UX2T]1H6IM/$V&C%I(6 ^F,UR__  A_BG_H6]8_\ 9?_B:^O:*
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M6M8_\ 9?_B:^O:* /D+_ (0[Q1_T+>L?^ ,O_P 31_PAOB@?\RWK'_@#+_\
M$U]>T4 ?-&L^%_$$GAG3H8]"U-Y%^\BVDA*_48KF?^$.\49_Y%K6/_ &7_XF
MOKVB@#Y"_P"$.\4_]"WK'_@#+_\ $T?\(=XI_P"A;UC_ , 9?_B:^O:* /D,
M>#O%'_0M:Q_X R__ !-=+)X8\0GP1';C0M3\X29,?V23=^6,U]+T4 ?(8\'>
M*/\ H6]8_P# &7_XFC_A#O%/_0MZQ_X R_\ Q-?7E% 'R'_PAWBG_H6]8_\
M &7_ .)I#X.\4YY\.:S_ . ,O_Q-?7M% 'S)X/\ "GB&UU.:>?0M3B586P9+
M21<GT&17/W7A#Q3+<RN/#>L'<Q/_ !XR_P#Q-?7=% 'QY_PAGBK_ *%G6?\
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M#M8C&*Y/5+%[);J!^JGB@#Z6E^*W@J&T2ZDUK$+_ '6^RS<_ALS58?&3P"2
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MNCW?VFWCE,3/Y;IAP 2,, >C#\ZO7MY;Z=87%]=2>7;6T332O@G:B@DG Y/
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M.C)?7T#=?FS0!]*-\3/""Z=_:!U?%KG'F?9I?Y;,U2/QB\! 9.O<'_ISG_\
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MJ#405U:Y!&/G- 'T[_PM[P+_ -!S_P E)_\ XBNWKXB-?;M !7-^+OO^'_\
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M^L[0M%M/#NAV>D6/F?9;2/RX_,;<Q'7)/KS6C0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%17%Q':V\D\S%8XUW,0I) ^@YKS
M#6?BW=:7JT]HFD1RPHW[J5I'3S%['!7(_P#K5I3I3J?"C.I5A3^)GJE8VO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!X8#B@"@:^BO@'_R(M]_V$Y/_145?.F>:^B_@)_R(M]_V$Y/_145 ';>-?\
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M<2.^\Y)(7V&:UJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#P[]HG_F6_^WK_ -I5X?G%>X?M$?\ ,M_]O7_M*O#\#.:
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MBCM[=R!@J* /.-7U73=1DGTJ^5-V#MWCGZ@UY:MJ?[16UB^9C)M7'UK1\87
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M<JL2PRQY(8<?G7']JW?%.%U(M%,V)!EES6%]*@1]OU\Y?'[_ )'NQ_[!D?\
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MY/\ T5%7;^-/^1$\0_\ 8,N?_135Q'P$_P"1%OO^PG)_Z*BKM_&G_(B>(?\
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M<;>O3-;4*\Z%15(;H<9.+NCS#2M,UG28IQK%T)C_  $-G%<3)JEC<^(YC?\
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M_P!=\#:MI>EL!>W$.V++[,G<"1GMD BNCJCK&KV6@Z1<ZIJ4WDV=LN^5]I;
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[=AX>Q)YH V1"8P0>AKB?'\1?1+@CG]V0:[]V^7!'7I7,>)[0W.FS1D=5(H
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M<L?5CU)^M37^HVFFP>==S+&O8'JWT'>E*M9<M-67XCC1N^:H[O\  L@!0
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MCXG\3ZA\<=7TWP]X>TJ^M]&@NUDNKN6-6V;EP'<#A-H\W"[_ )_K@5]'444
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M_P 2=,%EJ<,P&/,7!I_PPL3<Z^\F,[170?%FWWFV(7A6QFIOA%9?OYI,8]Z
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MUM1!J:,!C<*Y<T ?;U?./Q^_Y'RQ_P"P9'_Z-EKZ.KYQ^/W_ "/=C_V#(_\
MT;+0!Y8*LV4!N+^")1DLXJL,UJ:!<);:U;228VAN<T >U^&;=K7RR!G(P:])
MTZ<# ST%<+82)"T3+@QNN<UU=O)AT=#P10!T,G[R,\\5YM\4=.^T^&IQMZ<U
MWXN,IR0/6N9\=,C^&;K.,[,T ?+42%-1MP>H<#]:]Y\/[E\H@GL:\2B02ZI"
M1_SV KWW2K7RXHVQCY10!Z!IK9B4YR"*L746Y<CI5+37VPQ@\C%:;.-N..:
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MM_&G_(B>(?\ L&7/_HIJXCX!_P#(BWW_ &$Y/_145=OXT_Y$3Q#_ -@RY_\
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M1D=1BO&-2L9-/OYK:0$%6X]Q7T7<VZ?:F7'&>*\@^(L"_P!MJL"%B%^;:,T
M<,:^W:^(FR.#7V[0 5S?B[[_ (?_ .PQ!_Z"]=)7-^+OO^'_ /L,0?\ H+T
M=)1110 4444 %%%% !1110 4444 %%%% &%XN\*:=XS\/S:/J0<1.P=)8\;X
MG'1ESWZCZ$UXO'^SQ'%XFNA?:J8O#P3_ $><2J)R^%X8%=N,[NGH*^A:^;O%
M'AS7/B?\9M8T-]0^R6NFH"@ERRQQ@+@JG<L6SGW^E '0#X >#<C/B6]([CSH
M?_B:]5\)>'M(\+^'X=+T4[K2-F;>7#L[$\DD=Z\9_P"&:)/^AH7_ , __LZ]
M:^'_ (0/@CPM'HIO!=E)7D\T1[,[CG&,F@#J**** "L^/1-.BUZ?6TM\:C/
MMO)-O;YD!R!C..OM6A10!S_B/P1X<\6F)M<TN*ZDB&$DW,CJ/3<I!Q[5H:-H
M>F>'M.33])LHK2U4DB.,=2>I)ZD^YK0HH **** "N7T'_D>/%O\ OVG_ *)%
M=17+Z#_R/'BW_?M/_1(H ZBBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M43)RQY)/4U<K(T(X((K6!(8(UCB0855& *DHHH **** "BBB@ HHHH ****
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ME8+,G##-8/C#QY):WQM+$@LI^9NM 'H6N:I%::5-,[#"J>37SC+/]KUIYO\
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M9CDDGK0 2R-+(TC8W,<FOMNOB U]OT %<WXN^_X?_P"PQ!_Z"]=)7-^+OO\
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M*S29).:.] %RWU*\M9HY8IW!0\?-7J^@^,MWA^2\F4CRQAB/6O'<UU^GMM\
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M/@%_R(M]_P!A.3_T5%7SH<\BOHOX!?\ (B7W_83D_P#145 ';^-?^1#\1?\
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M0%9L$FH2>3]:3=S0!VVKZTNF6$=C8% C+]Z,_P ZXXN6)+'+$Y)-1%L]Z :
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MD8*>JYXK4T#65T>[>5X_,5UVG'45F(VFN(?!\#P6\K3W4H^?LHKDY)#,[R,
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M?Q!H^@1))J^IVEBLAPAGE";OIGK0^I/>Z.+W0#9:B7P8B;G;$XSS\ZJW3Z4
M:5%<YX6\0:CKTFI"\TVWMH;.?[.DT%T9DF=?O[<HO"GY<^H/I71T %<OH/\
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M /*?C1X.U[Q9_8?]AV'VK[+Y_G?OHTV[O+V_>89SM/3TKRG_ (4]X]_Z /\
MY.0?_%U]644 ?*O_  I[QY_T O\ R;@_^+I1\'_'@_Y@7_DW!_\ %U]4T4 ?
M/EE\-?%Z>$+O3YM(VW#.&C3[3$<_CNQ7._\ "HO'?_0"_P#)N#_XNOJ6B@#Y
M:'PB\==]#_\ )N#_ .+I?^%1>.O^@'_Y-P?_ !=?4E% 'RY_PJ+QU_T _P#R
M;@_^+KHK/X;>+HO"-U8R:3BY=LJGVF+G\=V*^@:* /ES_A4?CK_H!_\ DW!_
M\71_PJ+QU_T _P#R;@_^+KZCHH ^7/\ A47CK_H!_P#DW!_\71_PJ+QU_P!
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M/^^Z^FZ* /EO_A47CK_H!?\ DW!_\71_PJ+QU_T _P#R;@_^+KZDHH ^6_\
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MI]K!I.Z6(?O%^TQ#'YM7T%10!\N_\*C\=9_Y ?\ Y-P?_%TG_"HO'7_0#_\
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MVEM8^,/%EO:6\5O"LEJ1'$@11F$9X'% '74444 %%%% !1110 4444 %%%%
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MP.H(K D&(,$88-0!]22?%3P7%8B]?6<6Y;:'^RS=?ILS5=?C%X#=U1==RS'
M'V2?_P"(KYSU#_D281ZSYK!MA_IL/^^* /K.\^*/@W3[@076L^7(5W!?LLQX
M_!*1/BIX+=RBZSE@NXC[+-T_[XKYO\6$-K\9#!AY*]#5WPS;+=:Y-$V/^/=L
M$_04 >_GXM^!QG.M].O^B3__ !%30_%#P;<6DUU%K&Z&'[[?99AC\-F:^9[Z
MQDMKV:%T([@D<$5:TAT3PQJJM(BL1PI/)H ^@_\ A<?@+9O_ +>^7U^QS_\
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MQ!X]\->%[^.QUG4OLUS)$)E3R)'RA) .54CJI_*NCKYQ^/W_ "/=C_V#(_\
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M*"2<#D\#M7F7P"_Y$6^_["<G_HJ*NX\:?\B)XA_[!ES_ .BFH P_^%P> _\
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MRZ2W2SU*-GSAIK&6-1]69<"ES(MTYI7:-6BBBF0%%%% !1110 4444 %%%%
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M*^ ?_(BWW_83D_\ 145?.@/:OHSX!_\ (BWW_83D_P#145 ';^-/^1$\0_\
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M>(?^P9<_^BFH ^.N!UHW8Y!(]P:0C-:.D:-<ZQ=>1!C@99FZ 4 )HUK]KNA
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MJX<]P<<)C'&+NI:^E^AE/>]K7.6-?;U?$(SBOMZO'("N;\7??\/_ /88@_\
M07KI*YOQ=]_P_P#]AB#_ -!>@#I**** "BBB@ HHHH **** "BBB@ HHHH *
M**\E^('QOM?!^O2:+8:8=0NX //=Y=B(2,[1@$DX(].M 'K5%?/'_#26I_\
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MMYY]!U*.\2!PDH"LC(2,C*L <'G!Q@X/H: -NBBB@ HHHH ***Y/7_B7X/\
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MV[R3@=J^A_@'_P B+??]A.3_ -%15\Z]J^BO@'_R(M]_V$Y/_145 '<>-/\
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M$JDM/;RYVY/*UZO?(?(9Q\K#I7DWQ%OY)K%HYQE@<*30!YBTADD9R.6)---
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M/_145=OXT_Y$3Q#_ -@RY_\ 134 ?'6<5JZ5K4NDPRK;+B:4@&0]A[5E <T
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M+TH/6EV[69?0XI#0!]OU\Y?'[_D>['_L&1_^C9:^C:^<OC]_R/=C_P!@R/\
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M9A&]G:B1?.#[N) ,$JH ?)P,C<N06J3X'>%V\/?#Z&ZN(T%WJK_;&(1=PB(
MC4L"=PV_..F/,(P#FNHUSP%X8\2:S;:MK.DQWEY;(J1M)(^W:K%@"@;:PRQX
M(.<X/%='0 5Y9XR^"ECXC\2)K^D:K)H5^6\R9X(=X>4$$2+AE*/GDD'DX/!R
M3ZG10!Y1X=^"-OI_B>/Q#K_B*^UW4()8YH6E!3YT'!<EF9L83'(QMP<CBO5Z
M** "BBB@ HHHH \._:(_YEO_ +>O_:5>("O;_P!HG_F6_P#MZ_\ :5>'B@#N
M?A_8M*T\P3Y5ZM7=^*+\Z=I-E(EG!=%I<%94+ 5P7P_UI=.U V5Q\D<_W2PQ
MS7KNG720RF"55=>J[AFNNA7C"JIN/R-(RL[G=:-<++HUI(0J$Q*=HX XIVH[
M6MI,$9V'^5<7I/BI-2UF\T^.-HXK500YX)/IBM^&\5Y I?('K6=6+IU+R5NH
MI:2NSYTU?P[>QZ#_ &N4+6\DK _*?D(/?ZUR]K;M<:C!"HY=Q7T#\7KFWM_"
M#1)L0R, B@8S7B7AXPP:S;7-PVV*,<G&:WQ%>IC:BM'5=ARDZDM#VG1[4QV&
MU1T0(<?2N3F\0_\ "$:C<V6BHQ=SF=KCD$^V*]-T6*#[.LD3!XVCW97G->4>
M,-,N]3U75=<M[61-/B8;GD4H?3@'K7HY)&$JLJ=?X>W2YMAEJTSV?PEJD^N>
M$K+4;DIYTRY=4Z#DC^E<=\6+9)O#MP^WI@CCO3OA4;Q--A2&QB-K*I::X%QE
ML@G'R=JT?B0D?_"+732DA20/Q->;B\.XXF5.'?0RJ0M.R/"_!-J;GQ1;DCY5
M'4],U[];V^W3+X<C$+?RKPOP[I=W?ZK;V]B-SJX)(.. :^BK>*,,T$HRDB;3
M[@]:VQ6%AA'3DI7;W78<H*#3N>3?#3Q=%X>O+R"\EBBLW5I"S'EF'0"O7M+U
MVR\1Z3'?V3Y5A\Z=T;T->6>(?!N@:1KD>F33O E\V^&< DQ<\)CO]:]6TO3H
M=$T&STV)@X@B">9C!;'<UU9L\-54:]-/FE]QKB'!I26[.(^(]CY_AR[!QD(2
M*^>=I*1CG)8"O>?BB^H3:7Y5O;%[4'<\RGD'Z>E>)R1A+BV!&-TBDY^HKC>
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MUMY!PQKA])A%QK%A$>C2BO8_B'!"/#MP\F"<<5Y1X5"MXFT[>0%#9R::3>B
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MQXM_W[3_ -$B@#J**** "BBB@"M?V%IJ5JUO>V\<\).3'(,@D=*^39U N9@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!X;^T5_S+?_;U_P"TJ\.%>_\
MQYT75=8_X1_^S-,O;[ROM'F?9K=I=F?*QG:#C.#^1KQS_A"_%?\ T+.L_P#@
M!+_\30!B"GBMD>"_%7_0LZS_ . $O_Q-.'@SQ5_T+.L_^ $O_P 30!L> 1^\
MU-O2V-<G)GS&^IKT'P7X9\0VAU%;C0=3A#VY"F2SD7)]!D5S#^#?%.]C_P (
MUK!Y_P"?&7_XF@#%5BC!E.".0:DFNIKAMTTC.P&,L:U?^$.\4=/^$:UG_P
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M/4,%+?LW!=O3W%<=_P (=XI_Z%O6/_ &7_XFG'PCXK*!/^$<UG:/X?L,N/\
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M%K6/_ &7_P")H R'D:21G<Y9CDDUUWA)]^@:S;]]FX?E61_PAWBG_H6M8_\
M &7_ .)KIO!OACQ#;W%]'<Z#J<22P$ R6DB@G\10!Y^O"CZ4M;<G@WQ0)& \
M-ZP0"<8L9?\ XFF_\(=XI_Z%O6/_  !E_P#B: -&;Q!91^&H[*T+I<JH'3CW
M-<L&R<UL?\(;XI_Z%K6/_ &7_P")H'@WQ3_T+>L?^ ,O_P 30!L>"'_T+6H^
MQBS^AKCAQGZFO0?!_ACQ!;#4EGT+4XM\.%\RSD7<?09%<RW@[Q1N;'AO6.I_
MY<9?_B: ,5)&CD#H2&4Y!':M'4]>O-5BACG<[8A@8/7ZU./!WBG_ *%K6/\
MP!E_^)H_X0[Q3C_D6M8_\ 9?_B: ,2I(!NN(A_MC^=:__"&^*?\ H6]9_P#
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MXO9?,N)6D;MD]*@S6S_PAOBG_H6M8_\  &7_ .)H_P"$-\4_]"UK'_@!+_\
M$T :'@.4#4[J ])(3BN:N%V7<Z^DC#]:[#PGX7\26GB"&2?P_JT<94JS/92
M#\2*H:KX-\2_VK=&+P[JSH9"0R64A!_';0!S.:<KLARK$'V-;'_"&^*?^A:U
MG_P!E_\ B:/^$-\4_P#0MZQ_X R__$T 8V23UKLKG_DFEOG_ )ZXK&'@WQ3_
M -"UK'_@#+_\3757'AKQ"? -O:#0=3,XER8Q:2;@/IC- 'GA-)FMK_A#?%/_
M $+>L?\ @#+_ /$T?\(;XI_Z%K6/_ "7_P")H S;:\GLW9K>0H6&"143R/*[
M.[%F/4GO6O\ \(;XI_Z%K6/_  !E_P#B:/\ A#?%/_0M:Q_X R__ !- ">%X
M_-\262GL^:=XKG,WB:\8G.UMH_"MGPKX4\1V_B&VEG\/ZK%&N<N]E( ./4BJ
MNM>$?$TVM7DJ>'M7=6E)5ELI""/^^: *&F>(IM*TZ6WMXDWOTD[BL>21Y9&=
MV+.QR6/<UL?\(;XI_P"A:UC_ , 9?_B:3_A#?%/_ $+6L?\ @#+_ /$T 4=,
M@2YU*WAE.(V<;OI6UXLU!GFCL(0(K6(?*B=#55?!_BI3E?#>L@]O]!E_^)I&
M\'^*F.6\-ZR3ZFQE_P#B: ,3[V5%=3XQD\NPTJS[I$&(JM:>#/$YO(0_AS5U
M0N,DV,H &?\ =K7\8>%O$=SK(^SZ!JLL21*H:.SD8=/4"@#@R:::W?\ A#?%
M0.?^$9UD_P#;A+_\32'P9XJQC_A&=9_\ )?_ (F@#W#X!?\ (B7W_83D_P#1
M45=OXU_Y$/Q%_P!@RY_]%-7)?!#3-0TGP7>0:E8W5G,VHNZQW,+1L5\N,9PP
M!QD'GVKL?%T,MSX+UV"")Y9I=.N$CCC4LSL8V   Y))[4 ?&HIPK:'@OQ7_T
M+.L_^ $O_P 32CP7XK_Z%G6?_ "7_P")H Q@:EB/[Q/]X5K#P9XJ_P"A9UG_
M , )?_B:E@\&^*!/'GPWK(&X9)L9>/\ QV@"_P"-FW7&GYZBW%<M7>>+_"WB
M*YOK8P:#JDRK H)CLY& /IP*YW_A#O%/_0M:Q_X 2_\ Q- &.K,H.UB,]<&D
M[5L_\(;XI_Z%K6/_  !E_P#B:/\ A#?%/_0M:Q_X 2__ !- &-FNS\+D2>%-
M9C/.U21^58O_  AOBG/_ "+6L?\ @#+_ /$UU?A?PSX@M]%UB.?0M3C:2/"*
M]I("W'8$<T >==A16U_PAOBG_H6M8_\  &7_ .)H_P"$-\4_]"UK'_@#+_\
M$T 8U -;/_"&^*?^A:UC_P  9?\ XFE_X0WQ3_T+6L?^ ,O_ ,30!IZ3!"O@
MG4;IHU,V[8KD<@&N2KT.S\,^($\"W=L="U,3O*"(S:2;B/IC-<M_PAOBG_H6
MM8_\ 9?_ (FFY-[@8N:,UL_\(;XI_P"A:UC_ , 9?_B:/^$-\4_]"UK'_@#+
M_P#$T@,8&NTM#]G^&]TXX,LN#6*/!OBC_H6]8_\  &7_ .)KJI/#/B$?#Z.V
M&AZF9S-DQ"TDW ?3&: // ?:D)K:_P"$-\4Y_P"1:UC_ , 9?_B:#X-\4_\
M0MZQ_P" ,O\ \30!B\T$DUM?\(=XIS_R+6L?^ ,O_P 31_PAWBG_ *%K6/\
MP!E_^)H PZV_"BY\2V(_VZ/^$-\4_P#0M:Q_X R__$UN>$?"7B*#Q%;S7.@:
MI%&F6W26<BC\R* .;\3G_BH[[_KH:QZZK5_"?BBYU>ZF7PYK#*\A((L92#S_
M +M4?^$-\5<?\4SK/'_3A+_\30!A5]P5\='P9XJ)_P"19UG_ , )?_B:^Q:
M"N;\7??\/_\ 88@_]!>NDKF_%WW_  __ -AB#_T%Z .DHHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !16%XB\8Z#X3^S?VW?\ V7[3N\G]R[[MN-WW5./O#KZUA_\ "X?
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MXAUW3)#Z)=QG^1H U:*Q6\8>&%&6\1Z0!ZF^C_\ BJD;Q3X>6U%TVO:6+<G
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MSUC2].-YH3-?M* _V.4;-B;NGF<YKMZYG7/^1U\*_P"_=?\ HDT +]G\;?\
M02T'_P  9?\ X[1]G\;?]!+0?_ &7_X[72T4 <U]G\;?]!+0?_ &7_X[1]G\
M;?\ 02T'_P  9?\ X[72T4 <U]G\;?\ 02T'_P  9?\ X[1]G\;?]!+0?_ &
M7_X[72T4 <U]G\;?]!+0?_ &7_X[1]G\;?\ 02T'_P  9?\ X[72T4 <U]G\
M;?\ 02T'_P  9?\ X[6=HE]XTUG3VNUO="B"W$T&TV<I_P!7(R9_UG?;G\:[
M:N:\"_\ (NR_]A"]_P#2B2@ ^S^-O^@EH/\ X R__':/L_C;_H):#_X R_\
MQVNEHH YK[/XV_Z"6@_^ ,O_ ,=H^S^-O^@EH/\ X R__':Z6B@#FOL_C;_H
M):#_ . ,O_QVC[/XV_Z"6@_^ ,O_ ,=KI:* .:^S^-O^@EH/_@#+_P#':/L_
MC;_H):#_ . ,O_QVNEHH XG4K[QIIU[I=L;W0G-_<& -]CE&S$;/G_6<_<Q^
M-:/V?QM_T$M!_P# &7_X[1XF_P"0[X5_["3?^B):Z6@#FOL_C;_H):#_ . ,
MO_QVC[/XV_Z"6@_^ ,O_ ,=KI:* .:^S^-O^@EH/_@#+_P#':/L_C;_H):#_
M . ,O_QVNEHH YK[/XV_Z"6@_P#@#+_\=H^S^-O^@EH/_@#+_P#':Z6B@#FO
ML_C;_H):#_X R_\ QVC[/XV_Z"6@_P#@#+_\=KI:* .(T>^\::NEZRWFA1_9
M;R6U.;.4[BAQN_UG?TK2^S^-O^@EH/\ X R__':3P7_J=<_[#-W_ .AUTU '
M-?9_&W_02T'_ , 9?_CM'V?QM_T$M!_\ 9?_ ([72T4 <U]G\;?]!+0?_ &7
M_P".T?9_&W_02T'_ , 9?_CM=+10!S7V?QM_T$M!_P# &7_X[1]G\;?]!+0?
M_ &7_P".UTM% '-?9_&W_02T'_P!E_\ CM9NK7WC32CIX:\T*3[9>):C%G*-
MI8$Y_P!9STZ5V]<SXQ^_X>_[#,'\GH 7[/XV_P"@EH/_ ( R_P#QVC[/XV_Z
M"6@_^ ,O_P =KI:* .:^S^-O^@EH/_@#+_\ ':/L_C;_ *"6@_\ @#+_ /':
MZ6B@#FOL_C;_ *"6@_\ @#+_ /':/L_C;_H):#_X R__ !VNEHH YK[/XV_Z
M"6@_^ ,O_P =H^S^-O\ H):#_P" ,O\ \=KI:* .:^S^-O\ H):#_P" ,O\
M\=K-TF^\::J^H*MYH4?V*\>U.;.4[BH4Y_UG'WOTKMZYKPA_KO$?_89F_P#0
M(Z #[/XV_P"@EH/_ ( R_P#QVC[/XV_Z"6@_^ ,O_P =KI:* .:^S^-O^@EH
M/_@#+_\ ':/L_C;_ *"6@_\ @#+_ /':Z6B@#FOL_C;_ *"6@_\ @#+_ /':
M/L_C;_H):#_X R__ !VNEHH YK[/XV_Z"6@_^ ,O_P =H^S^-O\ H):#_P"
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M"+IZVD8@4",.W7'K7;@\OQ&,YO8J_+N7&#EL<5,,2V^!U(K1\:@_VO9#'_+
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M\'5QE94:6[#I=G'7BGR;@$8*L>*L:LK?\(IIK'U-2:Q<+>RO=1Q"(3$[T4<
MUE2O,]HD+2NT:'Y5)X%9UZ%3#U'2JJS0#;#_ )"UB>>)16CJRC^W[D'CGO67
M&"K(ZL593D$=JN,SSSF1I"\I')8\FL0.H\-6ZRZ;>9[, #^!KE;Y<6TX_NR5
MZ3X4^S6>@7,$BYEE*R,2N< "O/\ 5;=5NK@0ONA=B0<52C)KF2T'9[DNN!O*
MTYCW@%91I[3S31QK-*SB,84'L*8:D0TU]%_ '_D1+[_L)R?^BHJ^=#7T7\ ?
M^1$OO^PG)_Z*BH [GQI_R(GB'_L&7/\ Z*:OCH5]B^-/^1$\0_\ 8,N?_135
M\="@#IO @/\ ;4S#M"W\JR5_X\;D_P!^<T[1]8?1+B6=(!*70I@G&,TVV!ND
M@M@-I=RQ_&@#H-1FV^&H;94Q\RN6_"N:F'SQ>]>J:UX7BC\,JV0'6)"#GKQ7
ME]P-FP$<HV.: +/BHG[;8#TMZ@\+G'B2V/O4&I7TNI7,<DJ*OE)L&WTINF7$
MEE>K<Q!3(G(W4 7;[]YXFO"?^>M:.D/=F.^AMV;9)@NJ_P 6*Q/M,DM_-=2
M>8[%B!7I/P_TU;BWE+1X:122: . 9"#.CJ0PSUK3L?\ D1+\_P"U70>--(.G
MR&9(@5.0Q%<.-2NX=,ETZ-D^SR-E@1S0!DL/]$'TKK=6(_X0?2O]\US#)^["
M^U:-Q>W4^F06<CJ8(CE5QTH E@BWPQ(H)9V' KN/&^F7%O \B(5M8Y8RJJ.
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MZ[N[C'E)&Q.3T%,\106T>H"ZLW$ENX'([''-7[.?+SVT[CL[7*&BY72]5/\
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M#&"Q^0'-95TI^SL?+*AC@^Q]*]3%Y/B<)25:I:VFSU5^XN:#DX*2;6Z-&?\
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M'[)$T>WR/,W9(.?O#'2N&_X9G/\ T-/_ ))?_9U] 44 ?/\ _P ,SG_H:?\
MR2_^SKUCP!X0_P"$'\+1Z+]L^V;)7D\WR]F=QSC&37444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !6=>:2EYJ^F:BTK*]@9"J ##[TVG/TK1JIJ6I
MV.CV$E]J-U%:VL>-\LK849.!^IH MT4 Y&110 4444 %%%% !1110 5G:+I*
M:+8-:1RM*K3S3[F !S)(SD?ANQ5B_P!0L]+LI+R_NH;6VB&7EF<*J_B:I:)X
MGT/Q&LC:-JMK>^7]\0R E?J.HH UJ*** "BBB@ HHHH **** ,[4=)34;W3+
MEY61K"X,ZJ ,.2C)@_\ ?6?PK1KG-4\?>%-%U&73]2UVSMKN+'F1.WS+D C/
MX$&M;2M7T_7-/CO],NX[JTD)"2QG()!P?U% %VBBB@ HHHH **** "BBLW6M
M?TGPY9I=ZQ?0V=N\@C624X!8@G'UP#^5 "Z1I*:0EXL<K2?:KN6Z;< -I<Y(
M'L*T:Y%/BAX(=U1?$MB68X WGD_E774 %%%% !1110 4444 %9VJZ2FJFP+R
MM']CNTNEVC[Q4$8/MS6C63K?B?0_#B1MK.JVMEYGW!-( 6^@ZF@#6HJM8:A9
MZI9QWEA=0W5M(,I+"X96_$59H **** "BBB@ HHHH *SM*TE-*?4&25I/MEV
M]TVX?=+!1@>WRU-=ZG8V-Q:6]U=1137<GE6Z,W,C8S@#Z"K= !1533]3L=5@
M>>PNHKF))&B9XVR ZG##/L:MT %%%% !1110 4444 9VKZ2FKQVB22M']FNX
MKH%0#N,;;@/H:T:J6&IV.JQ2RV%U%<1Q2M"[1MD!U.&7ZBLN\\;^%]/U7^S+
MS7K""]R%,+S %2>Q[ _6@#?HI 00"#D'H12T %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X=^T3_S+
M?_;U_P"TJ\/%>X?M$_\ ,M_]O7_M*O#A0 I.!TJW:@/LB\L%RW%50,G.:Z#3
M-$F;2)=6+X"G:BCJ?>ML/1]M6C23M=I%17,TB2;4+QF2"W:>2.,8"ID@?E5C
M4;2WU.VB&GY^U[09HWX)/MFNB\':SIME9,C&!+P*03*N=U9_BS4-,=K673F3
M[>"#*\0P >]?68BA#%8I9;]7E%07NU-+/U/+AFLJF(="4+).WGZ[6M\SA)[>
MXMI&2:)T/?<N*;!'(\;L%)"GDXZ5U6N>(&U'1H89XT:4'!D5>>/6F^%?*O[6
M?2Y%"9<.9?05\IB<-/#5I4:FZ/4E%Q=F3:=I=[I^A/J36ZLIQAF_@&?3OFEM
M](U/6GDN8+5=K?,6 PM>AS7?ANYT:?2;F]$,:I\H7@EATK@M+\1W_AZ*6U",
M]M(^Y58<C'3%?69+&O#!2>'IKVM_M75T_/\ I&6,EBZ>&YL(O>]/\QTVF1ZY
M9FV@C-OJ%FIWQ_>#@=3[5QDRO%.T<BD,#@@BNP\/^()]-\1S:B0F+DD2!QD!
M3UK6\4+I>KZ7+<I$D=U'\RD<''O7D9]@/JN(YHJT9:_/J:6GR1E-6;6OKU/-
M86/FG'I74^$]&FU"\!9"(NQQU-<T@_>8499N !7I>D:K:^'M$"3,#? <HO49
MZ5Y-"A5KS4*2NQQBY.R,/Q=8V-K=16=ON>ZC&)\)C+>PK$-NT4(BN(WBWCY2
MPQC\*T]-UB*#Q(+[4MTP;.7;G![5I>+_ !)I^KK%#90J74_-*!_*OOJBQ2J4
MLNE1<Z4H^].]K/T.+$8VO#&*A"G==7W_ .&.-O;"ZMHP[1,T?:11E3^-4MQ+
M+76VOB-]*T\6TD2RV[D[E*YZUS\2B[U*-8HN))!A/;-?$9AA?JF)E1O>QW5(
M<LK%O2;9/M/G73%(5]L[CZ4EQYMV\UP!N",!@>GTK;UV]@D<6=LL0A@X5D')
M..<UG:;?RZ8LP2"*7S1@F1<XK[C(LN^J8?VUOWDE^'Z>9GBZ=:-!.@KR&VS0
MWMF]DL6+ACF-_4^E8MS');[HY$*NK8(-;=BH2\2=PX4-N;RN"![5VEW>^&-1
MM8[>[5"60#S&&'!]SZUXW$V 4:JQ%-/7?K_PQO.G-04Y+4\K0%E%;OAW3FU'
M6(8D7]VIW2'V%4KC3O(U4V$#B0-)M1@>H/2O7-'\/6^D6$:6^TS.H\QB><U\
MG:YB;VB64 69X(EP>&.,YK$\5^&[34+9A'&$D7D;%"X-=3X6L[>&2\6.[\V;
M>/,CW<)["L377U>3Q1(UM!Y=E#$8V,F"LAXY'H:ZJ>'<G*/-:ROKI_7D6HWT
M/%KO1[ZU=_,MF**?OJ*SJ[K6M<_L^^VF([3G<IKB;F59KJ65$V*S9 KE((C7
MT7\ O^1$OO\ L)R?^BHJ^=*^B_@%_P B)??]A.3_ -%14 =QXT_Y$3Q#_P!@
MRY_]%-7QUP*^Q?&G_(B>(?\ L&7/_HIJ^.B* $<@C KJ_"NEM?7B30\[,#++
MP*RM$\/W6N3E( %1/ONW05[1X9\.0Z7!#%&=V ,D]S0!;ETR\O=,\B>6/&T#
M 3L*\W\2>"KR,&:TVR@<L.AXKV\08.T#C%4-5M;;[$?-7''#T ?,4D4L3-YB
M$<XJ.$GS&KM_&>A+I\/VBV8O!+)\V?X37%Q !B?6@"_I-G+?WR0QQEBQY/I7
MM>A>&C':Q[I9U'< X!K#\ :%#:V,,TD0:\N#NY_A':O66A1 I8<@<@<8H XK
M6_"%M=PM@R!R.,L2*\3\0Z+?:/?/%<QG!.5=1P17TS<+$<;"1GUKA_&L\%KI
M<DLD:,>GS+0!X,S85>*L ,ZHH&2>@IVH+"UQF!@4(R<=,UZ)X+\,6*Z?!J=^
M!)*_,:GHHH T?!7AS4+&$73-Y.\9VE<FNY-O/<V[0S73<C .*W+:T^T6\9C0
M!<#&*MS:44B!*@D>E '@/CGPK<:>YO8P9$8_.V.E<#,Q#C-?4&I10O8S)=0A
MHB"&5AQ7AOC?PO#IN-0L&S:R-@H?X#_A0!R2??'UJ9I%$O(SZTR&-I)8T0$N
MQ  J[<:?-;7\=K<+MD<C]: .\\%QZG;VMK<6O[K>QV,RYP*V=?T"XU>,?:K@
M2LJX4[>E:FB0+#';6J_*B* .*WI+%FZ'*F@#Y\U31KS2IV%Q'A.BL.AK%!_>
M$5[SX@T.WNK4QW"97KQU%>2>(-*L-.N4%G(Y)/*L<T 95E:2WUTD$7WG->N^
M#_#L5G%$MS&LDI;<I<9->=>%+6:XUM'C;:L7+&O;=(M)Y;I)2A2/'WCWH U)
MM(@GA*/%$#C^X*\Q\3>!K8W32QCR9&[C[I->PM%M(&0P]:P/$%LTD1V#(QD$
MB@#P'4O#]]IF6F0-&/XDY%9F:[N_UB.VEN;/4HRF0=O&0PKA,JS,5Z9X^E '
MV]7SG\??^1[L?^P9'_Z-EKZ,KYR^/O\ R/=C_P!@R/\ ]&RT >5YP:DM]K7
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M?%O3KW5/AY>6FGVDUU<-/ 5BA0LQ E4G@>@% ':I]Q?I3J1/N+]*6@ HHHH
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M$:E7A[$^M?.NA7KZ=K=K=1G!5P#7TEX;NC/$)0<D\U49..PT[&WY4=I*\:@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\?\ VCO^2>:?_P!A6/\ ]%2U[!7C_P"T
M=_R3S3_^PK'_ .BI: /8*\0_:3M;1O#NAWCSXOHKMXH8=X^>-DR[;>IP4C&1
MP-W/45<G_:0\*K;R&WTK69)PA,:21Q(K-C@%A(2!GO@X]#7,62ZU\>_&%E?W
MNGI8>%M)<;XRQ;>3M+QAQM+.^!DC 1<'J1N .@^)7@V^U_QM#+XD\:Z=I7A-
MV0P6DU[Y4F$0;RB, A?<S#<22 XZ@!:\[T9]&\,?%GP\_@3Q-/>V%[=PVTZR
M1.DBH[JKH^Y%5U;.00.".@*ACT'Q(N+?P]\;'U?Q=H$^KZ'/#"+%7F.Q HCW
ME1]UMK>9F)L [\GA@3SGB'X@6VJ^+_"^JVFAR:7X8T6^!M;>&) '*RK)*5 "
MJ'*^7E,D X.?FR0#NYT?X>_M&QW0M/\ B6>)_P!TK*&;#RLN[!8@!O."L0"<
M(_ Y $?Q2C7QY\9/#O@F.9%@M4+W+@,KH7'F2*"003Y4:%>,9;D^G1_'WPS)
MK7@:/5+:#S+K2)?.)&XL(&&), <'!",2>@0G/7.)\!=.FUG6/$GCR\9%GO;B
M2W6*(D*&=EED.""<9,87YO[V>QH ]RK/US6;/P]H=[J]^^RUM(FE?! +8Z*N
M2 6)P ,\D@5H5Y1^T+?7%I\-8X89-D=W?Q0S#:#O0*[XYZ?,BGCT^M %#X*:
M3)K]WJ_Q#UN'S-3O[IX[5I(VQ"@'S&(L3\O/EC^Z(RN>2*]FKG/ .E)HOP_T
M&P6V>V9+*-I89 P996&^3(;D'>S<=NG%='0 4444 %%%% 'AW[1/_,M_]O7_
M +2KP\5[A^T3_P RW_V]?^TJ\/H &^[5Y<BTC] *HD<5H[=ME&#P1S7T_"G^
M^2_P_JC2%[2MV(!!("LC#"M6YI%K%=ZC:VTK%(Y'"LPZ@51GN8Y[%8T7#@YJ
MUH'EW6JVL<[!8FD 8[L8'UK[RO*3I2EM:YAE5>_,I*TCJ/B/I-CIFGV<=C$J
M@':9 .7XZFN)\-Q>=X@M8_\ ;&:]"^),VG&TM-.LIQ*T0!RIW#'U]:Y[X<:8
MEUXA+R, 5("@GDU^2UZ>(<N>JGKK=]4;24KW9;^(/AO^R[J&ZC\M8;H$HB]5
MQUS65X5T6VU%YGN7V^4/SKKOBAJ]A=RV=I:R>9):AA*1TR?0UQ>@74MM-.1P
MCC/(K]&RZ>(GED>?25OU_P CS<[A+ZMS1=I,IS"/^TIUC&$5B!4VJV^-)LY\
M8/F,IR.M1P-!-JA\URD3/\S 9('TKL_B)';IHNDQP+\JH"C[<;A@<FO-XIK<
MF&A2MO\ H>AAGRX.$3SZQ@:[U"&W49+L!7K/BO081X)BNV9E>U*HB#&#D\YK
MS'0;@6&J1WS()!'T7/\ .NF\5^,7U^UMXQ;_ &=(NH5\AOK7C9+E6,=>GB$K
M1WOY>GF;48-/G>R*_@69TUUH5("MDDGZ5L^/M106T5I"VY=_./6N;\*Q237C
MR1ML;!(/X53U>XEEU>196SM8U]?/!4JF8*NU[T4?'2PD,3G'.GHBQ?6:'P<L
M_EXD$IRV.<5S3?\ 'O7=ZMKEG?\ A!;(1>7<H H"CA@.]<;:0B>\MH6X5I%#
M9["O@<WIU_KDY58M<ST_X!]?5C)2U1W.JV%R/!VERB)S'&N78=%STS7&W$H8
M@'H#7T%?6VD0^ ))+[,MCL #1<Y;M^M?/\\:M> (/E+<5]=PO6<L*Z<E;E;_
M ,_O"K.2PS\C?O-(@E\.QW5M$0RC+''6JFC6":E;W*N2#'$6 '<UU5S?QP^$
M5MY$565< CO7+^&[];>[E4J"LX*$DXQ[UTXB5>I@:RAOK8^?X=Q%6?M8ON[%
M7P9:>=XILT(SL)->Y>,+F?3_  /<R6TC12 (H9>H!(!KR;P4UO;>+5DG81Q[
MV 9CQ73^-/B!!J6EW6CVMJ# 2N)R>>#GI7Q65Y?B*N)@U#1--W[7\SZ&E3ES
M)VT1Y?>'S)",\D]:UO#2P"_A$YDQGY=G][MGVK,@@^UR.=^T+4^GW'V2^5A\
MXB;(SWK]*Q,'.A*G'>QG1Q%.IB916X>)HV37YR?XCFLDUTOBM8YVM[U&7=(/
MF4'.*YH]:_()PE3DXR5FA--.S&FOHOX!?\B+??\ 83D_]%15\Z&OHOX _P#(
MB7W_ &$Y/_1452([CQI_R(GB'_L&7/\ Z*:OCL5]B>-/^1$\0_\ 8,N?_135
M\=B@!\(S<Q_[PKWKPZZ?88L.-RJ!BO!8<_:8\?WA7M6AJ\(CXX*@T =?;W+(
MV=V:U[:)[@;B",U0M-.26-)5.<G-=1:VH2WR>HH \D^+UMM\/@@?=<9KPU?]
M:H]Z^D?BA8?:?"]Q@<J0:^<E3%XB_P"T!0![_P" 5-KI=LQ'&T'FO4+1EE ?
M9DFO/?#3)_8ML0.B@5W.G3;$53VXH NW*>8N6' '>O#_ (P*RZ;E>%W\U[9>
M2$K@=Z\D^*UL9/#]PV/N\T >%](_PKUOX3VVR!I\?>:O(C_J@/45[C\/(?LN
MG0HWWBN: /6;)?D7GK6D6"CGM679L8D5W^[5@S>=*5'W: ,K75\VTF.,\5\L
M^(U":_= #^,\5]2ZL6CCD!/RXZU\V^.[,6_B!I$^Y)S0!SGI7I'POO'%S+ 6
M.U3D"O-QT%>E?"^Q<O+=$?*S8'X4 ?0FFM_HJ#VS6=K%G)/."!E:GTZ7"@G[
MN*O/*I3)P: ,+4,0Z.8NF5XKY6\4*4\3W8/_ #TKZ<\07H6W95Z+7S5XQ4_\
M)'(Y&-YS0!N_#.T\_P 02W&TE8QCBOI/3&CC@0 <X[UX9\(+?*WCD#[XKW6S
MC4PY- %MW!SD\5RNLX2)B#P,YKH;A_+0\]JXW69I90RY '- 'B/CQS)J2MVR
M:Y7M79>/+;9Y3@?Q<FN-[4 ?;M?.7Q]_Y'RQ_P"P9'_Z-EKZ-KYS^/O_ "/=
MC_V#(_\ T;+0!Y6?NUZ!\,+<->.YQUXS7G[=*[?P;--::?-/'(D9Z[W' ^M5
M"+G)174:5W8] T5KBPUC7++6[M9;41"1A(V4"DY_PJYI-[;>--22SM;."6WL
MFS+]H&0$Z#9[UP%GXANKMY-(FN+5([QC%+>2J254GKGTKVKP5HNCZ=HBG1YT
MN5;B2X7G<W<9]*^FS*A]5BZM5>^[<MOAVLWZOL==5*/O/<J>(;.TT?P_/!9P
MQPQ@%@$&!7RY<NTDDLC')+M7U5XOM6FTYTYP5.?RKY8NHC%)-&>JR,/UKYAR
M<G=[G'>YT7AK6FT2RFDA \^4;0Q_A&.H]Z]H^%WC9]?D;3;I,W4,>X2#HRC
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \L^+6D>//%#1>'- L;0Z#=I$UW=R2(K*X
MD)*G+9V#$;?*I/'!/(KO/"WA^W\*^%]/T.U;=':1!"^"/,<\N^"3C<Q8XSQG
M K7HH **** "BBB@ HHHH **** /#?VB?^9;_P"WK_VE7B%>W_M$_P#,M_\
M;U_[2KP\4 6[8#;(2H.!WJ:8AD^3.WL#5.*5XSE3CU'K6X;3[18+=0C='T;
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M\4 =CX<.WP?K;GT KBB>*Z[3)-G@752.-SJ*Y F@!,GUZTTDTM-- "&OH[X
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MIE>%  '8"@#<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M /1A^= &K13)IHK:"2>>5(H8E+R22,%5% R22>  .]8W_":>%?\ H9M&_P#
M^+_XJ@#<HK(3Q7X=DMWN$U_2F@3[\BWD95?J<X%1_P#"8^%]@?\ X231]IZ'
M[=%@_P#CU &W163-XI\/6YQ/KVEQ'.,/>1K_ #/O4:^,/#+N$7Q'I#.>BB^C
M)/\ X]0!M45B2>,?#$4K12>)-'21?O*U]$"/J-U/@\6^&[IREOXATF9E&2L=
M[&Q ]>#0!L45BKXP\,.2%\1Z0VWKB^B./_'JGB\1Z%/"TT.M:=)$N<NETA48
MY/(/:@#3HK%/C#PP%W'Q'I 'J;Z+_P"*IY\5^'1;?:3K^E>0#CS?MD>W/USB
M@#7HK"/C7PH!D^)]% ]?M\7_ ,54TGBKP[#!'/+K^EI#)]R1KR,*WT.>: ->
MBL7_ (3#PQC/_"1Z1CU^W1__ !533>)=!MQF?6]-B&0,O=(O49'4^G- &I16
M*?%_AD.J'Q%I =ONK]MCR?\ QZGW'BOPY:2B*YU_2H9",A9+R-2?P)H UZ*Q
M$\8^%Y)5B3Q)H[2,<*BWT1)^@W4^7Q;X;AF,,OB'28Y1U1[V,,/PS0!L45E1
M>)] G+B'7-,D,:;W"7<9VKZG!X'(Y]Z;+XJ\.P7#P3:]I<<T9VO&]Y&&4^A!
M.10!KT5C1>+O#4[E(?$.DR,!DA+V,D#_ +ZJ/_A-?"F2/^$FT;(ZC[?%_P#%
M4 ;M%8T?B_PS,CO%XBTF18_OLM[&0OU^;BFKXQ\+L"5\2:.0.N+Z+_XJ@#;H
MK*'B?0#"9AKFF&(=7^UQ[?SS4+>,?"Z(';Q)HZJ>C&^BQ_Z%0!MT5C2>+O#4
M04R>(=)0.,KNO8QD>WS4S_A,_"W_ $,NC?\ @?%_\50!N44R&:*Y@CG@E26&
M50\<B,&5U(R""."".]9MYXGT#3[I[6]US3+:YCQOAFNXT=<C(R"<C@@_C0!J
MT5D0>*O#MT7%OK^ES;!N;R[R-MH]3@\5&/&7A=E++XDT<@=2+Z+C_P >H VZ
M*R#XK\.+&LC:_I0C895C>1X(Z<'/L?RJ/_A,O"^0/^$DT?GI_IT7_P 50!MT
M5C2^+O#5O((YO$.DQN1D*][&"1Z\M1#XO\,W,PA@\1:1+*>B1WL;,?P#4 ;-
M%8W_  EWAKS6B_X2+2?,7AD^VQY'U&ZI8/$FA7(8V^M:;*%^\8[I&QWYP?8_
ME0!J45BGQ?X9 R?$>D8'?[;'_P#%4]/%7AV2!YTU_2VA3[T@O(RJ_4YXH UZ
M*PO^$U\*;=W_  D^BX]?M\7_ ,54S>*_#JVJW+:_I8MV.%E-Y'L)^N<4 :]%
M8H\8>&",CQ'I! [_ &Z+_P"*JPWB+1$MC<OK&GK -I,IND"_-G;SG'.#CUQ0
M!I45BGQAX94J#XCT@%ON@WT?/T^:GW/BKP[9LJW6O:7 S#*B6\C4GZ9- &O1
M6(OC+PN\BQKXDT=G8X51?1$GZ#=3YO%GANWF,,WB#2HY1U1[V,-^1- &Q165
M#XH\/W#,L&NZ9*R(9&"7<;%5'5C@]!ZTD_BCP];7#P7&NZ9%,GWHY+N-67Z@
MG(H UJ*QHO%OAJ=RD/B'29& R52]C) _ U'_ ,)KX4R1_P )-HV1U'V^+_XJ
M@#=HK&C\7>&9HWDB\1:2Z1_?9;V,A?K\W%-'C'PNP)7Q)HY ZD7T7_Q5 &W1
M63_PE/A[RO-_M[2_+_O_ &R/'YYJ)O&7A=%#-XDT=5/0F^B /_CU &W16-)X
MN\-0E1+XATE"PRH:]C&1ZCFF_P#"9^%O^AET?_P.B_\ BJ -NBJMAJ=AJL#3
MZ=?6UY"K;&DMY5D4-@'&5)YP1Q[U/-/%;023SRI%#$I>221@JHH&223P !WH
M ?16'_PFGA7_ *&;1O\ P/B_^*I\7B_PS/*L47B+2))&X5$O8R3]!NH V:*Q
MF\7>&DE:)O$6DB1.&0WL>1]1NIR^*O#KQ&5->TMHP<%Q>1D#OUS0!KT5B'QE
MX7'7Q)HX_P"WZ+_XJG2>+O#4*1O+XATE%D^X6O8P&^GS<T ;-%8B>,O"TDBQ
MIXET=I&. JWT1)_#=3Y/%GAN*<P2>(-*29>L;7L88?AG- &Q167!XFT&Y8K;
MZWILK @$1W<;$9^AJ(^+O#2YW>(=)&W@YO8^/_'J -FBLA/%7AV2!YTU_2VB
M3[\BWD95?J<\5#_PFWA3;N_X2?1=OK]OB_\ BJ -VBLAO%?AU+5;E]?TM;=S
MA93>1A&/L<XIG_"7^&2NX>(](V^OVV/_ .*H VJ*RY?$V@PIOEUO38TX^9[N
M,#D9'?TYJ+_A+?#7FK%_PD.D^8_W4^VQY/T&: -FBL>X\6>'+6;R;GQ!I4,O
M79)>1J?R)I(?%WAJYG$$'B'299FZ1QWL;,?P#4 ;-%8I\7^&5D:-O$6D!UZJ
M;V/(_#=5FV\0:+>?\>NL:?/AUC_=7*-\[9VKP>IP<#OB@#1HK%/B_P ,@D'Q
M%I VG!_TV/C_ ,>I5\7>&GB:5?$6DM&OWG%[&0/J=U &S16$/&OA0]/$^BG_
M +?XO_BJE?Q;X;CC61_$.DK&WW6:]C /T.:=G:X&Q16,/%WAIB /$.DDMTQ>
MQ\_^/4^7Q3X>@95FU[2XV;[H>\C!/TYI :U%8R>+O#4DWDQ^(=):7^XM[&6_
M+=3?^$S\+ D'Q+H^1U'VZ+_XJ@#;HK#_ .$S\+?]#+HW_@=%_P#%5N4 %%8?
MB'Q?H?A9[5-8NW@:Z#F%4MY)2P3;N^XIQC<O7UK&_P"%L^#/^@G<_P#@MNO_
M (W4N45NS2-&I-7C%M>AVM%<5_PMGP9_T$[G_P %MU_\;KI-$UW3?$>FC4-*
MN#/:EV3>8GC.Y3@C:P!'Y4U)/9A.E4@KSBU\C1HHHIF84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%8T^F:S)<2/%XADAC9B5C
M%I&VP>F2,FDV5%)[NQ@^//'TO@VZL88].2[^TH[$M-LV[2!Z'UKD?^%XW/\
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MF&0":ZCY\T)MLFOW;HP9&=B&!X(KM_ 2_:(9+;D"76;(%QU7)<?UK@4 1Y6
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MCA5B?#$L/-Z[2@ !T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 8NN>$]$\22PR:M9"X>!2L9\QEV@XS]TCT%97_"K_!W_ $!Q_P!_Y/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S]3UW1]$\K^UM5L;#
MSL^7]KN$BWXQG&XC.,CIZBL__A._"'_0UZ'_ .#&+_XJO-_C=8V^I^,OAU87
MD?F6MUJ#PS)N(W(TEN&&1R,@GI70WOP*\ 75I)##I4]G(V,3P7<I=.0> [,O
M/3D'K^- '?V5]::E:1W=A=075M)G9-!('1L$@X8<'D$?A5BOGG0XKSX/_&6R
M\-+J$]YH6L8$4)8DIYK;$9ER%\P/&JE@#E,X )P/0_%'QI\(^%=4?39I;J^N
MXF9)TL8@XA88X9F903SC )P00<&@#T.BN$\&?%OPSXWU-]-L#=6MX$WQQ7J*
MAF SNV;68$@#)'!QR,@'&AX-\?Z;XVN-4M[*QU&SGTQTCN8[Z)8V5F+#& Q.
M04.0<8H ZNBN0U_XC:1X=\9:7X7N[:^DOM2\KR7A1#&OF2&,;B6!'(.< \5U
M] $<\\-K;R7%Q*D,,2%Y))&"JB@9))/  '>H[&_L]3LX[RPNX+NUDSLF@D$B
M-@D'##@X((_"O(?BMJ'CS5SK^BZ1IWV'PY86GG7FI.2AN4$32,B,>JG&PA0>
M1AF"L173?!+_ ))#H7_;Q_Z/DH [#4]=TC1?*_M75;&P\W/E_:KA(M^,9QN(
MSC(_,4:9KND:UYO]E:K8W_E8\S[+<)+LSG&=I.,X/Y&O*-2^$EWK_CW5/$GC
MK6()M"CWR6Z17)C,4*OE$DR@"1A-V[:P.23G))K@5T_PUIWQJ\.1?#_4;V\C
M-^GVE8@S)$/-^=4D'+Q^7NR>1MYW-DX /J6BBB@ HHHH ^<?C\ ?'ECG_H&1
M_P#HV6O+"/ES7JGQ^_Y'NQ_[!D?_ *-EKRMONT >H_#,?OH)A+*FQ3E4;"OG
M^\._K6OXPNM$7PQ.FF:KI>HWNP_:)M0?S;R497:$88Z<CGL*X7PS<QV^FD7L
M;&PD+":1)"K( 1C ')Y]*N>%?"QU*U74?M.-K'$10'=@D=<U]1D]**IO&8BH
MTHM=K/5Z-ZN]^^VCZHXL=C*6$I<]7;^FNG_#$>@:DUK*MTD$UQ:J )!",SVN
M,9EB/1&[ G/6MOQ-J=G/X2\J&;2Y)I+L3L(@?/VE>3,>\W]XC@\UTUA:R1PY
MELH[<_<VJP;<!T/'K7GWBJQL+*6X2S=KB2:4RRRX*",EN8@.AP><UO6S*EC*
ME1THM.G;K=/U\O-;]+GDY)F;Q-:=%1LEJM5?_@E+PI=)'K[ [@/*E"A>F-IJ
M6LK3(5BUJV1D,@D.TH'V8R<=:ZGQ%8QZ;KUU9Q1^6D3 !=V['R@]?QKY+BIU
MU7I_6;\[YK>B:MZ_%N?J/!M51QE>E)/F<8ORT;_'WMC+HHHKY<_0PJ;Q/-A-
M'A+_ "M99V9[[CS4-3>(]9>73K#3H738D*^8IB&[<&/1NM?4\(0KRS%.C:R3
MO?M\NO8^ X]CS4L-I?WW_P"DO^O\A\,EY>:)$AMY#%IPVRS!?E!<\9/X56J3
M0+M5T/7(7#K+.\!"\D'!/X"HZY.)<,Z&8STLI6:WZKK?JWJ]-&[=#TN#:ZGE
M\J4594YR7K>TV_OFU\@HHHKP3ZTUO#TCQW\Q196/V>0?N^O3^59WA1$&N:=Y
M$JNS(_F$')4[3BHFA\V)MUQ+;J 3YD<9;GTX]:I^']233]26ZFM#)*I(3Y]@
MY!![<]:_2N%,*WD^(G15YRNK=[)V3OI;4_&N.:52>9U%3=W*FE;_ ,"[Z>?R
M+E%3W=I-97#07";9!C(SGK4%?FB=]4?L-*K"K352FTXM736J:[H*56*L&4X(
M.01244S0O:]J!/AZ.WU&:6XENQO@DW9$05AD-GN>V*B0W;>&M-:1B;8M)Y0;
M.X?-SG\:H^(;NVO;72[6WSYUM&ZSYSU+9'7V]*T? ;1W>OR:9=*T]O>X27DJ
M(=H+ CZGTQ7VM;+JL.&H2M9KW];+W5[1VWU]WWDK:W^[\?H9B\OS6IBZE--.
MI)/2UM>5.-[).R5WL]?YKE.BI;E%CNIHT^ZKL!] :BKXE.ZN?K\7=705:EA!
M\*:G.J#S8Y(0K@?,N6YP:JUI>)?L^G>$M-BMU(DU%2\YR3DHPQ].IKT\F<?[
M0I<U]&Y:?W4Y?H?*<9UW#+/91O><HK3LI)ROY.*9PK+M8C!!KZ(^ G_(BWW_
M &$Y/_145?/.X;6RI+'H<]*^AO@)_P B+??]A.3_ -%15ZTU&]X[?EZ_\ _.
MV=MXU_Y$/Q%_V#+G_P!%-7QSC XK['\:?\B)XA_[!ES_ .BFKXY[5(CHO!,S
MQ:ZK#[NW)'K7TAH'D3VBN5^9QDX[5\X^!UW:T>< )S7T!H<WDVZL. .!0!V4
M 0)Y9P0>QK'UG0-,ND_>0*LBG>LB\,/Q]*B746C8'."IX]ZL7EX)[(R8P<8-
M 'S3X_LDM_%-YLP S#@=N*J>#8C)K40ST.>34_C:[-QXHO0?X6 _2H?"$RPZ
M[#N[G ^M 'O]D9_LT<9Z'&"*[&UM'6#<LA5FYKG="5;F)'(VID;%_G78%P!@
M#I0!0N;577$[DGH<=Z\Z^)N@V%MHM[<QQ("UN6#].:])OVV)DCC!YKR?XH:N
MC^$I+61L2,^U,=P>U '@\P B7'KS7MOP?MU;3TDD!P,G\*\3G_U./0BO<OA.
MX&B1NQPH&,>M 'KOVJ(H%1>W&:RYY1&&W,$QT"G-:,9BFLO,1 "#6->Q L22
M2IYH R-12VO+-DE1?F[E>_K7@/C=73Q5*I_A0#([U]"W]N39$[3PN:^>?&4C
M2>)YMV>% YH Q6(')]*]F\%Z.FH:9H[S()6090MR4S_]:O%W&5Z]J]Y^&-V@
MT&U=B"(QL4>] '4'P[/;ON@BW*3P>N*Z"VTTV]E\XW,1D^E:-F^^.II6Q&?>
M@#S#Q=8SF!F5RA(()%?/^H7E[<7SQ3W#ND;8"Y^48]J^C?&LIAT^4D< &OFJ
M>3S-0F<=&D)H ]'^$:[KN]#'Y2PP*]_TD+'#L0<$]:^;?AI>M!KEQ;J?O@,/
MY5])Z=Q;Q@=^: +DLGEMN ]JPM6,-]9W$  20 LI'K6Q<AB"!P.V:YR]0JDD
MH.&Y_&@#YK\6/-_;4D$C,1%PJD_=]:Q@<J":ZCQ[ $U\S@<2CGZUS'\- 'V!
MX,_Y$7P__P!@VV_]%+7SE\8 /^%J:R?^N'_HB.OHWP9_R(OA_P#[!MM_Z*6O
MG+XP?\E4UK_MA_Z(CH XB)VCN$D0D,K @BOHOP?/<2VMJDF>5!&:\!T2S:_U
MFV@4#EP6SZ"O?SI#7OA^6Q2X^SO<((UE SMZ'../2J@DY)2=EW[>8(V_^%A>
M%+.X>.XUNWCDC8J5*/P>X^[70:9XATSQ#927&EW:7,,;;6D4$ '&<<@=B*\3
M\*VUC;QW$*[6O8YI$D\T9W*&QNY]:WO!!MX_B'>K9,3;G39#,!G:)O-7(].G
MI7L8C!8:,ZM*FIW@KW:7*_33]3Q\-FRKXR6%]FU:^OIW_0Y?XR*!KL)7E3$/
MYFO/_#<#3:U;1J=I,H&2:ZSXJ7IG\4O#GB.,<5ROAB[^R:Q;S'@^9C)[9KQ3
MV#Z-T:WAMH2=P+J.*Z!;[_0MQD/7OZ5SM@8I--5_- 9A@$D"MFSTO-J6=P_.
M#SD4 -BO&-PHCSN'/2L3QI.UQI,[%?F6-@<D>E=)::9C<RG[M<7\1Y6L="O2
M#RT9P: /G< F,<_Q$UKZ-<32ZU:R2RNS^8H+,<FLF/\ U0JWI\A2]@<':1(.
M?QH ^G]*$QLH9"YV8'WAS6K9>4;DK(0ZN.&(Z>U<WIET38Q$'(*BM6USYRR>
MIZGK0!T4T21P +T]17!^*[]+&PNHYF!A:%E^89 R*[UR9K;  ^8=:\I^*MO(
M="N'CY(0@^XH \2T;<=<M8XI659)"A*G&5STKZA\)Q!+-(UC56"X,F?O5\KZ
M1*(-3L92<!91DU]4^%KE);5/+_U:# /O0!TKLD$1>0C@=ZYBYU+[1<F- =HY
M9L<'VK4NHY;N7:6.T=AUJG+;K#E(TP0.30!X_P#$:QA:":=XEWKAE;O7D[ ;
M^*]C^)UY&NGO&57<Q %>.M]\4 :GAS_D9]/PN[,G3\*^B-&TO^TX06^ZG0=C
M]:^;M.N6L]7M;A>J2"OI/PC=.\ 1>AH ZNUTY;.':N Y&#MKF)_&/AF6\.FM
MK$7VPR^2D01\E\XV],9SQ6KXHM[R]\)ZI;6@)NI+9TA56 )8CCFO'(]2TJPT
M2:S"L;L(R3 HQ97VX8[L>OH:]7+\!#$P<FFW>UHVT\W?IZ'!C\;+"QBXTW.[
MZ=/S#XHV\,<!D7(8D;L^M>4ITKT?68KJY\"^9?\ R;2IM"V,M#@8)[YZ]>:\
MX7I7!B*/L:LJ3=[/='<G=)GT7\!/^1%O?^PE)_Z*BKM_&G_(B>(?^P9<_P#H
MIJXCX"?\B+??]A.3_P!%15VWC7_D0_$7_8,N?_135B,^0(=GER)MS)*0 2Q4
M)@Y]<'\:[34EECO6@F+$PJL8W8X4#CH ,5R^AS"'6;*3:683 8"[N/8#G/N*
MZG5)4GU6YEB "-(< =/PKAS2JW&$$M-?Z_%_AL?4\'4XO'5)6U4?S:V^[^M2
MG1117CGZ0%;WAJ2.-KF1X99#$H=/(3+DY^Z.V3TP:P:VM!4P+=ZD[LD-K'N)
MP=N>QST&.O-:T)<M2-^NGWZ?KUT[Z'SW%48RR>OS.VB:MO=--+YNR^90-S9W
M$NKR6]Q<K&SQ[;6=/N2#(8Y&1P!]3DU4JZP:'3)XW9-TEYYG"?ZSY>9 P^4@
MD]!TQ]:I5UYJX/%R4-E;\E_7;L<O!=)T\IC=WNW^&G;RZW?F%%%%>>?5CD,:
MEC*K,@5N%.#G!QW'>N6F9G@7S.9027D+$E\XZY]*Z^S\K[1NFC#QJC,03@<*
M<'/L<5R,OF#/G!A*>6#CG)&>17L9:X^S::UOOY>7IU]4?G/&#_VV"O\ 9VOY
MOIY_IY'1V:01Z/8K"Y=VC,DIR?E8G&W'L /SI]5M,O6NM)MXG'-OF-2% ^7J
M!QR3R>OK5FN'&JU>7]>A]7PZ[Y92]'Y]7Z!3D1I'5$4L['"JHR2?2FU);@&Y
MB!;8"X^;=C'/7/:N1^1[,Y*$7)]#&U_RQK,B1JB>6BHP5-OS#KGDY/O5R&\@
MN+F*VM%$<:Q%F5LC# <XR3G/K[UF:G/]IU>ZF(5 TA V\CCC\<^M6=%D5)+M
M-N6D11UZ8.:^BJ03P[<^D?QMV]3\HR?$5O[0@Z'VY*^U[7N]?3>V_0TZ***^
M>/UD*GLH8KB_MX9X4FCDD",C#@@G']:@J2&1(9#)(<*JL<XS@X./QS50YN9<
MKL^YRXZ$9X6I&2NG%Z?(RWT=+?6#;SRHUO'*RRI\VZ% Q 5AP?3IGZUH851M
M0$(.%!["H;)_LJVMP-B2W7R/=&8EPI!WYW<;B._Y5,6C<EX1)Y3'*>8NUMO;
M([<5[N<PE3C"FX[;OSMM^!\#P+4A*M63D^:RLO)-W?K?3^KA1117@'Z0'>L_
MQ(8KG7)+FUB8)<!2,9.YL -@GKSV[=*T5 9U4NJ G!9C@#W/M63K32?VO/ON
M+>4J1A[4C8>.V.,^M>KEBUD_3^OZ_4^%XT46Z&NOO?=I^MC+=2K%6!# X(/!
M%?;E?$;9W<YR>N:^W*]%GQ!Y_P".G\OQEX</_3G?#_QZVJI]J]Z=\1V*>+/#
M9'_/I??^A6]8OG-7P^?T7/&7\D?(YUCG1Q7)Y(V/M7O6U\-VW:#?MZZI=?\
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MP]O)0Y^=7[?IN=5K'BBRT2[2VN8KAW:,2 QJI&"2.Y'I6?\ \+ TK_GWO?\
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MLD,PF0='"E<_@:BKY_F<_>;NV??8/#4L+AX4**M"*22[)+0*?"ADGC0$ LP
M)Z=:95O39V@OX6148LP7#J".2/6D]C2M*4*<I1W29EZY;+::O>6TWEFXB8 2
M0<KT!ZFMKP':W0U**=+6^$<A.)%C^1\ CD^U5O&6FS)XLD>9 D4S;@5(Z #C
MBM*;7W@BDL])5[2QP!&A;=(G<_/UY.?SK]$S;-*6%RFE0C34W.%E+H_<BF_7
M56M?2ZNC\3P>78[B*DU1M%RUFW]F[=^5=[IZ?CL95SG[7-GKO;^=14I)8DDD
MD\DFDK\[1^W4X\L%'L3V2AKZW5E# RJ"IZ'GI5[XCI*DUG&MJL%O$'5!$#L
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M^P^7\*]9^%1=[5$+?()3M&?:O)7YAS[5[1\-;4VNG6K$<N-W3'6@#V6S 54
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M>1OO+6D$UON90 5"94#'8*RKSSE3]3V58EAX5T[38+^&V,RQWL?E."X.U0&
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MG\NPP !5VLZ]15)W6QI1ING"SW"BBBL34**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KA-3^$GAG6O'#>*M2%U<W+NCO:2.IMV*($7*[<D?*#@M@GKD<5W=
M% !1110 4444 %%%% !1110 4444 ?.7Q]_Y'NQ_[!D?_HV6N2\.:6-7L9X[
M:&(WT;J5+N0&3^(?C7;_ !NTZYU/XBV,%LFYO[+C+$G 4>;+R37*Z#I.IZ#J
M0N5-O-&PVN(I@2/?!QFNC"XJIAJBJ4]T)I-68GB"U-M#:SII<>E&0,8H8V8M
MP<'(<Y'_ ->M>R\87FFZ%92W,<TGG,X+RQ;8VP?X6[XSSZ5OW5Y'=ZA:"Z6T
M8(K%HYX@[,,?PD]/>JFCW&FZ#<KHEYI,NN7;D&-696B7=\W[M''RD@\GOBOK
ML-F=/%X?V<X<THW=KZVUZO:VE]?^!S8W+:&/BE4C>WX+M?L8OVR6\273-4L)
MX;J0&XTU(8V9GE?E<@]B">>:U?!FFW=C+=QZC97]K?R(YMY9K<JF>,<GCK[5
M>O=!NM0\07VIZO=?8O)L4:SNX<QI;.,;00O.5&0<>E9_B;QEJT-[I%GDQPQV
M\:?:I?F$YS@R^NT@9P>:G&1>9X66"PS2]HM7?9VOIW\UN8U<OIT<,U0BKIWU
MO9M:V?EY&-K,U])J4T>H3B:>)V1F7&"<\XQ6?78:_I\;Z1%>?8WFN9D607D!
M"Q-D\G;UYKCZ_(U&-.4J2:?*[:;:=C]HR#%PQ67TZL::IW7PJUEZ6[[]^X44
M451[(444^((9D$APA8;CZ#O03*7+%R[#**Z^6RT34X(;"RO+=;I ?+(4[F[G
M<<<\"L.^T&_L=[20,8E_Y:#H:Z*^#KT%%U8VND_D]OZ^X^9RGB_+,Q;AS>RF
MG;EG[LGK963WOM9:IZ&9116A8:+>:C%)+!$3&@/S>K#M]:PC&4OA5SZ#$XNA
MA:?M<1-0CW;27XF?16PFE-IUG)?ZE:321QN$\B-@K$G^+/3 JI?:S::O'#]E
MLEM_)!#LJ@;\]^/I77#+\5/"RQD8?NXNS?GMHNNO];GC4N),)B,?#!85^TO>
M\HM-1LKV\[^12HHHKC/H0HHHH V["\TR;2Y;36%DF"D>0H7A1U/(([XK$J>T
MM)[ZY6"WC+R-T ]N36K)X5U-G4V,)O;>3_53Q#"OCKC/H<C\*JIB9<BC4F^6
M.UWHK].RO:_=V?;3PL-ALMRW&UI0FHSK6DXW26FETNE[Z]WKW,.BG.C1NR.I
M#*<$'L:;4GNWN%%.CC>618XU+.Q"J!W)K0GL/[&WR:Q#)'L.%@SAG/L?;(K2
MA1J8BM&A25Y2V1YV99KA<MHNKB)6[+JWV2ZO_AW9%;Q=-)%X>T:Q>[<RQ&7S
M+1U ,&2"/?GKS7J_P$_Y$6^_["<G_HJ*O!=9U2;5]1EN[AE,CD9*C'0 ?TKW
MKX!_\B+??]A.3_T5%7T;PGU/_9KWY='ZWO*WES-V^]ZGY)7Q%3$5)5JMKR=]
M-E?HO3:_7<[?QK_R(GB+_L&7/_HIJ^.T!8A1U)QS7V)XT_Y$3Q#_ -@RY_\
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M6Q(^[G\:X7X@Z?%IWBV0Q *LP$A4=CWKT/X774,^B>5D>9'(010!WEI'F[9
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M;);!11106%6K-#=DV+R-Y$N28R<*S8XS^74$55J3 CL;N[:62,01\>6,L6/
M'L/4GM6V'YO:QY=[]#R<\C1EEU95K6L]^_V?G>UO,Y691YKD1B)=QPN[(&.V
M>]?;-?$K!A&K$#8^=OMCKCTK[:KZ6KR\WNJR/R..QY[X]('C'PX6.!]COO\
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M_'32 J:KXQU34[SSXYWAC#915/'X^M20-=^)I5:6\'VY& &\!55>Q]QFN7!
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M?WHN/Q/6_,FMULFM;63O8^3Q'-C9RJXSWIMWOMMM:VJ2V77<ZZ?Q=!JE\O\
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M5-I?*X52IIUI=>$M!TJZ@\13ZU:22VT#K+' (YOM$J(9D>- VXO)YF69]P+
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M0/'\TRHP)9)27)QA@!SD$E>G>+QI?V>J>*?"U_KT5W%HMUI\4[QQL652Q)8
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M^_1'/4JS@[Z?JSZ$HHHKE.D**** "BBB@ HHHH **** "BBB@ HHHH ****
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M&:^A_P#A0GA;_H(:S_W^B_\ C='_  H;PM_S_P"L?]_HO_C=(#YZ'J379^(
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M1ED>:0R2LTDAZLYR36M_PAOBG_H6M8_\ 9?_ (FE_P"$.\4_]"UK'_@#+_\
M$T 9MG=2V=S%+#(R,KCH?>NM^(<KK<6, =O+>,N03WK&3P;XH,B9\-ZOC<.3
M8R^O^[74>._#7B"\U*S^RZ%JDZ1V^"T=I(P!STX% 'GT<C12*Z'#J<@UZ#!J
MME<:!;:AJ&T_9I1+%&&!<,IZ#V/I7*_\(=XI_P"A;UC_ , 9?_B:/^$.\4_]
M"UK'_@#+_P#$T 4]6U*35-3FNY'=O,;(WGD#TJEFMG_A#?%/_0MZQ_X R_\
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M3K8:!J32QR$M']EDWCD_PXR!4RC&HTY:N.U^GH*46VFO^'_IZGG^:,X-;/\
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M  D?AZZTG[1]G\_9^]V;]NUPW3(STQUKCXOAMKT$*0P^/-2CBC4*B(CA5 X
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\WT?XN6
MFK>(+73SI;V]O<S>5'.\VY@6X3*!3R3M'7 SUP*[/Q'K<?AS0+K5I87F6 +B
M-" 69F"CD]!EAD]AG@]* -6BLCPQKG_"1^'K75A;_9_/W_NM^_;M=EZX&?N^
ME:] !1110 4444 %%0WEW!864]Y<OLM[>-I97P3M51DG Y/ [5SWASQBGB+0
M-1U>+3KA8[2:1$@C(DEF54## X&XA@-N3SW- '3T5C>&=9O-<TZ6YOM'N-+E
M28QB&?.6 53NY5>.2.G:MF@ HHHH **** "BBB@ HHHH ***H:UJ]IH.D7&I
MWI<6\"@L$7<Q)(  'J20.>.>2!S0!?HK'\+ZX?$GARUU8VPMC/OS$)-^W:[+
M][ S]WTK8H **** "BN0T#QQ_;?B_4M .G>0;+SL3>?NWB.0)]W:,9SGJ<5U
M] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 445A:QXQT'0+U;/4[_R+AHQ*$\F1LJ20
M#E5(ZJ?RH W:*Y+_ (69X0_Z"_\ Y+3?_$5TFGZA::I80WUC.L]M,NZ.1>X_
MF"#P0>000: +-%%% !115:_O[32[&:]OIT@MH5W/(YX'8?4DX  Y)( H LT5
ME)XCTA_#[:\+U1I@5F,[*R\!BIX(R3D8 QDG&,YI;OQ'I%AHL.L75ZD5C.J-
M%(RME]PRN%QN)QSC&< GL: -2BH;6ZAO;."[MWWP3QK+&^"-RL,@X//0U-0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<6+$\D^;^G?->FURWP[TW^S/ VFJR0B2X0W+M$/O[SN4L<#+!"@/TQT KJ:
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M@93MD*C&&;^$]^*R_@_I>G1Z!/J<6V6_DF:&5S&085&TB,$\$'AB1UR <[:
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M0)CC.?G88'7/TKU2O)?$(BUOXX:59QN\+V0A$CL@(8Q[KC YZ$$+GL<\''(
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M,8(0^5^8%TR0=PP1[BM6]USQEI/C'P[HESJ"W,EPL37:V]NC!P9W#'[@( C
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MDGJM !J>I?$[P_I<.KZC=0FV1P9XBD!*?.%57V@9#$C[A)P>2IH^(?BV/6?
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MP'LE ''^#_\ D8?$_P#U]_\ L\E'Q'_Y%ZW_ .OM?_0'H\'_ /(P^)_^OO\
M]GDH^(__ "+UO_U]K_Z ] '85P?Q.@MGL;&62;$ZNZ+%N'S(P&YL=3@JHST&
M[GJ*LS?$G2UAD,-I>/*%)17"JI/8$@G ]\'Z5BV_VSXB:S'//#'#I=F=CJK%
M@,X+IN&"6; ]-HP>OW@#TVBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.UG0
MM-\06B6FJ6WVB!)!*J[V7# $9RI!Z$UHT4 06=I!I]C;V5JGEV]O&L429)VJ
MHP!D\G@=ZQX_!/AR/63JXTQ#?&8S^8\CL/,))W;22N<G(XX.,8P*WZ* ,O6_
M#FD^(HH8M5LUN%A8M&=S(RDC!Y4@X/<=#@>@JAI_@/PQI=ZMW:Z1$)TP4:5W
MEVD$$, Y(# @8(Y'K71T4 >:?$_5&T^\LEU#P[::EH[QD"60M'(LN22BRJ<I
MD*AZ?, 1S@XX:6UTKQ9X@M='\*:-+8Q.X::>1_-?9P"Y#$[%7+<!L/E<\[0/
MH2B@#(U3PMHFLV=M:7VG1/!:\0(A,?EC&,+M(PN,<=.!Z"LM?AKX13?C1U.]
M=IW3RG R#QEN#QU&#C(Z$YZNB@#"N_!N@7^F6>G7=@9K:SS]G#S2%XP>JA]V
M[;T^7..%XX&*TWP^\*W&GPV,FDI]GA+LBK+(IR^-Q)#98G:HR2<  #@5TU%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>TEM2^UA&'5E;&01D<_*,'/KP<\:GAGP_;>&=#ATVW;S-A+2S% IE<]6./P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 445A>*]2UC3-+A;0M.%]?37"0A64E8P<DLP&..,9) &X$GC!%J!NT5P>
ME>*/%4?C&QT7Q!I-I!%>PLZ20!N"$WGYMS!BI!4KQR0<XQNSK[QQXLL+"?6)
M]*LK?34OO(2WO(Y(+EX_O @,V"=O&5W8()VX!JN5BYD>FT445(PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>gaz3apgusshz000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gaz3apgusshz000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .' MP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'NF^'2L<VYI&Z;35/P+H-SH]BL$LLC #'S&LK5OAZMYK2WUS<NT2/N(;H!0
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MX=2M([F$_(XR.:M5Y]\+Y+A]%A\W<5V<$FO0:!!1110 4444 %%%% !1110
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M6WO-&\T6#F'0PQP1A(QA1VJGJ.C6.JKMNX@X%6MYI-YHL%S%M?!6A6<HDAM
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M4F>:,U9F*33:":2@!:,TE% AU)1FC- "4444 %%%% #A1F@4N*!BYHI.]&:
M#/%)FES24 %(:6B@!M%*:2@ I:** %H[T9HS0 M&:3-+Q0 N:*2B@!:*,TE
M"T4E+0 4444@"BBBF 4444@"BBBF 444E "T444@"BDHI@+24"B@ HHI* "C
M-)10 N:6FTM "T9I,T9H =13<TN: %HI,TM(!:4&FTM QXJ0=*C%2#I292!C
MM1F]!FOGWXL:HVK:U:VD#=#M(%>Z:Q>I8:?+*YP-I'Z5\IZEJTTGBF2Y&&\N
M8E<TAGT/\-M)73_"EL&7$@ZG\!7,?&#0_MD O%7_ %2=:YJS^+&KV=NL,<<6
MT?Y]*J:Y\3-4UC3)K2:*+;(N"1_^J@9TGP;UWS0FFEN(TSC\*]GKY3^'FKG1
MO$?F,V-P"U]2V<GG6<,O]Y :!,GHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ IK_=IU-?[M %4]:2E/6DJS(**** "BBB@ HHHH **** "
MBBB@!12YYIM+WH 6B@THH&)1124 )WI:2B@04M)10 M%)10 M)110,6EI**
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M8+V)?WC2<G'N*I_!G6C%!+:2M\S/@"@9[;1110(**** "BBB@ HHHH ****
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MK<'B*SFX:9%->67LCB=U/4&J2_:!)E35QA='K5,IIVO<]OAO[>7[DJGZ5:#
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M%>Z:/C^SH\5CB%9(RQ/0TZ***Y#C"BBB@ HHHH **** "BBB@ HHHH ****
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MZ***@YPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&YWN0Q]ZM1PK@!3^%4E'>K]FFYQ[4V$U97- X@L\FL/*^8S8ZFM+4I@%,0/
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M!O+'S >E9NEV5ZLG[[U]*5DU<YDDXFV LH^90:K30JIPM:"VD@ .*BFMGSD
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M<-(J_4XI&N(5^]-&,^K"@"2BF++&_P!R16^AS7&^./&<7AV+R@Q\UU^4J>E
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M6*_09KS[4/#?B^]TOR;K6[<V[H,J7'3\ZV/"OA6]T71[AGN8Y5\A@-A!_A-
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MM=710!X#!H'BW1XFL[.SD>'/#%C75>"/!5]!>27FHR3H['=M+G%>J44 (!@
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M4KC!%6J* /"[SX>ZG8>)OMVGQ2%#+N(!(%>RZ0]R]BOVI-D@&,5?HH ****
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MT+??\Y.,5J$9!'J*QI-!1[Y+A6 VG-)W$K&U12#@8I: "BC%+B@!*2EQ010
ME+3:*!!WI<TE!H 6N6\7VOFVKR8X KJ*S]9A$VFR+MSF@TI2M-,XGP9<O!>R
M(Q^7H*]%!R ?:O*SFWU")4;RSO&?>O3K8DVZ$_W10:8F-I7+%)FDHH.<7-&:
M2BF M%)10 M+2"B@!:*** %HHHH+0HZBK2?=JJ/O"K2?=J66.HHHJ0"BBB@
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M7/Z+X?32+\+"NU,YKJS5.]NDLXC*0,BFFTK%1?0N9"CD@?C0)$/1U_.N&O\
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M,!UKQ;0-,MUFA9C\Q->VZ.BIIL:KTKGK-=#'$RDTKFI1117.<84444 %%%%
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M(]*GTV/[+*QE&!V)KJ[ QW*>;@'''2E.5B(IR>I4;31<01B3'R>M6(HX[>/
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M=K=*@6RAC)*CK0:QY.77<MA@1Q2U"I51C-2@\4&;%I:;2T"%I*2ES0 444M
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M2.XC/"EC7L&D'.G1G->/QVVVZ@8#A#7KFA.'TJ)A6-4RK>9KT445@<X4444
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MSQMG/I5OR8+N,@X)QSS2);):P!4&,>E%T5RMOR*#2LJNC+UI;"X0,(L]*MO
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M6C,T7S'FI'4@EJMAM[;_ &B/;O*_2L2#2IK:XW++(XSGDU;U.\E3*Q9S["L
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M8=\FL<Z[>@>48AFO6KNW2X7##([UAW.A:?NW")0U6IKJ=-.H[F+82-+ K2*
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M=Q*6&<U[%I)']GQX-*I<X<2TTC1HHHK,XPHHHH **** "BBB@ HHHH ****
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/T@A$:C %%%(4IRENS__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>27
<FILENAME>caba-20201231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Instance Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-15T17:02:46.7673149+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : b469dc7abe284c828e6850b36ac62ee6 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:caba="http://www.cabalettabio.com/20201231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="caba-20201231.xsd" />
  <xbrli:unit id="U_xbrlishares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD_xbrlishares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlipure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_cabaSegment">
    <xbrli:measure>caba:Segment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_cabaFaculty">
    <xbrli:measure>caba:Faculty</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="C_0001759138_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_20210310">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-10</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_20191015_20191016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-15</xbrli:startDate>
      <xbrli:endDate>2019-10-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_20191016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191028_20191029">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-28</xbrli:startDate>
      <xbrli:endDate>2019-10-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191029">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191101_20191130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2019-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_cabaLaboratoryEquipmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">caba:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapRelatedPartyTransactionAxis_cabaProfessionalServicesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">caba:ProfessionalServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapRelatedPartyTransactionAxis_cabaProfessionalServicesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">caba:ProfessionalServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateNoteSecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateNoteSecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapInvestmentTypeAxis_us-gaapCorporateNoteSecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapSupplyCommitmentAxis_cabaLicenseAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapSupplyCommitmentAxis_cabaLicenseAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapSupplyCommitmentAxis_cabaLicenseAgreementMember_20200501_20200531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-05-01</xbrli:startDate>
      <xbrli:endDate>2020-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_cabaRegentsOfUniversityOfCaliforniaMember_us-gaapSupplyCommitmentAxis_cabaSponsoredResearchAgreementsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:SponsoredResearchAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">caba:RegentsOfUniversityOfCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_cabaRegentsOfUniversityOfCaliforniaMember_us-gaapSupplyCommitmentAxis_cabaSponsoredResearchAgreementsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:SponsoredResearchAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">caba:RegentsOfUniversityOfCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_cabaRegentsOfUniversityOfCaliforniaMember_us-gaapSupplyCommitmentAxis_cabaSponsoredResearchAgreementsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:SponsoredResearchAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">caba:RegentsOfUniversityOfCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_cabaRegentsOfUniversityOfCaliforniaMember_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapSupplyCommitmentAxis_cabaSponsoredResearchAgreementsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:SponsoredResearchAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">caba:RegentsOfUniversityOfCaliforniaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_cabaRegentsOfUniversityOfCaliforniaMember_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapSupplyCommitmentAxis_cabaSponsoredResearchAgreementsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:SponsoredResearchAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">caba:RegentsOfUniversityOfCaliforniaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_cabaRegentsOfUniversityOfCaliforniaMember_us-gaapBalanceSheetLocationAxis_cabaAccruedAndOtherCurrentLiabilitiesMember_us-gaapSupplyCommitmentAxis_cabaSponsoredResearchAgreementsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:SponsoredResearchAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">caba:RegentsOfUniversityOfCaliforniaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">caba:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapSupplyCommitmentAxis_cabaMasterTranslationalResearchServicesAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:MasterTranslationalResearchServicesAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapSupplyCommitmentAxis_cabaMasterTranslationalResearchServicesAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:MasterTranslationalResearchServicesAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapSupplyCommitmentAxis_cabaSubscriptionAndTechnologyTransferAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:SubscriptionAndTechnologyTransferAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapSupplyCommitmentAxis_cabaSubscriptionAndTechnologyTransferAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:SubscriptionAndTechnologyTransferAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapSupplyCommitmentAxis_cabaOperatingLeaseAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:OperatingLeaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapSupplyCommitmentAxis_cabaOperatingLeaseAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:OperatingLeaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_cabaSeriesA1PreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:SeriesA1PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_cabaSeriesA2PreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:SeriesA2PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_cabaSeriesA2PreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:SeriesA2PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_cabaSeriesA1PreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:SeriesA1PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_20190131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20190131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_cabaSeriesA2PreferredStockMember_20190101_20190131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:SeriesA2PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_20190101_20190131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_20191001_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-01</xbrli:startDate>
      <xbrli:endDate>2019-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_20200831">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapPlanNameAxis_cabaAtTheMarketOfferingSalesAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:AtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_20180501_20180531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_srtTitleOfIndividualAxis_cabaFoundersMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">caba:FoundersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_srtTitleOfIndividualAxis_cabaFoundersMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">caba:FoundersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_srtTitleOfIndividualAxis_cabaFoundersMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">caba:FoundersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_srtTitleOfIndividualAxis_cabaFoundersMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">caba:FoundersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandEighteenStockOptionAndGrantPlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandEighteenStockOptionAndGrantPlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandEighteenStockOptionAndGrantPlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandEighteenStockOptionAndGrantPlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20191023">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20200101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20191021_20191023">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-21</xbrli:startDate>
      <xbrli:endDate>2019-10-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_srtRangeAxis_srtMinimumMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_srtRangeAxis_srtMinimumMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_srtRangeAxis_srtMaximumMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_srtRangeAxis_srtMaximumMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_srtTitleOfIndividualAxis_cabaFoundersMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">caba:FoundersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_srtTitleOfIndividualAxis_cabaFoundersMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">caba:FoundersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapPlanNameAxis_cabaTwoThousandNineteenEmployeeStockPurchasePlanMember_20191023">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapPlanNameAxis_cabaTwoThousandNineteenEmployeeStockPurchasePlanMember_20200101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenEmployeeStockPurchasePlanMember_20191023">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenEmployeeStockPurchasePlanMember_20191021_20191023">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-21</xbrli:startDate>
      <xbrli:endDate>2019-10-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenEmployeeStockPurchasePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapPlanNameAxis_cabaTwoThousandNineteenEmployeeStockPurchasePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapIncomeTaxAuthorityAxis_cabaFederalMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">caba:FederalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapIncomeTaxAuthorityAxis_cabaFederalMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">caba:FederalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cabaNonVestedCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">caba:NonVestedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cabaNonVestedCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">caba:NonVestedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_srtCounterpartyNameAxis_cabaWuXiAdvancedTherapiesMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSupplyCommitmentAxis_cabaDevelopmentAndManufacturingServicesAgreementMember_20210131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">caba:WuXiAdvancedTherapiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001759138_srtCounterpartyNameAxis_cabaChildrenSHospitalOfPhiladelphiaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSupplyCommitmentAxis_cabaResearchServiceAgreementMember_20210201_20210228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:ResearchServiceAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">caba:ChildrenSHospitalOfPhiladelphiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-02-01</xbrli:startDate>
      <xbrli:endDate>2021-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <dei:DocumentType id="F_000000" contextRef="C_0001759138_20200101_20201231">10-K</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001759138_20200101_20201231">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001759138_20200101_20201231">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000003" contextRef="C_0001759138_20200101_20201231">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="F_000004" contextRef="C_0001759138_20200101_20201231">FY</dei:DocumentFiscalPeriodFocus>
  <dei:TradingSymbol id="F_000005" contextRef="C_0001759138_20200101_20201231">CABA</dei:TradingSymbol>
  <dei:EntityRegistrantName id="F_000006" contextRef="C_0001759138_20200101_20201231">CABALETTA BIO, INC.</dei:EntityRegistrantName>
  <dei:EntityCurrentReportingStatus id="F_000007" contextRef="C_0001759138_20200101_20201231">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityCentralIndexKey id="F_000008" contextRef="C_0001759138_20200101_20201231">0001759138</dei:EntityCentralIndexKey>
  <dei:EntityVoluntaryFilers id="F_000009" contextRef="C_0001759138_20200101_20201231">No</dei:EntityVoluntaryFilers>
  <dei:CurrentFiscalYearEndDate id="F_000010" contextRef="C_0001759138_20200101_20201231">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory id="F_000011" contextRef="C_0001759138_20200101_20201231">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityWellKnownSeasonedIssuer id="F_000012" contextRef="C_0001759138_20200101_20201231">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityShellCompany id="F_000013" contextRef="C_0001759138_20200101_20201231">false</dei:EntityShellCompany>
  <dei:EntitySmallBusiness id="F_000014" contextRef="C_0001759138_20200101_20201231">true</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany id="F_000015" contextRef="C_0001759138_20200101_20201231">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod id="F_000016" contextRef="C_0001759138_20200101_20201231">false</dei:EntityExTransitionPeriod>
  <dei:IcfrAuditorAttestationFlag id="F_000017" contextRef="C_0001759138_20200101_20201231">false</dei:IcfrAuditorAttestationFlag>
  <dei:EntityCommonStockSharesOutstanding id="F_000018" contextRef="C_0001759138_20210310" decimals="INF" unitRef="U_xbrlishares">24062775</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityPublicFloat id="F_000019" contextRef="C_0001759138_20200630" decimals="-6" unitRef="U_iso4217USD">214000000</dei:EntityPublicFloat>
  <dei:EntityFileNumber id="F_000020" contextRef="C_0001759138_20200101_20201231">001-39103</dei:EntityFileNumber>
  <dei:EntityTaxIdentificationNumber id="F_000021" contextRef="C_0001759138_20200101_20201231">82-1685768</dei:EntityTaxIdentificationNumber>
  <dei:EntityAddressAddressLine1 id="F_000022" contextRef="C_0001759138_20200101_20201231">2929 Arch Street</dei:EntityAddressAddressLine1>
  <dei:EntityAddressAddressLine2 id="F_000023" contextRef="C_0001759138_20200101_20201231">Suite 600</dei:EntityAddressAddressLine2>
  <dei:EntityAddressCityOrTown id="F_000024" contextRef="C_0001759138_20200101_20201231">Philadelphia</dei:EntityAddressCityOrTown>
  <dei:EntityAddressStateOrProvince id="F_000025" contextRef="C_0001759138_20200101_20201231">PA</dei:EntityAddressStateOrProvince>
  <dei:EntityAddressPostalZipCode id="F_000026" contextRef="C_0001759138_20200101_20201231">19104</dei:EntityAddressPostalZipCode>
  <dei:CityAreaCode id="F_000027" contextRef="C_0001759138_20200101_20201231">267</dei:CityAreaCode>
  <dei:LocalPhoneNumber id="F_000028" contextRef="C_0001759138_20200101_20201231">759-3100</dei:LocalPhoneNumber>
  <dei:EntityInteractiveDataCurrent id="F_000029" contextRef="C_0001759138_20200101_20201231">Yes</dei:EntityInteractiveDataCurrent>
  <dei:Security12bTitle id="F_000030" contextRef="C_0001759138_20200101_20201231">Common Stock, par value $0.00001 per share</dei:Security12bTitle>
  <dei:SecurityExchangeName id="F_000031" contextRef="C_0001759138_20200101_20201231">NASDAQ</dei:SecurityExchangeName>
  <dei:EntityIncorporationStateCountryCode id="F_000032" contextRef="C_0001759138_20200101_20201231">DE</dei:EntityIncorporationStateCountryCode>
  <dei:DocumentAnnualReport id="F_000033" contextRef="C_0001759138_20200101_20201231">true</dei:DocumentAnnualReport>
  <dei:DocumentTransitionReport id="F_000034" contextRef="C_0001759138_20200101_20201231">false</dei:DocumentTransitionReport>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000035" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">101429000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000036" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">136204000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ShortTermInvestments id="F_000037" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">7233000</us-gaap:ShortTermInvestments>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000038" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">4873000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000039" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">4348000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000040" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">113535000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000041" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">140552000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000042" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">890000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000043" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">815000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OtherAssetsNoncurrent id="F_000044" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">299000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000045" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">101000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="F_000046" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">114724000</us-gaap:Assets>
  <us-gaap:Assets id="F_000047" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">141468000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000048" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">1243000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000049" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">920000</us-gaap:AccountsPayableCurrent>
  <caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent id="F_000050" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">3937000</caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
  <caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent id="F_000051" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">2227000</caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000052" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">5180000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000053" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">3147000</us-gaap:LiabilitiesCurrent>
  <us-gaap:CommitmentsAndContingencies id="F_000054" xsi:nil="true" contextRef="C_0001759138_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000055" xsi:nil="true" contextRef="C_0001759138_20191231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000056" xsi:nil="true" contextRef="C_0001759138_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000057" xsi:nil="true" contextRef="C_0001759138_20191231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockValue id="F_000058" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000059" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000060" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">175836000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000061" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">171280000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000062" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000063" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">-66298000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000064" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">-32959000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000065" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">109544000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000066" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">138321000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000067" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">114724000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000068" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">141468000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000069" contextRef="C_0001759138_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000070" contextRef="C_0001759138_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000071" contextRef="C_0001759138_20201231" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000072" contextRef="C_0001759138_20191231" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="F_000073" contextRef="C_0001759138_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000074" contextRef="C_0001759138_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000075" contextRef="C_0001759138_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000076" contextRef="C_0001759138_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000077" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000078" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000079" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000080" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000081" contextRef="C_0001759138_20201231" decimals="INF" unitRef="U_xbrlishares">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000082" contextRef="C_0001759138_20191231" decimals="INF" unitRef="U_xbrlishares">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000083" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">143590481</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000084" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">143590481</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000085" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">6409519</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000086" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">6409519</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000087" contextRef="C_0001759138_20201231" decimals="INF" unitRef="U_xbrlishares">24062775</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000088" contextRef="C_0001759138_20191231" decimals="INF" unitRef="U_xbrlishares">24034022</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000089" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">19387160</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000090" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">17624503</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000091" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">4675615</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000092" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">6409519</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000093" contextRef="C_0001759138_20201231" decimals="INF" unitRef="U_xbrlishares">24062775</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000094" contextRef="C_0001759138_20191231" decimals="INF" unitRef="U_xbrlishares">24034022</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000095" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">19387160</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000096" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">17624503</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000097" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">4675615</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000098" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">6409519</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000099" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">21376000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000100" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">11671000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000101" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">12457000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000102" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">7012000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000103" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">33833000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000104" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">18683000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000105" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-33833000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000106" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-18683000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InvestmentIncomeInterest id="F_000107" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">494000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="F_000108" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1740000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NetIncomeLoss id="F_000109" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-33339000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000110" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-16943000</us-gaap:NetIncomeLoss>
  <us-gaap:Dividends id="F_000111" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">5326000</us-gaap:Dividends>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000112" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-33339000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000113" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-22269000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="F_000114" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000115" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-33333000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000116" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-22269000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000117" contextRef="C_0001759138_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-1.44</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000118" contextRef="C_0001759138_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-4.07</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000119" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">12393047</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000120" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">43921000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:CommonStockSharesOutstanding id="F_000121" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">3848320</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000122" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" unitRef="U_iso4217USD">1762000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000123" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" unitRef="U_iso4217USD">-12452000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000124" contextRef="C_0001759138_20181231" decimals="-3" unitRef="U_iso4217USD">-10690000</us-gaap:StockholdersEquity>
  <caba:TemporaryEquityStockIssuedDuringPeriodShareNewIssues id="F_000125" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">6963788</caba:TemporaryEquityStockIssuedDuringPeriodShareNewIssues>
  <caba:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesNetOfIssuanceCosts id="F_000126" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">48707000</caba:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesNetOfIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000127" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">7275501</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000128" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">71020000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000129" contextRef="C_0001759138_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">71020000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <caba:StockIssuedDuringPeriodShareStockOptionsExercised id="F_000130" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">5667</caba:StockIssuedDuringPeriodShareStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000131" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000132" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:ReclassificationsOfTemporaryToPermanentEquity id="F_000133" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">5326000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
  <us-gaap:ReclassificationsOfTemporaryToPermanentEquity id="F_000134" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-1762000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
  <us-gaap:ReclassificationsOfTemporaryToPermanentEquity id="F_000135" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-3564000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
  <us-gaap:ReclassificationsOfTemporaryToPermanentEquity id="F_000136" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-5326000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
  <caba:TemporaryEquityStockConvertedIntoCommonStock id="F_000137" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-19356835</caba:TemporaryEquityStockConvertedIntoCommonStock>
  <caba:TemporaryEquityConvertedIntoCommonStockValue id="F_000138" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-97954000</caba:TemporaryEquityConvertedIntoCommonStockValue>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits id="F_000139" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">12904534</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits id="F_000140" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">97954000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits id="F_000141" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">97954000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000142" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000143" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000144" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-16943000</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockSharesOutstanding id="F_000145" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">24034022</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000146" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" unitRef="U_iso4217USD">171280000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000147" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" unitRef="U_iso4217USD">-32959000</us-gaap:StockholdersEquity>
  <caba:StockIssuedDuringPeriodShareStockOptionsExercised id="F_000148" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">25611</caba:StockIssuedDuringPeriodShareStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000149" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">139000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000150" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">139000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="F_000151" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">3142</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000152" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">29000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000153" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">29000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss id="F_000154" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
  <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss id="F_000155" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000156" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">4388000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000157" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">4388000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000158" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-33339000</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockSharesOutstanding id="F_000159" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">24062775</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000160" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" unitRef="U_iso4217USD">175836000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000161" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20201231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000162" contextRef="C_0001759138_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" unitRef="U_iso4217USD">-66298000</us-gaap:StockholdersEquity>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000163" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1293000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000164" contextRef="C_0001759138_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3408000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PreferredStockConversionBasis id="F_000165" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231">1.5 for 1 basis</us-gaap:PreferredStockConversionBasis>
  <us-gaap:ProfitLoss id="F_000166" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-33339000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000167" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-16943000</us-gaap:ProfitLoss>
  <us-gaap:ShareBasedCompensation id="F_000168" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">4388000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000169" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2300000</us-gaap:ShareBasedCompensation>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="F_000170" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-119000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:Depreciation id="F_000171" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">354000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="F_000172" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">104000</us-gaap:Depreciation>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000173" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">524000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000174" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3372000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="F_000175" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">198000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="F_000176" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">101000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000177" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">555000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000178" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">246000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities id="F_000179" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1875000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities id="F_000180" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1721000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000181" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-26770000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000182" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-16045000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000183" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">635000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000184" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">693000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt id="F_000185" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">11097000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities id="F_000186" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3751000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000187" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-7981000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000188" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-693000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000189" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-192000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000190" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">71212000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000191" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">50000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000192" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1293000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000193" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">139000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000194" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans id="F_000195" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">29000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000196" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-24000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000197" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">119925000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="F_000198" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-34775000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="F_000199" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">103187000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000200" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">136204000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000201" contextRef="C_0001759138_20181231" decimals="-3" unitRef="U_iso4217USD">33017000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000202" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">101429000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:ConversionOfStockAmountConverted1 id="F_000203" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">97954000</us-gaap:ConversionOfStockAmountConverted1>
  <caba:ExchangeOfConvertiblePreferredStockIncludingDeemedDividend id="F_000204" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">10090000</caba:ExchangeOfConvertiblePreferredStockIncludingDeemedDividend>
  <caba:DeferredOfferingCostsInAccountsPayableAndAccruedAndOtherCurrentLiabilities id="F_000205" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">192000</caba:DeferredOfferingCostsInAccountsPayableAndAccruedAndOtherCurrentLiabilities>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000206" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">20000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000207" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">226000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <dei:DocumentsIncorporatedByReferenceTextBlock id="F_000208" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/p&gt;
&lt;p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;Part III of this Annual Report on Form 10-K incorporates by reference certain information from the registrant&amp;#8217;s definitive Proxy Statement for its 2021 annual meeting of shareholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&amp;#8217;s fiscal year end of December&amp;#160;31, 2020. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part of this Form&amp;#160;10-K.&lt;/font&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock id="F_000209" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. Basis of Presentation &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cabaletta Bio, Inc. (the Company or Cabaletta) was incorporated in April 2017 in the State of Delaware as Tycho Therapeutics, Inc. and, in August 2018, changed its name to Cabaletta Bio, Inc. The Company is headquartered in Philadelphia, Pennsylvania. Cabaletta is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principal operations commenced in April 2018, when the Company executed two sponsored research agreements with the Trustees of the University of Pennsylvania (Penn). &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 16, 2019, the Company effected a 1-for-1.5 reverse split of the Company&amp;#8217;s issued and outstanding shares of common stock, par value $0.00001 per share (Common Stock). Upon the effectiveness of the reverse stock split: (i) all shares of outstanding Common Stock were adjusted; (ii) the conversion price of the Series A convertible preferred stock (Series A Preferred), Series A-1 convertible preferred stock (Series A-1 Preferred), Series A-2 convertible preferred stock (Series A-2 Preferred) and Series B convertible preferred stock (Series B Preferred; collectively, the Preferred Shares) was adjusted; (iii) the number of shares of Common Stock for which each outstanding option to purchase Common Stock is exercisable was adjusted; and (iv) the exercise price of each outstanding option to purchase Common Stock was adjusted. All of the outstanding Common Stock share numbers (including shares of Common Stock subject to the Company&amp;#8217;s options and as converted for the outstanding convertible preferred stock shares), share prices, exercise prices and per share amounts contained in the financial statements have been retroactively adjusted in the financial statements to reflect this reverse stock split for all periods presented. The par value per share and the authorized number of shares of Common Stock and convertible preferred stock were not adjusted as a result of the reverse stock split.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 29, 2019, the Company completed its initial public offering (IPO) of 6,800,000&amp;#160;shares of Common Stock at an offering price of $11.00 per share. The Company received net proceeds of $66,156 after deducting underwriting discounts, commissions and estimated offering expenses. In connection with the IPO, the Company&amp;#8217;s outstanding shares of convertible preferred stock were automatically converted into 12,904,534 shares of Common Stock. In November 2019, the underwriters partially exercised their option and purchased an additional 475,501 shares of Common Stock resulting in net proceeds to the Company of $4,864, after deducting underwriting discounts and commissions. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Risks and Uncertainties &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company does not expect to generate revenue from sales of engineered T cell therapies for B cell-mediated autoimmune diseases or any other revenue unless and until the Company completes preclinical and clinical development and obtains regulatory approval for one or more product candidates. If the Company seeks to obtain regulatory approval for any of its product candidates, the Company expects to incur significant commercialization expenses. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. As a result, the Company is unable to predict the timing or amount of increased expenses or when or if the Company will be able to achieve or maintain profitability. Further, the Company is currently dependent on University of Pennsylvania (Penn) for much of its preclinical research, clinical research and development activities and initial manufacturing activities (Note 6). Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. Even if the Company is able to generate revenues from the sale of its product candidates, if approved, it may not become profitable. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then it may be unable to continue its operations at planned levels and be forced to reduce its operations.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, a novel strain of coronavirus surfaced in Wuhan, China and has since reached multiple other regions and countries.&amp;#160;The COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures, which have delayed the commencement of non-COVID-19-related clinical trials, among other restrictions. The Company&amp;#8217;s financial results for the year ended December 31, 2020 were not significantly impacted by COVID-19, however, &lt;font style="color:#000000;"&gt;the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic, including &lt;/font&gt;new information that may emerge concerning the severity of COVID-19, the impact of new strains of the virus, the effectiveness and availability of vaccines and the actions to contain COVID-19 or treat its impact &lt;font style="color:#000000;"&gt;will have on its financial condition, operations, and business plans, including its ability to raise additional capital, the timing and enrollment of patients in its ongoing and&amp;#160;planned clinical trials, future financings and other expected milestones of its product candidates.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Liquidity &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has sustained annual operating losses since inception and expects to continue to generate operating losses for the foreseeable future. The Company&amp;#8217;s ultimate success depends on the outcome of its research and development activities. The Company had cash and cash equivalents and investments of $108,662 as of December&amp;#160;31, 2020. Through December&amp;#160;31, 2020, the Company has incurred an accumulated deficit of $66,298. Management expects to incur additional losses in the future as it continues its research and development and will need to raise additional capital to fully implement its business plan and to fund its operations. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company intends to raise such additional capital through a combination of equity offerings, debt financings, government funding arrangements, strategic alliances or other sources. However, if such financing is not available at adequate levels and on a timely basis, or such agreements are not available on favorable terms, or at all, as and when needed, the Company will need to reevaluate its operating plan and may be required to delay or discontinue the development of one or more of its product candidates or operational initiatives. The Company expects that its cash, cash equivalents and investments as of December&amp;#160;31, 2020 will be sufficient to fund its projected operations for at least 12 months from the date the Company&amp;#8217;s Annual Report on Form 10-K is filed with the Securities and Exchange Commission (SEC).&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="F_000210" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. Summary of Significant Accounting Policies &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, stock-based compensation and the valuation allowance on the Company&amp;#8217;s deferred tax assets. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Off-Balance Sheet Risk and Concentrations of Credit Risk &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, which are primarily invested in U.S. treasury-based money market funds, and available-for-sale debt securities, which are invested in investment grade corporate bonds with&amp;#160;&lt;font style="Background-color:#FFFFFF;color:#212529;"&gt;high credit quality issuers&lt;/font&gt;.&amp;#160;These investments have maturities in 2021. A portion of the Company&amp;#8217;s cash is maintained at a federally insured financial institution. The deposits held at this institution are in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held.&amp;#160; The cash in this account is swept daily into U.S. treasury-based and U.S. government-based money market funds. The Company has no off&amp;#8209;balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Investments&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments are available-for-sale and carried at estimated fair value. The Company&amp;#8217;s valuations of available-for-sale debt securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than, twelve months from the balance sheet date are classified as current.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors including the severity and duration of the unrealized loss as well as the Company&amp;#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or if more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other-than-temporary, if any, on available-for-sale securities are included in interest and other income, net. The cost of investments sold is based on the specific-identification method. Interest income on investments as well as amortization of discount or premium is included in interest income.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property, Plant and Equipment &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying statements of operations. Expenditures for normal, recurring or periodic repairs and maintenance related to property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful lives for property and equipment are as follows:&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Three years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Three years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Three years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Lesser of estimated useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value Measurement &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&amp;#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&amp;#8212;Inputs (other than quoted prices included in Level&amp;#160;1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;3&amp;#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs include costs incurred for internal and external research and development activities and are expensed as incurred in the accompanying statements of operations. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to entities that conduct certain research and development activities on the Company&amp;#8217;s behalf. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers, which include activities under agreements with Penn (Note 6), the conduct of sponsored research, preclinical studies and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided and includes these costs in accrued and other current liabilities and prepaid expenses and other current assets in the accompanying balance sheets and within research and development expense in the accompanying statements of operations. Non-refundable advance payments made for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as expense as the goods are received or the related services are rendered.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with service providers. The Company makes significant judgments and estimates in determining the accrued liabilities and prepaid expenses in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities and prepaid expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-based Compensation &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures its stock-based awards granted to employees and non-employees based on the estimated fair values of the awards on the respective grant dates. The Company uses the Black-Scholes option-pricing model (Black-Scholes) to estimate the fair value of its stock-based awards. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company accounts for forfeitures of stock option awards as they occur. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the Company&amp;#8217;s IPO, the assumptions used in the Company&apos;s Black-Scholes option-pricing model represented management&apos;s best estimates and involve a number of variables, uncertainties and assumptions and the application of management&apos;s judgment, as they are inherently subjective.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities, which relate primarily to the carrying amount of the Company&amp;#8217;s property and equipment and its net operating loss carryforwards, are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the two-class method required for participating securities. The Company has voting and non-voting common stock. The rights, including the liquidation and dividend rights, of the holders of the voting and non-voting common stock are identical, except with respect to voting. Each share of non-voting common stock may be converted at any time into one share of voting common stock at the option of its holder by providing written notice to the Company, subject to the limitations provided for in the amended and restated certificate of incorporation. The Company also considers its unvested shares of common stock held by the Company&amp;#8217;s founders and, prior to its conversion to common stock, its convertible preferred stock to be participating securities as, in the event a dividend is paid on common stock, the holders of convertible preferred stock and unvested shares of common stock would be entitled to receive dividends on a basis consistent with the common stockholders. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock, which excludes unvested shares of common stock. The undistributed loss for each year is allocated to common stockholders based on the contractual participation rights of the voting and non-voting common stock as if the losses for the year had been distributed. As the liquidation and dividend rights are identical, the undistributed losses are allocated on a proportionate basis. Net loss attributable to common stockholders for the year ended December 31, 2019 is calculated by adjusting the net loss of the Company for the deemed dividend associated with the exchange of Series A-2 Preferred for Series B Preferred. Diluted net loss per share attributable to common stockholders is computed under the if-converted method and assumes that all non-voting common stock has been converted to common stock. Since the Company was in a loss position for all periods presented, the effects of the other potentially dilutive securities are antidilutive. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segments &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&amp;#8217;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has one reportable segment. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Related Party Transactions &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company engaged a firm controlled by a former executive (until February 2019) of the Company for professional services related to accounting, finance and other administrative functions. For the years ended December 31, 2020 and 2019, the costs incurred under this arrangement totaled $311 and $601, respectively. These amounts were recorded as general and administrative expense in the accompanying statements of operations. As of December&amp;#160;31, 2020 and 2019, amounts owed under this arrangement totaled $13&amp;#160;and $36, respectively, and are included in accounts payable in the accompanying balance sheets.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Emerging Growth Company Status &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS&amp;#160;Act). Under the JOBS&amp;#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&amp;#160;Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&amp;#160;is no longer an emerging growth company or (ii)&amp;#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS&amp;#160;Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the Financial Accounting Standards Board (FASB) issued ASU 2016-02, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt; (Topic 842), with guidance regarding the accounting for and disclosure of leases. The update requires lessees to recognize the liabilities related all leases, including operating leases, with a term greater than 12 months on the balance sheet. This update also requires lessees and lessors to disclose key information about their leasing transactions. This guidance will be effective for public companies for annual and interim periods beginning after December&amp;#160;15, 2018. For all other entities, including Emerging Growth Companies, this standard is effective for annual reporting periods beginning after December&amp;#160;15, 2020, and interim periods within annual periods beginning after December&amp;#160;15, 2021. Early adoption is permitted. As an Emerging Growth Company, the Company expects to adopt Topic 842 for its annual period ending December 31, 2021 and has not yet finalized the assessment of the impact that ASU 2016-02 will have on its financial statements or financial statement disclosures. &lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000211" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. Fair Value Measurements &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&amp;#160;December 31, 2020 and 2019, the Company&amp;#8217;s financial instruments included cash and cash equivalents, available-for-sale debt securities, accounts payable and accrued expenses. The carrying amounts for cash and cash equivalents, accounts payable and accrued expenses reported in the Company&amp;#8217;s financial statements for these instruments approximate their respective fair values because of the short-term nature of these instruments.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables present information about the Company&amp;#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prices in&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Active Markets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;for Identical&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets (Level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Observable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unobservable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;101,429&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;101,429&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,233&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,233&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108,662&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;101,429&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,233&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted Prices in Active Markets for Identical Assets (Level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant Other Observable Inputs (Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant Unobservable Inputs (Level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;136,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;136,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;136,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;136,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level 1. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs. There were no transfers of assets between the fair value measurement levels during the years ended December 31, 2020 or 2019.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For debt securities classified as available-for-sale investments, the Company records unrealized gains or losses resulting from changes in fair value between measurement dates as a component of other comprehensive income. The Company did not hold any available-for-sale securities as of December 31, 2019.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Included in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;101,429&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;101,429&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds - due in one year or less&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Included in short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,227&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,233&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.18%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108,656&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108,662&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="F_000212" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. Property, Plant and Equipment&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property plant and equipment consists of the following:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;961&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;544&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;277&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;277&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property, plant and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,348&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;919&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(458&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;890&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;815&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense was $354 and $104 for the years ended December 31, 2020 and 2019, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock id="F_000213" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. Accrued and Other Current Liabilities &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued and other current liabilities consist of the following: &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,294&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;231&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;297&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,445&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,522&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;177&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,937&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,227&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <caba:CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock id="F_000214" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. &lt;font style="color:#000000;"&gt;Collaborations, Licensing Agreements&lt;/font&gt; and other Agreements&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Amended and Restated License Agreement with the Trustees of the University of Pennsylvania and Children&amp;#8217;s Hospital of Philadelphia&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the Company entered into a license agreement with Penn, as amended and restated in July 2019 to include CHOP as a party, and as amended in May 2020 (the License Agreement) pursuant to which the Company obtained (a)&amp;#160;a non-exclusive, non-sublicensable worldwide license to certain of Penn&amp;#8217;s intellectual property to conduct research, product development, clinical trials, cell manufacturing and other activities, and (b)&amp;#160;an exclusive, worldwide, royalty-bearing right and license, with a right to sublicense, on a target-by-target basis, under certain of Penn&amp;#8217;s intellectual property to make, use, sell, offer for sale, import, and otherwise commercialize products for the treatment of autoimmune and alloimmune diseases.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unless earlier terminated, the License Agreement expires on the expiration or abandonment or other termination of the last valid claim in Penn&amp;#8217;s intellectual property licensed by the Company. The Company may terminate the License Agreement at any time for convenience upon 60 days written notice. In the event of an uncured, material breach, Penn may terminate the License Agreement upon 60 days written notice.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the License Agreement, the Company was obligated to pay $2,000 annually for three years beginning August 2018 for funding to the laboratories of each of Drs.&amp;#160;Milone and Payne (see&amp;#160;&lt;font style="font-style:italic;"&gt;Sponsored Research Agreements&lt;/font&gt;). During the term of the License Agreement until the first commercial sale of the first product, the Company is obligated to pay Penn a non-refundable, non-creditable annual license maintenance fee of $10. In May 2020, the Company paid Penn an additional, non-refundable, non-creditable license fee of $33 under the amended License Agreement. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is required to pay certain milestone payments upon the achievement of specified clinical and commercial milestones. Milestone payments are reduced by a certain percentage for the second product that achieves a milestone, by an additional percentage for the third product that achieves a milestone, and so on, for each subsequent product that achieves a milestone. In the event that the Company is able to successfully develop and launch multiple products under the License Agreement, total milestone payments could be approximately $21,000. Penn is also eligible to receive tiered royalties at percentage rates in the low single-digits, subject to an annual minimum royalty, on annual worldwide net sales of any products that are commercialized by the Company or its sublicensees that contain or incorporate, or are covered by, the intellectual property licensed by the Company. To the extent the Company sublicenses its license rights under the License Agreement, Penn would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits. There were no amounts due under the License Agreement as of December 31, 2020.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;font style="font-weight:bold;font-style:italic;"&gt;Sponsored Research Agreements &lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has sponsored research agreements with two faculty members at Penn, who are also scientific co-founders of the Company and members of the Company&amp;#8217;s scientific advisory board. &lt;font style="color:#000000;"&gt;In May 2020, one of the agreements was amended to&lt;/font&gt;&lt;font style="Background-color:#FFFFFF;color:#000000;"&gt;&amp;#160;expand the scope of sponsored research.&amp;#160;In August 2020, this agreement was further amended to extend the term of the original research plan.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the amended agreements, the Company has committed to funding a defined research plan through February 2023. The total estimated cost of $11,781 under the agreements satisfies the Company&amp;#8217;s annual obligation under the License Agreement (see&amp;#160;&lt;font style="font-style:italic;"&gt;Amended and Restated License Agreement&lt;/font&gt;&amp;#160;&lt;font style="font-style:italic;"&gt;with the Trustees of the University of Pennsylvania&lt;/font&gt;&amp;#160;above). &lt;font style="color:#000000;"&gt;As of December 31, 2020, $7,090 of cost has been incurred pursuant to these agreements. For the years ended December&amp;#160;31, 2020 and 2019, the Company recognized research and development expense of $2,995 and $2,137, respectively, related to these agreements in the accompanying statements of operations. As of December 31, 2020 and 2019, $1,851 and $1,588 respectively, of advance payments are included in Prepaid expenses and other current assets in the accompanying balance sheets &lt;/font&gt;and there was $217 included in Accrued and other current liabilities in the accompanying balance sheets as of December 31, 2020.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Master Translational Research Services Agreement &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;I&lt;font style="color:#000000;"&gt;n October 2018, the Company entered into a services agreement (the Services Agreement) with Penn for additional research and development services from various laboratories within Penn. The research and development activities are detailed in separately executed Penn organization-specific addenda. In May 2020, the Company amended its Addendum with the Center for Advanced Retinal and Ocular Therapeutics (CAROT) to expand access to vector manufacturing.&lt;/font&gt; &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expense related to executed addenda under the master translational research service agreement with Penn recognized in the accompanying statements of operations for the years ended December 31, 2020 and 2019 was $2,474 and $2,355, respectively. The Company may incur additional expenses up to $1,360 through the remaining term of the CAROT Amended Addendum.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:5.94%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Subscription and Technology Transfer Agreement&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2019, the Company entered into a subscription and technology transfer agreement pursuant to which the Company owed Penn an upfront subscription fee, which was paid in 2019, and a nominal non-refundable royalty on the net sales of products, a portion of which will be credited toward milestone payments and royalties, respectively, under the Amended License Agreement.&amp;#160;Technology transfer activities will be at the Company&amp;#8217;s cost and subject to agreement as to the technology to be transferred. Under this agreement, the Company recognized $250 of research and development expense for the year ended December 31, 2019. No expense was recognized under this agreement for the year ended December 31, 2020.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6.73%;font-weight:bold;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6.73%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Collaboration and License Agreement&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2020, the Company entered into a collaboration and license agreement with Artisan Bio, Inc. (Artisan), wherein the Company and Artisan agreed to collaborate to potentially enhance certain pipeline products of the Company at specific targets using Artisan&amp;#8217;s gene editing and engineering technology.&amp;#160;If the Artisan technology is applied to any of the Company&amp;#8217;s products, the Company will be responsible for the development, manufacturing, and commercialization of any such products. Under the terms of the agreement, the Company was required to pay Artisan a nominal upfront fee, as well as costs associated with research and development activities. Artisan is eligible to receive future research, development&amp;#160;and regulatory milestones, and is also eligible to receive sales milestones and tiered royalties on net sales of products that incorporate the Artisan technology. The Company can terminate the agreement at will upon advance written notice with payment of a nominal cancellation fee.&lt;/p&gt;</caba:CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="F_000215" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. Commitments and Contingencies &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Operating Lease Agreement &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2019, the Company entered into an operating lease agreement for new office space in Philadelphia, Pennsylvania. The lease term commenced in May 2019 and will expire in July 2022. The initial annual base rent is $261, and such amount will increase by 2% annually on each anniversary of the commencement date. The Company records rent expense on a straight-line basis over the lease term. Rent expense related to this lease agreement recognized in the accompanying statement of operations was $266 and $178 for the years ended December 31, 2020 and 2019.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the future minimum payments for operating leases are as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;268&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;426&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:5.94%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Other Purchase Commitments&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the normal course of business, the Company enters into various purchase commitments with third-party contract manufacturers for the manufacture and processing of its product candidates and related raw materials, contracts with contract research organizations for clinical trials and agreements with vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Indemnification &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into certain types of contracts that contingently requires the Company to indemnify various parties against claims from third parties. These contracts primarily relate to (i)&amp;#160;the Company&amp;#8217;s bylaws, under which the Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their relationship, (ii)&amp;#160;contracts under which the Company must indemnify directors and certain officers and consultants for liabilities arising out of their relationship, (iii)&amp;#160;contracts under which the Company may be required to indemnify partners against certain claims, including claims from third parties asserting, among other things, infringement of their intellectual property rights, and (iv)&amp;#160;procurement, consulting, or license agreements under which the Company may be required to indemnify vendors, consultants or licensors for certain claims, including claims that may be brought against them arising from the Company&amp;#8217;s acts or omissions with respect to the supplied products, technology or services. From time to time, the Company may receive indemnification claims under these contracts in the normal course of business. In addition, under these contracts, the Company may have to modify the accused infringing intellectual property and/or refund amounts received. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or settlement, may cause a material adverse effect on the Company&amp;#8217;s future business, operating results or financial condition. It is not possible to determine the maximum potential amount under these contracts due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:PreferredStockTextBlock id="F_000216" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. Convertible Preferred Stock &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;Preferred Stock&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;Preferred Stock&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has 10,000,000 shares of authorized preferred stock as of December 31, 2020, none of which is issued or outstanding. The preferred stock is not redeemable and does not have a stated voting, dividend or liquidation preference.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;Convertible Preferred Stock&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has issued Series A Preferred, Series A-1 Preferred, Series A-2 Preferred, and Series B Preferred of Convertible Preferred Stock. The Company classified Convertible Preferred Stock outside of stockholders&amp;#8217; equity (deficit) because the shares contained deemed liquidation rights that were a contingent redemption feature not solely within the control of the Company.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="right"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A Preferred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A-1 Preferred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A-2 Preferred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B Preferred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total Convertible&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&amp;#8212;December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,146,551&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,575&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,372,719&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,994&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,873,777&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,352&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,393,047&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,921&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,963,788&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,963,788&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exchange, including&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; deemed dividend&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,405,332&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,764&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,405,332&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,090&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,326&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,293&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,293&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion to common&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,146,551&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,575&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,372,719&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24,994&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(468,445&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,588&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,369,120&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(58,797&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,356,835&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(97,954&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&amp;#8212;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2019, the Company&amp;#8217;s certificate of incorporation was amended to increase the authorized shares of Convertible Preferred Stock to 20,762,168 shares, and the Company issued 6,963,788 shares of Series B Preferred, resulting in gross proceeds of $50,000. In connection, the Company issued a further 1,405,332 shares of Series B Preferred in exchange for 1,405,332 shares of Series A-2 Preferred. The Company determined the terms of the Series&amp;#160;B Preferred to be materially, qualitatively different than the terms of the&amp;#160;Series&amp;#160;A-2&amp;#160;Preferred and, as such, applied extinguishment accounting with respect to the&amp;#160;Series&amp;#160;A-2&amp;#160;Preferred received in the exchange resulting in removal of the carrying amount of the&amp;#160;Series&amp;#160;A-2&amp;#160;Preferred received ($4,764), the addition of the Series&amp;#160;B Preferred issued at fair value determined with reference to the contemporaneous issuance of Series&amp;#160;B Preferred ($10,090) and the difference ($5,326) determined to be a deemed dividend recorded to additional&amp;#160;paid-in&amp;#160;capital (to the extent of&amp;#160;paid-in&amp;#160;capital) and accumulated deficit within stockholders&amp;#8217; deficit on the balance sheet. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The shares of Convertible Preferred Stock had various rights, including voting and dividend rights, preferences and privileges, including optional and mandatory conversion rights. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2019, the Convertible Preferred Stock was converted into 12,904,534 shares of Common Stock. Certain holders of the Company&amp;#8217;s Convertible Preferred Stock elected to have such shares convert into 6,409,519 shares of non-voting Common Stock following the closing of the Company&amp;#8217;s IPO. The non-voting shares of Common Stock have the same rights and preferences as the Common Stock but are non-voting. &lt;font style="color:#000000;"&gt;No&lt;/font&gt; Convertible Preferred Stock was outstanding as of December 31, 2020 or 2019.&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
  <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock id="F_000217" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;9. Common Stock &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Common Stock &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the Company&amp;#8217;s Third Amended and Restated Certificate of Incorporation filed in October 2019, the Company is authorized to issue 143,590,481 shares of voting common stock and 6,409,519 shares of non-voting common stock. Holders of voting common &lt;font style="color:#000000;"&gt;stock&lt;/font&gt; shall have the exclusive right to vote for the election of directors of the Company and on all other matters requiring stockholder action. &lt;font style="color:#000000;"&gt;Each share of the Company&amp;#8217;s non-voting common stock may be converted at any time into one share of common stock at the option of its holder by providing written notice to the Company, subject to the limitations provided for in the amended and restated certificate of incorporation. In August 2020, 1,733,904 shares of non-voting common stock were converted to voting common stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;At-The-Market Offering Sales Agreement &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On&amp;#160;November 10, 2020, the Company filed a Shelf Registration Statement in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, the Company&amp;#8217;s&amp;#160;common stock, debt securities or other equity securities&amp;#160;in one or more offerings.&amp;#160;The Company also simultaneously entered into a Sales Agreement with Cowen and Company, LLC, to provide for the offering, issuance and sale of up to an aggregate amount of $75.0 million of the Company&amp;#8217;s common stock from time to time in &amp;#8220;at-the-market&amp;#8221; offerings under the Shelf Registration Statement and subject to the limitations thereof.&amp;#160;No shares have been sold under the Sales Agreement as of December 31, 2020.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Share-based Payment Awards&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2018, several of the Company&amp;#8217;s founders agreed to modify their shares of common stock outstanding to include vesting provisions that require continued service to the Company in order to vest in those shares. As such, the 2,904,000 modified shares of common stock became compensatory upon such modification. The fair value of the awards on the modification date was determined to be $0.74 per share of common stock, based on the issuance of convertible notes in May 2018, considering the maximum conversion price and the seniority of the notes. The total compensation cost resulting from the modification was $2,126. The total compensation cost is being recognized over the three-year vesting term attendant to the founders&amp;#8217; common shares. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December 31, 2020, the Company recognized $495 and $177 of this amount in research and development expense and general and administrative expense, respectively. During the year ended December 31, 2019, the Company recognized $529 and $177 of this amount in research and development expense and general and administrative expense, respectively.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;font style="font-weight:bold;font-style:italic;font-size:10pt;"&gt;2018 Stock Option and Grant Plan &lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2018, the Company adopted the 2018 stock option and grant plan (the 2018 Plan), which provided for the Company to sell or issue common stock, or other stock-based awards, to employees, members of the board of directors and consultants of the Company. The Company generally granted stock-based awards with service conditions only (service-based awards), although there was one grant with performance conditions. As of December 31, 2020, there are no unvested options with performance conditions. Stock options granted under the 2018 Plan generally vest over three to four years. There were 1,959,411&amp;#160;options granted under the 2018 Plan prior to the Company&amp;#8217;s IPO in October 2019. No further grants may be made under the 2018 Plan subsequent to the IPO. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:5.94%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;2019 Stock Option and Incentive Plan&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2019 Stock Option and Incentive Plan (2019 Plan) was approved by the Company&amp;#8217;s board of directors on October 14, 2019, and became effective on October 23, 2019. The 2019 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&amp;#8217;s officers, employees, directors and consultants. The number of shares initially reserved for issuance under the 2019 Plan was 2,342,288, &lt;font style="color:#000000;"&gt;which will be increased &lt;/font&gt;each January 1 thereafter by 4% of the number of shares of the Company&amp;#8217;s common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company&amp;#8217;s board of directors or compensation committee of the board of directors. On January 1, 2&lt;font style="color:#000000;"&gt;021, the total number of shares under the 2019 Plan was increased by&amp;#160;962,511&amp;#160;shares. As of December 31, 2020, there were 2,314,303 shares remaining available for issuance.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the stock option activity is presented below: &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;971,353&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,051&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,340,839&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.97&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,667&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(176,893&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,129,632&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,844&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;813,172&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.03&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25,611&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.44&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;183&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,714&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,900,479&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,303&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,068,675&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.04&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,059&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic value of options granted is calculated as the difference between the exercise price of the options and the estimated fair value of the Company&amp;#8217;s common stock. The weighted average grant-date fair value of stock options granted during the year ended December&amp;#160;31, 2020 and 2019 was $8.31 and $5.24, respectively. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each award is estimated using Black-Scholes based on the following assumptions: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.28%&amp;#8212;1.48%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.39%&amp;#8212;2.59%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.7&amp;#8212;6.1 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.3&amp;#8212;6.1 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70%&amp;#8212;79%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70%&amp;#8212;76%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include: &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Fair value of common stock&lt;font style="font-style:normal;"&gt;&amp;#8212;Prior to the Company&amp;#8217;s IPO in October 2019, the fair value of the Company&amp;#8217;s common stock underlying stock-based awards was estimated on each grant date by the Company&amp;#8217;s board of directors. In order to determine the fair value of the Company&amp;#8217;s common stock underlying stock-based awards, the Company&amp;#8217;s board of directors considered, among other things, a valuation of the Company&amp;#8217;s common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice Guide,&lt;/font&gt;&amp;#160;Valuation of Privately-Held-Company Equity Securities Issued as Compensation&lt;font style="font-style:normal;"&gt;. &lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected term&lt;font style="font-style:normal;"&gt;&amp;#8212;The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method, which is&lt;/font&gt;&lt;font style="color:#000000;font-style:normal;"&gt; the midpoint between the vesting period and the contractual term of the option.&lt;/font&gt; &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;font style="font-style:normal;"&gt;&amp;#8212;As a privately held company prior to the Company&amp;#8217;s IPO in October 2019, the Company has limited trading history for its common stock and, as such, the expected volatility is estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock-based awards. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. &lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;font style="font-style:normal;"&gt;&amp;#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of a stock-based award. &lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend&lt;font style="font-style:normal;"&gt;&amp;#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero. &lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-based Compensation &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has recorded stock-based compensation in the accompanying statements of operations as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,989&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,304&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,399&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;996&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.76%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,388&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,300&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020, there was $9,809 of unrecognized compensation cost related to unvested option awards, &lt;font style="color:#000000;"&gt;which is expected to be recognized over a weighted-average period of 2.8 years&lt;/font&gt;. As of December&amp;#160;31, 2020, there was $239 of unrecognized compensation cost related to unvested founder stock awards, which is expected to be recognized over a weighted-average period of 0.3 years. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:5.94%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;2019 Employee Stock Purchase Plan&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2019 Employee Stock Purchase Plan (2019 ESPP) was approved by the Company&amp;#8217;s board of directors on October&amp;#160;14, 2019, and became effective on October 23, 2019. A total of 234,229 shares of common stock were initially reserved for issuance under the 2019 ESPP, and will be increased each January 1 thereafter through January 1, 2029 by the least of (i) 234,229 shares of common stock, (ii) 1% of the number of shares of the Company&amp;#8217;s common stock outstanding on the immediately preceding December 31 or (iii) such lesser number of shares determined by the 2019 ESPP&amp;#8217;s administrator. On January 1, 2021, &lt;font style="color:#000000;"&gt;the total number of shares under the 2019 ESPP was increased by&amp;#160;234,229&amp;#160;shares.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee contributions&amp;#160;are&amp;#160;made through payroll deductions of up to 15% of eligible compensation over the offering period. A participant may not accrue rights to purchase more than $25&amp;#160;worth of the Company&amp;#8217;s common stock for each calendar year in which such right is outstanding.&amp;#160;At the end of each offering period, shares of the Company&amp;#8217;s common stock may be purchased at 85% of the lesser of the Company&amp;#8217;s common stock on (i) the first trading day of the relevant offering period and (ii) the last trading day of the relevant offering period.&amp;#160;The first offering period commenced on July&amp;#160;1, 2020 and ended on November&amp;#160;30, 2020. Thereafter, offerings will be six months in duration and will commence on each December 1 and June 1. The Company recognized stock-based compensation expense of $18 during the year ended December 31, 2020 related to the 2019 ESPP.&lt;/p&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000218" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;10. Income Taxes &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reconciliation of federal statutory income tax rate to the Company&amp;#8217;s effective income tax rate is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected income tax benefit at the federal statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State and local taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credit, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-deductible items and other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(35.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(33.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The principal components of the Company&amp;#8217;s deferred tax assets consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal, state and local net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,241&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,688&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License fee deductions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;340&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;362&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,317&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;452&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation deductions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,243&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;264&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;837&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;457&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,978&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,223&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,978&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,223&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company increased its valuation allowance by $11,755&amp;#160;for the year ended December&amp;#160;31, 2020 in order to maintain a full valuation allowance against its deferred tax assets. Based on the Company&amp;#8217;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December&amp;#160;31, 2020. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020, the Company had federal, state and local net operating loss carryforwards of $45,550, $47,735 and $38,645, respectively; $45,301 of the federal amounts do not expire, and the remaining $249 expire in 2037. The state net operating losses begin to expire in 2037. The local net operating losses begin to expire in 2039. As of December&amp;#160;31, 2020, the Company had federal research and development tax credit carryforwards of $1,317, which begin to expire in 2038. Under the provisions of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the IRC), these net operating losses, credit carryforwards and other tax attributes may be subject to limitation based on previous significant changes in ownership and upon future significant changes in ownership of the Company, as defined by the IRC.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company files income tax returns in the U.S. federal jurisdiction as well as in Pennsylvania and Philadelphia. The tax years 2019, 2018 and 2017 remain open to examination by the jurisdictions where the Company is subject to tax. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&amp;#160;31, 2020, the Company had no unrecognized income tax benefits that would affect the Company&amp;#8217;s effective tax rate if recognized. &lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000219" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;11. Net Loss Per Share &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the two-class method required for participating securities. For the years ended December 31, 2020 and 2019, the Company had voting and non-voting common stock outstanding. Since the rights of the voting and non-voting common stock are identical, except with respect to voting, the undistributed losses of the Company have been allocated on a proportionate basis to the two classes. Diluted net loss per share is calculated using the if-converted method, which assumes conversion of all non-voting common stock to voting common stock.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.02%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Voting common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-voting common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allocation of undistributed losses attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25,090&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,249&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of shares used in basic per share computation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,417,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,727,327&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, basic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.44&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.44&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Diluted net loss per share:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allocation of undistributed losses for basic computation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25,090&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,249&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reallocation of undistributed losses as a result of conversion of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; non-voting to voting common shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,249&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allocation of undistributed losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(33,339&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,249&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of shares used in basic per share computation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,417,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,727,327&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Add: Conversion of non-voting to voting common shares outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,727,327&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of shares used in diluted per share computation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,145,227&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,727,327&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.44&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.44&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Voting common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-voting common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allocation of undistributed losses attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,693&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of shares used in basic per share computation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,345,530&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,123,861&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, basic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Diluted net loss per share:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allocation of undistributed losses for basic computation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,693&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reallocation of undistributed losses as a result of conversion of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; non-voting to voting common shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allocation of undistributed losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,269&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of shares used in basic per share computation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,345,530&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,123,861&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Add: Conversion of non-voting to voting common shares outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,123,861&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of shares used in diluted per share computation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,469,391&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,123,861&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,900,479&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,129,632&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-vested founder stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;465,801&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,388,977&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,366,280&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,518,609&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock id="F_000220" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12. 401(k) Savings Plan&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company maintains a defined-contribution savings plan under Section&amp;#160;401(k) of the IRC, or the 401(k) Plan. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. In 2019, the Company made a safe harbor nonelective contribution of 3% of eligible compensation on behalf of all employees. Effective January 1, 2020, the Plan provided for matching contributions on a portion of participant contributions pursuant to the 401(k) Savings Plan&amp;#8217;s matching formula, up to 4% of eligible compensation. All matching contributions and participant contributions vest immediately. Contributions totaled $203 and $74 for the years ended December&amp;#160;31, 2020 and 2019, respectively, and have been recorded in the statements of operations.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
  <us-gaap:SubsequentEventsTextBlock id="F_000221" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;13. Subsequent Events&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2021, the Company entered into a Development and Manufacturing Services Agreement (Wuxi Agreement) with &lt;font style="color:#000000;"&gt;WuXi Advanced Therapies (Wuxi) to serve as the Company&amp;#8217;s cell processing manufacturing partner for the anticipated MuSK-CAART Phase 1 clinical trial.&lt;/font&gt; The Company has the right to terminate the Wuxi Agreement for convenience or other reasons specified in the Wuxi Agreement upon prior written notice. If the Company terminates the Wuxi Agreement, it will be obligated to pay an early termination fee of $1,500.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2021, the Company entered into a research service agreement with CHOP for vector manufacturing, with a total cost of $670, expected to be incurred during 2021.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:UseOfEstimates id="F_000222" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, stock-based compensation and the valuation allowance on the Company&amp;#8217;s deferred tax assets. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates. &lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock id="F_000223" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Off-Balance Sheet Risk and Concentrations of Credit Risk &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, which are primarily invested in U.S. treasury-based money market funds, and available-for-sale debt securities, which are invested in investment grade corporate bonds with&amp;#160;&lt;font style="Background-color:#FFFFFF;color:#212529;"&gt;high credit quality issuers&lt;/font&gt;.&amp;#160;These investments have maturities in 2021. A portion of the Company&amp;#8217;s cash is maintained at a federally insured financial institution. The deposits held at this institution are in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held.&amp;#160; The cash in this account is swept daily into U.S. treasury-based and U.S. government-based money market funds. The Company has no off&amp;#8209;balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.&lt;/p&gt;</us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="F_000224" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:InvestmentPolicyTextBlock id="F_000225" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Investments&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments are available-for-sale and carried at estimated fair value. The Company&amp;#8217;s valuations of available-for-sale debt securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than, twelve months from the balance sheet date are classified as current.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors including the severity and duration of the unrealized loss as well as the Company&amp;#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or if more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other-than-temporary, if any, on available-for-sale securities are included in interest and other income, net. The cost of investments sold is based on the specific-identification method. Interest income on investments as well as amortization of discount or premium is included in interest income.&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="F_000226" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property, Plant and Equipment &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying statements of operations. Expenditures for normal, recurring or periodic repairs and maintenance related to property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful lives for property and equipment are as follows:&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Three years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Three years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Three years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Lesser of estimated useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock id="F_000227" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value Measurement &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&amp;#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&amp;#8212;Inputs (other than quoted prices included in Level&amp;#160;1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;3&amp;#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="F_000228" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs include costs incurred for internal and external research and development activities and are expensed as incurred in the accompanying statements of operations. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to entities that conduct certain research and development activities on the Company&amp;#8217;s behalf. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers, which include activities under agreements with Penn (Note 6), the conduct of sponsored research, preclinical studies and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided and includes these costs in accrued and other current liabilities and prepaid expenses and other current assets in the accompanying balance sheets and within research and development expense in the accompanying statements of operations. Non-refundable advance payments made for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as expense as the goods are received or the related services are rendered.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with service providers. The Company makes significant judgments and estimates in determining the accrued liabilities and prepaid expenses in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities and prepaid expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="F_000229" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-based Compensation &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures its stock-based awards granted to employees and non-employees based on the estimated fair values of the awards on the respective grant dates. The Company uses the Black-Scholes option-pricing model (Black-Scholes) to estimate the fair value of its stock-based awards. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company accounts for forfeitures of stock option awards as they occur. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the Company&amp;#8217;s IPO, the assumptions used in the Company&apos;s Black-Scholes option-pricing model represented management&apos;s best estimates and involve a number of variables, uncertainties and assumptions and the application of management&apos;s judgment, as they are inherently subjective.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:IncomeTaxPolicyTextBlock id="F_000230" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities, which relate primarily to the carrying amount of the Company&amp;#8217;s property and equipment and its net operating loss carryforwards, are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock id="F_000231" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the two-class method required for participating securities. The Company has voting and non-voting common stock. The rights, including the liquidation and dividend rights, of the holders of the voting and non-voting common stock are identical, except with respect to voting. Each share of non-voting common stock may be converted at any time into one share of voting common stock at the option of its holder by providing written notice to the Company, subject to the limitations provided for in the amended and restated certificate of incorporation. The Company also considers its unvested shares of common stock held by the Company&amp;#8217;s founders and, prior to its conversion to common stock, its convertible preferred stock to be participating securities as, in the event a dividend is paid on common stock, the holders of convertible preferred stock and unvested shares of common stock would be entitled to receive dividends on a basis consistent with the common stockholders. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock, which excludes unvested shares of common stock. The undistributed loss for each year is allocated to common stockholders based on the contractual participation rights of the voting and non-voting common stock as if the losses for the year had been distributed. As the liquidation and dividend rights are identical, the undistributed losses are allocated on a proportionate basis. Net loss attributable to common stockholders for the year ended December 31, 2019 is calculated by adjusting the net loss of the Company for the deemed dividend associated with the exchange of Series A-2 Preferred for Series B Preferred. Diluted net loss per share attributable to common stockholders is computed under the if-converted method and assumes that all non-voting common stock has been converted to common stock. Since the Company was in a loss position for all periods presented, the effects of the other potentially dilutive securities are antidilutive. &lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock id="F_000232" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segments &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&amp;#8217;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has one reportable segment. &lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <caba:RelatedPartyTransactionsPolicyTextBlock id="F_000233" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Related Party Transactions &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company engaged a firm controlled by a former executive (until February 2019) of the Company for professional services related to accounting, finance and other administrative functions. For the years ended December 31, 2020 and 2019, the costs incurred under this arrangement totaled $311 and $601, respectively. These amounts were recorded as general and administrative expense in the accompanying statements of operations. As of December&amp;#160;31, 2020 and 2019, amounts owed under this arrangement totaled $13&amp;#160;and $36, respectively, and are included in accounts payable in the accompanying balance sheets.&lt;/p&gt;</caba:RelatedPartyTransactionsPolicyTextBlock>
  <caba:EmergingGrowthCompanyStatusPolicyTextBlock id="F_000234" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Emerging Growth Company Status &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS&amp;#160;Act). Under the JOBS&amp;#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&amp;#160;Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&amp;#160;is no longer an emerging growth company or (ii)&amp;#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS&amp;#160;Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. &lt;/p&gt;</caba:EmergingGrowthCompanyStatusPolicyTextBlock>
  <caba:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock id="F_000235" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the Financial Accounting Standards Board (FASB) issued ASU 2016-02, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt; (Topic 842), with guidance regarding the accounting for and disclosure of leases. The update requires lessees to recognize the liabilities related all leases, including operating leases, with a term greater than 12 months on the balance sheet. This update also requires lessees and lessors to disclose key information about their leasing transactions. This guidance will be effective for public companies for annual and interim periods beginning after December&amp;#160;15, 2018. For all other entities, including Emerging Growth Companies, this standard is effective for annual reporting periods beginning after December&amp;#160;15, 2020, and interim periods within annual periods beginning after December&amp;#160;15, 2021. Early adoption is permitted. As an Emerging Growth Company, the Company expects to adopt Topic 842 for its annual period ending December 31, 2021 and has not yet finalized the assessment of the impact that ASU 2016-02 will have on its financial statements or financial statement disclosures. &lt;/p&gt;</caba:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock>
  <caba:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock id="F_000236" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful lives for property and equipment are as follows:&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Three years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Three years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Three years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Lesser of estimated useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</caba:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock id="F_000237" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables present information about the Company&amp;#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prices in&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Active Markets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;for Identical&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets (Level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Observable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unobservable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;101,429&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;101,429&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,233&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,233&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108,662&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;101,429&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,233&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted Prices in Active Markets for Identical Assets (Level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant Other Observable Inputs (Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant Unobservable Inputs (Level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;136,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;136,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;136,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;136,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock id="F_000238" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Included in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;101,429&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;101,429&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds - due in one year or less&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Included in short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,227&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,233&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.18%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108,656&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108,662&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000239" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property plant and equipment consists of the following:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;961&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;544&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;277&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;277&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property, plant and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,348&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;919&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(458&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(104&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;890&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;815&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <caba:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock id="F_000240" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued and other current liabilities consist of the following: &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,294&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;231&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;297&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,445&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,522&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;177&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,937&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,227&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</caba:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
  <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock id="F_000241" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the future minimum payments for operating leases are as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;268&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;426&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
  <us-gaap:TemporaryEquityTableTextBlock id="F_000242" contextRef="C_0001759138_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="right"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A Preferred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A-1 Preferred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A-2 Preferred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B Preferred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total Convertible&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&amp;#8212;December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,146,551&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,575&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,372,719&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,994&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,873,777&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,352&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,393,047&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,921&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,963,788&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,963,788&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exchange, including&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; deemed dividend&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,405,332&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,764&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,405,332&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,090&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,326&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,293&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,293&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion to common&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,146,551&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,575&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,372,719&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24,994&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(468,445&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,588&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,369,120&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(58,797&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,356,835&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(97,954&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&amp;#8212;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:TemporaryEquityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000243" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the stock option activity is presented below: &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;971,353&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,051&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,340,839&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.97&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,667&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(176,893&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,129,632&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,844&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;813,172&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.03&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25,611&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.44&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;183&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,714&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,900,479&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,303&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,068,675&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.04&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,059&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000244" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each award is estimated using Black-Scholes based on the following assumptions: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.28%&amp;#8212;1.48%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.39%&amp;#8212;2.59%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.7&amp;#8212;6.1 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.3&amp;#8212;6.1 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70%&amp;#8212;79%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70%&amp;#8212;76%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000245" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has recorded stock-based compensation in the accompanying statements of operations as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,989&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,304&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,399&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;996&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.76%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,388&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,300&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="F_000246" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reconciliation of federal statutory income tax rate to the Company&amp;#8217;s effective income tax rate is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected income tax benefit at the federal statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State and local taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credit, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-deductible items and other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(35.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(33.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="F_000247" contextRef="C_0001759138_20200101_20201231">The principal components of the Company&amp;#8217;s deferred tax assets consisted of the following:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal, state and local net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,241&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,688&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License fee deductions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;340&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;362&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,317&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;452&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation deductions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,243&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;264&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;837&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;457&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,978&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,223&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,978&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,223&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="F_000248" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.02%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Voting common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-voting common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allocation of undistributed losses attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25,090&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,249&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of shares used in basic per share computation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,417,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,727,327&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, basic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.44&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.44&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Diluted net loss per share:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allocation of undistributed losses for basic computation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25,090&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,249&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reallocation of undistributed losses as a result of conversion of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; non-voting to voting common shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,249&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allocation of undistributed losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(33,339&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,249&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of shares used in basic per share computation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,417,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,727,327&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Add: Conversion of non-voting to voting common shares outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,727,327&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of shares used in diluted per share computation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,145,227&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,727,327&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.44&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.44&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Voting common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-voting common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allocation of undistributed losses attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,693&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of shares used in basic per share computation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,345,530&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,123,861&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, basic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Diluted net loss per share:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allocation of undistributed losses for basic computation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,693&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reallocation of undistributed losses as a result of conversion of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; non-voting to voting common shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allocation of undistributed losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,269&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of shares used in basic per share computation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,345,530&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,123,861&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Add: Conversion of non-voting to voting common shares outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,123,861&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of shares used in diluted per share computation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,469,391&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,123,861&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000249" contextRef="C_0001759138_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,900,479&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,129,632&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-vested founder stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;465,801&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,388,977&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,366,280&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,518,609&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:StockholdersEquityReverseStockSplit id="F_000250" contextRef="C_0001759138_20200101_20201231">1-for-1.5 reverse split</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="F_000251" contextRef="C_0001759138_20191015_20191016" decimals="2" unitRef="U_xbrlipure">0.67</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000252" contextRef="C_0001759138_20191016" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000253" contextRef="C_0001759138_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191028_20191029" decimals="INF" unitRef="U_xbrlishares">6800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SaleOfStockPricePerShare id="F_000254" contextRef="C_0001759138_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191029" decimals="INF" unitRef="U_iso4217USD_xbrlishares">11.00</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="F_000255" contextRef="C_0001759138_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191028_20191029" decimals="-3" unitRef="U_iso4217USD">66156000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000256" contextRef="C_0001759138_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191029" decimals="INF" unitRef="U_xbrlishares">12904534</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <caba:NumberOfAdditionalCommonStockPurchasedByUnderwritersUponPartialExerciseOfOption id="F_000257" contextRef="C_0001759138_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191101_20191130" decimals="INF" unitRef="U_xbrlishares">475501</caba:NumberOfAdditionalCommonStockPurchasedByUnderwritersUponPartialExerciseOfOption>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="F_000258" contextRef="C_0001759138_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191101_20191130" decimals="-3" unitRef="U_iso4217USD">4864000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:CashCashEquivalentsAndShortTermInvestments id="F_000259" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">108662000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
  <caba:InvestmentsMaturityYear id="F_000260" contextRef="C_0001759138_20200101_20201231">2021</caba:InvestmentsMaturityYear>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000261" contextRef="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_cabaLaboratoryEquipmentMember_20200101_20201231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000262" contextRef="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000263" contextRef="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives id="F_000264" contextRef="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">Lesser of estimated useful life or remaining lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued id="F_000265" contextRef="C_0001759138_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:NumberOfOperatingSegments id="F_000266" contextRef="C_0001759138_20200101_20201231" decimals="INF" unitRef="U_cabaSegment">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:NumberOfReportingUnits id="F_000267" contextRef="C_0001759138_20200101_20201231" decimals="INF" unitRef="U_cabaSegment">1</us-gaap:NumberOfReportingUnits>
  <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty id="F_000268" contextRef="C_0001759138_us-gaapRelatedPartyTransactionAxis_cabaProfessionalServicesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">311000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty id="F_000269" contextRef="C_0001759138_us-gaapRelatedPartyTransactionAxis_cabaProfessionalServicesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">601000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent id="F_000270" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent id="F_000271" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">36000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000272" contextRef="C_0001759138_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">101429000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000273" contextRef="C_0001759138_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">101429000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:ShortTermInvestments id="F_000274" contextRef="C_0001759138_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateNoteSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">7233000</us-gaap:ShortTermInvestments>
  <us-gaap:ShortTermInvestments id="F_000275" contextRef="C_0001759138_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateNoteSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">7233000</us-gaap:ShortTermInvestments>
  <us-gaap:AssetsFairValueDisclosure id="F_000276" contextRef="C_0001759138_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">108662000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000277" contextRef="C_0001759138_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">101429000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000278" contextRef="C_0001759138_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">7233000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000279" contextRef="C_0001759138_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">136204000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000280" contextRef="C_0001759138_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">136204000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000281" contextRef="C_0001759138_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">136204000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000282" contextRef="C_0001759138_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">136204000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount id="F_000283" contextRef="C_0001759138_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount id="F_000284" contextRef="C_0001759138_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount id="F_000285" contextRef="C_0001759138_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount id="F_000286" contextRef="C_0001759138_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet id="F_000287" contextRef="C_0001759138_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet id="F_000288" contextRef="C_0001759138_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000289" contextRef="C_0001759138_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000290" contextRef="C_0001759138_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231" decimals="-3" unitRef="U_iso4217USD">101429000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000291" contextRef="C_0001759138_us-gaapInvestmentTypeAxis_us-gaapCorporateNoteSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">7227000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000292" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">108656000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000293" contextRef="C_0001759138_us-gaapInvestmentTypeAxis_us-gaapCorporateNoteSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000294" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000295" contextRef="C_0001759138_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231" decimals="-3" unitRef="U_iso4217USD">101429000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000296" contextRef="C_0001759138_us-gaapInvestmentTypeAxis_us-gaapCorporateNoteSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">7233000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000297" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">108662000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000298" contextRef="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">961000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000299" contextRef="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">544000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000300" contextRef="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" unitRef="U_iso4217USD">277000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000301" contextRef="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231" decimals="-3" unitRef="U_iso4217USD">277000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000302" contextRef="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" unitRef="U_iso4217USD">57000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000303" contextRef="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231" decimals="-3" unitRef="U_iso4217USD">57000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000304" contextRef="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">53000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000305" contextRef="C_0001759138_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">41000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000306" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">1348000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000307" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">919000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000308" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">458000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000309" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">104000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <caba:AccruedResearchAndDevelopmentServicesCurrent id="F_000310" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">1294000</caba:AccruedResearchAndDevelopmentServicesCurrent>
  <caba:AccruedResearchAndDevelopmentServicesCurrent id="F_000311" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">231000</caba:AccruedResearchAndDevelopmentServicesCurrent>
  <caba:AccruedGeneralAndAdministrativeServicesCurrent id="F_000312" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">160000</caba:AccruedGeneralAndAdministrativeServicesCurrent>
  <caba:AccruedGeneralAndAdministrativeServicesCurrent id="F_000313" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">297000</caba:AccruedGeneralAndAdministrativeServicesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000314" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">2445000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000315" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">1522000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000316" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">38000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000317" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">177000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:ContractualObligation id="F_000318" contextRef="C_0001759138_us-gaapSupplyCommitmentAxis_cabaLicenseAgreementMember_20201231" decimals="-3" unitRef="U_iso4217USD">2000000</us-gaap:ContractualObligation>
  <caba:PaymentOfObligationTerm id="F_000319" contextRef="C_0001759138_us-gaapSupplyCommitmentAxis_cabaLicenseAgreementMember_20200101_20201231">P3Y</caba:PaymentOfObligationTerm>
  <caba:ObligationToBePaidCommencementDate id="F_000320" contextRef="C_0001759138_us-gaapSupplyCommitmentAxis_cabaLicenseAgreementMember_20200101_20201231">2018-08</caba:ObligationToBePaidCommencementDate>
  <caba:LicenseMaintenanceFee id="F_000321" contextRef="C_0001759138_us-gaapSupplyCommitmentAxis_cabaLicenseAgreementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">10000</caba:LicenseMaintenanceFee>
  <caba:LicenseMaintenanceFee id="F_000322" contextRef="C_0001759138_us-gaapSupplyCommitmentAxis_cabaLicenseAgreementMember_20200501_20200531" decimals="-3" unitRef="U_iso4217USD">33000</caba:LicenseMaintenanceFee>
  <caba:MilestonePayments id="F_000323" contextRef="C_0001759138_us-gaapSupplyCommitmentAxis_cabaLicenseAgreementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">21000000</caba:MilestonePayments>
  <caba:CollaborativeAgreementPaymentsDue id="F_000324" contextRef="C_0001759138_us-gaapSupplyCommitmentAxis_cabaLicenseAgreementMember_20201231" decimals="INF" unitRef="U_iso4217USD">0</caba:CollaborativeAgreementPaymentsDue>
  <caba:NumberOfFaculty id="F_000325" contextRef="C_0001759138_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_cabaRegentsOfUniversityOfCaliforniaMember_us-gaapSupplyCommitmentAxis_cabaSponsoredResearchAgreementsMember_20201231" decimals="INF" unitRef="U_cabaFaculty">2</caba:NumberOfFaculty>
  <caba:FundingTermEndingDate id="F_000326" contextRef="C_0001759138_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_cabaRegentsOfUniversityOfCaliforniaMember_us-gaapSupplyCommitmentAxis_cabaSponsoredResearchAgreementsMember_20200101_20201231">2023-02</caba:FundingTermEndingDate>
  <us-gaap:ContractualObligation id="F_000327" contextRef="C_0001759138_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_cabaRegentsOfUniversityOfCaliforniaMember_us-gaapSupplyCommitmentAxis_cabaSponsoredResearchAgreementsMember_20201231" decimals="-3" unitRef="U_iso4217USD">11781000</us-gaap:ContractualObligation>
  <caba:ContractualCostIncurred id="F_000328" contextRef="C_0001759138_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_cabaRegentsOfUniversityOfCaliforniaMember_us-gaapSupplyCommitmentAxis_cabaSponsoredResearchAgreementsMember_20201231" decimals="-3" unitRef="U_iso4217USD">7090000</caba:ContractualCostIncurred>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000329" contextRef="C_0001759138_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_cabaRegentsOfUniversityOfCaliforniaMember_us-gaapSupplyCommitmentAxis_cabaSponsoredResearchAgreementsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2995000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000330" contextRef="C_0001759138_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_cabaRegentsOfUniversityOfCaliforniaMember_us-gaapSupplyCommitmentAxis_cabaSponsoredResearchAgreementsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2137000</us-gaap:ResearchAndDevelopmentExpense>
  <caba:AdvancePayments id="F_000331" contextRef="C_0001759138_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_cabaRegentsOfUniversityOfCaliforniaMember_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapSupplyCommitmentAxis_cabaSponsoredResearchAgreementsMember_20201231" decimals="-3" unitRef="U_iso4217USD">1851000</caba:AdvancePayments>
  <caba:AdvancePayments id="F_000332" contextRef="C_0001759138_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_cabaRegentsOfUniversityOfCaliforniaMember_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapSupplyCommitmentAxis_cabaSponsoredResearchAgreementsMember_20191231" decimals="-3" unitRef="U_iso4217USD">1588000</caba:AdvancePayments>
  <us-gaap:ContractualObligation id="F_000333" contextRef="C_0001759138_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_cabaRegentsOfUniversityOfCaliforniaMember_us-gaapBalanceSheetLocationAxis_cabaAccruedAndOtherCurrentLiabilitiesMember_us-gaapSupplyCommitmentAxis_cabaSponsoredResearchAgreementsMember_20201231" decimals="-3" unitRef="U_iso4217USD">217000</us-gaap:ContractualObligation>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000334" contextRef="C_0001759138_us-gaapSupplyCommitmentAxis_cabaMasterTranslationalResearchServicesAgreementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2474000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000335" contextRef="C_0001759138_us-gaapSupplyCommitmentAxis_cabaMasterTranslationalResearchServicesAgreementMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2355000</us-gaap:ResearchAndDevelopmentExpense>
  <caba:MaximumResearchAndDevelopmentAdditionalExpenseDueInRemainingTerm id="F_000336" contextRef="C_0001759138_us-gaapSupplyCommitmentAxis_cabaMasterTranslationalResearchServicesAgreementMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">1360000</caba:MaximumResearchAndDevelopmentAdditionalExpenseDueInRemainingTerm>
  <caba:ContractualExpenses id="F_000337" contextRef="C_0001759138_us-gaapSupplyCommitmentAxis_cabaSubscriptionAndTechnologyTransferAgreementMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">250000</caba:ContractualExpenses>
  <caba:ContractualExpenses id="F_000338" contextRef="C_0001759138_us-gaapSupplyCommitmentAxis_cabaSubscriptionAndTechnologyTransferAgreementMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</caba:ContractualExpenses>
  <us-gaap:LesseeOperatingLeaseDescription id="F_000339" contextRef="C_0001759138_us-gaapSupplyCommitmentAxis_cabaOperatingLeaseAgreementMember_20200101_20201231">The lease term commenced in May 2019 and will expire in July 2022.</us-gaap:LesseeOperatingLeaseDescription>
  <caba:LeaseCommencementMonthAndYear id="F_000340" contextRef="C_0001759138_us-gaapSupplyCommitmentAxis_cabaOperatingLeaseAgreementMember_20200101_20201231">2019-05</caba:LeaseCommencementMonthAndYear>
  <caba:LeaseExpirationMonthAndYear id="F_000341" contextRef="C_0001759138_us-gaapSupplyCommitmentAxis_cabaOperatingLeaseAgreementMember_20200101_20201231">2022-07</caba:LeaseExpirationMonthAndYear>
  <us-gaap:OperatingLeasesRentExpenseMinimumRentals id="F_000342" contextRef="C_0001759138_us-gaapSupplyCommitmentAxis_cabaOperatingLeaseAgreementMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">261000</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
  <caba:AnnualIncreasePercentageOfBaseRent id="F_000343" contextRef="C_0001759138_us-gaapSupplyCommitmentAxis_cabaOperatingLeaseAgreementMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.02</caba:AnnualIncreasePercentageOfBaseRent>
  <caba:RentExpense id="F_000344" contextRef="C_0001759138_us-gaapSupplyCommitmentAxis_cabaOperatingLeaseAgreementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">266000</caba:RentExpense>
  <caba:RentExpense id="F_000345" contextRef="C_0001759138_us-gaapSupplyCommitmentAxis_cabaOperatingLeaseAgreementMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">178000</caba:RentExpense>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths id="F_000346" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">268000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo id="F_000347" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">158000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue id="F_000348" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">426000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000349" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">3146551</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000350" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">12575000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000351" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaSeriesA1PreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">7372719</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000352" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaSeriesA1PreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">24994000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000353" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaSeriesA2PreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">1873777</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000354" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaSeriesA2PreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">6352000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <caba:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="F_000355" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">6963788</caba:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="F_000356" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">50000000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <caba:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="F_000357" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">6963788</caba:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="F_000358" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">50000000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <caba:TemporaryEquitySharesExchangeIncludingDeemedDividend id="F_000359" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaSeriesA2PreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-1405332</caba:TemporaryEquitySharesExchangeIncludingDeemedDividend>
  <caba:TemporaryEquityValueExchangeIncludingDeemedDividend id="F_000360" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaSeriesA2PreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-4764000</caba:TemporaryEquityValueExchangeIncludingDeemedDividend>
  <caba:TemporaryEquitySharesExchangeIncludingDeemedDividend id="F_000361" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">1405332</caba:TemporaryEquitySharesExchangeIncludingDeemedDividend>
  <caba:TemporaryEquityValueExchangeIncludingDeemedDividend id="F_000362" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">10090000</caba:TemporaryEquityValueExchangeIncludingDeemedDividend>
  <caba:TemporaryEquityValueExchangeIncludingDeemedDividend id="F_000363" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">5326000</caba:TemporaryEquityValueExchangeIncludingDeemedDividend>
  <caba:TemporaryEquityIssuanceCosts id="F_000364" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1293000</caba:TemporaryEquityIssuanceCosts>
  <caba:TemporaryEquityIssuanceCosts id="F_000365" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1293000</caba:TemporaryEquityIssuanceCosts>
  <caba:TemporaryEquityConversionOfStockSharesForCommonStock id="F_000366" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-3146551</caba:TemporaryEquityConversionOfStockSharesForCommonStock>
  <caba:TemporaryEquityConversionOfStockValueForCommonStock id="F_000367" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-12575000</caba:TemporaryEquityConversionOfStockValueForCommonStock>
  <caba:TemporaryEquityConversionOfStockSharesForCommonStock id="F_000368" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaSeriesA1PreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-7372719</caba:TemporaryEquityConversionOfStockSharesForCommonStock>
  <caba:TemporaryEquityConversionOfStockValueForCommonStock id="F_000369" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaSeriesA1PreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-24994000</caba:TemporaryEquityConversionOfStockValueForCommonStock>
  <caba:TemporaryEquityConversionOfStockSharesForCommonStock id="F_000370" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaSeriesA2PreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-468445</caba:TemporaryEquityConversionOfStockSharesForCommonStock>
  <caba:TemporaryEquityConversionOfStockValueForCommonStock id="F_000371" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaSeriesA2PreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-1588000</caba:TemporaryEquityConversionOfStockValueForCommonStock>
  <caba:TemporaryEquityConversionOfStockSharesForCommonStock id="F_000372" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-8369120</caba:TemporaryEquityConversionOfStockSharesForCommonStock>
  <caba:TemporaryEquityConversionOfStockValueForCommonStock id="F_000373" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-58797000</caba:TemporaryEquityConversionOfStockValueForCommonStock>
  <caba:TemporaryEquityConversionOfStockSharesForCommonStock id="F_000374" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-19356835</caba:TemporaryEquityConversionOfStockSharesForCommonStock>
  <caba:TemporaryEquityConversionOfStockValueForCommonStock id="F_000375" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-97954000</caba:TemporaryEquityConversionOfStockValueForCommonStock>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000376" contextRef="C_0001759138_20190131" decimals="INF" unitRef="U_xbrlishares">20762168</us-gaap:TemporaryEquitySharesAuthorized>
  <caba:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="F_000377" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20190131" decimals="INF" unitRef="U_xbrlishares">6963788</caba:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000378" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20190131" decimals="-3" unitRef="U_iso4217USD">50000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <caba:TemporaryEquitySharesExchangeIncludingDeemedDividend id="F_000379" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20190131" decimals="INF" unitRef="U_xbrlishares">1405332</caba:TemporaryEquitySharesExchangeIncludingDeemedDividend>
  <caba:TemporaryEquitySharesExchangeIncludingDeemedDividend id="F_000380" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaSeriesA2PreferredStockMember_20190101_20190131" decimals="INF" unitRef="U_xbrlishares">-1405332</caba:TemporaryEquitySharesExchangeIncludingDeemedDividend>
  <caba:TemporaryEquityValueExchangeIncludingDeemedDividend id="F_000381" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaSeriesA2PreferredStockMember_20190101_20190131" decimals="-3" unitRef="U_iso4217USD">4764000</caba:TemporaryEquityValueExchangeIncludingDeemedDividend>
  <caba:TemporaryEquityValueExchangeIncludingDeemedDividend id="F_000382" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20190131" decimals="-3" unitRef="U_iso4217USD">10090000</caba:TemporaryEquityValueExchangeIncludingDeemedDividend>
  <caba:TemporaryEquityValueExchangeIncludingDeemedDividend id="F_000383" contextRef="C_0001759138_20190101_20190131" decimals="-3" unitRef="U_iso4217USD">5326000</caba:TemporaryEquityValueExchangeIncludingDeemedDividend>
  <caba:ConvertiblePreferredStockConvertIntoVotingCommonStock id="F_000384" contextRef="C_0001759138_20191001_20191031" decimals="INF" unitRef="U_xbrlishares">12904534</caba:ConvertiblePreferredStockConvertIntoVotingCommonStock>
  <caba:ConvertiblePreferredStockConvertIntoNonVotingCommonStock id="F_000385" contextRef="C_0001759138_20191001_20191031" decimals="INF" unitRef="U_xbrlishares">6409519</caba:ConvertiblePreferredStockConvertIntoNonVotingCommonStock>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000386" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000387" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:CommonStockSharesAuthorized id="F_000388" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20191031" decimals="INF" unitRef="U_xbrlishares">143590481</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000389" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20191031" decimals="INF" unitRef="U_xbrlishares">6409519</us-gaap:CommonStockSharesAuthorized>
  <caba:ConversionOfNonVotingCommonStockToVotingCommonStockSharesConverted id="F_000390" contextRef="C_0001759138_20200831" decimals="INF" unitRef="U_xbrlishares">1733904</caba:ConversionOfNonVotingCommonStockToVotingCommonStockSharesConverted>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000391" contextRef="C_0001759138_us-gaapPlanNameAxis_cabaAtTheMarketOfferingSalesAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">75000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000392" contextRef="C_0001759138_us-gaapPlanNameAxis_cabaAtTheMarketOfferingSalesAgreementMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <caba:ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModified id="F_000393" contextRef="C_0001759138_20180501_20180531" decimals="INF" unitRef="U_xbrlishares">2904000</caba:ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModified>
  <caba:ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModifiedFairValue id="F_000394" contextRef="C_0001759138_20180501_20180531" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.74</caba:ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModifiedFairValue>
  <caba:ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStockSharesCompensationCost id="F_000395" contextRef="C_0001759138_20180501_20180531" decimals="-3" unitRef="U_iso4217USD">2126000</caba:ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStockSharesCompensationCost>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000396" contextRef="C_0001759138_20180501_20180531">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000397" contextRef="C_0001759138_srtTitleOfIndividualAxis_cabaFoundersMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">495000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000398" contextRef="C_0001759138_srtTitleOfIndividualAxis_cabaFoundersMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">529000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000399" contextRef="C_0001759138_srtTitleOfIndividualAxis_cabaFoundersMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">177000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000400" contextRef="C_0001759138_srtTitleOfIndividualAxis_cabaFoundersMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">177000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_000401" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandEighteenStockOptionAndGrantPlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000402" contextRef="C_0001759138_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandEighteenStockOptionAndGrantPlanMember_20200101_20201231">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000403" contextRef="C_0001759138_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandEighteenStockOptionAndGrantPlanMember_20200101_20201231">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000404" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandEighteenStockOptionAndGrantPlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">1959411</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000405" contextRef="C_0001759138_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20191023" decimals="INF" unitRef="U_xbrlishares">2342288</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000406" contextRef="C_0001759138_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20200101" decimals="INF" unitRef="U_xbrlishares">962511</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <caba:IncreaseInShareReservedPercentage id="F_000407" contextRef="C_0001759138_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20191021_20191023" decimals="2" unitRef="U_xbrlipure">0.04</caba:IncreaseInShareReservedPercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000408" contextRef="C_0001759138_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">2314303</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000409" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20181231" decimals="INF" unitRef="U_xbrlishares">971353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000410" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">1340839</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000411" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">5667</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000412" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">176893</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000413" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">2129632</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000414" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">813172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000415" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">25611</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000416" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">16714</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000417" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">2900479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000418" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">1068675</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000419" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000420" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">7.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000421" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000422" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">4.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000423" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">5.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000424" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">13.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000425" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">5.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000426" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000427" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">7.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000428" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">4.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000429" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20180101_20181231">P9Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000430" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20190101_20191231">P9Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000431" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20200101_20201231">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000432" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20200101_20201231">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000433" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20181231" decimals="-3" unitRef="U_iso4217USD">4051000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000434" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20191231" decimals="-3" unitRef="U_iso4217USD">18844000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000435" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">183000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000436" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20201231" decimals="-3" unitRef="U_iso4217USD">16303000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="F_000437" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20201231" decimals="-3" unitRef="U_iso4217USD">9059000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000438" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">8.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000439" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenStockOptionAndIncentivePlanMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">5.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000440" contextRef="C_0001759138_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.0028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000441" contextRef="C_0001759138_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.0139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000442" contextRef="C_0001759138_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.0148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000443" contextRef="C_0001759138_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.0259</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000444" contextRef="C_0001759138_srtRangeAxis_srtMinimumMember_20200101_20201231">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000445" contextRef="C_0001759138_srtRangeAxis_srtMinimumMember_20190101_20191231">P3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000446" contextRef="C_0001759138_srtRangeAxis_srtMaximumMember_20200101_20201231">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000447" contextRef="C_0001759138_srtRangeAxis_srtMaximumMember_20190101_20191231">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="F_000448" contextRef="C_0001759138_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="F_000449" contextRef="C_0001759138_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="F_000450" contextRef="C_0001759138_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="F_000451" contextRef="C_0001759138_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000452" contextRef="C_0001759138_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000453" contextRef="C_0001759138_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000454" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1989000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000455" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1304000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000456" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2399000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000457" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">996000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000458" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">4388000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000459" contextRef="C_0001759138_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2300000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="F_000460" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">9809000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000461" contextRef="C_0001759138_20200101_20201231">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="F_000462" contextRef="C_0001759138_srtTitleOfIndividualAxis_cabaFoundersMember_20201231" decimals="-3" unitRef="U_iso4217USD">239000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000463" contextRef="C_0001759138_srtTitleOfIndividualAxis_cabaFoundersMember_20200101_20201231">P3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000464" contextRef="C_0001759138_us-gaapPlanNameAxis_cabaTwoThousandNineteenEmployeeStockPurchasePlanMember_20191023" decimals="INF" unitRef="U_xbrlishares">234229</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000465" contextRef="C_0001759138_us-gaapPlanNameAxis_cabaTwoThousandNineteenEmployeeStockPurchasePlanMember_20200101" decimals="INF" unitRef="U_xbrlishares">234229</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000466" contextRef="C_0001759138_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenEmployeeStockPurchasePlanMember_20191023" decimals="INF" unitRef="U_xbrlishares">234229</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <caba:IncreaseInShareReservedPercentage id="F_000467" contextRef="C_0001759138_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenEmployeeStockPurchasePlanMember_20191021_20191023" decimals="INF" unitRef="U_xbrlipure">0.01</caba:IncreaseInShareReservedPercentage>
  <caba:PercentageOfPayrollDeductionOnEligibleCompensation id="F_000468" contextRef="C_0001759138_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.15</caba:PercentageOfPayrollDeductionOnEligibleCompensation>
  <caba:EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock id="F_000469" contextRef="C_0001759138_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">25000</caba:EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock>
  <caba:PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock id="F_000470" contextRef="C_0001759138_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_cabaTwoThousandNineteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.85</caba:PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000471" contextRef="C_0001759138_us-gaapPlanNameAxis_cabaTwoThousandNineteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">18000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000472" contextRef="C_0001759138_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000473" contextRef="C_0001759138_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000474" contextRef="C_0001759138_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.125</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000475" contextRef="C_0001759138_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.131</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="F_000476" contextRef="C_0001759138_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.026</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="F_000477" contextRef="C_0001759138_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <caba:EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther id="F_000478" contextRef="C_0001759138_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.008</caba:EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther>
  <caba:EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther id="F_000479" contextRef="C_0001759138_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.033</caba:EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000480" contextRef="C_0001759138_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.353</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000481" contextRef="C_0001759138_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.331</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000482" contextRef="C_0001759138_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000483" contextRef="C_0001759138_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal id="F_000484" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">15241000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal id="F_000485" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">5688000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <caba:DeferredTaxAssetsLicenseFeesDeductions id="F_000486" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">340000</caba:DeferredTaxAssetsLicenseFeesDeductions>
  <caba:DeferredTaxAssetsLicenseFeesDeductions id="F_000487" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">362000</caba:DeferredTaxAssetsLicenseFeesDeductions>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000488" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">1317000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000489" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">452000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000490" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">1243000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000491" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">264000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities id="F_000492" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">837000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities id="F_000493" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">457000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
  <us-gaap:DeferredTaxAssetsGross id="F_000494" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">18978000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross id="F_000495" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">7223000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000496" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">18978000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000497" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">7223000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet id="F_000498" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet id="F_000499" contextRef="C_0001759138_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000500" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">11755000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <caba:DeferredTaxAssetsOperatingLossCarryforwardsFederal id="F_000501" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">45550000</caba:DeferredTaxAssetsOperatingLossCarryforwardsFederal>
  <caba:DeferredTaxAssetsOperatingLossCarryforwardsState id="F_000502" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">47735000</caba:DeferredTaxAssetsOperatingLossCarryforwardsState>
  <caba:DeferredTaxAssetsOperatingLossCarryforwardsLocal id="F_000503" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">38645000</caba:DeferredTaxAssetsOperatingLossCarryforwardsLocal>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration id="F_000504" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">45301000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration id="F_000505" contextRef="C_0001759138_20201231" decimals="-3" unitRef="U_iso4217USD">249000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
  <caba:OperatingLossCarryforwardsFederalCommencementOfExpirationDate id="F_000506" contextRef="C_0001759138_20200101_20201231">2037</caba:OperatingLossCarryforwardsFederalCommencementOfExpirationDate>
  <caba:OperatingLossCarryforwardsStateCommencementOfExpirationDate id="F_000507" contextRef="C_0001759138_20200101_20201231">2037</caba:OperatingLossCarryforwardsStateCommencementOfExpirationDate>
  <caba:OperatingLossCarryforwardsLocalCommencementOfExpirationDate id="F_000508" contextRef="C_0001759138_20200101_20201231">2039</caba:OperatingLossCarryforwardsLocalCommencementOfExpirationDate>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000509" contextRef="C_0001759138_us-gaapIncomeTaxAuthorityAxis_cabaFederalMember_20201231" decimals="-3" unitRef="U_iso4217USD">1317000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <caba:DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate id="F_000510" contextRef="C_0001759138_us-gaapIncomeTaxAuthorityAxis_cabaFederalMember_20200101_20201231">2038</caba:DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate>
  <us-gaap:OpenTaxYear id="F_000511" contextRef="C_0001759138_20200101_20201231">2017 2018 2019</us-gaap:OpenTaxYear>
  <caba:PercentageOfEligibleTaxPositionsForRecognition id="F_000512" contextRef="C_0001759138_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.50</caba:PercentageOfEligibleTaxPositionsForRecognition>
  <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate id="F_000513" contextRef="C_0001759138_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
  <us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic id="F_000514" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-25090000</us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic>
  <us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic id="F_000515" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-8249000</us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="F_000516" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">17417900</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="F_000517" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">5727327</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:EarningsPerShareBasic id="F_000518" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-1.44</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic id="F_000519" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-1.44</us-gaap:EarningsPerShareBasic>
  <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic id="F_000520" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-25090000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
  <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic id="F_000521" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-8249000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
  <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther id="F_000522" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-8249000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
  <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted id="F_000523" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-33339000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
  <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted id="F_000524" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-8249000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment id="F_000525" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">5727327</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="F_000526" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">23145227</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="F_000527" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">5727327</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:EarningsPerShareDiluted id="F_000528" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-1.44</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted id="F_000529" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-1.44</us-gaap:EarningsPerShareDiluted>
  <us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic id="F_000530" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-17693000</us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic>
  <us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic id="F_000531" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-4576000</us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="F_000532" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">4345530</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="F_000533" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">1123861</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:EarningsPerShareBasic id="F_000534" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-4.07</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic id="F_000535" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-4.07</us-gaap:EarningsPerShareBasic>
  <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic id="F_000536" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-17693000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
  <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic id="F_000537" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-4576000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
  <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther id="F_000538" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-4576000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
  <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted id="F_000539" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-22269000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
  <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted id="F_000540" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-4576000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment id="F_000541" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">1123861</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="F_000542" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">5469391</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="F_000543" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">1123861</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:EarningsPerShareDiluted id="F_000544" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_cabaVotingCommonStockMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-4.07</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted id="F_000545" contextRef="C_0001759138_us-gaapStatementClassOfStockAxis_us-gaapNonvotingCommonStockMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-4.07</us-gaap:EarningsPerShareDiluted>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000546" contextRef="C_0001759138_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">2900479</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000547" contextRef="C_0001759138_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">2129632</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000548" contextRef="C_0001759138_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cabaNonVestedCommonStockMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">465801</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000549" contextRef="C_0001759138_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cabaNonVestedCommonStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">1388977</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000550" contextRef="C_0001759138_20200101_20201231" decimals="0" unitRef="U_xbrlishares">3366280</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000551" contextRef="C_0001759138_20190101_20191231" decimals="0" unitRef="U_xbrlishares">3518609</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:DefinedContributionPlanCostRecognized id="F_000552" contextRef="C_0001759138_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">203000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:DefinedContributionPlanCostRecognized id="F_000553" contextRef="C_0001759138_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">74000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent id="F_000554" contextRef="C_0001759138_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch id="F_000555" contextRef="C_0001759138_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
  <us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees id="F_000556" contextRef="C_0001759138_srtCounterpartyNameAxis_cabaWuXiAdvancedTherapiesMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSupplyCommitmentAxis_cabaDevelopmentAndManufacturingServicesAgreementMember_20210131" decimals="-3" unitRef="U_iso4217USD">1500000</us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees>
  <caba:ExpectedResearchServiceAgreementCost id="F_000557" contextRef="C_0001759138_srtCounterpartyNameAxis_cabaChildrenSHospitalOfPhiladelphiaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSupplyCommitmentAxis_cabaResearchServiceAgreementMember_20210201_20210228" decimals="-3" unitRef="U_iso4217USD">670000</caba:ExpectedResearchServiceAgreementCost>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>28
<FILENAME>caba-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-15T17:02:46.7673149+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : b469dc7abe284c828e6850b36ac62ee6 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:caba="http://www.cabalettabio.com/20201231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cabalettabio.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.cabalettabio.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="caba-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="caba-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="caba-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="caba-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/StatementBalanceSheets" id="Role_StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" id="Role_StatementBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" id="Role_StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity">
        <link:definition>100040 - Statement - Statements of Convertible Preferred Stock and Stockholders&apos; (Deficit) Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" id="Role_StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical">
        <link:definition>100050 - Statement - Statements of Convertible Preferred Stock and Stockholders&apos; (Deficit) Equity (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" id="Role_StatementStatementsOfCashFlows">
        <link:definition>100060 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureBasisOfPresentation" id="Role_DisclosureBasisOfPresentation">
        <link:definition>100070 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100090 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipment" id="Role_DisclosurePropertyPlantAndEquipment">
        <link:definition>100100 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilities" id="Role_DisclosureAccruedAndOtherCurrentLiabilities">
        <link:definition>100110 - Disclosure - Accrued and Other Current Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCollaborationsLicensingAgreementsAndOtherAgreements" id="Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreements">
        <link:definition>100120 - Disclosure - Collaborations, Licensing Agreements and other Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100130 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock" id="Role_DisclosureConvertiblePreferredStock">
        <link:definition>100140 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>100150 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100160 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100170 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/Disclosure401KSavingsPlan" id="Role_Disclosure401KSavingsPlan">
        <link:definition>100180 - Disclosure - 401(k) Savings Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100190 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100200 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100210 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100220 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentTables" id="Role_DisclosurePropertyPlantAndEquipmentTables">
        <link:definition>100230 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables">
        <link:definition>100240 - Disclosure - Accrued and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100250 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockTables" id="Role_DisclosureConvertiblePreferredStockTables">
        <link:definition>100260 - Disclosure - Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockTables" id="Role_DisclosureCommonStockTables">
        <link:definition>100270 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100280 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100290 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100300 - Disclosure - Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100310 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails">
        <link:definition>100320 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives for Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100330 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100340 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails">
        <link:definition>100350 - Disclosure - Fair Value Measurements - Schedule of Debt Securities Classified as Available-for-Sale Investments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" id="Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails">
        <link:definition>100360 - Disclosure - Property, Plant and Equipment - Schedule of Property Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" id="Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Property, Plant and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails">
        <link:definition>100380 - Disclosure - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails" id="Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Collaborations, Licensing Agreements and other Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails">
        <link:definition>100410 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Payments for Operating Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails" id="Role_DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails">
        <link:definition>100430 - Disclosure - Convertible Preferred Stock - Summary of Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" id="Role_DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfStockOptionActivityDetails" id="Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails">
        <link:definition>100450 - Disclosure - Common Stock - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" id="Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails">
        <link:definition>100460 - Disclosure - Common Stock - Schedule of Assumptions Used to Estimate Fair Value of Stock Options (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfStockBasedCompensationDetails" id="Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails">
        <link:definition>100470 - Disclosure - Common Stock - Summary of Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails" id="Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails">
        <link:definition>100480 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company&apos;s Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails">
        <link:definition>100490 - Disclosure - Income Taxes - Summary of Principal Components of Company&apos;s Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails">
        <link:definition>100510 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>100520 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/Disclosure401KSavingsPlanAdditionalInformationDetails" id="Role_Disclosure401KSavingsPlanAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - 401 (k) Savings Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="Role_DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" name="AccruedLiabilitiesAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="caba_VotingCommonStockMember" name="VotingCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" name="TemporaryEquityStockIssuedDuringPeriodShareNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesNetOfIssuanceCosts" name="TemporaryEquityStockIssuedDuringPeriodValueNewIssuesNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="caba_StockIssuedDuringPeriodShareStockOptionsExercised" name="StockIssuedDuringPeriodShareStockOptionsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_TemporaryEquityStockConvertedIntoCommonStock" name="TemporaryEquityStockConvertedIntoCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_TemporaryEquityConvertedIntoCommonStockValue" name="TemporaryEquityConvertedIntoCommonStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="caba_ExchangeOfConvertiblePreferredStockIncludingDeemedDividend" name="ExchangeOfConvertiblePreferredStockIncludingDeemedDividend" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="caba_DeferredOfferingCostsInAccountsPayableAndAccruedAndOtherCurrentLiabilities" name="DeferredOfferingCostsInAccountsPayableAndAccruedAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" name="CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" name="CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_RelatedPartyTransactionsPolicyTextBlock" name="RelatedPartyTransactionsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_EmergingGrowthCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" name="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" name="AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_BasisOfPresentationLineItems" name="BasisOfPresentationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_BasisOfPresentationTable" name="BasisOfPresentationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_NumberOfAdditionalCommonStockPurchasedByUnderwritersUponPartialExerciseOfOption" name="NumberOfAdditionalCommonStockPurchasedByUnderwritersUponPartialExerciseOfOption" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_InvestmentsMaturityYear" name="InvestmentsMaturityYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_ProfessionalServicesMember" name="ProfessionalServicesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_AccruedResearchAndDevelopmentServicesCurrent" name="AccruedResearchAndDevelopmentServicesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="caba_AccruedGeneralAndAdministrativeServicesCurrent" name="AccruedGeneralAndAdministrativeServicesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="caba_PaymentOfObligationTerm" name="PaymentOfObligationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_ObligationToBePaidCommencementDate" name="ObligationToBePaidCommencementDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_LicenseMaintenanceFee" name="LicenseMaintenanceFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="caba_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="caba_CollaborativeAgreementPaymentsDue" name="CollaborativeAgreementPaymentsDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" name="CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" name="CollaborationsLicensingAgreementsAndOtherAgreementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_LicenseAgreementMember" name="LicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_SponsoredResearchAgreementsMember" name="SponsoredResearchAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_RegentsOfUniversityOfCaliforniaMember" name="RegentsOfUniversityOfCaliforniaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_AccruedAndOtherCurrentLiabilitiesMember" name="AccruedAndOtherCurrentLiabilitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_MasterTranslationalResearchServicesAgreementMember" name="MasterTranslationalResearchServicesAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_SubscriptionAndTechnologyTransferAgreementMember" name="SubscriptionAndTechnologyTransferAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_NumberOfFaculty" name="NumberOfFaculty" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="caba_FundingTermEndingDate" name="FundingTermEndingDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_AdvancePayments" name="AdvancePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="caba_ContractualCostIncurred" name="ContractualCostIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="caba_MaximumResearchAndDevelopmentAdditionalExpenseDueInRemainingTerm" name="MaximumResearchAndDevelopmentAdditionalExpenseDueInRemainingTerm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="caba_ContractualExpenses" name="ContractualExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="caba_LeaseCommencementMonthAndYear" name="LeaseCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_LeaseExpirationMonthAndYear" name="LeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_AnnualIncreasePercentageOfBaseRent" name="AnnualIncreasePercentageOfBaseRent" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_RentExpense" name="RentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="caba_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_OperatingLeaseAgreementMember" name="OperatingLeaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="caba_SeriesA2PreferredStockMember" name="SeriesA2PreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_TemporaryEquitySharesExchangeIncludingDeemedDividend" name="TemporaryEquitySharesExchangeIncludingDeemedDividend" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_TemporaryEquityValueExchangeIncludingDeemedDividend" name="TemporaryEquityValueExchangeIncludingDeemedDividend" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="caba_TemporaryEquityIssuanceCosts" name="TemporaryEquityIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="caba_TemporaryEquityConversionOfStockSharesForCommonStock" name="TemporaryEquityConversionOfStockSharesForCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_TemporaryEquityConversionOfStockValueForCommonStock" name="TemporaryEquityConversionOfStockValueForCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="caba_SeriesA1PreferredStockMember" name="SeriesA1PreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_ConvertiblePreferredStockConvertIntoVotingCommonStock" name="ConvertiblePreferredStockConvertIntoVotingCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_ConvertiblePreferredStockConvertIntoNonVotingCommonStock" name="ConvertiblePreferredStockConvertIntoNonVotingCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_ConversionOfNonVotingCommonStockToVotingCommonStockSharesConverted" name="ConversionOfNonVotingCommonStockToVotingCommonStockSharesConverted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="caba_AtTheMarketOfferingSalesAgreementMember" name="AtTheMarketOfferingSalesAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_FoundersMember" name="FoundersMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_TwoThousandEighteenStockOptionAndGrantPlanMember" name="TwoThousandEighteenStockOptionAndGrantPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" name="TwoThousandNineteenStockOptionAndIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" name="TwoThousandNineteenEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModified" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModified" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModifiedFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModifiedFairValue" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStockSharesCompensationCost" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStockSharesCompensationCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="caba_IncreaseInShareReservedPercentage" name="IncreaseInShareReservedPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_PercentageOfPayrollDeductionOnEligibleCompensation" name="PercentageOfPayrollDeductionOnEligibleCompensation" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" name="EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" name="PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" name="EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_DeferredTaxAssetsLicenseFeesDeductions" name="DeferredTaxAssetsLicenseFeesDeductions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="caba_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_FederalMember" name="FederalMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal" name="DeferredTaxAssetsOperatingLossCarryforwardsFederal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="caba_DeferredTaxAssetsOperatingLossCarryforwardsState" name="DeferredTaxAssetsOperatingLossCarryforwardsState" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal" name="DeferredTaxAssetsOperatingLossCarryforwardsLocal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" name="OperatingLossCarryforwardsFederalCommencementOfExpirationDate" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" name="OperatingLossCarryforwardsStateCommencementOfExpirationDate" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" name="DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" name="OperatingLossCarryforwardsLocalCommencementOfExpirationDate" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_PercentageOfEligibleTaxPositionsForRecognition" name="PercentageOfEligibleTaxPositionsForRecognition" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="caba_EarningPerShareBasicAndDilutedLineItems" name="EarningPerShareBasicAndDilutedLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_EarningsPerShareBasicAndDilutedTable" name="EarningsPerShareBasicAndDilutedTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_NonVestedCommonStockMember" name="NonVestedCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_WuXiAdvancedTherapiesMember" name="WuXiAdvancedTherapiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_DevelopmentAndManufacturingServicesAgreementMember" name="DevelopmentAndManufacturingServicesAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_ChildrenSHospitalOfPhiladelphiaMember" name="ChildrenSHospitalOfPhiladelphiaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_ResearchServiceAgreementMember" name="ResearchServiceAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="caba_ExpectedResearchServiceAgreementCost" name="ExpectedResearchServiceAgreementCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>29
<FILENAME>caba-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-15T17:02:46.7673149+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : b469dc7abe284c828e6850b36ac62ee6 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="caba-20201231.xsd#TemplateLink" roleURI="http://www.cabalettabio.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/StatementBalanceSheets" xlink:href="caba-20201231.xsd#Role_StatementBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/StatementBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="caba-20201231.xsd#caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:href="caba-20201231.xsd#Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends" xlink:type="locator" xlink:label="us-gaap_Dividends" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_Dividends" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" xlink:href="caba-20201231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10140.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10190.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails" xlink:href="caba-20201231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="caba-20201231.xsd#Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:href="caba-20201231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="caba-20201231.xsd#caba_AccruedGeneralAndAdministrativeServicesCurrent" xlink:type="locator" xlink:label="caba_AccruedGeneralAndAdministrativeServicesCurrent" />
    <link:loc xlink:href="caba-20201231.xsd#caba_AccruedResearchAndDevelopmentServicesCurrent" xlink:type="locator" xlink:label="caba_AccruedResearchAndDevelopmentServicesCurrent" />
    <link:loc xlink:href="caba-20201231.xsd#caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="caba_AccruedResearchAndDevelopmentServicesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="caba_AccruedGeneralAndAdministrativeServicesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails" xlink:href="caba-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails">
    <link:loc xlink:href="caba-20201231.xsd#caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" xlink:type="locator" xlink:label="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails" xlink:href="caba-20201231.xsd#Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="caba-20201231.xsd#caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" xlink:type="locator" xlink:label="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails" xlink:href="caba-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="caba-20201231.xsd#caba_DeferredTaxAssetsLicenseFeesDeductions" xlink:type="locator" xlink:label="caba_DeferredTaxAssetsLicenseFeesDeductions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="caba_DeferredTaxAssetsLicenseFeesDeductions" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:href="caba-20201231.xsd#Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:type="locator" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="locator" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:type="locator" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10350.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="10360.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" order="10370.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:to="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" order="10380.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>30
<FILENAME>caba-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-15T17:02:46.7673149+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : b469dc7abe284c828e6850b36ac62ee6 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="caba-20201231.xsd#TemplateLink" roleURI="http://www.cabalettabio.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" xlink:href="caba-20201231.xsd#Role_StatementBalanceSheetsParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:type="locator" xlink:label="us-gaap_NonvotingCommonStockMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_VotingCommonStockMember" xlink:type="locator" xlink:label="caba_VotingCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_VotingCommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10740.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:href="caba-20201231.xsd#Role_StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityConvertedIntoCommonStockValue" xlink:type="locator" xlink:label="caba_TemporaryEquityConvertedIntoCommonStockValue" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityStockConvertedIntoCommonStock" xlink:type="locator" xlink:label="caba_TemporaryEquityStockConvertedIntoCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="caba-20201231.xsd#caba_StockIssuedDuringPeriodShareStockOptionsExercised" xlink:type="locator" xlink:label="caba_StockIssuedDuringPeriodShareStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" xlink:type="locator" xlink:label="caba_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesNetOfIssuanceCosts" xlink:type="locator" xlink:label="caba_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesNetOfIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesNetOfIssuanceCosts" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_StockIssuedDuringPeriodShareStockOptionsExercised" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_TemporaryEquityStockConvertedIntoCommonStock" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_TemporaryEquityConvertedIntoCommonStockValue" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" xlink:href="caba-20201231.xsd#Role_StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:type="locator" xlink:label="us-gaap_PreferredStockConversionBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConversionBasis" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetails" xlink:href="caba-20201231.xsd#Role_DisclosureBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="caba-20201231.xsd#caba_NumberOfAdditionalCommonStockPurchasedByUnderwritersUponPartialExerciseOfOption" xlink:type="locator" xlink:label="caba_NumberOfAdditionalCommonStockPurchasedByUnderwritersUponPartialExerciseOfOption" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_BasisOfPresentationTable" xlink:type="locator" xlink:label="caba_BasisOfPresentationTable" />
    <link:loc xlink:href="caba-20201231.xsd#caba_BasisOfPresentationLineItems" xlink:type="locator" xlink:label="caba_BasisOfPresentationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="caba_BasisOfPresentationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_BasisOfPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="caba_NumberOfAdditionalCommonStockPurchasedByUnderwritersUponPartialExerciseOfOption" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10540.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="caba-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportingUnits" xlink:type="locator" xlink:label="us-gaap_NumberOfReportingUnits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="caba-20201231.xsd#caba_InvestmentsMaturityYear" xlink:type="locator" xlink:label="caba_InvestmentsMaturityYear" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ProfessionalServicesMember" xlink:type="locator" xlink:label="caba_ProfessionalServicesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="caba_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="caba-20201231.xsd#caba_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="caba_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="caba_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="caba_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="caba_ProfessionalServicesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="caba_InvestmentsMaturityYear" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportingUnits" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="10330.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails" xlink:href="caba-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="caba_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="caba_LaboratoryEquipmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="caba-20201231.xsd#Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateNoteSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ShortTermInvestmentsAbstract" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestments" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11690.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails" xlink:href="caba-20201231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateNoteSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10650.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="caba-20201231.xsd#Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails" xlink:href="caba-20201231.xsd#Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="caba-20201231.xsd#caba_ContractualExpenses" xlink:type="locator" xlink:label="caba_ContractualExpenses" />
    <link:loc xlink:href="caba-20201231.xsd#caba_MaximumResearchAndDevelopmentAdditionalExpenseDueInRemainingTerm" xlink:type="locator" xlink:label="caba_MaximumResearchAndDevelopmentAdditionalExpenseDueInRemainingTerm" />
    <link:loc xlink:href="caba-20201231.xsd#caba_AdvancePayments" xlink:type="locator" xlink:label="caba_AdvancePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ContractualCostIncurred" xlink:type="locator" xlink:label="caba_ContractualCostIncurred" />
    <link:loc xlink:href="caba-20201231.xsd#caba_FundingTermEndingDate" xlink:type="locator" xlink:label="caba_FundingTermEndingDate" />
    <link:loc xlink:href="caba-20201231.xsd#caba_NumberOfFaculty" xlink:type="locator" xlink:label="caba_NumberOfFaculty" />
    <link:loc xlink:href="caba-20201231.xsd#caba_CollaborativeAgreementPaymentsDue" xlink:type="locator" xlink:label="caba_CollaborativeAgreementPaymentsDue" />
    <link:loc xlink:href="caba-20201231.xsd#caba_MilestonePayments" xlink:type="locator" xlink:label="caba_MilestonePayments" />
    <link:loc xlink:href="caba-20201231.xsd#caba_LicenseMaintenanceFee" xlink:type="locator" xlink:label="caba_LicenseMaintenanceFee" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ObligationToBePaidCommencementDate" xlink:type="locator" xlink:label="caba_ObligationToBePaidCommencementDate" />
    <link:loc xlink:href="caba-20201231.xsd#caba_PaymentOfObligationTerm" xlink:type="locator" xlink:label="caba_PaymentOfObligationTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:loc xlink:href="caba-20201231.xsd#caba_SubscriptionAndTechnologyTransferAgreementMember" xlink:type="locator" xlink:label="caba_SubscriptionAndTechnologyTransferAgreementMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_MasterTranslationalResearchServicesAgreementMember" xlink:type="locator" xlink:label="caba_MasterTranslationalResearchServicesAgreementMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_AccruedAndOtherCurrentLiabilitiesMember" xlink:type="locator" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_RegentsOfUniversityOfCaliforniaMember" xlink:type="locator" xlink:label="caba_RegentsOfUniversityOfCaliforniaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_SponsoredResearchAgreementsMember" xlink:type="locator" xlink:label="caba_SponsoredResearchAgreementsMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_LicenseAgreementMember" xlink:type="locator" xlink:label="caba_LicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentArrangementMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentAxis" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:type="locator" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" />
    <link:loc xlink:href="caba-20201231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:type="locator" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_SupplyCommitmentAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_LicenseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_SponsoredResearchAgreementsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="caba_RegentsOfUniversityOfCaliforniaMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="caba_AccruedAndOtherCurrentLiabilitiesMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_MasterTranslationalResearchServicesAgreementMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_SubscriptionAndTechnologyTransferAgreementMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="us-gaap_ContractualObligation" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_PaymentOfObligationTerm" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_ObligationToBePaidCommencementDate" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_LicenseMaintenanceFee" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_MilestonePayments" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_CollaborativeAgreementPaymentsDue" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_NumberOfFaculty" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_FundingTermEndingDate" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_ContractualCostIncurred" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_AdvancePayments" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_MaximumResearchAndDevelopmentAdditionalExpenseDueInRemainingTerm" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_ContractualExpenses" order="11270.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="caba-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="caba-20201231.xsd#caba_RentExpense" xlink:type="locator" xlink:label="caba_RentExpense" />
    <link:loc xlink:href="caba-20201231.xsd#caba_AnnualIncreasePercentageOfBaseRent" xlink:type="locator" xlink:label="caba_AnnualIncreasePercentageOfBaseRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals" />
    <link:loc xlink:href="caba-20201231.xsd#caba_LeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="caba_LeaseExpirationMonthAndYear" />
    <link:loc xlink:href="caba-20201231.xsd#caba_LeaseCommencementMonthAndYear" xlink:type="locator" xlink:label="caba_LeaseCommencementMonthAndYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="caba-20201231.xsd#caba_OperatingLeaseAgreementMember" xlink:type="locator" xlink:label="caba_OperatingLeaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentAxis" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="caba_CommitmentsAndContingenciesDisclosureTable" />
    <link:loc xlink:href="caba-20201231.xsd#caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="caba_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_CommitmentsAndContingenciesDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_SupplyCommitmentAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_OperatingLeaseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_LeaseCommencementMonthAndYear" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_LeaseExpirationMonthAndYear" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_AnnualIncreasePercentageOfBaseRent" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_RentExpense" order="10420.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="caba-20201231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ConvertiblePreferredStockConvertIntoNonVotingCommonStock" xlink:type="locator" xlink:label="caba_ConvertiblePreferredStockConvertIntoNonVotingCommonStock" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ConvertiblePreferredStockConvertIntoVotingCommonStock" xlink:type="locator" xlink:label="caba_ConvertiblePreferredStockConvertIntoVotingCommonStock" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityValueExchangeIncludingDeemedDividend" xlink:type="locator" xlink:label="caba_TemporaryEquityValueExchangeIncludingDeemedDividend" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquitySharesExchangeIncludingDeemedDividend" xlink:type="locator" xlink:label="caba_TemporaryEquitySharesExchangeIncludingDeemedDividend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_SeriesA2PreferredStockMember" xlink:type="locator" xlink:label="caba_SeriesA2PreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_SeriesA2PreferredStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_TemporaryEquitySharesExchangeIncludingDeemedDividend" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_TemporaryEquityValueExchangeIncludingDeemedDividend" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_ConvertiblePreferredStockConvertIntoVotingCommonStock" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_ConvertiblePreferredStockConvertIntoNonVotingCommonStock" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10680.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails" xlink:href="caba-20201231.xsd#Role_DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails">
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityConversionOfStockSharesForCommonStock" xlink:type="locator" xlink:label="caba_TemporaryEquityConversionOfStockSharesForCommonStock" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityConversionOfStockValueForCommonStock" xlink:type="locator" xlink:label="caba_TemporaryEquityConversionOfStockValueForCommonStock" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityIssuanceCosts" xlink:type="locator" xlink:label="caba_TemporaryEquityIssuanceCosts" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquitySharesExchangeIncludingDeemedDividend" xlink:type="locator" xlink:label="caba_TemporaryEquitySharesExchangeIncludingDeemedDividend" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityValueExchangeIncludingDeemedDividend" xlink:type="locator" xlink:label="caba_TemporaryEquityValueExchangeIncludingDeemedDividend" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_SeriesA2PreferredStockMember" xlink:type="locator" xlink:label="caba_SeriesA2PreferredStockMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_SeriesA1PreferredStockMember" xlink:type="locator" xlink:label="caba_SeriesA1PreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_SeriesA1PreferredStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_SeriesA2PreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_TemporaryEquityValueExchangeIncludingDeemedDividend" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_TemporaryEquitySharesExchangeIncludingDeemedDividend" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_TemporaryEquityIssuanceCosts" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_TemporaryEquityConversionOfStockValueForCommonStock" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_TemporaryEquityConversionOfStockSharesForCommonStock" order="11200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:href="caba-20201231.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails">
    <link:loc xlink:href="caba-20201231.xsd#caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" xlink:type="locator" xlink:label="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" />
    <link:loc xlink:href="caba-20201231.xsd#caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" xlink:type="locator" xlink:label="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" />
    <link:loc xlink:href="caba-20201231.xsd#caba_PercentageOfPayrollDeductionOnEligibleCompensation" xlink:type="locator" xlink:label="caba_PercentageOfPayrollDeductionOnEligibleCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="caba-20201231.xsd#caba_IncreaseInShareReservedPercentage" xlink:type="locator" xlink:label="caba_IncreaseInShareReservedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStockSharesCompensationCost" xlink:type="locator" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStockSharesCompensationCost" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModifiedFairValue" xlink:type="locator" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModifiedFairValue" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModified" xlink:type="locator" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModified" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ConversionOfNonVotingCommonStockToVotingCommonStockSharesConverted" xlink:type="locator" xlink:label="caba_ConversionOfNonVotingCommonStockToVotingCommonStockSharesConverted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TwoThousandEighteenStockOptionAndGrantPlanMember" xlink:type="locator" xlink:label="caba_TwoThousandEighteenStockOptionAndGrantPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_FoundersMember" xlink:type="locator" xlink:label="caba_FoundersMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_AtTheMarketOfferingSalesAgreementMember" xlink:type="locator" xlink:label="caba_AtTheMarketOfferingSalesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:type="locator" xlink:label="us-gaap_NonvotingCommonStockMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_VotingCommonStockMember" xlink:type="locator" xlink:label="caba_VotingCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_VotingCommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_AtTheMarketOfferingSalesAgreementMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="caba_FoundersMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandEighteenStockOptionAndGrantPlanMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_ConversionOfNonVotingCommonStockToVotingCommonStockSharesConverted" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModified" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModifiedFairValue" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStockSharesCompensationCost" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_IncreaseInShareReservedPercentage" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="12000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_PercentageOfPayrollDeductionOnEligibleCompensation" order="12300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" order="12340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" order="12380.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfStockOptionActivityDetails" xlink:href="caba-20201231.xsd#Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfStockOptionActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:type="locator" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:type="locator" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="11770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="12270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" order="13000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="13200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="13500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" order="13630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="13830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="13930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="14330.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" xlink:href="caba-20201231.xsd#Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10380.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfStockBasedCompensationDetails" xlink:href="caba-20201231.xsd#Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfStockBasedCompensationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="caba-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <link:loc xlink:href="caba-20201231.xsd#caba_PercentageOfEligibleTaxPositionsForRecognition" xlink:type="locator" xlink:label="caba_PercentageOfEligibleTaxPositionsForRecognition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:loc xlink:href="caba-20201231.xsd#caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" xlink:type="locator" xlink:label="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="caba-20201231.xsd#caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" xlink:type="locator" xlink:label="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" />
    <link:loc xlink:href="caba-20201231.xsd#caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" xlink:type="locator" xlink:label="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" />
    <link:loc xlink:href="caba-20201231.xsd#caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" xlink:type="locator" xlink:label="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:loc xlink:href="caba-20201231.xsd#caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal" xlink:type="locator" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal" />
    <link:loc xlink:href="caba-20201231.xsd#caba_DeferredTaxAssetsOperatingLossCarryforwardsState" xlink:type="locator" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsState" />
    <link:loc xlink:href="caba-20201231.xsd#caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal" xlink:type="locator" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="caba-20201231.xsd#caba_FederalMember" xlink:type="locator" xlink:label="caba_FederalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="caba_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="caba-20201231.xsd#caba_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="caba_IncomeTaxDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_IncomeTaxDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="caba_FederalMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_DeferredTaxAssetsOperatingLossCarryforwardsState" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OpenTaxYear" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_PercentageOfEligibleTaxPositionsForRecognition" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="10530.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:href="caba-20201231.xsd#Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:type="locator" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:type="locator" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="locator" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:type="locator" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:type="locator" xlink:label="us-gaap_NonvotingCommonStockMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_VotingCommonStockMember" xlink:type="locator" xlink:label="caba_VotingCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_EarningsPerShareBasicAndDilutedTable" xlink:type="locator" xlink:label="caba_EarningsPerShareBasicAndDilutedTable" />
    <link:loc xlink:href="caba-20201231.xsd#caba_EarningPerShareBasicAndDilutedLineItems" xlink:type="locator" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="caba_EarningsPerShareBasicAndDilutedTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_VotingCommonStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="10950.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="caba-20201231.xsd#Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="caba-20201231.xsd#caba_NonVestedCommonStockMember" xlink:type="locator" xlink:label="caba_NonVestedCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="caba_NonVestedCommonStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="caba-20201231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:href="caba-20201231.xsd#caba_ExpectedResearchServiceAgreementCost" xlink:type="locator" xlink:label="caba_ExpectedResearchServiceAgreementCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:type="locator" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ResearchServiceAgreementMember" xlink:type="locator" xlink:label="caba_ResearchServiceAgreementMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ChildrenSHospitalOfPhiladelphiaMember" xlink:type="locator" xlink:label="caba_ChildrenSHospitalOfPhiladelphiaMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_DevelopmentAndManufacturingServicesAgreementMember" xlink:type="locator" xlink:label="caba_DevelopmentAndManufacturingServicesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentAxis" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_WuXiAdvancedTherapiesMember" xlink:type="locator" xlink:label="caba_WuXiAdvancedTherapiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="caba_WuXiAdvancedTherapiesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SupplyCommitmentAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_DevelopmentAndManufacturingServicesAgreementMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="caba_ChildrenSHospitalOfPhiladelphiaMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_ResearchServiceAgreementMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="caba_ExpectedResearchServiceAgreementCost" order="10470.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>31
<FILENAME>caba-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-15T17:02:46.7673149+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : b469dc7abe284c828e6850b36ac62ee6 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued liabilities and other liabilities current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (see Note 7)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.00001 par value: 10,000,000 shares authorized as of December 31, 2020 and 2019, respectively; no shares issued or outstanding at December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Voting and non-voting common stock, $0.00001 par value: 150,000,000 (143,590,481 voting and 6,409,519 non-voting) shares authorized as of December 31, 2020 and 2019, respectively; 24,062,775 (19,387,160 voting and 4,675,615 non-voting) shares issued and outstanding as of December 31, 2020 and 24,034,022 (17,624,503 voting and 6,409,519 non-voting) issued and outstanding as of December 31, 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_VotingCommonStockMember" xlink:type="locator" xlink:label="caba_VotingCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="caba_VotingCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Voting common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_VotingCommonStockMember" xlink:to="caba_VotingCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_VotingCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Voting Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_VotingCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Voting Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:type="locator" xlink:label="us-gaap_NonvotingCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvotingCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-voting Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvotingCommonStockMember" xlink:to="us-gaap_NonvotingCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvotingCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonvoting Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, authorized shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issued shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, outstanding shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, authorized shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, issued shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, outstanding shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends" xlink:type="locator" xlink:label="us-gaap_Dividends" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Dividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deemed dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Dividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized gain on available-for-sale investments, net of tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per voting and non-voting share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" xlink:type="locator" xlink:label="caba_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" />
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityStockIssuedDuringPeriodShareNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period share new issues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" xlink:to="caba_TemporaryEquityStockIssuedDuringPeriodShareNewIssues_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesNetOfIssuanceCosts" xlink:type="locator" xlink:label="caba_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesNetOfIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period value new issues net of issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesNetOfIssuanceCosts" xlink:to="caba_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesNetOfIssuanceCosts_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_StockIssuedDuringPeriodShareStockOptionsExercised" xlink:type="locator" xlink:label="caba_StockIssuedDuringPeriodShareStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="caba_StockIssuedDuringPeriodShareStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period share stock options exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_StockIssuedDuringPeriodShareStockOptionsExercised" xlink:to="caba_StockIssuedDuringPeriodShareStockOptionsExercised_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityStockConvertedIntoCommonStock" xlink:type="locator" xlink:label="caba_TemporaryEquityStockConvertedIntoCommonStock" />
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityStockConvertedIntoCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock converted into common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TemporaryEquityStockConvertedIntoCommonStock" xlink:to="caba_TemporaryEquityStockConvertedIntoCommonStock_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityConvertedIntoCommonStockValue" xlink:type="locator" xlink:label="caba_TemporaryEquityConvertedIntoCommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityConvertedIntoCommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity converted into common stock value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TemporaryEquityConvertedIntoCommonStockValue" xlink:to="caba_TemporaryEquityConvertedIntoCommonStockValue_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aoci Including Portion Attributable To Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues Net Of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityStockIssuedDuringPeriodShareNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, net of issuance cost, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityStockIssuedDuringPeriodShareNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Share New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in conjunction with exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_StockIssuedDuringPeriodShareStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in conjunction with exercise of stock options, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_StockIssuedDuringPeriodShareStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Share Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized gains on available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Unrealized Gain Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange of convertible preferred stock, including deemed dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassifications Of Temporary To Permanent Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Units</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityStockConvertedIntoCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityStockConvertedIntoCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Converted Into Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityConvertedIntoCommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityConvertedIntoCommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Converted Into Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:type="locator" xlink:label="us-gaap_PreferredStockConversionBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock conversion basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConversionBasis" xlink:to="us-gaap_PreferredStockConversionBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Conversion Basis</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_ExchangeOfConvertiblePreferredStockIncludingDeemedDividend" xlink:type="locator" xlink:label="caba_ExchangeOfConvertiblePreferredStockIncludingDeemedDividend" />
    <link:label xml:lang="en-US" xlink:label="caba_ExchangeOfConvertiblePreferredStockIncludingDeemedDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange of convertible preferred stock, including deemed dividend.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ExchangeOfConvertiblePreferredStockIncludingDeemedDividend" xlink:to="caba_ExchangeOfConvertiblePreferredStockIncludingDeemedDividend_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_DeferredOfferingCostsInAccountsPayableAndAccruedAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="caba_DeferredOfferingCostsInAccountsPayableAndAccruedAndOtherCurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="caba_DeferredOfferingCostsInAccountsPayableAndAccruedAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs in accounts payable and accrued and other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_DeferredOfferingCostsInAccountsPayableAndAccruedAndOtherCurrentLiabilities" xlink:to="caba_DeferredOfferingCostsInAccountsPayableAndAccruedAndOtherCurrentLiabilities_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premium on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Available For Sale Securities Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Issuance costs of convertible preferred stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in connection with the exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock under employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents&#8212;beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents&#8212;end of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Amount Converted1</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ExchangeOfConvertiblePreferredStockIncludingDeemedDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange of convertible preferred stock, including deemed dividend</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ExchangeOfConvertiblePreferredStockIncludingDeemedDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Of Convertible Preferred Stock Including Deemed Dividend</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_DeferredOfferingCostsInAccountsPayableAndAccruedAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs in accounts payable and accrued and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_DeferredOfferingCostsInAccountsPayableAndAccruedAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs In Accounts Payable And Accrued And Other Current Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases included in accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and Other Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" xlink:type="locator" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborations licensing agreements and other agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" xlink:type="locator" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborations licensing agreements and other agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborations Licensing Agreements And Other Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborations, Licensing Agreements and other Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborations Licensing Agreements And Other Agreements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders Equity And Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(k) Savings Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Off-Balance Sheet Risk and Concentrations of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:to="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Off Balance Sheet Credit Exposure Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_RelatedPartyTransactionsPolicyTextBlock" xlink:type="locator" xlink:label="caba_RelatedPartyTransactionsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="caba_RelatedPartyTransactionsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transactions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_RelatedPartyTransactionsPolicyTextBlock" xlink:to="caba_RelatedPartyTransactionsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_RelatedPartyTransactionsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_RelatedPartyTransactionsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Policy [Text Block]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:type="locator" xlink:label="caba_EmergingGrowthCompanyStatusPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="caba_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging growth company status.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="caba_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status Policy [Text Block]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:type="locator" xlink:label="caba_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="caba_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently issued accounting pronouncements not yet adopted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="caba_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Pronouncements Not Yet Adopted Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:type="locator" xlink:label="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of estimated useful lives of property and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Useful Lives for Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Estimated Useful Lives Of Property And Equipment Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Debt Securities Classified as Available-for-Sale Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Payments for Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PartnersCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_PartnersCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PartnersCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Partners Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnersCapitalAbstract" xlink:to="us-gaap_PartnersCapitalAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions Used to Estimate Fair Value of Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Federal Statutory Income Tax Rate to Company&apos;s Effective Income Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Principal Components of Company&apos;s Deferred Tax Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Earnings Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_BasisOfPresentationLineItems" xlink:type="locator" xlink:label="caba_BasisOfPresentationLineItems" />
    <link:label xml:lang="en-US" xlink:label="caba_BasisOfPresentationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="caba_BasisOfPresentationLineItems_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_BasisOfPresentationTable" xlink:type="locator" xlink:label="caba_BasisOfPresentationTable" />
    <link:label xml:lang="en-US" xlink:label="caba_BasisOfPresentationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_BasisOfPresentationTable" xlink:to="caba_BasisOfPresentationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_BasisOfPresentationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis Of Presentation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_BasisOfPresentationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_BasisOfPresentationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis Of Presentation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_BasisOfPresentationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Reverse Stock Split</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_NumberOfAdditionalCommonStockPurchasedByUnderwritersUponPartialExerciseOfOption" xlink:type="locator" xlink:label="caba_NumberOfAdditionalCommonStockPurchasedByUnderwritersUponPartialExerciseOfOption" />
    <link:label xml:lang="en-US" xlink:label="caba_NumberOfAdditionalCommonStockPurchasedByUnderwritersUponPartialExerciseOfOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional common stock purchased by underwriters upon partial exercise of option.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_NumberOfAdditionalCommonStockPurchasedByUnderwritersUponPartialExerciseOfOption" xlink:to="caba_NumberOfAdditionalCommonStockPurchasedByUnderwritersUponPartialExerciseOfOption_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued, per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of convertible preferred stock to common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_NumberOfAdditionalCommonStockPurchasedByUnderwritersUponPartialExerciseOfOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional common stock purchased by underwriters upon partial exercise of option</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_NumberOfAdditionalCommonStockPurchasedByUnderwritersUponPartialExerciseOfOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Additional Common Stock Purchased By Underwriters Upon Partial Exercise Of Option</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents and investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_InvestmentsMaturityYear" xlink:type="locator" xlink:label="caba_InvestmentsMaturityYear" />
    <link:label xml:lang="en-US" xlink:label="caba_InvestmentsMaturityYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Investments maturity year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_InvestmentsMaturityYear" xlink:to="caba_InvestmentsMaturityYear_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="caba_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="caba_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="caba_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="caba_SummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="caba_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_SummaryOfSignificantAccountingPoliciesTable" xlink:to="caba_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_ProfessionalServicesMember" xlink:type="locator" xlink:label="caba_ProfessionalServicesMember" />
    <link:label xml:lang="en-US" xlink:label="caba_ProfessionalServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Professional services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ProfessionalServicesMember" xlink:to="caba_ProfessionalServicesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_ProfessionalServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional Services</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ProfessionalServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Professional Services [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_InvestmentsMaturityYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments maturity year</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_InvestmentsMaturityYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Maturity Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="caba_LaboratoryEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="caba_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LaboratoryEquipmentMember" xlink:to="caba_LaboratoryEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest or penalties related to uncertain income tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportingUnits" xlink:type="locator" xlink:label="us-gaap_NumberOfReportingUnits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfReportingUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportingUnits" xlink:to="us-gaap_NumberOfReportingUnits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfReportingUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Reporting Units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs incurred under the arrangement recorded as general and administrative expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts due to related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Current And Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value By Balance Sheet Grouping [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateNoteSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateNoteSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Investments - Corporate Bonds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateNoteSecuritiesMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateNoteSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Note Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Other Observable Inputs (Level 2)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Unobservable Inputs (Level 3)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestmentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestmentsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestmentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Financial Assets Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, level 1 to level 2 transfers, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level1 To Level2 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, level 2 to level 1 transfers, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level2 To Level1 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds Included in Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateNoteSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Corporate Bonds - due in One Year or Less</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, plant and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_AccruedResearchAndDevelopmentServicesCurrent" xlink:type="locator" xlink:label="caba_AccruedResearchAndDevelopmentServicesCurrent" />
    <link:label xml:lang="en-US" xlink:label="caba_AccruedResearchAndDevelopmentServicesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development services current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AccruedResearchAndDevelopmentServicesCurrent" xlink:to="caba_AccruedResearchAndDevelopmentServicesCurrent_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_AccruedGeneralAndAdministrativeServicesCurrent" xlink:type="locator" xlink:label="caba_AccruedGeneralAndAdministrativeServicesCurrent" />
    <link:label xml:lang="en-US" xlink:label="caba_AccruedGeneralAndAdministrativeServicesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued general and administrative services current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AccruedGeneralAndAdministrativeServicesCurrent" xlink:to="caba_AccruedGeneralAndAdministrativeServicesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_AccruedResearchAndDevelopmentServicesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development services</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_AccruedResearchAndDevelopmentServicesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Services Current</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_AccruedGeneralAndAdministrativeServicesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative services</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_AccruedGeneralAndAdministrativeServicesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued General And Administrative Services Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued and other current liabilities</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_PaymentOfObligationTerm" xlink:type="locator" xlink:label="caba_PaymentOfObligationTerm" />
    <link:label xml:lang="en-US" xlink:label="caba_PaymentOfObligationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of obligation, term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_PaymentOfObligationTerm" xlink:to="caba_PaymentOfObligationTerm_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ObligationToBePaidCommencementDate" xlink:type="locator" xlink:label="caba_ObligationToBePaidCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="caba_ObligationToBePaidCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Obligation to be paid, commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ObligationToBePaidCommencementDate" xlink:to="caba_ObligationToBePaidCommencementDate_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_LicenseMaintenanceFee" xlink:type="locator" xlink:label="caba_LicenseMaintenanceFee" />
    <link:label xml:lang="en-US" xlink:label="caba_LicenseMaintenanceFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License maintenance fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LicenseMaintenanceFee" xlink:to="caba_LicenseMaintenanceFee_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_MilestonePayments" xlink:type="locator" xlink:label="caba_MilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="caba_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_MilestonePayments" xlink:to="caba_MilestonePayments_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_CollaborativeAgreementPaymentsDue" xlink:type="locator" xlink:label="caba_CollaborativeAgreementPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="caba_CollaborativeAgreementPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative agreement payments due.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CollaborativeAgreementPaymentsDue" xlink:to="caba_CollaborativeAgreementPaymentsDue_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:type="locator" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" />
    <link:label xml:lang="en-US" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborations licensing agreements and other agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:type="locator" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" />
    <link:label xml:lang="en-US" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborations licensing agreements and other agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborations Licensing Agreements And Other Agreements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborations Licensing Agreements And Other Agreements [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentAxis" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplyCommitmentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply Commitment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplyCommitmentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supply Commitment [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentArrangementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplyCommitmentArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply Commitment Arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="us-gaap_SupplyCommitmentArrangementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplyCommitmentArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supply Commitment Arrangement [Member]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_LicenseAgreementMember" xlink:type="locator" xlink:label="caba_LicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="caba_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LicenseAgreementMember" xlink:to="caba_LicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_SponsoredResearchAgreementsMember" xlink:type="locator" xlink:label="caba_SponsoredResearchAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="caba_SponsoredResearchAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sponsored Research Agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_SponsoredResearchAgreementsMember" xlink:to="caba_SponsoredResearchAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_SponsoredResearchAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sponsored Research Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_SponsoredResearchAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sponsored Research Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity of Counterparty, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Notes Loans And Financing Receivables By Legal Entity Of Counterparty Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity Type of Counterparty</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity Type Of Counterparty [Domain]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_RegentsOfUniversityOfCaliforniaMember" xlink:type="locator" xlink:label="caba_RegentsOfUniversityOfCaliforniaMember" />
    <link:label xml:lang="en-US" xlink:label="caba_RegentsOfUniversityOfCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Regents of the university of California.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_RegentsOfUniversityOfCaliforniaMember" xlink:to="caba_RegentsOfUniversityOfCaliforniaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_RegentsOfUniversityOfCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Penn</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_RegentsOfUniversityOfCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Regents Of University Of California [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Member]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_AccruedAndOtherCurrentLiabilitiesMember" xlink:type="locator" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued and other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AccruedAndOtherCurrentLiabilitiesMember" xlink:to="caba_AccruedAndOtherCurrentLiabilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued And Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_MasterTranslationalResearchServicesAgreementMember" xlink:type="locator" xlink:label="caba_MasterTranslationalResearchServicesAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="caba_MasterTranslationalResearchServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Master translational research services agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_MasterTranslationalResearchServicesAgreementMember" xlink:to="caba_MasterTranslationalResearchServicesAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_MasterTranslationalResearchServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Master Translational Research Services Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_MasterTranslationalResearchServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Master Translational Research Services Agreement [Member]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_SubscriptionAndTechnologyTransferAgreementMember" xlink:type="locator" xlink:label="caba_SubscriptionAndTechnologyTransferAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="caba_SubscriptionAndTechnologyTransferAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Subscription and technology transfer agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_SubscriptionAndTechnologyTransferAgreementMember" xlink:to="caba_SubscriptionAndTechnologyTransferAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_SubscriptionAndTechnologyTransferAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subscription and Technology Transfer Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_SubscriptionAndTechnologyTransferAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subscription And Technology Transfer Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborations, Licensing Agreements And Other Agreements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborations Licensing Agreements And Other Agreements [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Obligation to be paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_PaymentOfObligationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment term</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_PaymentOfObligationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Obligation Term</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ObligationToBePaidCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ObligationToBePaidCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Obligation To Be Paid Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_LicenseMaintenanceFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License maintenance fee</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_LicenseMaintenanceFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Maintenance Fee</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_CollaborativeAgreementPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts due to agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_CollaborativeAgreementPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Agreement Payments Due</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_NumberOfFaculty" xlink:type="locator" xlink:label="caba_NumberOfFaculty" />
    <link:label xml:lang="en-US" xlink:label="caba_NumberOfFaculty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of faculty.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_NumberOfFaculty" xlink:to="caba_NumberOfFaculty_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_FundingTermEndingDate" xlink:type="locator" xlink:label="caba_FundingTermEndingDate" />
    <link:label xml:lang="en-US" xlink:label="caba_FundingTermEndingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding term ending date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_FundingTermEndingDate" xlink:to="caba_FundingTermEndingDate_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_AdvancePayments" xlink:type="locator" xlink:label="caba_AdvancePayments" />
    <link:label xml:lang="en-US" xlink:label="caba_AdvancePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AdvancePayments" xlink:to="caba_AdvancePayments_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ContractualCostIncurred" xlink:type="locator" xlink:label="caba_ContractualCostIncurred" />
    <link:label xml:lang="en-US" xlink:label="caba_ContractualCostIncurred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual cost incurred.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ContractualCostIncurred" xlink:to="caba_ContractualCostIncurred_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_NumberOfFaculty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of faculty member</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_NumberOfFaculty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Faculty</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_FundingTermEndingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding term end date</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_FundingTermEndingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Funding Term Ending Date</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ContractualCostIncurred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost incurred</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ContractualCostIncurred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Cost Incurred</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_AdvancePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance payments</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_AdvancePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Advance Payments</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_MaximumResearchAndDevelopmentAdditionalExpenseDueInRemainingTerm" xlink:type="locator" xlink:label="caba_MaximumResearchAndDevelopmentAdditionalExpenseDueInRemainingTerm" />
    <link:label xml:lang="en-US" xlink:label="caba_MaximumResearchAndDevelopmentAdditionalExpenseDueInRemainingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum research and development additional expense due in remaining term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_MaximumResearchAndDevelopmentAdditionalExpenseDueInRemainingTerm" xlink:to="caba_MaximumResearchAndDevelopmentAdditionalExpenseDueInRemainingTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_MaximumResearchAndDevelopmentAdditionalExpenseDueInRemainingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum research and development additional expense incurred</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_MaximumResearchAndDevelopmentAdditionalExpenseDueInRemainingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Research And Development Additional Expense Due In Remaining Term</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_ContractualExpenses" xlink:type="locator" xlink:label="caba_ContractualExpenses" />
    <link:label xml:lang="en-US" xlink:label="caba_ContractualExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ContractualExpenses" xlink:to="caba_ContractualExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_ContractualExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expense related to agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ContractualExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Expenses</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_LeaseCommencementMonthAndYear" xlink:type="locator" xlink:label="caba_LeaseCommencementMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="caba_LeaseCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LeaseCommencementMonthAndYear" xlink:to="caba_LeaseCommencementMonthAndYear_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_LeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="caba_LeaseExpirationMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="caba_LeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LeaseExpirationMonthAndYear" xlink:to="caba_LeaseExpirationMonthAndYear_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_AnnualIncreasePercentageOfBaseRent" xlink:type="locator" xlink:label="caba_AnnualIncreasePercentageOfBaseRent" />
    <link:label xml:lang="en-US" xlink:label="caba_AnnualIncreasePercentageOfBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual increase percentage of base rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AnnualIncreasePercentageOfBaseRent" xlink:to="caba_AnnualIncreasePercentageOfBaseRent_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_RentExpense" xlink:type="locator" xlink:label="caba_RentExpense" />
    <link:label xml:lang="en-US" xlink:label="caba_RentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Rent expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_RentExpense" xlink:to="caba_RentExpense_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="caba_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="caba_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_CommitmentsAndContingenciesDisclosureLineItems_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="caba_CommitmentsAndContingenciesDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="caba_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="caba_CommitmentsAndContingenciesDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_OperatingLeaseAgreementMember" xlink:type="locator" xlink:label="caba_OperatingLeaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="caba_OperatingLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Lease Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OperatingLeaseAgreementMember" xlink:to="caba_OperatingLeaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_OperatingLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_OperatingLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Description</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_LeaseCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement period</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_LeaseCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_LeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration period</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_LeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month And Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial annual base rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Rent Expense Minimum Rentals</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_AnnualIncreasePercentageOfBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual increase of base rent</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_AnnualIncreasePercentageOfBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Increase Percentage Of Base Rent</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_RentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_RentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Rent Expense</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" xlink:type="locator" xlink:label="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" />
    <link:label xml:lang="en-US" xlink:label="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due after rolling year three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" xlink:to="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due In Rolling Year Two</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Rolling Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_SeriesA2PreferredStockMember" xlink:type="locator" xlink:label="caba_SeriesA2PreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="caba_SeriesA2PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-2 preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_SeriesA2PreferredStockMember" xlink:to="caba_SeriesA2PreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_SeriesA2PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-2 Preferred</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_SeriesA2PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A2 Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, authorized shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, issued shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, outstanding shares</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period, shares, new issues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquitySharesExchangeIncludingDeemedDividend" xlink:type="locator" xlink:label="caba_TemporaryEquitySharesExchangeIncludingDeemedDividend" />
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquitySharesExchangeIncludingDeemedDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity shares exchange including deemed dividend.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TemporaryEquitySharesExchangeIncludingDeemedDividend" xlink:to="caba_TemporaryEquitySharesExchangeIncludingDeemedDividend_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityValueExchangeIncludingDeemedDividend" xlink:type="locator" xlink:label="caba_TemporaryEquityValueExchangeIncludingDeemedDividend" />
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityValueExchangeIncludingDeemedDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity value exchange including deemed dividend.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TemporaryEquityValueExchangeIncludingDeemedDividend" xlink:to="caba_TemporaryEquityValueExchangeIncludingDeemedDividend_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityIssuanceCosts" xlink:type="locator" xlink:label="caba_TemporaryEquityIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TemporaryEquityIssuanceCosts" xlink:to="caba_TemporaryEquityIssuanceCosts_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityConversionOfStockSharesForCommonStock" xlink:type="locator" xlink:label="caba_TemporaryEquityConversionOfStockSharesForCommonStock" />
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityConversionOfStockSharesForCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity conversion of stock shares for common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TemporaryEquityConversionOfStockSharesForCommonStock" xlink:to="caba_TemporaryEquityConversionOfStockSharesForCommonStock_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityConversionOfStockValueForCommonStock" xlink:type="locator" xlink:label="caba_TemporaryEquityConversionOfStockValueForCommonStock" />
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityConversionOfStockValueForCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity conversion of stock value for common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TemporaryEquityConversionOfStockValueForCommonStock" xlink:to="caba_TemporaryEquityConversionOfStockValueForCommonStock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_SeriesA1PreferredStockMember" xlink:type="locator" xlink:label="caba_SeriesA1PreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="caba_SeriesA1PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-1 preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_SeriesA1PreferredStockMember" xlink:to="caba_SeriesA1PreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_SeriesA1PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1 Preferred</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_SeriesA1PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A1 Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityValueExchangeIncludingDeemedDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange, including deemed dividend</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityValueExchangeIncludingDeemedDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Value Exchange Including Deemed Dividend</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquitySharesExchangeIncludingDeemedDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange, including deemed dividend, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquitySharesExchangeIncludingDeemedDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Exchange Including Deemed Dividend</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityConversionOfStockValueForCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion to common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityConversionOfStockValueForCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion Of Stock Value For Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityConversionOfStockSharesForCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion to common stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityConversionOfStockSharesForCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion Of Stock Shares For Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, authorized shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Gross proceeds from convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquitySharesExchangeIncludingDeemedDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of preferred shares in exchange</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TemporaryEquityValueExchangeIncludingDeemedDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Preferred stock exchange including deemed dividend</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_ConvertiblePreferredStockConvertIntoVotingCommonStock" xlink:type="locator" xlink:label="caba_ConvertiblePreferredStockConvertIntoVotingCommonStock" />
    <link:label xml:lang="en-US" xlink:label="caba_ConvertiblePreferredStockConvertIntoVotingCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock convert into voting common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ConvertiblePreferredStockConvertIntoVotingCommonStock" xlink:to="caba_ConvertiblePreferredStockConvertIntoVotingCommonStock_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ConvertiblePreferredStockConvertIntoNonVotingCommonStock" xlink:type="locator" xlink:label="caba_ConvertiblePreferredStockConvertIntoNonVotingCommonStock" />
    <link:label xml:lang="en-US" xlink:label="caba_ConvertiblePreferredStockConvertIntoNonVotingCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock convert into non-voting common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ConvertiblePreferredStockConvertIntoNonVotingCommonStock" xlink:to="caba_ConvertiblePreferredStockConvertIntoNonVotingCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_ConvertiblePreferredStockConvertIntoVotingCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock convert into common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ConvertiblePreferredStockConvertIntoVotingCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Convert Into Voting Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ConvertiblePreferredStockConvertIntoNonVotingCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock convert into non-voting common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ConvertiblePreferredStockConvertIntoNonVotingCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Convert Into Non Voting Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, outstanding shares</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_ConversionOfNonVotingCommonStockToVotingCommonStockSharesConverted" xlink:type="locator" xlink:label="caba_ConversionOfNonVotingCommonStockToVotingCommonStockSharesConverted" />
    <link:label xml:lang="en-US" xlink:label="caba_ConversionOfNonVotingCommonStockToVotingCommonStockSharesConverted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of non voting common stock to voting common stock shares converted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ConversionOfNonVotingCommonStockToVotingCommonStockSharesConverted" xlink:to="caba_ConversionOfNonVotingCommonStockToVotingCommonStockSharesConverted_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_AtTheMarketOfferingSalesAgreementMember" xlink:type="locator" xlink:label="caba_AtTheMarketOfferingSalesAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="caba_AtTheMarketOfferingSalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market offering sales agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AtTheMarketOfferingSalesAgreementMember" xlink:to="caba_AtTheMarketOfferingSalesAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_AtTheMarketOfferingSalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-The-Market Offering Sales Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_AtTheMarketOfferingSalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering Sales Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_FoundersMember" xlink:type="locator" xlink:label="caba_FoundersMember" />
    <link:label xml:lang="en-US" xlink:label="caba_FoundersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Founders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_FoundersMember" xlink:to="caba_FoundersMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_FoundersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founders</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_FoundersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Founders [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_TwoThousandEighteenStockOptionAndGrantPlanMember" xlink:type="locator" xlink:label="caba_TwoThousandEighteenStockOptionAndGrantPlanMember" />
    <link:label xml:lang="en-US" xlink:label="caba_TwoThousandEighteenStockOptionAndGrantPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen stock option and grant plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TwoThousandEighteenStockOptionAndGrantPlanMember" xlink:to="caba_TwoThousandEighteenStockOptionAndGrantPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_TwoThousandEighteenStockOptionAndGrantPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Thousand Eighteen Stock Option And Grant Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TwoThousandEighteenStockOptionAndGrantPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Stock Option And Grant Plan [Member]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen stock option and incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" xlink:to="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Stock Option And Incentive Plan [Member]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:to="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ConversionOfNonVotingCommonStockToVotingCommonStockSharesConverted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of non-voting common stock to voting common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ConversionOfNonVotingCommonStockToVotingCommonStockSharesConverted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Non Voting Common Stock To Voting Common Stock Shares Converted</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModified" xlink:type="locator" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModified" />
    <link:label xml:lang="en-US" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModified_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award common stock shares modified</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModified" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModified_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModifiedFairValue" xlink:type="locator" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModifiedFairValue" />
    <link:label xml:lang="en-US" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModifiedFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award common stock shares modified fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModifiedFairValue" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModifiedFairValue_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStockSharesCompensationCost" xlink:type="locator" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStockSharesCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStockSharesCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award modified common stock shares compensation cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStockSharesCompensationCost" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStockSharesCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModified_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares modified</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModified_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Common Stock Shares Modified</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModifiedFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock shares modified</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModifiedFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Common Stock Shares Modified Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStockSharesCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total compensation cost of common stock shares modified</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStockSharesCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Modified Common Stock Shares Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost, period for recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation cost recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation unvested number of shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation, vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_IncreaseInShareReservedPercentage" xlink:type="locator" xlink:label="caba_IncreaseInShareReservedPercentage" />
    <link:label xml:lang="en-US" xlink:label="caba_IncreaseInShareReservedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in share reserved percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IncreaseInShareReservedPercentage" xlink:to="caba_IncreaseInShareReservedPercentage_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_IncreaseInShareReservedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in share reserved percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_IncreaseInShareReservedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Share Reserved Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation, number of shares available for grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Arrangements To Obtain Goods And Services [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Shares, Granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Forfeited/Cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Options Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited/Cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Options Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:type="locator" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" />
    <link:label xml:lang="en-US" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (years)</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (years), Options Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:type="locator" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" />
    <link:label xml:lang="en-US" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options outstanding aggregate intrinsic value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant-date fair value of stock options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to unvested stock-based awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_PercentageOfPayrollDeductionOnEligibleCompensation" xlink:type="locator" xlink:label="caba_PercentageOfPayrollDeductionOnEligibleCompensation" />
    <link:label xml:lang="en-US" xlink:label="caba_PercentageOfPayrollDeductionOnEligibleCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of payroll deduction on eligible compensation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_PercentageOfPayrollDeductionOnEligibleCompensation" xlink:to="caba_PercentageOfPayrollDeductionOnEligibleCompensation_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" xlink:type="locator" xlink:label="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" />
    <link:label xml:lang="en-US" xlink:label="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan maximum annual rights to purchase common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" xlink:to="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" xlink:type="locator" xlink:label="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of shares purchased at fair market value of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" xlink:to="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_PercentageOfPayrollDeductionOnEligibleCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll deduction percentage of eligible compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_PercentageOfPayrollDeductionOnEligibleCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Payroll Deduction On Eligible Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan maximum annual rights to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Maximum Annual Rights To Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of shares to be purchased</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Shares Purchased At Fair Market Value Of Common Stock</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" xlink:type="locator" xlink:label="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" />
    <link:label xml:lang="en-US" xlink:label="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation nondeductible items and other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" xlink:to="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected income tax benefit at the federal statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State and local taxes, net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits Research</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-deductible items and other</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Items And Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_DeferredTaxAssetsLicenseFeesDeductions" xlink:type="locator" xlink:label="caba_DeferredTaxAssetsLicenseFeesDeductions" />
    <link:label xml:lang="en-US" xlink:label="caba_DeferredTaxAssetsLicenseFeesDeductions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets license fees deductions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_DeferredTaxAssetsLicenseFeesDeductions" xlink:to="caba_DeferredTaxAssetsLicenseFeesDeductions_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal, state and local net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards State And Local</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_DeferredTaxAssetsLicenseFeesDeductions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fee deductions</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_DeferredTaxAssetsLicenseFeesDeductions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets License Fees Deductions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation deductions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="caba_IncomeTaxDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="caba_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_IncomeTaxDisclosureLineItems_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="caba_IncomeTaxDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="caba_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IncomeTaxDisclosureTable" xlink:to="caba_IncomeTaxDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_FederalMember" xlink:type="locator" xlink:label="caba_FederalMember" />
    <link:label xml:lang="en-US" xlink:label="caba_FederalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_FederalMember" xlink:to="caba_FederalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_FederalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_FederalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal" xlink:type="locator" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal" />
    <link:label xml:lang="en-US" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating loss carryforwards federal.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal" xlink:to="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_DeferredTaxAssetsOperatingLossCarryforwardsState" xlink:type="locator" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsState" />
    <link:label xml:lang="en-US" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsState_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating loss carryforwards state.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_DeferredTaxAssetsOperatingLossCarryforwardsState" xlink:to="caba_DeferredTaxAssetsOperatingLossCarryforwardsState_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal" xlink:type="locator" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal" />
    <link:label xml:lang="en-US" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating loss carryforwards local.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal" xlink:to="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" xlink:type="locator" xlink:label="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" />
    <link:label xml:lang="en-US" xlink:label="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards federal commencement of expiration date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" xlink:to="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" xlink:type="locator" xlink:label="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" />
    <link:label xml:lang="en-US" xlink:label="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards state commencement of expiration date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" xlink:to="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" xlink:type="locator" xlink:label="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" />
    <link:label xml:lang="en-US" xlink:label="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax credit carryforwards commencement of expiration date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" xlink:to="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" xlink:type="locator" xlink:label="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" />
    <link:label xml:lang="en-US" xlink:label="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards local commencement of expiration date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" xlink:to="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets operating loss carryforwards federal</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Federal</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsState_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets operating loss carryforwards state</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsState_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards State</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets operating loss carryforwards local</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Local</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, operating loss carryforwards, not subject to expiration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, operating loss carryforwards, subject to expiration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards federal commencement of expiration date</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Federal Commencement Of Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards state commencement of expiration date</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards State Commencement Of Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards local commencement of expiration date</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Local Commencement Of Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets tax credit carryforwards commencement of expiration date</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Commencement Of Expiration Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open tax year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_PercentageOfEligibleTaxPositionsForRecognition" xlink:type="locator" xlink:label="caba_PercentageOfEligibleTaxPositionsForRecognition" />
    <link:label xml:lang="en-US" xlink:label="caba_PercentageOfEligibleTaxPositionsForRecognition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of eligible tax positions for recognition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_PercentageOfEligibleTaxPositionsForRecognition" xlink:to="caba_PercentageOfEligibleTaxPositionsForRecognition_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_PercentageOfEligibleTaxPositionsForRecognition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of eligible tax positions for recognition</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_PercentageOfEligibleTaxPositionsForRecognition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Eligible Tax Positions For Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized income tax benefits that would affect effective tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits That Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_EarningPerShareBasicAndDilutedLineItems" xlink:type="locator" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems" />
    <link:label xml:lang="en-US" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Earning per share basic and diluted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="caba_EarningPerShareBasicAndDilutedLineItems_lbl" />
    <link:loc xlink:href="caba-20201231.xsd#caba_EarningsPerShareBasicAndDilutedTable" xlink:type="locator" xlink:label="caba_EarningsPerShareBasicAndDilutedTable" />
    <link:label xml:lang="en-US" xlink:label="caba_EarningsPerShareBasicAndDilutedTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Earnings per share basic and diluted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="caba_EarningsPerShareBasicAndDilutedTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_EarningsPerShareBasicAndDilutedTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Basic And Diluted [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_EarningsPerShareBasicAndDilutedTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earning Per Share Basic And Diluted [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earning Per Share Basic And Diluted [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic net loss per share:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:type="locator" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allocation of undistributed losses attributable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:to="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Undistributed Earnings Loss Available To Common Shareholders Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of shares used in basic per share computation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted net loss per share:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="locator" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allocation of undistributed losses for basic computation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Undistributed Earnings Loss Allocated To Participating Securities Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:type="locator" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reallocation of undistributed losses as a result of conversion of non-voting to voting common shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:to="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dilutive Securities Effect On Basic Earnings Per Share Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:type="locator" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Allocation of undistributed losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Undistributed Earnings Loss Allocated To Participating Securities Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Add: Conversion of non-voting to voting common shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted average number of shares used in diluted per share computation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Diluted Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options to Purchase Common Stock</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_NonVestedCommonStockMember" xlink:type="locator" xlink:label="caba_NonVestedCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="caba_NonVestedCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-vested common stock member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_NonVestedCommonStockMember" xlink:to="caba_NonVestedCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_NonVestedCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-vested Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_NonVestedCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Vested Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive shares have been excluded from calculation of diluted net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, contribution amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Cost Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees&apos; Gross Pay</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent Of Match</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_WuXiAdvancedTherapiesMember" xlink:type="locator" xlink:label="caba_WuXiAdvancedTherapiesMember" />
    <link:label xml:lang="en-US" xlink:label="caba_WuXiAdvancedTherapiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">WuXi Advanced Therapies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_WuXiAdvancedTherapiesMember" xlink:to="caba_WuXiAdvancedTherapiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_WuXiAdvancedTherapiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WuXi Advanced Therapies</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_WuXiAdvancedTherapiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Wu Xi Advanced Therapies [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_DevelopmentAndManufacturingServicesAgreementMember" xlink:type="locator" xlink:label="caba_DevelopmentAndManufacturingServicesAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="caba_DevelopmentAndManufacturingServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and manufacturing services agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_DevelopmentAndManufacturingServicesAgreementMember" xlink:to="caba_DevelopmentAndManufacturingServicesAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_DevelopmentAndManufacturingServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Wuxi Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_DevelopmentAndManufacturingServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development And Manufacturing Services Agreement [Member]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_ChildrenSHospitalOfPhiladelphiaMember" xlink:type="locator" xlink:label="caba_ChildrenSHospitalOfPhiladelphiaMember" />
    <link:label xml:lang="en-US" xlink:label="caba_ChildrenSHospitalOfPhiladelphiaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Children&#8217;s Hospital of Philadelphia.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ChildrenSHospitalOfPhiladelphiaMember" xlink:to="caba_ChildrenSHospitalOfPhiladelphiaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_ChildrenSHospitalOfPhiladelphiaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CHOP</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ChildrenSHospitalOfPhiladelphiaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Children S Hospital Of Philadelphia [Member]</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_ResearchServiceAgreementMember" xlink:type="locator" xlink:label="caba_ResearchServiceAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="caba_ResearchServiceAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research service agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ResearchServiceAgreementMember" xlink:to="caba_ResearchServiceAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_ResearchServiceAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Service Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ResearchServiceAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Service Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:type="locator" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early termination fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:to="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Subject To Compromise Early Contract Termination Fees</link:label>
    <link:loc xlink:href="caba-20201231.xsd#caba_ExpectedResearchServiceAgreementCost" xlink:type="locator" xlink:label="caba_ExpectedResearchServiceAgreementCost" />
    <link:label xml:lang="en-US" xlink:label="caba_ExpectedResearchServiceAgreementCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected research service agreement cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ExpectedResearchServiceAgreementCost" xlink:to="caba_ExpectedResearchServiceAgreementCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="caba_ExpectedResearchServiceAgreementCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cost</link:label>
    <link:label xml:lang="en-US" xlink:label="caba_ExpectedResearchServiceAgreementCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expected Research Service Agreement Cost</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>32
<FILENAME>caba-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-15T17:02:46.7683343+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : b469dc7abe284c828e6850b36ac62ee6 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/role/TemplateLink" xlink:href="caba-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="caba-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/StatementBalanceSheets" xlink:href="caba-20201231.xsd#Role_StatementBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/StatementBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="caba-20201231.xsd#caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" xlink:href="caba-20201231.xsd#Role_StatementBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:type="locator" xlink:label="us-gaap_NonvotingCommonStockMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_VotingCommonStockMember" xlink:type="locator" xlink:label="caba_VotingCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_VotingCommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:href="caba-20201231.xsd#Role_StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends" xlink:type="locator" xlink:label="us-gaap_Dividends" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Dividends" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:href="caba-20201231.xsd#Role_StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityConvertedIntoCommonStockValue" xlink:type="locator" xlink:label="caba_TemporaryEquityConvertedIntoCommonStockValue" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityStockConvertedIntoCommonStock" xlink:type="locator" xlink:label="caba_TemporaryEquityStockConvertedIntoCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="caba-20201231.xsd#caba_StockIssuedDuringPeriodShareStockOptionsExercised" xlink:type="locator" xlink:label="caba_StockIssuedDuringPeriodShareStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" xlink:type="locator" xlink:label="caba_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesNetOfIssuanceCosts" xlink:type="locator" xlink:label="caba_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesNetOfIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesNetOfIssuanceCosts" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_StockIssuedDuringPeriodShareStockOptionsExercised" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_TemporaryEquityStockConvertedIntoCommonStock" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_TemporaryEquityConvertedIntoCommonStockValue" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_li0l2" order="12330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_li0l2" order="12370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" xlink:href="caba-20201231.xsd#Role_StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:type="locator" xlink:label="us-gaap_PreferredStockConversionBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConversionBasis" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" xlink:href="caba-20201231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="caba-20201231.xsd#caba_DeferredOfferingCostsInAccountsPayableAndAccruedAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="caba_DeferredOfferingCostsInAccountsPayableAndAccruedAndOtherCurrentLiabilities" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ExchangeOfConvertiblePreferredStockIncludingDeemedDividend" xlink:type="locator" xlink:label="caba_ExchangeOfConvertiblePreferredStockIncludingDeemedDividend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="caba_ExchangeOfConvertiblePreferredStockIncludingDeemedDividend" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="caba_DeferredOfferingCostsInAccountsPayableAndAccruedAndOtherCurrentLiabilities" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureBasisOfPresentation" xlink:href="caba-20201231.xsd#Role_DisclosureBasisOfPresentation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureBasisOfPresentation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="caba-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="caba-20201231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipment" xlink:href="caba-20201231.xsd#Role_DisclosurePropertyPlantAndEquipment" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipment">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilities" xlink:href="caba-20201231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilities">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCollaborationsLicensingAgreementsAndOtherAgreements" xlink:href="caba-20201231.xsd#Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCollaborationsLicensingAgreementsAndOtherAgreements">
    <link:loc xlink:href="caba-20201231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" xlink:type="locator" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" />
    <link:loc xlink:href="caba-20201231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" xlink:type="locator" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="caba-20201231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock" xlink:href="caba-20201231.xsd#Role_DisclosureConvertiblePreferredStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStock" xlink:href="caba-20201231.xsd#Role_DisclosureCommonStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStock">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="caba-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="caba-20201231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShare">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/Disclosure401KSavingsPlan" xlink:href="caba-20201231.xsd#Role_Disclosure401KSavingsPlan" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/Disclosure401KSavingsPlan">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="caba-20201231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="caba-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="caba-20201231.xsd#caba_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:type="locator" xlink:label="caba_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" />
    <link:loc xlink:href="caba-20201231.xsd#caba_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:type="locator" xlink:label="caba_EmergingGrowthCompanyStatusPolicyTextBlock" />
    <link:loc xlink:href="caba-20201231.xsd#caba_RelatedPartyTransactionsPolicyTextBlock" xlink:type="locator" xlink:label="caba_RelatedPartyTransactionsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="caba_RelatedPartyTransactionsPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="caba_EmergingGrowthCompanyStatusPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="caba_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="caba-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="caba-20201231.xsd#caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:type="locator" xlink:label="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="caba-20201231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentTables" xlink:href="caba-20201231.xsd#Role_DisclosurePropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables" xlink:href="caba-20201231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables">
    <link:loc xlink:href="caba-20201231.xsd#caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="caba-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockTables" xlink:href="caba-20201231.xsd#Role_DisclosureConvertiblePreferredStockTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PartnersCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_PartnersCapitalAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PartnersCapitalAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockTables" xlink:href="caba-20201231.xsd#Role_DisclosureCommonStockTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="caba-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="caba-20201231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetails" xlink:href="caba-20201231.xsd#Role_DisclosureBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="caba-20201231.xsd#caba_NumberOfAdditionalCommonStockPurchasedByUnderwritersUponPartialExerciseOfOption" xlink:type="locator" xlink:label="caba_NumberOfAdditionalCommonStockPurchasedByUnderwritersUponPartialExerciseOfOption" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="caba-20201231.xsd#caba_BasisOfPresentationLineItems" xlink:type="locator" xlink:label="caba_BasisOfPresentationLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_BasisOfPresentationTable" xlink:type="locator" xlink:label="caba_BasisOfPresentationTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="caba_BasisOfPresentationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_BasisOfPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_BasisOfPresentationTable" xlink:to="caba_BasisOfPresentationLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="caba_NumberOfAdditionalCommonStockPurchasedByUnderwritersUponPartialExerciseOfOption" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_BasisOfPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="caba-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportingUnits" xlink:type="locator" xlink:label="us-gaap_NumberOfReportingUnits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="caba-20201231.xsd#caba_InvestmentsMaturityYear" xlink:type="locator" xlink:label="caba_InvestmentsMaturityYear" />
    <link:loc xlink:href="caba-20201231.xsd#caba_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="caba_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ProfessionalServicesMember" xlink:type="locator" xlink:label="caba_ProfessionalServicesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="caba_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="caba_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="caba_ProfessionalServicesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_SummaryOfSignificantAccountingPoliciesTable" xlink:to="caba_SummaryOfSignificantAccountingPoliciesLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="caba_InvestmentsMaturityYear" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportingUnits" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails" xlink:href="caba-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="caba_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="caba_LaboratoryEquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="caba-20201231.xsd#Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateNoteSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ShortTermInvestmentsAbstract" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestments" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="caba-20201231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails" xlink:href="caba-20201231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateNoteSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="caba-20201231.xsd#Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" xlink:href="caba-20201231.xsd#Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:href="caba-20201231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:href="caba-20201231.xsd#caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="caba-20201231.xsd#caba_AccruedGeneralAndAdministrativeServicesCurrent" xlink:type="locator" xlink:label="caba_AccruedGeneralAndAdministrativeServicesCurrent" />
    <link:loc xlink:href="caba-20201231.xsd#caba_AccruedResearchAndDevelopmentServicesCurrent" xlink:type="locator" xlink:label="caba_AccruedResearchAndDevelopmentServicesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="caba_AccruedResearchAndDevelopmentServicesCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="caba_AccruedGeneralAndAdministrativeServicesCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails" xlink:href="caba-20201231.xsd#Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="caba-20201231.xsd#caba_ContractualExpenses" xlink:type="locator" xlink:label="caba_ContractualExpenses" />
    <link:loc xlink:href="caba-20201231.xsd#caba_MaximumResearchAndDevelopmentAdditionalExpenseDueInRemainingTerm" xlink:type="locator" xlink:label="caba_MaximumResearchAndDevelopmentAdditionalExpenseDueInRemainingTerm" />
    <link:loc xlink:href="caba-20201231.xsd#caba_AdvancePayments" xlink:type="locator" xlink:label="caba_AdvancePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ContractualCostIncurred" xlink:type="locator" xlink:label="caba_ContractualCostIncurred" />
    <link:loc xlink:href="caba-20201231.xsd#caba_FundingTermEndingDate" xlink:type="locator" xlink:label="caba_FundingTermEndingDate" />
    <link:loc xlink:href="caba-20201231.xsd#caba_NumberOfFaculty" xlink:type="locator" xlink:label="caba_NumberOfFaculty" />
    <link:loc xlink:href="caba-20201231.xsd#caba_CollaborativeAgreementPaymentsDue" xlink:type="locator" xlink:label="caba_CollaborativeAgreementPaymentsDue" />
    <link:loc xlink:href="caba-20201231.xsd#caba_MilestonePayments" xlink:type="locator" xlink:label="caba_MilestonePayments" />
    <link:loc xlink:href="caba-20201231.xsd#caba_LicenseMaintenanceFee" xlink:type="locator" xlink:label="caba_LicenseMaintenanceFee" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ObligationToBePaidCommencementDate" xlink:type="locator" xlink:label="caba_ObligationToBePaidCommencementDate" />
    <link:loc xlink:href="caba-20201231.xsd#caba_PaymentOfObligationTerm" xlink:type="locator" xlink:label="caba_PaymentOfObligationTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:loc xlink:href="caba-20201231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:type="locator" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" />
    <link:loc xlink:href="caba-20201231.xsd#caba_SubscriptionAndTechnologyTransferAgreementMember" xlink:type="locator" xlink:label="caba_SubscriptionAndTechnologyTransferAgreementMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_MasterTranslationalResearchServicesAgreementMember" xlink:type="locator" xlink:label="caba_MasterTranslationalResearchServicesAgreementMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_AccruedAndOtherCurrentLiabilitiesMember" xlink:type="locator" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_RegentsOfUniversityOfCaliforniaMember" xlink:type="locator" xlink:label="caba_RegentsOfUniversityOfCaliforniaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_SponsoredResearchAgreementsMember" xlink:type="locator" xlink:label="caba_SponsoredResearchAgreementsMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_LicenseAgreementMember" xlink:type="locator" xlink:label="caba_LicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentAxis" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:type="locator" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" />
    <link:loc xlink:href="caba-20201231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" xlink:type="locator" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_SupplyCommitmentAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_LicenseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_SponsoredResearchAgreementsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="caba_RegentsOfUniversityOfCaliforniaMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="caba_AccruedAndOtherCurrentLiabilitiesMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_MasterTranslationalResearchServicesAgreementMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_SubscriptionAndTechnologyTransferAgreementMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="us-gaap_ContractualObligation" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_PaymentOfObligationTerm" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_ObligationToBePaidCommencementDate" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_LicenseMaintenanceFee" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_MilestonePayments" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_CollaborativeAgreementPaymentsDue" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_NumberOfFaculty" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_FundingTermEndingDate" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_ContractualCostIncurred" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_AdvancePayments" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_MaximumResearchAndDevelopmentAdditionalExpenseDueInRemainingTerm" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_ContractualExpenses" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="caba-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="caba-20201231.xsd#caba_RentExpense" xlink:type="locator" xlink:label="caba_RentExpense" />
    <link:loc xlink:href="caba-20201231.xsd#caba_AnnualIncreasePercentageOfBaseRent" xlink:type="locator" xlink:label="caba_AnnualIncreasePercentageOfBaseRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals" />
    <link:loc xlink:href="caba-20201231.xsd#caba_LeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="caba_LeaseExpirationMonthAndYear" />
    <link:loc xlink:href="caba-20201231.xsd#caba_LeaseCommencementMonthAndYear" xlink:type="locator" xlink:label="caba_LeaseCommencementMonthAndYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="caba-20201231.xsd#caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="caba_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:loc xlink:href="caba-20201231.xsd#caba_OperatingLeaseAgreementMember" xlink:type="locator" xlink:label="caba_OperatingLeaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentAxis" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="caba_CommitmentsAndContingenciesDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="caba_CommitmentsAndContingenciesDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_SupplyCommitmentAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_OperatingLeaseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="caba_CommitmentsAndContingenciesDisclosureLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_LeaseCommencementMonthAndYear" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_LeaseExpirationMonthAndYear" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_AnnualIncreasePercentageOfBaseRent" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_RentExpense" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails" xlink:href="caba-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="caba-20201231.xsd#caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" xlink:type="locator" xlink:label="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="caba-20201231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ConvertiblePreferredStockConvertIntoNonVotingCommonStock" xlink:type="locator" xlink:label="caba_ConvertiblePreferredStockConvertIntoNonVotingCommonStock" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ConvertiblePreferredStockConvertIntoVotingCommonStock" xlink:type="locator" xlink:label="caba_ConvertiblePreferredStockConvertIntoVotingCommonStock" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityValueExchangeIncludingDeemedDividend" xlink:type="locator" xlink:label="caba_TemporaryEquityValueExchangeIncludingDeemedDividend" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquitySharesExchangeIncludingDeemedDividend" xlink:type="locator" xlink:label="caba_TemporaryEquitySharesExchangeIncludingDeemedDividend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_SeriesA2PreferredStockMember" xlink:type="locator" xlink:label="caba_SeriesA2PreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_SeriesA2PreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_TemporaryEquitySharesExchangeIncludingDeemedDividend" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_TemporaryEquityValueExchangeIncludingDeemedDividend" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_ConvertiblePreferredStockConvertIntoVotingCommonStock" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_ConvertiblePreferredStockConvertIntoNonVotingCommonStock" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails" xlink:href="caba-20201231.xsd#Role_DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityConversionOfStockSharesForCommonStock" xlink:type="locator" xlink:label="caba_TemporaryEquityConversionOfStockSharesForCommonStock" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityConversionOfStockValueForCommonStock" xlink:type="locator" xlink:label="caba_TemporaryEquityConversionOfStockValueForCommonStock" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityIssuanceCosts" xlink:type="locator" xlink:label="caba_TemporaryEquityIssuanceCosts" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquitySharesExchangeIncludingDeemedDividend" xlink:type="locator" xlink:label="caba_TemporaryEquitySharesExchangeIncludingDeemedDividend" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityValueExchangeIncludingDeemedDividend" xlink:type="locator" xlink:label="caba_TemporaryEquityValueExchangeIncludingDeemedDividend" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_SeriesA2PreferredStockMember" xlink:type="locator" xlink:label="caba_SeriesA2PreferredStockMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_SeriesA1PreferredStockMember" xlink:type="locator" xlink:label="caba_SeriesA1PreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_SeriesA1PreferredStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_SeriesA2PreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_TemporaryEquityValueExchangeIncludingDeemedDividend" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_TemporaryEquitySharesExchangeIncludingDeemedDividend" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_TemporaryEquityIssuanceCosts" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_TemporaryEquityConversionOfStockValueForCommonStock" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="caba_TemporaryEquityConversionOfStockSharesForCommonStock" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:href="caba-20201231.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails">
    <link:loc xlink:href="caba-20201231.xsd#caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" xlink:type="locator" xlink:label="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" />
    <link:loc xlink:href="caba-20201231.xsd#caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" xlink:type="locator" xlink:label="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" />
    <link:loc xlink:href="caba-20201231.xsd#caba_PercentageOfPayrollDeductionOnEligibleCompensation" xlink:type="locator" xlink:label="caba_PercentageOfPayrollDeductionOnEligibleCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="caba-20201231.xsd#caba_IncreaseInShareReservedPercentage" xlink:type="locator" xlink:label="caba_IncreaseInShareReservedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStockSharesCompensationCost" xlink:type="locator" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStockSharesCompensationCost" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModifiedFairValue" xlink:type="locator" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModifiedFairValue" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModified" xlink:type="locator" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModified" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ConversionOfNonVotingCommonStockToVotingCommonStockSharesConverted" xlink:type="locator" xlink:label="caba_ConversionOfNonVotingCommonStockToVotingCommonStockSharesConverted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TwoThousandEighteenStockOptionAndGrantPlanMember" xlink:type="locator" xlink:label="caba_TwoThousandEighteenStockOptionAndGrantPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_FoundersMember" xlink:type="locator" xlink:label="caba_FoundersMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_AtTheMarketOfferingSalesAgreementMember" xlink:type="locator" xlink:label="caba_AtTheMarketOfferingSalesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:type="locator" xlink:label="us-gaap_NonvotingCommonStockMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_VotingCommonStockMember" xlink:type="locator" xlink:label="caba_VotingCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_VotingCommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_AtTheMarketOfferingSalesAgreementMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="caba_FoundersMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandEighteenStockOptionAndGrantPlanMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_ConversionOfNonVotingCommonStockToVotingCommonStockSharesConverted" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModified" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModifiedFairValue" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStockSharesCompensationCost" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_IncreaseInShareReservedPercentage" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_PercentageOfPayrollDeductionOnEligibleCompensation" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" order="12330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" order="12370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfStockOptionActivityDetails" xlink:href="caba-20201231.xsd#Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfStockOptionActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:type="locator" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:type="locator" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="caba-20201231.xsd#caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" order="12990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="13190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="13490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" order="13620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="13820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="13920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_li0l2" order="14020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="14320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" xlink:href="caba-20201231.xsd#Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfStockBasedCompensationDetails" xlink:href="caba-20201231.xsd#Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfStockBasedCompensationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails" xlink:href="caba-20201231.xsd#Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="caba-20201231.xsd#caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" xlink:type="locator" xlink:label="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails" xlink:href="caba-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="caba-20201231.xsd#caba_DeferredTaxAssetsLicenseFeesDeductions" xlink:type="locator" xlink:label="caba_DeferredTaxAssetsLicenseFeesDeductions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="caba_DeferredTaxAssetsLicenseFeesDeductions" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="caba-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <link:loc xlink:href="caba-20201231.xsd#caba_PercentageOfEligibleTaxPositionsForRecognition" xlink:type="locator" xlink:label="caba_PercentageOfEligibleTaxPositionsForRecognition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:loc xlink:href="caba-20201231.xsd#caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" xlink:type="locator" xlink:label="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="caba-20201231.xsd#caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" xlink:type="locator" xlink:label="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" />
    <link:loc xlink:href="caba-20201231.xsd#caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" xlink:type="locator" xlink:label="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" />
    <link:loc xlink:href="caba-20201231.xsd#caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" xlink:type="locator" xlink:label="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:loc xlink:href="caba-20201231.xsd#caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal" xlink:type="locator" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal" />
    <link:loc xlink:href="caba-20201231.xsd#caba_DeferredTaxAssetsOperatingLossCarryforwardsState" xlink:type="locator" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsState" />
    <link:loc xlink:href="caba-20201231.xsd#caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal" xlink:type="locator" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="caba-20201231.xsd#caba_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="caba_IncomeTaxDisclosureLineItems" />
    <link:loc xlink:href="caba-20201231.xsd#caba_FederalMember" xlink:type="locator" xlink:label="caba_FederalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="caba_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="caba_IncomeTaxDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="caba_FederalMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureTable" xlink:to="caba_IncomeTaxDisclosureLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_DeferredTaxAssetsOperatingLossCarryforwardsState" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OpenTaxYear" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_PercentageOfEligibleTaxPositionsForRecognition" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:href="caba-20201231.xsd#Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:type="locator" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:type="locator" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="locator" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:type="locator" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" />
    <link:loc xlink:href="caba-20201231.xsd#caba_EarningPerShareBasicAndDilutedLineItems" xlink:type="locator" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:type="locator" xlink:label="us-gaap_NonvotingCommonStockMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_VotingCommonStockMember" xlink:type="locator" xlink:label="caba_VotingCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_EarningsPerShareBasicAndDilutedTable" xlink:type="locator" xlink:label="caba_EarningsPerShareBasicAndDilutedTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="caba_EarningsPerShareBasicAndDilutedTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_VotingCommonStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="caba_EarningPerShareBasicAndDilutedLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="caba-20201231.xsd#Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="caba-20201231.xsd#caba_NonVestedCommonStockMember" xlink:type="locator" xlink:label="caba_NonVestedCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="caba_NonVestedCommonStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/Disclosure401KSavingsPlanAdditionalInformationDetails" xlink:href="caba-20201231.xsd#Role_Disclosure401KSavingsPlanAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/Disclosure401KSavingsPlanAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="caba-20201231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:href="caba-20201231.xsd#caba_ExpectedResearchServiceAgreementCost" xlink:type="locator" xlink:label="caba_ExpectedResearchServiceAgreementCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:type="locator" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ResearchServiceAgreementMember" xlink:type="locator" xlink:label="caba_ResearchServiceAgreementMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_ChildrenSHospitalOfPhiladelphiaMember" xlink:type="locator" xlink:label="caba_ChildrenSHospitalOfPhiladelphiaMember" />
    <link:loc xlink:href="caba-20201231.xsd#caba_DevelopmentAndManufacturingServicesAgreementMember" xlink:type="locator" xlink:label="caba_DevelopmentAndManufacturingServicesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentAxis" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="caba-20201231.xsd#caba_WuXiAdvancedTherapiesMember" xlink:type="locator" xlink:label="caba_WuXiAdvancedTherapiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="caba_WuXiAdvancedTherapiesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SupplyCommitmentAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_DevelopmentAndManufacturingServicesAgreementMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="caba_ChildrenSHospitalOfPhiladelphiaMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_ResearchServiceAgreementMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="caba_ExpectedResearchServiceAgreementCost" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495015281128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 10, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CABA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CABALETTA BIO, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001759138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,062,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1685768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2929 Arch Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">759-3100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Part III of this Annual Report on Form 10-K incorporates by reference certain information from the registrant&#8217;s definitive Proxy Statement for its 2021 annual meeting of shareholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year end of December&#160;31, 2020. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part of this Form&#160;10-K.</font></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495014191944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 101,429<span></span>
</td>
<td class="nump">$ 136,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">7,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,873<span></span>
</td>
<td class="nump">4,348<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">113,535<span></span>
</td>
<td class="nump">140,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">890<span></span>
</td>
<td class="nump">815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">114,724<span></span>
</td>
<td class="nump">141,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,243<span></span>
</td>
<td class="nump">920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">3,937<span></span>
</td>
<td class="nump">2,227<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,180<span></span>
</td>
<td class="nump">3,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (see Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.00001 par value: 10,000,000 shares authorized as of December 31, 2020 and 2019, respectively; no shares issued or outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Voting and non-voting common stock, $0.00001 par value: 150,000,000 (143,590,481 voting and 6,409,519 non-voting) shares authorized as of December 31, 2020 and 2019, respectively; 24,062,775 (19,387,160 voting and 4,675,615 non-voting) shares issued and outstanding as of December 31, 2020 and 24,034,022 (17,624,503 voting and 6,409,519 non-voting) issued and outstanding as of December 31, 2019, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">175,836<span></span>
</td>
<td class="nump">171,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(66,298)<span></span>
</td>
<td class="num">(32,959)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">109,544<span></span>
</td>
<td class="nump">138,321<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 114,724<span></span>
</td>
<td class="nump">$ 141,468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495019802584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized shares</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="nump">24,062,775<span></span>
</td>
<td class="nump">24,034,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="nump">24,062,775<span></span>
</td>
<td class="nump">24,034,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember', window );">Voting Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">143,590,481<span></span>
</td>
<td class="nump">143,590,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="nump">19,387,160<span></span>
</td>
<td class="nump">17,624,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="nump">19,387,160<span></span>
</td>
<td class="nump">17,624,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Non-voting Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">6,409,519<span></span>
</td>
<td class="nump">6,409,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="nump">4,675,615<span></span>
</td>
<td class="nump">6,409,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="nump">4,675,615<span></span>
</td>
<td class="nump">6,409,519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495012657048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 21,376<span></span>
</td>
<td class="nump">$ 11,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,457<span></span>
</td>
<td class="nump">7,012<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">33,833<span></span>
</td>
<td class="nump">18,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(33,833)<span></span>
</td>
<td class="num">(18,683)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">1,740<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(33,339)<span></span>
</td>
<td class="num">(16,943)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,326)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(33,339)<span></span>
</td>
<td class="num">(22,269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain on available-for-sale investments, net of tax</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net comprehensive loss</a></td>
<td class="num">$ (33,333)<span></span>
</td>
<td class="num">$ (22,269)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per voting and non-voting share, basic and diluted</a></td>
<td class="num">$ (1.44)<span></span>
</td>
<td class="num">$ (4.07)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495012005896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Initial Public Offering</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Initial Public Offering</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Initial Public Offering</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">$ (10,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,452)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,393,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,848,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesNetOfIssuanceCosts', window );">Issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityStockIssuedDuringPeriodShareNewIssues', window );">Issuance of convertible preferred stock, net of issuance cost, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,963,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,275,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock in conjunction with exercise of stock options</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_StockIssuedDuringPeriodShareStockOptionsExercised', window );">Issuance of common stock in conjunction with exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Exchange of convertible preferred stock, including deemed dividend</a></td>
<td class="num">(5,326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,762)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,564)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="nump">97,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityStockConvertedIntoCommonStock', window );">Conversion of convertible preferred stock into common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,356,835)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityConvertedIntoCommonStockValue', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (97,954)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of convertible preferred stock into common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,904,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,943)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,943)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 138,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,959)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2019</a></td>
<td class="nump">24,034,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,034,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock in conjunction with exercise of stock options</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_StockIssuedDuringPeriodShareStockOptionsExercised', window );">Issuance of common stock in conjunction with exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Net unrealized gains on available-for-sale securities</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(33,339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,339)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 109,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">$ (66,298)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2020</a></td>
<td class="nump">24,062,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,062,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_StockIssuedDuringPeriodShareStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period share stock options exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_StockIssuedDuringPeriodShareStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_TemporaryEquityConvertedIntoCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity converted into common stock value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_TemporaryEquityConvertedIntoCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_TemporaryEquityStockConvertedIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock converted into common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_TemporaryEquityStockConvertedIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_TemporaryEquityStockIssuedDuringPeriodShareNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period share new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_TemporaryEquityStockIssuedDuringPeriodShareNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period value new issues net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=120519210&amp;loc=d3e90193-114008<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495019787032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 1,293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 1,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Convertible preferred stock conversion basis</a></td>
<td class="text">1.5 for 1 basis<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 3,408<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495014191880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (33,339)<span></span>
</td>
<td class="num">$ (16,943)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,388<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium on investments</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(524)<span></span>
</td>
<td class="num">(3,372)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(198)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">555<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">1,875<span></span>
</td>
<td class="nump">1,721<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(26,770)<span></span>
</td>
<td class="num">(16,045)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(635)<span></span>
</td>
<td class="num">(693)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(11,097)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of investments</a></td>
<td class="nump">3,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(7,981)<span></span>
</td>
<td class="num">(693)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="num">(192)<span></span>
</td>
<td class="nump">71,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,293)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock in connection with the exercise of stock options</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from the issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(24)<span></span>
</td>
<td class="nump">119,925<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(34,775)<span></span>
</td>
<td class="nump">103,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents&#8212;beginning of year</a></td>
<td class="nump">136,204<span></span>
</td>
<td class="nump">33,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents&#8212;end of year</a></td>
<td class="nump">101,429<span></span>
</td>
<td class="nump">136,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_ExchangeOfConvertiblePreferredStockIncludingDeemedDividend', window );">Exchange of convertible preferred stock, including deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_DeferredOfferingCostsInAccountsPayableAndAccruedAndOtherCurrentLiabilities', window );">Deferred offering costs in accounts payable and accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_DeferredOfferingCostsInAccountsPayableAndAccruedAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs in accounts payable and accrued and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_DeferredOfferingCostsInAccountsPayableAndAccruedAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ExchangeOfConvertiblePreferredStockIncludingDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exchange of convertible preferred stock, including deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ExchangeOfConvertiblePreferredStockIncludingDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495016938552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Basis of Presentation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cabaletta Bio, Inc. (the Company or Cabaletta) was incorporated in April 2017 in the State of Delaware as Tycho Therapeutics, Inc. and, in August 2018, changed its name to Cabaletta Bio, Inc. The Company is headquartered in Philadelphia, Pennsylvania. Cabaletta is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal operations commenced in April 2018, when the Company executed two sponsored research agreements with the Trustees of the University of Pennsylvania (Penn). </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 16, 2019, the Company effected a 1-for-1.5 reverse split of the Company&#8217;s issued and outstanding shares of common stock, par value $0.00001 per share (Common Stock). Upon the effectiveness of the reverse stock split: (i) all shares of outstanding Common Stock were adjusted; (ii) the conversion price of the Series A convertible preferred stock (Series A Preferred), Series A-1 convertible preferred stock (Series A-1 Preferred), Series A-2 convertible preferred stock (Series A-2 Preferred) and Series B convertible preferred stock (Series B Preferred; collectively, the Preferred Shares) was adjusted; (iii) the number of shares of Common Stock for which each outstanding option to purchase Common Stock is exercisable was adjusted; and (iv) the exercise price of each outstanding option to purchase Common Stock was adjusted. All of the outstanding Common Stock share numbers (including shares of Common Stock subject to the Company&#8217;s options and as converted for the outstanding convertible preferred stock shares), share prices, exercise prices and per share amounts contained in the financial statements have been retroactively adjusted in the financial statements to reflect this reverse stock split for all periods presented. The par value per share and the authorized number of shares of Common Stock and convertible preferred stock were not adjusted as a result of the reverse stock split.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 29, 2019, the Company completed its initial public offering (IPO) of 6,800,000&#160;shares of Common Stock at an offering price of $11.00 per share. The Company received net proceeds of $66,156 after deducting underwriting discounts, commissions and estimated offering expenses. In connection with the IPO, the Company&#8217;s outstanding shares of convertible preferred stock were automatically converted into 12,904,534 shares of Common Stock. In November 2019, the underwriters partially exercised their option and purchased an additional 475,501 shares of Common Stock resulting in net proceeds to the Company of $4,864, after deducting underwriting discounts and commissions. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Risks and Uncertainties </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not expect to generate revenue from sales of engineered T cell therapies for B cell-mediated autoimmune diseases or any other revenue unless and until the Company completes preclinical and clinical development and obtains regulatory approval for one or more product candidates. If the Company seeks to obtain regulatory approval for any of its product candidates, the Company expects to incur significant commercialization expenses. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. As a result, the Company is unable to predict the timing or amount of increased expenses or when or if the Company will be able to achieve or maintain profitability. Further, the Company is currently dependent on University of Pennsylvania (Penn) for much of its preclinical research, clinical research and development activities and initial manufacturing activities (Note 6). Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. Even if the Company is able to generate revenues from the sale of its product candidates, if approved, it may not become profitable. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then it may be unable to continue its operations at planned levels and be forced to reduce its operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, a novel strain of coronavirus surfaced in Wuhan, China and has since reached multiple other regions and countries.&#160;The COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures, which have delayed the commencement of non-COVID-19-related clinical trials, among other restrictions. The Company&#8217;s financial results for the year ended December 31, 2020 were not significantly impacted by COVID-19, however, <font style="color:#000000;">the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic, including </font>new information that may emerge concerning the severity of COVID-19, the impact of new strains of the virus, the effectiveness and availability of vaccines and the actions to contain COVID-19 or treat its impact <font style="color:#000000;">will have on its financial condition, operations, and business plans, including its ability to raise additional capital, the timing and enrollment of patients in its ongoing and&#160;planned clinical trials, future financings and other expected milestones of its product candidates.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has sustained annual operating losses since inception and expects to continue to generate operating losses for the foreseeable future. The Company&#8217;s ultimate success depends on the outcome of its research and development activities. The Company had cash and cash equivalents and investments of $108,662 as of December&#160;31, 2020. Through December&#160;31, 2020, the Company has incurred an accumulated deficit of $66,298. Management expects to incur additional losses in the future as it continues its research and development and will need to raise additional capital to fully implement its business plan and to fund its operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company intends to raise such additional capital through a combination of equity offerings, debt financings, government funding arrangements, strategic alliances or other sources. However, if such financing is not available at adequate levels and on a timely basis, or such agreements are not available on favorable terms, or at all, as and when needed, the Company will need to reevaluate its operating plan and may be required to delay or discontinue the development of one or more of its product candidates or operational initiatives. The Company expects that its cash, cash equivalents and investments as of December&#160;31, 2020 will be sufficient to fund its projected operations for at least 12 months from the date the Company&#8217;s Annual Report on Form 10-K is filed with the Securities and Exchange Commission (SEC).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495114584984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, stock-based compensation and the valuation allowance on the Company&#8217;s deferred tax assets. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Off-Balance Sheet Risk and Concentrations of Credit Risk </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, which are primarily invested in U.S. treasury-based money market funds, and available-for-sale debt securities, which are invested in investment grade corporate bonds with&#160;<font style="Background-color:#FFFFFF;color:#212529;">high credit quality issuers</font>.&#160;These investments have maturities in 2021. A portion of the Company&#8217;s cash is maintained at a federally insured financial institution. The deposits held at this institution are in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held.&#160; The cash in this account is swept daily into U.S. treasury-based and U.S. government-based money market funds. The Company has no off&#8209;balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investments</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments are available-for-sale and carried at estimated fair value. The Company&#8217;s valuations of available-for-sale debt securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than, twelve months from the balance sheet date are classified as current.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors including the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or if more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other-than-temporary, if any, on available-for-sale securities are included in interest and other income, net. The cost of investments sold is based on the specific-identification method. Interest income on investments as well as amortization of discount or premium is included in interest income.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property, Plant and Equipment </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying statements of operations. Expenditures for normal, recurring or periodic repairs and maintenance related to property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful lives for property and equipment are as follows:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Three years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Three years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Three years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Lesser of estimated useful life or remaining lease term</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurement </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2&#8212;Inputs (other than quoted prices included in Level&#160;1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs include costs incurred for internal and external research and development activities and are expensed as incurred in the accompanying statements of operations. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to entities that conduct certain research and development activities on the Company&#8217;s behalf. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers, which include activities under agreements with Penn (Note 6), the conduct of sponsored research, preclinical studies and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided and includes these costs in accrued and other current liabilities and prepaid expenses and other current assets in the accompanying balance sheets and within research and development expense in the accompanying statements of operations. Non-refundable advance payments made for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as expense as the goods are received or the related services are rendered.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with service providers. The Company makes significant judgments and estimates in determining the accrued liabilities and prepaid expenses in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities and prepaid expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based Compensation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures its stock-based awards granted to employees and non-employees based on the estimated fair values of the awards on the respective grant dates. The Company uses the Black-Scholes option-pricing model (Black-Scholes) to estimate the fair value of its stock-based awards. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company accounts for forfeitures of stock option awards as they occur. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company&#8217;s IPO, the assumptions used in the Company's Black-Scholes option-pricing model represented management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities, which relate primarily to the carrying amount of the Company&#8217;s property and equipment and its net operating loss carryforwards, are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the two-class method required for participating securities. The Company has voting and non-voting common stock. The rights, including the liquidation and dividend rights, of the holders of the voting and non-voting common stock are identical, except with respect to voting. Each share of non-voting common stock may be converted at any time into one share of voting common stock at the option of its holder by providing written notice to the Company, subject to the limitations provided for in the amended and restated certificate of incorporation. The Company also considers its unvested shares of common stock held by the Company&#8217;s founders and, prior to its conversion to common stock, its convertible preferred stock to be participating securities as, in the event a dividend is paid on common stock, the holders of convertible preferred stock and unvested shares of common stock would be entitled to receive dividends on a basis consistent with the common stockholders. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock, which excludes unvested shares of common stock. The undistributed loss for each year is allocated to common stockholders based on the contractual participation rights of the voting and non-voting common stock as if the losses for the year had been distributed. As the liquidation and dividend rights are identical, the undistributed losses are allocated on a proportionate basis. Net loss attributable to common stockholders for the year ended December 31, 2019 is calculated by adjusting the net loss of the Company for the deemed dividend associated with the exchange of Series A-2 Preferred for Series B Preferred. Diluted net loss per share attributable to common stockholders is computed under the if-converted method and assumes that all non-voting common stock has been converted to common stock. Since the Company was in a loss position for all periods presented, the effects of the other potentially dilutive securities are antidilutive. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segments </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has one reportable segment. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Related Party Transactions </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company engaged a firm controlled by a former executive (until February 2019) of the Company for professional services related to accounting, finance and other administrative functions. For the years ended December 31, 2020 and 2019, the costs incurred under this arrangement totaled $311 and $601, respectively. These amounts were recorded as general and administrative expense in the accompanying statements of operations. As of December&#160;31, 2020 and 2019, amounts owed under this arrangement totaled $13&#160;and $36, respectively, and are included in accounts payable in the accompanying balance sheets.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Emerging Growth Company Status </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS&#160;Act). Under the JOBS&#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&#160;Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS&#160;Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements Not Yet Adopted</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the Financial Accounting Standards Board (FASB) issued ASU 2016-02, <font style="font-style:italic;">Leases</font> (Topic 842), with guidance regarding the accounting for and disclosure of leases. The update requires lessees to recognize the liabilities related all leases, including operating leases, with a term greater than 12 months on the balance sheet. This update also requires lessees and lessors to disclose key information about their leasing transactions. This guidance will be effective for public companies for annual and interim periods beginning after December&#160;15, 2018. For all other entities, including Emerging Growth Companies, this standard is effective for annual reporting periods beginning after December&#160;15, 2020, and interim periods within annual periods beginning after December&#160;15, 2021. Early adoption is permitted. As an Emerging Growth Company, the Company expects to adopt Topic 842 for its annual period ending December 31, 2021 and has not yet finalized the assessment of the impact that ASU 2016-02 will have on its financial statements or financial statement disclosures. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495016938552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Fair Value Measurements </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of&#160;December 31, 2020 and 2019, the Company&#8217;s financial instruments included cash and cash equivalents, available-for-sale debt securities, accounts payable and accrued expenses. The carrying amounts for cash and cash equivalents, accounts payable and accrued expenses reported in the Company&#8217;s financial statements for these instruments approximate their respective fair values because of the short-term nature of these instruments.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prices in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active Markets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Identical</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets (Level 1)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,429</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,429</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,233</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,233</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,662</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,429</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,233</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in Active Markets for Identical Assets (Level 1)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other Observable Inputs (Level 2)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Unobservable Inputs (Level 3)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,204</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,204</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,204</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,204</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level 1. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs. There were no transfers of assets between the fair value measurement levels during the years ended December 31, 2020 or 2019.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For debt securities classified as available-for-sale investments, the Company records unrealized gains or losses resulting from changes in fair value between measurement dates as a component of other comprehensive income. The Company did not hold any available-for-sale securities as of December 31, 2019.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Included in cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,429</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,429</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds - due in one year or less</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Included in short-term investments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,227</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,233</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,656</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,662</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495015857240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. Property, Plant and Equipment</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property plant and equipment consists of the following:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">961</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">277</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">277</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property, plant and equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,348</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">919</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(458</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(104</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">890</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">815</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense was $354 and $104 for the years ended December 31, 2020 and 2019, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495021026328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued and Other Current Liabilities</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5. Accrued and Other Current Liabilities </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities consist of the following: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development services</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,294</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">231</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative services</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation expense</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,445</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,522</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">177</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,937</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,227</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495017060936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations, Licensing Agreements and other Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract', window );"><strong>Collaborations Licensing Agreements And Other Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock', window );">Collaborations, Licensing Agreements and other Agreements</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. <font style="color:#000000;">Collaborations, Licensing Agreements</font> and other Agreements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Amended and Restated License Agreement with the Trustees of the University of Pennsylvania and Children&#8217;s Hospital of Philadelphia</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Company entered into a license agreement with Penn, as amended and restated in July 2019 to include CHOP as a party, and as amended in May 2020 (the License Agreement) pursuant to which the Company obtained (a)&#160;a non-exclusive, non-sublicensable worldwide license to certain of Penn&#8217;s intellectual property to conduct research, product development, clinical trials, cell manufacturing and other activities, and (b)&#160;an exclusive, worldwide, royalty-bearing right and license, with a right to sublicense, on a target-by-target basis, under certain of Penn&#8217;s intellectual property to make, use, sell, offer for sale, import, and otherwise commercialize products for the treatment of autoimmune and alloimmune diseases.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the License Agreement expires on the expiration or abandonment or other termination of the last valid claim in Penn&#8217;s intellectual property licensed by the Company. The Company may terminate the License Agreement at any time for convenience upon 60 days written notice. In the event of an uncured, material breach, Penn may terminate the License Agreement upon 60 days written notice.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the License Agreement, the Company was obligated to pay $2,000 annually for three years beginning August 2018 for funding to the laboratories of each of Drs.&#160;Milone and Payne (see&#160;<font style="font-style:italic;">Sponsored Research Agreements</font>). During the term of the License Agreement until the first commercial sale of the first product, the Company is obligated to pay Penn a non-refundable, non-creditable annual license maintenance fee of $10. In May 2020, the Company paid Penn an additional, non-refundable, non-creditable license fee of $33 under the amended License Agreement. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to pay certain milestone payments upon the achievement of specified clinical and commercial milestones. Milestone payments are reduced by a certain percentage for the second product that achieves a milestone, by an additional percentage for the third product that achieves a milestone, and so on, for each subsequent product that achieves a milestone. In the event that the Company is able to successfully develop and launch multiple products under the License Agreement, total milestone payments could be approximately $21,000. Penn is also eligible to receive tiered royalties at percentage rates in the low single-digits, subject to an annual minimum royalty, on annual worldwide net sales of any products that are commercialized by the Company or its sublicensees that contain or incorporate, or are covered by, the intellectual property licensed by the Company. To the extent the Company sublicenses its license rights under the License Agreement, Penn would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits. There were no amounts due under the License Agreement as of December 31, 2020.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;font-style:italic;">Sponsored Research Agreements </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has sponsored research agreements with two faculty members at Penn, who are also scientific co-founders of the Company and members of the Company&#8217;s scientific advisory board. <font style="color:#000000;">In May 2020, one of the agreements was amended to</font><font style="Background-color:#FFFFFF;color:#000000;">&#160;expand the scope of sponsored research.&#160;In August 2020, this agreement was further amended to extend the term of the original research plan.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the amended agreements, the Company has committed to funding a defined research plan through February 2023. The total estimated cost of $11,781 under the agreements satisfies the Company&#8217;s annual obligation under the License Agreement (see&#160;<font style="font-style:italic;">Amended and Restated License Agreement</font>&#160;<font style="font-style:italic;">with the Trustees of the University of Pennsylvania</font>&#160;above). <font style="color:#000000;">As of December 31, 2020, $7,090 of cost has been incurred pursuant to these agreements. For the years ended December&#160;31, 2020 and 2019, the Company recognized research and development expense of $2,995 and $2,137, respectively, related to these agreements in the accompanying statements of operations. As of December 31, 2020 and 2019, $1,851 and $1,588 respectively, of advance payments are included in Prepaid expenses and other current assets in the accompanying balance sheets </font>and there was $217 included in Accrued and other current liabilities in the accompanying balance sheets as of December 31, 2020.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Master Translational Research Services Agreement </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<font style="color:#000000;">n October 2018, the Company entered into a services agreement (the Services Agreement) with Penn for additional research and development services from various laboratories within Penn. The research and development activities are detailed in separately executed Penn organization-specific addenda. In May 2020, the Company amended its Addendum with the Center for Advanced Retinal and Ocular Therapeutics (CAROT) to expand access to vector manufacturing.</font> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense related to executed addenda under the master translational research service agreement with Penn recognized in the accompanying statements of operations for the years ended December 31, 2020 and 2019 was $2,474 and $2,355, respectively. The Company may incur additional expenses up to $1,360 through the remaining term of the CAROT Amended Addendum.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:5.94%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Subscription and Technology Transfer Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, the Company entered into a subscription and technology transfer agreement pursuant to which the Company owed Penn an upfront subscription fee, which was paid in 2019, and a nominal non-refundable royalty on the net sales of products, a portion of which will be credited toward milestone payments and royalties, respectively, under the Amended License Agreement.&#160;Technology transfer activities will be at the Company&#8217;s cost and subject to agreement as to the technology to be transferred. Under this agreement, the Company recognized $250 of research and development expense for the year ended December 31, 2019. No expense was recognized under this agreement for the year ended December 31, 2020.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6.73%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6.73%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Collaboration and License Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company entered into a collaboration and license agreement with Artisan Bio, Inc. (Artisan), wherein the Company and Artisan agreed to collaborate to potentially enhance certain pipeline products of the Company at specific targets using Artisan&#8217;s gene editing and engineering technology.&#160;If the Artisan technology is applied to any of the Company&#8217;s products, the Company will be responsible for the development, manufacturing, and commercialization of any such products. Under the terms of the agreement, the Company was required to pay Artisan a nominal upfront fee, as well as costs associated with research and development activities. Artisan is eligible to receive future research, development&#160;and regulatory milestones, and is also eligible to receive sales milestones and tiered royalties on net sales of products that incorporate the Artisan technology. The Company can terminate the agreement at will upon advance written notice with payment of a nominal cancellation fee.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborations licensing agreements and other agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborations licensing agreements and other agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495091040840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. Commitments and Contingencies </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Lease Agreement </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, the Company entered into an operating lease agreement for new office space in Philadelphia, Pennsylvania. The lease term commenced in May 2019 and will expire in July 2022. The initial annual base rent is $261, and such amount will increase by 2% annually on each anniversary of the commencement date. The Company records rent expense on a straight-line basis over the lease term. Rent expense related to this lease agreement recognized in the accompanying statement of operations was $266 and $178 for the years ended December 31, 2020 and 2019.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the future minimum payments for operating leases are as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">426</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:5.94%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Purchase Commitments</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the normal course of business, the Company enters into various purchase commitments with third-party contract manufacturers for the manufacture and processing of its product candidates and related raw materials, contracts with contract research organizations for clinical trials and agreements with vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Indemnification </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into certain types of contracts that contingently requires the Company to indemnify various parties against claims from third parties. These contracts primarily relate to (i)&#160;the Company&#8217;s bylaws, under which the Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their relationship, (ii)&#160;contracts under which the Company must indemnify directors and certain officers and consultants for liabilities arising out of their relationship, (iii)&#160;contracts under which the Company may be required to indemnify partners against certain claims, including claims from third parties asserting, among other things, infringement of their intellectual property rights, and (iv)&#160;procurement, consulting, or license agreements under which the Company may be required to indemnify vendors, consultants or licensors for certain claims, including claims that may be brought against them arising from the Company&#8217;s acts or omissions with respect to the supplied products, technology or services. From time to time, the Company may receive indemnification claims under these contracts in the normal course of business. In addition, under these contracts, the Company may have to modify the accused infringing intellectual property and/or refund amounts received. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or settlement, may cause a material adverse effect on the Company&#8217;s future business, operating results or financial condition. It is not possible to determine the maximum potential amount under these contracts due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495016995032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Convertible Preferred Stock </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Preferred Stock</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Preferred Stock</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has 10,000,000 shares of authorized preferred stock as of December 31, 2020, none of which is issued or outstanding. The preferred stock is not redeemable and does not have a stated voting, dividend or liquidation preference.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Convertible Preferred Stock</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has issued Series A Preferred, Series A-1 Preferred, Series A-2 Preferred, and Series B Preferred of Convertible Preferred Stock. The Company classified Convertible Preferred Stock outside of stockholders&#8217; equity (deficit) because the shares contained deemed liquidation rights that were a contingent redemption feature not solely within the control of the Company.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A-1 Preferred</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A-2 Preferred</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance&#8212;December 31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,146,551</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,575</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,372,719</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,994</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,873,777</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,352</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,393,047</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,921</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,963,788</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,963,788</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange, including</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; deemed dividend</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,405,332</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,764</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,405,332</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,090</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,326</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,293</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,293</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,146,551</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,575</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,372,719</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,994</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(468,445</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,588</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,369,120</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,797</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,356,835</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(97,954</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance&#8212;December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2019, the Company&#8217;s certificate of incorporation was amended to increase the authorized shares of Convertible Preferred Stock to 20,762,168 shares, and the Company issued 6,963,788 shares of Series B Preferred, resulting in gross proceeds of $50,000. In connection, the Company issued a further 1,405,332 shares of Series B Preferred in exchange for 1,405,332 shares of Series A-2 Preferred. The Company determined the terms of the Series&#160;B Preferred to be materially, qualitatively different than the terms of the&#160;Series&#160;A-2&#160;Preferred and, as such, applied extinguishment accounting with respect to the&#160;Series&#160;A-2&#160;Preferred received in the exchange resulting in removal of the carrying amount of the&#160;Series&#160;A-2&#160;Preferred received ($4,764), the addition of the Series&#160;B Preferred issued at fair value determined with reference to the contemporaneous issuance of Series&#160;B Preferred ($10,090) and the difference ($5,326) determined to be a deemed dividend recorded to additional&#160;paid-in&#160;capital (to the extent of&#160;paid-in&#160;capital) and accumulated deficit within stockholders&#8217; deficit on the balance sheet. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The shares of Convertible Preferred Stock had various rights, including voting and dividend rights, preferences and privileges, including optional and mandatory conversion rights. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, the Convertible Preferred Stock was converted into 12,904,534 shares of Common Stock. Certain holders of the Company&#8217;s Convertible Preferred Stock elected to have such shares convert into 6,409,519 shares of non-voting Common Stock following the closing of the Company&#8217;s IPO. The non-voting shares of Common Stock have the same rights and preferences as the Common Stock but are non-voting. <font style="color:#000000;">No</font> Convertible Preferred Stock was outstanding as of December 31, 2020 or 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495016724136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Common Stock</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9. Common Stock </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common Stock </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Company&#8217;s Third Amended and Restated Certificate of Incorporation filed in October 2019, the Company is authorized to issue 143,590,481 shares of voting common stock and 6,409,519 shares of non-voting common stock. Holders of voting common <font style="color:#000000;">stock</font> shall have the exclusive right to vote for the election of directors of the Company and on all other matters requiring stockholder action. <font style="color:#000000;">Each share of the Company&#8217;s non-voting common stock may be converted at any time into one share of common stock at the option of its holder by providing written notice to the Company, subject to the limitations provided for in the amended and restated certificate of incorporation. In August 2020, 1,733,904 shares of non-voting common stock were converted to voting common stock.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">At-The-Market Offering Sales Agreement </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On&#160;November 10, 2020, the Company filed a Shelf Registration Statement in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, the Company&#8217;s&#160;common stock, debt securities or other equity securities&#160;in one or more offerings.&#160;The Company also simultaneously entered into a Sales Agreement with Cowen and Company, LLC, to provide for the offering, issuance and sale of up to an aggregate amount of $75.0 million of the Company&#8217;s common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf Registration Statement and subject to the limitations thereof.&#160;No shares have been sold under the Sales Agreement as of December 31, 2020.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Share-based Payment Awards</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2018, several of the Company&#8217;s founders agreed to modify their shares of common stock outstanding to include vesting provisions that require continued service to the Company in order to vest in those shares. As such, the 2,904,000 modified shares of common stock became compensatory upon such modification. The fair value of the awards on the modification date was determined to be $0.74 per share of common stock, based on the issuance of convertible notes in May 2018, considering the maximum conversion price and the seniority of the notes. The total compensation cost resulting from the modification was $2,126. The total compensation cost is being recognized over the three-year vesting term attendant to the founders&#8217; common shares. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, the Company recognized $495 and $177 of this amount in research and development expense and general and administrative expense, respectively. During the year ended December 31, 2019, the Company recognized $529 and $177 of this amount in research and development expense and general and administrative expense, respectively.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-weight:bold;font-style:italic;font-size:10pt;">2018 Stock Option and Grant Plan </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, the Company adopted the 2018 stock option and grant plan (the 2018 Plan), which provided for the Company to sell or issue common stock, or other stock-based awards, to employees, members of the board of directors and consultants of the Company. The Company generally granted stock-based awards with service conditions only (service-based awards), although there was one grant with performance conditions. As of December 31, 2020, there are no unvested options with performance conditions. Stock options granted under the 2018 Plan generally vest over three to four years. There were 1,959,411&#160;options granted under the 2018 Plan prior to the Company&#8217;s IPO in October 2019. No further grants may be made under the 2018 Plan subsequent to the IPO. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:5.94%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2019 Stock Option and Incentive Plan</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2019 Stock Option and Incentive Plan (2019 Plan) was approved by the Company&#8217;s board of directors on October 14, 2019, and became effective on October 23, 2019. The 2019 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#8217;s officers, employees, directors and consultants. The number of shares initially reserved for issuance under the 2019 Plan was 2,342,288, <font style="color:#000000;">which will be increased </font>each January 1 thereafter by 4% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company&#8217;s board of directors or compensation committee of the board of directors. On January 1, 2<font style="color:#000000;">021, the total number of shares under the 2019 Plan was increased by&#160;962,511&#160;shares. As of December 31, 2020, there were 2,314,303 shares remaining available for issuance.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the stock option activity is presented below: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of January 1, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">971,353</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.01</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,051</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,340,839</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.97</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,667</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.01</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(176,893</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.22</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,129,632</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.12</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,844</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">813,172</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.03</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,611</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.44</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,714</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.30</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,900,479</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.33</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,303</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options Exercisable at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,068,675</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.04</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,059</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of options granted is calculated as the difference between the exercise price of the options and the estimated fair value of the Company&#8217;s common stock. The weighted average grant-date fair value of stock options granted during the year ended December&#160;31, 2020 and 2019 was $8.31 and $5.24, respectively. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each award is estimated using Black-Scholes based on the following assumptions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December 31,</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.28%&#8212;1.48%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39%&#8212;2.59%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7&#8212;6.1 years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3&#8212;6.1 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70%&#8212;79%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70%&#8212;76%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Fair value of common stock<font style="font-style:normal;">&#8212;Prior to the Company&#8217;s IPO in October 2019, the fair value of the Company&#8217;s common stock underlying stock-based awards was estimated on each grant date by the Company&#8217;s board of directors. In order to determine the fair value of the Company&#8217;s common stock underlying stock-based awards, the Company&#8217;s board of directors considered, among other things, a valuation of the Company&#8217;s common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice Guide,</font>&#160;Valuation of Privately-Held-Company Equity Securities Issued as Compensation<font style="font-style:normal;">. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected term<font style="font-style:normal;">&#8212;The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method, which is</font><font style="color:#000000;font-style:normal;"> the midpoint between the vesting period and the contractual term of the option.</font> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility<font style="font-style:normal;">&#8212;As a privately held company prior to the Company&#8217;s IPO in October 2019, the Company has limited trading history for its common stock and, as such, the expected volatility is estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock-based awards. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate<font style="font-style:normal;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of a stock-based award. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend<font style="font-style:normal;">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based Compensation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has recorded stock-based compensation in the accompanying statements of operations as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,989</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,304</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,399</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">996</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,388</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,300</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, there was $9,809 of unrecognized compensation cost related to unvested option awards, <font style="color:#000000;">which is expected to be recognized over a weighted-average period of 2.8 years</font>. As of December&#160;31, 2020, there was $239 of unrecognized compensation cost related to unvested founder stock awards, which is expected to be recognized over a weighted-average period of 0.3 years. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:5.94%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2019 Employee Stock Purchase Plan</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2019 Employee Stock Purchase Plan (2019 ESPP) was approved by the Company&#8217;s board of directors on October&#160;14, 2019, and became effective on October 23, 2019. A total of 234,229 shares of common stock were initially reserved for issuance under the 2019 ESPP, and will be increased each January 1 thereafter through January 1, 2029 by the least of (i) 234,229 shares of common stock, (ii) 1% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31 or (iii) such lesser number of shares determined by the 2019 ESPP&#8217;s administrator. On January 1, 2021, <font style="color:#000000;">the total number of shares under the 2019 ESPP was increased by&#160;234,229&#160;shares.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee contributions&#160;are&#160;made through payroll deductions of up to 15% of eligible compensation over the offering period. A participant may not accrue rights to purchase more than $25&#160;worth of the Company&#8217;s common stock for each calendar year in which such right is outstanding.&#160;At the end of each offering period, shares of the Company&#8217;s common stock may be purchased at 85% of the lesser of the Company&#8217;s common stock on (i) the first trading day of the relevant offering period and (ii) the last trading day of the relevant offering period.&#160;The first offering period commenced on July&#160;1, 2020 and ended on November&#160;30, 2020. Thereafter, offerings will be six months in duration and will commence on each December 1 and June 1. The Company recognized stock-based compensation expense of $18 during the year ended December 31, 2020 related to the 2019 ESPP.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495091231896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Income Taxes </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reconciliation of federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected income tax benefit at the federal statutory rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State and local taxes, net of federal benefit</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible items and other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35.3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The principal components of the Company&#8217;s deferred tax assets consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal, state and local net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,241</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,688</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License fee deductions</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,317</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">452</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation deductions</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,243</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">837</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">457</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,978</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,223</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,978</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,223</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company increased its valuation allowance by $11,755&#160;for the year ended December&#160;31, 2020 in order to maintain a full valuation allowance against its deferred tax assets. Based on the Company&#8217;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December&#160;31, 2020. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company had federal, state and local net operating loss carryforwards of $45,550, $47,735 and $38,645, respectively; $45,301 of the federal amounts do not expire, and the remaining $249 expire in 2037. The state net operating losses begin to expire in 2037. The local net operating losses begin to expire in 2039. As of December&#160;31, 2020, the Company had federal research and development tax credit carryforwards of $1,317, which begin to expire in 2038. Under the provisions of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the IRC), these net operating losses, credit carryforwards and other tax attributes may be subject to limitation based on previous significant changes in ownership and upon future significant changes in ownership of the Company, as defined by the IRC.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the U.S. federal jurisdiction as well as in Pennsylvania and Philadelphia. The tax years 2019, 2018 and 2017 remain open to examination by the jurisdictions where the Company is subject to tax. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&#160;31, 2020, the Company had no unrecognized income tax benefits that would affect the Company&#8217;s effective tax rate if recognized. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495091095352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. Net Loss Per Share </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the two-class method required for participating securities. For the years ended December 31, 2020 and 2019, the Company had voting and non-voting common stock outstanding. Since the rights of the voting and non-voting common stock are identical, except with respect to voting, the undistributed losses of the Company have been allocated on a proportionate basis to the two classes. Diluted net loss per share is calculated using the if-converted method, which assumes conversion of all non-voting common stock to voting common stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2020</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Voting common stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-voting common stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of undistributed losses attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,090</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,249</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares used in basic per share computation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,417,900</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,727,327</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.44</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.44</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted net loss per share:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of undistributed losses for basic computation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,090</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,249</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reallocation of undistributed losses as a result of conversion of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; non-voting to voting common shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,249</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of undistributed losses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,339</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,249</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares used in basic per share computation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,417,900</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,727,327</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Add: Conversion of non-voting to voting common shares outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,727,327</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares used in diluted per share computation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,145,227</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,727,327</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.44</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.44</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2019</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Voting common stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-voting common stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of undistributed losses attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,693</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,576</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares used in basic per share computation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,345,530</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,123,861</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted net loss per share:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of undistributed losses for basic computation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,693</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,576</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reallocation of undistributed losses as a result of conversion of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; non-voting to voting common shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,576</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of undistributed losses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,269</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,576</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares used in basic per share computation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,345,530</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,123,861</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Add: Conversion of non-voting to voting common shares outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,123,861</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares used in diluted per share computation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,469,391</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,123,861</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,900,479</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,129,632</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-vested founder stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">465,801</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,388,977</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,366,280</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,518,609</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495091203016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Savings Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">401(k) Savings Plan</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. 401(k) Savings Plan</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains a defined-contribution savings plan under Section&#160;401(k) of the IRC, or the 401(k) Plan. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. In 2019, the Company made a safe harbor nonelective contribution of 3% of eligible compensation on behalf of all employees. Effective January 1, 2020, the Plan provided for matching contributions on a portion of participant contributions pursuant to the 401(k) Savings Plan&#8217;s matching formula, up to 4% of eligible compensation. All matching contributions and participant contributions vest immediately. Contributions totaled $203 and $74 for the years ended December&#160;31, 2020 and 2019, respectively, and have been recorded in the statements of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495021034232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13. Subsequent Events</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, the Company entered into a Development and Manufacturing Services Agreement (Wuxi Agreement) with <font style="color:#000000;">WuXi Advanced Therapies (Wuxi) to serve as the Company&#8217;s cell processing manufacturing partner for the anticipated MuSK-CAART Phase 1 clinical trial.</font> The Company has the right to terminate the Wuxi Agreement for convenience or other reasons specified in the Wuxi Agreement upon prior written notice. If the Company terminates the Wuxi Agreement, it will be obligated to pay an early termination fee of $1,500.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, the Company entered into a research service agreement with CHOP for vector manufacturing, with a total cost of $670, expected to be incurred during 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495015348552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, stock-based compensation and the valuation allowance on the Company&#8217;s deferred tax assets. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock', window );">Off-Balance Sheet Risk and Concentrations of Credit Risk</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Off-Balance Sheet Risk and Concentrations of Credit Risk </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, which are primarily invested in U.S. treasury-based money market funds, and available-for-sale debt securities, which are invested in investment grade corporate bonds with&#160;<font style="Background-color:#FFFFFF;color:#212529;">high credit quality issuers</font>.&#160;These investments have maturities in 2021. A portion of the Company&#8217;s cash is maintained at a federally insured financial institution. The deposits held at this institution are in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held.&#160; The cash in this account is swept daily into U.S. treasury-based and U.S. government-based money market funds. The Company has no off&#8209;balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investments</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments are available-for-sale and carried at estimated fair value. The Company&#8217;s valuations of available-for-sale debt securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than, twelve months from the balance sheet date are classified as current.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors including the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or if more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other-than-temporary, if any, on available-for-sale securities are included in interest and other income, net. The cost of investments sold is based on the specific-identification method. Interest income on investments as well as amortization of discount or premium is included in interest income.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property, Plant and Equipment </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying statements of operations. Expenditures for normal, recurring or periodic repairs and maintenance related to property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful lives for property and equipment are as follows:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Three years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Three years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Three years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Lesser of estimated useful life or remaining lease term</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurement </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2&#8212;Inputs (other than quoted prices included in Level&#160;1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs include costs incurred for internal and external research and development activities and are expensed as incurred in the accompanying statements of operations. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to entities that conduct certain research and development activities on the Company&#8217;s behalf. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers, which include activities under agreements with Penn (Note 6), the conduct of sponsored research, preclinical studies and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided and includes these costs in accrued and other current liabilities and prepaid expenses and other current assets in the accompanying balance sheets and within research and development expense in the accompanying statements of operations. Non-refundable advance payments made for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as expense as the goods are received or the related services are rendered.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with service providers. The Company makes significant judgments and estimates in determining the accrued liabilities and prepaid expenses in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities and prepaid expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based Compensation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures its stock-based awards granted to employees and non-employees based on the estimated fair values of the awards on the respective grant dates. The Company uses the Black-Scholes option-pricing model (Black-Scholes) to estimate the fair value of its stock-based awards. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company accounts for forfeitures of stock option awards as they occur. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company&#8217;s IPO, the assumptions used in the Company's Black-Scholes option-pricing model represented management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities, which relate primarily to the carrying amount of the Company&#8217;s property and equipment and its net operating loss carryforwards, are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the two-class method required for participating securities. The Company has voting and non-voting common stock. The rights, including the liquidation and dividend rights, of the holders of the voting and non-voting common stock are identical, except with respect to voting. Each share of non-voting common stock may be converted at any time into one share of voting common stock at the option of its holder by providing written notice to the Company, subject to the limitations provided for in the amended and restated certificate of incorporation. The Company also considers its unvested shares of common stock held by the Company&#8217;s founders and, prior to its conversion to common stock, its convertible preferred stock to be participating securities as, in the event a dividend is paid on common stock, the holders of convertible preferred stock and unvested shares of common stock would be entitled to receive dividends on a basis consistent with the common stockholders. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock, which excludes unvested shares of common stock. The undistributed loss for each year is allocated to common stockholders based on the contractual participation rights of the voting and non-voting common stock as if the losses for the year had been distributed. As the liquidation and dividend rights are identical, the undistributed losses are allocated on a proportionate basis. Net loss attributable to common stockholders for the year ended December 31, 2019 is calculated by adjusting the net loss of the Company for the deemed dividend associated with the exchange of Series A-2 Preferred for Series B Preferred. Diluted net loss per share attributable to common stockholders is computed under the if-converted method and assumes that all non-voting common stock has been converted to common stock. Since the Company was in a loss position for all periods presented, the effects of the other potentially dilutive securities are antidilutive. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segments </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has one reportable segment. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_RelatedPartyTransactionsPolicyTextBlock', window );">Related Party Transactions</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Related Party Transactions </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company engaged a firm controlled by a former executive (until February 2019) of the Company for professional services related to accounting, finance and other administrative functions. For the years ended December 31, 2020 and 2019, the costs incurred under this arrangement totaled $311 and $601, respectively. These amounts were recorded as general and administrative expense in the accompanying statements of operations. As of December&#160;31, 2020 and 2019, amounts owed under this arrangement totaled $13&#160;and $36, respectively, and are included in accounts payable in the accompanying balance sheets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Emerging Growth Company Status </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS&#160;Act). Under the JOBS&#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&#160;Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS&#160;Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements Not Yet Adopted</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the Financial Accounting Standards Board (FASB) issued ASU 2016-02, <font style="font-style:italic;">Leases</font> (Topic 842), with guidance regarding the accounting for and disclosure of leases. The update requires lessees to recognize the liabilities related all leases, including operating leases, with a term greater than 12 months on the balance sheet. This update also requires lessees and lessors to disclose key information about their leasing transactions. This guidance will be effective for public companies for annual and interim periods beginning after December&#160;15, 2018. For all other entities, including Emerging Growth Companies, this standard is effective for annual reporting periods beginning after December&#160;15, 2020, and interim periods within annual periods beginning after December&#160;15, 2021. Early adoption is permitted. As an Emerging Growth Company, the Company expects to adopt Topic 842 for its annual period ending December 31, 2021 and has not yet finalized the assessment of the impact that ASU 2016-02 will have on its financial statements or financial statement disclosures. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_RelatedPartyTransactionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_RelatedPartyTransactionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5144-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919272-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495016948104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock', window );">Schedule of Estimated Useful Lives for Property and Equipment</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful lives for property and equipment are as follows:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Three years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Three years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Three years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Lesser of estimated useful life or remaining lease term</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated useful lives of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495100832280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Financial Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prices in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active Markets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Identical</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets (Level 1)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,429</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,429</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,233</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,233</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,662</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,429</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,233</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in Active Markets for Identical Assets (Level 1)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other Observable Inputs (Level 2)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Unobservable Inputs (Level 3)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,204</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,204</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,204</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,204</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Debt Securities Classified as Available-for-Sale Investments</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Included in cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,429</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,429</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds - due in one year or less</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Included in short-term investments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,227</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,233</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,656</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,662</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495016959224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property Plant and Equipment</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property plant and equipment consists of the following:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">961</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">277</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">277</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property, plant and equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,348</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">919</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(458</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(104</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">890</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">815</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495091216840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued and Other Current Liabilities</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities consist of the following: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development services</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,294</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">231</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative services</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation expense</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,445</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,522</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">177</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,937</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,227</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495114277480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Payments for Operating Leases</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the future minimum payments for operating leases are as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">426</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495020922152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAbstract', window );"><strong>Partners Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Summary of Convertible Preferred Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A-1 Preferred</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A-2 Preferred</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance&#8212;December 31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,146,551</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,575</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,372,719</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,994</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,873,777</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,352</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,393,047</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,921</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,963,788</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,963,788</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange, including</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; deemed dividend</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,405,332</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,764</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,405,332</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,090</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,326</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,293</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,293</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,146,551</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,575</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,372,719</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,994</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(468,445</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,588</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,369,120</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,797</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,356,835</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(97,954</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance&#8212;December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495019654968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the stock option activity is presented below: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of January 1, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">971,353</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.01</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,051</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,340,839</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.97</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,667</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.01</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(176,893</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.22</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,129,632</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.12</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,844</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">813,172</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.03</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,611</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.44</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,714</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.30</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,900,479</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.33</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,303</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options Exercisable at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,068,675</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.04</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,059</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Estimate Fair Value of Stock Options</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each award is estimated using Black-Scholes based on the following assumptions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December 31,</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.28%&#8212;1.48%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39%&#8212;2.59%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7&#8212;6.1 years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3&#8212;6.1 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70%&#8212;79%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70%&#8212;76%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.66%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has recorded stock-based compensation in the accompanying statements of operations as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,989</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,304</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,399</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">996</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,388</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,300</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495017000616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reconciliation of federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected income tax benefit at the federal statutory rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State and local taxes, net of federal benefit</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible items and other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35.3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Principal Components of Company's Deferred Tax Assets</a></td>
<td class="text">The principal components of the Company&#8217;s deferred tax assets consisted of the following:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal, state and local net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,241</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,688</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License fee deductions</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,317</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">452</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation deductions</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,243</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">837</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">457</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,978</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,223</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,978</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,223</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495016976200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Earnings Per Share</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2020</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Voting common stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-voting common stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of undistributed losses attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,090</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,249</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares used in basic per share computation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,417,900</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,727,327</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.44</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.44</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted net loss per share:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of undistributed losses for basic computation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,090</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,249</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reallocation of undistributed losses as a result of conversion of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; non-voting to voting common shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,249</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of undistributed losses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,339</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,249</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares used in basic per share computation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,417,900</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,727,327</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Add: Conversion of non-voting to voting common shares outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,727,327</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares used in diluted per share computation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,145,227</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,727,327</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.44</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.44</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2019</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Voting common stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-voting common stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of undistributed losses attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,693</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,576</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares used in basic per share computation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,345,530</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,123,861</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted net loss per share:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of undistributed losses for basic computation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,693</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,576</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reallocation of undistributed losses as a result of conversion of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; non-voting to voting common shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,576</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of undistributed losses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,269</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,576</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares used in basic per share computation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,345,530</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,123,861</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Add: Conversion of non-voting to voting common shares outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,123,861</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares used in diluted per share computation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,469,391</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,123,861</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,900,479</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,129,632</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-vested founder stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">465,801</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,388,977</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,366,280</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,518,609</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495011518120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 29, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 16, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-1.5 reverse split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and investments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (66,298)<span></span>
</td>
<td class="num">$ (32,959)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares | shares</a></td>
<td class="nump">6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock issued, per share | $ / shares</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from initial public offering | $</a></td>
<td class="nump">$ 66,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Conversion of convertible preferred stock to common stock | shares</a></td>
<td class="nump">12,904,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_NumberOfAdditionalCommonStockPurchasedByUnderwritersUponPartialExerciseOfOption', window );">Number of additional common stock purchased by underwriters upon partial exercise of option | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_BasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_BasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_NumberOfAdditionalCommonStockPurchasedByUnderwritersUponPartialExerciseOfOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional common stock purchased by underwriters upon partial exercise of option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_NumberOfAdditionalCommonStockPurchasedByUnderwritersUponPartialExerciseOfOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495014455912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_InvestmentsMaturityYear', window );">Investments maturity year</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest or penalties related to uncertain income tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reportable segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Amounts due to related party</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=caba_ProfessionalServicesMember', window );">Professional Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty', window );">Costs incurred under the arrangement recorded as general and administrative expense</a></td>
<td class="nump">$ 311,000<span></span>
</td>
<td class="nump">$ 601,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_InvestmentsMaturityYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments maturity year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_InvestmentsMaturityYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=caba_ProfessionalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=caba_ProfessionalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495019859368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives for Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=caba_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful life</a></td>
<td class="text">Lesser of estimated useful life or remaining lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=caba_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=caba_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495014363128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">$ 7,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">108,662<span></span>
</td>
<td class="nump">$ 136,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">101,429<span></span>
</td>
<td class="nump">136,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">101,429<span></span>
</td>
<td class="nump">136,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">101,429<span></span>
</td>
<td class="nump">$ 136,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">7,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Short-term Investments - Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">7,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Short-term Investments - Corporate Bonds | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">$ 7,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495019803080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Fair value, assets, level 1 to level 2 transfers, amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Fair value, assets, level 2 to level 1 transfers, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">$ 108,662,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495015363128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Debt Securities Classified as Available-for-Sale Investments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 108,656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">108,662,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember', window );">Money Market Funds Included in Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">101,429,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">101,429,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember', window );">Corporate Bonds - due in One Year or Less</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">7,227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 7,233,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495014323768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment - Schedule of Property Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 1,348<span></span>
</td>
<td class="nump">$ 919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(458)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">890<span></span>
</td>
<td class="nump">815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">961<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495017071704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 354<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495011496984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_AccruedResearchAndDevelopmentServicesCurrent', window );">Research and development services</a></td>
<td class="nump">$ 1,294<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_AccruedGeneralAndAdministrativeServicesCurrent', window );">General and administrative services</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation expense</a></td>
<td class="nump">2,445<span></span>
</td>
<td class="nump">1,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 3,937<span></span>
</td>
<td class="nump">$ 2,227<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_AccruedGeneralAndAdministrativeServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued general and administrative services current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_AccruedGeneralAndAdministrativeServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_AccruedResearchAndDevelopmentServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development services current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_AccruedResearchAndDevelopmentServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495011723864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations, Licensing Agreements and other Agreements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Faculty</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,376,000<span></span>
</td>
<td class="nump">$ 11,671,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_LicenseAgreementMember', window );">License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Obligation to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_PaymentOfObligationTerm', window );">Payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_ObligationToBePaidCommencementDate', window );">Payment commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018-08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_LicenseMaintenanceFee', window );">License maintenance fee</a></td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_MilestonePayments', window );">Total milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_CollaborativeAgreementPaymentsDue', window );">Amounts due to agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_SponsoredResearchAgreementsMember', window );">Sponsored Research Agreements | Penn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Obligation to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,781,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_NumberOfFaculty', window );">Number of faculty member | Faculty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_FundingTermEndingDate', window );">Funding term end date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_ContractualCostIncurred', window );">Cost incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,090,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,995,000<span></span>
</td>
<td class="nump">2,137,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_SponsoredResearchAgreementsMember', window );">Sponsored Research Agreements | Penn | Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_AdvancePayments', window );">Advance payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,851,000<span></span>
</td>
<td class="nump">1,588,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_SponsoredResearchAgreementsMember', window );">Sponsored Research Agreements | Penn | Accrued and Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Obligation to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_MasterTranslationalResearchServicesAgreementMember', window );">Master Translational Research Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,474,000<span></span>
</td>
<td class="nump">2,355,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_MaximumResearchAndDevelopmentAdditionalExpenseDueInRemainingTerm', window );">Maximum research and development additional expense incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_SubscriptionAndTechnologyTransferAgreementMember', window );">Subscription and Technology Transfer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_ContractualExpenses', window );">Expense related to agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_AdvancePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advance payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_AdvancePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborations licensing agreements and other agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_CollaborativeAgreementPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative agreement payments due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_CollaborativeAgreementPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ContractualCostIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual cost incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ContractualCostIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ContractualExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ContractualExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_FundingTermEndingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding term ending date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_FundingTermEndingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_LicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License maintenance fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_LicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_MaximumResearchAndDevelopmentAdditionalExpenseDueInRemainingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum research and development additional expense due in remaining term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_MaximumResearchAndDevelopmentAdditionalExpenseDueInRemainingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_NumberOfFaculty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of faculty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_NumberOfFaculty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ObligationToBePaidCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligation to be paid, commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ObligationToBePaidCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_PaymentOfObligationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of obligation, term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_PaymentOfObligationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_SponsoredResearchAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_SponsoredResearchAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=caba_RegentsOfUniversityOfCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=caba_RegentsOfUniversityOfCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=caba_AccruedAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=caba_AccruedAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_MasterTranslationalResearchServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_MasterTranslationalResearchServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_SubscriptionAndTechnologyTransferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_SubscriptionAndTechnologyTransferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495098486184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - Operating Lease Agreement - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease, description</a></td>
<td class="text">The lease term commenced in May 2019 and will expire in July 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_LeaseCommencementMonthAndYear', window );">Lease commencement period</a></td>
<td class="text">2019-05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_LeaseExpirationMonthAndYear', window );">Lease expiration period</a></td>
<td class="text">2022-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Initial annual base rent</a></td>
<td class="nump">$ 261,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_AnnualIncreasePercentageOfBaseRent', window );">Percentage of annual increase of base rent</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_RentExpense', window );">Rent expense</a></td>
<td class="nump">$ 266,000<span></span>
</td>
<td class="nump">$ 178,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_AnnualIncreasePercentageOfBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual increase percentage of base rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_AnnualIncreasePercentageOfBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_LeaseCommencementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease commencement month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_LeaseCommencementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_LeaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_LeaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_RentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rent expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_RentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121595440&amp;loc=d3e34039-112682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseMinimumRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_OperatingLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_OperatingLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495014073416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Payments for Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">2021</a></td>
<td class="nump">$ 268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2022</a></td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">$ 426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495011910072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,762,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds from convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityValueExchangeIncludingDeemedDividend', window );">Preferred stock exchange including deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_ConvertiblePreferredStockConvertIntoVotingCommonStock', window );">Convertible preferred stock convert into common stock</a></td>
<td class="nump">12,904,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_ConvertiblePreferredStockConvertIntoNonVotingCommonStock', window );">Convertible preferred stock convert into non-voting common stock</a></td>
<td class="nump">6,409,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,963,788<span></span>
</td>
<td class="nump">6,963,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds from convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquitySharesExchangeIncludingDeemedDividend', window );">Number of preferred shares in exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405,332<span></span>
</td>
<td class="nump">1,405,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityValueExchangeIncludingDeemedDividend', window );">Preferred stock exchange including deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,090)<span></span>
</td>
<td class="num">$ (10,090)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caba_SeriesA2PreferredStockMember', window );">Series A-2 Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquitySharesExchangeIncludingDeemedDividend', window );">Number of preferred shares in exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,405,332)<span></span>
</td>
<td class="num">(1,405,332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityValueExchangeIncludingDeemedDividend', window );">Preferred stock exchange including deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,764)<span></span>
</td>
<td class="nump">$ 4,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,873,777<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,963,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityValueExchangeIncludingDeemedDividend', window );">Preferred stock exchange including deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,393,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ConvertiblePreferredStockConvertIntoNonVotingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock convert into non-voting common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ConvertiblePreferredStockConvertIntoNonVotingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ConvertiblePreferredStockConvertIntoVotingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock convert into voting common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ConvertiblePreferredStockConvertIntoVotingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_TemporaryEquitySharesExchangeIncludingDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity shares exchange including deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_TemporaryEquitySharesExchangeIncludingDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period, shares, new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_TemporaryEquityValueExchangeIncludingDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity value exchange including deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_TemporaryEquityValueExchangeIncludingDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caba_SeriesA2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caba_SeriesA2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495015498392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Summary of Convertible Preferred Stock (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityValueExchangeIncludingDeemedDividend', window );">Exchange, including deemed dividend</a></td>
<td class="nump">$ 5,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">$ 12,575<span></span>
</td>
<td class="nump">$ 12,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, Shares</a></td>
<td class="nump">3,146,551<span></span>
</td>
<td class="nump">3,146,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityConversionOfStockValueForCommonStock', window );">Conversion to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,575)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityConversionOfStockSharesForCommonStock', window );">Conversion to common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,146,551)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caba_SeriesA1PreferredStockMember', window );">Series A-1 Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">$ 24,994<span></span>
</td>
<td class="nump">$ 24,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, Shares</a></td>
<td class="nump">7,372,719<span></span>
</td>
<td class="nump">7,372,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityConversionOfStockValueForCommonStock', window );">Conversion to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (24,994)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityConversionOfStockSharesForCommonStock', window );">Conversion to common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,372,719)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caba_SeriesA2PreferredStockMember', window );">Series A-2 Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">$ 6,352<span></span>
</td>
<td class="nump">$ 6,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, Shares</a></td>
<td class="nump">1,873,777<span></span>
</td>
<td class="nump">1,873,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityValueExchangeIncludingDeemedDividend', window );">Exchange, including deemed dividend</a></td>
<td class="nump">$ 4,764<span></span>
</td>
<td class="num">$ (4,764)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquitySharesExchangeIncludingDeemedDividend', window );">Exchange, including deemed dividend, Shares</a></td>
<td class="num">(1,405,332)<span></span>
</td>
<td class="num">(1,405,332)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityConversionOfStockValueForCommonStock', window );">Conversion to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,588)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityConversionOfStockSharesForCommonStock', window );">Conversion to common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(468,445)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance, shares</a></td>
<td class="nump">6,963,788<span></span>
</td>
<td class="nump">6,963,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityValueExchangeIncludingDeemedDividend', window );">Exchange, including deemed dividend</a></td>
<td class="nump">$ 10,090<span></span>
</td>
<td class="nump">$ 10,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquitySharesExchangeIncludingDeemedDividend', window );">Exchange, including deemed dividend, Shares</a></td>
<td class="nump">1,405,332<span></span>
</td>
<td class="nump">1,405,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,293)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityConversionOfStockValueForCommonStock', window );">Conversion to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (58,797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityConversionOfStockSharesForCommonStock', window );">Conversion to common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,369,120)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">$ 43,921<span></span>
</td>
<td class="nump">$ 43,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, Shares</a></td>
<td class="nump">12,393,047<span></span>
</td>
<td class="nump">12,393,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,963,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityValueExchangeIncludingDeemedDividend', window );">Exchange, including deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,293)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityConversionOfStockValueForCommonStock', window );">Conversion to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (97,954)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_TemporaryEquityConversionOfStockSharesForCommonStock', window );">Conversion to common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,356,835)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_TemporaryEquityConversionOfStockSharesForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity conversion of stock shares for common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_TemporaryEquityConversionOfStockSharesForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_TemporaryEquityConversionOfStockValueForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity conversion of stock value for common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_TemporaryEquityConversionOfStockValueForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_TemporaryEquityIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_TemporaryEquityIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_TemporaryEquitySharesExchangeIncludingDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity shares exchange including deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_TemporaryEquitySharesExchangeIncludingDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period, shares, new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_TemporaryEquityValueExchangeIncludingDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity value exchange including deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_TemporaryEquityValueExchangeIncludingDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caba_SeriesA1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caba_SeriesA1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caba_SeriesA2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caba_SeriesA2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495007927576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 23, 2019</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_ConversionOfNonVotingCommonStockToVotingCommonStockSharesConverted', window );">Conversion of non-voting common stock to voting common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,733,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModified', window );">Common stock shares modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,904,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModifiedFairValue', window );">Fair value of common stock shares modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStockSharesCompensationCost', window );">Total compensation cost of common stock shares modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to unvested stock-based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,388<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=caba_FoundersMember', window );">Founders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to unvested stock-based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,989<span></span>
</td>
<td class="nump">1,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development | Founders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495<span></span>
</td>
<td class="nump">529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,399<span></span>
</td>
<td class="nump">996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense | Founders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_AtTheMarketOfferingSalesAgreementMember', window );">At-The-Market Offering Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandEighteenStockOptionAndGrantPlanMember', window );">Two Thousand Eighteen Stock Option And Grant Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Share-based compensation unvested number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,959,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandEighteenStockOptionAndGrantPlanMember', window );">Two Thousand Eighteen Stock Option And Grant Plan | Stock Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandEighteenStockOptionAndGrantPlanMember', window );">Two Thousand Eighteen Stock Option And Grant Plan | Stock Options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenStockOptionAndIncentivePlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="nump">2,342,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">962,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_IncreaseInShareReservedPercentage', window );">Increase in share reserved percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based compensation, number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,314,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenStockOptionAndIncentivePlanMember', window );">2019 Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">813,172<span></span>
</td>
<td class="nump">1,340,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.31<span></span>
</td>
<td class="nump">$ 5.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="nump">234,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 ESPP | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="nump">234,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_IncreaseInShareReservedPercentage', window );">Increase in share reserved percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 ESPP | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_PercentageOfPayrollDeductionOnEligibleCompensation', window );">Payroll deduction percentage of eligible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock', window );">Employee stock purchase plan maximum annual rights to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock', window );">Percentage of shares to be purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember', window );">Voting Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,590,481<span></span>
</td>
<td class="nump">143,590,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,590,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Non-voting Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,409,519<span></span>
</td>
<td class="nump">6,409,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,409,519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ConversionOfNonVotingCommonStockToVotingCommonStockSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of non voting common stock to voting common stock shares converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ConversionOfNonVotingCommonStockToVotingCommonStockSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan maximum annual rights to purchase common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_IncreaseInShareReservedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in share reserved percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_IncreaseInShareReservedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_PercentageOfPayrollDeductionOnEligibleCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of payroll deduction on eligible compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_PercentageOfPayrollDeductionOnEligibleCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares purchased at fair market value of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award common stock shares modified</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModifiedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award common stock shares modified fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockSharesModifiedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStockSharesCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award modified common stock shares compensation cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedCommonStockSharesCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=caba_FoundersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=caba_FoundersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_AtTheMarketOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_AtTheMarketOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_TwoThousandEighteenStockOptionAndGrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_TwoThousandEighteenStockOptionAndGrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_TwoThousandNineteenStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_TwoThousandNineteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495014223800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Summary of Stock Option Activity (Details) - Stock Options - 2019 Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Beginning Balance</a></td>
<td class="nump">2,129,632<span></span>
</td>
<td class="nump">971,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="nump">813,172<span></span>
</td>
<td class="nump">1,340,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Exercised</a></td>
<td class="num">(25,611)<span></span>
</td>
<td class="num">(5,667)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, Forfeited/Cancelled</a></td>
<td class="num">(16,714)<span></span>
</td>
<td class="num">(176,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Ending Balance</a></td>
<td class="nump">2,900,479<span></span>
</td>
<td class="nump">2,129,632<span></span>
</td>
<td class="nump">971,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Options Exercisable</a></td>
<td class="nump">1,068,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 5.12<span></span>
</td>
<td class="nump">$ 1.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">13.03<span></span>
</td>
<td class="nump">7.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">5.44<span></span>
</td>
<td class="nump">1.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/Cancelled</a></td>
<td class="nump">6.30<span></span>
</td>
<td class="nump">4.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">7.33<span></span>
</td>
<td class="nump">$ 5.12<span></span>
</td>
<td class="nump">$ 1.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Exercisable</a></td>
<td class="nump">$ 4.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Term (years)</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (years), Options Exercisable</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning Balance</a></td>
<td class="nump">$ 18,844<span></span>
</td>
<td class="nump">$ 4,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised</a></td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
<td class="nump">16,303<span></span>
</td>
<td class="nump">$ 18,844<span></span>
</td>
<td class="nump">$ 4,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options Exercisable</a></td>
<td class="nump">$ 9,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options outstanding aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_TwoThousandNineteenStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495012640808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Schedule of Assumptions Used to Estimate Fair Value of Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.28%<span></span>
</td>
<td class="nump">1.39%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.48%<span></span>
</td>
<td class="nump">2.59%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495016768488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Summary of Stock-Based Compensation (Details) - Stock Options - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 4,388<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">1,989<span></span>
</td>
<td class="nump">1,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 2,399<span></span>
</td>
<td class="nump">$ 996<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495100810280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Expected income tax benefit at the federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local taxes, net of federal benefit</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credit, net</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther', window );">Non-deductible items and other</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(3.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(35.30%)<span></span>
</td>
<td class="num">(33.10%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation nondeductible items and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495019861672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Principal Components of Company's Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Federal, state and local net operating loss carryforwards</a></td>
<td class="nump">$ 15,241<span></span>
</td>
<td class="nump">$ 5,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_DeferredTaxAssetsLicenseFeesDeductions', window );">License fee deductions</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">1,317<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation deductions</a></td>
<td class="nump">1,243<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">837<span></span>
</td>
<td class="nump">457<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">18,978<span></span>
</td>
<td class="nump">7,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(18,978)<span></span>
</td>
<td class="num">(7,223)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_DeferredTaxAssetsLicenseFeesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets license fees deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_DeferredTaxAssetsLicenseFeesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495011893336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 11,755,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal', window );">Deferred tax assets operating loss carryforwards federal</a></td>
<td class="nump">45,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_DeferredTaxAssetsOperatingLossCarryforwardsState', window );">Deferred tax assets operating loss carryforwards state</a></td>
<td class="nump">47,735,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal', window );">Deferred tax assets operating loss carryforwards local</a></td>
<td class="nump">38,645,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Deferred tax assets, operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">45,301,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Deferred tax assets, operating loss carryforwards, subject to expiration</a></td>
<td class="nump">$ 249,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate', window );">Operating loss carryforwards federal commencement of expiration date</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate', window );">Operating loss carryforwards state commencement of expiration date</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate', window );">Operating loss carryforwards local commencement of expiration date</a></td>
<td class="text">2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">$ 1,317,000<span></span>
</td>
<td class="nump">$ 452,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2017 2018 2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_PercentageOfEligibleTaxPositionsForRecognition', window );">Percentage of eligible tax positions for recognition</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized income tax benefits that would affect effective tax rate</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=caba_FederalMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">$ 1,317,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate', window );">Deferred tax assets tax credit carryforwards commencement of expiration date</a></td>
<td class="text">2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carryforwards federal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carryforwards local.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_DeferredTaxAssetsOperatingLossCarryforwardsState">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carryforwards state.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_DeferredTaxAssetsOperatingLossCarryforwardsState</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax credit carryforwards commencement of expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards federal commencement of expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards local commencement of expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards state commencement of expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_PercentageOfEligibleTaxPositionsForRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of eligible tax positions for recognition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_PercentageOfEligibleTaxPositionsForRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=caba_FederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=caba_FederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495007892472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Basic and Diluted Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember', window );">Voting Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic', window );">Allocation of undistributed losses attributable to common stockholders</a></td>
<td class="num">$ (25,090)<span></span>
</td>
<td class="num">$ (17,693)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares used in basic per share computation</a></td>
<td class="nump">17,417,900<span></span>
</td>
<td class="nump">4,345,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (1.44)<span></span>
</td>
<td class="num">$ (4.07)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Allocation of undistributed losses for basic computation</a></td>
<td class="num">$ (25,090)<span></span>
</td>
<td class="num">$ (17,693)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther', window );">Reallocation of undistributed losses as a result of conversion of non-voting to voting common shares</a></td>
<td class="num">(8,249)<span></span>
</td>
<td class="num">(4,576)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Allocation of undistributed losses</a></td>
<td class="num">$ (33,339)<span></span>
</td>
<td class="num">$ (22,269)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares used in basic per share computation</a></td>
<td class="nump">17,417,900<span></span>
</td>
<td class="nump">4,345,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Add: Conversion of non-voting to voting common shares outstanding</a></td>
<td class="nump">5,727,327<span></span>
</td>
<td class="nump">1,123,861<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares used in diluted per share computation</a></td>
<td class="nump">23,145,227<span></span>
</td>
<td class="nump">5,469,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (1.44)<span></span>
</td>
<td class="num">$ (4.07)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Non-voting Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic', window );">Allocation of undistributed losses attributable to common stockholders</a></td>
<td class="num">$ (8,249)<span></span>
</td>
<td class="num">$ (4,576)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares used in basic per share computation</a></td>
<td class="nump">5,727,327<span></span>
</td>
<td class="nump">1,123,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (1.44)<span></span>
</td>
<td class="num">$ (4.07)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Allocation of undistributed losses for basic computation</a></td>
<td class="num">$ (8,249)<span></span>
</td>
<td class="num">$ (4,576)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Allocation of undistributed losses</a></td>
<td class="num">$ (8,249)<span></span>
</td>
<td class="num">$ (4,576)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares used in basic per share computation</a></td>
<td class="nump">5,727,327<span></span>
</td>
<td class="nump">1,123,861<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares used in diluted per share computation</a></td>
<td class="nump">5,727,327<span></span>
</td>
<td class="nump">1,123,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (1.44)<span></span>
</td>
<td class="num">$ (4.07)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2793-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2740-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2793-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to common stock as if earnings had been distributed. Excludes distributed earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495012745608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares have been excluded from calculation of diluted net loss per share</a></td>
<td class="nump">3,366,280<span></span>
</td>
<td class="nump">3,518,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares have been excluded from calculation of diluted net loss per share</a></td>
<td class="nump">2,900,479<span></span>
</td>
<td class="nump">2,129,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=caba_NonVestedCommonStockMember', window );">Non-vested Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares have been excluded from calculation of diluted net loss per share</a></td>
<td class="nump">465,801<span></span>
</td>
<td class="nump">1,388,977<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=caba_NonVestedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=caba_NonVestedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495019601768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401 (k) Savings Plan - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, contribution amount</a></td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140495011652344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - Subsequent Events - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=caba_WuXiAdvancedTherapiesMember', window );">WuXi Advanced Therapies | Wuxi Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees', window );">Early termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=caba_ChildrenSHospitalOfPhiladelphiaMember', window );">CHOP | Research Service Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caba_ExpectedResearchServiceAgreementCost', window );">Total cost</a></td>
<td class="nump">$ 670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ExpectedResearchServiceAgreementCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected research service agreement cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ExpectedResearchServiceAgreementCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of early contract termination fees included in liabilities subject to compromise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56145-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116635682&amp;loc=d3e55717-112764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120604989&amp;loc=d3e56015-112765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=caba_WuXiAdvancedTherapiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=caba_WuXiAdvancedTherapiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_DevelopmentAndManufacturingServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_DevelopmentAndManufacturingServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=caba_ChildrenSHospitalOfPhiladelphiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=caba_ChildrenSHospitalOfPhiladelphiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_ResearchServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_ResearchServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>88
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M<[FXPN?7A%B%5N*;X(]Z<(UL*'=2/MC%'^O+A6\1\8)GQII@\+7EU[PHK"7
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M%UJ0Y64]8HEG$\X.@.MHI:8O\K')LU4U--.O<2FYNDM5GIP]X 1G$0%+K2#
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MMSG+/BT6I]>F%(G=2BK^V;5?9(_7-2Y6G?JH&-!KR,WY)]Y%/;L*0:L71<]
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M2/N)%X[2VBJOB&72U-0,6,DEBP8H3-H:V'2'$N+('8C/,"R5UBZ5G@E9QBU
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M+_!N0-TQO>/2$ $54N/Q=!(2W9F^.UC5>J/ERJ)M_;;&.0G: ?!]I90]'5R
M8?(N_P!02P,$%     @ \4%P4HP^@3W/"@  T1X  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&ULO5E=<]NZ$?TK&#?3<69H69+MV+EU/./X-I/<:1I/
M/MJ'3A\@$I+0D 0O %K6_?4]NR!(4+8<YZ%]L2426.S'V;.+U>7&V.]NK907
M]U59NS<':^^;7XZ/7;Y6E703TZ@:;Y;&5M+CJUT=N\8J6?"FJCR>3Z>OCBNI
MZX.K2WYV:Z\N3>M+7:M;*UQ;5=)NWZK2;-X<S [B@\]ZM?;TX/CJLI$K]47Y
M;\VMQ;?C7DJA*U4[;6IAU?+-P?7LE[>GM)X7_$.KC4L^"[)D8<QW^O*A>',P
M)854J7)/$B3^W:D;598D"&K\WLD\Z(^DC>GG*/T=VPY;%M*I&U/^4Q=^_>;@
MXD 4:BG;TG\VF_>JL^>,Y.6F=/Q7;,+:5UB<M\Z;JML,#2I=A__ROO-#LN%B
MNF?#O-LP9[W#0:SEK]++JTMK-L+2:DBC#VPJ[X9RNJ:@?/$6;S7V^2M84\J%
ML9)\Y#+Q-YV3Q^N5N%Y9I>!^[X2L"V'\6MGDX>6QQ_$DY#COCGH;CIKO.6HV
M%Q]-[==._+4N5#$6< R]>^7G4?FW\R<E_JKRB3B996(^G4^?D'?2.^.$Y9T\
MRQF/^^(:OOBTXPOQK^N%\Q8(^_<36ISV6IRR%J?_CY \?=2KB7C6:=?XAY#Q
MJ9^5\]+C2UBIAG6 KE\+*"6^6B!7*2?,DK]_JY%ZUFF_I2>WJJ[=MKR3M98L
M\F:MR\*J^L]_NIC/SO_BQ'OC&NUER:OQ4A:J;-98_:$6U^T*PA'RV47&PF],
MU<AZ*Z"!LM!+U]X(*<I./3E6CP[/A(0'$YMLM$G7XK>VW)+TUP)B=)V7;8$S
MWG^ZY4VBD=9O,]Z5",&^CW++.!2'I-0#Y[P436M=*Z$'Y&[6.E^/M#<+#PJ%
MJ$/Y$L?4ICY2]SC<P7,9?W7M(M@D%Z4BLBL+<(7J#8787%F2$IW<^Q,N >^!
M"%OXM+&@=!C!&TQ=M+DG!RAI\W5&;_E)H>[ V VIGHD<P-$Y]GJK90F4Y! '
M&JK;)4#?6H++@$AF6NVU<L%/APM85(O$G%[Y3%BSE:7?'BUP/HFQ1*.\K;,K
M"W&3W1LHW3L"[XC8A9=VI?S18GL4/A%/:QS>(C;VYYU2R>^0W))XE(\2ARR7
MD(,**)PL\517C;$^&TS>:/@_-U6E; X'Z3]4]*/C;11HCYKI&8=01+;>Z*IJ
M:Q605);Q:P%1J#)N@J0IE7,"?BDUC@>XP?^$T@#[A^FG[AMM*>EJ7L!?.:T%
M5) +'&3JH(#M(A5E\IJ0JJ5$<MW!A@)1E[HB:#_#;5U "K'8IK">B*\)QBND
M2&_&'B,D!1_+4/G9=4#HG:JUJG,EV@9ZOIJ*0FZ=V%CMO:J1&AY")D0-;/5=
M='&-^.>M)7^A>BM"KE@@"(1RLNA9ZCQYY#?&%P<78GJV>R!ES%,;\(8!@E?,
M.,!; SU>S+/I= JE:[@5!!10@_UB"P XL5 K7==,RP/_\:HE4$[/(2C$C\G<
M6!WHE^RE_[]:0.JC+DT'N5NYQ:=#AQ.^P$9GB#H_=S20<G\:0.W %+^WV@Z*
MQ^RJ--#J23J>AIWL.]()*FC$)8+?-2K72ZV*@5=(HR%_!F%!YUW!TBKH@?0*
M>).]$L B7._13?9IYQ1Q7$]K?DT "_H0G?<G92P);%(4FO*!P/U0FE]K^RQA
M9) S2,6,]W(4P%L.WB,O_%#"#IYYG1]'@LL TV&>@RB6+>&FH^U H!()L!85
M&E3=E DEM3UN'X.J\6D$!J_GIBWA;X2S@:1[34E5$G)G!-U)R"G2JX3A"OC6
MG8)6Y0JTCYSF^AP8G^ )FQ(? [6*Z"7 &#T3=2&E.BH@R8/-X;[_J)PK ,6)
M,X5:8EVU52PCH2"$5T.%K%$2B+E=X(7MX(G@?[M#WKLL1H0)%9+"H[JMP%:H
M+99:!6,;RCTJ2[:3>L<F+[:! GZ6.TU'Y#Y@8%!HT,2Q9K$'X!KY@P!SG#8Q
MF$\$:CB$C0,A/Q&P2A='(6 DB<)7&.R/X>-" (]LZ$^-"%:F)5 5K7I*6^JQ
MB+R@6+7 HMCL3WZ"M-:0X?K5L=,9^D+7]:T;(]#-(%E0J/@T!FCH%S=KPP%E
M;+L<Y<B#P7($^&AI6/^>_>.QE(%1SOA57TH30;*XTU!P*Q9&VH*S/S:4A&D5
M1:1:)_TG7(YR3T<RY^5 5F#:7;,GHQ::A(/27-HD0^JRM:&12Z4#@T5?ZZ(Z
M*#.H2P!S[]:FE'5:&?LVNU=\7 TI.I1\5%GYI%C/)%VNN2,>R::J:-K56KQ3
M"]M*RSXZ"7U&H"[P%G,3513'!>?%;):=7\P2H"5N=&A_W%)S1C\,4<<E7;VF
M/NDIM'(Y_1]>EJX?SX9,O#C/IJ^G]))M)J<N%#H531T0Q3^]?."0]%Z$W'S7
ME;?0:P3U'YS"!M'%:!Q D(99U<R:0VYA97*!(&RR]12+>?;Z]1FOP,?9R7E&
MVQK%TYER2]_*V!CM*AJY1N9Y.)QPP@X.KR&>*#5<92?[O)78\6*679S-@C*S
M[.SB8D<7*A<%7)_O-!_=M9#O?;=6-1+=<F=C>C5GWS.).;5'^X4L63Q/<!QR
M'E"P@(2L72F[/J0GN"_*W@%'+D'1!U&+3[DW9. /K\0N[A_2G2^K#^6^'"[+
MW+\D7='>(/?2E]94N$)8;5HW[D=):'>?"!F[5]APAV2'%PIEM@P.=_"W#;V'
MNE=Y2V!A18U=(4O^8+<==4TF,6L!0,L=2ATQ=;S$TZ2#5Z.AZ-/SAIW(7K@.
M6*"T]LQZI/4GE QIN;S)1K6X&3AQ>'/]^=/7EPDM2^[1Z,$=X 59H\OS9(CQ
MOM1)TJ*WNC,MH:0JX,>/\-,[N8O08R.1-(U_)LOZSOAYU,'E!7E_>GX:*>#D
M[&Q, 0_OC,QB*0;[7&L;<@AR]P1WM%@9/ .+)M)\+TK*%8>E)^@8:S03Z,QS
MJYLP*(9>7U6^KDUI5MN0B\MTT$9(ZJ=$3R?<KEP_R/51[A"-'TR(-A'H=+5M
MD&64=.D)2T73$MY(?F9:0C"#FHQ"M%X5(Y<&2E91K>5K1-<^Q]'!J&&.S7)&
MTR]CX["@.T>7);61.:S6 9\;-#"/W1]XT!9[_UW6'R <H_.@8D[2J S>&X@B
MZC*^*O6EG"LCW\N2BT3::'8WZ#1&AN3%LV#BT-FD3=/>@OAB?L9%^8>%,<VB
MQY-H]GHB_F[Z#13?Y*#V$:V>(90:Z=$ F!5\V*L,@-_ESAW YP^$[1G#7@-'
M#CA^JTT&\?E$'':/7A*$(;-CH;2=CIM85A'FE_$\OG8TAFY*FB<HJEYS9>UG
M [I1-/\>+G^[#;L7?=$(<T3P2YB$AW-[)*T4Q!#>X]Q3U>B"E;*!;R)\4'+"
M"5'O!%D4J*8I=3"#T_OQ.\*0?:,94@=U2B*P,%_@8KA'D]M1F<EVYBQ=K8RW
M8M=2C]V=MW>ZM0?U 9#CV5 ?KYYV(FTQ4V''AN;(,N2FHS[)0"^B$0;),[J#
M27\(//K877;9PG:5#+A'<GCVOT(!]W3W&L9.P5-/#3,"/0X[ KWO3CC@W$>Y
M-$P/DI'!'IR,:V'.[]*!I4SGI@P*'KK%IG4\L Q.[?B8@]['):?E9>@8*#B3
MQW['.DY^9@2"5OQC*L^%:A]^<>R?]K_77H>?*8?EX<?>C\@OC>ZA5$MLG4[.
MSP["[")^\:;A'RT7QGM3\<>UD@ D+<#[I4&J=U_H@/Y7[*O_ E!+ P04
M" #Q07!2)5'CJ>(&  "W$   &0   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6RM6.]OW#82_>Z_@MC+'5I@NVLKCN.FM@$G:7 Y-*B1]JX?BOO E48K7BE2
M(:E=;__ZOAE*VK5CN[VB7[SZP7GS9N;-D/+%UH=?8D.4U&UK7;R<-2EUKY;+
M6#;4ZKCP'3F\J7UH=<)M6"]C%TA78M3:97%\?+9LM7&SJPMY=A.N+GR?K'%T
M$U3LVU:'W6NR?GLY.YF-#SZ:=9/XP?+JHM-K^H'2O[N;@+OEA%*9EEPTWJE
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M<\2"8/;A_BGJ8]7NT )FQ$E+CT/D_^?UQX@A/2L:M5#=K3]7U0FAL? #TRR
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MFEW&*+:C+O:Z+U:P=X(WV-8P'#8[&4G-.\IQXDZH3!"@Z4H)LDW/K@F>_5Q
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M<VAE971S+W-H965T,3@N>&ULS5=M;]LV$/ZN7T%XP[ !C"U1\HNR)$#29-B
M-0B:KL4P[ ,MG2.BDJB25)S\^]U1DNTL<9:BZSH@CBF*]]QSKSX>K;7Y8 L
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M 0YY2.50HR6RY SN,FA<YP$#ML&V03[K)#NB+2JUG4O1+'(V;!1NC;@%M@3
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MM,3) @  $ 8  !D   !X;"]W;W)K<VAE971S+W-H965T,C N>&ULI57;;MI
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MUOK75Q7N=&F!9N%G$9=,5XKJAFU.FW$WK+O\*;R>E6-A%E)9R''.T*AU?!B
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M;#;_TFY#WX%>WI26_\TV<N]W='/>VZZIW,/$065J^5_=.T$D#WQ_?N"!2_?
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M<L_AYZ%7!OY7K+)?4TCXTC=@#;=H!C""Z=TAT-F3$EB*?*5JAV8))7)/24S
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MZ21".XZ1C+@R?8751W?B+'L" GP?(,#WDU'\AIRX;A%\;DK@8L@(H&H-?L=
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M5ARUB\1+@!&H;XT43OU&G]+%&$ Y-#B,2E'*44$9@7$NFWLW(.<T@]ARM:9
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MN(&^7S2$W=T'+!!^^>?%_P-02P,$%     @ \4%P4H4#DK"' @  L 4  !D
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M5I:F"R_F-,ZA=@ITGBEB]6;A M0#XN@_4$L#!!0    ( /%!<%(06?&1J (
M ,4%   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;(54VV[;, Q]]U<(
MQAY:H*@O<9H+D@!)+]B %@C:;GL8]J#83"Q4EER)7MJ_'R4G;CJT&9#H2I[#
M0YF<;+5YLB4 LI=**CL-2\1Z'$4V+Z'B]ES7H.AFK4W%D;9F$]G: "^\4R6C
M-(XOHHH+%<XF_FQI9A/=H!0*EH;9IJJX>5V U-MIF(3[@WNQ*=$=1+-)S3?P
M /B]7AK:11U*(2I05FC%#*RGX3P9+S)G[PU^"-C:@S5S2E9:/[G-MV(:QBX@
MD)"C0^ T_8%+D-(!41C/.\RPHW2.A^L]^HW73EI6W,*EEC]%@>4T'(:L@#5O
M)-[K[5?8Z>D[O%Q+ZT>V;6TS8LP;B[K:.=.^$JJ=^<LN#P<.P_@3AW3GD/JX
M6R(?Y15'/IL8O67&61.:6WBIWIN"$\H]R@,:NA7DA[.EH?<U^'K&EI(K9%P5
M[/JY$34E'MG)(U])L*>3"(G+>43Y#G?1XJ:?X"8IN],*2\NN50'%>X"(@NPB
M3?>1+M*CB%>0G[-><L;2.(V/X/4ZY3V/U_N/\IWP^3OAO^8KBX8^F=]'F+*.
M*?-,V2=,#U1)12.!Z37[A_5=NC_*\G'D#JWNT*#3D&LJ'8O6T6();*TEE:!0
MFW% N81J!<;E,W#YI"$9!;=\I0U';5[?8((OP>@BH;&?9<%-8Y3 QH"G6HL7
MM[9!.ACX_RU0?91:%DQ4M=%_P '8H#]POTM=U0T2YQMTOQ=D2?"HD4M6=Q_B
M!UJ"Y*R7#8.1BQ&L'5,QYTW52(Y04 U2.\H%=U4>G&3]87 :G"1Q1M/R&.@9
M4^#D#4>Q&Y/^1T\='916!6;C&XBEW#8*VRKK3KL>-6]+\\V\;7!WW&R$LDS"
MFESC\T$_9*9M&NT&=>T+=:61RMXO2^JS8)P!W:^UQOW&$72=>_874$L#!!0
M   ( /%!<%+]?"L)C0(  '$%   9    >&PO=V]R:W-H965T<R]S:&5E=#(U
M+GAM;(U4RV[;,!"\ZRL(H8<6,"*)LN,XL W83E] @QI)'X>B!TI:640H4B6I
M./G[+BE9<8'8Z$5\[<SN#C6<[Y5^,!6 )4^UD&815M8VUU%D\@IJ9BY4 Q)/
M2J5K9G&I=Y%I-+#"@VH1T3B^C&K&9;B<^[VM7LY5:P67L-7$M'7-]/,:A-HO
MPB0\;-SQ767=1K2<-VP']V"_-UN-JVA@*7@-TG EB89R$:Z2Z_78Q?N 'QSV
MYFA.7">94@]N\;E8A+$K" 3DUC$P'!YA T(X(BSC3\\9#BD=\'A^8/_@>\=>
M,F9@H\1/7MAJ$5Z%I("2M<+>J?TGZ/N9.+Y<">._9-_%3N*0Y*VQJN[!6$'-
M93>RIUZ'(\#5*0#M =37W27R5=XPRY9SK?9$NVAD<Q/?JD=C<5RZ2[FW&D\Y
MXNQRE>>ZA8(P69"OM@)--JW6("WYPEG&!;<<#'G[C64"S+MY9#&G0T9YS[_N
M^.D)_H226R5M9<A[64#Q+T&$Q0X5TT/%:WJ6\0;R"Y(F(T)C&I_A2P<%4L^7
MGN#;LF??'%FA!%X.)@SYM<J,U?C/_#Z38CRD&/L4XQ,I[M%*12N J)+\E^"O
MZ7P^Q3&M\K1Y3RN.[C%7Z"9C71T80THET)1<[JX#5!7J#&&H;."4Q4\R"^[
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MOEU@O />EUJ[@^$)^M=P_AM02P,$%     @ \4%P4DA1CG\D P  S0<  !D
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M&^;X,03*&N#[3$ISG-@ W>?5ZE]02P,$%     @ \4%P4G/"PB9A!   + X
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M#(8'')*-0^)Y-X$\RTMFV62DU1JTLR8TM_"I>F\BQZ6KRL)J^LK)STX6335
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M]:ON:+&I;C +H<U]J&IFYLH*T@XP[U?"?"J:CKT4M9?@Z6]02P,$%     @
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MB-5(N=HHGI=3V90K/>.5RT2/X2",@7X_XURM-V;0JP?[X3]02P,$%     @
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MVFH<? F@Q!5KA;U6F^_8YW/J^ HEC/_"IO>- BA:8U7=@TE!S67W9X]]'78
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MY3.$ZXPE;+4OLFY9C[#K2]MJ=/#.&AU8C0[<&ETV)14G55Q*W=[:#Y=P]4W
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MACG^"P!E#7!_):7936R YG_%^"]02P,$%     @ \4%P4D8W/S T @  [00
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MW?UY')JUK-IS:"0<F27<N,?IM3.[K2*T5N@P<((@.$*N:0'(Z4VN?XM!30-
M[OM4>*/=R*S=/5K,'!UNL8V= S7RC%ZTU7Y=@<ZK(#WW8ZC17_03V^M^?PK0
MX09[_U_!:9/;#A.(G)%CN_L5;.V<C&2$+XLS+*&Z<4YE>1)0WZW/R:Z+TZ&]
M^U-X.2M/NQHWY>';9\R7"14@)0OETKX(%"U>GF>5 \E6Q?G+(Y.29<5E3'!$
MN#90SQ>,R>U !ZA/%2?_ U!+ P04    " #Q07!2S-GA'A<%   U&@  &0
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M$"S.#[?4#VB:!<COGQ@3QY/L M6;HOE_4$L#!!0    ( /%!<%+=X/$DS@<
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M?:[6C//LQ>%ULHGY,V,5X#?;;+%6N;%1*W!2^A[0--W2&&1JL<C5@7[=K.]
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M)C8H-8G?RH$SA]V7?L *SDTXDB;4A(!^+P1-NU+0P5DCFIM6EWG?S)L'(QT
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M8;NS?#J268=T2NF77HCI:F"Z"EI]5,3$6.YA67)L2_AC69=U_.S(:U!O_4W
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MS@"_;Y6R;Q-W6W>OL^5/4$L#!!0    ( /%!<%+Q'L;:! 0  "L/   9
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;+67VV[C-A"&7X4P6F 7R$:B9%OV
MPC&0Q%TT0!<-DDU[4?2"ED8VNQ3IDK2=].D[I!S)B24Y-=(;'3DS'X?D_.1D
MJ_1WLP2PY+$0TESTEM:N/@>!29=0,'.N5B#Q3ZYTP2R^ZD5@5AI8YHT*$41A
M. P*QF5O.O'?;O5THM96< FWFIAU43#]= 5";2]ZM/?\X8XOEM9]"*:3%5O
M/=B'U:W&MZ#RDO$"I.%*$@WY1>^2?KZ.0F?@6_S&86OVGHGKRERI[^[E)KOH
MA8X(!*36N6!XV\ U".$\(<??.Z>]*J8SW']^]O[%=QX[,V<&KI7XG6=V>=$;
M]4@&.5L+>Z>V/\.N0P/G+U7"^"O9EFV3I$?2M;&JV!DC0<%E>6>/NT3L&=!A
MBT&T,XA>&_1;#.*=0>P[6I+Y;LV89=.)5ENB76OTYAY\;KPU]H9+-XSW5N-?
MCG9V>B-350#YQA[!D$_D,LNX2R\3Y$:6D\0E^\,,+./"?,0F#_<S\N&'CY/
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M889_#E V />74IK=Q"9H_D7Q'U!+ P04    " #Q07!2;CU^-S@"  "$"@
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M96QS+W=O<FMB;V]K+GAM;"YR96QSS=H[3L- %(7AK41> )/[F/!00D5#B]B
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " #Q07!2F5R<(Q &  "<)P  $P
M            @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M /%!<%*9(]NW,P<  %D<   8              " @0T(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " #Q07!2 S+NYQT%  #=$@  &
M            @(%V#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ \4%P4B2EMZDW P  ;PX  !@              ("!R10  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( /%!<%(7\=[+X0,  %(,
M   8              " @388  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    " #Q07!2>KT%:_L%  ""'   &               @(%-'
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ \4%P4ASA;8=]
M @  A@8  !@              ("!?B(  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( /%!<%(?"#<]+P8  *H8   8              "
M@3$E  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #Q07!2
MCB"GU^0+  !='P  &               @(&6*P  >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ \4%P4OTH8Y/5%0  3$   !@
M     ("!L#<  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M /%!<%)VT?HA'P4  .@-   9              " @;M-  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ \4%P4I;T"4G, @  -P8  !D
M             ("!$5,  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    " #Q07!2YLU6,7\"  "%!0  &0              @($45@  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( /%!<%*,/H$]SPH
M -$>   9              " @<I8  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ \4%P4B51XZGB!@  MQ   !D              ("!
MT&,  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #Q07!2
M(6]/RW$&  !.$0  &0              @('I:@  >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( /%!<%)U':^7YPX  #@J   9
M      " @9%Q  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ \4%P4H8+J&0#!P  ,Q$  !D              ("!KX   'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #Q07!2?8H\S_D$  #$#P
M&0              @('IAP  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( /%!<%(10;8A> ,  ,@'   9              " @1F-  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ \4%P4KZ/M,3)
M @  $ 8  !D              ("!R)   'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    " #Q07!2W@@'B.X6   %2   &0
M@('(DP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( /%!
M<%*% Y*PAP(  + %   9              " @>VJ  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ \4%P4CA!-)'M P  + H  !D
M         ("!JZT  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    " #Q07!2$%GQD:@"  #%!0  &0              @('/L0  >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( /%!<%+]?"L)C0(  '$%
M   9              " @:ZT  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ \4%P4DUEX^=B @  &04  !D              ("!<K<
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #Q07!22%&.
M?R0#  #-!P  &0              @($+N@  >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( /%!<%(+3$YFJ@0  $4*   9
M  " @6:]  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
M\4%P4CYUJ_@+!   :@D  !D              ("!1\(  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    " #Q07!2<\+")F$$   L#@  &0
M            @(&)Q@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( /%!<%('A;LU" 0  )X,   9              " @2'+  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ \4%P4M\\4<%* P
M8 D  !D              ("!8,\  'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    " #Q07!2"%U6]=,"  !-"0  &0              @('A
MT@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( /%!<%)=
MF#-0GP,  ! /   9              " @>O5  !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ \4%P4O+#PW'+ @  D@<  !D
M     ("!P=D  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M" #Q07!2(%#_&1H#  #S"0  &0              @('#W   >&PO=V]R:W-H
M965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( /%!<%*5"'"5(0,  .0+   9
M              " @13@  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L!
M A0#%     @ \4%P4I-F$EE) @  - 4  !D              ("!;.,  'AL
M+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " #Q07!2*ZP+:J\"
M  !)!P  &0              @('LY0  >&PO=V]R:W-H965T<R]S:&5E=#,Y
M+GAM;%!+ 0(4 Q0    ( /%!<%(<X-7E_P0  )L5   9              "
M@=+H  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ \4%P
M4AJ!%T<! P  8P@  !D              ("!".X  'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    " #Q07!21C<_,#0"  #M!   &0
M        @(% \0  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( /%!<%(D(J3DCP0  &$4   9              " @:OS  !X;"]W;W)K
M<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ \4%P4LS9X1X7!0  -1H
M !D              ("!<?@  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q0
M2P$"% ,4    " #Q07!2W>#Q),X'  #S*0  &0              @(&__0
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( /%!<%)S2E@_
MJ@0  ,<3   9              " @<0% 0!X;"]W;W)K<VAE971S+W-H965T
M-#8N>&UL4$L! A0#%     @ \4%P4L:XWDA& P  20P  !D
M ("!I0H! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " #Q
M07!2Z1?NPI0"  #E!@  &0              @($B#@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( /%!<%*C:NX1(@,  *8)   9
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M970U,RYX;6Q02P$"% ,4    " #Q07!2-(,0RJ\"  #G!@  &0
M    @('Y(P$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (
M /%!<%(;:JI_E@(  )<&   9              " @=\F 0!X;"]W;W)K<VAE
M971S+W-H965T-34N>&UL4$L! A0#%     @ \4%P4FX]?C<X @  A H   T
M             ( !K"D! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #Q07!2
MEXJ[',     3 @  "P              @ $/+ $ 7W)E;',O+G)E;'-02P$"
M% ,4    " #Q07!2MF3D1)0$  #.)   #P              @ 'X+ $ >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ \4%P4KP!UL'@ 0  ["   !H
M         ( !N3$! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ \4%P4A34<>30 0  K2   !,              ( !T3,! %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     #\ /P P$0  TC4!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>147</ContextCount>
  <ElementCount>359</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquity</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Accrued and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Collaborations, Licensing Agreements and other Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCollaborationsLicensingAgreementsAndOtherAgreements</Role>
      <ShortName>Collaborations, Licensing Agreements and other Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - 401(k) Savings Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/Disclosure401KSavingsPlan</Role>
      <ShortName>401(k) Savings Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Accrued and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Convertible Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockTables</Role>
      <ShortName>Convertible Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStock</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives for Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives for Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Fair Value Measurements - Schedule of Debt Securities Classified as Available-for-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Debt Securities Classified as Available-for-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Property, Plant and Equipment - Schedule of Property Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment - Schedule of Property Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Property, Plant and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property, Plant and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Collaborations, Licensing Agreements and other Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaborations, Licensing Agreements and other Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Payments for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Payments for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Convertible Preferred Stock - Summary of Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails</Role>
      <ShortName>Convertible Preferred Stock - Summary of Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Common Stock - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Common Stock - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Common Stock - Schedule of Assumptions Used to Estimate Fair Value of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails</Role>
      <ShortName>Common Stock - Schedule of Assumptions Used to Estimate Fair Value of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Common Stock - Summary of Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfStockBasedCompensationDetails</Role>
      <ShortName>Common Stock - Summary of Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Income Taxes - Summary of Principal Components of Company's Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Summary of Principal Components of Company's Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Basic and Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - 401 (k) Savings Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/Disclosure401KSavingsPlanAdditionalInformationDetails</Role>
      <ShortName>401 (k) Savings Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20201231/taxonomy/role/Disclosure401KSavingsPlan</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="caba-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>caba-20201231.xml</File>
    <File>caba-20201231.xsd</File>
    <File>caba-20201231_cal.xml</File>
    <File>caba-20201231_def.xml</File>
    <File>caba-20201231_lab.xml</File>
    <File>caba-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>93
<FILENAME>0001564590-21-013329-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-013329-xbrl.zip
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M>F=S%/RHZ,[FU,5DRPZ5%A/%Q61)C^BPQ42]8/-AGX5L+\2CM&QN)\7S (5
M59=,2]4!2M7).(:[%'8M6]I6'/?V6_.CUK+[%I.:<X)*6WXDF^+:D'?-PH][
MDWFJAT;Z &3=C.^JRP2'S!&-DKOW='?@ )GBL#V>PV**77H1F[OG=C+\L?_K
M;<KKCUI6.2%5HA*K**I5%MTX.QE>4>"BF?)ZI9Y93DBQ*,4LBFJ6NNO2)\,H
M>[XEK;Q&F<\D)Z1-E&&2G?9:2"83#ZL$CET*(.4U8UP;L,ENGT+&CDAM5*TW
M+0Q3N>+CUA&KD/\HKJ<KRP<'="=])>:Y%,S3N=3,LW7FN6S,//#*;ICGUK:#
M!-QU/):(/@66'U%TP+=\V_6?OC&;N<]8QSAZ-_W$GBSO R'AZ_ .WV+AA(H
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M*+*Y;]'0$G$2$G&:F]G4W]>[VM/@\O)]H*;^_O4^,B\*Z5 '[ZVLFQ-T2B[
M(E8X\("%BJR@:A2@/A_K*+5"DZ2DD]8*)58X0JVP;U9052NLY4;K6\3J7I[<
MEF]_2GI2#>$X<&VLA4-;CE6$0]\VWN,%RT,2D%.U'OH&LA:0$[0@1Z/Q#X%U
MCDNW'HTN/ 36457K-"D'<J@J1LWZ&+NO"M"(T =M5-2D^ &9DF52 @KZ]2$)
M[9$5G=[MOP58V+TV4>WNWV(V.86;?\JQR4[N_2U5BD;KFATQT;*64X4<@AWK
MLUTSZJE<7CTACCV$Z[%+52':I%$_V!W$0;#YOM,X3F(3HQE9WR>I83)^$/-H
M_;A-XE$0P@+SJ IS\/CEP*-GQ1.G\D+3@(J\U".-H*U"\*-0'>I1_H#TPZKM
MUHZ$=Q3ONW84C"0>J&W6=OSLE#ZR_ZYM1\%4BYI!'L7)\0%I)U4/D#>BG8Z?
MG=343HHSU2TLRG&]!'/6OC,[ =?39=&''[:7.,RY#X,Q8'&2Q)3Z]G7XP0I]
MP&STP,+O(RMD[Z;5 YQ:9M7VL*AHLHWB1G?/;'TDRO;TV/J$M35Z8V Z_\:B
MF#E'O+_9*E.32SL?BUI3J\726D\?)$NKJJ6C,+X+$O@QG ! T\+!V'\G_^/>
M.L^6;S/G<<1":P(8+IX*?T\&$?LS 9Q\>(;_E-/,2S^7WYU,O"E2QXT1S]F\
MTJW&6]_Y;/G)T++CA!J(L_#9M2O[J(-4'*XX5.%"\'%S;&SJ8+F*,010-:RQ
MB=ESM%2R5^Z)53+8'DZ:4+1WD*L]5U3O1J[GA,S__A]!-'%CR_LZ?("O+(=Y
MDY%K[4!HTUO)@B<K!;3+?3'XHWM]A)):CX(=2.527' Z\EEP*4%"NPU=2GJE
M>[V>_768^_9]8"=C@1^2ZWN4:_C?F2&>_<:&)6FOV+R8G?/__.5-><!\FEOX
MRL&O[SWK29[';#;/T/(BQB<J##F[H =:_ >.&'G&;K,99?]][OBST]^[D6UY
M_PM"=P_?1#( O>8 %*<NC3UO<@[AS/07S::__]^JR:6Q\^D?0\M!TS\=#P)/
MGO*RV91WM^]N^:2%$?.)/I"<?6-/=$'8CU'7R//UF\_WZ</CXZWQ[N/7EO'Q
MRUV;3U\U3QF*NR0$M08338(0P^084B\B_*H9-/_+(GGVZO%GH(!'0LO[Z#OL
MQW^RJ3S]=;/I96,U=_SR]'\+/-#\5CB]=ST6%E9_TVSZ+X$\;6G<?%J!E5P2
M9@7=;*C"SF4IGS=^>>$$UQW\\!2$,M;-AGH-=H3GEFTS& T&<PP:5\9$8:(R
M%/_-/.\__>#%_\ZL*/"9\S&*$C"+$CP-M5Z1#'/&+X/Q?03/X=[8\@NX:*CP
M)!T_.^[,G&/+\]XED>NS2.8[LZ&:B\.D.*<\;GG2#V,6/H$L_C4,7N)1Q8H;
M*KSRY)7CSP#Q [0C.#T8A>#J6(:@H0J<P?GLZ/G\'^UA>)LX;AR$MW',(AX)
M*5EVLZ':DR"8/_Z,VLOC)Q1[B;XF,6YOT&C(L"S0@6:GA]K"8;8+9(]^/?OX
MY?[,2'R7/_[[W\EYBF@&,,@7G7[WZNJRH!]K "D#_9 ,P+6\]P(KEF%<J"C[
MO0*,Y_T"B&X47'3-J]^_OP<(S0ONQ,D@2M-6:;$O"7G2.4#=AOJS@]O,&T!E
M66WQD<MS/EH_/HI=$*\$,@M 0QUZW3TW^]>75_V"Y9HS3QF<6P=V)U$D_OD$
M8F_*H#1U&F^Z-\8M[+>,[S'LM&(9H(J9%@/3E8%IJ$^_)RX8QGZ1&RJFF /%
M'?SY-7P$[2_#T%"]RGN]"C#R.>8 08D*7\.','AV?5LV\]V&NO;AMF+^TO!S
M@'@(0*2]_\^=W 5. 82&RA;O45U40%$87_)U\(F06>59&RK8;O]*^#;2>/DL
M6)#'>QB!=9\5Q(8N)/P"CE3*;^6!R\C]B"$#R\9@.7A8EO"\Y.D;NI E![IZ
M_!P*$:&?FMT!W<"79NXU5('<"AAD!EK&Q J-9\M+F/%3ITTJWIA@M CM P>P
M//4L4!]^V".\0U/:X?2:NI>WW]_?_E=Q4GGH69K800@;#E*8)!P4V@FG)1[L
M-=2+[S\4*5,SR^RN]M;W$\OC&R$9AH;J,'>VJ@:NB(QD?M#LU VUH.3CS!N=
MSY_&J.ZL"&LIXC\?_DQ<X"9X);J-[ZPPG()K\3=B+PF@1<J0X)"=B-Y<)P)
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M.CIS$("O.)"$%K#513SQ>7+9M"@&1M/R*W2I+S#D1U&@XJ/4:P8S;<'N9<!
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MPP(MHWPL+<ZB^;4'SF8%;Q!D$.,-(C8"EHT53%UZ_,FU)1A()^&2V$*%,4Q
M)7. \*26OS+#,S*="V>8Z"_(9ZTT!*H0($GX1*%3V$E@924."ZY06+1\Y8+9
M$ 2D(0S)A24+[)*LM"H"OQ3YXC>^A')#)K5MY+@\O".83>@RE,)L@4A%$*Z8
MAQTX#$O@GPP9<2/6NXAE!H$IN"UK23J/R]E G-22WBS(#@Z1+@'UIH51-\DH
MVCSEI27[+A1.\+$P5\K]$YB,%S;A0 &7!^+)7">D.GM&*H8)IM+D;I4LG=PY
M1P7DPKXD#GR^_:FV;O-.N8]]^_S)!<?&01(>]0F>O"<A"\6]# KA4/Y)D%Z#
M-KP@0B^:VS#\3Q[XD;9[F8,ANU0S@Z0*%_X%#Y&1=\)9=K[:1FN)T3: T;91
M\+B#':5GN4$2DP\E6'D)![D8)AQ9($=6Q%^@/UB>!"M\Z;S<$$4=.]>M?K^+
M0>$%B2V/HS!(GD8USQ0W$B-^3D]I<!1,L^UDG' +B E$-C^UPP!F]^:Z;7RV
M?.N)&\Z9K;>D>03VT^@\UQ$X59S1+5J //A,^C+=RLW3;I2"E'C<0'HBVP9&
M+JC-U&$9)KY3=BQ/1^ZDI"V.S0BW@54H%5R$'O]X *H]=>48KZB81J$CW+4/
M8DG[M^2=.6*;+$D88I(&\7.+K'0,+JB-!R^TI:<=,S<949# -@"(\A^I7P-[
M'@(SFR/-I;+2.]L4K7< -)19:5-!6Q9T;( WQ'8%YN%KS@_\K?3D)1L.<^NL
MYR#D6QD6COF+.(L'QM3BH],.'YD3]V(S>_R,:QG#\R.$3&([/%)(N5+LG,3^
MEKO5Z*OBE$Z>^,ZS2(IY(W+X;:Y=)=RFW$Z1&=RGHR]44DN9/(^$8X.JJ;58
M02U22EG0(TJ&J% 8SQ+,1!% _@=W$Z1MXI CW -7/C;,+JS1CT?23IEV'O-.
M-^I2+".1=M<D*_'5]P]WK]MRXMWJ672E:GFYAR^RR*FBJH=HBJHR[\QF)>?6
MS;R[5BOSKMLVOB?C,48.@>4DY!DY]HP4?2=T!/-[1 K@@S@FC(XY5D+'\EC#
M(\RL4N7IOTO'HC@B6BP2=RMGD@E/*,,#&>X\H@,!OX.OF6<58/<V3$^)N1X=
M&K>P/05^,U[]]?;VX76JLR.,>:9>$6BVL?4'RXYLTSR+*!F+O O2KQ:_DLF/
M]5%-H?LE4B-@(HL7<<-7/>FR"SE)8!/ O4JXSN?FX8D\ICGO9/MA1R1;SDV8
M2+>^51!EP6V'!W;SYPB=E#[1+HCD? R,P5JG.$::D ;'8>80$O>[C X>4F.=
M'S[PU5ANFJ<QDRE&_YQ307@Z1<A*DJ:KY?:9OO&\X,42!Q#SC(N3GHO'U@^!
M\Y(=%0:?.[CSL4 @9+MM<E ,-"=/QL@%H$/:9B/:0Y<.1?)]-8;7@U",2 DC
MR%5!5,=UY*[@BR+NYX;@Z&,. +I?&/6!M]J@1N-$"E>!N'C(<>CNI;:W,,TI
MG7-_'0[/WUD>\<?W$6.Q@2??A,V[@$H@I,X+AJDPE":>V*XV+L:9]JN;[S/Y
M=7UP\Q/A\?,P["3 0"+/[<B.)"6YP:.'PN%M&:<VQRF>8>*!H \"@RD<P(DA
MK(^>F+>K3F$0>6KB#>[%<GW_>_M[FX)ZH%FG0EV %F%3T%;A'XQO9D1$+MLJ
M4)HK'=K0-BC*7$EY/GF6W&\VGD+4@EF&O#$(<&N&=BIWH9>^:B0^=<WN9?>&
MTV($A$U1!ELC"A)2DFT8%2)MQ<!_Q J^/04KQUGM+%P"WAD"16%,>-W_NIQ>
MHH(;94>;:%% AQM#V#2%XEX-&C)'4OS(.&Z<\).T1]KS3(((->F(>4X6KY8>
M$T@&56F+K-[9\<E>S(1A\K0-KF(=RCS(8Q=\JVA+*3Z2H1\P#X]N(RG^G9_U
MB7'I.*/,USD7@RUEF0G+,$#+E3 K$!#0,7R^:H OO9F%*CE#$V(#4271E9;-
MB2%N*XE%47; "]Z$<BPN$ !-E210=@]^+QW7S).1*BQCQ"!EC<[-SP.A1B-2
MHUR@.;)IYP<ZB<C)-V+42 (-5RM- 9._20,'Z6LCYCR58PZ;RY)4WDC=I1J0
M_I NUY],P@L9!KRY2'F]J 6!L3T*LA=46YY#2'L#\+=@A92_D&D[$L"0L33Z
M ,Q&^559%"++\N;A"+K55S8];4X*.8)2:;M27ULV%P7A2A51(Y]KKL6HI7'Y
MRFUE,C"_#(M"[0^B29,3FXT#52]L*WM(30_Q,^;:GJS=*.;QR8T1*#E^UC7B
M_E@()I;,=Y[+G._:YI_%9)LSOBU>Z'@1$/F.'O0 )623Q"(2TTPIS.BFY&?>
M#BPRN#5+\*;0GTF X(GK"Y@^1D?'0@YY;#("A\*SPJ++AWHDO?20YO'CPU.7
M7!=?OBA UYHI6$#J9DJFC -!QETDWHT#!\/9?%\(6L:"GR8)A=&%O71%<R4C
MS/9] @9R3,#G0*WDN"'XVZAI!KADG"5$YS,,!OD%S>(Z"X<]#L- .!V0TZY]
MPK/X4.W9V%6&O)O4:W$S-9:%8F;(E"74T98]4Z3D7O/?Q#5NNF0S&VF0&6^N
M A^P:4"[?$F)B]'38$AA9NY0T0!XJM#*-'Y,.3;Q"_.>V4PLNNC-T,#(A2E>
M^&4.D>"VY30FE51#WB;2>**T#(I,<><:\<.HDE<JG$QTTN(<$,I!J(B?0_$V
M7"+ ,PG92"3QN=3@KNAU<BX1]Q3R@,S+B)&SZ%#:'Q?N7 MER0D5:D9B77#\
M@Q=Q)V$0!'^(P!/"3*[H.3++><S&N+$+IP@8Y4YE829A_FDZ2FT!IN4[-#J6
M(0S\B<44TB_2>$^>^5'(BJ&H8)*'0_F=B@SYB')$X@LFFEO1W-U:FDG"SW=B
M$<S$,A!<Y.<B92J2S2URPL'_B>ENK;CO'-CP$"B3O#5>>@$P)18&T8@K4O+
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M(U,-PK(P7\JN98KR5$IQ+-@2Z::5G80QKBD..0GN4-H="A2):P9(GWR#.I]
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MC4=)UL>@*K*ES%F(A>P.CP&.B5% .)^9[S+?9D8R 5C['<.QII'Q$KIQS'Q
M6PR#M(V/8N7/*4/YP/$V.$: LS',AT)K#(#E4,!Q54N!4S?E2?$CZ@X26D!8
M9LQG\%6T3-CS+ #M]$0V!O3(!##^4[<%ZP'R^,! 8'*X-H#W12.T 0.\^.2
MY1:/GAJ"!L/O82#.K>2V!:'+O0ND+/[[/@15D:G:SZX7")T"_CK\]2IB+/^Y
M["'.>E*T_N_ !E& 5C8KQCK'/7S=-MYS6Y!B:RZR@#]CU^/]KMP05IKK2U*K
M63,L^E&HSR*&W0H$$V]S QHRQ!F:2VY!;5B!RQM4<?QGMG-LH5S[%HK9D-'4
M/YD=DJK4P!=GGEB@)?A4\'^P(T9%8GFM1?.F$Z:3]'K",.'@J5LQ@ZKVQMJ
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MQA^9/?)!7SY-N349RAD?Q[Q)_R@E ]3;@S+*XAQE<8JR7(06) *\L/Q (9F
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M&*M??WUK8%<SRU0()V^"448K\+X8'HOR2A<JE@ /NX)77*&9*H,SST>#3E?
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M3V2187JB@@334U.A8Y[:JE;D.54<F:;((L,T104)IBF>19TN._6-[H"G4<1
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M#0]K4Y/@8OYJ/(2L<;SUK\'PW#^&[YUTY'PB(]'C@_A(0-2(W RNR]U,Z+A
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M$^W U5>!Z.;J:5/;B\HWXV]OP_G"#FX5+O]U;IFCU_#Z<#X/ P A=+YU!'9
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M )?:HL?BXBJ22HG$B_])OWOEYY?BQDMF F6(#<K%6'=#]8ECZ?\'][G7=N#
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M!(6@%*(Z]2D&N-%@+(LRC.#-@U$&(UCUE3R<!03X1"^YS0:QXX0I&%6TM3!
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M>D>J-^ :PL0A#;*)7CD3KK0UW\EMX[2RK"ET_\4YKQL%_KH<Q@P9+RGKLV(
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MQ%K$,KKVG)W/N3O OF4DN5.$Y#26@7F)EQ1BUF8N R_?8F]-PQKSN;C$0&F
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M7$K/-X-+U<(+7 J\0:H@59 J8:,%J:J%%T@5"U1P*;@47$K/-S?$I=VP. J
M@4R!-U@5K I6)6RT6*&JA1=(%2M4<"FX%%Q*SS>#2]7""UP*O$&J(%60*F&C
M!:FJA1=(%0M4<"FXE":7&C0]<[$"UO>9SY6Y?-<X>!2O?_Q^FKZZ]?V'U]?L
M_B%._.3I[7^G0?9T+=Y]S4?T)HQ'?_[\][]IVH^+MWX=W;'Q-&17DZ]W') W
M?LK&%_'] XM2/POBZ&O&/W+U(%ZFYZ,L>'SQ/"T8_W3V[@^N1-.VSK01EY+_
MZ0N;_'1V(7YK>,[0L 9_F+K)?]"-_(5A6L;9SUNM]#_3- LF3^5V:IC\YR+,
M,[]20%(_/I3G6CJ]YX-\TN*)EMTQ+IS049QK4//G&M2"5'M(6,I'S<;:#0OC
MOUYKS]COIQ=]32WZBD[,'3K9.B'S0<VGVLR?B&DP-_.?SG0./0M#8<C<)2Q_
MGKN(_.>Y\QD)J9.EJYG["6Z.H?^0LM>+%S]H<U^B<P&>7<+FZF\O'5JSM?P<
MO6_MJ,0H?ZA@IH F2&CW[%XS!&(19<,%%_NFV7;]VJ*6;^)PO)5F!C*^Z?#8
M\.%QA7!PS+-6Z];J?>-E@<6-8>&Q;(L,DI^F>1G%>")!$"<H?AZ7I#0<S#^/
M%ZZ2T3^<O/+8P,F31_*W? QLW$T??_[($O^6=5/XM]]8,@I2IGU.@A&CX61!
M=.UCD!,== X"4P))$%AG">P+N_>#B%M,-\6_X'])_%$V]<-N*N":)??:=T_,
M3U(:C:PH=EXA@Q;"'+(Z1YA#'LGSV]N$W?I91ZG^/:>Z($J#43?%_]4/IV16
MZ*"XILY3'+6CV/9C4;,]YL-@LP&*UK:-KZ99FOF1T(+FI^*@Q/_YT52<F:#1
M*6P[,1XP5J$$T&F<%#V:WP-T5: ;K@27>Z)WI).=K<$Y](R>Y5A4L3SF/@$E
M6.A;&:B*#!*@*L7N)X"A*J!H]'6#*I"@)[+(@)ZH( %Z4A4Z\%25E51_0!5'
MT!199$!35)  36$5=;KL9/=T!\LH8J <9!OQX*<W.K.-^&_^QI4#IZULQR-V
MH'*>#/Y+.61F,0)"@#R1VK-LO3>PZIY^@!EUUHQ -620@(T01094\XR6UQ]Z
M5'&"!9%%!BQ#!0G8"%%DP#(JH04[(HL,N(8*$K 1HLB :U1""W;4X"8:[N(U
M!<^B^%3=;30<P:'BP7 ,H+/((!)X1NL[I^>Z=;.;L*$#H5*W+A#HI3-.K*NF
M01\9T NNNU'&A+X%@67(( $;(8H,6$8EM&!'9)$!UU!! C9"%!EPC4IHP8X:
MW#JCUA?QQ#"[\"/1]K+U:VETFF510D>)8P(R=;?A#TFB-Y0NG([8(]^L,SRW
M-QC6K6]Y^B6U*8%%I+<'*(VF4X01*0C7;L*JCMBIDY;-/1 )\&!K2MD:F(LV
M/+ FE> "<RD/(2Q.+;C 7Z3A@36I!!?X2WD(87&X^J<P/"_;\%VR$;N_88EF
MH1$?"8B4.)N!NMQJ0H<"W17@-'N&.>RY5MW,+PY)==;.0%9DD("-$$4&!W*?
MT7+Z!EB&&";T+0@L0P8)V A19, RSV@-^R 98I#0-R"0#!DD.FHCQ-O=@5N$
MM,:@-[!MJDAUU71(7R?$=AS:V9& @<P9 _@OY9!!#/",UL"P>H;7]D4)&)%R
M1@2B(8,$;(0H,B":PF+3ZNMM7R"'"2EG0J 9,DC 1H@B YI1"2W8$5EDP#54
MD("-$$4&7*,26K"C!O?0<*6M*7C0S8X($#A  V00"310(--T>JZ!CD/$8$$[
M.W@QF(:BR(!?BG?-<$Z3&B;T+0@L0P8)V A19, R*J$%.R*+#+B&"A*P$:+(
M@&N*=\_J'@:$ :FT:=9L*4_TL5O#[%V<3%C0_GTTE)Y6]H  ^M@IBQ[ZV%7<
MIC/<GF?4S:2B*K4*>W=@M$[X1!B1@G"AF4)U"-V^I9, #[:FE*V!N6C# VM2
M"2XPE_(0PN+4@@O\11H>6)-*<(&_E(<0%J?PG;^R[<MQ/+T)F6;VNT=J.WO;
MF75S'\T"MS$8Z3!N],_:R#2\*\,3.Y^DX95LBM<<PJ<>[)B]H:[W;*_M7J+;
M8IVMSA8&2@ NT"-I>&!-I)M5E"S1]P3JU%G+ZUMM'R.&B:GH$4%8I.&!-:D$
M%YBK.H2#OD,".YB:4J8&XJ(-#ZP)*ZV3Y"O#[5FU^S? R*CY1)+W. _&8X;5
M]\C#=O60!7&4:O/BJ+Y0A9\UMB%ZA--9B$/:/RLBNR&Z<2L,&Z+*POMR0_3
M")]\P-/3W4'/]>HNTP]]^ LQ#TD#!3VJ  ^LZ2#+]".<6<8RO10YNZ]3+6\
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MJLKG*:PYST>C9,K7F^R;6&ZRMO<O&ZKOB=C@&(DS= 15%[W5 @[[(WCJ,<;
M:GMK%/U E3(],!DQ0,!DIXD>F*SJ9BR83 6<.KU#:WI]RR'(9O].1$FB#>W%
MR":@D#Y'24,571N)_#KA H>4\#0&O:%7MR0%<O#=M3*0$\@)9@-R.B2>7L\T
M<>Z(&"C8'U:!Q3ZP-'TMM#V=G4/V1<-L/QHQ&@DDY-;I9V>16U<9/>36JT'Z
MW5XK8>37CXG5OVB@!!*C[P9!8BJC!Q*K2&+[K)C!840X[&2WABERV'6<^2&V
MA2E H4#ZEE+F'6"IGFLG@. _!J9ATH40K>[H8 '> >\ +/ .>*=CYH3=W+91
MNBPN3\/ OPG"( M8^II&J@>)</JI5&*)<.!U JEO B#N%4><?L:; $(4S P\
M10P0\-2IX 6> D^=!$)=O:^K*B#(AG=6]\B&+\"JV_8=27 *5H8D."$P:+L\
MT WHIGVP0#>* @>ZH0:&BGNNXWAZ$S+-['<A5_J)90T>"SY")KM3Z"B0&2T'
M")$#$9@V)K#W@ K!P_$3V%M=7T>LBXPW!#T1 P3T!'H"/8&>GE%8@%"&5[OK
MW>\SGZMK^:YQ\%@ZC?\S3;-@\K1[(J]HY9]%G9@[E+)5C!^_GZ:O;GW_X?77
MT1T;3T-V-5D<UKWVOYWG2\;S:/SA^<SNM1#NF@_E31B/_OSY[W_3M!]?/N2M
MGT1\=J6?6?+UCD^6-WX:C/B#+H-PFHEG%Q^B!>.?SM[]P9V :0_.M!&7A/_I
M"YO\='8A?FMXSM"P!G^8NLE_T(W\A6%:QMG/^VG5&&Q1ZWP"W<3A^(=U%[!5
MF?E8BFCG\V!N2S^=Z5PR%H;"6KAFEC_/[3#_>6[A(SX4EBSM>6Z,W-I#_R%E
MKQ<O?M#F!JOKQ=SZYG1+"[[?]?HZ-OC;(MZ<=X]6AV"F[77G?,'EOTF"%A'@
M0^4&QR%PSPZ=>=P*A:7W]<V[7P5_-;/YQJ*9H@/;!M= ADKW@.AWYB<:XR,;
M:Y=LQ.YO6*)91D\3WEO*;(X-U-%3^!10:B:;?^B@=,XE>QQ^/FU;(T-(1?8!
M6@V1EWG6:BAA]1U7[HQTYY#\-<ZXSCA2]_=QQ$7FJQD:!@@J:Q\#.$$XP2X@
M^2F.7CW"$=(!1-$+(8?,%U&JG9@G0[6(95HH>KH]\'5Q*I*D=<LA'.'X[E&3
M2>JF];IUF!?05=P*+480!,_X D^JV4(@ [I2$@G0E;+0@:Y."T_057-K857.
M3KC]@4,>H4_3>Y;X69S@+ 5]4VG]U"^<&$UD9N$"H@%%X((A444&9$,%"=@(
M561 -DK!!4/JWC:L8?4]\@B=AV$\FG48CR?:-!H':98$-^**2KXWRX?C9[/?
MY'<YLGCEA,-='(Y90KC5&D()(DATU -2+KB$"&*!TG>FT].'<G<R8#P46JR"
M5\ K738-\(H**'TWZ)GVD"Q4';6=)CMWJ[(/JL1B5(%$#HB?"A(==5X*((,(
M0"FX8$A4D0'94$$"-D(5&9"-4G#!D+JW]E3B#.XEB^+[(,(IW/:A@!L#,H@'
MN@$7#(DJ,B ;*DC 1J@B [)1"BX8$KU3N$U5-SV]W=#?\J>QL>8_LL2_95HT
MS2L(QY-9L:14FZ;\KT&DW>3EE)95E,0)W8=IEI_J;?GL04-U #MHD*T?#9$I
M] =W2A,]4[I4(V(7(:WA]6S^SU!O^PBPE/6UTH"&$EQD+!#T1AH>T-MIH@=Z
MJP:IT_-,KV>9'@UW"793=Z^X;+E^Y :AE##[]**4<6^V*F\Y%U82H'08+252
ME3OK#I+J_DH)7LJ]8*4J2M)N%DL)ZN^,OFW3\+$$F\920JKN75XP(9@03 @F
M!!.""4\#J2Y>/Z:/B@),B!-Y5)!892[$&PI!]S+P0%"A,IXXTT<5&= 5%21
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MT\__?\U$1CI^$#G25-2&>9@FHSL_9<OJ,.(-5$_KHMH<"1@,M)E6%CI;*K#
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M+4Y07 T<7I[-I5SG]\8W?[T@499R_YY_4WH=9Z(NTNIC/\79[RP3#>1N(T&
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M=R^!)DVT:K;.<.;ZJJZ#@@*WCVXF[WD4<1;[(@X,<7)9O.%B4V]:V]W1F8>
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MAY:)GC2Q2]'$H4MY&@,G+K,UB1I#IW"Z:DB$*652BZ&?Q4^72X].6?0('JI
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M]RN'4#F+YBU0)-P;5!.9&W*W83"?O%[#H-'O)1*@5(1P?I;!6RR+QEFT#VI
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MTV9XX2/X/KHJ"CJY'\\1!3=\O%LZI*0$*"&B0P9:RLL*L_Y$WKWS?$*FS80
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MG -D;9:JQ[7D$:3S>;"@%K[/LN9'$3&='H%2 (@-3R9=&F"+$>!*+G^^K6]
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MS@S!2QBZ&7^'G-SXDJL9[G/).0 6C6P\*+5'7^ T](C%"=R!-Q_K2NO=^TF
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MT5C5=(^/'J0BVM3CPW175SN67%575-,)G1WW#+4_5[S;C@4]:)K:T8[?D6.
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MY/C=U\<GW]R??/?#N],?_O3ME]]]^]W7)W_Z_O]^]^Z'=^\D C_S80'I_WX
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MV<$D@\7ZN3;+ZKB $CES3!3(NW<0P11 SE7>55G5$K0P?$8'46R@VAF@A^K
M"89LTF$L03W'FW(Y8[R,<99$.W*8ZH7ZO['7ZH/TC4$O<&KO_BQ[4ON]2?$.
MIOGK#=% 3GR*IG [.G=]A)IS11\=FS#33=?'[,"Y'8$=Y<<F!UAP/ ()G/A
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MS&GLVALGNS)^]F'&W'FYZ]QI"61)J+>YXF\[9:0-E* V3&X(+4BF-;Y[I%T
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M!S$WMMI*?*IT@:[5": )7+'+H9_B_ GD3Q! (1C]>_Z'F$L<7K3J1[XC/O6
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M)F1NV*<IF0K.HBRV?(Q:F;:#8BY%7AX*\N(D2E9QA  7H2CO(KEI#J2J+YR
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M=NDW8.@.G8QSXI/?R>3IIS3N4S<.=>K'H4Z]+>"DYLW+_(E6 S_03N^L'EN
M)?SG-&#_::(WX#^G_OS'*5+]_G,:DO]\[<9_OO;C/U^/X3\_);C+=[X.V'>:
MR WXSM?^?,<I2OV^\_5D6XA1]K1(ULWW2S6W._JHV#VLVD[5X]NXS1=5PW 4
M!9BPNN+"A01):"Q:T)CJ':HL)RD^2?7;Q]_^J?X,9,?'YLZ$.=_/SA6=& -V
MJ?PY R\<OA($=/M^3U289O+\@!/XRM?Z[_?)VL#CNRB80]I.T4-Q(>4C-CH
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M*>I <]&!IK,#'7$/K3% Z0:<Y@)/F9Y==X8A^EY;;_3>V0MAB:<+*C91[AP
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M?KM^YXJKD:_3&PC"TZDPQ-VQB_VDR=/#6J>=)TB63I37FQB:$<Y,G@;45*1
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M((6IV#DJ^L0K"-?9>Z+Z8OY=;B1SJ6^)N1GB#F=Q'C_#>\E"?TQQEA';Y.(
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MT>KCF@AZE<.M5MU)!P'S0Y=6@A[Z6[%.(V7OD5\I*\!X!=(1IA\9K*2P(%%
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MB1X9W>=KE-GQAG"C-0B,'4@)OR.PY1S?H&^KV*4O!Q_$]G.Q0=^S%1T H",
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MWYRLR$ZD-M/?WIR_.8E#P@Q>4;8MC_X;]50$R+E+YEW*)N.1\/""0\1^M\^
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M4F46)D=IH!*X.+\V@V6HOKCR_&@.S4 E,"#Q/<-*AW_NW]X=0$7><G\IKMG
M1 B=_H7ET:H83PN$HBR8M;)*0_6G7==E*.&N-B)S&Y YL\(7MD9Q^'9N6:LD
M*A-Y4;C]R7YX9OKC/^]<PIM'#AD*)[[#[*$+[)&=$U[_(R:;121J4YQ6?8QI
M\QDUFT-77#^BR')]Y%Q;@>_Z\W!BDX,>TY(HSA6:N;8K%#\+H:9C5KEQI]$"
M!=1[%: %(F)]C:@(6Z(['(;W*)K.GJU7R!3!I+7,UW'<1*0^6*YSZU]:*Y<\
MP7/.!M 4!:CIF%5NP-\M+Q:*+R__5@?'#]OK3([IPL^[D5V0Z'D1*KKVBQLQ
M-87< Y?8IQ%X1#LA]P)TZY22T3&/W'T&*$-2]74UUX>J"_T)E71!3#2SG=N5
MR3PY!B6(:KHKZ.,P?+ VUHN')! OH]#-7I$YN554-,^B4(-K.*<:FEIV61@>
MZ/TUNRK]0@=W[  F ]YCWX8?@1(">NY<O$)!M'D@+QA66(ZL[HI*;Z*"P2[?
M*CKZ]HB, -K]4).FLR+*X?7KBFB^:"O#I6<@1$Z+)K3 0?2,@N6MOT9AH@6
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MR&GQ^*"H /9GG+M$TI <=L! ;B H:1WSO7+7KD-D+,B/D?M(^YI((ZZ'5YZ
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M6.$KM>IQP(9UJ5;"!;#K9OA]&"_:9EX CJ3RQ]8Q'MUV7$P<Y _C=I7Q4&8
M?AS50Y #FP-G8 2'6#U8A4$=Z@;L3YR'@CGIJ' 9HV><*UU.6$JKLQ"9<8]]
M._D+Q#PK3%)/.\C"JNQ/R/-HO7'DH\#R:"D;9^GZ+C6ITNBN;<$:JC'E:[G_
MX4:+/$586$R[G.A <WN!9^T!?A U$N0[*:.@D_NL7D?:[$!J @5$M+3J\X,L
MO^S9>KT@VV9& .3=01 1):S>)&VO0JX2<M>G59@@LVPTC)03+*>6; NG_!U9
M0A[2ZN^EN!$3WH=:1&UU<BA=*>[)@V^&PI!=*VG>8BCN<*XET:'<AGN>:PAU
M.!>HV[F23(N['.:+!M$<"^UK+[0/69Y!.(QE#@$6/)5#\2*+2+AZS(;F0A:[
MX[# C3P(7[+D0973NWAW.(,-X;):+J[3N4UO)-H4/27/+ ZRF6)2%<@5+_9!
M1$<HA'#?:F-Z*T-5^+5M^^/K,/C[OW(=A$W3/(Y P\NGG^Z=ZI9L-S@HZLG6
MIOM'!4/'YAYJ-.<N&[ 4L0NQMP )=]IL9LO)#)3O)D2NTWF!S-L0:CIFQ6JQ
MTQC/V^4JP.LD:0*>=55)1E.6Y2HF=T:&(WP.I22TM-F+ Z(KTEI3OG/COM(_
M22Q#%14ITS>Y@'% !]Q( %M'H=-3^TP8A[M)A,AU.J^+#64%ZC01(J>W/%-U
M-SC(Y,1ICLW86K#?2C5C$U\ST[TOTB=#I+5=_G@/Q0L#$9U"[0%SHG\H/AG(
MM8KK-0'3'3.2L(FH=:9[8!I"5ZK4<]S,OC8D<:M\T''LS,PG:/7*O2ORG@[T
MMJBT0@M9?CB$GT<(Q2$L-@]J]5/I-N=G?>F_$]%&_LXD6E8Q)*G8G?Z3,XFR
MWY[ZC[2&*<W[8PDR<J;[=@;OCYE>\?QTQ#LRGC).^%1 X8[E1+08#;< W_KD
M)1T7@7YA>32/]6F!4/0MP/&*96I)6!J:CZ7%?-2P;*E,@=+V.)=9IVHZN@K*
MTCZQN[F5#4\:@&AW<Y1J!EQ#28L<V<)8=((/BVI=6DE?+"G'5_.Q="#R'?MH
M\]T*_D+13>P[$JZ8,@IZ,BG([G%MHMX5[Z[BG\+GV&R<#L\IT#M2147K^;SU
M5W$4WJ$U\MY+> >KR'0UCW,U\SCO>AYG:N9QULD\=K3V[0__TT4!>: N-G W
M*9"PWCMN<\@(@QXJ%40IZ@E_"&CGZPBQ"EU9TPV9((A*0GI:MVT55VJBO"2\
MS'&0UO^4J <L0$W_K*![K>CKSB1$]F9O(/(JZ74ULYL _2-&OJU(XAV0TRSG
MBEAI(.3*R6F>5]'+ 1P4(D9/Z\SX(U;.0E-)IW,+MM T,72!AA+] =K^Q2B6
MG]^A1'Y 9&,1AE6R?2B1'Y![LP;#PXM_*'$@LJ>Y2 W</;SGQF)6H4"7(E2L
M[G.?L=F[#/"0PL(O0--KC"N\<"NM KO']L,0<!2QN]1=&>5&)+XQS0Y*DC/:
M%>%:9';D* Y/C6F,XODABF;?,*V@^/X Q??C55-X4U>XI7:OET_&8B?@X-LI
M,-#$8<GWH]DWC!+W<0[U,E=XBVT;>H5G<U52-E1BBS 1 P-!N&$ 2[UTS2R6
M'%NSI8%@J%,M<H6Q6AF(@WE-JMN@U9%^'%FS55"AN,D:U')H&=HAH\U]V#PR
M.$/_H^%.'%7QVCGT*T+0,U@_:1 !O4CG4-AK0YI^SY,RNNZD,5F3D:C&>X,#
MVJ",6YBOT$O$_P9*PQ"FV55D":U%]\/'+R$*UI31Q-SQB&Q,SK[GLD78385A
MYYJ5LR/',KQ'<J$ JEG0BE\BVA++VC-.[)09.Y,EK0$F!8H0W:YF>I9R=*YX
MIN5TQQB7[F-<A!:*V_3,+,.J$L7R@\U1-+-';6,45=\9'' S6]O* BZNM?"
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M&JW@TDN0H(ZY46>!190^PLL56B,/KZBHD)Z9$#D=\R(J(%ZB+"/NCG)-8R'
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MDIV6!JV&,NT 9$?H/+:O(33%[06:[HD!-B-0='9%BP2:BVG710(-#T]O5:D
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ME;OITW^A__-"Y/J__W]02P$"% ,4    " #Q07!2M(S[,E<D 0!V]!H $0
M            @ $     8V%B82TR,#(P,3(S,2YX;6Q02P$"% ,4    " #Q
M07!2$+C,/=84  ")Z@  $0              @ &&) $ 8V%B82TR,#(P,3(S
M,2YX<V102P$"% ,4    " #Q07!2@S423R(-  ![L   %0
M@ &+.0$ 8V%B82TR,#(P,3(S,5]C86PN>&UL4$L! A0#%     @ \4%P4G(D
MAYHP*@  .OT" !4              ( !X$8! &-A8F$M,C R,#$R,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( /%!<%)V "G\ W,  #[[!@ 5              "
M 4-Q 0!C86)A+3(P,C Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #Q07!2$-,/
M'X-#  #:+P4 %0              @ %YY $ 8V%B82TR,#(P,3(S,5]P<F4N
9>&UL4$L%!@     &  8 B@$  "\H @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
